<html lang="en"><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <link rel="shortcut icon" href="./favicon.png">
    <link rel="preload" href="./static/media/SourceSansPro-Regular.DZLUzqI4.woff2" as="font" type="font/woff2" crossorigin="">
    <link rel="preload" href="./static/media/SourceSansPro-SemiBold.sKQIyTMz.woff2" as="font" type="font/woff2" crossorigin="">
    <link rel="preload" href="./static/media/SourceSansPro-Bold.-6c9oR8J.woff2" as="font" type="font/woff2" crossorigin="">

    <title>app</title>

    <!-- initialize window.prerenderReady to false and then set to true in React app when app is ready for indexing -->
    <script>
      window.prerenderReady = false
    </script>
    <script type="module" crossorigin="" src="./static/js/index.BlylrL8P.js"></script>
    <link rel="stylesheet" crossorigin="" href="./static/css/index.DpJG_94W.css">
  <style media=""></style><style data-emotion="st-emotion-cache-global" data-s=""></style><style data-emotion="st-emotion-cache" data-s=""></style><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/index.BqlD3NTA.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/index.DW_MHI2K.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/FormClearHelper.UtDFKbpT.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/FileHelper.DV2KuUj6.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/ProgressBar.BtMHwdZZ.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/Hooks.YZgOFmbn.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/UploadFileInfo.C-jY39rj.js"></head>
  <body>
    <noscript>You need to enable JavaScript to run this app.</noscript>
    <div id="root"><div class=""><div class="withScreencast" data-testid="stScreencast"><div class="stApp stAppEmbeddingId-t797t1oningx st-emotion-cache-1r4qj8v ee4bbma0" data-testid="stApp" data-test-script-state="notRunning" data-test-connection-state="CONNECTED"><header tabindex="-1" class="stAppHeader st-emotion-cache-12fmjuu e4hpqof0" data-testid="stHeader"><div class="stDecoration st-emotion-cache-1dp5vir e4hpqof1" data-testid="stDecoration" id="stDecoration"></div><div class="stAppToolbar st-emotion-cache-15ecox0 e4hpqof2" data-testid="stToolbar"><div class="stToolbarActions st-emotion-cache-1p1m4ay e1i26tt72" data-testid="stToolbarActions"></div><span id="MainMenu" class="stMainMenu st-emotion-cache-czk5ss ev04twb8" data-testid="stMainMenu" aria-haspopup="true" aria-expanded="false"><button kind="headerNoPadding" data-testid="stBaseButton-headerNoPadding" aria-label="" class="st-emotion-cache-l1ktzw em9zgd018"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-1pbsqtx ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M12 8c1.1 0 2-.9 2-2s-.9-2-2-2-2 .9-2 2 .9 2 2 2zm0 2c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2zm0 6c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2z"></path></svg></button></span></div></header><div class="stAppViewContainer appview-container st-emotion-cache-1yiq2ps eht7o1d0" data-testid="stAppViewContainer" data-layout="narrow"><section tabindex="0" class="stMain st-emotion-cache-bm2z3a eht7o1d1" data-testid="stMain"><div class="stMainBlockContainer block-container st-emotion-cache-mtjnbi eht7o1d4" data-testid="stMainBlockContainer"><div data-testid="stVerticalBlockBorderWrapper" data-test-scroll-behavior="normal" class="st-emotion-cache-0 eu6p4el5"><div class="st-emotion-cache-b95f0i eu6p4el4"><div class="stVerticalBlock st-emotion-cache-1n76uvr eu6p4el3" data-testid="stVerticalBlock" width="704"><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stHeading" data-testid="stHeading"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 id="olmocr">OLMOCR<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#olmocr" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="st-emotion-cache-8atqhb e1mlolmg0"><div class="stFileUploader st-emotion-cache-0 e17y52ym15" data-testid="stFileUploader" width="704"><label data-testid="stWidgetLabel" aria-hidden="true" class="st-emotion-cache-1s2v671 e1dx5vew0"><div data-testid="stMarkdownContainer" class="st-emotion-cache-wq5ihp e1icttdg0"><p>Upload a PDF or Image</p></div></label><section role="presentation" data-testid="stFileUploaderDropzone" aria-label="Upload a PDF or Image" class="st-emotion-cache-1gulkj5 e17y52ym0" tabindex="0"><input data-testid="stFileUploaderDropzoneInput" accept="application/streamlit,.pdf,.png,.jpg,.jpeg" type="file" style="border: 0px; clip: rect(0px, 0px, 0px, 0px); clip-path: inset(50%); height: 1px; margin: 0px -1px -1px 0px; overflow: hidden; padding: 0px; position: absolute; width: 1px; white-space: nowrap;" tabindex="-1"><div data-testid="stFileUploaderDropzoneInstructions" class="st-emotion-cache-u8hs99 e17y52ym1"><span class="st-emotion-cache-nwtri e17y52ym2"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-6rlrad ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M19.35 10.04A7.49 7.49 0 0012 4C9.11 4 6.6 5.64 5.35 8.04A5.994 5.994 0 000 14c0 3.31 2.69 6 6 6h13c2.76 0 5-2.24 5-5 0-2.64-2.05-4.78-4.65-4.96zM19 18H6c-2.21 0-4-1.79-4-4 0-2.05 1.53-3.76 3.56-3.97l1.07-.11.5-.95A5.469 5.469 0 0112 6c2.62 0 4.88 1.86 5.39 4.43l.3 1.5 1.53.11A2.98 2.98 0 0122 15c0 1.65-1.35 3-3 3zM8 13h2.55v3h2.9v-3H16l-4-4z"></path></svg></span><div class="st-emotion-cache-j7qwjs e17y52ym4"><span class="st-emotion-cache-9ycgxx e17y52ym3">Drag and drop file here</span><small class="st-emotion-cache-1rpn56r ejh2rmr0">Limit 200MB per file • PDF, PNG, JPG, JPEG</small></div></div><button kind="secondary" data-testid="stBaseButton-secondary" aria-label="" class="st-emotion-cache-ocsh0s em9zgd02">Browse files</button></section><div class="st-emotion-cache-fis6aj e17y52ym5"><ul class="st-emotion-cache-14m29r0 e17y52ym6"><li class="st-emotion-cache-1l95nvm e17y52ym7"><div class="stFileUploaderFile st-emotion-cache-12xsiil e17y52ym10" data-testid="stFileUploaderFile"><div class="st-emotion-cache-10ix4kq e17y52ym12"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-4mjat2 ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zM6 20V4h7v5h5v11H6z"></path></svg></div><div class="stFileUploaderFileData st-emotion-cache-1l4firl e17y52ym8"><div class="stFileUploaderFileName st-emotion-cache-1uixxvy e17y52ym9" data-testid="stFileUploaderFileName" title="501_PDFsam_Pharmacology_and_Pharmacotherapeutics,_24e_etc_Z_Library.pdf">501_PDFsam_Pharmacology_and_Pharmacotherapeutics,_24e_etc_Z_Library.pdf</div><small class="st-emotion-cache-1rpn56r ejh2rmr0">8.4MB</small></div><div data-testid="stFileUploaderDeleteBtn"><button kind="minimal" data-testid="stBaseButton-minimal" aria-label="" class="st-emotion-cache-8ccstr em9zgd06"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-1pbsqtx ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M19 6.41L17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41z"></path></svg></button></div></div></li></ul></div></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stButton st-emotion-cache-8atqhb e1mlolmg0" data-testid="stButton"><button kind="secondary" data-testid="stBaseButton-secondary" aria-label="" class="st-emotion-cache-ocsh0s em9zgd02"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1hyd1ho e1icttdg0"><p>Submit</p></div></button></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stMarkdown" data-testid="stMarkdown"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><p><strong>Processing file:</strong> 501_PDFsam_Pharmacology_and_Pharmacotherapeutics,_24e_etc_Z_Library.pdf</p></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stMarkdown" data-testid="stMarkdown"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><p>having a poor ability to hydrolyse succinylcholine, or acquired deficiency of normal pseudocholinesterase as in liver disease, predisposes to its development. Metabolic acidosis can also precipitate succinylcholine apnoea. It is treated by artificial respiration and fresh blood transfusion. No antidote is available.</p>
<ul>
<li>Malignant hyperthermia: The drug can rarely trigger serious malignant hyperthermic crisis in patients receiving ether or halothane.</li>
<li>Miscellaneous: Muscle soreness is a frequent complaint following succinylcholine. Increase in intraocular tension can also occur.</li>
<li>Drug interactions: They are similar to those of d-tubocurarine. AntiChE drugs, however, act synergistically with depolarising blockers.
Preparations and dosage: Succinylcholine chloride 50 mg per ml . Dose: 1 mg per kg given slowly IV, followed by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.3</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.3 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.3</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> as needed.
Therapeutic uses of peripheral skeletal muscle relaxants:</li>
<li>Adjuvant to anaesthesia: The main use of skeletal muscle relaxants is to promote skeletal muscle relaxation during abdominal surgery, orthopaedic manipulations, and various brief procedures like laryngoscopy, bronchoscopy and oesophagoscopy. When the procedure involved is of short duration, succinylcholine or mivacurium is the drug of choice.</li>
<li>In electroconvulsive therapy: Succinylcholine or mivacurium is often administered along with diazepam to protect the patient from injury during electroconvulsive therapy.</li>
<li>In spastic disorders: The curarimimetic skeletal muscle relaxants have been used to treat the severe spasms of tetanus. This use, however, involves risk and needs expert supervision.
III Drugs which inhibit ACh release from motor nerve terminals.
BOTULINUM TOXIN TYPE A is produced by Clostridium botulinum. It binds irreversibly to presynaptic, cholinergic sites and inhibits the release of ACh from the motor nerve terminals. Local injection of the toxin weakens the overactive muscle and decreases the hypersecretion of glands innervated by cholinergic neurons. It has been used to treat:
(1) Spastic conditions such as spasmodic torticolis, hemifacial spasm, strabismus, blepharospasm, dystonias, lower esophageal spasm and painful anal fissure;
(2) Wrinkles on the face and neck;
(3) Palmar hyperhidrosis.
(4) Overactive bladder (Chapter 20). It appears to be safe and effective in these conditions. Its action lasts for 3-4 months.
Adverse reactions include ptosis, diplopia, reduced blinking leading to dry eyes, minor bruises and lid swelling; reversible muscle atrophy can occur after repeated administration.</li>
</ul>
<p>Botulinum toxin Type B can be used in patients who have become resistant to Type A toxin.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-acting-directly-on-skeletal-muscle">Drugs Acting Directly on Skeletal Muscle<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-acting-directly-on-skeletal-muscle" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>DANTROLENE: This phenytoin analogue relaxes the skeletal muscles by binding to the ryanodine receptors (RYR) on the sarcoplasmic reticulum, blocking their opening. This prevents the release of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>from the sarcoplasmic stores. Thus, the muscle contraction is weakened without muscle paralysis. It does not alter the neuromuscular transmission. It has relatively little effect on cardiac and smooth muscle. Given orally, it is incompletely (about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">1 / 3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0991em; vertical-align: -0.25em;"></span><span class="mord">1/</span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> ) absorbed and is largely metabolised in the liver. It can also be given IV. Dose: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">d</mi></mrow><annotation encoding="application/x-tex">25 \mathrm{mg} / \mathrm{d}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord mathrm">d</span></span></span></span></span>, increased weekly to a maximum of 100 mg bid or qid.</p>
<p>Adverse reactions: These include generalised muscle weakness, dizziness, drowsiness, fatigue and diarrhoea. Rarely, it may cause serious hepatotoxicity.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Spasticity: The drug is particularly useful for the treatment of spasticity (especially cerebral spasticity) in patients in whom nursing care is made difficult by muscle spasm. Patients in whom spastic, dystonic stiffness is useful as a sort of protective endogenous crutch should not be treated with dantrolene.</li>
<li>Malignant hyperthermia: Intravenous dantrolene ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>, bolus, repeated if required to a maximum total dose of 100 mg ) is life-saving in this rare, fatal and familial, genetic disorder of skeletal muscle triggered by any potent inhalation anaesthetic, depolarising muscle relaxant, curare-like neuromuscular blocking agent and even by stress. In susceptible individuals, these can cause excessive release of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>from the sarcoplasmic reticulum, leading to muscle rigidity, hyperpyrexia (temperature more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>42</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">42^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">4</span><span class="mord"><span class="mord">2</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> ), hyperkalemia, tachycardia and metabolic acidosis. It is a medical emergency.
It must be noted that management of the patient with spasticity implies more than just treatment of the spasticity. For many patients the increased tone is not harmful and may even be helpful. Active measures to reduce spasticity are only justified where the reflex hyperexcitability interferes with function, making rehabilitation, physiotherapy and nursing care difficult.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="section-v-br-other-biogenic-amines-and-polypeptides">SECTION V &lt;br&gt; Other Biogenic Amines and Polypeptides<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#section-v-br-other-biogenic-amines-and-polypeptides" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="outline">OUTLINE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#outline" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Chapter 23: Histamine and Antihistaminic Drugs
Chapter 24: 5-Hydroxytryptamine (Serotonin), its Agonists and Antagonists; and Treatment of Migraine
Chapter 25: Angiotensin, Kinins, Leukotrienes, Prostaglandins and Cytokines</p>
<p>23</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="histamine-and-antihistaminic-drugs">Histamine and Antihistaminic Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#histamine-and-antihistaminic-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>HISTAMINE ('tissue amine'), a potent biogenic amine, was synthesised even before its isolation from plants and animals by Windaus and Vogt in 1907. The compound was isolated from ergot extracts by Barger and Dale in 1910 and reports regarding its pharmacological actions were published by Dale and Laidlaw in 1910-1911. The role of this extremely potent natural substance in the genesis of allergic and anaphylactic manifestations was forecast by the brilliant work of Lewis.</p>
<p>Distribution and synthesis: Histamine, an imidazole compound, is widely distributed in plant and animal tissues, and is also present in the venom of bees and wasps. Almost all tissues in mammals synthesise histamine, from amino acid histidine by decarboxylation with the help of histidine decarboxylase (Fig 23.1). Histamine is also synthesised by the microflora in the GI tract from dietary histidine. Very little, however, reaches the circulation as most of what is absorbed is rapidly metabolised in the intestinal wall and the liver.
<img src="assets/images/image-20251214-941ae906.jpeg" alt="img-0.jpeg"></p>
<p>Histamine is present in various biological fluids, and in platelets, leucocytes, basophils and mast cells. A major portion of histamine is stored in mast cells and circulating basophils. These cells possess histidine decarboxylase, and also contain specialised granules, wherein histamine is stored in an inactive form. In the mast cells of majority of animals, histamine is stored along with heparin, and in rodents, along with 5-HT. Tissues devoid of mast cells, e.g., human epidermis, gastric mucosa and CNS neurons also contain a significant concentration of histamine. Within the gut, the histamine concentration is highest in the stomach wall and gastric and intestinal glands. In the CNS, the area postrema, mast cells (histaminocytes) and histaminergic neurons of the pituitary stalk and the hypothalamus contain significant amounts of histamine.</p>
<p>Mechanism of action: Four types of receptors, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub><mo separator="true">,</mo><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub><mo separator="true">,</mo><msub><mi mathvariant="normal">H</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}, \mathrm{H}_{2}, \mathrm{H}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> have been identified and cloned. All these receptors belong to the family of GPCR (G protein coupled receptors). (Table 23.1).</p>
<p>Table 23.1
Histamine receptors and their functions</p>
<table><thead><tr><th style="text-align: center;">Receptor</th><th style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></th><th style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></th><th style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></th><th style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></th></tr></thead><tbody><tr><td style="text-align: center;">Distribution</td><td style="text-align: center;">Widespread in the neuronal system, smooth muscles, endothelium and other cells</td><td style="text-align: center;">Widespread - gastric mucosa, smooth muscle, heart, brain and mast cells</td><td style="text-align: center;">Mainly in the histaminergic neurons and myenteric plexus</td><td style="text-align: center;">Mainly bone marrow and eosinophils, neutrophils and CD4 T cells</td></tr><tr><td style="text-align: center;">General role</td><td style="text-align: center;">On stimulation: itching, pain, vasodilatation, tachycardia, hypotension, increased permeability, bronchoconstriction, cough</td><td style="text-align: center;">Increased gastric acidity, vascular permeability (hypotension); and chronotropic, inotropic actions on heart; increased airway mucus production</td><td style="text-align: center;">Prevent excessive bronchoconstriction; mediate pruritus</td><td style="text-align: center;">Differentiation of myeloblasts and promyelocytes</td></tr><tr><td style="text-align: center;">Role in CNS</td><td style="text-align: center;">Control: sleep-awake cycle, food intake, temperature regulation, emotional behaviour, memory and learning (Feedback inhibitor)</td><td style="text-align: center;">Neuroendocrine regulation</td><td style="text-align: center;">Presynaptic heteroreceptor; decrease histamine, NA, DA, 5HT and ACh release</td><td style="text-align: center;">Not known</td></tr><tr><td style="text-align: center;">Role in allergy and immune modulation</td><td style="text-align: center;">Increased release of histamine and other mediators; promote chemotaxis of eosinophils and neutrophils; block humoral immunity and IgE production. Induction of cellular immunity</td><td style="text-align: center;">Decrease neutrophil and eosinophil chemotaxis; induce humoral immunity; suppress cellular immunity; induce IL-10 and suppress IL-12</td><td style="text-align: center;">Control neurogenic inflammation; proinflammatory activity</td><td style="text-align: center;">Increase eosinophil chemotaxis and IL-16 production</td></tr><tr><td style="text-align: center;">Antagonists (see text)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor blockers</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor blockers</td><td style="text-align: center;">Under evaluation</td><td style="text-align: center;">Under evaluation</td></tr></tbody></table>
<ul>
<li>Activation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors causes pain, pruritus, bronchoconstriction, vasodilatation, increase in vascular permeability and in secretions. It is associated with increase in intracellular cyclic guanosine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>3</mn><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup><mo separator="true">,</mo><msup><mn>5</mn><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup></mrow><annotation encoding="application/x-tex">3^{\prime}, 5^{\prime}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9463em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7519em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord">5</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7519em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span></span></span></span></span> monophosphate (cGMP). In the tissues, histamine serves as a chemotactic agent for neutrophils and eosinophils.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">H_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0813em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor effects can be competitively blocked specifically by the conventional antihistaminics ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">H_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0813em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor blockers).</li>
<li>Activation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors increases the gastric acid secretion and myocardial contractility. These effects are not blocked by the conventional antihistaminics but are specifically blocked by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">H_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0813em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists such as cimetidine. Impromidine is a potent <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor agonist and behaves as a competitive antagonist at the autoinhibitory receptors. Both <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">H_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0813em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">H_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0813em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors appear to be involved in vascular dilatation, hypotension and edema formation.</li>
<li>For <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">H</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{H}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">H</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{H}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors, see Table 23.1.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacological-actions-of-histamine">Pharmacological actions of histamine:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-actions-of-histamine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cardiovascular-system">Cardiovascular system:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cardiovascular-system" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Blood vessels: Although histamine may produce pulmonary and systemic vasoconstriction in certain herbivores like rabbits and guinea pigs, it causes marked vasodilatation in human beings. In man, the pulmonary vessels are dilated by histamine, producing a fall in pulmonary artery pressure. The cerebral blood vessels are dilated in majority of the species. It produces throbbing headache, palpable temporal pulsations, and a transient increase in the CSF pressure. The headache is attributed to stretching of sensory nerve endings around the cranial arteries. Histamine constricts large veins.</li>
</ul>
<p>It acts on the blood vessels in several ways:
(a) Activation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">H_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0813em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors on the endothelial cells causes rapid and short-lived</p>
<p>vasodilatation, mainly of arterioles through the release of NO.
(b) Activation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors in the vascular smooth muscle causes slower but more prolonged vasodilatation, and
(c) Direct relaxation of the smooth muscle of the arterioles and capillaries leads to their dilatation and fall in BP.
In man, histamine causes marked flushing, a sense of warmth; and marked increase in capillary permeability after large doses, which causes edema and reduction in plasma volume.</p>
<ul>
<li>Blood pressure: Hypotension, induced by moderate doses of histamine is transient due to its rapid degradation and the presence of protective reflexes. Large doses, however, produce prolonged hypotension. Histamine-induced hypotension can be prevented but only partially reversed by antihistaminic agents. However, it can be reversed by adrenaline (Physiological antagonism).
Triple response: When a pointed object is drawn lightly over the skin, the stroke line becomes blanched, i.e. white reaction, owing to contraction of the precapillary sphincters. It lasts for about 15 seconds.
When histamine ( 20 mcg ) is injected ID or the skin is stroked firmly with the pointed object in man, a triple response develops at the site. It comprises sequentially:
(a) Flush or red reaction which is a red line/spot developing within 10 seconds, owing to local dilatation of capillaries and venules; then
(b) Wheal which is local swelling due to edema, and mottled reddening around the injury, and lasts for about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>11</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">11 / 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">11/2</span></span></span></span></span> minute; it is due to increased permeability of capillaries and post capillary venules, with consequent extravasation of fluid; and finally
(c) Flare in which the redness with irregular margins spreads out from the injury.</li>
</ul>
<p>The triple response (Lewis response) is a part of the normal reaction to injury. Its prevention is used to evaluate antihistaminic activity of a new drug.</p>
<ul>
<li>Heart: Histamine increases the sinus rate (positive chronotropic action); increases the amplitude of ventricular contraction (positive inotropic action); decreases A-V conduction time and increases coronary blood flow. High concentrations induce ventricular fibrillation.
Smooth muscle: Histamine stimulates the smooth muscle of various tissues directly ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> action). However, the individual tissue responses show a marked variation. The bronchial and the uterine smooth muscle is highly sensitive to histamine. Its action on the pregnant uterus is, however, not significant. Individuals suffering from bronchial asthma and certain other pulmonary diseases develop a sharp fall in vital capacity and considerable respiratory embarrassment in response to histamine. Histamine-induced bronchospasm is antagonised by adrenaline, isoprenaline and aminophylline but not by antihistaminics or atropine.</li>
</ul>
<p>The GI and the ureteral smooth muscles respond moderately to histamine. Histamine, through <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-receptors, causes gall bladder contraction while <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-receptors mediate gall bladder relaxation.</p>
<p>Exocrine glands: Histamine is an important physiological mediator of gastric acid secretion. It acts by activating <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors (Chapter 43). It is blocked by the specific <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists.</p>
<p>Central nervous system: Histamine does not readily cross the BBB. The histamine</p>
<p>receptors in the brain mediate the actions of locally synthesised, stored and released histamine. There are two types of histamine containing cells in the brain: (1) Histaminergic neurons and (2) Mast cells. Histamine is thought to be a waking amine within the brain and is believed to act by "increasing the sensitivity of large cerebral areas to excitatory inputs". It acts through <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors which release intracellular <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>, and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors which release intracellular cyclic AMP. Competitive blocking of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">H_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0813em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors by the 'classical' antihistaminic drugs and of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors by cimetidine causes drowsiness as an adverse effect.</p>
<p>Histamine also modulates the release of neurotransmitters via presynaptic <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors located on histaminergic and non-histaminergic neurons in the central and peripheral nervous systems. The evidence suggests a role of histamine as a neurotransmitter in the CNS.</p>
<p>Immunomodulation: All the four histamine receptors are involved in immunomodulation (Table 23.1).</p>
<p>Miscellaneous actions: Histamine, on intra-epidermal injection, evokes itching and pain.
Histamine has an effect on lymphocytes via <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors and it also inhibits the secretory activity of the mast cells and the basophils by a negative feedback via <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors. It facilitates pro-inflammatory activity through <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors. It also probably plays a part in embryonic development and wound healing.</p>
<p>Absorption, fate and excretion: Histamine is a very stable compound and is absorbed from all sites. However, only a small quantity of oral histamine reaches the circulation because of its first pass metabolism. Histamine metabolism varies according to the animal species, sex and the organ studied. In man, it is mainly converted into methylhistamine by an enzyme imidazole-n-methyltransferase and then further converted by MAO-B into 1methylimidazole acetic acid. In some species like rats, it is mainly metabolised by oxidative deamination by the enzyme diamine oxidase (histaminase) present in the liver, kidney and intestinal mucosa.</p>
<p>Adverse reactions: These are due to its pharmacological actions and include hypotension, flushing, angioedema, headache, visual disturbances, diarrhoea and dyspnea due to bronchospasm. Man and guinea pig are extremely sensitive to histamine while rats and mice are highly resistant. Large quantities of histamine may be formed by bacteria in the small intestine acting on spoiled fish which may have high histidine content. Ingestion of such fish may lead to severe nausea, griping, headache and sweating. Similar reaction may be observed in susceptible subjects after consumption of red wine.</p>
<p>Uses: It was used to study gastric acid secretion.
BETAHISTINE HYDROCHLORIDE: is a histamine substitute, claimed to reduce the frequency of episodes of vertigo in some patients with Meniere's syndrome. The drug causes vasodilatation and improves blood flow to the labyrinth and brainstem. The improvement is short lived. The compound may aggravate peptic ulcer and bronchial asthma. It can cause drowsiness.</p>
<p>Histamine liberators: Various agents can release tissue histamine and may thus cause histamine reactions. They are:
I Those which release histamine mainly from the mast cells with minimal tissue damage:</p>
<ul>
<li>Proteolytic enzymes like Trypsin, certain Venoms, Food products, e.g. Crabs, Lobsters and Fish.</li>
</ul>
<ul>
<li>Surface tension reducing substances like Bile salts, Anionic and Cationic surfactants.</li>
<li>Substances with a high molecular weight like Dextran, and Polyvinyl pyrrollidone.</li>
<li>Drugs, particularly organic bases such as quaternary ammonium compounds, dTubocurarine, Morphine, Pethidine, Amphetamine, Hydralazine, Tolazoline, basic polypeptides (Polymyxin B) and a few Antihistaminic drugs; and</li>
<li>The polybasic compound 48/40 and the compound 19/35L, the most potent histamine liberators, used in animal experiments.
II Those which release histamine accompanied by substantial tissue damage:</li>
<li>Trauma due to cold and chemical, thermal or radiant energy.</li>
<li>Antigen-antibody reactions (Chapter 2).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="histamine-anaphylaxis-and-allergy">Histamine, Anaphylaxis and Allergy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#histamine-anaphylaxis-and-allergy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The term anaphylaxis is used clinically to describe a medical emergency caused by allergy to a variety of agents such as drugs, foods, plants, chemicals, latex and insect/reptile bites. It is mediated by IgE (Chapter 2), and histamine is the most important mediator involved in it. The clinical features in man are due to laryngeal edema, bronchospasm and hypotension (anaphylactic shock). An anaphylactic reaction may progress either slowly or rapidly, the latter especially after parenteral drug administration.</p>
<p>The term anaphylactoid is used for a similar condition, not IgE induced, commonly caused by vancomycin, quinolone antibiotics, opioids and iodine containing contrast dyes. It is, however, safer to assume that all such reactions are immune mediated, and avoid future exposure to the same agent.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="treatment-of-anaphylactic-shock">Treatment of anaphylactic shock:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment-of-anaphylactic-shock" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Anaphylactic shock needs immediate treatment for laryngeal edema, bronchospasm and hypotension:</p>
<ul>
<li>Lay the patient flat and raise his legs.</li>
<li>When possible, apply a tourniquet to obstruct the draining blood flow from the site of deposition of the antigen or inciting medication.</li>
<li>Attend to the airway.</li>
<li>Administer adrenaline: Adrenaline, 1:1000 solution IM, produces a dramatic reversal of the hypotension, bronchospasm and laryngeal edema and is life-saving. It may be repeated cautiously after 15 to 20 minutes, if necessary. When the patient is severely ill and there is doubt about the adequacy of circulation and absorption from the IM site, adrenaline ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>:</mo><mn>10</mn><mo separator="true">,</mo><mn>000</mn></mrow><annotation encoding="application/x-tex">1: 10,000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000</span></span></span></span></span>; never <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>:</mo><mn>1</mn><mo separator="true">,</mo><mn>000</mn></mrow><annotation encoding="application/x-tex">1: 1,000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000</span></span></span></span></span>; solution) may be injected IV, slowly, in the dose of 500 mcg , at the rate of 100 mcg per minute. (Table 23.2).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-23-2">Table 23.2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-23-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Adrenaline doses in anaphylaxis</p>
<ul>
<li>Adults: 0.5 ml of a 1:1000 solution IM. or 3-5 ml of a 1:10000 solution IM or slowly IV.</li>
<li>Children: 0.01 ml of a 1:1000 solution per kg IM or 0.1 ml a 1:10000 solution per kg slowly IV.</li>
</ul>
<p>Rapid IV injection of adrenaline or IV injection of the 1:1000 solution can induce lethal cardiac arrhythmias like fibrillations.
In patients on a non-selective beta blocker, severe anaphylaxis may not respond to adrenaline and may need additional IV salbutamol.</p>
<ul>
<li>
<p>IV fluids: Hypotension associated with anaphylactic shock should be corrected by immediate IV administration of large quantities of fluids (preferably colloids). If necessary, dopamine or norepinephrine can be infused IV. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blocker has been used in refractory cases.</p>
</li>
<li>
<p>Glucocorticoids: Glucocorticoids are routinely administered in the treatment of anaphylactic shock, as they inhibit the late phase of an allergic reaction (Chapter 27). Hydrocortisone hemisuccinate 100 mg is given IV, followed by oral prednisolone. They do not inhibit the early phase of the anaphylactic reactions and are not a substitute for adrenaline which is the drug of first choice.</p>
</li>
<li>
<p>Antihistaminic drugs: The antihistaminic drugs do not counter the hypotension and bronchospasm characteristic of anaphylactic shock. This is due to involvement of mediators other than histamine in the genesis of anaphylaxis or to release of histamine in intimate contact with cells not accessible to conventional antihistaminics. However, an antihistaminic such as chlorpheniramine, 10-20 mg over one minute by slow IV injection, and repeated for upto 24-48 hours, may prevent late manifestations of allergy. It must be given after adrenaline.
Injection of an <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonist e.g. ranitidine 50 mg , IV over 3-5 min may be helpful.
Bronchodilators: Aminophylline IV or nebulised salbutamol may be needed in patients with resistant bronchospasm.</p>
</li>
<li>
<p>Supportive measures: These include oxygen and assisted ventilation.</p>
</li>
</ul>
<p>The methods of countering the actions of histamine in the body are listed in Table 23.3.
Table 23.3
Methods of countering the actions of histamine</p>
<p><sup><a href="#user-content-fn-0" id="user-content-fnref-0" data-footnote-ref="true" aria-describedby="footnote-label">1</a></sup></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="9e682e6e"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> Receptor Antagonists<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#9e682e6e" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>In 1933, Fourneau and Bovet showed that certain phenolic ethers possessed antihistamine properties. Since then, many specific, competitive <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists with different chemical structures have been synthesised; the term antihistaminics, unless qualified, refers to these agents. In addition to their antihistaminic activity, many of them also have CNS and ANS actions.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antihistaminic agents can be classified either clinically or chemically.
Clinical classification: (Table 23.4)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-23-4">Table 23.4<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-23-4" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> Receptor blocking antihistaminic agents</p>
<table><thead><tr><th style="text-align: center;">Drug</th><th style="text-align: center;">Adult oral dose (mg)</th><th style="text-align: center;">Remarks</th></tr></thead><tbody><tr><td style="text-align: center;">Potent and sedative <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi>a</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{a}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6644em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6644em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">a</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Diphenhydramine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{HCl}^{\prime}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8362em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HCl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8362em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">25 to 50 (parenteral: 10)</td><td style="text-align: center;">Moderate antispasmodic, antimuscarinic.</td></tr><tr><td style="text-align: center;">Dimenhydrinate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mo lspace="0em" rspace="0em">∗</mo></msup></mrow><annotation encoding="application/x-tex">{ }^{*}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6887em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6887em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∗</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">25 to 100</td><td style="text-align: center;">Mainly used for motion sickness.</td></tr><tr><td style="text-align: center;">Promethazine HCl*</td><td style="text-align: center;">12.5 to 25</td><td style="text-align: center;">Marked antimuscarinic action.</td></tr><tr><td style="text-align: center;">Promethazine chloro- &lt;br&gt; theophyllinate</td><td style="text-align: center;">25 to 75</td><td style="text-align: center;">Marked antimuscarinic action; used mainly in motion sickness. Superiority over promethazine HCl is doubtful</td></tr><tr><td style="text-align: center;">Pheniramine maleate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mrow><mo>∗</mo><mo>∗</mo></mrow></msup></mrow><annotation encoding="application/x-tex">{ }^{* *}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6887em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6887em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∗∗</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">25 to 75</td><td style="text-align: center;">Antimuscarinic</td></tr><tr><td style="text-align: center;">Trimeprazine **</td><td style="text-align: center;">5 to10</td><td style="text-align: center;">Mainly anti-pruritic.</td></tr><tr><td style="text-align: center;">Doxylamine</td><td style="text-align: center;">25</td><td style="text-align: center;">Anti-allergic. OTC sleep-aid</td></tr><tr><td style="text-align: center;">Potent and less sedative <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi>b</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{b}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">b</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Chlorpheniramine maleate *</td><td style="text-align: center;">4 to 20 (parenteral: 5 to &lt;br&gt; 20)</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Triprolidine **</td><td style="text-align: center;">2.5 to 5.0</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Cyclizine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mtext>*&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">\mathrm{HCl}^{\text {* }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9723em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HCl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.9723em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">*&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">50</td><td style="text-align: center;">Used in motion sickness.</td></tr><tr><td style="text-align: center;">Meclizine HCl **</td><td style="text-align: center;">25 to 50</td><td style="text-align: center;">Mainly used for motion sickness.</td></tr><tr><td style="text-align: center;">Buclizine</td><td style="text-align: center;">25 to 75</td><td style="text-align: center;">Antiemetic</td></tr><tr><td style="text-align: center;">Less potent and less sedative <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi>b</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{b}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">b</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Mepyramine maleate: *</td><td style="text-align: center;">50 to 100 (parenteral: 25 to 50)</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Antazoline HCl</td><td style="text-align: center;">50 to 100</td><td style="text-align: center;">Moderately active; antiarrhythmic</td></tr><tr><td style="text-align: center;">Cinnarizine *</td><td style="text-align: center;">25</td><td style="text-align: center;">Anti-vertigo; to treat EP reactions</td></tr><tr><td style="text-align: center;">Flunarizine</td><td style="text-align: center;">5 to 10</td><td style="text-align: center;">Anti-vertigo; to treat EP reactions</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">Non-sedative (Second generation)</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Loratadine **</td><td style="text-align: center;">10 (once daily)</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Desloratadine</td><td style="text-align: center;">5 (once daily)</td><td style="text-align: center;">Less antimuscarinic and relatively</td></tr><tr><td style="text-align: center;">Fexofenadine **</td><td style="text-align: center;">120 (once daily)</td><td style="text-align: center;">free from cardiac toxicity.</td></tr><tr><td style="text-align: center;">Acrivastine *</td><td style="text-align: center;">8 (tid)</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Cetirizine **</td><td style="text-align: center;">5-10 (once daily)</td><td style="text-align: center;">May cause some sedation</td></tr></tbody></table>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi>a</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{a}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6644em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6644em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">a</span></span></span></span></span></span></span></span></span></span></span></span></span> First generation or classical
*Short acting;
*Long acting.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-potent-and-sedative-ii-potent-but-less-sedative">I Potent and sedative II Potent but less sedative<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-potent-and-sedative-ii-potent-but-less-sedative" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>III Less potent and less sedative
IV Non-sedative They do not cross the BBB in significant amounts.</p>
<p>Chemical classification: Most of the antihistaminic agents can be represented by the general formula:
<img src="assets/images/image-20251214-0b737f1f.jpeg" alt="img-1.jpeg"></p>
<p>Depending upon the configuration of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>X</mi></mrow><annotation encoding="application/x-tex">X</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07847em;">X</span></span></span></span></span>, the antihistaminic agents can be classified as: I Ethanolamines where <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>X</mi><mo>=</mo><mi>O</mi></mrow><annotation encoding="application/x-tex">X=O</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07847em;">X</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.02778em;">O</span></span></span></span></span>, e.g. Diphenhydramine and Doxylamine II Ethylenediamines where <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>X</mi><mo>=</mo><mi>N</mi></mrow><annotation encoding="application/x-tex">X=N</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07847em;">X</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.10903em;">N</span></span></span></span></span>, e.g., Tripelennamine, Mepyramine and Antazoline. They have negligible anticholinergic and antiemetic effects.
III Alkylamines where <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>X</mi><mo>=</mo><mi>C</mi></mrow><annotation encoding="application/x-tex">X=C</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07847em;">X</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span></span></span></span></span>, e.g. Chlorpheniramine, Triprolidine, Acrivastine.
IV Piperazines where <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>X</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">X=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07847em;">X</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> carbon in conjunction with a piperazine ring, e.g., Hydroxyzine, Buclizine, Meclizine, Cinnarizine, Cetirizine.
V Phenothiazines where <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>X</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">X=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07847em;">X</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> nitrogen as a part of phenothiazine nucleus, e.g., Promethazine, Trimeprazine. They have potent antiemetic effect.
VI Piperidines: Cyproheptadine, Loratadine, Fexofenadine and Ketotifen.
VII Dibenzoxepines: Doxepin, an anti-depressant, with potent antihistaminic properties. Pharmacological actions of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists:</p>
<ul>
<li>Antihistaminic actions: The anti-histaminics competitively block histamine actions at many sites. Thus, they antagonise the stimulant action of histamine on the smooth muscle of the GI tract, the bronchi, the uterus and the blood vessels and inhibit histamine-augmented salivary secretion. They also reduce histamine-induced triple response and itching, but fail to produce resorption of the edema fluid. Antihistaminics prevent the itching, edema, urticaria and increased gastric motility and to a lesser extent, the hypotension produced by the histamine releasing drugs.
Antiallergic and anti-inflammatory actions involve (a) inhibition of the release of mediators from mast cells and basophils and (b) downregulation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors. Pretreatment with an oral <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> antihistamic reduces the early response to an allergen challenge in the conjunctiva, nose, lower airways and skin. However, as described above, the bronchospasm and hypotension during anaphylaxis are not adequately reversed by them. This is probably because of the other mediators released during the reaction. These agents do not antagonise the cardiovascular actions of histamine.
Other actions: These actions vary according to the drug used and are related to their blocking of muscarinic, 5-HT as well as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> adrenergic receptors. They are:</li>
<li>Sedation and hypnosis: CNS depression is a common side effect with the classical (first generation) antihistaminics. They induce varying degrees of sedation, drowsiness and sleep. Sedation is sometimes beneficial, particularly in the treatment of allergic reactions. Drugs like promethazine and diphen-hydramine are potent sedativehypnotics. Sedation is often accompanied by inability to concentrate, dizziness and disturbances of co-ordination, and thus may interfere with daily work. Sedation is negligible with Second generation antihistaminics such as fexofenadine and</li>
</ul>
<p>desloratadine.</p>
<ul>
<li>CNS stimulation: Stimulation is less commonly encountered than depression. Conventional doses of a few drugs such as promethazine may occasionally produce paradoxical restlessness, tremors and insomnia.</li>
<li>Autonomic nervous system: Majority of the first generation antihistaminics exhibit muscarinic blocking activity. Dryness of mouth is common. Antihistaminics, such as antazoline and promethazine, exert an alpha adrenergic blocking effect. The second generation antihistaminics usually do not have these actions.</li>
<li>Antiemetic and anti-motion sickness effects: Motion sickness, attributed commonly to vestibular disturbances, is benefited to a considerable extent by diphenhydramine, dimenhydrinate, promethazine and the piperazine antihistaminics. They block the histaminergic signals from the vestibular nucleus to the vomiting centre. Vomiting due to other labyrinthine disturbances, such as labyrinthitis and fenestration operation also responds to antihistaminics. These agents, except the phenothiazine antihistaminics, however, are of limited value in treating emesis due to jaundice, radiation, and alkylating agents (Chapter 41).</li>
<li>Antiparkinsonian effect: Central anti-muscarinic actions of some antihistaminics, such as diphenhydramine or promethazine, are useful in treating parkinsonism. (Chapter 15).</li>
<li>Cardiovascular system: Although therapeutic doses of antihistaminics fail to affect the cardiovascular system, rapid IV administration of diphenhydramine, antazoline, and tripelennamine may cause dose related prolongation of QT interval due to their membrane stabilising action.</li>
<li>Local anaesthesia: Antihistaminics such as promethazine and diphenhydramine exhibit some local anaesthetic activity due to blockade of sodium channels.
Absorption, fate and excretion: They are absorbed well orally and parenterally; the antihistaminic effect starts within 15 to 30 minutes, peaks by 1 hour and lasts for 3 to 6 hours. The actions of medizine, however, persist for 12 to 24 hours. All first generation compounds are mainly metabolised in the liver by CYP3A4, and the products are eliminated in urine. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists can induce hepatic microsomal enzymes, facilitating their own metabolism.</li>
</ul>
<p>Adverse reactions: They are as a rule mild and can be grouped as follows:</p>
<ul>
<li>CNS: The first generation antihistaminics commonly cause sedation, hypnosis and fatigue. Individuals taking antihistaminics should not drive vehicles because of drowsiness and impaired motor coordination. Extrapyramidal reactions (Table 23.4), excitement and delirium may occur rarely. In children less than 2 years, promethazine may cause apnoea.</li>
<li>Antimuscarinic effects: The commonest effects are dry mouth, blurring of vision, bladder disturbances and rarely impotence, seen with first generation drugs.</li>
<li>GI: Nausea, vomiting, and epigastric distress may occur rarely.</li>
<li>Miscellaneous: The antihistaminics, in spite of their antiallergic properties, may themselves produce allergic manifestations, especially after topical use.
Acute, first generation antihistaminic poisoning is characterised by marked central stimulation. In children the clinical picture often resembles that of atropine intoxication, while in adults, fever and flushing are uncommon, and drowsiness often precedes the development of delirium and convulsion. Blood pressure and respiration are usually well</li>
</ul>
<p>maintained. Death is due to central depression leading to cardiorespiratory collapse and coma. The treatment is symptomatic and supportive. Diazepam can control convulsions.</p>
<p>Preparations and dosage: The number of antihistaminic drugs available in the market far exceeds their utility. Only the commonly available antihistaminics are listed in Table 23.4.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic Uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Allergic disorders: The antihistaminics are beneficial in the suppression of allergic manifestations like polinosis and urticaria. They are extremely effective in the treatment of seasonal hay fever, where they reduce the sneezing, rhinorrhoea, and other manifestations associated with this condition. Their efficacy in the treatment of perennial vasomotor rhinitis, however, is much less (Chapter 27).
Antihistaminics effectively counter the pruritus and urticaria in atopic and contact dermatitis and that induced by various drugs, chemicals and plants. They partially control the pruritus of eczema. Combination of a phenothiazine such as chlorpromazine with an antihistaminic may give better results in severe pruritus than the antihistaminic alone. Systemic administration also controls, to some extent, the pain and the itch due to bee or wasp stings. The antipruritic action of the antihistaminics is probably nonspecific. Their topical use is not recommended owing to the risk of sensitisation and tendency to cause eczema.
Adequate treatment of pruritus (Chapter 71) depends upon recognition of the local and/or systemic factor(s) responsible for it. For example, adequate treatment of scabies would generally relieve the itching in this condition. The itching in elderly patients, which is due to dryness of the skin, is best treated by moisturising the skin by applying a little edible oil or moisturising cream to the affected area immediately after bath and by minimising the use of soap for washing and bathing. Itching due to inflammatory skin conditions can be relieved by a combination of a weak corticosteroid applied locally and a systemically administered antihistaminic. Antihistaminics, however, are ineffective in itching of clinically normal skin.
Reaginic allergy (Chapter 2) is known to be familial. A period of relative immunodeficiency may precede frank development of allergic illness in genetically predisposed children. Infants of allergic parents kept on "allergen avoidance regimen" (avoidance of exposure to cow's milk, dairy products, eggs, house dust and pets) for first six months of life may have strikingly low incidence of eczema.
Antihistaminics are of some value in controlling mild blood transfusion reactions but not pyrexia or hemolysis (Chapter 32). Weak atropine like activity of the classical antihistaminics and the occasional superimposition of acute cold on chronic allergic rhinitis may account for the beneficial effects of antihistaminic drugs on rhinorrhoea in a few cases of common cold (Chapter 27).
Allergic conjunctivitis is a common condition and causes itching. Local treatment with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists (emedastine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.05</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.05 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.05%</span></span></span></span></span>, levocabastine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>0.05</mn><mi mathvariant="normal">%</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(0.05 \%)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">0.05%</span><span class="mclose">)</span></span></span></span></span>, mast cell stabilisers (cromolyn sodium 4%, nedocromil sodium 2%; Chapter 27) and drugs having both actions (ketotifen <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.025</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.025 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.025%</span></span></span></span></span>; Chapter 27) can give symptomatic relief. Their use is safe. The adverse reactions are mild and include ocular irritation, burning and stinging; headache may occur. Routine long term use of local glucocorticoids (Chapter 66) is not justified for fear of causing cataract and raised intraocular pressure.
Antihistaminics are effective in the treatment of urticaria and angioedema. Urticaria</li>
</ul>
<p>may occur as acute episodes but is considered chronic when it lasts longer than six weeks. It may occur in a person with atopic history (Chapter 27) but often such history is absent. In a few cases, an allergen (fish, seafood, nuts, eggs; food additives such as citric acid, preservatives and colouring agents like tartrazine; drugs such as aspirin and other NSAID; vegetable gums), an offending physical agent (mechanical trauma, cold, heat), history of insect bites and stings, or underlying disease (infection, connective tissue disorder) may be identified. However, no such factor is found in majority of cases. A detailed history and thorough physical examination must precede laboratory tests. If a causative agent can be identified, it must be avoided if possible and treated if it is a systemic disease. But, a witch-hunt for a 'septic focus' is unrewarding.
The treatment of choice for acute urticaria (and acute angioedema) is a SC injection of adrenaline (1:1000 aqueous solution) in the dose of 0.3 ml , repeated if necessary. If adrenaline is contraindicated, an antihistaminic ( 50 mg of diphenhydramine IM or IV) may be used. Ecallantide, a selective and reversible Kallikrein inhibitor is approved for acute attacks of hereditary angioedema (see Chapter 33).
Oral antihistaminics are the drugs of choice in chronic urticarias; they are more effective when given, prophylactically on a regular basis, than after urticarial lesions start; the non-sedative antihistaminics may be preferred. Alternatives to the antihistaminics are cyproheptadine, doxepin (an antidepressant with a potent antihistaminic action) or a beta adrenergic agonist such as ephedrine. In resistant cases, an <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blocker such as cimetidine or ranitidine may be added to the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blocker. Very few patients need corticosteroids and then, they should be used for the shortest possible period. Topical application of calamine lotion is useful for its cooling and soothing effects and can be used alone in mild cases.</p>
<ul>
<li>Mastocytosis: This rare disease is characterised by an abnormal increase in mast cells in the body leading to an increase in the production of mast cell mediators mainly histamine. This gives rise to symptoms such as pruritus, diarrhoea and anaphylaxis. Partial symptomatic relief can be obtained by a combination of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists.</li>
<li>Other uses:
(i) As hypnotics e.g., Diphenhydramine and Promethazine.
(ii) As antiemetics, e.g., Dimenhydrinate and Meclizine and Doxylamine. (Chapter 41)
(iii) In parkinsonism e.g., Diphenhydramine and Promethazine (Chapter 15).
(iv) In motion sickness and vertigo (Chapter 41).
(v) As antitussives e.g. Diphenhydramine.
(vi) In drug-induced acute dystonias Diphenhydramine, Promethazine (Chapter 15).</li>
</ul>
<p>Drug interactions: Sedation is enhanced when the sedative antihistaminics are used concurrently with alcohol, barbiturates, benzodiazepines or tricyclic antidepressants.</p>
<p>Nonsedative <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> antihistaminics (second generation): Most of the classical <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor blocking drugs (antihistaminics) are highly lipid soluble and have marked CNS adverse effects. They also have anticholinergic, antiserotoninergic and antibradykinin effects.</p>
<p>A second generation competitive <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor blockers, which poorly cross the BBB, are available. They are:</p>
<ul>
<li>
<p>The highly specific <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists.</p>
</li>
<li>
<p>Non-sedating in therapeutic doses.</p>
</li>
<li>
<p>Devoid of antimuscarinic, anti-serotonergic and antibradykinin action;</p>
</li>
<li>
<p>Less prone to clinically relevant drug interactions.</p>
</li>
<li>
<p>More expensive.</p>
</li>
</ul>
<p>Preparations and dosage: See Table 23.4.
Cetirizine is largely excreted as such in the urine; fexofenadine is primarily excreted in the feces. Fexofenadine is an active metabolite of terfenadine whereas cetirizine is an active metabolite of hydroxyzine.</p>
<p>Adverse reactions: Astemizole and terfenadine cause prolongation of QT interval with potential for lethal ventricular arrhythmias.</p>
<p>They are no more used. Fexofenadine and desloratadine are relatively safer.
Therapeutic uses:</p>
<ul>
<li>Allergic rhinitis but not vasomotor rhinitis (Chapter 27).</li>
<li>Urticaria; and</li>
<li>Dermographia.</li>
</ul>
<p>In practice, the choice of an antihistaminic drug depends upon efficacy, onset and duration of action, adverse effects and cost. These vary among different preparations, and among individuals. Sedative-hypnotic property may be beneficial, particularly when sleep is disturbed. None of the preparations available is ideal for all conditions in all the patients.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ecf8b38c"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> Receptor Antagonists<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ecf8b38c" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors (Table 23.1) are responsible for histamine induced gastric acid secretion and are useful in the treatment of peptic ulcer (see Chapter 43). Experimentally, they block positive chronotropic action of histamine, counter the enhanced automaticity of atria and ventricles, and prevent ventricular tachyarrhythmias induced by histamine.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="fe4732e"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> Receptors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#fe4732e" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors are thought to be presynaptic heteroreceptors that exert a tonic autoinhibitory control on histamine synthesis and release within the brain. Betahistine, a weak, partial agonist at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors, behaves as a weak <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonist. For <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors, see Table 23.1.</p>
<p>24</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="5-hydroxytryptamine-serotonin-its-agonists-and-antagonists-and-treatment-of-migraine">5-Hydroxytryptamine (Serotonin), its Agonists and Antagonists; and Treatment of Migraine<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#5-hydroxytryptamine-serotonin-its-agonists-and-antagonists-and-treatment-of-migraine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>5-HYDROXYTRYPTAMINE (5-HT), also termed serotonin (Fig 24.1), was isolated in 1948. The same compound, studied earlier independently, termed enteramine by Erspamer and co-workers, was found to have a wide tissue distribution and a variety of pharmacological actions.
<img src="assets/images/image-20251214-5e922b9e.jpeg" alt="img-2.jpeg"></p>
<p>FIG. 24.1 5-Hydroxytryptamine
Distribution and synthesis: 5-HT is widely distributed in plants and in animal tissues, mast cells and platelets. In the mammalian tissues, the highest concentration ( 60 to 180 micrograms per g) is present in the pineal gland, where it serves as a precursor for the synthesis of the hormone melatonin. It is also present in the venoms of wasps, bees and scorpions. Fruits like pineapples, bananas, tomatoes, plums and various nuts contain considerable amounts of 5-HT. However, it largely undergoes metabolic degradation on entering the circulation.</p>
<p>The compound is synthesised from the essential amino acid tryptophan (Fig. 24.2). The enzyme L-aromatic amino acid decarboxylase also decarboxylates histidine and DOPA. Within the CNS and the GI tract, 5-HT is stored in the chromaffin granules.
<img src="assets/images/image-20251214-9545336c.jpeg" alt="img-3.jpeg"></p>
<p>5-HT receptors: Four 5-HT receptor groups with defined functions have been identified:</p>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub><mo separator="true">,</mo><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>2</mn></msub><mo separator="true">,</mo><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1}, 5-\mathrm{HT}_{2}, 5-\mathrm{HT}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, with further subdivision into several subtypes. The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub><mo separator="true">,</mo><mn>5</mn></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1}, 5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">5</span></span></span></span></span> <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{HT}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors belong to G-protein-coupled receptor (GPCR) families, while <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo></mrow><annotation encoding="application/x-tex">5-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mord">−</span></span></span></span></span> <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{HT}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is a ligand-operated ion channel receptor.</p>
<p>The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn mathvariant="bold">5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{5}-\mathrm{HT}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord mathbf">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor has six subtypes. Of these, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">A</mi></mrow></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1 \mathrm{~A}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mtight"><span class="mspace nobreak mtight"><span class="mtight">&nbsp;</span></span><span class="mord mathrm mtight">A</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is found in the raphe cell bodies and dendrites, and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>1</mn><mi mathvariant="normal">D</mi></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1 \mathrm{D}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathrm mtight">D</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> on the axon terminals (presynaptic). They function as autoreceptors and regulate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord mathrm">HT</span></span></span></span></span></span> release. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>1</mn><mi mathvariant="normal">D</mi></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1 \mathrm{D}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathrm mtight">D</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is also found in the substantia nigra and basal ganglia.</p>
<p>The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn mathvariant="bold">5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{5}-\mathrm{HT}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord mathbf">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor has three subtypes. Of these, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">A</mi></mrow></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{2 \mathrm{~A}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight"><span class="mspace nobreak mtight"><span class="mtight">&nbsp;</span></span><span class="mord mathrm mtight">A</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors are found in the frontal cortex, clustrum, GI tract and platelets.</p>
<p>The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn mathvariant="bold">5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{5}-\mathrm{HT}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord mathbf">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor is a monoamine neurotransmitter receptor, located at the cholinergic terminals in the GI tract, nucleus solitarius and in the area postrema. Both the CNS and GI tract <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors participate in the process of vomiting.</p>
<p>The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn mathvariant="bold">5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{5}-\mathrm{HT}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord mathbf">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor are widely distributed throughout the body, including the CNS, smooth muscles and secretory cells. Their stimulation causes increased mucus secretion in the GI tract and facilitates the peristaltic process.</p>
<p>Although <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>5</mn></msub><mo separator="true">,</mo><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>6</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{5}, 5-\mathrm{HT}_{6}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">5</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">6</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>7</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{7}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">7</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors have been described, their exact function is not known.</p>
<p>The handling of 5-HT at the receptor level is similar to that of NA. Thus a large portion of 5-HT released from the neuronal endings is retaken up (Uptake 1) and stored in the granules by the neurons (Fig. 24.3). It is metabolised by the enzyme MAO. The metabolite 5-Hydroxy-indole-acetic-acid (5-HIAA) is actively transported out of the brain by a process which can be blocked by probenecid.
<img src="assets/images/image-20251214-b1878099.jpeg" alt="img-4.jpeg"></p>
<p>FIG. 24.3 Synthesis and metabolism of 5-HT at serotonergic neuronal endings
*Autoreceptors Dotted line indicates inhibition of release of the transmitter
Functions of various 5-HT receptors are summarised in Table 24.1.</p>
<p>Table 24.1
Important 5-HT receptors and their functions</p>
<table><thead><tr><th style="text-align: center;">Receptor</th><th style="text-align: center;">Signal transduction</th><th style="text-align: center;">Subtype</th><th style="text-align: center;">Location</th><th style="text-align: center;">Functions</th></tr></thead><tbody><tr><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">G-protein coupled. Inhibits AC</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">A</mi></mrow></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1 \mathrm{~A}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mtight"><span class="mspace nobreak mtight"><span class="mtight">&nbsp;</span></span><span class="mord mathrm mtight">A</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Raphe nuclei, hippocampus,</td><td style="text-align: center;">Mood and behaviour : anxiety sleep, feeding, thermoregulation. Autoreceptor regulating 5-HT release</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">B</mi></mrow></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1 \mathrm{~B}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mtight"><span class="mspace nobreak mtight"><span class="mtight">&nbsp;</span></span><span class="mord mathrm mtight">B</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Substantia nigra and basal ganglia; vascular smooth muscles</td><td style="text-align: center;">Autoreceptors (may be regulating dopamine release); locomotor function. Behaviour; pulmonary vasoconstriction</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>1</mn><mi mathvariant="normal">D</mi></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1 \mathrm{D}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathrm mtight">D</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">CNS; cerebral vessels</td><td style="text-align: center;">Cerebral vasoconstriction: migraine</td></tr><tr><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">G-protein coupled.</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">A</mi></mrow></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{2 \mathrm{~A}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight"><span class="mspace nobreak mtight"><span class="mtight">&nbsp;</span></span><span class="mord mathrm mtight">A</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Frontal cortex, clustrum, platelets, smooth muscles, autonomic neurons</td><td style="text-align: center;">Neural excitation; behavioral effects (of LSD); platelet aggregation; smooth muscle contraction (GI tract, bronchi, bladder)</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">Activates PLC</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">B</mi></mrow></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{2 \mathrm{~B}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight"><span class="mspace nobreak mtight"><span class="mtight">&nbsp;</span></span><span class="mord mathrm mtight">B</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Gastric fundus</td><td style="text-align: center;">Contraction</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>2</mn><mi mathvariant="normal">C</mi></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{2 \mathrm{C}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mathrm mtight">C</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Choroid plexus</td><td style="text-align: center;">CSF secretion</td></tr><tr><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Ligand operated ion channels</td><td style="text-align: center;"></td><td style="text-align: center;">Cholinergic terminals of GI tract; tractus solitarius; area postrema; hippocampus</td><td style="text-align: center;">Emesis &lt;br&gt; Behaviour: anxiety Neuronal excitation (autonomic, nociceptive neurons)</td></tr><tr><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">G-protein coupled. Activates AC</td><td style="text-align: center;"></td><td style="text-align: center;">Hippocampus; myenteric neurons; smooth muscles of esophagus, secretory cells</td><td style="text-align: center;">Neuronal excitation; contraction of muscle; stimulation of secretion</td></tr></tbody></table>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">C</mi></mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{AC}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord mathrm">AC</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Adenylyl cyclase
PLC <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span></span></span></span></span> Phospholipase C
Significance of 5-HT: The available data on this subject has not yet been synthesised into a unitary hypothesis. However, 5-HT
(i) Plays a major role in the regulation of GI motility,
(ii) Acts as a central neurotransmitter and
(iii) Serves as an autocoid in the peripheral vascular system.</p>
<ul>
<li>Neurohumoral transmission: 5-HT is present in the nervous system of all the vertebrates and many invertebrates. It is a chemical transmitter released by 'tryptaminergic' neurons widely distributed in the brain. One of the important functions attributed to the tryptaminergic dorsal raphe neurons is dampening of over-reactiveness to various stimuli, and 5-HT is involved in some way in regulation of the state of consciousness. Altered tryptaminergic function may be responsible for disturbances in sleep, appetite, mood, sexual behaviour, motor activity, perception and for migraine. These neurons are also involved in other functions such as temperature regulation, endocrine control and extra-pyramidal activity. 5-HT receptors have been identified in brain areas implicated in learning and memory. Many centrally acting drugs are known to influence responses to 5-HT or alter its reuptake, synthesis, storage, release or catabolism. Prominent among these are anti-psychotic drugs like chlorpromazine, reserpine, antidepressants, hallucinogens like LSD, mescaline and even analgesics like morphine.</li>
<li>Sleep: 5-HT controls sleep-wakefulness cycle; depletion of 5-HT causes insomnia, which can be reversed by 5-hydroxytryptophan.</li>
<li>Behaviour: Disturbances in the brain 5-HT metabolism are suspected as a cause of certain psychiatric disorders such as schizophrenia and affective disorders. 5- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{HT}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors present in brain in limbic and cortical areas are known to be involved in controlling mood, emotion, reward and memory. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists reduce the increased psychomotor drive associated with a mesolimbic dopamine excess. Low CSF 5HIAA is associated with impulsive, violent and suicidal behaviour, and 5-HT reuptake inhibitors (SSRI) are used to treat mental depression (Chapter 14). 5-HT receptor</li>
</ul>
<p>function is altered in anorexia nervosa and bulimia, the major eating disorders.</p>
<ul>
<li>Emesis and migraine: Antiemetic activity has generally been associated with dopamine antagonist drugs such as metoclopramide but studies in animals indicate that selective 5<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{HT}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists can prevent emesis associated with anti-cancer drugs and radiotherapy. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors are present in high densities on afferent vagus nerves and in the area postrema and dorsal vagal complex of animals.
Role of 5-HT in migraine has been suspected for a long time. 5-HT metabolism is abnormal in patients with migraine and IV administration of 5-HT can alleviate migraine attacks. It is not clear if the relevant 5-HT receptors are vascular or neural in location. However, sumatriptan, a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>1</mn><mi mathvariant="normal">D</mi></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1 \mathrm{D}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathrm mtight">D</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonist, is used to treat acute attacks of migraine. (see later).</li>
<li>Gastrointestinal tract: Entero-chromaffin cells in the GI tract synthesise 5-HT which forms the major source of circulating 5-HT. A part of it is metabolised by the hepatic MAO during its first pass through the liver. 5-HT released by mechanical or vagal stimulation from the neuronal endings acts locally to regulate the GI motility. 5-HT is believed to act as a local hormone for the initiation and sustenance of intestinal peristalsis.
It reduces the volume, acidity, and pepsin content of the gastric juice and promotes the production of mucus.</li>
<li>Cardiovascular system: 5-HT constricts the renal, pulmonary, splanchnic and cerebral blood vessels. It also has some positive inotropic and chronotropic action on the heart.</li>
<li>Platelets: Platelets do not synthesize 5-HT but take it up from the circulation and store it. 5-HT release, following a vascular injury along with other mediators of injury, activates platelets, which then promote vascular occlusion and vasoconstriction.</li>
<li>Hormone secretion: There is some evidence to suggest that tryptaminergic mechanisms are involved in the control of release of certain hormones. Sex hormones may affect mood and the mental state by activating the central 5-HT receptors.</li>
<li>Carcinoid syndrome: This clinical syndrome is associated with argentaffin cell tumours of the GI tract which secrete 5-HT. These tumours are locally invasive and may occasionally metastasize. Carcinoid syndrome is characterised by intermittent attacks of flushing, hypotension, bronchospasm, colic and diarrhoea. Associated tricuspid incompetence and pulmonary stenosis are occasionally observed. Some of these manifestations are due to excessive production of 5-HT. The diagnosis is usually confirmed by demonstrating high plasma 5-HT and high urinary HIAA levels. The drug, parachlorophenylalanine (PCPA) inhibits 5-HT synthesis by inhibiting tryptophan hydroxylase. PCPA administration results in almost complete inhibition of this enzyme leading to stoppage of diarrhoea, cramps and decrease in 5-HIAA excretion in urine. The toxicity of PCPA includes allergic reactions, tinnitus, fatigue, dizziness and mental changes. Marked hypothermia following PCPA has been reported. Some benefit may also be achieved by cyproheptadine and methysergide. However, treatment of choice is surgery.
It appears that 5-HT is a mediator of acute inflammation only in rats and mice. Unlike with histamine the human skin does not contain significant amounts of 5-HT and the 5-HT antagonists are not effective in controlling inflammation in human skin.
Pharmacological actions:</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cardiovascular-system">Cardiovascular system:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cardiovascular-system" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Peripheral blood vessels: 5-HT constricts majority of blood vessels including the renal, splanchnic, meningeal and pulmonary arteries, while it dilates the blood vessels of skeletal muscles, the coronaries and the capillaries of the skin. In several species, the cerebral blood vessels are constricted. It also constricts the veins and venules. Administration of 5-HT in humans results in cutaneous vasodilatation, producing initially a bright red flush, that may be converted to cyanosis.</li>
<li>Heart: 5-HT has weak direct positive inotropic and chronotropic effects on the myocardium; these, however, are usually not demonstrable in human beings, as it also causes reflex bradycardia.</li>
<li>Blood pressure: A characteristic 'triphasic response' is observed in BP after IV injection of 5-HT in majority of the species including man. It consists of:
(a) Initial transient depression of BP due to increased vagal activity following stimulation of carotid chemoreceptors;
(b) Rise in BP due to peripheral vasoconstriction; and finally
(c) Sustained hypotension which is due to dilatation of skeletal muscle blood vessels.</li>
</ul>
<p>Central nervous system: Considerable quantities of 5-HT are found in the midbrain, the limbic system, hypothalamus, caudate nucleus and pituitary gland. 5-HT, administered exogenously, does not readily cross the BBB. The barrier, however, does not exist for its precursor, 5-HTP. Intraventricular administration of 5-HT in an unanaesthetised cat evokes tremors and muscular weakness, and sometimes profuse salivation. The cat becomes catatonic but not sleepy.</p>
<p>Smooth muscle: 5-HT stimulates smooth muscles; the most significant effect is seen on the small intestine. After stimulation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors in the GI tract, both the tone and the motility are initially augmented followed by an inhibition of the spontaneous activity. 5-HT also evokes bronchoconstriction.</p>
<p>Absorption, fate and excretion: 5-HT is not significantly absorbed orally as it is degraded rapidly within the GI tract. Although platelets cannot synthesise 5-HT, they do have the capacity for its uptake and storage. It is mainly metabolised by the hepatic enzyme MAO and excreted as 5-HIAA in the urine (Fig. 24.4). The upper limit of normal urinary 5-HIAA in man is about 10 mg per day.</p>
<p><img src="assets/images/image-20251214-8d20d5da.jpeg" alt="img-5.jpeg"></p>
<p>Uses: 5-HT is not used therapeutically. However, many drugs act by manipulating 5-HT at various receptor sites, centrally as well as peripherally. Drugs can also act directly on 5HT receptors as agonists or antagonists; because of multiple types of 5-HT receptors, their actions and therapeutic uses vary. Further, some drugs in addition act on histaminergic, dopaminergic and adrenergic receptors. Some of the drugs acting through 5-HT receptors are summarised in Table 24.2.</p>
<p>Table 24.2
5-Hydroxytryptamine and drugs</p>
<table><thead><tr><th style="text-align: center;">Drug</th><th style="text-align: center;">5-HT receptor subtype</th><th style="text-align: center;">Other receptors</th><th style="text-align: center;">Uses</th></tr></thead><tbody><tr><td style="text-align: center;">Agonists:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Ergotamine</td><td style="text-align: center;">All 5-HT, 2A,2B</td><td style="text-align: center;">Dopamine; alpha-adrenergic agonist</td><td style="text-align: center;">Acute attack of migraine</td></tr><tr><td style="text-align: center;">LSD</td><td style="text-align: center;">2A,2C,1A</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;">Hallucinogen</td></tr><tr><td style="text-align: center;">Triptans</td><td style="text-align: center;">1B,1D</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;">Acute attack of migraine</td></tr><tr><td style="text-align: center;">Buspirone</td><td style="text-align: center;">1A (partial agonist)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;">Anxiety states</td></tr><tr><td style="text-align: center;">Cisapride</td><td style="text-align: center;">4</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;">Gastroesophageal reflux disease (GERD)</td></tr><tr><td style="text-align: center;">Metoclopramide</td><td style="text-align: center;">4</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>D</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">D_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0278em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blocker</td><td style="text-align: center;">GERD, gastroparesis</td></tr><tr><td style="text-align: center;">Antagonists:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Cyproheptadine</td><td style="text-align: center;">2A, 2C</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blocker Antimuscarinic</td><td style="text-align: center;">Migraine prophylaxis; carcinoid syndrome; postgastrectomy dumping syndrome</td></tr><tr><td style="text-align: center;">Metoclopramide</td><td style="text-align: center;">3</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">D</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{D}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blocker</td><td style="text-align: center;">Antiemetic</td></tr><tr><td style="text-align: center;">Methysergide</td><td style="text-align: center;">2A, 2C</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;">Carcinoid syndrome; migraine prophylaxis</td></tr><tr><td style="text-align: center;">Ketanserin</td><td style="text-align: center;">2A, 2C</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-adrenergic blocker</td><td style="text-align: center;">Migraine, hypertension</td></tr><tr><td style="text-align: center;">Mianserin</td><td style="text-align: center;">3, 2A, 2C</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-adrenergic blocker</td><td style="text-align: center;">Antidepressant</td></tr><tr><td style="text-align: center;">Atypical antipsychotics:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Clozapine</td><td style="text-align: center;">2A, 2C</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">D</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{D}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> antagonist</td><td style="text-align: center;">Schizophrenia</td></tr><tr><td style="text-align: center;">Risperidone</td><td style="text-align: center;">2A, 2C</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">D</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{D}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> antagonist</td><td style="text-align: center;">Schizophrenia</td></tr><tr><td style="text-align: center;">Others</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Alosetron</td><td style="text-align: center;">3</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;">Irritable bowel syndrome</td></tr><tr><td style="text-align: center;">Ondansetron</td><td style="text-align: center;">3</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;">Antiemetic</td></tr><tr><td style="text-align: center;">5-HT uptake inhibitors:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">(a) Selective (SSRI) &lt;br&gt; (Chapter 14)</td><td style="text-align: center;"></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, antimuscarinic</td><td style="text-align: center;">Antidepressant Obsessive compulsive disorder; Panic disorder</td></tr><tr><td style="text-align: center;">(b) Nonselective (Chapter &lt;br&gt; 14)</td><td style="text-align: center;"></td><td style="text-align: center;">NA- reuptake inhibitor</td><td style="text-align: center;">Antidepressant Obsessive compulsive disorder</td></tr><tr><td style="text-align: center;">5-HT depletors:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Reserpine</td><td style="text-align: center;">Depletion of intraneuronal stores of 5-HT and NA</td><td style="text-align: center;"></td><td style="text-align: center;">Antihypertensive; antipsychotic</td></tr></tbody></table>
<p>NA = Noradrenaline
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">H</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{H}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm">H</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Histamine
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">D</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{D}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm">D</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Dopamine
5-HT-receptor agonists: These compounds differ in their chemical structures and actions. The important agents are:
(1) 5-HT <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mrow><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">A</mi></mrow></mrow></msub></mrow><annotation encoding="application/x-tex">{ }_{1 \mathrm{~A}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4783em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mtight"><span class="mspace nobreak mtight"><span class="mtight">&nbsp;</span></span><span class="mord mathrm mtight">A</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonists e.g. Buspirone used as an antianxiety agent (Chapter 14).
(2) 5-HT <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mrow><mn>1</mn><mi mathvariant="normal">D</mi></mrow></msub></mrow><annotation encoding="application/x-tex">{ }_{1 \mathrm{D}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4783em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathrm mtight">D</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor agonists e.g. Sumatriptan used in the treatment of migraine (see later).
(3) 5-HT <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonists e.g. Cisapride used in the treatment of gastroesophageal reflux disease.
(4) Non-selective 5-HT agonists e.g. LSD (Chapter 14).</p>
<p>SUMATRIPTAN: This drug, an indole derivative (Fig 24.5), is a selective agonist of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">B</mi></mrow></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1 \mathrm{~B}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mtight"><span class="mspace nobreak mtight"><span class="mtight">&nbsp;</span></span><span class="mord mathrm mtight">B</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>1</mn><mi mathvariant="normal">D</mi></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1 \mathrm{D}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathrm mtight">D</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors located in cranial blood vessels and nerve terminals. Activation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo></mrow><annotation encoding="application/x-tex">5-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mord">−</span></span></span></span></span> <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{HT}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors leads to (a) blocking the release of several vasodilator neuropeptides, and (b) selective constriction of extracerebral, intracranial blood vessels. It also constricts other blood vessels such as the coronary. Triptans also reduce the increased concentration of</p>
<p>CGRP in migraine attacks (see later). Given orally, sumatriptan is highly effective in treating acute attacks of migraine.
<img src="assets/images/image-20251214-cc4c0ad7.jpeg" alt="img-6.jpeg"></p>
<p>Absorption, fate, excretion: The oral bioavailability is only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>14</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">14 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">14%</span></span></span></span></span>. It can also be given by nasal spray and SC. The drug is metabolised in the liver by MAO-A enzyme to an inactive metabolite. Its <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is about 2 hours. It does not cross the BB barrier.</p>
<p>Adverse reactions: These are usually mild to moderate in intensity. It may cause a sensation of flushing and heat at the injection site, neck pain, dizziness, asthenia and tingling in the hands. Occasionally it may cause myocardial ischemia due to coronary vasoconstriction. It is, therefore, contraindicated in patients with symptomatic IHD, angina or hypertension. It should not be combined with ergotamine and other vasoconstrictor drugs.</p>
<p>Although analogues of sumatriptan (triptans) such as Zolmitriptan, Rizatriptan, Almotriptan, Frovatriptan and Naratriptan, have been introduced, their superiority over sumatriptan has not been established. They differ in their other pharmacokinetic properties but cross the BB barrier.</p>
<p>Ergotamine: See Chapter 44.
Cisapride: This substituted piperidinyl benzamide compound is a prokinetic agent used previously for the treatment of gastroesophageal reflux disease and gastroparesis (Chapter 40). It is banned because of its cardiac toxicity.</p>
<p>5-HT antagonists: Apart from PCPA, 5-HT synthesis can be inhibited by alpha methyldopa, some halogenated tryptophans, and phenylalanine.</p>
<p>A number of compounds antagonise the actions of 5-HT on the tissues. These include lysergic acid diethylamide (LSD) and its derivative 2-brom LSD or BOL (Chapter 14). By acting as agonists on the inhibitory 5-HT autoreceptors, they inhibit the release of 5-HT from the neurons in the raphe nuclei. Other compounds like chlorpromazine, and yohimbine block the actions of 5-HT. Since there are multiple types of 5-HT receptors, a drug acting as an antagonist at one site may not act similarly at others. The 5-HT antagonists of therapeutic importance are:</p>
<p>METHYSERGIDE: Methysergide, a congener of LSD, is a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">A</mi></mrow></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{2 \mathrm{~A}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight"><span class="mspace nobreak mtight"><span class="mtight">&nbsp;</span></span><span class="mord mathrm mtight">A</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>2</mn><mi mathvariant="normal">C</mi></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{2 \mathrm{C}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mathrm mtight">C</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> antagonist. It is an effective prophylactic agent in the management of migrainous headaches. The protective effect of the drug develops within 24 to 48 hours after administration and persists for a similar period after its withdrawal. Rebound headaches may occur after sudden cessation of therapy. It is indicated for use in patients with resistant migraine but is of no value in treating an acute attack.</p>
<p>Methysergide is not used for diarrhoea due to carcinoid syndrome, because it has no action against the kinins released by the carcinoid tumour. Instead, somatostatin analogue octreotide (Chapter 63) which inhibits all the mediators released by the tumour is</p>
<p>preferred.
Adverse reactions: Significant toxicity is observed in almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> of the patients on chronic therapy. The serious toxic effects include peripheral arterial insufficiency, precipitation of angina, retroperitoneal fibrosis with obstruction of the urinary tract, pleuro-pulmonary fibrosis and cardiac valve damage. It is now rarely used because of its toxicity.</p>
<p>CYPROHEPTADINE: This compound (Fig 24.6), with structural resemblance to phenothiazines, is a potent antagonist of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors and to a certain extent of histamine and acetylcholine. As a central depressant it exhibits anticonvulsant and antitremor activities. Cyproheptadine is satisfactorily absorbed from the GI tract. The metabolic fate of the compound is not known.
<img src="assets/images/image-20251214-04b56320.jpeg" alt="img-7.jpeg"></p>
<p>It stimulates appetite probably by acting directly on the hypothalamus. Weight is gained rapidly during the first few weeks of therapy and is lost when the drug is stopped. There is evidence that 5-HT is involved in the control of ACTH secretion, possibly by stimulating corticotropin releasing factor (CRF) secretion from the hypothalamus. Administration of cyproheptadine can block the release of hydrocortisone and has, in fact, been used in the treatment of ACTH dependent Cushing's disease. It also suppresses aldosterone production in idiopathic aldosteronism.</p>
<p>The drug is available as 4 mg tablets. Dose: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">4-20 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day in divided doses.
Adverse reactions: The common adverse effect is transient drowsiness which seldom necessitates withdrawal of the drug. Other adverse reactions include dryness of mouth, mental confusion, ataxia, dizziness, headache and visual hallucinations.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Migraine prophylaxis: See later.</li>
<li>Treatment of postgastrectomy dumping syndrome and carcinoid syndrome; its 5-HT antagonizing action is probably useful.</li>
<li>Relief of pruritus associated with allergic dermatitis, urticaria and neurodermatosis. This action is probably due to its antihistaminic effect as the human skin does not contain significant quantities of 5-HT.</li>
<li>For symptomatic relief in seasonal and perennial pollinosis.</li>
<li>As an appetite stimulant in certain conditions.</li>
</ul>
<p>However, its promotion as a general appetite stimulant or tonic is not justifiable.</p>
<ul>
<li>In certain cases of Cushing's disease.</li>
</ul>
<p>PIZOTIFEN: This is an antihistaminic and 5-HT antagonist, structurally related to tricyclic antidepressants. It is effective in the prophylaxis of migraine and other vascular headaches. It may cause drowsiness, weight gain and urinary retention due to antimuscarinic action. Dose: 0.5 to 2.0 mg as a single dose at bedtime.</p>
<p>KETANSERIN: Ketanserin blocks 5-HT receptors, mainly 5-HT <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mrow><mn>2</mn><mi>A</mi></mrow></msub></mrow><annotation encoding="application/x-tex">{ }_{2 A}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4783em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mathnormal mtight">A</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and thereby antagonises vasoconstriction, platelet aggregation and bronchoconstriction. It has affinity for adrenergic alpha <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors which it blocks. It can cause lowering of blood pressure. The drug is used to improve digital circulation in patients with vasospastic conditions such as Raynaud's syndrome.</p>
<p>ONDANSETRON: This is a specific <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonist and is particularly useful as an antiemetic in nausea and vomiting following cytotoxic drugs and radiotherapy. Its action is partly central and partly peripheral. It is given orally in the dose of 8 mg 1 - 2 hours before treatment and in the same dose 12 hourly thereafter. The drug can also be given by slow IV infusion and as mouth dissolving tablets. It sometimes causes headache, constipation, allergic reaction and chest pain. Unlike phenothiazine, it causes neither sedation nor EPR (Chapter 41).</p>
<p>Granisetron, Alosetron and Palanosetron have similar antiemetic properties as ondansetron</p>
<p>CLOZAPINE: This atypical antipsychotic drug acts as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">A</mi></mrow><mi mathvariant="normal">/</mi><mn>2</mn><mi mathvariant="normal">C</mi></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{2 \mathrm{~A} / 2 \mathrm{C}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1.0385em; vertical-align: -0.3552em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3448em;"><span style="top: -2.5198em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight"><span class="mspace nobreak mtight"><span class="mtight">&nbsp;</span></span><span class="mord mathrm mtight">A</span></span><span class="mord mtight">/2</span><span class="mord mathrm mtight">C</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.3552em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonist and is used in the treatment of schizophrenia. Many other antipsychotic drugs have 5-HT antagonist action (Chapter 13).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacotherapy-of-migraine">Pharmacotherapy of Migraine<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacotherapy-of-migraine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Migraine, tension type of headache and cluster headache are grouped as primary headaches which occur without any exogenous cause. Migraine is an episodic headache, unilateral or bilateral, throbbing in quality and exacerbated by physical activity. It may be associated with GI, autonomic or behavioural disturbances. It is common in females. It shows a strong hereditary tendency. In practice, it is one of the most underdiagnosed and undertreated neurological disorders. It is classified as:</p>
<ul>
<li>Migraine with aura (classical migraine);. and</li>
<li>Migraine without aura (common migraine).</li>
</ul>
<p>Attacks of headache may be triggered by factors like food (chocolate, cheese) visual stimuli, impending menstruation, stress and relaxation after emotional tension. Classically, the headache is unilateral and may vary in duration from a few minutes to days. In 10-15% of cases, it is preceded by visual and neurologic phenomena such as scintillating scotomata and visual field defects. These are often accompanied by nausea, vomiting, diarrhoea and prostration. Rarely, migrainous headaches are due to structural lesions in the CNS like an aneurysm or an angioma.</p>
<p>Pathophysiology: Migraine is a neurovascular disorder where there is an interaction between the intracranial nerves and blood vessels. Its exact mechanism is not known. According to the current concept, migraine involves abnormal cortical activity leading to dilatation of meningeal blood vessels and activation of perivascular trigeminal nerve terminals. Activated nerve terminals release vasoactive neuropeptides within the meninges. Those peptides give rise to inflammation characterised by vasodilatation, mast cell degranulation and vessel leakage. In addition, they are also involved in the genesis of pain. The throbbing headache is mostly due to dilatation of pain- sensitive arteries.</p>
<p>Evidence suggests that calcitonin gene related peptide (CGRP) released from the trigeminal nerve terminals plays an important role in the genesis of migraine and other vascular headaches. The peptide is present in peripheral and central nervous systems. It is a potent vasodilator of the meningeal and cerebral blood vessels, and is probably important in regulating blood flow to the brain and the pain-sensitive meninges. It is also capable of causing the release of pro-inflammatory cytokines from the meningeal mast cells. Infusion of CGRP causes migrainous headache in susceptible subjects. Triptans which block the release of CGRP rapidly relieve the headache.</p>
<p>The aims of treatment of migraine are:</p>
<ul>
<li>To produce quick symptomatic relief by nonspecific analgesics.</li>
<li>To suppress the attack, using a specific triptan.</li>
<li>Prevention of further attacks by behavioural or pharmacological means.</li>
</ul>
<p>Non-pharmacological means for prevention include:
(a) Avoidance of precipitating factors such as loud noise, bright light, stress, certain foods and hypoglycaemia and
(b) The use of cognitive behaviour and relaxation therapy.</p>
<p>The behavioural approach involves education of the patient about the precipitating causes of attacks and their avoidance; a regular lifestyle with moderation in everything including regular meal hours, adequate but not excessive sleep, and minimising work-related and family stress.</p>
<p>Treatment of acute attacks: See Table 24.3. In all cases of migraine, aspirin (300-600 mg) or paracetamol ( 500 mg ) with or without metoclopramide should be tried in the first instance. If taken at the very onset of headache and repeated every 4 hours till the headache subsides, many patients may not need any more medication. Opioids such as codeine are considered unsuitable for routine use because of their dependence liability. If nausea is prominent, an antiemetic such as chlorpromazine or prochlorperazine may be added to the above medication. An adequate dose of one of the other NSAID (ibuprofen) is as effective as aspirin in relieving an acute attack of migraine. The NSAID may be used prophylactically if headaches are predictable, as in menstrual migraine. NSAID act by inhibiting PG synthesis, thus preventing neurologically mediated inflammation in the trigemino-vascular system. Prolonged, excessive use of any of the above medication can lead to chronic daily headache.</p>
<p>Table 24.3
Drugs used for treatment of migraine attacks</p>
<table><thead><tr><th style="text-align: center;">Drug</th><th style="text-align: center;">Dose (mg)</th></tr></thead><tbody><tr><td style="text-align: center;">Analgesic</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Aspirin</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>300</mn><mo>−</mo><mn>600</mn></mrow><annotation encoding="application/x-tex">300-600</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">300</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">600</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Paracetamol</td><td style="text-align: center;">600</td></tr><tr><td style="text-align: center;">Codeine"</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>60</mn></mrow><annotation encoding="application/x-tex">15-60</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">60</span></span></span></span></span></td></tr><tr><td style="text-align: center;">NSAID</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Naproxen</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>250</mn><mo>−</mo><mn>500</mn></mrow><annotation encoding="application/x-tex">250-500</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">250</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">500</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Ibuprofen</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>400</mn><mo>−</mo><mn>800</mn></mrow><annotation encoding="application/x-tex">400-800</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">400</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">800</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Diclofenac (IM)</td><td style="text-align: center;">75</td></tr><tr><td style="text-align: center;">Ketorolac (IM)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>120</mn></mrow><annotation encoding="application/x-tex">30-120</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">120</span></span></span></span></span></td></tr><tr><td style="text-align: center;">5-HT <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mrow><mn>1</mn><mi>D</mi></mrow></msub></mrow><annotation encoding="application/x-tex">{ }_{1 D}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4783em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathnormal mtight" style="margin-right: 0.02778em;">D</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonist</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Sumatriptan</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Oral</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>100</mn></mrow><annotation encoding="application/x-tex">25-100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span></span></span></span></span></td></tr><tr><td style="text-align: center;">SC</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">4-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Nasal Spray</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>40</mn></mrow><annotation encoding="application/x-tex">10-40</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">40</span></span></span></span></span></td></tr><tr><td style="text-align: center;">5-HT partial agonists/antagonists</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Ergotamine</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Oral</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>4</mn></mrow><annotation encoding="application/x-tex">1-4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Sublingual</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>4</mn></mrow><annotation encoding="application/x-tex">1-4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4</span></span></span></span></span></td></tr><tr><td style="text-align: center;">DHE (IV/IM-SC/Nasal Spray)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mi mathvariant="normal">/</mi><mn>1</mn><mo>−</mo><mn>3</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">1-2 / 1-3 / 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2/1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3/2</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Dopamine antagonists (Oral/IV)</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Metoclopramide</td><td style="text-align: center;">10</td></tr><tr><td style="text-align: center;">Haloperidol</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>10</mn></mrow><annotation encoding="application/x-tex">5-10</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">10</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Prochlorperazine</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">/</mi><mn>10</mn></mrow><annotation encoding="application/x-tex">25 / 10</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">25/10</span></span></span></span></span></td></tr></tbody></table>
<p>'Oral, unless specified
"For occasional use only.
Ergotamine tartrate ( 1 mg ) with or without caffeine ( 100 mg ) constitutes specific therapy. It is a partial agonist of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>1</mn><mi mathvariant="normal">D</mi></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1 \mathrm{D}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathrm mtight">D</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">B</mi></mrow></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1 \mathrm{~B}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mtight"><span class="mspace nobreak mtight"><span class="mtight">&nbsp;</span></span><span class="mord mathrm mtight">B</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors. A tablet is chewed and swallowed early during an attack, preferably during the preheadache aura phase. A repeat dose is</p>
<p>taken 45 min . later, if necessary. Not more than four tablets should be taken in 24 hours, nor more than 12 tablets per week. The drug can also be given rectally. Ergotamine may make the nausea of migraine worse; this may be pretreated with an antiemetic drug. It is also available in sublingual form ( 2 mg ). Dihydroergotamine (DHE) 1 mg SC together with pretreatment with an antiemetic is effective in many cases; its main disadvantage is the need for an injection. As the tissue binding effect of ergotamine on arteries persists as long as 24 hours, repeated doses may cause a cumulative effect. The drug can precipitate angina. Persistent, chronic headache may be a symptom of overtreatment with ergot preparations.</p>
<p>Ergot preparations are contraindicated in the presence of peripheral vascular disease or coronary artery disease. They should be avoided in hypertension, during pregnancy, and in hepatic and renal disease. Ergotamine should never be used in migraine prophylaxis.</p>
<p>The triptans are highly effective in the specific treatment of an acute attack of migraine and are now preferred in a moderate to severe attack. They are given orally, SC or by nasal spray. Orally, it is given in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25-50 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>, which may be repeated every 2 hours, if necessary, to the maximum total dose of 300 mg within 24 hours. It can also be given by nasal spray in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5-20 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>, repeated after 2 hours, if needed. It may be given SC in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>6</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">4-6 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">6</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> It is effective in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> of patients within 2 hours. Sumatriptan and zolmitriptan nasal sprays have a faster onset of action. A triptan should not be used until 24 hours after the last dose of ergotamine.</p>
<p>In resistant acute attacks, a 5-HT antagonist, either prochlorperazine 10 mg IV or haloperidol IM may be useful.</p>
<p>Telcagepant: This CGRP receptor antagonist is effective orally. It blocks the CGRP-receptor complex at several sites in CNS including trigeminal nucleus. It does not cause vasoconstriction. However manufacturers have terminated its further clinical development.</p>
<p>Migraine Prophylaxis: See Table 24.4. Preventive treatment is considered when attacks occur oftener than 2-3 times a month or are severe enough to limit normal activity; and when symptomatic therapy causes serious ADR. Medications containing vasodilators should be discontinued, if possible. Therapy is started with small doses, and the lowest effective maintenance dose be used; it may take as much as 3 months to show the desired result. If the therapy is effective, the attacks become less frequent and milder in intensity. Overuse of acute medication may reduce the efficacy of the preventive medication. If the response is good, the medication may be tapered gradually after 9-12 months. If headaches recur, the treatment should be restarted. Propranolol if used, should not be stopped abruptly.</p>
<p>Table 24.4
Drugs used for prevention of migraine attacks</p>
<table><thead><tr><th style="text-align: left;">Drug</th><th style="text-align: center;">Dose (mg)</th></tr></thead><tbody><tr><td style="text-align: left;">5-HT antagonists:</td><td style="text-align: center;"></td></tr><tr><td style="text-align: left;">Pizotifen</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1.5</mn></mrow><annotation encoding="application/x-tex">0.5-1.5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1.5</span></span></span></span></span> OD</td></tr><tr><td style="text-align: left;">Beta-adrenergic antagonists:</td><td style="text-align: center;"></td></tr><tr><td style="text-align: left;">Propranolol</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><msup><mn>240</mn><mo lspace="0em" rspace="0em">∘</mo></msup></mrow><annotation encoding="application/x-tex">40-240^{\circ}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6741em;"></span><span class="mord">24</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Atenolol</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>50</mn></mrow><annotation encoding="application/x-tex">25-50</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">50</span></span></span></span></span> OD</td></tr><tr><td style="text-align: left;">Antidepressants:</td><td style="text-align: center;"></td></tr><tr><td style="text-align: left;">Amitripty line</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>50</mn></mrow><annotation encoding="application/x-tex">10-50</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">50</span></span></span></span></span> OD</td></tr><tr><td style="text-align: left;">Calcium channel blockers:</td><td style="text-align: center;"></td></tr><tr><td style="text-align: left;">Verapamil</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><msup><mn>200</mn><mo lspace="0em" rspace="0em">∘</mo></msup></mrow><annotation encoding="application/x-tex">100-200^{\circ}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6741em;"></span><span class="mord">20</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Anticonvulsants:</td><td style="text-align: center;"></td></tr><tr><td style="text-align: left;">Valproic acid</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>300</mn><mo>−</mo><msup><mn>600</mn><mo lspace="0em" rspace="0em">∘</mo></msup></mrow><annotation encoding="application/x-tex">300-600^{\circ}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">300</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6741em;"></span><span class="mord">60</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Gabapentin</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1800</mn><mo>−</mo><msup><mn>2400</mn><mo lspace="0em" rspace="0em">∘</mo></msup></mrow><annotation encoding="application/x-tex">1800-2400^{\circ}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1800</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6741em;"></span><span class="mord">240</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Topiramate</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>100</mn></mrow><annotation encoding="application/x-tex">25-100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span></span></span></span></span> bid</td></tr></tbody></table>
<p>'Daily-divided
The 5-HT antagonists methysergide and pizotifen (discussed earlier) and the tricyclic antidepressant amitriptyline (Chapter 14) are effective for prophylaxis. Methysergide is a toxic drug and should be used only in resistant cases. Amitriptyline in the low dose of 5-10 mg at bedtime daily is especially useful in patients who have concomitant depression. Propranolol, a beta adrenergic blocker (Chapter 18), is considered the drug of choice in patients with attacks related to stress. Valproic acid and topiramate have been reported to be useful in some patients.</p>
<p>Menstrual migraine (attacks occurring during menses) is generally refractory and may need prophylactic treatment with amitriptyline/beta blocker, plus NSAID/ergotamine at the onset of menses. Oral diuretics are sometimes helpful in such cases as they counter fluid retention.</p>
<p>25</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="angiotensin-kinins-leukotrienes-prostaglandins-and-cytokines">Angiotensin, Kinins, Leukotrienes, Prostaglandins and Cytokines<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#angiotensin-kinins-leukotrienes-prostaglandins-and-cytokines" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>ANGIOTENSINS are peptide hormones derived from a protein precursor angiotensinogen (a serum globulin, also called renin substrate) by the sequential actions of proteolyltic enzymes in the circulation and several tissues. Angiotensinogen, synthesised by the liver, is converted by the circulating renin from the kidney into angiotensin I, a decapeptide. By itself, the latter is inactive. It is converted by angiotensin converting enzyme (ACE) located in the plasma and the capillary endothelial cells mainly in the lungs into the octapeptide angiotensin II. Angiotensin II is further converted to either angiotensin III or angiotensin IV. ACE is also found in various tissues including the brain, kidney and the adrenals. Local renin-angiotensin system in the tissues exists independently of the renal-hepatic based system.</p>
<p>ACE is nonspecific and it also acts on other natural substrates such as bradykinin, which it inactivates.</p>
<p>Angiotensin II is the most potent angiotensin. It can also be synthesised by a pathway that does not require ACE. It acts through G protein coupled receptors, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AT}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AT}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>.</p>
<p>Angiotensin III acts on the same <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AT}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AT}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors.
Most of the classic actions of angiotensin are mediated by the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AT}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors. Thus:</p>
<ul>
<li><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AT}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors
(i) mediate the vasoconstrictor action
(ii) stimulate aldosterone production and
(iii) promote cell growth and hypertrophy of the arterial and the ventricular wall muscle in the diseased and failing heart.</li>
<li><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AT}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors ameliorate the adverse effects of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AT}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor activation by inhibiting cell growth and hypertrophy. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AT}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors abound in several tissues in fetal life and may be involved in fetal tissue development and cell differentiation. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AT}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors are less abundant in adults; they are present in brain, adrenal medulla, vascular endothelium and reproductive tissues.
Actions of angiotensin II: It acts at several sites in the body (Table 25.1). It increases the peripheral resistance, prevents renal sodium excretion and modulates cardiovascular morphological structure. It is a 40-50 times more potent vasoconstrictor than NA on molar basis:</li>
</ul>
<p>Table 25.1
Actions of Angiotensin II via <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AT}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors</p>
<table><thead><tr><th style="text-align: left;">Tissue</th><th style="text-align: left;">Action(s)</th></tr></thead><tbody><tr><td style="text-align: left;">- Artery</td><td style="text-align: left;">Contraction and growth</td></tr><tr><td style="text-align: left;">- Heart</td><td style="text-align: left;">Contraction and ventricular hypertrophy</td></tr><tr><td style="text-align: left;">- Adrenal</td><td style="text-align: left;">Stimulates aldosterone biosynthesis</td></tr><tr><td style="text-align: left;">- Kidney</td><td style="text-align: left;">Inhibits renin release; stimulates sodium reabsorption; stimulates vasoconstriction (efferent glomerular arterioles in low concentrations, and &lt;br&gt; both afferent and efferent in higher concentrations); releases PGE</td></tr><tr><td style="text-align: left;">- Sympathetic &lt;br&gt; nervous system</td><td style="text-align: left;">Increased release of NA and adrenaline from autonomic ganglia and adrenal medulla respectively. Facilitates peripheral transmission</td></tr></tbody></table>
<ul>
<li>It causes rapid regulation of arterial BP in response to acute fall in BP, by constricting the arterioles, and to a smaller extent, venules.</li>
<li>Long term maintenance of BP (slow response) is mediated by regulation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> excretion by the kidney. Angiotensin II directly promotes renal <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>reabsorption in the proximal tubules, and also causes <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>retention through the release of aldosterone.</li>
<li>It also causes hypertrophy of the heart and thickening of the blood vessels (Chapter 66). Angiotensin II contributes to the pathogenesis of hypertension, cardiac hypertrophy, heart failure and diabetic renal disease. The direct action of angiotensin on some tissues stimulates the formation of counterregulatory substances, including vasodilating prostaglandins and nitric oxide. On the other hand, the target organs may release substances such as catecholamines, endothelin and growth factors, which may amplify the effects of angiotensin. The balance between the vasoconstrictors and the vasodilators determines the response of blood vessels to angiotensin II.</li>
<li>It stimulates vasopressin (ADH) and ACTH release. It increases the thirst.</li>
</ul>
<p>The ill effects of excess angiotensin II can be countered by:
(a) Angiotensin Converting Enzyme Inhibitors (ACEI) and
(b) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AT}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor blockers (ARBs) (Chapter 30).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="kinins">Kinins<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#kinins" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The kinins are vasoactive polypetides released from an alpha <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> globulin fraction of the plasma, termed as kininogens, by the action of enzymes termed kallikreins. Kininogens are present in two forms: (1) Low molecular weight kininogen (LMWK); and (2) High molecular weight kininogen (HMWK). HMWK is limited to the blood stream whereas LMWK can reach the tissues.</p>
<p>The kallikreins (Kallikreas, the Greek name for pancreas) are highly specific proteases, and exist in two forms: (a) plasma kallikreins, and (b) tissue kallikreins. Both normally exist in inactive forms called prekallikreins (PK).</p>
<p>Plasma prekallikrein is bound to its substrate HMWK; the protease inhibitors present in plasma prevent its proteolysis. When this system binds to a receptor complex on the endothelial cell membrane, it gets activated to kallikrein. The generated kallikrein activates clotting factor XII and cleaves HMWK to a nonapeptide, bradykinin.</p>
<p>Tissue prekallikrein is present in epithelial or secretory cells of salivary glands, pancreas, prostate, distal nephron and human neutrophils. The activation sequence of this tissue form is not well delineated but the active tissue kallikrein acts locally near the site of its origin. It converts HMWK and LMWK to a decapeptide, kallidin (lysyl bradykinin) (Fig. 25.1). Various factors such as tissue damage, infection, inflammation and allergic reactions can generate tissue kinins.
<img src="assets/images/image-20251214-892980dd.jpeg" alt="img-8.jpeg"></p>
<p>Both kallidin and bradykinin are referred to as 'plasma kinins' and have essentially identical pharmacological properties. In addition to kallikreins, various other serine proteases like trypsin and certain snake venoms are capable of generating kinins. Preformed kinins exist in the venoms of wasps and hornets.</p>
<p>Physiological role: The kinins are potent vasodilators. They may also modulate migration of leucocytes and tissue cells that take part in the inflammatory process. They are also most potent activators of PG-release, including <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> from vessels.</p>
<p>Bradykinin acts on two receptors: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">B_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>2</mn></msub><mi mathvariant="normal">.</mi><msub><mi>B</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">B_{2} . B_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">.</span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> are absent from the normal tissues and are induced by inflammation. In the absence of inflammation, most of the actions of the kinin are mediated through <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors which are constitutive.</p>
<p>Kinins have been incriminated in the processes of inflammatory and allergic reactions (asthma), shock, disseminated intravascular coagulation and inflammatory bowel disease. Pharmacological actions:</p>
<ul>
<li>Vessels and heart: The kinins have about 10 times the vasodilator activity as histamine. They produce mainly arteriolar dilatation in the skeletal muscle, heart, kidneys, intestines and liver, via the local release of nitric oxide and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. The kinins also have direct positive chronotropic and inotropic actions on the myocardium and in moderate doses, release adrenaline from the adrenal medulla.</li>
<li>Smooth muscle contraction: The kinins stimulate smooth muscles including those of the uterus, the bronchi and the GI tract. The term bradykinin was coined initially to signify the slow contraction of the GI smooth muscle by the nonapeptide. They promote epithelial ion transport and fluid secretion in the airways and GI tract, leading to cough/angioedema in the former and diarrhoea in the latter.</li>
<li>Genesis of pain: The kinins evoke pain (algesia) and itching on application to the base of a blister via the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors. NSAID can antagonise this pain producing property.</li>
<li>Vascular permeability: They are more potent than histamine in increasing vascular permeability and inducing edema.</li>
<li>Release of PGs and PAF: Kinins can cause the release of biologically active lipids such as platelet activating factor (PAF) and prostaglandins (PGs) from a variety of cells; some of the actions of kinins may be indirect via the release of such mediators of inflammation. The kinins are rapidly inactivated by the plasma and erythrocyte aminopeptidases and carboxypeptidases. They have very short plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of 15 seconds. The enzyme (ACE) that converts angiotensin I to angiotensin II also metabolises bradykinin.</li>
</ul>
<p>A high molecular weight polypeptide aprotinin, extracted from the parotid glands and lymph nodes of cattle, also present in mast cells, inhibits and inactivates kallikrein, trypsin and other proteolytic enzymes. It has been used in the treatment of acute pancreatitis, to prevent blood loss during open heart surgery, and in the treatment of hemorrhage due to hyperplasminemia (Chapter 33).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="leukotrienes-lts">Leukotrienes (LTs)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#leukotrienes-lts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Leukotrienes along with PGs, thromboxanes and lipoxins, are the major constituents of a group of eicosanoids. All the leukotrienes are derived from a common precursor, leukotriene <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">A</mi><mn>4</mn></msub><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">L</mi><mi mathvariant="normal">T</mi><mi mathvariant="normal">A</mi></mrow><mn>4</mn></msub><mo fence="true">)</mo></mrow></mrow><annotation encoding="application/x-tex">\mathrm{A}_{4}\left(\mathrm{LTA}_{4}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">A</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">LTA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span>; they are <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">L</mi><mi mathvariant="normal">T</mi><mi mathvariant="normal">B</mi></mrow><mn>4</mn></msub><mo separator="true">,</mo><msub><mrow><mi mathvariant="normal">L</mi><mi mathvariant="normal">T</mi><mi mathvariant="normal">C</mi></mrow><mn>4</mn></msub><mo separator="true">,</mo><msub><mrow><mi mathvariant="normal">L</mi><mi mathvariant="normal">T</mi><mi mathvariant="normal">D</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{LTB}_{4}, \mathrm{LTC}_{4}, \mathrm{LTD}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">LTB</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">LTC</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">LTD</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">L</mi><mi mathvariant="normal">T</mi><mi mathvariant="normal">E</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{LTE}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">LTE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>; the last three are also collectively known as slow reacting substance of anaphylaxis (SRS-A). They are produced locally and act as "local hormones". Their <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is very short.</p>
<p>The sites at which the LTs are synthesised are determined by the cellular distribution of the enzymes controlling the biosynthetic pathways. The enzymes involved are phospholipase <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">A</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{A}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">A</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and 5 -lipooxygenase (Fig. 25.4) The distribution of 5-lipooxygenase is limited to specific number of cells types: neutrophils, eosinophils, monocytes, macrophages, mast cells, basophils and B-lymphocytes. LTs exert their biological actions through specific ligand-receptor interactions.
<img src="assets/images/image-20251214-f10630c3.jpeg" alt="img-9.jpeg"></p>
<p>Pharmacological/biological actions: LTs have several potent actions. Thus, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">L</mi><mi mathvariant="normal">T</mi><mi mathvariant="normal">B</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{LTB}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">LTB</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> :
(1) Is the most potent neutrophil chemotactic agent and plays an important role in the induction of neutrophil-endothelial-cell adhesion.
(2) Causes the release of substantial quantities of glucuronidase and lysozyme from the neutrophils.
(3) Stimulates myelopoiesis and proliferation of T lymphocytes; and
(4) Is an important mediator of infiammatory pain.</p>
<p>LTC <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>4</mn></msub><mo separator="true">,</mo><msub><mrow><mi mathvariant="normal">L</mi><mi mathvariant="normal">T</mi><mi mathvariant="normal">D</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">_{4}, \mathrm{LTD}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">LTD</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">L</mi><mi mathvariant="normal">T</mi><mi mathvariant="normal">E</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{LTE}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">LTE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (SRS) are also called sulfidopeptides or cysteinyl LTs. They play an important role in the inflammatory process. They cause:</p>
<ul>
<li>Vigorous and sustained contraction of smooth muscle. They are the most potent bronchoconstrictors known and are involved in the pathogenesis of asthma.</li>
<li>Vasodilatation and modulation of vascular (venular endothelial) permeability, leading to</li>
</ul>
<p>the development of edema. They constrict the cutaneous and small coronary blood vessels.</p>
<ul>
<li>Increased mucus secretion in the airway; and</li>
<li>Immune modulation.</li>
</ul>
<p>Clinical implications of cysteinyl leukotrienes: LT release has been implicated in the pathogenesis of anaphylactic shock, asthma and various inflammatory diseases such as cystic fibrosis, glomerulonephritis, rheumatoid arthritis, psoriasis, inflammatory bowel disease and adult respiratory distress syndrome. Various LT synthesis inhibitors and antagonists are available for use in asthma (Chapter 27).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="prostaglandins-pgs">Prostaglandins (PGs)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#prostaglandins-pgs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>In 1930, Kurzrok and Lieb demonstrated the activity of human semen on isolated strips of human uterine muscle. This was confirmed by von Euler (1935) who demonstrated a substance present in the extracts of human seminal fluid, which caused contraction of the isolated intestinal and uterine muscle, and vasodilatation. This substance was named as prostaglandin because of its probable origin from the prostate. Bergstrom (Nobel prize, 1982) and associates showed that the various PGs are closely related derivatives of the lipid soluble prostanoic acid (Fig. 25.2). Although human seminal fluid is the richest known source, PGs are also present in extracts of other tissues such as iris, lung, human menstrual fluid, brain, thymus, pancreas and kidneys.
<img src="assets/images/image-20251214-1de23c73.jpeg" alt="img-10.jpeg"></p>
<p>Prostaglandin of the human semen is a mixture of six closely related substances belonging to the groups E, F, A and B. The other human tissues contain mostly groups E and F prostaglandins, though <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">D</mi></mrow><mn>2</mn></msub><mo separator="true">,</mo><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">G</mi></mrow><mn>2</mn></msub><mo separator="true">,</mo><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">H</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGD}_{2}, \mathrm{PGG}_{2}, \mathrm{PGH}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGD</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGG</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGH</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (Prostacyclin) have also been described. The corals, native to the Caribbean sea, contain large quantities of PGA as a natural constituent.</p>
<p>Chemistry and biosynthesis: Fatty acids (FA) occurring in natural fats are mostly straight chain aliphatic compounds, with even number of carbon atoms connected by C-C bonds, carboxy <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi><mi mathvariant="normal">O</mi><mi mathvariant="normal">H</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(\mathrm{COOH})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">COOH</span></span><span class="mclose">)</span></span></span></span></span> group at one end and methyl <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">H</mi></mrow><mn>3</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{CH}_{3}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">CH</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> group at the other. The FA may be saturated (SFA, no double bond); or unsaturated (UFA, with double bonds). The UFAs may be mono-unsaturated (MUFA with a single double bond) or; polyunsaturated (PUFA with two or more double bonds). The names of the SFAs end in -anoic e.g. prostanoic acid (Fig. 25.2) and of the UFAs in-enoic e.g. eicosapentaenoic acid.</p>
<p>Fatty acids serve many functions: energy production; electrical insulation; transport of plasma lipids; maintenance of cell membrane integrity; proper development of the CNS; participation in cell communication and oxygen transport; and regulation of inflammation. Animals can synthesise SFA from carbohydrates and some amino acids. However, unlike plants, they cannot synthesise the two PUFAs, linoleic acid (LA) and alpha linolenic acid (alpha-LNA), which are, therefore essential in animals. Using these two, animals</p>
<p>synthesise all other UFAs they need e.g. arachidonic acid, an important constituent of the cell membrane.</p>
<p>Eicosanoids are oxygenation products derived from 20 (eicosa) carbon UFAs: dihomo-gamma-linolenic acid (DGLA), arachidonic acid (AA) and eicosapentaenoic acid (EPA). They are ubiquitous both in animals and (together with the precursor oil) in various plants. AA is the major source of prostanoids (eicosanoids) in mammals.</p>
<p>The three respective series of eicosanoids viz, PG-1, PG-2 and PG-3 are defined by the number of double bonds in their side chains.</p>
<p>The PG-1 and PG-2 series are synthesised from LA (an omega-6 PUFA) and its derivative GLA via DGLA (G1 series), and from AA (G2 series), respectively. The PG-3 series is derived from alpha-LNA via EPA, an omega-3 fatty acid, and docosa-hexaeonic acid (DHA).</p>
<p>Almost all the tissues are capable of synthesising these lipid derived autocoids. Their biosynthesis is trigerred by trauma, infection and inflammation. During their synthesis AA is first released from the cell membrane phospholipids by lipases. It is then oxygenated by four separate routes including cyclo-oxygenase (COX) and lipo-oxygenase (LOX) (Fig. 25.4). Various factors determine the type of eicosanoid synthesised. Besides the cell type, an important factor is the nature of the precursor PUFA that is present in the respective membrane phospholipid. Nature of the substituents in the side chain determines the type (A, B, C, D, E, F) of the eicosanoid. The term omega is used to denote the position of the carbon atom ( 3,6 or 9 from the methyl end) after which the first double bond occurs in an FA. Prostanoids of PG-2 series carry the subscript 2 e.g. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">F</mi></mrow><mrow><mn>2</mn><mi>α</mi></mrow></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGF}_{2 \alpha}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGF</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mathnormal mtight" style="margin-right: 0.0037em;">α</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>.</p>
<p>The dietary sources of LA are polyunsaturated vegetable oils such as safflower, sunflower and corn oils, lean meats and eggs. Hydrogenation and heating of vegetable oils for production of margarine converts the cis FA present in the oil into trans FA; the latter behave like saturated FA metabolically and are considered atherogenic (Chapter 40).</p>
<p>Coconut oil and animal fats contain SFAs. They are atherogenic. Olive oil and canola oil contain the omega-9 MUFA; almonds, groundnut oil, til oil and mustard oil are the alternative sources. MUFAs are believed to protect from atherogenesis.</p>
<p>Arachidonic acid, a PG-2 series FA, is a constituent of the phospholipids normally present in the human cell membrane. It gives rise to derivatives, PGs of PG-2 series and LT (Fig 25.4), with marked pro-inflammatory activity. They have been incriminated in the pathogenesis of chronic inflammatory disorders such as psoriasis and RA.</p>
<p>Eicosapentaenoic acid and docosahexaenoic acid (both omega-3 PUFA), present in fatty sea-fish, when ingested regularly, can partially replace AA (of PG-2 series) with the less pro-inflammatory eicosanoids of the PG-3 series <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">X</mi><mi mathvariant="normal">A</mi></mrow><mn>3</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{TXA}_{3}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">TXA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> in the tissues, which may benefit patients with chronic, inflammatory diseases such as RA and psoriasis; it may also help to protect from atherosclerosis. The other dietary sources of omega-3 FA are flax seeds, nuts (particularly walnuts and hazelnuts), dark green leafy vegetables and soyabeans. The fatty fish contain EPA and DHA, and are a better source of omega-3 fatty acids than the vegetable sources which contain LNA but not EPA or DHA. It has been suggested that certain constituents of onions, apples and spices such as turmeric and red peppers (red chilly) may enhance the anti-inflammatory effect of omega-3 fatty acids.</p>
<p>Physiologically, tissue cells synthesise PGs at the site of action from the essential fatty acids LA and LNA (Fig. 25.3). The two principal mammalian PGs are <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">F</mi></mrow><mrow><mn>2</mn><mi>α</mi></mrow></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGF}_{2 \alpha}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGF</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mathnormal mtight" style="margin-right: 0.0037em;">α</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. PGs are very active even in very low concentrations and are degraded rapidly.</p>
<p><img src="assets/images/image-20251214-d7d95885.jpeg" alt="img-11.jpeg"></p>
<p>FIG. 25.3 Biosynthesis of eicosanoids from linoleic and alpha linolenic acids. PGs = Prostaglandins, leukotrienes etc. of Series 1, 2, 3. Those of PGs 1 and 3 are less inflammatory than those of PGs2 (see text).</p>
<p>The PGs A, B and C are artifacts that arise during extraction procedures.
Under stimulation by mechanical, thermal, chemical and bacterial insults, PGs are released in large amounts into the body Both <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (Fig. 25.4) are potent vasodilators and hyperalgesic agents. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is also a potent pyrogenic substance. In association with other mediators, PGs play an important role in the development of the inflammatory response.</p>
<p>Because of their instability, short duration of action and lack of tissue specificity, the natural PGs have limited clinical applications. Various synthetic derivatives available, however, overcome some of these limitations.</p>
<p>Pharmacological actions: PGs produce their effects by acting on PG receptors.</p>
<ul>
<li>Smooth muscles: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub><mo separator="true">,</mo><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">F</mi></mrow><mrow><mn>2</mn><mi>α</mi></mrow></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}, \mathrm{PGF}_{2 \alpha}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGF</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mathnormal mtight" style="margin-right: 0.0037em;">α</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">X</mi><mi mathvariant="normal">A</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{TXA}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">TXA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> stimulate the human myometrium and increase the intestinal motility. PGE inhibits the tone of tracheal and bronchial muscles and thus has a bronchodilator action.</li>
<li>Gastrointestinal system: Prostaglandins are distributed throughout the gut though their concentration varies in different parts,
(a) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> synthesised by COX-1 inhibit the gastric acid secretion, enhance the mucosal blood flow, and thus have a cytoprotective effect on gastric and duodenal mucosa.
(b) Both PGE and PGF cause contraction of the longitudinal muscle of the gut.
(c) Further, PGs stimulate intestinal fluid secretion and cause diarrhoea when given orally or parenterally. This suggests their possible role in certain diarrhoeas.</li>
<li>Cardiovascular system: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> are potent peripheral vasodilators. They mainly dilate the arterioles, and postcapillary venules. The blood flow to most organs increases. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">X</mi><mi mathvariant="normal">A</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{TXA}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">TXA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is a potent vasoconstrictor. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">F</mi></mrow><mrow><mn>2</mn><mi>α</mi></mrow></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGF}_{2 \alpha}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGF</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mathnormal mtight" style="margin-right: 0.0037em;">α</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, however, is neutral in this respect in humans. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (Alprostadil) is a potent relaxant of the smooth muscle of the ductus arteriosus and preserves the ductal patency in the newborn.</li>
<li>Kidney: The kidney cells that synthesise PGs contain mostly COX-1 (Chapter 11). Although PGs are not involved in maintaining the normal renal blood flow, their local production is important in maintaining blood flow in compromised kidneys. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> cause diuresis, natriuresis and kaliuresis by direct action on the renal tubules. PGE inhibits water reabsorption induced by ADH ; it also inhibits chloride reabsorption.</li>
<li>Reproductive system: Apart from their stimulant action on the uterine smooth muscle, PGs exert other actions on the reproductive system. In animal experiments, PGs cause</li>
</ul>
<p>regression of the corpus luteum (luteolysis) and reduction in secretion of progesterone. This can prevent the implantation of ovum. Both COX-1 and COX-2 are expressed in the uterine epithelium at different times in early pregnancy. COX-2 may play a role in the birth process and its excessive activity may be responsible for premature labour (Chapter 44). Functions of PGs present in the semen are not clear.</p>
<ul>
<li>CNS: The role of PGs as neurotransmitters has been suggested. COX-1 is distributed in neurons throughout the brain, being most prevalent in the forebrain. COX-2 is also expressed constitutively in a few areas. PGs are probably involved in the central mechanisms that cause hyperalgesia. Further, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is implicated in the causation of fever (Chapter 11).</li>
<li>Platelet aggregation: In the platelets, the only isoform detectable is COX-1. PG endoperoxide and thromboxane <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">A</mi><mn>2</mn></msub><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">X</mi><mi mathvariant="normal">A</mi></mrow><mn>2</mn></msub><mo fence="true">)</mo></mrow></mrow><annotation encoding="application/x-tex">\mathrm{A}_{2}\left(\mathrm{TXA}_{2}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">A</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">TXA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span>, cause platelet aggregation and vasoconstriction, while <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (Prostacyclin) which is found in the vascular endothelium is a potent inhibitor of platelet aggregation and causes vasodilatation. When the platelets are damaged they release PG endoperoxides which cause aggregation of platelets. However, the vascular endothelial <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> has anti-aggregatory effect. Damage to the endothelium reduces <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> synthesis and increases the tendency to thrombosis because of the unopposed action of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">X</mi><mi mathvariant="normal">A</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{TXA}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">TXA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. Aspirin blocks formation of both <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">X</mi><mi mathvariant="normal">A</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{TXA}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">TXA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> but COX-1 in the vascular endothelial cells regenerates so that <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> synthesis is reestablished. The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">X</mi><mi mathvariant="normal">A</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{TXA}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">TXA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> synthesis however, is irreversibly inhibited for the lifetime (8-10 days) of the platelets in circulation (Chapter 33).</li>
<li>Role in inflammation: Presence of PGE and kinins in the inflammatory exudates suggests their role in the genesis of inflammation. COX-2 is clearly associated with inflammation. Selective COX-2 inhibitors may control inflammation without affecting the beneficial effects of PGE on the stomach (Chapter 11).</li>
<li>Miscellaneous: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> block the lipolytic effect of adrenaline, ACTH and glucagon. They also produce pain when applied to an exposed blister base. Some PGs are potent bone resorbing agents which act by stimulating osteoclasts. Experimentally, bone destruction induced by implanted metastasising tumours in rats and rabbits, can be reduced by PG inhibition by aspirin or indomethacin. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> also stimulates the adrenal steroid production and insulin release.
Therapeutic uses of prostaglandins:
(1) As abortifacients and cervical ripeners (Chapter 44).
(2) As gastric cytoprotectives: Misoprostol <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>1</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{PGE}_{1}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> (Chapter 43).
(3) In erectile dysfunction: Alprostadil is injected intracavernosally (Chapter 69).
(4) For maintenance of patency of ductus arteriosus ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> analogue, Alprostadil IV) (Chapter 11).
(5) In the treatment of primary pulmonary hypertension, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (epoprostenol) by IV infusion, is effective.
(6) In the treatment of glaucoma (Latanoprost) (Chapter 72).
(7) For treatment of peripheral vascular disease (Epoprostenol).
(8) Post AMI to reduce infarct size (Iloprost).</li>
</ul>
<p>Endocannabinoids, derived from AA in the brain, are the endogenous ligands for the</p>
<p>cannabinoid receptors, and mimic some of the pharmacological actions of D9-tetrahydrocannabinol, dronabinol (Chapters 14 and 41).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cytokines">Cytokines<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cytokines" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Inflammation is an integral part of the body's defence mechanisms against foreign insults, and natural as well as acquired (specific) immunity play an important role in human defence. Several polypeptides are known to act as mediators of the inflammatory process.</p>
<p>The effector phases of both natural and acquired immunity are in large part mediated by protein hormones called cytokines, which are released from a variety of cell types in response to a number of stimuli (induced secretion). These cytokines activate, modulate and control various aspects of body defence and repair. In case of natural immunity, effector cytokines are mainly derived from the mononuclear phagocytes and the natural killer (NK) cells. Most cytokines in acquired immunity are released from activated T lymphocytes. T cells produce several cytokines that serve primarily to regulate the growth, differentiation and activation of various lymphocyte populations (constitutive secretion). They activate and regulate inflammatory cells such as monocytes, neutrophils and eosinophils.</p>
<p>Both lymphocytes and mononuclear phagocytes also produce other cytokines such as colony stimulating factors (CSF) which stimulate the growth and differentiation of immature lymphocytes in the bone marrow.</p>
<p>Like other polypeptide hormones, the cytokines act by binding to specific receptors on the surface of target cells. Such target cells may be (1) the same cells that secrete the cytokine (autocrine action); (2) nearby cells (paracrine action); or (3) distant cells as in the case of classical hormones (endocrine action).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="general-properties-of-cytokines">General properties of cytokines:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#general-properties-of-cytokines" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Cytokines are low molecular weight proteins secreted mainly by white blood cells and other cells, and are responsible for cell to cell communication. Many individual cytokines are produced by multiple types of cells.</li>
<li>They are produced during the effector phase of natural and acquired immunity and play an important role in mediating and regulating intensity and duration of immune and inflammatory responses, including the termination of the inflammatory response, angiogenesis, healing and repair.</li>
<li>They are not stored as preformed molecules. Their constitutive secretion is brief and self-limited. Failure of termination of their induced secretion can lead to chronic inflammatory disorders.</li>
<li>A given cytokine has different biological effects on different cell types (pleotropism).</li>
<li>Cytokines influence the synthesis of other cytokines, which may affect the other cells in turn. Thus, even if small number of cells are involved in the beginning, this cascade induction leads to amplification of the biological effects and involves a larger cellular network. It is also possible that cytokines may enhance or suppress the production of other cytokines.</li>
<li>Two or more cytokines may interact with each other to produce additive, synergistic or antagonistic effects.</li>
<li>For many target cells, cytokines act as regulators of cell division (growth factors). Classification of cytokines:
I Hematopoietin family (e.g. GM-CSF, erythropoietin, IL-2, IL-4);
II Interferon family (e.g. alpha, beta and gamma, IL-10);
III Chemokine family (e.g. IL-8, monocyte chemotactic protein, neutrophil activating</li>
</ul>
<p>protein, platelet factor 4); and
IV Tumor necrosis factor (TNF) family.
Cytokines can also be classified into four groups according to their functions (Table 25.2). IL-1 and TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> have many similarities in regard to physical and biochemical properties, synthesis and release, and they possess overlapping biological properties and functions.</p>
<p>Table 25.2
Cytokine groups according to functions</p>
<table><thead><tr><th style="text-align: center;">Group</th><th style="text-align: center;">Members</th><th style="text-align: center;">Major sources</th></tr></thead><tbody><tr><td style="text-align: center;">Mediators of natural immunity</td><td style="text-align: center;">Interferon <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span></td><td style="text-align: center;">Macrophages, fibroblasts</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span></td><td style="text-align: center;">Macrophages</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">IL-1</td><td style="text-align: center;">MNP, endothelial and epithelial cells</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">IL-6</td><td style="text-align: center;">Macrophages, endothelial cells</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">IL-8</td><td style="text-align: center;">Macrophages, epithelial cells</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">IL-12</td><td style="text-align: center;">Macrophages, dendritic cells</td></tr><tr><td style="text-align: center;">Regulators of lymphocyte activation, growth, and differentiation</td><td style="text-align: center;">IL-2</td><td style="text-align: center;">T cells</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">IL-4</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mi mathvariant="normal">H</mi></msub><mn>2</mn></mrow><annotation encoding="application/x-tex">\mathrm{T}_{\mathrm{H}} 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">H</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">2</span></span></span></span></span> cells; mast cells</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">IL-5</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mi mathvariant="normal">H</mi></msub><mn>2</mn></mrow><annotation encoding="application/x-tex">\mathrm{T}_{\mathrm{H}} 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">H</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">2</span></span></span></span></span> cells</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">TGF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span></td><td style="text-align: center;">T cells; macrophages; others</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">Interferong</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mi mathvariant="normal">H</mi></msub><mn>1</mn></mrow><annotation encoding="application/x-tex">\mathrm{T}_{\mathrm{H}} 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">H</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">1</span></span></span></span></span> cells, NK cells</td></tr><tr><td style="text-align: center;">Regulators of immune mediated inflammation and repair</td><td style="text-align: center;">Interferong</td><td style="text-align: center;">T cells; NK cells</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">IL-5</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mi mathvariant="normal">H</mi></msub><mn>2</mn></mrow><annotation encoding="application/x-tex">\mathrm{T}_{\mathrm{H}} 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">H</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">2</span></span></span></span></span> cells</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">IL-10, IL-17</td><td style="text-align: center;">T cells</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">IL-12 IL-18</td><td style="text-align: center;">Macrophages and dendritic cells</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">Lymphotoxin</td><td style="text-align: center;">Macrophages</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">MIF</td><td style="text-align: center;">T cells T cells</td></tr><tr><td style="text-align: center;">Stimulators of immature leucocytes, growth and differentiation</td><td style="text-align: center;">IL-3, IL-9</td><td style="text-align: center;">T cells</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">IL-7</td><td style="text-align: center;">Fibroblasts, bone marrow stromal cells</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">GM CSF</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">M CSF</td><td style="text-align: center;">MNP; endothelial cells; fibroblasts</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">G CSF</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Stimulation of erythropoiesis</td><td style="text-align: center;">Erythropoietin</td><td style="text-align: center;">Kidney</td></tr><tr><td style="text-align: center;">Stimulation of platelet production</td><td style="text-align: center;">Thrombopoietin, IL-11</td><td style="text-align: center;">Liver, Bone marrow</td></tr></tbody></table>
<p>TNF - Tumor Necrosis Factor
TGF - Transforming Growth Factor
MIF - Migration Inhibition Factor
CSF-Colony Stimulating Factor
GM - Granulocyte Macrophage
MNP - Mononuclear phagocytes
M - Macrophage
G - Granulocyte
IL - Interleukin</p>
<p>Functions of cytokines: The target cell responses that require cytokines fall broadly into the:
(i) Defence role of alerting the body to invasion and dealing with it, and
(ii) Repair role of cleaning up the debris and replacing lost matrix and tissue
(iii) Controlling cellular proliferation and differentiation. IL-1 also produces metabolic responses; thereby, the necessary energy resources and rebuilding materials are mobilised, and
(iv) Hematopoiesis.</p>
<ul>
<li>Role in body defence and regulation of inflammatory responses: IL-1 and TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> are mediators of biological responses to endotoxins and promote inflammation. IL-1 causes erythema, edema, chemo-attraction, and adherence as well as migration of defence cells into the sites of inflammation. IL-1 is responsible for the immune component of inflammatory diseases. Both can induce the burst in neutrophils and monocytes and the associated production of free radicals, myeloperoxide and hydrogen peroxide, that play an important role in killing the invading organisms. The cytokines activate the cells leading to release of hydrolytic enzymes and to increase in PG production. Inhibition and killing of stray tumour cells is yet another property of TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> and to a lesser extent of IL-1. These cytokines inhibit the replication of certain RNA and DNA viruses and induce viral resistance in a variety of cell types; this is not due to induction of interferons. Thus, many of the events associated with the acute inflammatory reaction and defence against infections of various kinds are mediated by IL-1 and TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>.
TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> and IL-2 are potent upregulators of several cell types including fibroblasts and T cells.
The cytokines secreted from subpopulation of helper T cells ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mi mathvariant="normal">H</mi></msub><mn>1</mn></mrow><annotation encoding="application/x-tex">\mathrm{T}_{\mathrm{H}} 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">H</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">1</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mi mathvariant="normal">H</mi></msub><mn>2</mn></mrow><annotation encoding="application/x-tex">\mathrm{T}_{\mathrm{H}} 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">H</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">2</span></span></span></span></span> ) are important determinants of the immune response generated to eliminate the pathogens. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mi mathvariant="normal">H</mi></msub><mn>1</mn></mrow><annotation encoding="application/x-tex">\mathrm{T}_{\mathrm{H}} 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">H</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">1</span></span></span></span></span> cells secretes interferon gamma and IgG which help in defence mechanisms. Cytokines from <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mi mathvariant="normal">H</mi></msub><mn>1</mn></mrow><annotation encoding="application/x-tex">\mathrm{T}_{\mathrm{H}} 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">H</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">1</span></span></span></span></span> cells prepare body to respond to viral and intracellular pathogens. On the other hand, IL-4 and IL-5 secreted from <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mi mathvariant="normal">H</mi></msub><mn>2</mn></mrow><annotation encoding="application/x-tex">\mathrm{T}_{\mathrm{H}} 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">H</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">2</span></span></span></span></span> cells induce production of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">IgE</mi><mo>⁡</mo></mrow><annotation encoding="application/x-tex">\operatorname{IgE}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mop"><span class="mord mathrm">IgE</span></span></span></span></span></span>. IL-5 is also responsible for eosinophil differentiation and activation; these defense mechanisms help to tackle helminth infections.</li>
<li>Role in body repair: Both IL-1 and TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> appear to have considerable influence on the earlier repair events of debridement, mitogenesis and differentiation. Release of enzymes including proteoglycanase, collagenase, and gelatinase can be induced from fibroblasts, synoviocytes and chondrocytes by IL-1, and the same is true for TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>. Enzyme release is accompanied by release of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, which may also contribute to the degradation process.
Biological actions of TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> : They are related to the quantity released. Thus:</li>
<li>At low concentrations: TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> acts as a paracrine and autocrine regulator of leucocytes and endothelial cells. These actions are useful in generating the inflammatory responses which help to counter the microbial infections. TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> is also an endogenous pyrogen, and acts on cells in the hypothalamus to produce fever, a property which it shares with IL-1.</li>
<li>Moderate amounts of TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> : enter the blood stream and may cause systemic effects, including an increase in the acute phase proteins (APP); further. TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> may be the</li>
</ul>
<p>mediator of matrix destruction in rheumatoid arthritis.</p>
<ul>
<li>Very high concentrations of TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> : on the other hand, cause depressed myocardial contractility, relaxation of vascular smooth muscle and intravascular thrombosis, leading to fall of BP, decreased tissue perfusion and metabolic acidosis; thus, TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> contributes in a major way to death in septic shock. It also causes depletion of hepatic and muscle glycogen. TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> and IL-1 both can induce bone resorption.
Overall, IL-1 and TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> possess the potential for mediating many of the events crucial to defence of the host, and subsequent repair; but by the same token they may also mediate much of the tissue destruction which characterises the connective tissue diseases.</li>
<li>Metabolic role: It is likely that the body wasting and cachexia seen with severe disease states is due to the catabolic properties of TNF.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, like cytokines, causes a rise in APP by different mechanisms. The severity and outcome of connective tissue diseases such as RA, and number of ischemic heart events during atherosclerosis correlate with APP levels.</li>
</ul>
<p>Other cytokines like IL-10 decrease cytokine and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> formation by monocytes. TGF beta which also serves as immunosuppresant, reduces inflammation and increases extracellular matrix formation required for repair. This activity of TGF beta is kept under control by interferon gamma which inhibits collagen production and also has myelosuppressive activity.</p>
<p>Although over 200 cytokines have been detected and shown to be involved in physiological functions, only a few have been shown to be clinically relevant.</p>
<p>Human recombinant IL-2 (Aldesleukin) though structurally different from native IL-2, enhances lymphocyte proliferation, cytotoxic and killer cell activity and IFN gamma activity, all of which contribute to activation of cellular immunity. It is presently used in therapy of melanoma and metastatic renal cell carcinoma.</p>
<p>For uses of gamma interferon, see Chapter 59; of growth factors, GCSF and GM- CSF, Chapter 35; and of TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> antagonists, Chapter 75.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="platelet-activating-factor-paf-acether">Platelet activating factor (PAF-acether):<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#platelet-activating-factor-paf-acether" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>This ether-linked phospholipid possess a wide range of activities. It is released during mast cell degranulation and is implicated in pathophysiological states including allergic inflammation, anaphylactic shock and bronchial asthma. It is also formed by eosinophils, macrophages, neutrophils, vascular endothelium and the renal medullary cells. Like the eicosanoids, PAF is not stored in the cells but is synthesised and released in response to stimuli.</p>
<p>PAF is a potent vasodilator. It activates most inflammatory cells and is believed to be responsible for mobilisation of eosinophils, neutrophils and/or platelets in lungs after exposure to the allergen. Intradermal injection of PAF in man causes a biphasic inflammatory response in the skin, with acute and late onset components similar to the response to moderate doses of allergens in sensitised individuals. Given by aerosol inhalation, it causes dose dependent broncho-constriction and inflammation of airways. Increased microvascular permeability causes edema of the airways. Further, it also induces non-specific bronchial hyper-responsiveness in non- asthmatic subjects. It promotes platelet aggregation and release of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">X</mi><mi mathvariant="normal">A</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{TXA}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">TXA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, acts as a chemotactic agent and is a gastric ulcerogen.</p>
<p>A substance called Ginkgolides isolated from the extract of the tree Ginkgo biloba has been used in China for the treatment of asthma and other disorders. It has been claimed to exert specific PAF receptor antagonistic activity. It causes inhibition of PAF induced platelet aggregation, of degranulation of isolated, human neutrophils, and of oxygen free radical production by the human neutrophils. Its possible use in the treatment of bronchial asthma and other allergic disorders is under investigation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="section-vi-br-drugs-used-in-respiratory-disorders">SECTION VI &lt;br&gt; Drugs Used in Respiratory Disorders<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#section-vi-br-drugs-used-in-respiratory-disorders" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="outline">OUTLINE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#outline" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Chapter 26: Pharmacotherapy of Cough
Chapter 27: Pharmacotherapy of Bronchial Asthma, COPD and Rhinitis</p>
<p>26</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacotherapy-of-cough">Pharmacotherapy of Cough<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacotherapy-of-cough" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Cough, a protective reflex, helps to expel irritant matter from the respiratory tract. This is necessary for preventing mechanical obstruction to breathing. Stimulation of the mucosal Rapidly Adapting Receptors (RAR) and C fibre receptors ending in the respiratory tract at sites such as pharynx, larynx, trachea or bronchi generate tussal impulses. These are carried by afferent fibres in the vagus and sympathetic nerves to the brain stem nucleus solitarius which is connected to the respiration-related neurons in the central cough generator (cough centre), which initiates the act of coughing. C fibre receptors are chemoreceptors, highly sensitive to bradykinin, capsaicin and H ions ( pH ).</p>
<p>The respiratory mucosa contains cells bearing cilia which transport the locally produced mucus towards the throat, from where it can be either coughed out or swallowed to keep the respiratory tract clean (mucociliary clearance). This mucociliary clearance can be defective or even absent in persons with immotile, dysfunctional or congenitally absent cilia. This leads to retention of secretions in the respiratory tract and recurrent respiratory infections including sinusitis and bronchiectasis. In turn, respiratory infection impairs the mucociliary clearance further, with worsening of the infection. Chronic cough is an important symptom in these patients.</p>
<p>The act of coughing involves an initial deep inspiration followed by forced expiration against a temporarily closed glottis. Closure of the glottis causes an increase in intrathoracic pressure. When the glottis opens suddenly, the pulmonary air is forced through the trachea almost at the speed of sound, throwing out the respiratory tract secretions as expectoration. The cough reflex has a tremendous reserve capacity and most coughs are greatly in excess of that required to expel particulate material. Furthermore, the strong expiration leads to a stronger succeeding inspiration and thus produces a vicious cycle in the form of a fit of coughing. Cough may be:</p>
<ul>
<li>Productive, associated with a large amount of sputum; or</li>
<li>Non-productive, dry and usually useless.</li>
</ul>
<p>Environmental pollutants may cause cough by irritating the lungs, trachea or bronchi. Smoking cigarettes is a well known cause of chronic persistent cough. Cough due to the inhalation of allergens such as dust, chemicals and pollen is commonly observed in asthmatics. The commonest cause of transient cough is common cold, and is due to postnasal drip that stimulates receptors in the upper respiratory tract. A similar mechanism probably operates in case of chronic persistent cough observed in persons with allergic rhinitis, chronic sinusitis and obstruction due to enlarged adenoids. Enlarged, infected tonsils, an abnormally elongated uvula or nasal polyps can also cause chronic persistent cough.</p>
<p>Other important causes of cough are:</p>
<ul>
<li>
<p>Upper respiratory tract infections, which may be self-limiting or persistent.</p>
</li>
<li>
<p>Acute lung infections and pleural diseases where therapy of the underlying cause will relieve cough.</p>
</li>
<li>
<p>Chronic pulmonary diseases like asthma, chronic bronchitis, bronchiectasis, tuberculosis and lung cancer where symptomatic treatment for cough is essential along with the specific therapy.</p>
</li>
<li>
<p>Secondary to acute LVF, which calls for immediate attention to the cardiac condition.</p>
</li>
<li>
<p>Gastroesophageal reflux disease (GERD): (Chapter 43).</p>
</li>
<li>
<p>Drug-induced cough: see Table 26.1.</p>
</li>
</ul>
<p>Table 26.1
Some drugs which induce cough</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>- ACE inhibitors such as captopril
</span>- Betablockers
- Inhaled corticosteroids and disodium chromoglycate
- Nebulised acetylcysteine
- Amiodarone
- Iodides
- Inhaled ether</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="- ACE inhibitors such as captopril
- Betablockers
- Inhaled corticosteroids and disodium chromoglycate
- Nebulised acetylcysteine
- Amiodarone
- Iodides
- Inhaled ether" style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>Outside the respiratory tract, disorders of the external auditory canal and ear drum, pericardium and even of stomach can give rise to chronic non-productive cough. Thus, wax impacted in the ear, inflammation or eczema or even irritation of the drum by hair can cause dry cough. The entity called 'psychogenic cough' induced voluntarily, is well known; it is non-productive and not present during sleep, usually becoming worse with emotional stress.</p>
<p>Definitive treatment of cough depends upon its cause which should be treated. Stoppage of smoking would correct chronic cough in smokers. Mild acute cough generally does not need drugs. Only when cough serves no useful purpose and causes insomnia, or interferes with daily work, symptomatic treatment is indicated.</p>
<p>In case of productive cough, the patient should be encouraged to cough voluntarily in appropriate posture from time to time. In cases of bronchiectasis or lung abscess, postural drainage aided by percussion of the chest is useful. Since inflamed trachea or bronchi are irritated by cold or dry air, a warm room with humid atmosphere is beneficial. Many patients with cough feel comfortable after a cup of warm tea or even warm water; and simple steam inhalation with or without tincture benzoin, menthol or eucalyptus oil effectively liquifies tenacious respiratory tract secretions (Hydroponic therapy).</p>
<p>Cough can be:
(1) Acute self limiting (less than 3 weeks);
(2) Subacute (3-8 weeks) or
(3) Chronic (more than 8 weeks).</p>
<p>Acute cough such as during and after common cold is usually due to upper respiratory viral infection. Non-viral causes include environmental pollution, asthma, cough-variant asthma and occupational exposure. From therapeutic point of view, chronic cough with normal chest X-ray can be either:
(a) Glucocorticoid responsive, due to eosinophilic disorders as in asthma, eosinophilic bronchitis and allergic rhinitis; or
(b) Inhaled glucocorticoid resistant e.g. postnasal drip, GERD, post-respiratory infection and drug induced.</p>
<p>Barking cough, stridor and chest wall withdrawal are characteristic of croup, common in children. Cough becomes worse at night. Nebulised budesonide or oral/IM dexamethasone <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>0.2</mn><mo>−</mo><mn>0.6</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">(0.2-0.6 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">0.2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.6</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>, single dose) gives dramatic relief. As dexamethasone effect lasts for 2-4 days, second dose is rarely required. Nebulised adrenaline gives immediate but short lived</p>
<p>relief.
Drugs used in the symptomatic treatment of cough classification:
I Pharyngeal demulcents and local sialogogues, e.g., Syrups and Linctuses.
II Expectorants which increase the respiratory tract fluid, e.g., Ammonium salt.
III Central cough suppressants,</p>
<ul>
<li>Opioids and related drugs e.g. Codeine, Dextromethorphan, Pholcodeine, Levopropoxyphene, Noscapine.</li>
<li>Non-opioids e.g., Caramiphene, Pipezethate.</li>
<li>Antihistaminics e.g. Diphenhydramine, Chlorcyclizine.</li>
</ul>
<p>IV Peripherally acting compounds:</p>
<ul>
<li>Local anaesthetics e.g. Benzonatate, Levodropropizine and Nebulised lignocaine.</li>
<li>Mucolytics that help by liquefying thick secretions e.g. Acetylcysteine; and</li>
<li>Anticholinergics e.g. Ipratropium bromide by metered dose inhalation (Chapter 27).</li>
</ul>
<p>Antitussives (tussis: Latin for 'cough') or cough suppressants are used for immediate symptomatic relief of dry cough and are not substitutes for the specific therapy of the underlying cause. They act either centrally or peripherally.</p>
<p>A mucoactive drug is defined as an agent with the capability of modifying mucus production, secretion, its nature and composition, or its interactions with the mucociliary epithelium. Mucoactive drugs include:
(i) Expectorants: which induce cough or increase the volume of secretions.
(ii) Mucolytics: which reduce the viscosity of mucus.
(iii) Mucokinetic drugs: which increase the mobility and transportability of mucus, and (iv) Mucoregulators: which control the process of hypersecretion.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharyngeal-demulcents">Pharyngeal Demulcents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharyngeal-demulcents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Demulcents are useful in cough due to irritation of the pharyngeal mucosa above the larynx. They are administered in the form of lozenges, troches, cough drops or linctuses. They act by increasing the flow of saliva, the best natural demulcent which produces a protective and soothing effect. The 'syrup' part of most cough syrups serves the same function. Salivary secretion can be increased by such simple methods as using a few lemon drops, candy sugar, glycerrhiza or drops of lemon juice in a syrupy base. Costly preparations like lozenges and troches containing multiple ingredients such as menthol and antiseptics are usually unnecessary and wasteful.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="expectorants">Expectorants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expectorants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The Latin word 'expectorare' means 'to drive from the chest'. Expectorants are the drugs which increase the production of demulcent respiratory tract fluid that covers and protects the irritated mucosa. These drugs are useful in the treatment of useless cough due to irritation of the respiratory mucosa below the larynx and respiratory conditions in which the secretion is thick and viscid, needing liquefaction.</p>
<p>Expectorants can stimulate the output of respiratory tract fluid either directly or reflexly (reflex expectorants).</p>
<p>Direct stimulants: Volatile oils like oil of eucalyptus, anise and lemon, administered orally or inhaled with steam, increase the respiratory secretions probably by a direct action. Alcohol and cedar wood oil (active ingredient terpene hydrochloride), added to steam inhalation, have a similar effect. Large doses of creosote and guaiacol have also been shown to possess this action in animals; and glyceryl guaiacolate forms an important ingredient of many commercial cough mixtures. Guaifenesin, in addition, inhibits coughreflex sensitivity in URTI. However, usefulness of these compounds is limited.</p>
<p>Reflex expectorants: These drugs act by stimulating the gastric reflex which helps to increase the respiratory secretions. Obviously, they produce mild irritation of the gastric mucosa and may produce nausea. Thus, emetic drugs in subemetic doses increase bronchial secretion producing a less tenacious sputum, easier to expectorate. Certain salts which produce such an action are called as saline expectorants.</p>
<p>Ipecacuanha containing an alkaloid emetine is sometimes used as an expectorant. Tincture ipecacuanha 1 ml may increase the respiratory tract fluid and lower the viscosity of the sputum. However, it often produces anorexia and nausea.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="saline-expectorants">Saline expectorants:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#saline-expectorants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Ammonium carbonate, once, used as a saline expectorant, causes anorexia and nausea. It is no more recommended.</p>
<p>POTASSIUM SALTS: Potassium iodide used commonly for this purpose, probably acts both directly and reflexly. It increases the respiratory secretion, and has a reputation for liquefying the thick, viscid fluid. It is generally advocated in productive cough associated with chronic bronchitis, asthma and emphysema. It is administered orally in a dose of 300 mg thrice daily in mixture form. The mixture has a slightly bitter saline taste.</p>
<p>Potassium iodide can cause symptoms of iodism, characterised by nasal catarrh, conjunctival swelling, edema of eyelids, lacrimation, edema of the larynx, headache and various types of skin rashes. Chronic administration occasionally gives rise to goitre and may rarely cause hypothyroidism. It should be avoided in children and pregnant women.</p>
<p>Potassium citrate, though less effective than potassium iodide, is less unpleasant.
The active alkaloid, vasicine, and its derivative vasicinone, from the leaves of Adhatoda vasaca, possess weak bronchodilator, expectorant and mucolytic properties. The aqueous extract of leaves of this plant in syrupy base appears to be safe and effective and has been used as a home remedy in India for ages.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="central-cough-suppressants">Central Cough Suppressants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#central-cough-suppressants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These drugs inhibit the cough reflex by directly suppressing the cough centre in the medulla and are useful in the symptomatic relief of dry irritant cough. They are only partially successful in suppressing cough due to carinal irritation. They are invaluable in the treatment of cough due to pleural diseases. Cough suppressants are particularly useful when complications of severe cough, such as rib fracture or cough syncope, produce discomfort. They should not generally be used in patients with productive cough, especially if they are elderly, not fully alert, or neurologically impaired. In general, cough suppressants do not impair voluntary coughing to clear secretions. Cough suppressants are not recommended in young children particularly those below the age of two years. They are:</p>
<p>CODEINE: This alkaloid of opium resembles morphine in its actions. Like morphine, it depresses the cough centre but is less constipating. Tolerance is not common and drug dependence is rare. A commonly employed preparation is linctus codeine which contains 15 mg of codeine phosphate in 5 ml . Dose: 5 ml by mouth. It can also be used as an analgesic. It is a relatively safe drug and its only bothersome adverse effect is constipation. Codeine preparations are not recommended in children.</p>
<p>Codeine is unlikely to be effective in the distressful cough of terminal lung cancer. In that condition, diamorphine linctus ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">3 \mathrm{mg} / 5 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/5</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> ) in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">2.5-10 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> every 4 hours or methadone linctus ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">2 \mathrm{mg} / 5 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/5</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> ) in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo>−</mo><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">2.5-5 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> every 4 hours is likely to be effective.</p>
<p>With several opioids, the dose required to suppress cough is lower than the analgesic dose.
DEXTROMETHORPHAN HYDROBROMIDE: It is the d-isomer of codeine analogue methorphan. However, it does not act through the opioid receptors and has no analgesic or sedative property. This has led to the belief that distinct receptors (other than the usual opioid receptors) mediate the antitussive action of opioids. It acts centrally to elevate the threshold for coughing. It is as effective as codeine and is much safer; hence, it is commonly used in pediatric practice. It does not depress respiration in the usual doses. It can sometimes cause excitement, irritability and confusion. Adult dose: 10-20 mg every 6-8 hours (maximum <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>120</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">120 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">120</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day). It is a drug of abuse.</p>
<p>Levopropoxyphene mesylate: This levo-isomer of dextropropoxyphene, in the dose of 50100 mg , appears to be as effective as an antitussive as 30 mg of dextropropoxyphene. It has no analgesic activity.</p>
<p>Pholcodeine, though related to opioids, has no opioid-like action. It is as effective as codeine as a cough suppressant, with a longer duration of action. It is non-sedating and non-addicting. It is a common constituent of OTC cough mixtures.</p>
<p>NOSCAPINE: This opium alkaloid, belonging to benzylisoquinoline group, is a smooth muscle relaxant like papaverine. Its antitussive action is approximately equal to that of codeine. It does not produce constipation or drowsiness. Addiction does not occur. Sometimes it causes nausea. The antitussive dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mn>3</mn><mo>−</mo><mn>4</mn></mrow><annotation encoding="application/x-tex">15-30 \mathrm{mg} 3-4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4</span></span></span></span></span> times a day. Large doses can cause bronchospasm and hypotension due to histamine release.</p>
<p>The other synthetic compounds used include oxeladine, pipezethate and piperidone. There is no convincing evidence about their superiority over codeine. All cough suppressants are dangerous in the presence of excessive secretions as failure to expel them may produce mechanical obstruction and atelectasis of the lung. They are also contraindicated in the presence of respiratory failure.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="peripherally-acting-agents">Peripherally Acting Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#peripherally-acting-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Benzonatate, chemically related to procaine, probably acts on the stretch and cough receptors in the lungs. It also possesses some central action and can cause sedation and headache. It is not recommended below the age of 10 years. The dose is 100 mg tid.</p>
<p>Levodropropizine and moguisteine are other non-opioid antitussives. The mechanism of action and uses of the former are similar to those of benzonatate; mechanism of action of moguisteine remains to be elucidated.</p>
<p>Lignocaine in nebulised form is used for suppressing cough during pharyngeal examination, bronchoscopy and persistent cough in bronchial carcinoma.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="other-antitussives">Other Antitussives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#other-antitussives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Cough may be the only symptom of bronchial hyper-responsiveness, including asthma. Bronchodilators are useful in these cases, as bronchospasm aggravates and may even initiate cough. The drugs commonly used are: salbutamol and orciprenaline, usually given by inhalation (Chapter 27).</p>
<p>An inhaled glucocorticoid (Chapter 26) may be prescribed for a short period (2-3 weeks) for symptomatic treatment of persistent cough following a viral respiratory infection.</p>
<p>Therapeutic usefulness of antihistaminics as antitussives is limited to the cases where cough is due to conditions associated with post-nasal drip. They are of little value in allergic bronchospasm and may even have a deleterious effect because of their drying effect on the bronchial secretion. Antihistaminics with a sedative action (eg. diphenhyramine) may be useful in children who do not sleep because of cough, provided no contraindication to their use (such as bronchial pathology) exists. However, they may occasionally cause paradoxical excitement. Antibiotics are useful in controlling cough due to respiratory infections.</p>
<p>Sympathomimetic decongestants present in some cough mixtures can cause nervousness, insomnia, hallucinations, hypertension and dystonic reactions especially in children.</p>
<p>Some commercially available preparations promoted for cough and cold contain phenylpropanolamine (PPA). However the use of PPA in cough mixtures has been banned as it may cause hemorrhagic stroke. The safety of other oral decongestants such as pseudoephedrine and phenylephrine is unclear.</p>
<p>The commonest cause of cough is common cold, a viral infection which usually clears within 7 days. Most of the proprietary preparations available as "cough remedies" generally contain a central cough suppressant, an expectorant, an antihistaminic, a bronchodilator and a decongestant in pleasantly flavoured syrupy base. Such remedies may dry up the secretions, prevent natural drainage, cause drowsiness and suppress cough, a protective reflex that helps to get rid of infective material. Multiplicity of such preparations itself indicates that there is no ideal remedy for 'cough'.</p>
<p>Chronic cough hypersensitivity syndrome is characterized by refractory cough not responding to conventional antitussives. It is believed to be due to cough hypersensitivity, abnormal laryngeal and pharyngeal sensations, allotussia and urge to cough. Gabapentin which inhibits central sensitization has been claimed to help patients with chronic cough syndrome.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mucolytic-agents">Mucolytic Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mucolytic-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These drugs are used to make the sputum thin and less viscid, so that it can be easily expectorated. Many patients with chest disease become dehydrated and adequate hydration along with steam inhalation or aerosolised water inhalation can help to liquify viscid sputum. Finally, oxygen should never be administered without adequate humidification as dry oxygen causes drying of the respiratory mucosa (Chapter 77).</p>
<p>ACETYLCYSTEINE: This derivative of a naturally occurring amino acid, 1-cys-teine, reduces viscosity of sputum in vitro. The drug is rapidly metabolised in the body. Clinically, 2 ml of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> solution is nebulised into a face mask every 8 hours for 5-10 days to liquefy viscous tracheobronchial secretions. It can also be administered by direct instillation into the tracheobronchial tree through a tracheostomy, a bronchoscope or a percutaneous intratracheal catheter, or as an aerosol.</p>
<p>Adverse reactions include bronchospasm, fever, nausea, vomiting, stomatitis, rhinorrhoea and haemoptysis. It reacts with most metals and with rubber.</p>
<p>Carbocysteine and methylcysteine have similar properties as acetylcysteine. They can be given orally or by inhalation.</p>
<p>BROMHEXINE: This is a synthetic benzylamine derivative of alkaloid vasicine obtained from the plant Adhatoda vasaca. It is given orally, parenterally and by inhalation. Experimentally, the drug reduces the viscosity of sputum by dissolving mucopolysaccharide fibres. It is usually administered in doses of 8-16 mg thrice daily. Adverse reactions are minor and infrequent. It can be combined with bronchodilators.</p>
<p>AMBROXOL: This, active metabolite of bromhexine, is used orally ( 15 mg tid) as an alternative to bromhexine.</p>
<p>Dornase alpha: This phosphorylated, glycosylated, recombinant, human deoxyribonuclease, given by nebulisation, can decrease the viscosity of purulent sputum by cleaving long strands of denatured DNA that are released by degenerating neutrophils. It acts extracellularly and does not affect living material. It improves lung function and is well tolerated. It is moderately effective in patients with cystic fibrosis.</p>
<p>It must be remembered that cough serves the useful purpose of clearing the respiratory tract. It should not be severely obtunded in patients with productive cough. Use of antitussives in sedated or debilitated patients may prove dangerous. They should be used cautiously in the acute phase of pertussis and bronchial asthma, as inspissation of mucus plugs may contribute to fatal outcome. The possible anti-tussive effect of pain relieving drugs such as morphine must be kept in mind while prescribing them in post-operative patients. Finally, cough suppressants, especially in syrupy base, should be kept out of the reach of small children, as poisoning with them has been reported.</p>
<p>27</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacotherapy-of-bronchial-asthma-copd-and-rhinitis">Pharmacotherapy of Bronchial Asthma, COPD and Rhinitis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacotherapy-of-bronchial-asthma-copd-and-rhinitis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Bronchial asthma is a heterogenous group of conditions, which affects people worldwide, from infancy to old age. It is a clinical syndrome characterised by recurrent cough/paroxysmal dyspnea, chest tightness and wheeze due to increased resistance to air flow through the narrowed bronchi. This narrowing is brought about by:</p>
<ul>
<li>Bronchial hyperreactivity and bronchospasm.</li>
<li>Cellular infiltration and edema of the bronchial mucosa; and</li>
<li>Blockage of the bronchial lumen by inspissated mucus.</li>
</ul>
<p>Patients with asthma have increased susceptibility of developing chest symptoms when infected (rhinovirus)</p>
<p>The diagnosis of asthma is made in a patient with reversible obstructive airway disease by objective evidence of variability in ventilatory function over time or improvement following bronchodilator treatment.</p>
<p>Pathophysiology: The etiology of bronchial asthma is multifactorial: genetic, developmental, environmental, inflammatory and immunological. Its pathogenesis is complex and involves:
(a) Inflammation due to infiltration of eosinophils, mast cells, CD4 lymphocytes,
(b) Mucus cell hyperplasia, and
(c) Re-modelling of the airways with fibrosis</p>
<p>The major role of Th2 (T-helper type 2) cells in pathogenesis of asthma is now recognized.</p>
<p>Many patients have had well defined allergen exposures which are partly or substantially responsible for the asthmatic inflammation. These patients (even the asymptomatic ones, with normal lung function and no recent acute asthmatic episode) have inflamed airways and infiltration with mast cells, eosinophils, basophils, macrophages and activated helper T lymphocytes. Lymphocyte-directed eosinophilic bronchitis is the hallmark of asthma. Mediators released from the cells, damage the bronchial epithelium. Such subacute mucosal inflammation and disruption of the protective epithelial barrier on the mucosal surface contribute to bronchial hyper-responsiveness, an exaggerated response to a variety of stimuli (asthmatic diathesis). This inflammation is clinically silent with no apparent bronchoconstriction during the basal state of the disease.</p>
<p>Exposure to an antigen causes cross-linking of IgE bound to the surface of mast cells (Fig 27.1). A clinical acute attack is produced when the concerned antigen binds to the mast cell which gets activated and degranulated, with the release of histamine and various cytokines. This causes immediate bronchial reactions (Early Reaction) leading to bronchospasm, local vasodilatation, increased capillary permeability, edema, and chemotaxis, with consequent influx of more inflammatory cells into the walls of the bronchi. The newly arrived cells release inflammatory mediators such as PG, LT etc. which aggravate the airway inflammation and cause more sustained bronchoconstriction (Late Phase Reaction). The final common pathway for a clinical attack of asthma is the release of many mediators (Table 27.1) from a variety of inflammatory cells.</p>
<p>Table 27.1
Some important mediators released by mast cells and leucocytes
<img src="assets/images/image-20251214-aa8c5436.jpeg" alt="img-12.jpeg"></p>
<p>FIG. 27.1 Mast cell dependent immediate and late phase reactions
An attack may also be triggered by factors like viral infection, irritants like dust and other air pollutants, cold air, exercise, drugs, chemicals and histamine. The airway hyperresponsiveness may persist for weeks after the acute insult has abated.</p>
<p>Majority of asthmatics ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> ) are atopic, forming IgE antibody on exposure to common environmental allergens, house-dust, mites, cockroaches, pets, pollen and so on. In such atopic subjects, challenge of the airways with allergens to which they are specifically sensitive triggers early and late phases of bronchoconstriction. Mast cells are important in the acute airway response to an allergen and also contribute to their remodelling in chronic asthma.</p>
<p>The early reaction is rapid in onset, reaching maximum in 15-30 min. after challenge and recovering over next 24 hours.</p>
<p>Late-phase bronchoconstriction response begins 4-6 hours after challenge and lasts for up to 24 hours. During this late phase reaction, the airways become non-specifically hyperresponsive to stimuli such as histamine, which may last up to two weeks after a single allergen exposure. During this late (but not early) reaction, there occurs influx of neutrophils, eosinophils and macrophages into the airways which suggests their role in the pathogenesis of this reaction. The acute inflammatory response usually resolves with the repair process restoring normal lung structure and function.</p>
<p>In chronic asthma, the recovery is incomplete due to ineffective repair. This leads to remodelling of the airway structure. Persistent epithelial damage and the loss of its protective function expose the deeper airway structures to further insults, and promote persistent inflammation and cellular infiltration. Various mediators released cause angiogenesis, smooth muscle proliferation, fibrosis and airways thickening, causing persistent obstruction to airflow.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="asthma-is-considered-as">Asthma is considered as:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#asthma-is-considered-as" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Extrinsic when it is associated with history of atopy in patient's childhood, a family history of allergies, illnesses like hay fever, positive skin tests, and raised serum IgE level. This is the commonest form and it starts in childhood or at an early age and usually manifests clinically in 'episodic form;' and</li>
<li>Intrinsic when it occurs in middle aged subjects with no family history of allergies, and clinically assumes a 'chronic form'; there is a lack of identifiable allergen; plasma IgE is not raised.
This classification would appear to imply that there is an allergic factor in extrinsic asthma but none in intrinsic asthma. This is not strictly true and an allergic factor may be involved in many cases of intrinsic asthma as well.</li>
</ul>
<p>Currently, based on molecular phenotyping asthma can also be classified as:
I Th2 high phenotype
II Th2 low phenotype.
Patients expressing high Th2 can be further subdivided into:</p>
<ul>
<li>Early onset allergic asthma which is associated with high levels of Th2 cytokines and IgE and respond to corticosteroids and Th2 targeted therapies; and</li>
<li>Late onset eosinophilic asthma, that occurs with increased severity and high levels of IL5 and eosinophilia. These patients respond poorly to corticosteroids but respond to leukotriene modifiers and IL-5 antibody.
Patients expressing low Th2 can be further subdivided into:
(a) Obesity related, seen frequently in adolescent and adult women, is characterized by absence of Th2 cytokine and respond to antioxidants, weight loss programs and possibly hormonal therapy; and
(b) Neutrophilic adult onset asthma, which is associated with neutrophilia, high levels of Th17 and IL-8 and respond to macrolide antibiotics.</li>
</ul>
<p>Irrespective of type of asthma, persistent bronchial narrowing causes hyperinflation of the alveoli and disruption of alveolar walls with loss of elastic tissue (emphysema-like picture). It promotes infection distal to the obstruction and leads to hypoxemia (reduction in arterial <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">O</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{O}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> tension) and hypercapnia (increase in arterial <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> tension). Prolonged</p>
<p>hypoxemia may cause pulmonary hypertension and right ventricular failure. Hypercapnia causes cerebral vasodilatation, rise in intracranial tension, mental confusion, twitching, drowsiness and finally coma. In severely ill patients, unregulated treatment with oxygen aggravates hypercapnia and the respiratory failure.</p>
<p>Prolonged asthmatic attacks produce dehydration as the patient cannot eat or drink.
Clinically, bronchial asthma presents as:
I Mild intermittent asthma: The patient gets discrete, infrequent, acute attacks, which are relieved by bronchodilators, with no disability between the attacks. There is often a recognisable precipitating factor such as allergy, an upper respiratory tract infection or psychological trauma.
II Chronic persistent asthma: This is generally due to the presence of chronic inflammation and thickening of mucosa of the bronchioles with resultant excessive secretion of mucus, decreased elastic recoil of the lung tissue and finally hyperreactivity of the bronchi with bronchospasm. Symptoms are persistent and relief of bronchospasm with drugs is incomplete.</p>
<p>Chronic form can be subdivided into mild, moderate and severe grades, depending on the interference with daily activities and with sleep, and the degree of incapacity. Clinically, there is more or less persistent dyspnoea and wheeze, with superadded acute attacks. In some patients, chronic asthma co-exists with COPD.</p>
<p>III Severe acute asthma (Status asthmaticus): This is a condition where an acute attack is severe, persistent and does not respond to standard treatment. It is accompanied by evidence of respiratory insufficiency or failure.
IV Exercise-induced bronchospasm in which the attack is precipitated by exercise or by inhalation of cold air.</p>
<p>Principles of therapy: Control of asthma involves:
(1) Environmental control
(2) Pharmacological therapy; and
(3) Treatment of co-morbidities</p>
<p>Environmental control involves avoidance of triggers (respiratory irritants like infection and smoking and environmental/ocupational pollutants) and allergens (dust, mite, pollen, etc.), if known. However, only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">1 / 3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0991em; vertical-align: -0.25em;"></span><span class="mord">1/</span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> of the patients show symptomatic recovery after avoidance of such exposure.</p>
<p>Aims of Pharmacological therapy are:
(1) Relieving bronchospasm
(2) Reducing bronchial inflammation; and
(3) Prevention of repeated attacks. Bronchodilators and anti-inflammatory drugs are the mainstay of the therapy.</p>
<p>Treatment of co-morbidities include treatment of infection, correction of dehydration and acidosis in severe acute attack, controlled administration of oxygen, when needed.</p>
<p>In addition, a programme of graded exercise training is advised to improve the sense of well being and exercise tolerance. As physial excercise tends to precipitate acute attacks in some patients, an exercise which does not precipitate such attacks (e.g., swimming) is preferred in these patients. Psychological treatment by itself, is rarely of much help, except in functional cases. However, a sympathetic discussion of the patient's problems and patient education about his disease are very helpful.</p>
<p>All these measures, when successful, enable the subject to live as normal a life as possible, including normal exercise tolerance, without experiencing severe adverse drug reactions.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antiasthmatics-classification">Antiasthmatics - classification:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antiasthmatics-classification" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-bronchodilators">I Bronchodilators:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-bronchodilators" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Selective beta-2 adrenergic receptor agonists:
(a) Short acting e.g. Salbutamol, Isoetharine, Bitolterol, (a prodrug), Fenoterol and Rimeterol; (b) Long acting Salmeterol, Formoterol, Arformoterol, Indacaterol</li>
<li>Non-selective beta adrenergic agonists e.g. Orciprenaline, Adrenaline and Ephedrine.</li>
<li>Phosphodiesterase inhibitors: Theophylline derivatives - Aminophylline.</li>
<li>Anticholinergics such as Ipratropium bromide, Tiotropium, Aclidinium</li>
</ul>
<p>II Anti-inflammatory drugs:</p>
<ul>
<li>Glucocorticoids.</li>
<li>Leukotriene (LT) modifiers:
(a) LT receptor antagonists: Montelukast; Zafirlukast.
(b) LT synthesis inhibitors: Zileuton;</li>
<li>Mast cell stabilisers: Sodium cromoglycate; Nedocromil.</li>
<li>PAF antagonists: Ketotifen.</li>
</ul>
<p>III Anti-IgE antibody: Omalizumab.
As the pathophysiology of asthma is restricted to the airways, direct, local delivery of drugs to the airways is the preferred method of administration. This route is convenient, promptly effective and reduces the systemic toxicity. It is carried out by using:
(1) Pressurised, metered dose (aerosol) inhalers (MDI) which deliver small doses of the drugs.
(2) Nebulisers which deliver much larger doses with minimal efforts from patients, and
(3) Dry powder inhalers (DPI): The disadvantages of this method are the irritation of the airways; less stability during storage; and the difficulty that the children, the old and the very ill may have in generating the high inspiratory air flow needed to operate the system.</p>
<p>Nonadherence to regular inhaled therapy and faulty inhalation technique are important causes of treatment failure. Patients who find the inhalation route inconvenient or difficult to follow are given oral drug therapy which invariably causes more systemic adverse effects.</p>
<p>With all the methods of local administration, only about 10-30% of the administered drug reaches the desired site, the distal bronchial tree. The rest is swallowed but undergoes first pass metabolism, thus minimising the systemic adverse effects.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-during-an-acute-attack">Drug Therapy During an Acute Attack<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-during-an-acute-attack" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Drugs used to produce quick relief from acute attack are called rescue drugs. Selective short acting <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> adrenergic receptor agonists (SABA) are the rescue drugs par excellence as both airway smooth muscle and mast cells have <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> adrenergic receptors. They:</p>
<ul>
<li>Relax the smooth muscle of all airways from trachea to the terminal bronchi, irrespective of the spasmogen involved. Therefore, they serve as physiological antagonists.</li>
<li>Enhance mucociliary clearance from the respiratory tract.</li>
<li>Suppress microvascular leakage in the airway.</li>
<li>Inhibit mediator release from the mast cells and the basophils, and cytokine release from the inflammatory cells in the airway; and</li>
<li>May inhibit release of acetylcholine from the postganglionic cholinergic nerves in the respiratory tract.
These drugs, however, do not inhibit either the late response to allergens or the subsequent bronchial hyper-responsiveness.
There is no evidence that one <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> stimulant is superior to others, except with regard to the duration of action. The choice depends upon the convenience and the cost. Salbutamol is usually preferred and is the prototype of this class.</li>
</ul>
<p>SALBUTAMOL (Albuterol): It is a selective <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">\beta 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="mord">2</span></span></span></span></span> adrenergic agonist related chemically to isoprenaline. (Chapter 18)</p>
<ul>
<li>It has a prominent bronchodilator action of rapid onset (1-5 minutes after inhalation).</li>
<li>It has poor cardiac (beta <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor) action. Hence, it causes less palpitation or a rise of blood pressure; and</li>
<li>It is resistant to inactivation by COMT and, therefore, has a longer duration of action.</li>
</ul>
<p>The effect of a single inhalation or a single oral dose lasts for about 4-6 hours.
Methods of Administration: It is more rapidly effective by pressurised metered dose inhalation (MDI) (dose 100 micrograms/puff) than orally (dose <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2-4 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> ) as it reaches smaller bronchi. Each inhalation may improve the effectiveness of subsequent inhalations. The dose must be prescribed clearly as "so many puffs at a time and the maximum number of puffs per day". It may also be given SC or IM in the dose of 0.5 mg every 4 hours and IV slowly, in the dose of 0.25 mg at the rate of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5-10 \mathrm{mcg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span></span></span></span></span> per minute. It is generally well tolerated. Larger doses can cause dose dependent ADR such as tachycardia, tremor and anxiety.</p>
<p>When a patient is prescribed an inhaler, he must be taught to synchronise the actuation of the inhaler with inspiration, so as to maximise the delivery of the drug to the lungs (Table 27.2).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-27-2">Table 27.2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-27-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Technique of using a pressurised inhaler when a spacer is not available</p>
<p><sup><a href="#user-content-fn-0" id="user-content-fnref-0-2" data-footnote-ref="true" aria-describedby="footnote-label">1</a></sup></p>
<p>Children, old people and those who are breathless find such synchronisation difficult. Further, the velocity of the aerosol causes the latter to impinge on the oropharynx, leading to the decreased delivery of the drug to airways. Spacers are available (Fig. 27.2) which reduce the velocity of the aerosol and allow more of the drug to reach the airways. The coordination between actuation of the aerosol and inspiration is less critical when a spacer is used.
<img src="assets/images/image-20251214-293678b7.jpeg" alt="img-13.jpeg"></p>
<p>Salbutamol may also be administered by a nebuliser wherein synchronisation with breathing is not required. The dose administered <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>2</mn><mo>−</mo><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(2-5 \mathrm{mg})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mclose">)</span></span></span></span></span> is much larger than that by a puff of the inhaler ( 100 mcg ). The drug can also be administered by a dry-powder inhaler.</p>
<p>Salbutamol is used in mild intermittent asthma on 'as needed' basis and may be the only treatment needed. In an acute attack, it must be administered in adequate doses such as 10-12 puffs in one hour. Inadequate dosage is the cause of apparent 'resistance'.</p>
<p>Levosalbutamol (Levolin): Salbutamol is a racemate. The active compound levosalbutamol is available in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">50 \mathrm{mcg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span></span></span></span></span> puff MDI. It is not clinically superior to salbutamol either in efficacy or ADR.</p>
<p>Terbutaline, fenoterol, bitolterol, pirbuterol, tolubuterol and rimiterol are other selective SABA with similar properties as salbutamol. However, the use of more potent <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonist than salbutamol, such as fenoterol has been associated with greater cardiac toxicity in patients with acute asthma.</p>
<p>SABA are very effective for:
(1) Treating acute attacks and
(2) Prevention of exercise-induced asthma.</p>
<p>They are less useful when taken regularly, and hence should be used only as needed. They are safe during pregnancy.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonists are also useful in treating wheezing following upper respiratory tract viral infection in infants and children under 5 years and are used orally in syrup form or by a nebuliser.</p>
<p>They may be less effective in some patients who use a beta blocker concurrently. In such a patient, aminophylline is preferred.</p>
<p>Excessive use of beta <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonists has been associated with asthma deaths.
It must be kept in mind that all beta-adrenergic agonists may cause hypokalemia which can be aggravated by concurrent use of theophylline and its derivatives, diuretics and glucocorticoids, and</p>
<p>by hypoxemia.
ORCIPRENALINE (Metaproterenol): This derivative of isoprenaline stimulates both <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors. Thus it is less selective than salbutamol. It is given orally ( 20 mg qid); or IM/SC <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.5-1 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>, and by inhalation.</p>
<p>Adrenaline hydrochloride: This is a potent bronchodilator. It also relieves pulmonary congestion by constricting the pulmonary arterioles. When administered SC in the dose of 0.2 to 0.5 ml of a 1 in 1000 aqueous solution ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">1 \mathrm{mg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> ), it is effective within a few minutes. It must be injected slowly and no further injection is given if the attack subsides. The relief of an acute attack by adrenaline is generally dramatic. Once used extensively, adrenaline is now no more recommended because of the inconvenience of administration and its CVS toxicity.</p>
<p>Ephedrine ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">15-30 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> ), if taken early, orally may abort an acute attack. It is a cheap, convenient and relatively safe medication for treating mild acute attacks of asthma, but it lacks selectivity (Chapter 18).</p>
<p>AMINOPHYLLINE: This is a stable mixture of theophylline and ethylene diamine; the latter makes theophylline more water soluble (Chapter 12). It can be given orally or slowly IV. It:</p>
<ul>
<li>Causes bronchodilatation by its weak and non-selective inhibition of pulmonary enzyme PDE-4.</li>
<li>Inhibits adenosine receptors in the airways.</li>
<li>Inhibits the late response to allergens but does not inhibit the release of mediators.</li>
<li>Acts synergistically with beta adrenergic agonists.</li>
</ul>
<p>It is less effective orally because though it is absorbed, it undergoes first pass metabolism. Given rapidly IV, it may cause nausea, vomiting, cardiac arrhythmias and collapse. Deaths have been reported following rapid IV aminophylline, particularly in the presence of cardiac damage. Rapid IV administration can also cause twitching of the facial muscles, severe hyperventilation and seizures. The repeated use of theophylline in children may cause learning difficulties and sleep disturbances. Hepatic enzyme inhibitors eg. ciprofloxacin, erythromycin and OC (pills) can increase the plasma concentration of theophylline.</p>
<p>It is safer than adrenaline in hypoxic subjects in status asthmaticus, and in patients with concomitant cardiac disease. It is especially helpful when one cannot decide whether a given attack is one of bronchial or cardiac asthma.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Acute attack of asthma: If treatment with inhaled selective SABA in adequate doses fails to relieve an acute attack in about half to one hour, aminophylline is administered by IV infusion in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> glucose in a dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> over <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>30</mn></mrow><annotation encoding="application/x-tex">15-30</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">30</span></span></span></span></span> minutes, followed by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.5-1 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> per hour for several hours. The infusion rate should be lowered in patients with cirrhosis, pneumonia, acute viral infection and congestive heart failure and in patients receiving drugs which interfere with its metabolic degradation. Smokers may need a larger dose.</li>
<li>Chronic persistent asthma: Slow release oral preparations may be useful in patients with persistent bronchospasm between acute attacks and in preventing nocturnal attacks. However, these preparations may also prolong the toxic effects as peak plasma level is reached 12-24 hours after the ingestion.</li>
</ul>
<p>If an acute asthmatic attack is not terminated within 2 hours by the above measures, the patient should be treated as a case of severe acute asthma (status asthmaticus).</p>
<p>Selective and potent PDE-4 inhibitors with anti-inflammatory action, cilomilast and roflumilast are being evaluated in asthma and COPD.</p>
<p>Anticholinergics: As the airways have parasympathetic innervation, atropine-like drugs can induce bronchodilatation and have been used as a remedy for bronchial asthma:</p>
<p>IPRATROPIUM BROMIDE is a congener of methylatropine. Administered by inhalation in the dose of 1-2 puffs ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>80</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">40-80 \mathrm{mcg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">80</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span></span></span></span></span> ) tid, it is as effective as 200 mcg of salbutamol in relieving bronchospasm in patients with chronic bronchitis, and in prolonged bronchial hyperresponsiveness following viral respiratory infections. It is the preferred drug in patients with COPD.</p>
<p>It has a slow onset of action ( 30 min .) and lower efficacy than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonists in the management of acute attacks. Hence, it is not recommended for acute attacks. It is particularly useful in patients with concomitant heart disease and those intolerant to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> agonists. A combination of ipratropium and a beta adrenergic agonist by inhalation produces additive effects because ipratropium acts on large and medium sized bronchi whereas <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonist act on the smaller bronchi. It is also useful in asthmatic attack induced by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>-blockers.</p>
<p>Oxitropium bromide and tiotropium bromide are other analogues with similar properties; tiotropium has a longer duration of action.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="prevention-of-acute-attacks">Prevention of Acute Attacks<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#prevention-of-acute-attacks" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Currently, there is no definite strategy for primary prevention of asthma or preventing the development of airflow limitation in patients. It is interesting to note that children raised on farms and in rural areas were consistently found to have low incidence of asthma as against those raised in affluent and urban areas. This could be associated with microbial deversity seen in urban and rural areas, particularly innocuous microorganisms triggering protective immunological responses in the rural children.</p>
<p>Avoidance of the causal factors, such as an allergen, may eliminate acute attacks. This is not easy, and if the allergen is not easily detected, extensive skin testing and desensitisation are unlikely to yield much success. Patients in whom acute attacks are precipitated by a psychologically unpleasant situation are likely to benefit from some readjustment in their family and social life; in case of children, a discussion with the parents is helpful in identifying the problem.</p>
<p>The drugs used in the prevention of acute attacks (maintenance therapy) are:
(1) Inhaled long acting <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>-agonists (LABA) e.g. salmeterol, formoterol.
(2) Inhaled glucocorticoids
(3) Oral theophylline and
(4) Oral leukotriene modifiers</p>
<p>As the beta-adrenergic agonists and theophylline act by different mechanisms, their concurrent use has an additive effect.</p>
<p>GLUCOCORTICOIDS: When attacks are frequent (more than 3 per week), are not easily relieved by the inhaled bronchodilators and interfere with daily activities and with sleep, the current practice is to start prophylactic inhaled glucocorticoids, on a regular basis. The glucocorticoids beclomethasone, budesonide and fluticasone have the advantages that they are potent, lipid soluble and effective promptly in small doses. Because of their low bioavailability due to high first pass metabolism, their systemic toxicity is low, although almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> of the drug is swallowed during inhalation. Intake of at least <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">75 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">75%</span></span></span></span></span> of the prescribed ICS dose is necessary to achieve satisfactory control of exacerbation. In case of failure to achieve 'good asthma' control, by inhaled corticosteriod alone, inhaled LABA may be added. The use of micronised MDI may also improve the asthma control.</p>
<p>SALMETEROL is a long acting <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> partial adrenergic agonist, weaker than salbutamol. It is used as the drug of choice in the prevention of nocturnal asthmatic attacks and those induced by exercise. Its onset of action is slow (10-15 min) and the duration of action long (12 hours). It is not useful in relieving acute attacks. It is available in pressurised MDI delivering 25 mcg per puff. The dose is 1-2 puffs every 12 hours. It should not be used more than twice a day.</p>
<p>Formoterol, an analogue, has quicker onset (3-5 min.) than and similar duration of action as salmeterol.</p>
<p>These drugs are usually well tolerated. However, tolerance may develop during long term therapy. They are always used in combination with an inhaled glucocorticoid to reduce incidence of fatal asthmatic attacks seen in patients receiving LABA alone.</p>
<p>EPHEDRINE HYDROCHLORIDE: This sympathomimetic drug, given orally in the dose of 30 mg at bed time, was considered useful in preventing nocturnal asthmatic</p>
<p>attacks. Patients who get daytime attacks need 60 mg on waking and 30 mg at mid-day. Taken later in the day, it may cause insomnia. Sometimes, it causes palpitation and difficulty in passing urine, particularly in the elderly. Repeated at frequent interval, it may cause tachyphylaxis. It also raises the BP in hypertensive patients. Tolerance to ephedrine develops after several weeks of continuous therapy but it is reversible (Chapter 18).</p>
<p>THEOPHYLLINE and AMINOPHYLLINE may not be tolerated orally in therapeutically effective doses ( 1 g daily in divided doses) because of nausea. However, given in the form of tablets, they are cost effective for general use. Their major drawback is the variability in bioavailability. Slow release preparations of theophylline given in the evening may be useful as adjuncts in preventing nocturnal attacks.</p>
<p>Cromolyn sodium: See later.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="leukotriene-modifiers">Leukotriene Modifiers<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#leukotriene-modifiers" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Leukotrienes liberated during inflammation are more potent and longer acting bronchoconstrictors than histamine (Chapter 25). They increase bronchial secretion, decrease mucociliary clearance, and increase vascular permeability. Drugs can modify the leukotriene system by:</p>
<ul>
<li>Acting as competitive antagonist on type-1 cysteinyl LT receptors eg. Montelukast; or</li>
<li>Blocking the leukotriene synthesis e.g. Zileuton.</li>
</ul>
<p>MONTELUKAST: This is a competitive and selective <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">L</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{LT}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">LT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonist. Its oral bioavailability is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60-70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mn>3</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2} 3-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9713em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> hours. It is highly protein bound and metabolised by the liver. It is moderately effective in asthma with once to twice daily administration.</p>
<p>Adverse reactions: These are mild, self-limited and include dyspepsia, headache, eosinophilia and raised liver enzymes. The drug may rarely cause systemic vasculitis.</p>
<p>Therapeutic uses:</p>
<ul>
<li>Aspirin-induced bronchospasm.</li>
<li>Cold-air-induced airway obstruction.</li>
<li>Exercise-induced bronchospasm; and</li>
<li>Mild to moderate chronic persistent asthma.</li>
<li>Allergic rhinitis.</li>
</ul>
<p>Pranlukast and Zafirlukast are the analogues of montelukast. The latter can cause severe hepatitis, and can interact with warfarin to enhance its effect.</p>
<p>Zileuton, a 5 lipoxygenase inhibitor, is as effective as montelukast. It is available only as extended release formulation.</p>
<p>Leukotriene modifiers have no bronchodilator action and cannot be used as rescue drugs. For prophylaxis they are less potent than low dose inhaled glucocorticoids. Combined use of glucocorticoids and leukotriene modifiers may permit a reduction in steroid dose (steroid sparing role). They can be used as an alternative to low dose inhaled glucocorticoid therapy in mild asthma, and in children. Their main advantage is that they are effective orally and hence can be used as substitute for cromolyn. Their use mandates periodic monitoring of hepatic function. Their superiority over the older drugs is not established and they are expensive. They should be used only in selected cases.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="treatment-of-chronic-persistent-asthma">Treatment of Chronic Persistent Asthma<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment-of-chronic-persistent-asthma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Over and above the treatment during acute attack, patients with persistent asthma need some form of maintenance therapy.</p>
<p>Inhaled <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>-agonists: Salmeterol and formoterol are the beta <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonists of choice for this purpose. However, they lack anti-inflammatory action and their efficacy diminishes with continued use owing to development of tolerance. They are best used concurrently with an inhaled glucocorticoid.</p>
<p>Salbutamol should be used additionally (preferably by inhalation) to treat acute attacks when they occur. Inappropriate administration of repeated doses of potent sympathomimetics can induce lethal cardiac arrhythmias.</p>
<p>Inhalational Glucocorticoids: They are the first-line therapy for chronic persistent asthma since chronic inflammation is important in its pathogenesis. Glucocorticoids suppress the inflammatory response and improve lung function at multiple levels. They do not cure the asthmatic inflammation. They:</p>
<ul>
<li>Inhibit phospholipase <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">A</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{A}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">A</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and thereby reduce the cellular histamine and SRS-A content.</li>
<li>They also reduce the microvascular leakage due to the mediators, thereby decreasing mucosal edema</li>
<li>Inhibit the influx of inflammatory cells into the lungs after exposure to an allergen.</li>
<li>Stabilise the cellular lysosomal membranes.</li>
<li>Inhibit the release of mediators from the macrophages and the eosinophils in the lungs. Therefore, they are useful in blocking the late response and the consequent bronchial hyperresponsiveness.</li>
<li>Reduce bronchial hyperactivity by blocking expression of COX-2 and cytokines.</li>
<li>Prevent and reverse the downregulation of the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> adrenergic receptors, and thus maintain/restore the responsiveness of the airway smooth muscle to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonists.</li>
<li>Long term administration also reduces the immediate response to allergens, and prevents exercise-induced asthma.
Clinically, they reduce the frequency of acute attacks as well as interval symptoms; and thus improve the quality of life. During long term steroid therapy, the reduction in bronchial hyper-responsiveness is gradual, and may take several months. Effective, long term suppression of airway inflammation reduces the need for bronchodilators, and may reduce the morbidity and perhaps mortality in bronchial asthma. Concurrent use of glucocorticoids and a LABA is beneficial.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="limitations-of-inhaled-glucocorticoids">Limitations of inhaled glucocorticoids:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#limitations-of-inhaled-glucocorticoids" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(1) Locally, they may cause sore throat, coughing, hoarseness and rarely candidiasis.
(2) Higher doses produce limited additional benefits; and
(3) Long term use of high doses may cause systemic adverse effects such as skin bruising, osteoporosis, cataract, glaucoma, HPA axis suppression and growth retardation in children.</p>
<p>Hence, once good control is obtained attempt should be made to taper down the dose.
The macrolide antibiotics (erythromycin, trioleandomycin, clarithromycin) increase the half life of glucocorticoids and theophylline in the body.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="beclomethasone-dipropionate">BECLOMETHASONE DIPROPIONATE:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#beclomethasone-dipropionate" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This halogenated glucocorticoid ester is used in an MDI which delivers 50 micrograms of the drug per puff.</p>
<p>The usual dose recommended is 2 puffs ( 200 mcg ) 3-4 times a day. Modest but significant decrease in bone mineral density (BMD) occurs in women receiving doses as low as 500 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">\mathrm{mcg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span></span></span></span></span> day. Doses up to 1.5 mg daily in adults do not cause significant suppression of the hypothalamo- pituitary axis, and this is its major advantage.</p>
<p>BUDESONIDE: This drug has a higher ratio of topical to systemic activity and is more potent than beclomethasone. Its uses and limitations are similar to those of beclomethasone. Its major advantage is that it is effective in the dose of 1-2 puffs bid; this improves patient compliance.</p>
<p>Fluticasone has properties similar to those of budesonide. It is expensive.
The adverse reactions to budesonide and fluticasone are similar to those to beclomethasone.</p>
<p>Mometasone furoate is another glucocorticoid used as a powder for inhalation.
Table 27.3 lists the doses of inhaled steroids.
Table 27.3
Doses of inhaled steroids</p>
<table><thead><tr><th style="text-align: left;">Drug (formulation)</th><th style="text-align: left;">mcg/puff</th><th style="text-align: center;">Low dose, mcg</th><th style="text-align: center;">High dose, mcg/day, in divided doses</th></tr></thead><tbody><tr><td style="text-align: left;">Beclomethasone (MDI)</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo separator="true">,</mo><mn>200</mn><mo separator="true">,</mo><mn>250</mn></mrow><annotation encoding="application/x-tex">100,200,250</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">200</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">250</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>400</mn></mrow><annotation encoding="application/x-tex">100-400</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">400</span></span></span></span></span> bid</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>1000</mn></mrow><annotation encoding="application/x-tex">&gt;1000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1000</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Budesonide (DPI)</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo separator="true">,</mo><mn>200</mn><mo separator="true">,</mo><mn>400</mn></mrow><annotation encoding="application/x-tex">100,200,400</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">200</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">400</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>300</mn></mrow><annotation encoding="application/x-tex">100-300</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">300</span></span></span></span></span> bid</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>1000</mn></mrow><annotation encoding="application/x-tex">&gt;1000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1000</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Fluticasone (MDI, DPI)</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo separator="true">,</mo><mn>125</mn><mo separator="true">,</mo><mn>250</mn></mrow><annotation encoding="application/x-tex">50,125,250</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">50</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">125</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">250</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>125</mn></mrow><annotation encoding="application/x-tex">50-125</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">125</span></span></span></span></span> bid</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>500</mn></mrow><annotation encoding="application/x-tex">&gt;500</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">500</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Ciclesonide (MDI)</td><td style="text-align: left;">80,160</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mo>−</mo><mn>160</mn></mrow><annotation encoding="application/x-tex">80-160</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">80</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">160</span></span></span></span></span> bid</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>400</mn></mrow><annotation encoding="application/x-tex">&gt;400</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">400</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Mometasone furoate (DPI)</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo separator="true">,</mo><mn>60</mn><mo separator="true">,</mo><mn>120</mn></mrow><annotation encoding="application/x-tex">30,60,120</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">30</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">60</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">120</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>200</mn></mrow><annotation encoding="application/x-tex">100-200</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">200</span></span></span></span></span> bid</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>400</mn></mrow><annotation encoding="application/x-tex">&gt;400</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">400</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Flunisolide</td><td style="text-align: left;">250</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>500</mn><mo>−</mo><mn>1000</mn></mrow><annotation encoding="application/x-tex">500-1000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">500</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1000</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>2000</mn></mrow><annotation encoding="application/x-tex">&gt;2000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2000</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Triamcinolone</td><td style="text-align: left;">100</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>400</mn><mo>−</mo><mn>1000</mn></mrow><annotation encoding="application/x-tex">400-1000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">400</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1000</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>2000</mn></mrow><annotation encoding="application/x-tex">&gt;2000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2000</span></span></span></span></span></td></tr></tbody></table>
<p>'Solution for nebulisation is also available
Clinically, all the inhaled steroids are equally effective. They can cause localised infection with Candida albicans in the throat. This can be prevented by rinsing the mouth after every dose. It may interfere with the growth of lungs and other organs in young children; hence should be avoided in mild asthma. A flare up of allergic rhinitis and nasal polyps has been reported on stopping treatment. Steroid inhalation is of no value in treating acute attacks.</p>
<p>DISODIUM CHROMOGLYCATE: This is the sodium salt of 1,3-bis- (2-carboxychromon-5-yloxy)-2 hydroxy propane (Fig 27.3). It is useful in preventing attacks of bronchial asthma in selected cases.
<img src="assets/images/image-20251214-48ae3439.jpeg" alt="img-14.jpeg"></p>
<p>Pharmacological actions: The drug prevents mast cell and eosinophil activation. by</p>
<p>altering the function of the delayed chloride channels in the cell membrane. Thus, (a) It inhibits release of spasmogenic autocoids after combination of the antigen and antibody. In this respect, like glucocorticoids, it acts as an anti-inflammatory agent. (b) It also prevents the early response to allergens and exercise, and the subsequent bronchial hyper-responsiveness.</p>
<p>The drug relieves coughing due to asthma. It has few other significant pharmacological actions.</p>
<p>Absorption, fate and excretion: It is absorbed poorly after oral administration ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.5%</span></span></span></span></span> ) but is absorbed better after inhalation (5%). The absorbed portion is rapidly eliminated unchanged in urine and bile.</p>
<p>Adverse reactions: Except some local irritation, no serious toxicity has been observed.
Preparation and dosage: Disodium chromoglycate is administered in 20 mg capsules, given by inhalation, 3-4 times daily. It is inhaled by using a spinhaler. Its effect is enhanced when the patient's ventilation is improved by prior (but not simultaneous) inhalation of a beta stimulant. It is available as powder for nasal insufflation and as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> aqueous eye drops and ointment.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Allergic bronchial asthma: When inhaled during a symptom-free interval, it protects against an attack for several hours in most patients with extrinsic asthma. It is, however, ineffective when used after the beginning of an attack. The results in patients with intrinsic asthma are less satisfactory.
It is more beneficial in patients with clear evidence of allergic factors and in those with exercise-induced bronchospasm. A single dose taken 15-30 minutes before exercise may prevent an acute attack for 1-2 hours. It helps to reduce the requirement of glucocorticoids and bronchodilators. Some patients have to take the drug for 3-4 weeks before they notice its beneficial effects. Cromolyn is probably the antiinflammatory drug of first choice in children.</li>
<li>Other respiratory allergies: It has been used in allergic alveolitis and in allergic rhinitis.</li>
<li>Miscellaneous: It may also be useful in the treatment of allergic conjunctivitis, aphthous stomatitis, ulcerative colitis, food allergy and systemic mastocytosis with variable results.
Nedocromil sodium has properties similar to those of cromolyn but is effective orally. It also inhibits PAF. Nedocromil and its analogues have now been largely superceded by low dose inhaled glucocorticoids.
KETOTIFEN, a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor blocker, is claimed to be useful in asthma. It is believed to inhibit airway inflammation induced by platelet activating factor (PAF) in primates. It can cause drowsiness. Its usefulness in asthma is equivocal.
OMALIZUMAB: This is a recombinant, humanised anti-IgE monoclonal antibody. It binds to IgE and prevents it from binding to IgE receptors on mast cells and basophils. It thus prevents the allergic reaction at a very early step. Plasma level of IgE diminishes markedly. It is administered as a single SC injection once in 2-4 weeks. The IgE-Ab complex is degraded by the RE system in the liver; the elimination <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is 26 days. It is not a bronchodilator. In adults with allergic, moderate-to-severe persistent asthma, it reduces the dependance on glucocorticoids and decreases the frequency of asthma exacerbations. It may also be useful in seasonal allergic rhinitis and food allergy. It is</li>
</ul>
<p>generally well tolerated, but may cause local reactions and, rarely, anaphylaxis. Its use is not recommended in children below the age of 12 years. It is very expensive.</p>
<ul>
<li>Patients with late onset eosinophilic asthma with high levels of IL-5 have been reported to respond to Mepolizumab, an humanized monoclonal antibody against IL-5.
Other concurrent medications: Most chronic asthmatic patients have associated chronic bronchitis and lung damage. Such cases should receive antimicrobial therapy whenever the sputum turns yellow or other signs of infection develop. Those prone to get repeated infections, may need regular antimicrobial prophylaxis during winter or monsoon seasons.</li>
</ul>
<p>Antihistaminics are not so useful in the treatment of asthma except in the presence of definite allergy, where they may prevent the onset of an attack. They may, however, produce drowsiness and dry the respiratory secretions.</p>
<p>Although most of the cases of asthma can now be controlled by a stepwise approach (Table 27.4) using a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-adrenergic agonist, glucocorticoids and theophylline, a few cases may still be difficult to manage. These may be benefited by oral glucocorticoid therapy in larger doses. In such cases, careful monitoring for adverse effects is necessary (Chapter 66).</p>
<p>Table 27.4
Stepwise management of asthma</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>Mild, short-lived intermittent asthma:
</span>Inhaled, short acting beta, agonist as needed
Mild chronic persistent asthma: daily use of
- Low dose inhaled glucocorticoid (LIGS)
(If not controlled, select one of the following)
- LIGS + inhaled long acting beta, agonist
- LIGS + leucotriene antagonists
- ICS + sustained release theophylline
- Inhaled medium-high dose glucocorticoids
Moderate chronic persistent asthma: Daily use
(Select one or more of the following)
- Inhaled medium-high dose glucocorticoids plus inhaled LABA
- Leukotriene modifier
- Aminophylline
- Sustained release theophylline
Severe chronic persistent asthma:
(As above plus one of the following)
- Oral glucocorticoids (prednisolone 30 mg/day for 5-7 days);
- Anti-IgE, Anti-IL-5 monoclonal antibodies in refractory cases
Acute attack (in any of the above categories):
(Additional treatment)
- Inhaled SABA
- Aminophylline IV Prophylaxis: Disodiumchromoglycate Status asthmaticus: See text.</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="Mild, short-lived intermittent asthma:
Inhaled, short acting beta, agonist as needed
Mild chronic persistent asthma: daily use of
- Low dose inhaled glucocorticoid (LIGS)
(If not controlled, select one of the following)
- LIGS + inhaled long acting beta, agonist
- LIGS + leucotriene antagonists
- ICS + sustained release theophylline
- Inhaled medium-high dose glucocorticoids
Moderate chronic persistent asthma: Daily use
(Select one or more of the following)
- Inhaled medium-high dose glucocorticoids plus inhaled LABA
- Leukotriene modifier
- Aminophylline
- Sustained release theophylline
Severe chronic persistent asthma:
(As above plus one of the following)
- Oral glucocorticoids (prednisolone 30 mg/day for 5-7 days);
- Anti-IgE, Anti-IL-5 monoclonal antibodies in refractory cases
Acute attack (in any of the above categories):
(Additional treatment)
- Inhaled SABA
- Aminophylline IV Prophylaxis: Disodiumchromoglycate Status asthmaticus: See text." style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>Table 27.5 lists the drugs which cause bronchospasm and may precipitate asthma. They are to be avoided in patients with asthma. Beta blockers used commonly to treat hypertension, angina, glaucoma are contraindicated in patients with asthma. Even a use of eyedrops can cause fatal attacks.</p>
<p>Table 27.5
Some drugs known to cause bronchospasm</p>
<ul>
<li>Aspirin and other NSAID</li>
<li>Beta adrenergic blockers</li>
<li>Cholinergic drugs</li>
<li>Quinine</li>
<li>Morphine and other histamine liberators</li>
<li>Sedatives</li>
<li>Antihistaminics</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="severe-acute-asthma-status-asthmaticus-treatment">Severe Acute Asthma (Status Asthmaticus) Treatment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#severe-acute-asthma-status-asthmaticus-treatment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Severe acute asthma (Status asthmaticus) is a serious medical emergency, requiring urgent hospitalisation and vigorous therapy. It is often precipitated by:</p>
<ul>
<li>An acute respiratory infection.</li>
<li>Abrupt cessation of glucocorticoid therapy.</li>
<li>Drugs (aspirin or NSAID) or inhaled allergens; or</li>
<li>Acute emotional stress.</li>
</ul>
<p>A patient in status is markedly dyspnoeic, exhausted, cyanosed and dehydrated. He has tachycardia, may have pulsus paradoxus and may become drowsy if respiratory failure supervenes. Signs of right ventricular failure including a gallop may occur as a further complication. Pulsus paradoxus, prominence of the sternomastoid muscles and high pitched wheezing with absent breath sounds are indicative of the severity of status asthmaticus. Silent chest, feeble respiratory efforts, cyanosis, bradycardia, hypotension, exhaustion, confusion and coma are life-threatening features in status asthmaticus.</p>
<p>Relief of tachycardia and dyspnoea and evidence of better oxygenation, including a clearer mental state, are evidence of favourable response to therapy if repeated measurements of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">F</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">V</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{FEV}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">FEV</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> are not available. The intensity of wheezing can be misleading; it may decrease with worsening obstruction.</p>
<p>Table 27.6 outlines the principles of management of a severe acute asthma.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-27-6">Table 27.6<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-27-6" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Management of severe acute asthma</p>
<table><thead><tr><th style="text-align: left;">Initial treatment</th></tr></thead><tbody><tr><td style="text-align: left;">- Correct dehydration</td></tr><tr><td style="text-align: left;">- Humidified oxygen ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50-60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> ) by mask.</td></tr><tr><td style="text-align: left;">- Nebulised salbutamol and ipratropium.</td></tr><tr><td style="text-align: left;">- Oral prednisolone or IV hydrocortisone.</td></tr><tr><td style="text-align: left;">If poor response to above in 1 hour</td></tr><tr><td style="text-align: left;">- Hospitalise.</td></tr><tr><td style="text-align: left;">- Correct dehydration and acidosis.</td></tr><tr><td style="text-align: left;">- Repeat nebulised salbutamol every 30 minutes.</td></tr><tr><td style="text-align: left;">- Repeat nebulised ipratropium ( 0.5 mg 6 hif)</td></tr><tr><td style="text-align: left;">- IV hydrocortisone.</td></tr><tr><td style="text-align: left;">- IV infusion of aminophylline or salbutamol.</td></tr><tr><td style="text-align: left;">- Monitor serum IC, arterial oxygen saturation.</td></tr><tr><td style="text-align: left;">- Antibiotics for chest infection.</td></tr><tr><td style="text-align: left;">- Exclude pneumothorax (X-ray chest).</td></tr><tr><td style="text-align: left;">If still poor response after 1 hour</td></tr><tr><td style="text-align: left;">- Shift to intensive care unit.</td></tr></tbody></table>
<p>Glucocorticoids in large doses are the mainstay of therapy. Hydrocortisone is administered IV in the dose of 200-300 mg every 4-6 hours. Equivalent doses of another glucocorticoid, e.g., methylprednisolone <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">30-40 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> by slow IV infusion may be used. Prednisolone 30-60 mg orally every 6-8 hours is equally effective. The bronchodilator therapy should be continued in full dose, using nebulised salbutamol <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span> ipratropium, as glucocorticoids need at least 6 hours to produce a beneficial effect. In resistant cases, aminophylline or salbutamol may be administered by slow IV infusion.</p>
<p>Once the patient shows improvement, he should be switched to oral glucocorticoids; 50-</p>
<p>60 mg of prednisolone should be given as a single morning dose. If the patient continues to improve, the dose should be reduced by 5 mg every 3-4 days. If it is not possible to discontinue the glucocorticoid altogether, it should be continued in the minimum effective dose. An attempt should be made to change the treatment to inhaled glucocorticoid. Alternate day glucocorticoid therapy has not been successful in the management of asthma, as the patient deteriorates on the 'steroid-off' day.</p>
<p>Rehydration of the patient either orally (using liquids to which glucose and salt have been added) or by parenteral administration of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> glucose-saline (with appropriate quantities of potassium) is essential. It not only corrects dehydration but also makes the bronchial secretions less tenacious. Correction of acidosis by means of IV sodium bicarbonate is likely to restore the patient's sensitivity to the bronchodilators. Some cases would need treatment for acute respiratory failure.</p>
<p>Sedatives, tranquillizers and antihistaminics should be avoided in status asthmaticus. They make the patient drowsy, diminish the voluntary ventilatory drive and thus aggravate the hypoxemia.</p>
<p>Steroid resistant asthma: Rarely, inspite of adequate doses, glucocorticoids may not be effective. Glucocorticoids act by binding to nuclear receptors and attach to DNA sites that code for cytokine production. Corticosteroids resistance has been related to defective DNA binding, a decrease in number of glucocorticoid receptors and decreased ligand receptor affinity. Interestingly, glucocorticoid resistance in these cases is confined to T-cells. In such cases increase in dosage will cause toxicity without any relief from asthma.</p>
<p>Table 27.7 enumerates the important points to remember in the management of asthma.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-27-7">Table 27.7<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-27-7" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Points to remember in asthma</p>
<ul>
<li>Asthma is a heterogenous symptom complex.</li>
<li>Inhaled glucocorticoids is the mainstay therapy of persistent chronic asthma.</li>
<li>Where symptoms of asthma persist in spite of low dose inhaled glucocorticoids, add inhaled LABA instead of increasing the dose of inhaled glucocorticoids.</li>
<li>High dose inhaled glucocorticoids (more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1500</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">1500 \mathrm{mcg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1500</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span></span></span></span></span> day) increase the risk of its long term toxicity.</li>
<li>LABA are highly effective as prephylactics in exercise-induced and nocturnal asthma.</li>
<li>Inhaled LABA should not be used as monotherapy but combined with inhaled glucocorticoids for long term treatment.</li>
<li>Oral aminophylline is much less effective than inhaled glucocorticoids.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="copd-management">COPD - Management<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#copd-management" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Chronic Obstructive Pulmonary Disease (COPD) is characterized by "air flow resistance that is not reversible". It includes:
(1) Emphysema an anatomically defined entity associated with enlarged and distorted lung alveoli, and
(2) Chronic bronchitis, a clinical entity associated with disease of small brochioles with chronic airflow obstruction, chronic cough and marked expectoration.</p>
<p>Chronic bronchitis without airflow obstruction is not COPD.
COPD is a complex syndrome which results in slow albeit progressive loss of lung function due to chronic inflammation of small airways and lung parenchymatous tissue. The risk factors are smoking, indoor air pollution, biomass fuel and occupational exposure. It is a major cause of mortality and morbidity all over the world. Often asthma coexist with COPD.</p>
<p>COPD is a heterogeneous disorder, and responds differently according to its phenotype. The main physiological abnormality in COPD is an accelerated rate of decrease in the Forced Expiratory Volume <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">F</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">V</mi></mrow><mn>1</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{FEV}_{1}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">FEV</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> compared to normals. There is hyperinflation which is present at rest and worsens on exercise, increasing the work of breathing. The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> diffusing capacity decreases with resultant hypoxemia. The situation becomes worse with comorbidities such as cardio-vascular diseases.</p>
<p>The current therapy of COPD includes:</p>
<ul>
<li>Inhaled bronchodilators</li>
<li>Inhaled glucocorticoids</li>
<li>Oxygen inhalation</li>
<li>Prophylactic antibiotics</li>
<li>Preventation of dehydration; and</li>
<li>Physiotherapy, pulmonary rehabilitation and education.</li>
</ul>
<p>Inhaled bronchodilators are the mainstay of therapy, and any one of the regimens given in Table 27.8 may be used. However, long term use of combination therapy with an inhaled glucocorticoid (fluticasone, budesonide) and a LABA (salmeterol) gives better benefits with acceptable side effects. Indocaterol, another LABA, administered OD can be used as maintenance therapy in COPD. Unlike asthma, COPD has preponderance of CD8 lymphocytes and neutrophils in the airways. Inhaled glucocorticoids probably help to reduce the number of exacerbations; but they alone do not substantially modify airway obstruction. They are better avoided in elderly because of possible ADR. Addition of theophylline may be beneficial in some subjects.</p>
<p>Table 27.8
Bronchodilator regimens in COPD</p>
<table><thead><tr><th style="text-align: center;">Drug</th><th style="text-align: center;">Duration of action (hr)</th><th style="text-align: center;">Dose</th></tr></thead><tbody><tr><td style="text-align: center;"></td><td style="text-align: center;">Short acting</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Salbutamol sulfate</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">4-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span></td><td style="text-align: center;">2 puffs every 4 hours (MDI <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">100 \mathrm{mcg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span></span></span></span></span> puff)</td></tr><tr><td style="text-align: center;">Ipratropium bromide</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">4-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span></td><td style="text-align: center;">2 puffs every 4 hours (MDI <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">20 \mathrm{mcg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span></span></span></span></span> puff)</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">Long acting</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Formoterol fumarate</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>8</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">8-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span></td><td style="text-align: center;">One inhalation twice a day (DPI <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">12 \mathrm{mcg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">12</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span></span></span></span></span> inhalation)</td></tr><tr><td style="text-align: center;">Salmeterol xinafoate</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>8</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">8-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span></td><td style="text-align: center;">One inhalation twice a day (DPI <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">50 \mathrm{mcg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span></span></span></span></span> inhalation)</td></tr><tr><td style="text-align: center;">Arformoterol</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>8</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">8-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span></td><td style="text-align: center;">One nebulisation, 15 mcg Twice a day</td></tr><tr><td style="text-align: center;">Indacaterol</td><td style="text-align: center;">24</td><td style="text-align: center;">One inhalation once a day (DPI <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">75 \mathrm{mcg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">75</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span></span></span></span></span> inhalation)</td></tr><tr><td style="text-align: center;">Tiotropium bromide</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>24</mn></mrow><annotation encoding="application/x-tex">&gt;24</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">24</span></span></span></span></span></td><td style="text-align: center;">One inhalation once a day (DPI <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>18</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">18 \mathrm{mcg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">18</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span></span></span></span></span> inhalation)</td></tr><tr><td style="text-align: center;">Aclidinium</td><td style="text-align: center;">12</td><td style="text-align: center;">One inhalation twice a day (DPI <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>400</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">400 \mathrm{mcg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">400</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span></span></span></span></span> inhalation)</td></tr><tr><td style="text-align: center;">Roflumilast</td><td style="text-align: center;">24 &lt;br&gt; Long acting combinations</td><td style="text-align: center;">1 tablet per day ( 500 mcg ) orally</td></tr><tr><td style="text-align: center;">Budesonide + formoterol</td><td style="text-align: center;">12</td><td style="text-align: center;">Two inhalations twice a day (HFA MDI 160 mcg budesonide <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mn>4.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">+4.5 \mathrm{mcg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">+</span><span class="mord">4.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span></span></span></span></span> formoterol/inhalation)</td></tr><tr><td style="text-align: center;">Fluticasone + Salmeterol</td><td style="text-align: center;">12</td><td style="text-align: center;">Two inhalations twice a day (HFA MDI 45,115,230 mcg fluticasone +21 mcg salmeterol/inhalation)</td></tr><tr><td style="text-align: center;">Mometasone + Formoterol</td><td style="text-align: center;">12</td><td style="text-align: center;">Two inhalations twice a day (HFA MDI 100, 200 mcg mometasone +5 mcg formoterol/inhalation)</td></tr><tr><td style="text-align: center;">Fluticasone + Vilanterol</td><td style="text-align: center;">24</td><td style="text-align: center;">One inhalation once a day (DPI 100 mcg fluticasone +25 mcg vilanterol)</td></tr><tr><td style="text-align: center;">Umeclidinium + Vilanterol</td><td style="text-align: center;">24</td><td style="text-align: center;">One inhalation once a day (DPI 62.5 mcg umeclidinum +25 mcg vilanterol)</td></tr></tbody></table>
<p>MDI = Metered dose inhaler.
DPI <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span></span></span></span></span> Dry powder inhaler
Intermittently inhaled oxygen improves long term survival in COPD and home oxygen therapy (HOT) should be used along with pulmonary rehabilitation. Severe cases may need oral glucocorticoid therapy.</p>
<p>Antibacterial proplylaxis: An exacerbation of COPD can be defined as "an event in the natural course of the chronic disease, characterised by increase in the baseline dyspnea, cough and mucopurulent sputum beyond the normal variation". It is usually triggered by bacteria, viruses and pollutants. The most common viruses are rhinovirus, coronavirus and influenza virus. In COPD lungs have lower-airway bacterial colonisation mainly by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi></mrow><annotation encoding="application/x-tex">H</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span></span></span></span></span>. influenzae, Moraxella catarrhalis, S. pneumoniae and Ps. pyogenes. Purulent sputum is a reliable marker for bacterial infection, and should be treated promptly with antibiotics. Prophylactic use of fluoroquinolones (Moxifloxacin) for 5 days every 8 weeks or erythromycin/azithromycin has been reported to be useful in preventing exacerbation in subjects with mucopurulent sputum. Acute exacerbation must be treated with antibiotics and oral glucocorticoids administered after giving optimum combination inhaled therapy.</p>
<p>Mucolytic agent, carbocysteine given in the dose of 500 mg tid has been claimed to be useful in reducing the rate of exacerbations when used for long term management of COPD.</p>
<p>Giving up smoking provides definite benefit. Treatment of comorbid CVS conditions with statins, ACEI/ARB and selective <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> blockers may reduce overall mortality. Respiratory irritants such as smoke, chemicals and dust must be avoided.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="treatment-of-acute-respiratory-failure">Treatment of Acute Respiratory Failure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment-of-acute-respiratory-failure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Respiratory insufficiency indicates impaired ability of the lungs to eliminate carbon dioxide or to take up oxygen. It may become apparent at rest or only on exercise. Respiratory failure is said to exist when a serious abnormality of blood gases (arterial <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> tension of over 50 mm Hg or arterial <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">O</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{O}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> tension of 60 mm Hg or less) is present at rest. Respiratory failure may be:</p>
<ul>
<li>Ventilatory failure; or</li>
<li>Oxygenation failure</li>
</ul>
<p>In the commoner variety of acute ventilatory failure, prolonged bronchial obstruction in patients with already badly damaged lungs as in COPD leads to an inadequate uptake of oxygen and inefficient elimination of carbon dioxide. Hence, the immediate need is to correct the reduced oxygen tension of the blood. Since oxygen lack stimulates the respiration reflexly, its correction leads to a reduction of ventilatory drive, with the result that carbon dioxide accumulates further. The patient becomes drowsy or even comatose. To avoid this, oxygen is given continuously, preferably in a concentration of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25-30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> (Chapter 77), just enough to correct hypoxaemia without causing hypercapnea and respiratory acidosis.</p>
<p>The patient should be made to cough vigorously while his chest wall is being percussed. Coughing out mucus plugs may result in significant improvement and this is further helped by humidification.</p>
<p>Respiratory stimulants (analeptics) may be used to increase ventilation in patients in whom oxygen therapy is followed by a reduction in ventilation. They may also help by stimulating coughing and thus helping the patient to expel secretions. They are usually given IV and have to be repeated frequently. Satisfactory response is characterised by a return of deeper breathing and consciousness, and a reduction in carbon dioxide tension in the blood. Later, this may be maintained by orally administered drugs. There is no drug which selectively, safely and in a controlled manner stimulates the respiratory centre. Generally used is doxapram is used as an IV infusion of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.5</mn><mo>−</mo><mn>4.0</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">1.5-4.0 \mathrm{mg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4.0</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>, adjusted according to the response. It may be useful as a short term measure along with assisted ventilation, but is not useful in the long term management of respiratory insufficiency.</p>
<p>Almiprine bismethylate a piperaizne derivative selectively stimulates peripheral chemoreceptors. It has no central actions. It is claimed to stimulate ventilation in patients with hypoxia. Its long term use may cause peripheral neuropathy. It is under evaluation.</p>
<p>Other supportive measures in acute ventilatory failure in COPD include bronchodilators, antibiotics, large doses of glucocorticoids, a diuretic (furosemide) to treat heart failure and correction of acid-base imbalance. If these conservative measures do not help sufficiently, secretions from the respiratory passages may be aspirated through a bronchoscope or a cuffed endotracheal tube.</p>
<p>In acute ventilatory failure due to disorders of the CNS (narcotic poisoning, stroke, head injuries), peripheral nervous system and respiratory muscles, intensive nursing care, assisted mechanical ventilation, and other life supporting measures are the mainstay of treatment. In some cases e.g. morphine poisoning, specific antidote therapy is helpful.</p>
<p>In the syndrome of oxygenation failure, which occurs in patients with diffuse interstitial fibrosis, there is no tendency to retention of carbon dioxide, and oxygen can be administered without any reservation and safely. The response is, however, disappointing.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="surfactants-and-the-respiratory-distress-syndrome">Surfactants and the Respiratory Distress Syndrome<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#surfactants-and-the-respiratory-distress-syndrome" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Surfactant is secreted by the type II pneumocytes within the alveolar epithelium of the lungs, into the alveolar lumen. It is a complex mixture of phospholipids, proteins and carbohydrates. By its local action, it:</p>
<ul>
<li>Reduces surface tension within the alveoli and facilitates their aeration at lower ventilatory pressures; this increases the lung compliance and reduces the work of breathing.</li>
<li>Aids in keeping the alveoli dry (antiedema action).</li>
<li>Enhances oxygenation of blood at lower intra-alveolar, partial oxygen pressure; and</li>
<li>May play a role in the immune defence system of the lungs.</li>
</ul>
<p>The secretion of the surfactant is stimulated by cortisol, adrenergic agonists, cholinergic agonists and prostaglandins. Deficiency of surfactant action may be due to:</p>
<ul>
<li>Diminished production as in full term infants delivered by caesarian section, where stimulation of the adrenocortical production of cortisol occurring during vaginal delivery is absent and in prematurely born infants with immature secretory mechanisms. This is the cause of atelectasis and Neonatal Respiratory Distress Syndrome (Neonatal RDS).</li>
<li>More rapid degradation of the surfactant by the macrophages; and</li>
<li>Abnormal composition of the surfactant. The last two factors probably are at work in Adult Respiratory Distress Syndrome (ARDS).
Adverse reactions include bradycardia, hypotension and endotracheal tube blockage. Allergic reactions are rare.</li>
</ul>
<p>The preparations available are bovine-lung derived Calfactant and Beractant; porcinelung derived poractant alpha; and the recombinant calfasceril.</p>
<p>Therapeutic uses: Instillation of surfactant into the trachea of the newborns at risk of developing or already having RDS reduces the morbidity and mortality. The results in adult ARDS are less encouraging. Neonates born by caeserian section can be protected from RDS by administration of dexamethasone to the mother 24 hours prior to the surgery.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-rhinitis">Drug Therapy of Rhinitis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-rhinitis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Rhinitis, an inflammation of the nasal mucosa can be:</p>
<ul>
<li>Noninfectious e.g., allergic and nonallergic rhinitis, which is frequently caused by seasonal allergy (e.g., hay fever, pollinosis) and leads to sneezing, nasal stuffiness, ocular pruritus, lacrimation and a postnasal drip.</li>
<li>Infectious e.g., viral common cold and bacterial infection.</li>
</ul>
<p>Chronic or nonseasonal rhinitis, often referred to as perennial rhinitis, results in daily episodes of rhinorrhoea, nasal congestion and sneezing that are present for several weeks during most months of the year. It is caused by various allergic and nonallergic nasal disorders. It includes:
(1) Vasomotor Rhinitis (VMR), a no allergic, noninfectious rhinitis in which eosinophils are generally absent on nasal smear; and
(2) Nonallergic, Non-infectious Rhinitis with eosinophilia (NARES).</p>
<p>Chronic rhinitis can also be induced by drugs such as adrenergic blockers, cholinesterase inhibitors, estrogen preparations (including oral contraceptives), and by the presence of a foreign body, nasal polyps, tumours and nasociliary disorders.</p>
<p>Non-Drug therapy for all types of rhinitis is similar. Exposure to cigarette smoke, pollutants, allergens and other irritants should be avoided. In patients with pharyngitis, saline gargles, steam inhalation and warm mist therapy is helpful. Local instillation of hyperheated, humidified air directly into the nasal passages significantly relieves symptoms of allergic rhinitis. When nasal congestion is severe, nasal irrigation with warm saline solution, prepared by dissolving one tablespoonful each of table salt and baking soda in a pint of warm <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msup><mn>37</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(37^{\circ} \mathrm{C}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord">3</span><span class="mord"><span class="mord">7</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> tap water, may relieve the congestion. The patient should drink plenty of fluids.</p>
<p>Drug Therapy: No drug is likely to abolish the symptoms completely. In general, (i) drugs are more effective in allergic rhinitis than in nonallergic forms and (ii) Acute rhinitis responds more favourably than the chronic form.</p>
<p>The treatment is directed at preventing the release of inflammatory mediators such as histamine and leucotrienes, or blocking their effects. The drugs used are:</p>
<ul>
<li>Antihistaminics</li>
<li>Nasal decongestants</li>
<li>Antiallergic drugs</li>
<li>Anticholinergic drugs; and</li>
<li>Local corticosteroids</li>
</ul>
<p>The selection of drugs in individual patients requires that the noninfectious, allergic forms be distinguished from the infectious forms (common cold). The agents useful in the former, antihistaminics, cromolyn sodium and intranasal corticosteroids, have little value in the latter. Nasal decongestants are beneficial in both. However, antibiotics should be reserved only for patients with bacterial infections.</p>
<p>Antihistaminics and antiallergic drugs: In allergic rhinitis, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> antihistaminics help to relieve rhinorrhoea, sneezing, nasal pruritus and conjunctivitis but do not affect nasal congestion. They are usually effective in seasonal allergic rhinitis when sneezing and rhinorrhoea predominate and edema and congestion are minimal. They can be used prophylactically in smaller doses by susceptible patients during the allergen exposure</p>
<p>period even when symptoms are absent. A single daily dose of an antihistaminic with a long <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> taken at bedtime, may relieve symptoms the following day. The non-sedating antihistaminics such as cetirizine and loratadine, are preferred (Chapter 23) when sedation needs to be avoided.</p>
<p>Antiallergic drugs like glucocorticoids and cromolyn sodium prevent the release of inflammatory mediators. The nasal spray of cromolyn sodium is as effective as an oral antihistaminic in preventing the symptoms of allergic rhinitis. They are reasonably safe.</p>
<p>Nasal decongestants: These drugs are synthetic alpha-adrenergic agonists (Chapter 18). When used locally by spray or as drops, they constrict the dilated blood vessels in the mucosa of swollen turbinates and help to reduce edema. The drugs commonly used are:</p>
<ul>
<li>Ephedrine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.5%</span></span></span></span></span>.</li>
<li>Phenylephrine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.25%</span></span></span></span></span>.</li>
<li>Naphazoline <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.05</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.05 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.05%</span></span></span></span></span></li>
<li>Oxymetazoline <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.05</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.05 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.05%</span></span></span></span></span> and</li>
<li>Xylometazoline <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.05</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.05 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.05%</span></span></span></span></span>.</li>
</ul>
<p>They provide temporary symptomatic relief in allergic rhinitis, common cold, and acute rhinitis associated with other respiratory infections. NARES, sinusitis, and in acute otitis media with eustachian tube blockage. Oral decongestants such as pseudophedrine may be preferred when sinuses are involved. They are not useful in VMR.</p>
<p>The most common adverse effects of the orally administered nasal decongestants (phenylephrine, pseudoephedrine) are insomnia and irritability. Topical decongestants sometimes cause local discomfort, stinging, burning, dryness of the mucosa, rebound congestion and rhinitis medicamentosa.</p>
<p>Nasal decongestants are only palliative. Only a few drugs in very dilute solution are safe. Ephedrine hydrochloride in isotonic saline, used as nasal drops, is as effective as any other drug, and cost effective. In infants and children, imidazole drugs such as naphazoline and tetrahydrozoline are known to cause disturbance of body temperature, CNS depression and even coma. Hence, decongestants should be stored beyond the reach of children.</p>
<p>Anticholinergic drugs: Rhinorrhoea is primarily the result of glandular hypersecretion, mediated by the cholinergic innervation of the nasal mucosa. Some patients with severe rhinorrhoea and congestion obtain more relief from topical antimuscarinic, ipratropium bromide, than from nasal decongestants.</p>
<p>Topical glucocorticoids exert a marked anti-inflammatory effect on the nasal mucosa by inhibiting the release of inflammatory mediators from the mast cells and basophils, and by blocking the inflammatory effect of leucocytes in the nose. Intranasal glucocorticoids are safe, and are the most effective agents available for the prophylaxis and treatment of seasonal and nonseasonal allergic rhinitis and for weaning the patients with rhinitis medicamentosa from topical decongestants. NARES also responds to local glucocorticoids, but their effectiveness in VMR is limited. Topical glucocorticoids occasionally shrink nasal polyps and reduce nasal obstruction significantly. Small polyps may even disappear.</p>
<p>The efficacy of nasal spray preparation of beclomethasone dipropionate, flunisolide, budesonide, fluocortil butyl and fluticasone is similar. However, local use of dexamethasone formulations is contraindicated as the drug is rapidly absorbed and can cause systemic adverse effects. Sneezing, headache, drying and nasal bleeding can occur after the use of these drugs. In patients with infection, topical steroids, if required, should be used along with</p>
<p>appropriate systemic antibiotics. They should be used with caution in patients with ocular herpes zoster.</p>
<p>Injudicious use of commercially promoted combinations of decongestants with antihistaminics, glucocorticoids and antibiotics may be hazardous and not recommended.</p>
<p>Hyposensitisation: This comprises carrying out skin tests with several antigens individually, followed by serial injections of desensitising vaccines prepared from the 'offending' allergens. The use of such vaccines may benefit (i) patients with allergy to pollens (causing seasonal hay fever); and (ii) those with allergy to wasp and bee venom. It is currently felt that:
(a) Most atopic (allergic) patients are allergic to multiple allergens and are not likely to benefit from vaccines prepared from single allergen.
(b) Diagnostic tests are unreliable, if used by themselves.
(c) The allergen extract desensitising vaccines can precipitate either severe asthma or anaphylaxis and
(d) Vaccines prepared from house dust, house dust mite, animal danders and foods have not been shown to be effective.</p>
<p>All such vaccines should be avoided in asthmatics, pregnant women, children under 5 years and those taking beta-blockers.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="section-vii-br-cardiovascular-drugs">SECTION VII &lt;br&gt; Cardiovascular Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#section-vii-br-cardiovascular-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="outline">OUTLINE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#outline" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Chapter 28: Pharmacotherapy of Cardiac Arrhythmias
Chapter 29: Pharmacotherapy of Angina Pectoris, Acute MI and Peripheral Vascular Diseases
Chapter 30: Pharmacotherapy of Hypertension, Pulmonary Hypertension and Orthostatic Hypotension
Chapter 31: Pharmacotherapy of Heart Failure
Chapter 32: Pharmacotherapy of Shock</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacotherapy-of-cardiac-arrhythmias">Pharmacotherapy of Cardiac Arrhythmias<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacotherapy-of-cardiac-arrhythmias" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Cardiac arrhythmia is defined as disturbance of initiation or conduction of cardiac impulse. Most of us have occasional disturbances (ripple) of cardiac rhythm which are transient and go unnoticed. Normal healthy heart, not genetically predisposed to arrhythmia, is resistant to such minor disturbances by triggers. However, sometimes arrhythmias can be symptomatic and certain arrhythmias are fatal, e.g. those following acute MI.</p>
<p>Anti-arrhythmic drugs are the drugs used to prevent or correct cardiac arrhythmias. The antifibrillatory drugs are compounds which prevent the development of atrial and/or ventricular fibrillation. The antifibrillatory drugs must be differentiated from the defibrillatory drugs i.e. drugs capable of restoring normal sinus rhythm of the heart under atrial and/or ventricular fibrillation. Although many drugs are able to arrest rapid atrial and ventricular arrhythmias, no drug is available that can consistently restore normal rhythm to a fibrillating ventricle.</p>
<p>Electrophysiology of cardiac tissue: The cardiac cell is bounded by a lipoprotein membrane which has receptor channels crossing it. These are ion-selective membranespanning proteins which permit passive movement of ions <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo separator="true">,</mo><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup><mo separator="true">,</mo><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\left(\mathrm{Na}^{+}, \mathrm{K}^{+}, \mathrm{Ca}^{++}\right.</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.2em; vertical-align: -0.35em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;"><span class="delimsizing size1">(</span></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span>and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left.\mathrm{Cl}^{-}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.2057em; vertical-align: -0.35em;"></span><span class="minner"><span class="mopen nulldelimiter"></span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;"><span class="delimsizing size1">)</span></span></span></span></span></span></span>down their electrochemical gradients during the open but not during the closed state of the channels. The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>channels, known as 'fast' channels, are present in the myocytes of the atria, ventricles and the His-Purkinje tissue; they are absent from the SA node and the AV node. The other ion channels are present in all the cardiac tissues. The rapid depolarisation (Phase 0) is due to the influx of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>into the cell, with the late addition of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>, through the 'fast' channels. However, the SA and AV nodes depend upon the inward movement of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span> through the 'slow' <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>channels. The outward movement of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>is responsible for the repolarisation (Phases 1 to 3) of all cardiac tissues (Fig. 28.1).</p>
<p><img src="assets/images/image-20251214-05ff7d4c.jpeg" alt="img-15.jpeg"></p>
<p>FIG. 28.1 Relationship between transmembrane cationic fluxes, ECG recording and transmembrane action potential recorded from mammalian (A) sinus node and (B) His-Purkinje fibre (ventricular)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>R</mi><mi>P</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">R P=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">RP</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Resting potential. TP = Threshold potential
(O) = Phase of depolarisation
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>1</mn><mo separator="true">,</mo><mn>2</mn><mo separator="true">,</mo><mn>3</mn><mo separator="true">,</mo><mo stretchy="false">)</mo><mo>=</mo></mrow><annotation encoding="application/x-tex">(1,2,3,)=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">1</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">2</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">3</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mclose">)</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Phases of repolarisation
(4)= Resting period</p>
<p>In addition to the above mentioned 'channels', there are two, energy requiring exchange pumps in the cardiac myocyte cell membrane:
(1) The adenosine triphosphate (ATP) energised <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>exchange pump which pumps <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> out of the cell and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>into the interior of the cell (see below); and
(2) The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>exchange pump, which mainly extrudes <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>from the cell to the exterior. Such extrusion is dependent on the activity of the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>pump, and diminishes when the latter is made inoperative by digoxin (Chapter 31).</p>
<p>Normally, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ions are concentrated extracellularly and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ions intracellularly. Ordinarily, this would lead to diffusion of these ions across the cell membrane along their concentration gradients and to equalisation of concentrations on its two sides. Such diffusion is, however, opposed by the membrane <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>pump which actively pushes <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> ions out of the cell and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ions into the cell. For every three <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ions pushed out of the cell,</p>
<p>the pump pushes two <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ions into the cell, and the pump is thus electrogenic. The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> pump operates continuously and does not switch on and off during the action potential of the cardiac cells. During the diastole, more <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ions leave the cell than the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ions that enter it, because of the differences in the membrane permeability. Thus, there is a net loss of positive charges from the cell during the diastole. The anions <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Cl}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8557em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span>and proteins do not leave the cell along with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>because the cell membrane is impermeable to them, and contribute to the intracellular negativity. Thus, the inside of the resting myocardial cell remains (about 90 millivolts) negative to its outside; the cell membrane is said to be polarised.</p>
<p>During the excitation of the cell, larger quantities of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ions cross the cell membrane. These ion fluxes though too small to be measured directly, are, in fact, responsible for the phenomenon of the continuously varying potential difference (transmembrane electrical potential) across the cell membrane. These variations can be recorded as an action potential by inserting a microelectrode into the myocardiac cells. Figure 28.1 shows the action potentials as recorded from the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>driven tissues - SA and AV nodes wherein the resting potential is 30 to 40 mv (Fig 28.1 A) and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>driven tissues (others) of the heart (Fig 28.1 B).</p>
<p>In the normal heart, only the SA node and the AV node are capable of spontaneous depolarisation i.e. generating an action potential without external stimulation. As the frequency of spontaneous discharge at the SA node ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">70 / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">70/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span> ) is faster than at the AV node <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>45</mn><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(45 / \mathrm{min})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">45/</span><span class="mord"><span class="mord mathrm">min</span></span><span class="mclose">)</span></span></span></span></span>, the former acts as the pace-maker. The other cardiac tissues merely respond by depolarisation to an action potential generated by the SA node. The diseased heart may contain other sites capable of spontaneous depolarisation, giving rise to arrhythmias.</p>
<p>When an atrial or a ventricular cell receives an action potential, it starts depolarising and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>starts entering it; the intracellular negativity starts diminishing. When such depolarisation reaches a threshold potential (TP in Fig. 28.1), the sodium channels open abruptly and a large amount of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>enters the cell (potential becomes positive). Phase ' 0 ' of the action potential (Fig. 28.1) indicates rapid depolarisation of the cardiac cell membrane associated with fast selective inflow of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>. During the latter part of Phase 0 , <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>also enters the cell via the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>channels. The entry of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>continues through Phases 1 and 2 via the slow <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>channels. The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>which enters the cell causes release of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span> stored in the sarcoplasmic reticulum of the cardiac myocytes, raising the concentration of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>within these cells. The intracellular free calcium interacts with the troponin-actinmyosin system and causes contraction of the heart. The P wave, the P-R interval and the QRS complex of the ECG are inscribed during Phases 0 and 1 of the action potential propagation in the atria, the AV nodal tissue and the ventricles, respectively.</p>
<p>After depolarisation, the repolarisation occurs in several phases (Fig. 28.1):</p>
<ul>
<li>Phase ' 1 ' - A short rapid repolarisation due to beginning of outflow of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>and entry of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Cl}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8557em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span> ions into the cells.</li>
<li>Phase ' 2 ' - A prolonged plateau phase (delay in repolarisation) at the neutral level due to a balance between the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>entering the cell (through slow calcium channel) and the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> leaving the cell. The ST segment of the ECG coincides with this phase of the action potential.</li>
<li>Phase ' 3 ' - The rapid repolarisation upto the resting potential caused mainly by continued extrusion of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>; it corresponds to the T wave.
During Phase 3, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>is removed from the cytoplasm by reaccumulation into the</li>
</ul>
<p>sarcoplasmic reticulum sacs and by extrusion from the cell. The lowering of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span> concentration in the cytoplasm allows the cardiac muscle fibre to relax; and</p>
<ul>
<li>Phase ' 4 '- In this resting phase, the final ionic reconstitution of the cell is achieved by the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>exchange pump which actively pushes <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>out of the cell and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>into the cell. The cycle is then repeated. In the atria and the ventricles, the membrane potential is steady throughout the diastole; in contrast, the SA node, the AV node and the HisPurkinje tissue depolarise spontaneously because the cell membrane is leaky to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>.
During the greater part of the action potential, the cardiac muscle is resistant to further stimulation (refractoriness, Fig. 28.2). The earliest transient depolarisation that can be produced (without propagation) marks the end of the absolute refractory period (ARP, Phases 1 and 2). The part of the action potential during which a stimulus can evoke only a local, non-propagated response is called effective refractory period (ERP). Relative refractory period extends from the end of ERP to the time that the cardiac tissue has recovered fully; during this period, a stimulus of greater than threshold strength is needed to evoke response that is propagated, though slowly.
<img src="assets/images/image-20251214-a0ce3f6d.jpeg" alt="img-16.jpeg"></li>
</ul>
<p>FIG. 28.2 The normal pattern (dotted line) of transmembrane action potential of a pacemaker cardiac cell and mechanisms of action of antiarrhythmic drugs: (1) Delaying the spontaneous diastolic depolarisation from the resting potential (RP), thus decreasing the rate (all drugs); (2) Increasing excitation threshold potential (TP) e.g. quinidine, procainamide, propranolol; (3) Prolonging the resting period in part by increasing maximum diastolic intracellular negativity e.g. phenytoin and (4) Increasing the effective refractory period (ERP) e.g. quinidine, procainamide.</p>
<p>The above concepts are important for understanding the mechanisms of action of antiarrhythmics in terms of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>-channel blocking, Ca-channel blocking and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>-channel blocking.</p>
<p>Certain terms appear repeatedly during a discussion of cardioactive drugs; they are:</p>
<ul>
<li>
<p>Automaticity is the capacity of a cell to undergo spontaneous diastolic depolarisation. In the normal heart, it is maximum in the SA node (pacemaker). In the diseased heart, other areas of the myocardium may develop automaticity and act as ectopic foci.</p>
</li>
<li>
<p>Excitability is the ability of a cell to respond to an external stimulus by depolarisation. It depends upon the level of the resting (diastolic) intracellular negativity; if the negativity decreases (say from -90 to -70 mv ), the excitability of the cell increases.</p>
</li>
<li>
<p>Threshold potential (TP) is the level of intracellular negativity at which abrupt and complete depolarisation occurs. If the TP is raised (i.e. changed from -70 to -60 mv ), the automaticity of the tissue is suppressed.</p>
</li>
<li>
<p>The conduction velocity of an impulse is determined primarily by the slope of action potential and amplitude of Phase 0 (Fig. 28.1) in that tissue; any reduction in the slope leads to depression of conduction.
Propagation of an impulse in the cardiac tissue depends upon (a) the ERP of the tissue and (b) its conduction velocity.</p>
</li>
<li>
<p>Inotropic action is the action of a drug on the contractility of the myocardium.</p>
</li>
<li>
<p>Chronotropic action is the action of a drug on the heart rate.</p>
</li>
<li>
<p>Lusitropic action is the action on relaxation (diastolic function) of the heart.</p>
</li>
</ul>
<p>The autonomic nervous system modulates the inotropic state of the myocardium by regulating the transmembrane ion movements, e.g., beta adrenergic stimulation allows entry of larger amounts of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>through the slow channels and exerts a positive inotropic effect. Beta adrenergic blockers counter this adrenergic influence and exert a negative inotropic effect.</p>
<p>Cardiac arrhythmias, mechanisms: According to the present concept a triggering beat/s interact with a predisposed cardiac tissue (substrate) to initiate and perpetuate cardiac arrhythmia. They could be due to:
(a) Disorders of impulse formation and/or
(b) Disorders of impulse conduction</p>
<ul>
<li>Tachyarrhythmias due to disturbed impulse formation are associated with spontaneous, irregular and rhythmic discharge from ectopic pacemaker activity from areas other than the SA node. Production of such ectopic impulse involves an abnormality of the spontaneous diastolic depolarisation (Phases 3 and 4), leading to ectopic areas of automaticity.
The differences among various atrial arrhythmias could be explained on the basis of the rate of discharge of the ectopic focus. Thus, an ectopic pacemaker with a rate 160180/min. causes atrial tachycardia. If the ectopic rate becomes more rapid, 220-300/min., it produces atrial flutter, while very rapid rates over 350/min results in atrial fibrillation (AF).</li>
<li>Disorders of impulse conduction, commonly referred to as re-entry disturbances, are the commoner of the two mechanisms of arrhythmias. According to this theory, the affected myocardium has areas of depressed function with prolonged refractory period. Due to that, an impulse approaching such an area would be diverted to adjacent excitable tissue. It is possible that the same impulse, after taking a circuitous route through normal tissue, will again reach the depressed area which by then becomes excitable. Upon traversing it, the excitatory process is free to re-enter normal regions and restimulate the chamber or entire heart. Repetition of this cycle would produce an ectopic tachycardia. The presence of a single re-entry mechanism within the ventricle may account for ventricular premature systoles, ventricular tachycardia (VT) and ventricular fibrillations (VF). The presence of a similar mechanism within the atria could cause atrial flutter. Atrial and ventricular fibrillation are caused by the fragmentation of single re-entrant path into multiple smaller cycles. In arrhythmias of the re-entrant type, conduction velocity and duration of RP are the two most critical electrophysiological properties which could be altered by drugs.
Clinically, it is usually not possible to determine whether an arrhythmia represents a disorder of impulse formation or impulse conduction. Identical arrhythmias on the ECG</li>
</ul>
<p>may result from disparate mechanisms in different patients, or even in the same individual at different times. Hence, except in a few cases, an antiarrhythmic drug cannot be selected simply on the basis of its effect on electrophysiological properties.</p>
<p>Not all arrhythmias need the same aggressive drug therapy. If an arrhythmia is precipitated by hypotension, restitution of BP by vasopressor agents like DA or NA may reestablish normal sinus rhythm. Further, sinus tachycardia and sinus bradycardia generally need no treatment other than that of the underlying cause. Only those which are lethal (VF), herald more dangerous rhythm (ventricular premature beats in acute MI) or seriously compromise cardiac output (AF with fast ventricular rate) require rapid and effective therapy.</p>
<p>Apart from common risk factors such as smoking, hypertension, metabolic diseases (diabetes), genetic predisposition seems to be important. The presence of long QT syndrome phenotype has been associated with sudden death. Blacks have higher prevalence of high BP and metabolic disease but lower incidence of atrial fibrillation compared to white population. Familial occurrence of atrial fibrillation is well known. Every patient with an arrhythmia should be evaluated for a possible underlying cause such as : a cardiovascular disorder; pulmonary disease; autonomic disorders; electrolyte disturbances; systemic disease; and drug induced toxicity. Correction of an identifiable factor, when possible should precede the administration of an anti-arrhythmic drug. In many situations, arrhythmias tend to be benign. Their treatment should be expectant, and potentially toxic drugs should be avoided.</p>
<p>The basic electrophysiological actions of antiarrhythmic drugs (Fig. 28.2) are:</p>
<ul>
<li>Decreasing the slope of Phase 4 (diastolic depolarisation) of the action potential in the excitable cardiac tissues. This action is possessed by all antiarrhythmic drugs and suppresses the enhanced automaticity of ectopic foci.</li>
<li>Shifting the threshold potential towards zero (i.e., making it less negative). This again suppresses the automaticity of ectopic foci. Quinidine, Procainamide, Propranolol and Potassium possess this action.</li>
<li>Shifting the resting potential away from zero (i.e. making it more negative), which also slows the rate of diastolic depolarisation and suppressing automaticity. Lignocaine and Phenytoin possess this action.</li>
<li>Increase in the duration of the action potential, thus increasing the effective refractory period (ERP) and blocking re-entrant impulses. Quinidine, Procainamide, Propranolol and Potassium possess this action.</li>
<li>Shortening of the duration of action potential by Lignocaine and Phenytoin, on the other hand, reduces the refractoriness of the AV junctional tissue.</li>
<li>Decreasing the slope of Phase 0 of the action potential and slowing the conduction velocity of a propagated impulse. This blocks the re-entrant impulses responsible for an arrhythmia. Quinidine, Procainamide, Disopyramide, Lignocaine (in large doses) and Verapamil possess this action.
Antiarrhythmic drugs, classification: They are generally classified according to their mechanism of action as:</li>
</ul>
<p>Class I: Fast sodium channel blockers: Which predominantly block open and/or inactivated sodium channels rather than resting sodium channels. In higher concentrations, they also block nerve conduction. With the usual doses, most drugs, other</p>
<p>than group IC, have little effect on the normal conduction system. They impede the initial rapid depolarisation and slow the phase 0 depolarisation rate, without altering the resting potential and are sometimes called membrane stabilisers (Chapter 16). They are further subdivided into 3 groups:
(IA) Those which cause moderate phase <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>O</mi></mrow><annotation encoding="application/x-tex">O</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.02778em;">O</span></span></span></span></span> depression. and hence, moderately suppress conduction. They prolong repolarisation (refractoriness, phase 3) and prolong the action potential duration, in addition to suppression of automaticity e.g. Quinidine, Procainamide, Disopyramide;
(IB) Those which are weak phase <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>O</mi></mrow><annotation encoding="application/x-tex">O</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.02778em;">O</span></span></span></span></span> depressants and have little influence on conduction velocity. They shorten repolarisation (refractoriness, phase 3) and action potential duration. They suppress automaticity e.g. Lignocaine, Phenytoin, Mexiletine, Tocainide, and
(IC) Those which cause marked phase <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>O</mi></mrow><annotation encoding="application/x-tex">O</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.02778em;">O</span></span></span></span></span> depression; they markedly slow conduction. They have no effect on action potential duration and repolarisation. e.g., Flecainide, Propafenone.</p>
<p>Class II: Beta adrenergic blockers which block the beta-1 cardiac receptors and mainly suppress automatic discharge (phase 4 depolarisation). They do not prolong repolarisation (phase 3).</p>
<p>Class III: Potassium channel blockers: They markedly prolong repolarisation (phase 3) and increase action potential duration without affecting the conduction velocity. They increase RP e.g. Amiodarone, Sotalol, Ibutilide, Vernakalant, Sotalol is a noncardioselective beta blocker with additional class II activity.</p>
<p>Class IV: Calcium channel blockers (CCB: Verapamil but not Nifedipine) which shorten the action potential duration and depress the slow inward <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>current (phase 2). Their action is mostly limited to SA and AV node where they suppress automaticity in pacemaker cells and slow conduction and increase ERP.</p>
<p>Mechanism of action of some drugs does not fall in any of the four classes.
Class V: Miscellaneous:
(a) Those which do not cause prolongation of repolarisation, e.g. Adenosine.
(b) Digitalis (Chapter 31); Potassium; Magnesium.</p>
<p>Most of the antiarrhythmic drugs have multiple actions. Further, the metabolites of some of these drugs contribute to or even are primarily responsible for the action.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="clinical-classification">Clinical classification:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-classification" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>I Those used for supraventricular arrhythmias, viz. Adenosine, CCB such as Verapamil and Diltiazem.
II Those used for both supraventricular and ventricular arrhythmias, viz. Amiodarone, Beta blockers, Quinidine and Procainamide; and
III Those used for ventricular arrhythmias, viz. Lignocaine.
The choice of anti-arrhythmic agent in a given arrhythmia depends on :</p>
<ul>
<li>Correct diagnosis.</li>
<li>Urgency for treatment.</li>
<li>Route of administration.</li>
<li>Extent of cardiac damage; and</li>
<li>The risk-benefit ratio of the drug concerned.</li>
</ul>
<p>All the antiarrhythmic drugs have both cardiac and noncardiac adverse effects.</p>
<p>Table 28.1 lists the major risks with Group I antiarrhythmics. All drugs that block the sodium channels have the capacity to reduce ventricular function. This propensity is highest with flecainide (IC). Class III agents are also proarrhythmic but to a smaller extent. Further, flecainide is known to cause</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-28-1">Table 28.1<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-28-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cardiovascular-risks-with-group-i-antiarrhythmic-agents">Cardiovascular risks with Group I antiarrhythmic agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cardiovascular-risks-with-group-i-antiarrhythmic-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Torsade de pointes</li>
<li>Increased frequency of ventricular tachycardia.</li>
<li>Increased mortality during long term treatment.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><mo>−</mo><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">--&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span><span class="mord">−</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&gt;</span></span></span></span></span>
<img src="assets/images/image-20251214-bb097c42.jpeg" alt="img-17.jpeg">
(a) incessant, sustained ventricular tachycardia;
(b) ventricular fibrillation, particularly in patients with poor ventricular function, and
(c) unexplained, sudden deaths. Therefore, although the presence of ventricular premature beats and non-sustained ventricular tachycardia increase the risk in patients with recent MI, asymptomatic and mildly symptomatic patients with such arrhythmias may not benefit from atiarrhythmic drugs other than beta adrenergic blockers.</li>
</ul>
<p>QUINIDINE: This first antiarrhythmic agent used to treat both atrial and ventricular arrhythmias, is an isomer of the antimalarial drug quinine, one of the alkaloids occurring in the cinchona bark. The beneficial effect of quinine on AF was first noted by a Dutch colonial with atrial fibrillation, when he took quinine for malaria. Later, Wenckebach, an Austrian cardiologist confirmed this observation and introduced quinine as an antiarrhythmic drug.</p>
<p>Pharmacological actions: These are:
I Cardiac actions and
II Extracardiac actions
The cardiac actions are due to its direct myocardiac depressant properties, and to a smaller extent due to its vagolytic (antimuscarinic) action. It blocks the sodium channels. It also inhibits potassium channels in the cardiac cells.</p>
<ul>
<li>
<p>Automaticity: Quinidine depresses diastolic depolarisation and hence, automaticity in all tissues, especially the ectopic pacemaker. This action helps to suppress the arrhythmias due to enhanced impulse formation. Quinidine does not suppress the automaticity of the normal SA node.</p>
</li>
<li>
<p>Excitability: Quinidine depresses the excitability of the cardiac tissue and hence a weak ectopic impulse becomes ineffective.</p>
</li>
<li>
<p>Conduction velocity: Quinidine slows the conduction velocity in all the cardiac tissues. This property, along with the increased RP and decreased excitability, contributes to a decreased cardiac rate in arrhythmias due to the presence of an ectopic focus.</p>
</li>
<li>
<p>Refractory period: Quinidine blocks delayed rectifier potassium current, thus depressing the potassium efflux during repolarisation. Thus, it prolongs (by a direct action) repolarisation and hence, the RP. However, its vagolytic action (indirect action) increases the atrial RP, shortens that of the AV node while leaving that of the ventricles unaltered. The overall action of quinidine is:
(a) To prolong the RP markedly in the atria,
(b) To increase RP in the ventricles to a smaller extent and
(c) To decrease RP in the AV node.</p>
</li>
</ul>
<p>Simple prolongation of RP prevents the heart from responding to premature or rapid stimulation. Re-entrant impulse finds the originally depolarised tissue still inexcitable. Quinidine thus abolishes the arrhythmias due to re-entrant circuits.</p>
<ul>
<li>AV conduction: Quinidine depresses conduction predominantly within the atria and the His-Purkinje system. However, its vagolytic effect permits or even enhances conduction in the AV node, causing tachycardia.</li>
<li>Contractility: Quinidine exerts a negative inotropic action on the heart. This obviously is a disadvantage. Hyperkalemia enhances the depressant effects of quinidine.</li>
<li>Effects on ECG: Early changes comprise increase in Q-T interval. Decrease in amplitude or inversion of T wave and depression of S-T segment may also occur. Later changes include widening and frequent notching of the P wave, and prolonged P-R interval.
Widening of the QRS complex signifies reduction of conduction velocity, and if accompanied by a considerable increase in the RP of the ventricle, might lead to the development of VT and eventually to VF. When, the QRS complex is widened by 25 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> or above 0.12 to 0.14 second, quinidine should be withheld.</li>
</ul>
<p>Quinidine is known to cause unpredictable abnormalities of rhythm in digitalised heart. Extracardiac actions:</p>
<ul>
<li>Blood pressure: Quinidine lowers BP in most patients. In patients with low cardiac output, quinidine may shift it towards normal. This is accomplished by a reduction in BP which reduces the left ventricular load, permitting a more complete emptying of the ventricle.</li>
<li>Miscellaneous actions: Quinidine depresses the skeletal muscle and like quinine, shows antimalarial, antipyretic and weak oxytocic activities.
Absorption, fate and excretion: Quinidine is almost completely absorbed from the gut. Following a single oral dose, the peak effects are reached within 2 to 3 hours and persist for 6 to 8 hours. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> is bound to plasma albumin. It is primarily metabolised ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">75 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">75%</span></span></span></span></span> ) in the liver with half life of 4-8 hours. One metabolite 3-hydroxyquinidine is as potent as quinidine. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> of the drug is excreted in the urine unchanged. With the same quinidine regimen, there are wide differences in the serum quinidine levels in different persons. Electrophysiological and toxic effects correlate better with serum levels than with dosage. Hence, frequent clinical and ECG monitoring is mandatory. Adverse reactions: Quinidine given IV could be very toxic.</li>
<li>Cardiac toxicity: The drug causes bradycardia, conduction defects and heart failure, particularly in patients with marked cardiac damage. Further, there may be increased frequency of ventricular premature beats. In addition, two distinct, drug-induced ventricular arrhythmias may occur:
(a) Torsade de pointes; and</li>
</ul>
<p>(b) Incessant ventricular tachycardia.</p>
<p>All antiarrhythmics that prolong QT interval markedly can precipitate a polymorphic ventricular tachycardia known as torsade de pointes, which may result in syncope and sudden death. Presence of bradycardia and hypokalemia increases this risk. It is generally dose related and women and elderly are more susceptible. Drugs that cause similar prolongation of QTc (corrected QT) are listed in Table 28.2.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-28-2">Table 28.2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-28-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="some-drugs-causing-prolongation-of-qtc">Some drugs causing prolongation of QTc<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#some-drugs-causing-prolongation-of-qtc" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Antiarrhythmics (Class IA): Disopyramide, Procainamide, Quinidine</li>
<li>Antiarrhythmics (Class III): Amiodarone, Dofetilide, Ibutilide, Dronedarone, Sotalol</li>
<li>Antipsychotics: Chlorpromazine, Haloperidol, Thioridazine, Pimozide, Ziprasidone, Quetiapine</li>
<li>Antibiotics: Erythromycin, Clarithromycin, Moxifloxacin</li>
<li>Miscellaneous: Cisapride, Quinine, Methadone, Pentamidine</li>
<li>Hypotension: Hypotension has been observed more commonly in older patients.</li>
<li>Embolic phenomena: Sudden restoration of sinus rhythm by quinidine in a patient with chronic AF may dislodge the mural thrombi attached to auricular appendages. This might rarely precipitate embolic occlusion of the vessels of the vital organs.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="miscellaneous-toxicity">- Miscellaneous toxicity:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#miscellaneous-toxicity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(a) Allergic Reactions: The manifestations of intolerance include skin rashes, fever and thrombocytopenic purpura.
(b) Gastrointestinal: Nausea, vomiting and diarrhoea are common.
(c) CNS: Headache, dizziness and convulsions may result from a direct action of quinidine on the CNS.
(d) Cinchonism: It results from cumulative overdosage and includes impairment of hearing, ringing in ears, vertigo, blurred vision, light headedness, giddiness and tremor.
Drug interactions: Quinidine is metabolised by hepatic cytochrome P450 enzymes and hence, induction or inhibition of these enzymes affects plasma concentration of quinidine (Chapter 3). Quinidine increases the plasma digoxin level needing adjustment of digoxin dose.</p>
<p>Preparations and dosage: Quinidine sulfate, 200 mg Dose 200-400 mg. every 6 hours.
Therapeutic uses: Quinidine, because of its toxicity, is now rarely used to treat arrhythmias.</p>
<ul>
<li>Atrial fibrillation and atrial flutter: See later.</li>
<li>Paroxysmal atrial, nodal and ventricular tachycardia: Adenosine is usually preferred. Vasopressor agents and parasympathomimetic drugs may also help. Although carotid sinus massage may be effective, it is a potentially hazardous procedure and should be applied only by those with experience in treating its possible complications. Other treatment includes ventricular rate controllers (CCB and beta blockers) or rhythm controller (amiodarone). Quinidine may be used if the above measures prove ineffective.</li>
<li>Atrial, nodal and ventricular premature beats: Most supraventricular premature beats are benign, and patient should be reassured about their harmless nature. Smoking and consumption of tea and coffee should be stopped or at least minimised. If these</li>
</ul>
<p>therapies are ineffective, a beta blocker or amiodarone may be used. Ventricular premature beats, especially if they are frequent (more than 100 beats per 24 hours), need to be investigated to rule out an underlying cardiac lesion. The development of ventricular premature beats during acute MI may herald onset of ventricular tachycardia. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> blockers and amiodarone are effective in many patients; quinidine may be used as the last resort. Contraindications to quinidine therapy:</p>
<ul>
<li>QT prolongation</li>
<li>Chronic heart failure</li>
<li>History of quinidine intolerance.</li>
<li>Ventricular tachycardia associated with complete A-V block.</li>
<li>Hypotension.</li>
<li>Stokes-Adams syndrome.</li>
<li>Myasthenia gravis</li>
</ul>
<p>Quinidine must not be used to treat digitalis-induced arrhythmias.
PROCAINAMIDE: Procainamide, a derivative of procaine, a local anaesthetic (Chapter 16) is effective orally, IM and IV; it is not destroyed by esterase. The cardiac and hemodynamic effects of procainamide are similar to those of quinidine. It is free from CNS toxicity.</p>
<p>Absorption, fate and excretion: Procainamide is rapidly and almost completely absorbed from the gut. Given orally, peak plasma level is reached within 1 hour and declines by 4 hours. It is minimally bound to plasma proteins and about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> is excreted unchanged in urine. Impairment of renal function can produce cumulative toxicity.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-reactions">Adverse reactions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Allergic reactions which include chills, fever, itching, skin rash and angioedema.</li>
<li>Cardiotoxicity is similar to that of quinidine. Hypotension (or a shock-like state) occurs most often with the IV use.</li>
<li>Gastrointestinal ADR such as anorexia, nausea and vomiting.</li>
<li>Blood: Agranulocytosis and SLE are rare but serious manifestations.</li>
</ul>
<p>Preparations and dosage:
(i) Procainamide hydrochloride tablet 250 mg .
(ii) Procainamide hydrochloride injection, 100 mg per ml .</p>
<p>It is administered orally in the dose of 0.25 to 0.5 g every 4 to 6 hours. In serious cases, 0.5 to 1 g may be given every 2 to 4 hours. The maintenance dose is 0.25 to 0.5 g 6 hourly.</p>
<p>Therapeutic uses: Procainamide may be used as a substitute for quinidine. It is not recommended for more than 6 months treatment because of the risk of SLE.</p>
<p>DISOPYRAMIDE PHOSPHATE: This drug has membrane depressant (quinidine like) and anticholinergic properties. Its therapeutic effects and toxicity are similar to those of quinidine but it is better tolerated. Given orally, it is completely absorbed and has a plasma half life of 6 hours. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> of the drug is excreted in urine and the rest in the bile.</p>
<p>It is now rarely used.
LIGNOCAINE (Lidocaine): This drug belonging to Class IB is a local anaesthetic (Chapter 16). Given IV, it:</p>
<ul>
<li>
<p>Selectively acts on diseased or ischemic myocardium and depresses diastolic depolarisation and automaticity in ventricular tissue.</p>
</li>
<li>
<p>Has a rapid onset and short duration of action.</p>
</li>
<li>
<p>Shortens the ventricular action potential.</p>
</li>
<li>
<p>Has little influence on conduction velocity.</p>
</li>
<li>
<p>Does not significantly affect the electro physiological function of the atria, SA node and AV node, and causes hardly any change in the surface ECG.</p>
</li>
<li>
<p>Has no hemodynamic adverse effects; and</p>
</li>
<li>
<p>Toxicity, if it occurs, is of short duration.</p>
</li>
</ul>
<p>Since the electrophysiological effects of lignocaine are primarily limited to ventricular myocardium, it is most useful in abolishing ventricular arrhythmias. Its lack of action on AV nodal conduction velocity, makes it a suitable drug in the treatment of digitalis induced ventricular arrhythmia.</p>
<p>The drug is usually given IV, although it can also be used IM. The IV preparation must not contain a preservative nor a sympathomimetic or other vasoconstrictor. The common local anaesthetic preparation should not be used intravenously. It is not effective orally because of extensive hepatic first pass metabolism. Its plasma-protein-binding is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60-80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>30</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">15-30 \mathrm{~min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6679em;"></span><span class="mord">30</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span></span></span> after a single injection.</p>
<p>Adverse reactions: In recommended dosage, lignocaine is a relatively safe drug. Adverse reactions include drowsiness, disorientation, muscle twitching, blurred vision and rarely convulsions. An IV preparation of a barbiturate or diazepam should be at hand while using IV lignocaine. It diminishes the cardiac output and may cause hypotension, bradycardia and apnea. It should be avoided in the presence of liver damage.</p>
<p>Therapeutic uses: It is the drug of choice for:
(1) Severe ventricular arrhythmias.
(2) Emergency termination of ventricular tachycardia following recent MI and that occurring during cardiac surgery and cardiac catheterisation; and
(3) Digitalis-induced ventricular arrythmias. Because of its immediate effect and short duration of action ( 10 min ), lignocaine is given as a single large initial IV bolus, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1-2 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> in 30 sec , followed by a continuous IV infusion at the rate of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">1-4 \mathrm{mg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span> to maintain the effect. Smaller doses ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> ) are used in patients with congestive heart failure, shock, hepatic dysfunction and in those over 70 years.</p>
<p>MEXILETINE: This drug resembles lignocaine, chemically as well as in its pharmacological actions. It is, however, effective orally. Adverse reactions are common and are dose related. They include vomiting, tremor, ataxia, blurred vision and hypotension. The dose is 400 mg followed by 200 mg tid.</p>
<p>PHENYTOIN SODIUM (Diphenyl-hydantoin): The hypothesis that the excitatory processes or substances initiating the discharge of impulses in cardiac arrhythmias may be similar to those responsible for epilepsy, led to the use of phenytoin in the treatment of cardiac arrhythmias (Chapter 9).</p>
<p>Phenytoin, a sodium channel inhibitor, depresses the ventricular automaticity; but like lignocaine it does not decrease the conduction velocity between the ventricular fibres. It has less action on the A-V conduction. Similar to lignocaine, it reduces the duration of the action potential. Phenytoin has little effect on the surface electrocardiogram although it may shorten the QT interval.</p>
<p>It is administered orally in the dosage of 100-200 mg 4 times daily for the suppression of ectopic beats and for prophylaxis against recurrent paroxysmal tachycardia. Because of its long half life, the therapeutic effect can be maintained by oral administration of 1.0 g on</p>
<p>the first day, 0.6 g on the second and third days and 0.4 g per day thereafter.
Therapeutic uses: The main use of IV phenytoin is to terminate digitalis induced cardiac arrhythmias where it was preferred as it does not aggravate the A-V block and is relatively safe. However, lignocaine is more effective.</p>
<p>It is given by slow IV injection. A constant IV infusion is liable to cause phlebitis because of the high pH , and should be avoided.</p>
<p>TOCAINIDE: This is an amine analogue of lignocaine and can be given orally in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>400</mn><mo>−</mo><mn>800</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">400-800 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">400</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">800</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>. every 8 hours. It can cause serious dose related neurological adverse effects.</p>
<p>FLECAINIDE: This fluorinated analogue of procainamide belongs to class 1C. It is well absorbed on oral administration ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mn>14</mn><mo>−</mo><mn>20</mn></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2} 14-20</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9713em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mord">14</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">20</span></span></span></span></span> hours). It can also be given IV slowly. It is highly effective in AV nodal tachycardia and tachycardia associated with WPW syndrome. It, however, causes prolongation of PR, QRS and QT intervals, and is liable to cause arrythmias and sudden death. It has negative inotropic effect. It is contraindicated in cases with heart failure and sick sinus syndrome. Less common toxicities include nausea, tremors and blurred vision.</p>
<p>ENCAINIDE: It has properties similar to flecainide and is effective orally.Although encainide and flecainide readily suppress ventricular premature beats after MI, they can promote incessant ventricular tachycardia (proarrhythmic effect) which is difficult to terminate.</p>
<p>PROPAFENONE: This class 1C antiarrhythmic drug also has mild beta blocker and calcium channel blocker activities. It is relatively safe for suppression of supraventricular arrythmia including WPW syndrome and recurrent AF. It is also used for treating life threatening ventricular arrythmia provided there is no associated structural heart disease. At the onset of paroxysm, 600 mg is administered orally, followed by 300 mg 8 hourly.</p>
<p>The adverse effects are dose related and include prolongation of PR and QRS complex, conduction blocks, inhibition of sinus node and precipitation of CHF, dyspepsia and taste disturbances.</p>
<p>Moricizine: This phenothiazine derivative belongs to class IC and is used to treat supraventricular arrhythmias. It is given orally in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>200</mn><mo>−</mo><mn>300</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">200-300 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">200</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">300</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> tid. Its active metabolites contribute to its long <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span>. Mood change, nausea and tremors may occur.</p>
<p>Adrenergic Blocking Agents: Alpha-adrenergic blocking drugs like phenoxybenzamine, administered prophylactically, can prevent the cardiac arrhythmias during surgery of pheochromocytoma (Chapter 18).</p>
<p>Myocardial ß-receptor stimulation increases automaticity, enhances A-V conduction velocity and shortens the refractory period especially in supraventricular tissues.</p>
<p>Beta-adrenergic blocking agents are useful because they:</p>
<ul>
<li>Antagonise the effects of beta-adrenoreceptor activation on SA node and some ectopic foci.</li>
<li>Prolong the refractoriness of AV node and slow down the ventricular rate.</li>
<li>Have a membrane stabilising property (propranolol, oxprenolol and acebutolol).</li>
<li>Reduce myocardial oxygen demand, particularly in the presence of IHD.</li>
<li>Are mainly useful in supraventricular tachyarrhythmias, particularly those precipitated by exercise, emotions, thyrotoxicosis; and</li>
<li>Are generally well tolerated and are much safer than class I group of drugs.</li>
</ul>
<p>See Chapter 18 for the detailed pharmacology of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>-adrenergic receptor blocking drugs.</p>
<p>PROPRANOLOL This beta blocker is well absorbed on oral administration and it is used in the dose of 10-40 mg every 6 to 8 hours. Its plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is 2-3 hours following IV administration and 4 to 6 hours after oral use. The drug is given slowly IV at the rate of 1 mg . over 1 minute, repeated at 2 minutes interval upto a total dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.1 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>. Other beta blockers may such as atenolol ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">25-100 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day) can also be used. Severe propranolol toxicity may result in progressive bradycardia and cardiac asystole.</p>
<p>Beta blockers prolong PR interval, shorten <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">Q</mi><mi mathvariant="normal">T</mi></mrow><mi mathvariant="normal">C</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{QT}_{\mathrm{C}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9275em; vertical-align: -0.2441em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">QT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.2342em;"><span style="top: -2.4559em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">C</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.2441em;"><span></span></span></span></span></span></span></span></span></span></span> and may potentiate the negative inotropic action of antiarrhythmic drugs, particularly verapamil, which can result in marked bradycardia and even asystole.</p>
<p>They are useful for rate control in SVT.
They exhibit synergistic effect when combined with other antiarrhythmic drugs from class I and III. Broad spectrum of antiarrhythmic activity and established safety record make beta blockers agents of choice for general use as antiarrhythmic agents (see Chapter 31).</p>
<p>Esmolol is a rapidly acting cardioselective beta blocker with a short duration of action ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mn>9</mn></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2} 9</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mord">9</span></span></span></span></span> minutes). It is given IV in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>500</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">500 \mu \mathrm{~g} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">500</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> over one minute, followed by a 4 min infusion of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">50 \mu \mathrm{~g} / \mathrm{kg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>.</p>
<p>SOTALOL: This Class III drug is a non-cardioselective <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> blocker with potency similar to that of propranolol. However, it has no membrane stabilising action. It:
(a) Prolongs the duration of action potentials in the atria and the ventricles in a concentration-dependent fashion.
(b) Prolongs the ERP of all cardiac tissues, including the AV node and His-Purkinje system.</p>
<p>These actions are unrelated to its beta blocking action.
(c) Has no negative inotropic effect and clinically it does not reduce the left ventricular ejection fraction in the majority of cases.
(d) Increases the ventricular fibrillation threshold in normal and ischemic myocardium, when given experimentally IV.</p>
<p>The surface ECG shows prolongation of PR and QT intervals.
Absorption, fate and excretion: Given orally, it is absorbed completely and does not undergo first pass metabolism in the liver. It is excreted unchanged ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> ) in the urine. Its apparent plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is 7 to 18 hours.</p>
<p>Adverse reactions: These are due to its beta blocking properties viz. sinus bradycardia, conduction blocks and hypotension; and due to its property of prolonging the QT interval viz. torsade de pointes (similar to quinidine).</p>
<p>Preparations and dosage: Sotalol hydrochloride tablets ( 40,80 and 200 mg ) and a solution <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(10 \mathrm{mg} / \mathrm{ml})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mclose">)</span></span></span></span></span> for IV injection. The oral dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mo>−</mo><mn>160</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">80-160 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">80</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">160</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> per day in divided doses (maximum oral dose <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>640</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">640 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">640</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day). It is important to avoid hypokalemia during its use.</p>
<p>Therapeutic uses: Although sotalol is relatively safe in patients who have arrhythmias after MI, it is not recommended routinely as a substitute for other beta blockers. It has been found to be specifically useful in:</p>
<ul>
<li>Unsustained ventricular arrhythmias such as ventricular ectopic beats, even in patients with reduced left ventricular function.</li>
<li>Sustained ventricular tachycardia.</li>
<li>WPW syndrome or recurrent atrioventricular nodal tachycardia; and</li>
<li>Prevention of inducible ventricular tachycardia and fibrillation.</li>
</ul>
<p>The main advantage of sotalol is that its use is associated with low incidence of adverse</p>
<p>effects as compared to the Class I anti-arrhythmic agents. It is very expensive.
AMIODARONE: This Class III drug, structurally related to thyroxine, exerts Class I, as well as Class II (non competitive beta blockade) and Class IV actions. It:</p>
<ul>
<li>Depresses automaticity of sinus, atria and AV node.</li>
<li>Prolongs the ERP of myocardial cells, AV node and abnormal pathway; and</li>
<li>Slows the conduction in AV node and specialised conducting tissues.</li>
</ul>
<p>Thus, it reduces cardiac rate, increases cardiac output and causes a fall in peripheral and coronary vascular resistance due to direct effect on vascular smooth muscles, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>channel blockade and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> adrenergic blockade.</p>
<p>It is used orally as well as IV. It has a large apparent volume of distribution and is stored in fat and tissues. Its half life is 18-60 days. It is metabolised in the liver and excreted through bile. In an emergency, it is given by IV infusion.</p>
<p>Adverse reactions: It causes various dose-dependent adverse effects. Photosensitivity is common. Other ADR include anorexia, nausea, abdominalpain, tremor, hallucinations, peripheral neuropathy, hepatic damage, hypotension and A-V block. Rarely, it can cause hypersensitivity, pneumonitis, pulmonary fibrosis and asymptomatic corneal microdeposits. It contains iodine and can cause disorders of thyroid function and interferes with thyroid function tests (Chapter 64). The drug is embryotoxic.</p>
<p>It is also responsible for drug interactions. It inhibits warfarin metabolism. It enhances bradycardia and A-V block caused by beta blockers and Ca channel blockers.</p>
<p>Therapeutic uses: Amiodarone is a potent antiarrhythmic drug, useful in preventing and treating both supraventricular and ventricular tachyarrhythmias even in those with poor LV function. Though its toxicity profile is wide, in the doses recommended, it appears to be well tolerated.</p>
<p>It is particularly useful in patients with sustained ventricular tachycardia. It is now increasingly used to treat AF wherein it not only reduces ventricular rate but can also restore sinus rhythm (chemical cardioversion). Its beneficial effects are seen after 5 to 10 days and full improvement may not occur for 4 to 6 weeks of therapy.</p>
<p>Dronedarone: It is a structural analog of amiodarone. It, however, does not cause thyroid dysfunction or pulmonary fibrosis, probably because of absence of iodine moieties in its structure. Its common ADR include bradycardia and prolongation of QT-interval, nausea, diarrhoea, rash, severe hepatic damage and creatinine elevation.</p>
<p>The drug is less effective than amiodarone in the treatment of non-permanent AF and probably dangerous in patients with permanent AF.</p>
<p>Aprinidine, like amiodarone, is useful in controlling refractory ventricular (and, to a smaller extent, supraventricular) tachyarrhythmias. Its electrophysiological effects resemble those of quinidine.</p>
<p>IBUTILIDE: This Class III agent is used for chemical cardioversion of atrial flutter and fibrillation. It prolongs the atrial and ventricular RP with minimal effect on conduction, probably through its <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>channel inhibiting action. It also activates the inward <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>current. Given IV, it acts within 1 to 2 hours.</p>
<p>Dofetilide has similar properties as ibutilide but can be given orally. It blocks the delayed rectifier current in dose-dependent manner; the effects are more in hypokalemia. Given orally, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> undergoes renal excretion unchanged.</p>
<p>VERNAKALANT: This new drug acts as antiarrhythmic by blocking the ultra-rapid</p>
<p>delayed rectifier potassium current, mainly expressed in the atria. It also blocks the sodium channel and muscarinic receptor-operated potassium channel. It is administered IV and has been used for rapid conversion of AF of recent origin. It is contraindicated in patients with hypotension, bradycardia and severe heart disease.</p>
<p>VERAPAMIL: This CCB (Chapter 29) is the drug of choice for rapid conversion to sinus rhythm in cases of paroxysmal supraventricular tachycardia. It is given IV in the dose of 510 mg injected over a period 2 to 3 minutes; and can be repeated, if necessary, after 30 minutes. It can also be given orally in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>120</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">40-120 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">120</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>. three times a day. It can also be used to reduce the ventricular rate in patients with AF and atrial flutter. Verapamil IV is absolutely contraindicated in patients on beta blockers, quinidine or disopyramide (Chapter 29).</p>
<p>DILTIAZEM has similar uses as Verapamil in supra-ventricular arrythmias. In fact, it may be the preferred drug because of its less marked negative inotropic effect. Like verapamil, it may be used orally or IV. The IV dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.25</mn><mo>−</mo><mn>0.35</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.25-0.35 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.35</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> over 10 minutes, followed by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">5-15 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> hour. CCB are not likely to be useful in the prevention or suppression of most clinically important ventricular arrhythmias.</p>
<p>ADENOSINE: This is a naturally occurring purine nucleoside which is released during myocardial ischemia. It has antiarrhythmic and potent vasodilator properties. It stimulates <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">A</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{A}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">A</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors on cardiac cells and activates <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>current leading to increase in resting membrane potential. It suppresses automaticity and shortens APD, thereby slowing sinus rate. Further, it slows A-V conduction. It dilates the coronaries and peripheral arteries.</p>
<p>It is rapidly metabolised by circulating adenosine deaminase and has a very short plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mo stretchy="false">(</mo><mn>4</mn></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}(4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.138em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mopen">(</span><span class="mord">4</span></span></span></span></span> to 8 sec<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mclose">)</span></span></span></span></span>. Given IV, as a rapid bolus, it can rapidly terminate paroxysmal, supraventricular tachycardia and is safer than verapamil as it lacks negative inotropic action. It is not effective in converting AF or VT into sinus rhythm. Unlike verapamil, adenosine may be used after a beta blocker. It is contraindicated in the presence of asthma, sick sinus syndrome or A-V block.</p>
<p>Adverse effects are not serious and usually short lasting. They include flushing, nausea, dyspnoea, bronchospasm, cough, headache, ventricular ectopy (proarrhythmic), bradycardia and A-V block.</p>
<p>Digoxin, because of its positive inotropric action, is an important antiarrhythmic agent useful in slowing A-V conduction in AF with increased ventricular rate. (Chapter 31).</p>
<p>POTASSIUM: The basic cardiac effects of potassium administration without causing hyperkalemia are:</p>
<ul>
<li>Diminution in the automaticity</li>
<li>Reduction in conduction velocity and</li>
<li>Prolongation of the refractory period</li>
</ul>
<p>These effects are most marked in the Purkinje fibres. In toxic doses, it is more likely to cause intraventricular conduction defects than A-V block. Hypokalemia predisposes to digitalis toxicity (Chapter 31). Slight, induced hyperkalemia can protect against arrhythmias arising after cardiac surgery (Chapter 37). Correction of hypokalemia, hypoxia and acid-base disturbances often restores sinus rhythm without the use of antiarrhythmic drugs.</p>
<p>The administration of antiarrhythmic agents in the presence of hyperkalemia can be disastrous.
Magnesium, as magnesium sulfate 2-4 g by slow IV injection over 10-15 minutes, repeated once if necessary, is useful in the emergency treatment of ventricular tachycardia, including digoxin-induced and polymorphic ventricular tachycardia (especially torsades de</p>
<p>pointes). It is especially indicated in the presence of hypokalemia where hypomagnesemia may also be present.</p>
<p>Cholinergic and anticholinergic drugs: Similar to vagal action, acetylcholine decreases the automaticity and slows conduction through the AV node, increases its refractory period and may cause A-V block. Edrophonium, a short acting cholinesterase inhibitor, is sometimes useful in the treatment of supraventricular arrhythmia (Chapter 20).</p>
<p>Atropine, blocks the effects of vagal stimulation. It is useful for the diagnosis of sinus bradycardia, where it increases the heart rate, and in the treatment of heart block, (see below). Its indiscriminate use, however, to treat sinus bradycardia after MI may precipitate ventricular arrhythmias because the sympathetic activity is no longer moderated by vagal influences.</p>
<p>Table 28.3 illustrates electrophysiological, hemodynamic and ADR features of antiarrythmic agents from Group IA, IB, II and IV. Table 28.4 summarises the drug therapy of cardiac arrhythmias.</p>
<p>Table 28.3
Principal effects of some antiarrhythmic drugs on the heart</p>
<table><thead><tr><th style="text-align: left;"></th><th style="text-align: left;">Group IA (Quinidine, Procainamide, &lt;br&gt; Disopyramide)</th><th style="text-align: left;">Group IB (Lignocaine, &lt;br&gt; Phenytoin)</th><th style="text-align: left;">Group II (Propranolol)</th><th style="text-align: left;">Group IV (Verapamil)</th></tr></thead><tbody><tr><td style="text-align: left;">Electrophysiological</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr><td style="text-align: left;">Automaticity</td><td style="text-align: left;">Decrease</td><td style="text-align: left;">Decrease</td><td style="text-align: left;">Decrease</td><td style="text-align: left;">Decrease</td></tr><tr><td style="text-align: left;">Excitability</td><td style="text-align: left;">Decrease</td><td style="text-align: left;">No change</td><td style="text-align: left;">Decrease</td><td style="text-align: left;">Decrease</td></tr><tr><td style="text-align: left;">Conduction velocity</td><td style="text-align: left;">Decrease</td><td style="text-align: left;">No change or increase</td><td style="text-align: left;">Decrease</td><td style="text-align: left;">Decrease</td></tr><tr><td style="text-align: left;">ERP</td><td style="text-align: left;">Increase</td><td style="text-align: left;">Decrease</td><td style="text-align: left;">Increase</td><td style="text-align: left;">Increase</td></tr><tr><td style="text-align: left;">Electrocardiogram</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr><td style="text-align: left;">PR duration</td><td style="text-align: left;">No change or increase</td><td style="text-align: left;">No change or decrease</td><td style="text-align: left;">No change or increase</td><td style="text-align: left;">No change or increase</td></tr><tr><td style="text-align: left;">QRS duration</td><td style="text-align: left;">Increase</td><td style="text-align: left;">No change</td><td style="text-align: left;">No change</td><td style="text-align: left;">No change</td></tr><tr><td style="text-align: left;">Q-T duration</td><td style="text-align: left;">Increase</td><td style="text-align: left;">No change or decrease</td><td style="text-align: left;">No change or decrease</td><td style="text-align: left;">No change</td></tr><tr><td style="text-align: left;">Hemodynamic</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr><td style="text-align: left;">Blood pressure</td><td style="text-align: left;">No change or decrease</td><td style="text-align: left;">No change or decrease</td><td style="text-align: left;">No change or decrease</td><td style="text-align: left;">No change or decrease</td></tr><tr><td style="text-align: left;">Cardiac output</td><td style="text-align: left;">Decrease</td><td style="text-align: left;">No change or decrease</td><td style="text-align: left;">Decrease</td><td style="text-align: left;">Decrease</td></tr><tr><td style="text-align: left;">Contractility</td><td style="text-align: left;">Decrease</td><td style="text-align: left;">No change or decrease</td><td style="text-align: left;">Decrease</td><td style="text-align: left;">Decrease</td></tr><tr><td style="text-align: left;">Left ventricular end diastolic &lt;br&gt; pressure</td><td style="text-align: left;">May increase</td><td style="text-align: left;">No change or increase</td><td style="text-align: left;">May increase</td><td style="text-align: left;">May increase</td></tr><tr><td style="text-align: left;">Adverse effects</td><td style="text-align: left;">Proarrhythmic;</td><td style="text-align: left;">Negative inotropic effect</td><td style="text-align: left;">Sinus bradycardia;</td><td style="text-align: left;">Conduction block;</td></tr><tr><td style="text-align: left;"></td><td style="text-align: left;">Negative inotropic effect;</td><td style="text-align: left;"></td><td style="text-align: left;">Conduction block;</td><td style="text-align: left;">Negative inotropic &lt;br&gt; effect</td></tr><tr><td style="text-align: left;"></td><td style="text-align: left;">Conduction block</td><td style="text-align: left;"></td><td style="text-align: left;">Negative inotropic &lt;br&gt; effect</td><td style="text-align: left;"></td></tr></tbody></table>
<p>Table 28.4
Drug treatment of cardiac arrhythmias</p>
<table><thead><tr><th style="text-align: center;">Arrhythmia</th><th style="text-align: center;">Emergency Treatment*</th><th style="text-align: center;"></th><th style="text-align: center;">Chronic treatment prophylaxis</th></tr></thead><tbody><tr><td style="text-align: center;"></td><td style="text-align: center;">Preferred treatment</td><td style="text-align: center;">Other treatment</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">SA Node:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Sinus arrhythmia</td><td style="text-align: center;">Needs no treatment</td><td style="text-align: center;">-</td><td style="text-align: center;">-</td></tr><tr><td style="text-align: center;">Sinus tachycardia</td><td style="text-align: center;">Sedative, Propranolol</td><td style="text-align: center;">Treat the cause</td><td style="text-align: center;">-</td></tr><tr><td style="text-align: center;">Sinus bradycardia</td><td style="text-align: center;">Atropine or temporary or transvenous pacing</td><td style="text-align: center;">Treat the cause</td><td style="text-align: center;">Permanent pacemaker</td></tr><tr><td style="text-align: center;">Atria:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Premature beats</td><td style="text-align: center;">Reassurance, Propranolol</td><td style="text-align: center;">-</td><td style="text-align: center;">Radiofrequency ablation</td></tr><tr><td style="text-align: center;">Paroxysmal supraventricular tachycardia (PSVT)</td><td style="text-align: center;">DCC/Vagal maneuvers, Adenosine</td><td style="text-align: center;">Propranolol Verapamil/diltiazem If LVEF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&lt;40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> : Digoxin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mo lspace="0em" rspace="0em">∗</mo></msup></mrow><annotation encoding="application/x-tex">^{*}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6887em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6887em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∗</span></span></span></span></span></span></span></span></span></span></span></span></span> /Amiodaron</td><td style="text-align: center;">Radiofrequency ablation, Propranolol</td></tr><tr><td style="text-align: center;">Atrial fibrillation and Atrial flutter</td><td style="text-align: center;">DCC &lt;br&gt; To control ventricular rate: Verapamil, Diltiazem, Beta blockers If LVEF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&lt;40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> Digoxin</td><td style="text-align: center;">To terminate AF: &lt;br&gt; a) Elective DCC &lt;br&gt; b) Amiodarone/Ibutilid/Dofetilide &lt;br&gt; c) Procainamide</td><td style="text-align: center;">Rate controllers: &lt;br&gt; Diltiazem, Beta blockers &lt;br&gt; Rhythm controllers: &lt;br&gt; Amiodarone or &lt;br&gt; Dofetilide &lt;br&gt; Stroke prevention: &lt;br&gt; Warfarin</td></tr><tr><td style="text-align: center;">Ventricles:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Premature beats</td><td style="text-align: center;">If symptomatic:</td><td style="text-align: center;">-</td><td style="text-align: center;">Propranolol**</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">Beta blockers</td><td style="text-align: center;"></td><td style="text-align: center;">Digoxin</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">If LVF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&lt;40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> Digoxin</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Paroxysmal ventricular tachycardia (PVT)</td><td style="text-align: center;">Amiodarone DCC</td><td style="text-align: center;">Procainamide Lignocaine</td><td style="text-align: center;">Implantation of cardioverterdefibrillator (ICD)z Amiodarone/Beta blockers</td></tr><tr><td style="text-align: center;">Ventricular fibrillation</td><td style="text-align: center;">Defibrillation &lt;br&gt; Epinephrine/Vasopressin (if needed)</td><td style="text-align: center;">Amiodarone Lignocaine</td><td style="text-align: center;">Implantation of cardioverterdefibrillator (ICD)z Amiodarone/Beta blockers</td></tr><tr><td style="text-align: center;">Digitalis induced tachyarrhythmias</td><td style="text-align: center;">Lignocaine</td><td style="text-align: center;">Phenytoin</td><td style="text-align: center;">Procainamide</td></tr><tr><td style="text-align: center;">Tornados de Pointes</td><td style="text-align: center;">DCC, Magnesium Temporary pacing</td><td style="text-align: center;">Lignocaine, Phenytoin Isoprenaline</td><td style="text-align: center;">-</td></tr><tr><td style="text-align: center;">Second/Third degree A-V Block</td><td style="text-align: center;">Atropine &lt;br&gt; Temporary pacing</td><td style="text-align: center;">Isoprenaline</td><td style="text-align: center;">Permanent pacemaker</td></tr></tbody></table>
<p>When using digoxin, verapamil or a beta blocker IV, drugs such as atropine and isoprenaline and cardiac pacemaker equipment should be at hand in the event of complete A-V block; for verapamil-induced complete A-V block, calcium gluconate 1 g IV is also effective.
*DCC= Direct Current cardioversion (if hemodynamic unstability);
*= If related to congestive cardiac failure;
**= Useful when ventricular tachyarrhythmias are associated with increased sympathetic tone or circulating catecholamines.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="atrial-fibrillation-management">Atrial fibrillation: Management<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#atrial-fibrillation-management" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The management of AF, perhaps the most common sustained cardiac rhythm disorder, has undergone considerable changes during the last decade. Many patients of AF are asymptomatic; often they present themselves with complication such as stroke as first manifestation.</p>
<p>The predisposing risk factors for AF include cardiovascular (hypertension, CHF, diabetes mellitus etc.) and non- cardiovascular (smoking, chest diseases, infections etc). AF often coexists with other comorbid conditions such as hypertension and heart diseases.</p>
<p>The patient with established AF should be evaluated for:
(a) The risk of thromboembolism and the need for anticoagulation
(b) The need for either cardiac rate control or rhythm control; and
(c) Any underlying condition.</p>
<p>The medical management of AF involves:
(a) Treatment of predisposing factors
(b) Control of heart rate
(c) Control of cardiac rhythm (conversion)
(d) Thromboprophylaxis</p>
<p>Paroxysmal AF is self terminating usually within 48 hrs while in persistent AF, the attack lasts for more than 7 days. When the arrhythmia persists in spite of therapy, it is diagnosed as permanent. The treatment of AF should be carried out under supervision of the specialist.
(a) Treatment during an episode: If the patient is severely symptomatic or hemodynamically unstable, and in urgent need of lowering of ventricular rate, he is best treated by DC cardioversion. For patients with the first episode of AF or rare recurrences of AF, particularly those that terminate spontaneously, no specific therapy to control rhythm may be indicated.
(b) Rate control: The immediate goal is to control symptoms due to increased cardiac rate and or underlying structural cardiac disease. The drugs used are given in Table 28.5. For most patients, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> blockers or on dihydropyridine CCB are to be preferred for the initial treatment of ventricular rate control. In patients with decompensated CHF, digoxin is to be preferred</p>
<p>Table 28.5
Drugs for rate control and cardioversion in AF</p>
<table><thead><tr><th style="text-align: center;">Drug</th><th style="text-align: center;">Dose</th></tr></thead><tbody><tr><td style="text-align: center;">For rate control</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">- Beta blockers</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Propranolol</td><td style="text-align: center;">IV <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>3</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo separator="true">,</mo><mo>&lt;</mo><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">1-3 \mathrm{mg},&lt;1 \mathrm{mg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">3</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>; &lt;br&gt; Oral <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mo>−</mo><mn>240</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">80-240 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">80</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">240</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> tid</td></tr><tr><td style="text-align: center;">Metoprolol</td><td style="text-align: center;">IV <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo>−</mo><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2.5-5 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> bolus every 5 min upto 15 mg . &lt;br&gt; Oral <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25-200 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">200</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> od</td></tr><tr><td style="text-align: center;">Esmolol</td><td style="text-align: center;">IV infusion loading dose: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.5 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> Maintenance: dose <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.05</mn><mo>−</mo><mn>0.12</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">0.05-0.12 \mathrm{mg} / \mathrm{kg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.05</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.12</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>.</td></tr><tr><td style="text-align: center;">- Calcium channel blockers</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Verapamil</td><td style="text-align: center;">IV <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5-20 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> bolus; &lt;br&gt; Oral <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>140</mn><mo>−</mo><mn>80</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">140-80 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">140</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">80</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> tid</td></tr><tr><td style="text-align: center;">Diltiazem</td><td style="text-align: center;">IV <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.25 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> bolus, then <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">h</mi><mi mathvariant="normal">r</mi></mrow></mrow><annotation encoding="application/x-tex">5-20 \mathrm{mg} / \mathrm{hr}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">hr</span></span></span></span></span></span> &lt;br&gt; Oral <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>60</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">30-60 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">60</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> tid</td></tr><tr><td style="text-align: center;">- Amiodarone</td><td style="text-align: center;">IV <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> in 1st hr, then <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">0.5-1 \mathrm{mg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span> &lt;br&gt; Oral <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">100-200 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">200</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day</td></tr><tr><td style="text-align: center;">For rhythm control</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">- Propafenone</td><td style="text-align: center;">IV <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>; &lt;br&gt; Oral <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>450</mn><mo>−</mo><mn>600</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">450-600 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">450</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">600</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">- Amiodarone</td><td style="text-align: center;">IV <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> in 1 hr , then <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">0.5-1 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> per min.</td></tr><tr><td style="text-align: center;">- Ibutilide</td><td style="text-align: center;">IV <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1-2 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">- Flecainide</td><td style="text-align: center;">IV <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>; &lt;br&gt; Oral <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>200</mn><mo>−</mo><mn>300</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">200-300 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">200</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">300</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">- Vemakalant</td><td style="text-align: center;">IV <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">3-5 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span></td></tr></tbody></table>
<p>*Can also be used for AF more than a week. All others are used for AF less than a week.
(Ref : Lip GYH, Tsc HF, Lane DA. Lancet 2012; 379: 648-61).
so as to avoid any deterioration of hemodynamic status. Amiodarone IV is usually reserved for critically ill patients with severe heart failure or hypotension who do not respond to other agents.
(c) Rhythm control: Drugs used for control of rhythm are given in Table 28.5. For uncomplicated AF of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>7</mn></mrow><annotation encoding="application/x-tex">&lt;7</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">7</span></span></span></span></span> days duration, oral or IV administration of Class IC or III antiarrhythmic agents can be used. Propafenone is a safe and effective therapy for conversion to sinus rhythm.</p>
<p>Nearly 15-40% of the patients with AF &gt; 7 days duration (persistent AF), convert back to sinus rhythm with pharmacology cardioversion. For those who do not, electrical cardioversion can be considered. In patients with structural heart disease such as IHD and impaired left ventricular ejection fraction, Class I antiarrhythmic such as flecainide, propafenone are contraindicated as they are proarrhythmic and may precipitate VF.
(d) Thromboprophylaxis: Warfarin used prophylactically reduces the incidence of ischaemic stroke but not that of haemorrhagic stroke. Aspirin-clopidogrel combination is less active than aspirin + warfarin for stroke prevention. Aspirin is much less effective in patients older than 75 years. New anticoagulant drugs like dabigatran (100-150 mg bid), a direct thrombin inhibitor and apixaban, fraction Xa inhibitor are reported to be equally effective as warfarin (See Chapter 33).
(e) Maintenance Therapy: Patients with recurrent AF and minimal symptoms and those</p>
<p>with persistent or permanent AF can be managed by long term rate-control strategy. If acute episodes continues, an antiarrhythmic drug may have to be used. The commonly used drug for this purpose is oral amiodarone. The dose should be adjusted to achieve and maintain the ventricular rate at 60 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">80 / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">80/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span> at rest, and 90 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>115</mn><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">115 / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">115/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span> with moderate exercise. Procainamide may be used in patients intolerant to amiodarone. Flecainide, though effective, is proarrhythmic and is generally not preferred.</p>
<p>Resistant cases may need catheter ablation of the AV junction with insertion of a cardiac pacemaker. Anticoagulation, if started during an attack, has to be continued mostly lifelong.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-used-in-the-treatment-of-heart-block">Drugs Used in the Treatment of Heart-Block<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-used-in-the-treatment-of-heart-block" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>ISOPRENALINE (Isoproterenol): The effects of isoprenaline in enhancing the rhythmicity of sinus as well as subsidiary nodal and ventricular pacemakers have proved invaluable in the treatment of advanced second degree and high grade A-V block. In emergency, the drug is administered IV slowly in the dose of 2 mg in 500 ml of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> dextrose under ECG control. In less urgent situations, it is generally given sublingually in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10-15 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> every 4 to 6 hours. Isoprenaline is also effective in abolishing ventricular tachycardia in the presence of advanced AV block. It acts by:</p>
<ul>
<li>Accelerating the basic sinoauricular pacemaker resulting in the suppression of ectopic ventricular activity,</li>
<li>Enhancing A-V conduction, and</li>
<li>Increasing the cardiac output as a result of increased heart rate. This tends to augment the coronary flow.
A-V conduction can also be improved during an emergency by atropine 0.6 mg IV.
Other drugs used are adrenaline, dopamine, aminophylline and glucagon but they are less effective than isoprenaline.</li>
</ul>
<p>Glucocorticoids are helpful when the heart block is due to an inflammatory disorder such as rheumatic fever.</p>
<p>No drug, however, is useful in the treatment of advanced heart block and implantation of permanent pacemaker is essential.</p>
<p>Electrical depolarisation of the heart: Electroversion has been used successfully in supraventricular tachycardias (AF, flutter and paroxysmal atrial tachycardia). It is a lifesaving procedure in case of VT and VF. However, electrical cardioversion does not obviate the need for antiarrhythmic drugs which are used to prevent the recurrence.</p>
<p>It is contraindicated in digitalis-induced arrhythmias. When it is used for treating other types of arrhythmias, digitalis is generally omitted for 24 hours before electroversion. It may induce VF if employed in patients with advanced A-V block.</p>
<p>DC shock is used under IV diazepam cover.
Medical treatment of arrhythmia is complex and is better left for the specialists. No drug is safe. Selective surgical or radiofrequency (RF) ablation of arrhythmic focus using devices and sophisticated catheters guided by computerized mapping system has produced spectacular results (cure) in certain cardiac arrhythmias.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacotherapy-of-angina-pectoris-acute-mi-and-peripheral-vascular-diseases">Pharmacotherapy of Angina Pectoris, Acute MI and Peripheral Vascular Diseases<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacotherapy-of-angina-pectoris-acute-mi-and-peripheral-vascular-diseases" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Ischemic heart disease (IHD) develops due to myocardial ischemia produced in a variety of ways, of which Angina pectoris is a symptom complex. It is a result of an imbalance between the oxygen supply and the oxygen demand of the myocardium. The manifestations of IHD are:
(1) Silent (asymptomatic) ischemia.
(2) Angina of effort and variant angina of Prinzmetal.
(3) Acute coronary syndrome (ACS)
(a) Unstable angina (UA)
(b) Acute myocardial infarction (AMI)
(i) Non-ST-Segment Elevation MI (NSTEMI)
(ii) ST-Segment Elevation MI (STEMI)
(4) Congestive heart failure (CHF) and
(5) Sudden cardiac death (SCD)</p>
<p>These clinical modalities are related to:</p>
<ul>
<li>The physiology of the coronary circulation.</li>
<li>The factors governing myocardial metabolism; and</li>
<li>The mechanism regulating the genesis and appreciation of pain.</li>
</ul>
<p>The design of the coronary circulation has three bad features:</p>
<ul>
<li>The coronary arteries are functionally end arteries. In health, there is little communication between the larger branches of coronary arteries although collateral circulation does develop in patients who have had MI.</li>
<li>Unlike the skeletal muscle, the cardiac muscle shows almost maximum oxygen extraction at rest, as shown by the comparative values of oxygen saturation of coronary sinus blood ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> ) and skeletal muscle venous blood ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60-70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> ). Hence, during exercise the tissue demand for increased oxygen supply is met, at least partly, by increased oxygen extraction in the case of skeletal muscle, but in the case of cardiac muscle it can only be met by increasing the coronary blood flow. Such increase can be severely limited by coronary artery disease. Moreover, unlike the skeletal muscle the cardiac muscle has extremely limited capacity for anaerobic metabolism and, therefore, cannot incur 'oxygen debt'.</li>
<li>The coronary blood flow is influenced by the inflow (aortic) pressure and the resistance of the coronary vascular bed. The latter depends on: (a) the state of dilatation of the coronary arterioles, determined largely by local metabolites, and (b) the pressure exerted upon the coronary vessels from the exterior by the contracting myocardium during systole. Thus, in contrast to other areas where the arterial blood flow is continuous, coronary blood flow to the left ventricle is intermittent and mainly diastolic; whereas in the absence of pulmonary hypertension it is both systolic and diastolic in case of the right ventricle.
In spite of these limiting features, the coronary circulation has a very large reserve and the coronary flow can increase upto <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>500</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">500 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">500%</span></span></span></span></span> of the resting value in exercising healthy dogs.</li>
</ul>
<p>Physiologically, vascular endothelial cells control the vascular tone by producing (a) vasodilators such as prostacyclin (Chapter 25) and NO/EDRF; and (b) vasoconstrictors such as endothelin (Chapter 30). Thromboxane <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">A</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{A}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">A</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> produced by platelets also constricts vessels.</p>
<p>NITRIC OXIDE (Endothelium Derived Relaxing Factor - EDRF): Robert Furchgott (1980) first demonstrated that the endothelial cells release a labile factor that causes vascular relaxation. He designated it as EDRF, which later was identified as NO. Nitric oxide (NO), a simple diatomic molecule, is biosynthesised through the action of a class of enzymes nitric oxide synthases (NOS). These enzymes utilise the amino acid l-arginine as the endogenous substrate for NO generation. Organic nitrates are reduced by reductases to organic nitrites, which are then converted to NO which acts as a direct vasodilator. (Fig. 29.2) Thus, nitrates serve as exogenous sources of NO without involving endothelial cells and NOS and are termed as NO donors. Three NOS isoforms have been identified:
<img src="assets/images/image-20251214-eb412717.jpeg" alt="img-18.jpeg"></p>
<p>FIG. 29.2 NO-Cyclic GMP pathway and mechanism of action of nitrates and dipyridamole as vasodilators.
GTP: Guanosine triphosphate. Cyclic GMP: Cyclic guanosine monophosphate.
(1) nNOS (NOS-1), is found in high concentrations in central and peripheral neurons and some non-neural tissues such as endometrium and skeletal muscle.
(2) iNOS (NOS-2), is found in macrophages, Kupffer cells, fibroblasts, vascular smooth muscle cells, neutrophils and endothelial cells; and
(3) eNOS (NOS-3), first identified as the enzyme that produces EDRF and found in the vascular endothelium, brain and heart.</p>
<p>Types 1 and 3 are constitutive NOS and their activities are regulated by intracellular</p>
<p>calcium. These isoenzymes produce on demand short bursts of NO in small amounts. Type 2, on the other hand, is the inducible NOS and is not expressed in resting cells. When macrophages and other cells are activated, this enzyme triggers the production of large amounts of NO.</p>
<p>NO causes both:
(a) Direct effects, partly mediated by NO molecule itself and mainly by the interaction of NO with soluble guanylyl cyclase (which acts as the receptor for NO), resulting in the production of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>3</mn><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup><msup><mn>5</mn><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup></mrow><annotation encoding="application/x-tex">3^{\prime} 5^{\prime}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7519em;"></span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7519em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span><span class="mord"><span class="mord">5</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7519em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span></span></span></span></span>-cyclic guanosine monophosphate (cGMP); and
(b) Indirect effects mediated by the interaction of reactive nitrogen species (intermediates in NO synthesis) with oxygen and superoxide radicals, to yield cytotoxic peroxynitrite anion.</p>
<p>NO is a highly diffusible second messenger that can produce effects far from its site of production. The source of NO and its concentration determine its biological effects. At low concentrations, the direct (physiological) effects of NO predominate. Induced, high concentrations of NO cause indirect and often toxic effects.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="functions-of-no">Functions of NO:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#functions-of-no" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>NO as a vasodilator: NO causes vascular smooth muscle relaxation and vasodilatation that helps to regulate blood flow and BP. NO release from the endothelial cells is primarily the result of an influx of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>into the endothelial cells. Thus, any agent or stimulus capable of eliciting an influx of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>into these cells such as acetylcholine, bradykinin or shear force, can activate NO biosynthesis. The NO then acts through cyclic GMP and causes vascular muscle relaxation by lowering <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>influx (Fig 29.2).
Endothelial dysfunction (impaired NO production), is implicated in hypertension, cerebral and coronary vasospasm, atherosclerosis, ischemic reperfusion injury and diabetes mellitus.</li>
<li>NO and RBCs: NO appears to be a critical factor in the prevention of sickling of RBCs. Its precursor l-arginine is used to treat pulmonary hypertension in sickle cell disease.</li>
<li>NO as a platelets inhibitor: NO causes inhibition of platelet aggregation and adhesion. It diffuses from the vascular endothelial cells to function primarily as an inhibitor of platelet adhesion to the vascular endothelium.</li>
<li>NO and the CNS: Non-adrenergic, non-cholinergic (NANC) neurons innervate a variety of smooth muscles, such as those of the GI tract, the corpora cavernosa and the esophagus. The exclusive neurotransmitter in the NANC is NO. Thus NO is the physiological mediator of penile erection (Chapter 69) and gastric emptying.</li>
<li>NO and immune system: When the macrophages are exposed to infective agents, there is a dramatic local increase in NO production. NO synthesis induced by activated macrophages represents an immune response to infection. NO appears to be utilised by the immune system as a cytotoxic agent.
Adverse effects of NO: It is an important mediator of inflammation and neurodegenerative disorders. Exposure to bacterial endotoxins can lead to overproduction of NO, which can cause severe hypotension and/or endotoxic shock. Excessive NO can be toxic to the host cells, including pancreatic islet cells.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="methods-of-assessing-coronary-circulation">Methods of Assessing Coronary Circulation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#methods-of-assessing-coronary-circulation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Experimentally, the coronary blood flow can be studied either in animals or isolated hearts. The data obtained from such studies, however, are many times inapplicable to humans. Even in human studies, it has been observed that the responses of atherosclerosed and normal coronary vessels to a given drug differ. Important methods used clinically are:</p>
<ul>
<li>Methods using a radionuclide <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msup><mrow></mrow><mn>201</mn></msup></mrow><annotation encoding="application/x-tex">\left({ }^{201}\right.</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.2em; vertical-align: -0.35em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;"><span class="delimsizing size1">(</span></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">201</span></span></span></span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span> Thallium) or a radiopharmaceutical ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>99</mn></msup><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">{ }^{99} \mathrm{~m}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">99</span></span></span></span></span></span></span></span></span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">m</span></span></span></span></span></span> Technetium pyrophosphate) to study myocardial ischemia: The former localises in the healthy, well perfused myocardium but not in the ischemic one; the latter localises in the necrosed myocardium. These methods, with or without the use of exercise, permit detection, localisation and quantification of myocardial ischemia; they also permit assessment of LV function in the form of ejection fraction and localised wall motion abnormalities.</li>
<li>Coronary angiography: This is the definitive method of diagnosing CAD and has shown important differences between the response of normal and atherosclerotic arteries to drugs. Coronary angiography can be combined with pharmacological or exercise stress testing to assess the physiological significance of the observed coronary artery stenotic lesions. However, angina can occur even in the presence of normal coronary arteriograms.</li>
<li>Coronary CT/MR angiography: They give information about calcification and patency of coronary arteries but not about condition of the myocardium.</li>
<li>Computerised stress test: This test is used for evaluating anti-anginal drugs. Patients with angina pectoris are subjected to exercise, and the amount of exercise which they can tolerate without the development of pain with concomitant ECG changes is noted. The procedure is then repeated after the drug. An increase in the exercise tolerance, as shown by a delay in the development of precordial pain and ECG changes, is a measure of anti-anginal activity of the drug.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="angina-pectoris">Angina Pectoris<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#angina-pectoris" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Occurrence of angina pectoris depends upon two factors (a) Coronary blood flow; and (b) Oxygen consumption by the myocardium. The former may be compromised by either obstructive (atherosclerotic) or vasospastic disease of the coronary arteries.</p>
<p>Cardiac <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">O</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{O}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> consumption increases with increase in:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="heart-size">- Heart size<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#heart-size" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="heart-rate">- Heart rate<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#heart-rate" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Systemic blood pressure; and</li>
<li>Myocardial contractility, which is the rate at which the cardiac muscle fibre shortens.</li>
</ul>
<p>The last three are increased by heightened sympathetic activity. The myocardial oxygen consumption increases significantly during exercise and other states (emotional excitement, exposure to cold) with increased sympathetic activity. If, for any reason, the increase in coronary blood flow is unable to match this increased oxygen demand, angina develops. It is generally described by the patient as retrosternal pain, heaviness or discomfort which may radiate to the neck, shoulder, back or the arm. In each patient, there exists at a given time a threshold (angina index <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span></span></span></span></span> heart rate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>x</mi></mrow><annotation encoding="application/x-tex">x</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal">x</span></span></span></span></span> systolic BP) at which angina occurs. The angina index is a measure of the myocardial oxygen consumption. Spasm of the coronary arteries is also important in the production of angina.</p>
<p>Clinically angina can be:</p>
<ul>
<li>Stable, exertional angina: This commonest form is usually provoked by physical exertion or emotional stress and is relieved by rest and nitrates. It is diagnosed when the chest pain has remained unchanged in severity, frequency and duration over several weeks. The main pathophysiological factor appears to be increased myocardial oxygen demand, induced by tachycardia and rise of BP, in a person with fixed, atherosclerotic narrowing of epicardial, coronary arteries. The ECG shows ST depression during the attack.</li>
<li>Cardiac syndrome X: More common in women, this condition comprises of (1) Angina or angina-like chest pain on exercise; (2) ST segment depression on treadmill exercise testing; and (3) Normal coronary angiography. Endothelial or microvascular dysfunction is responsible for ischaemia and hence it is also termed as microvascular angina. Some patients having chest discomfort without ischaemia may have abnormal pain perception or sensitivity. Therapeutic response to physical training and to beta blockers is better than to nitrates and CCB.</li>
<li>Variant angina of Prinzmetal (Vasospastic angina): It is characterised by chest pain at rest rather than during exertion or stress, and ST elevation rather than depression. Spasm of large epicardial coronary arteries is responsible for this entity. It is relatively uncommon.
Unstable angina (UA) includes a variety of clinical syndromes such as new onset angina, angina occurring at rest or with minimal exertion, progressive angina with prolonged or more frequent attacks superimposed on chronic stable angina (Crescendo angina); it can progress to MI and sudden death (pre-infarction angina). The diagnosis is made by the ECG showing ST depression, and a negative troponin test.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-used-in-angina-pectoris">Drugs Used in Angina Pectoris<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-used-in-angina-pectoris" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The drugs effective in the treatment of angina pectoris act by:
(a) Dilating the coronary arteries and/or
(b) Reducing the cardiac workload by reducing pre- and after-load (Fig. 29.1). The agents currently used are:
<img src="assets/images/image-20251214-1d199df7.jpeg" alt="img-19.jpeg"></p>
<p>I Organic nitrates.
II Beta-adrenergic blocking agents.
III Calcium channel blockers (CCB); and
IV Potassium channel activators.
Additional beneficial effects can be obtained by using adjuncts such as:</p>
<ul>
<li>Antiplatelet drugs</li>
<li>Treatment of hyperlipidemia; and</li>
<li>Cytoprotectives</li>
</ul>
<p>ORGANIC NITRATES: Organic nitrates which are polyol esters of nitric acid are potent vasodilators. Usefulness of nitroglycerine was discovered by William Murrell, a physician, in 1879 .</p>
<p>Mechanism of action: All the effects of nitrates, except those produced by toxic doses, are mediated through the direct relaxant action on vascular smooth muscles. Organic nitrates are reduced by reductase to organic nitrites, which are then converted to NO which acts as a direct vasodilator. (Fig. 29.2) Thus, nitrates serve as exogenous sources of NO, and termed as NO donors.</p>
<p>Pharmacological actions
I Cardiovascular system:</p>
<ul>
<li>Hemodynamic actions: Nitrates cause a relaxation of the systemic venous and arteriolar bed. Venodilatation causes peripheral pooling of blood and a reduction in venous return and in cardiac output. On the arterial side, relaxation is maximum in the large arteries (resulting in bounding pulse), followed by the arterioles (resulting in lowered impedence). The BP falls, the systolic more than the diastolic accompanied by reflex tachycardia. Syncope may occur if the patient is standing.
These actions on the systemic venous (capacitance) and arteriolar (impedence) vascular beds reduce respectively the preload (end-diastolic left ventricular pressure) and the afterload (resistance to left ventricular ejection) on the heart. The left ventricular work load and energy expenditure thus decrease. The improvement in the left ventricular function as a result of this generally outlasts the measured pharmacological actions of individual doses of nitrates; this is of great importance in the therapy of angina pectoris.
Sublingual nitroglycerine (NTG) in clinically used doses is predominantly a venodilator causing reduction of ventricular preload. By contrast, inhalation of amyl nitrite, which acts very rapidly, has preferential systemic arteriolar dilator action which primarily reduces the afterload. Rapid arteriolar dilatation causes distinct fall in BP. Compensatory rise in sympathetic activity causes tachycardia and increased myocardial oxygen requirement. This is a disadvantage.</li>
<li>Coronary circulation: A transient decrease in the coronary resistance and an increase in the total coronary flow occur in a normal subject. In patients with angina nitrates:
(a) Dilate the large epicardial coronary arteries without affecting the resistance of the arterioles.
(b) Dilate collateral vessels, and
(c) Cause redistribution of the coronary blood flow along collaterals and from epicardial to endocardial region with improved perfusion of ischemic subendocardial areas.
Chronic administration promotes the development of inter-arterial anastomoses within the myocardium.</li>
<li>Effects in angina pectoris: Nitrates help most patients with angina by increasing their exercise tolerance but without increasing their 'angina index'. They achieve this by reducing the oxygen consumption of the heart at submaximal exercise levels and thus extending the duration of exercise. In such patients, they prevent the ECG changes of cardiac ischemia during exercise. However, they do not increase the maximum aerobic capacity of the heart.</li>
<li>Other vascular beds: Nitrates cause dilatation of other vascular beds as well, viz. (a) the skin, giving rise to flushing, (b) the meningeal vessels, resulting in throbbing headache, (c) pulmonary vessels, with fall in pulmonary arterial pressure, and (d) kidneys, with a reduction in renal flow.
II Other smooth muscles: Nitrates relax the smooth muscles of the gall bladder, the biliary ducts, the sphincter of Oddi, the bronchi, the GI tract and the ureteral and uterine smooth muscle.</li>
</ul>
<p>Absorption, fate and excretion: Organic nitrates are readily absorbed from the sublingual mucosa, and cause more rapid and more predictable effects. This is because after sublingual administration, they bypass the liver where normally they are rapidly metabolised by denitration. With relatively small sublingual doses, the various organic</p>
<p>nitrates have similar duration of action, 10-45 minutes.
Small oral doses ( 0.6 mg of NTG or 5 mg of isosorbide dinitrate) are of doubtful value as antianginal agents due to the first pass effect. Large oral doses ( 6.5 mg of NTG, 30 mg of isosorbide dinitrate or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>80</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">40-80 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">80</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> of pentaerythritol tetranitrate, every <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">4-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> hours) which exceed the metabolising capacity of the liver, however, produce beneficial hemodynamic effects and are useful in prophylaxis. NTG skin ointment and transdermal patches have similar prolonged effect. NTG lingual aerosol has onset and duration of action similar to those of the sublingual tablet.</p>
<p>Preparations and dosage: See Table 29.1. For IV use, NTG is diluted in 5% dextrose or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.9</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.9 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.9%</span></span></span></span></span> saline. It is administered in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">5 \mathrm{mcg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>, increasing the rate every 3-5 minutes upto <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">80-100 \mathrm{mcg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">80</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>. It is useful in the treatment of refractory chest pain of myocardial ischemia or MI, and refractory, variant angina.</p>
<p>Table 29.1
Nitrate and nitrite preparations for clinical use</p>
<table><thead><tr><th style="text-align: center;">Drug Preparations</th><th style="text-align: center;">Dose</th><th style="text-align: center;">Onset</th><th style="text-align: center;">Duration</th><th style="text-align: center;">Schedule</th><th style="text-align: center;"></th><th style="text-align: center;">Remark</th></tr></thead><tbody><tr><td style="text-align: center;">Glyceryl trinitrate &lt;br&gt; (Nitroglycerine)</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Tab 0.3, 0.4 and &lt;br&gt; 0.6 mg .</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.3</mn><mo>−</mo><mn>0.6</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">.</mi><msup><mrow><mi mathvariant="normal">S</mi><mi mathvariant="normal">L</mi></mrow><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup></mrow><annotation encoding="application/x-tex">0.3-0.6 \mathrm{mg} . \mathrm{SL}^{\prime}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1.0196em; vertical-align: -0.1944em;"></span><span class="mord">0.6</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">.</span><span class="mord"><span class="mord"><span class="mord mathrm">SL</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8251em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="center" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mn>1</mn><mo>−</mo><mn>2</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mtext>&nbsp;min&nbsp;</mtext></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{gathered} 1-2 \\ \text { min } \end{gathered}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-c"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">2</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">&nbsp;min&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>40</mn></mrow><annotation encoding="application/x-tex">15-40</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">40</span></span></span></span></span> min</td><td style="text-align: center;">SOS</td><td style="text-align: center;"></td><td style="text-align: center;">Volatile. Unstable in plastic containers. Store tablets in tightly closed amber coloured glass bottles, without cotton plugs, preferably in a fridge. &lt;br&gt; Once a bottle is opened, it should be discarded after 8 weeks and fresh supply obtained. Sublingual tablets give immediate relief. Capsules, oral tablets and ointment for prophylaxis.</td></tr><tr><td style="text-align: center;">Sustained release &lt;br&gt; cap. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>2.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">(2.5 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">2.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>.)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo>−</mo><mn>5.0</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2.5-5.0 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">5.0</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>. P 0</td><td style="text-align: center;">60 min</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>8</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">8-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span> hrs</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>8</mn><mo>−</mo><mn>12</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;hrly&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 8-12 \\ &amp; \text { hrly } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">12</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;hrly&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Sublingual spray</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">0.4 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> metered dose</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="center" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mn>1</mn><mo>−</mo><mn>2</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mtext>&nbsp;min&nbsp;</mtext></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{gathered} 1-2 \\ \text { min } \end{gathered}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-c"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">2</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">&nbsp;min&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="center" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mn>15</mn><mo>−</mo><mn>40</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mtext>&nbsp;for&nbsp;</mtext><mn>3</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mtext>&nbsp;doses&nbsp;</mtext></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{gathered} 15-40 \mathrm{~min} \\ \text { for } 3 \\ \text { doses } \end{gathered}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 4.5em; vertical-align: -2em;"></span><span class="mord"><span class="mtable"><span class="col-align-c"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 2.5em;"><span style="top: -4.66em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">40</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span><span style="top: -3.16em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">&nbsp;for&nbsp;</span></span><span class="mord">3</span></span></span><span style="top: -1.66em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">&nbsp;doses&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 2em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">every 5 &lt;br&gt; min.</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">2% skin ointment &lt;br&gt; ( 15 mg . per &lt;br&gt; inch)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn><mo>−</mo><mn>2</mn></mrow><annotation encoding="application/x-tex">1 / 2-2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span></span></span></span></span>-inch applied without rubbing</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>20</mn><mo>−</mo><mn>60</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;min&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 20-60 \\ &amp; \text { min } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">60</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;min&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">4-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> hrs</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">4-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> hrly</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Transdermal &lt;br&gt; patches</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5-15 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>30</mn><mo>−</mo><mn>60</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;min&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 30-60 \\ &amp; \text { min } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">60</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;min&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">12 hrs</td><td style="text-align: center;">once &lt;br&gt; daily</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Isosorbide dinitrate</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi>S</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">L</mi></mrow></mrow><annotation encoding="application/x-tex">2.5-10 \mathrm{mg} S \mathrm{~L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord mathnormal" style="margin-right: 0.05764em;">S</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">L</span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>10</mn><mo>−</mo><mn>30</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;min&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 10-30 \\ &amp; \text { min } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">30</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;min&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn></mrow><annotation encoding="application/x-tex">1-2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span></span></span></span></span> hrs</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>4</mn></mrow><annotation encoding="application/x-tex">3-4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4</span></span></span></span></span> hrly</td><td style="text-align: center;"></td><td style="text-align: center;">Hepatic metabolism to isosorbide mononitrate. Useful in immediate relief and in prophylaxis</td></tr><tr><td style="text-align: center;">Tab. 5, 10 mg</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Buccal spray</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">1.25 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> actuation</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>2</mn><mo>−</mo><mn>5</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;min&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 2-5 \\ &amp; \text { min } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">5</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;min&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">-</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Tab. Oral 10, 20, &lt;br&gt; 40 mg</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10-40 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> PO</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>30</mn><mo>−</mo><mn>60</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;min&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 30-60 \\ &amp; \text { min } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">60</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;min&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">4 hrs</td><td style="text-align: center;">6 hrly</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Tab. sustained release</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>80</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">40-80 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">80</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> PO</td><td style="text-align: center;">60 min</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">6-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span> hrs</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>8</mn><mo>−</mo><mn>12</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;hrly&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 8-12 \\ &amp; \text { hrly } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">12</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;hrly&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Isosorbide mononitrate</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Tab. 10, 20 mg</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10-20 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> PO</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>30</mn><mo>−</mo><mn>60</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;min&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 30-60 \\ &amp; \text { min } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">60</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;min&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mo>−</mo><mn>8</mn></mrow><annotation encoding="application/x-tex">6-8</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">8</span></span></span></span></span> hrs</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>8</mn><mo>−</mo><mn>12</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;hrly&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 8-12 \\ &amp; \text { hrly } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">12</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;hrly&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"></td><td style="text-align: center;">No first pass metabolism. &lt;br&gt; Used in prophylaxis.</td></tr><tr><td style="text-align: center;">Pentaerythritol tetranitrate</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Tab. 30 mg</td><td style="text-align: center;">30 mg PO</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>15</mn><mo>−</mo><mn>30</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;min&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 15-30 \\ &amp; \text { min } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">30</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;min&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">4-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> hrs</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>8</mn><mo>−</mo><mn>12</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;hrly&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 8-12 \\ &amp; \text { hrly } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">12</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;hrly&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"></td><td style="text-align: center;">Used in prophylaxis.</td></tr></tbody></table>
<p>'When the tablet, placed under the tongue, fails to produce local burning, flushing of the face and pounding in the head, it should be considered inert. Tab. = tablets. Cap. = capsules; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">S</mi><mi mathvariant="normal">L</mi></mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{SL}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord mathrm">SL</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> sublingually; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">O</mi></mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{PO}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord mathrm">PO</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> orally.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-reactions">Adverse reactions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Headache: Though common, it usually decreases gradually on repeated administration</li>
</ul>
<p>and can be controlled by aspirin.</p>
<ul>
<li>Hypotension and syncope: Transient episodes of giddiness, weakness and other signs of cerebral ischemia associated with postural hypotension may develop. These are seen especially when the patient stands immobile. Hypoxemia may stimulate the central vagal nuclei and cold sweats, nausea, vomiting, involuntary passage of urine and faeces may accompany postural hypotension. Head-low position to augment the venous return quickly corrects the nitrite syncope. Marked hypotension may occur when nitrates are used along with potent anti-hypertensive drugs especially vasodilators; it is also seen following the ingestion of alcoholic beverages or sildenafil (Chapter 69).</li>
<li>Tolerance to nitrates can develop after repeated administration. Cross tolerance is common. Tolerance to the anti-anginal action develops commonly when the patient is exposed to nitrate for all the 24 hours of the day. Hence, it is more common with long acting nitrate preparations such as SR tablets and transdermal preparations. It can be avoided by omitting the night-time dose of long acting preparations. However, during such nitratefree periods, the patient needs to be protected by another anti-anginal drug, especially if he has severe angina. Tolerance is rare with sublingual nitrate because of the intermittent exposure.</li>
<li>Withdrawal symptoms: Sudden stoppage of nitrates during chronic administration may precipitate severe angina.</li>
<li>Miscellaneous: Drug rash may occasionally be observed, most commonly with pentaerythritol tetranitrate.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses-of-nitrates">Therapeutic uses of nitrates:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses-of-nitrates" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>All varieties of angina pectoris: Discussed later.</li>
<li>At the onset of pain of acute MI (See later) except in those with inferior wall infarct (with right ventricular involvement).</li>
<li>Paroxysmal nocturnal dyspnoea due to LVF: NTG may give dramatic relief.</li>
<li>Acute LVF: Nitroglycerine by IV infusion is useful in this condition.</li>
<li>Chronic heart failure: Organic nitrates are sometimes used in the long term management of chronic heart failure due to ischemic heart disease (Chapter 31).</li>
<li>Achalasia cardia</li>
<li>Acute anal fissure: Chapter 42.</li>
<li>Cyanide poisoning: Amyl nitrite inhalation and IV sodium nitrite are used to treat cyanide poisoning. Nitrites convert hemoglobin to methemoglobin, which competes with cytochrome oxidase for the cyanide ion and forms cyanmethemoglobin, a relatively non-toxic product (Chapter 77).
BETA-ADRENERGIC BLOCKING AGENTS: These drugs are a cornerstone of the therapy of all stages of IHD, except Prinzmetal's, vasospastic, variant angina. Only their actions relevant to angina are discussed below (also see Chapter 18).</li>
</ul>
<p>Pharmacological actions: Increased sympathetic activity following exercise and emotional excitement increases heart rate, BP, myocardial contractility and oxidative metabolism and can precipitate an attack of angina in predisposed subjects. Beta blockers by blocking beta adrenergic activity prevent the angina attack. Moreover, they help to control BP in hypertensive patients. Like nitrates, beta-blockers:</p>
<ul>
<li>
<p>Increase the exercise tolerance without increasing the angina index;</p>
</li>
<li>
<p>Prevent both subjective and ECG manifestations of cardiac ischemia.</p>
</li>
<li>
<p>Prevent arrhythmias precipitated by exercise, emotion and conditions involving excessive sympathetic activity.</p>
</li>
<li>
<p>Decrease the NTG requirement. In most patients, the net effect is a beneficial reduction in cardiac work load and myocardial oxygen consumption. However, they are not useful in acute attacks.
Long term studies indicate their prophylactic value as they decrease the incidence of MI in such patients. For chronic prophylaxis, they are usually combined with nitrates. Patients with an cardiac decompensation should be stabilised before starting a beta-blocker.</p>
</li>
</ul>
<p>For use of beta blockers immediately after acute MI, see later. Long term use of beta blockers after MI has been shown to reduce the rate of re-infarction and sudden death.</p>
<p>Clinically, all beta blockers are probably equally effective. Generally, the more selective beta-blockers such as atenolol, metoprolol and bisoprolol are preferred.</p>
<p>Beta blockers are not useful in the therapy of Prinzmetal's, vasospastic, variant angina.
Absorption, fate and excretion: Chapter 18.
Adverse reactions: The adverse reactions of relevance to antianginal therapy are:
(a) Precipitation or aggravation of CHF. Patients receiving both digoxin and a beta-blocker should be watched for the development of heart block.
(b) Development of severe syncope on using NTG in patients on a beta-blocker.
(c) Bradycardia and bronchospasm may.</p>
<p>Abrupt withdrawal of beta-blockers, especially when large doses are being used, can cause aggravation of angina and even precipitation of MI (Chapter 18).</p>
<p>CALCIUM CHANNEL BLOCKERS (CCB): Calcium is necessary for the excitationcontraction coupling in the skeletal, cardiac and smooth muscle. However, in contrast to the contractile activity of the skeletal muscle, the contractility of the cardiac and vascular muscle is highly dependent on the extracellular calcium.</p>
<p>Calcium transport in myocardial and vascular smooth muscle involves:</p>
<ul>
<li>Voltage dependent channel which is controlled by a gate that opens and closes in response to a voltage gradient. There are 2 types of calcium channels in heart: the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>L</mi></mrow><annotation encoding="application/x-tex">L</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">L</span></span></span></span></span> and T :
(i) L-channels make the calcium ions available in the cytoplasm, that are required for initiation of contraction. These ions in turn induce calcium release from the sarcoplasmic reticulum.
(ii) T-channels open at more negative potentials than the L-channels and play a role in the initial depolarisation of sinus and AV nodal tissue.</li>
<li>Receptor operated channel, normally activated by an alpha adrenergic agonist, such as NA, or angiotensin interacting with the alpha adrenergic receptors. They increase degree of contraction of arterioles. Similarly, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonists increase calcium influx in cardiac muscles and enhance contraction, frequency and conduction velocity of heart.</li>
<li>Sodium-calcium exchange which is an electrogenic mechanism. It operates bidirectionally to mediate the movement of calcium ions across the sarcolemma.</li>
<li>Calcium ATPase which extrudes calcium from the cell in an energy dependent way. Sarcoplasmic calcium is also regulated by uptake and release of calcium by sarcoplasmic reticulum, mitochondria and by buffering of calcium by various intracellular proteins such as calmodulin and troponin C.</li>
</ul>
<p>Mechanism of action: CCB bind to alpha-1 subunit of L-channel, and inhibits the entry</p>
<p>of calcium into the myocardial and vascular smooth muscles, thus decreasing availability of the intra-cellular calcium. They are potent vasodilators.</p>
<p>CCB belong to 3 chemically distinct classes:
I Phenylalkylamines e.g., Verapamil
II Dihydropyridines (DHP) e.g., Nifedipine and Amlodipine.
III Benzothiazepines e.g., Diltiazem.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cardiovascular-actions">Cardiovascular actions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cardiovascular-actions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Antianginal action of these drugs is due to:
(1) Improvement in the coronary blood flow; and
(2) Decrease in the oxygen demand of the heart due to reduction in systemic vascular resistance (vasodilatation) and BP (afterload). Verapamil, in addition, reduces the heart rate. As a group, these drugs can be used in anginal patients with COPD in whom beta-blockers are contraindicated.</li>
<li>Coronary artery dilatation: These drugs are more potent than NTG as coronary artery dilators. Nitroglycerine dilates the large epicardial branches of coronary arteries but not the smaller intramyocardial coronary arterioles; CCB dilate both, even in the presence of coronary artery spasm. Further, they can prevent the spasm even in diseased, atherosclerotic coronary arteries. This effect accounts for their efficacy in Prinzmetal angina.</li>
<li>Effect on peripheral blood vessels: CCB relax the vascular smooth muscle in systemic as well as pulmonary arterial circulations. They thus decrease the vascular resistance and the BP in both territories, and are useful in the treatment of systemic and pulmonary hypertension. Further, reduction in the afterload contributes to their efficacy in angina of effort. The reduction in BP is accompanied by reflex tachycardia in the case of nifedipine but not in the case of verapamil which depresses the SA node. They have little effect on the venous capacitance (cardiac preload).</li>
<li>Negative inotropic effect: CCB depress myocardial contractility, and decrease the cardiac workload and oxygen consumption. This effect is beneficial in the treatment of angina of effort. Verapamil and diltiazem have negative inotropic actions and hence should not be combined generally with beta-blockers in the treatment of angina of effort; however, nifedipine can be used together with beta blockers (but see later).</li>
<li>Antiarrhythmic effect: CCB:
(a) Decrease the rate of discharge of the SA node.
(b) Suppress ectopic pacemaker activity.
(c) Increase the refractoriness of the AV node and;
(d) Slow the conduction (Chapter 28).</li>
</ul>
<p>The slowing of the conduction prevents re-entrant excitation. This effect plus the improvement of cardiac ischemia accounts for the potent (though selective) antiarrhythmic action. Verapamil and diltiazem are particularly potent in this respect. Verapamil and diltiazem (but not nifedipine), however, can aggravate A-V block.</p>
<p>Properties of commonly used CCB are summerized in Table 29.2.</p>
<p>Table 29.2
Properties of some calcium channel blockers</p>
<table><thead><tr><th style="text-align: center;"></th><th style="text-align: center;">Verapamil</th><th style="text-align: center;">Diltiazem</th><th style="text-align: center;">Nifedipine</th><th style="text-align: center;">Amiodipine</th></tr></thead><tbody><tr><td style="text-align: center;">Chemical class</td><td style="text-align: center;">Diphenylalky lamine</td><td style="text-align: center;">Benzothiazepine</td><td style="text-align: center;">Dihydropyridine</td><td style="text-align: center;">Dihydropyridine</td></tr><tr><td style="text-align: center;">Bioavailability</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>35</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20-35 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">35%</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40-70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40-70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Plasma half-life</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">6-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span> hr</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>5</mn></mrow><annotation encoding="application/x-tex">3-5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">5</span></span></span></span></span> hr</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>5</mn></mrow><annotation encoding="application/x-tex">2-5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">5</span></span></span></span></span> hr</td><td style="text-align: center;">35 hr</td></tr><tr><td style="text-align: center;">Blocks A-V conduction</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">0</td><td style="text-align: center;">0</td></tr><tr><td style="text-align: center;">Antiarrthymic effect</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">0</td><td style="text-align: center;">0</td></tr><tr><td style="text-align: center;">Negative inotropic effect</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Vasodilatation</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Heart rate</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↓</mo></mrow><annotation encoding="application/x-tex">\downarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↓</span></span></span></span></span></td><td style="text-align: center;">Nor <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↓</mo></mrow><annotation encoding="application/x-tex">\downarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↓</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↑</mo></mrow><annotation encoding="application/x-tex">\uparrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↑</span></span></span></span></span></td><td style="text-align: center;">N</td></tr><tr><td style="text-align: center;">Blocks reflex sympathetic effects</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">0</td><td style="text-align: center;">0</td></tr><tr><td style="text-align: center;">Dose (mg/day) in hypertension</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>120</mn><mo>−</mo><mn>240</mn></mrow><annotation encoding="application/x-tex">120-240</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">120</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">240</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>120</mn></mrow><annotation encoding="application/x-tex">60-120</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">120</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>60</mn></mrow><annotation encoding="application/x-tex">30-60</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">60</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo>−</mo><mn>10</mn></mrow><annotation encoding="application/x-tex">2.5-10</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">10</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Dose (mg/day) in angina</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>240</mn><mo>−</mo><mn>480</mn></mrow><annotation encoding="application/x-tex">240-480</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">240</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">480</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>120</mn><mo>−</mo><mn>360</mn></mrow><annotation encoding="application/x-tex">120-360</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">120</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">360</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>60</mn></mrow><annotation encoding="application/x-tex">15-60</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">60</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo>−</mo><mn>10</mn></mrow><annotation encoding="application/x-tex">2.5-10</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">10</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Dosage schedule</td><td style="text-align: center;">8 hourly</td><td style="text-align: center;">8 hourly</td><td style="text-align: center;">6-8 hourly</td><td style="text-align: center;">O.D.</td></tr><tr><td style="text-align: center;">Adverse effects</td><td style="text-align: center;">A-V block, constipation, nausea, possibly LVF</td><td style="text-align: center;">A-V block, hy potension, Rarely LVF</td><td style="text-align: center;">Palpitation, hy potension, nausea, edema</td><td style="text-align: center;">Palpitation, hy potension, nausea, edema</td></tr></tbody></table>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>=</mo></mrow><annotation encoding="application/x-tex">+=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Mild effect;
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>=</mo></mrow><annotation encoding="application/x-tex">++=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Moderate effect;
+++ = Potent effect;
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">N</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{N}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm">N</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Normal
VERAPAMIL: This drug is a synthetic papaverine derivative. It causes:</p>
<ul>
<li>Suppression of SA and AV nodes which are <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>dependent.</li>
<li>Coronary and peripheral vasodilatation.</li>
<li>Potent antiarrhythmic effect; and</li>
<li>Potent negative inotropic effect and may cause A-V block.</li>
</ul>
<p>It does not cause reflex sympathetic overactivity and tachycardia.
Given orally, it is absorbed completely but is substantially metabolised by first pass hepatic metabolism. It is highly protein bound. Adverse effects include constipation, vertigo, bradycardia, heart block, CHF, hypotension and rarely cardiac asystole.</p>
<p>It is available as 40 mg tablets and as sustained release tablets. It is used in the treatment of angina in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>80</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mn>3</mn><mo>−</mo><mn>4</mn></mrow><annotation encoding="application/x-tex">40-80 \mathrm{mg} 3-4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">80</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4</span></span></span></span></span> times a day. Its use in paroxysmal supraventricular tachycardia is described in Chapter 28.</p>
<p>DILTIAZEM: This drug has properties intermediate between those of verapamil and nifedipine (see Table 29.2). It has less negative inotropic effect than verapamil and less vasodilating effect than nifedipine and verapamil. It can be combined with nitrates.</p>
<p>NIFEDIPINE: The pharmacological properties of this dihydropyridine derivative (Fig 29.3) are shown in Table 29.2.</p>
<p><img src="assets/images/image-20251214-49fa29f8.jpeg" alt="img-20.jpeg"></p>
<p>Compared to verapamil, it:</p>
<ul>
<li>Has negligible negative inotropic effect</li>
<li>Is a more potent coronary and peripheral vasodilator,</li>
<li>Causes tachycardia.</li>
<li>Is a potent inhibitor of platelet aggregation.</li>
</ul>
<p>It also relaxes bronchial, ureteric and uterine smooth muscle. It is used either orally or (for a rapid effect) sublingually. However, for long term use a sustained release formulation in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>90</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">30-90 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">90</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> OD is preferred.</p>
<p>Adverse reactions: These include headache, tachycardia, dizziness, fatigue, orthostatic hypotension, leg cramps, skin rashes and gingival hyperplasia. Occasionally, CHF may be precipitated.</p>
<p>Angina may worsen with nifedipine because of decrease in coronary perfusion pressure resulting from rapid fall in BP, increase in oxygen demand due to reflex sympathetic activation, (tachycardia) and coronary steal phenomenon. In IHD, the narrowed coronary arteries are always maximally dilated to compensate for the decreased blood supply. Nifedipine induced arteriolar dilatation in the non-ischaemic zone (there is no further dilatation of arterioles of the ischaemic zone) shunts oxygenated blood away from ischaemic zone to highly perfused non-ischemic zones of the heart. This stealing of coronary blood away from ischaemic zone may precipitate angina. The slower-onset, longeracting calcium blockers such as amlodipine are less likely to cause this phenomenon.</p>
<p>Therapeutic uses: Its main use is in the treatment of:
(i) Variant angina refractory to nitrate therapy.
(ii) Hypertension and
(iii) Raynaud's syndrome (Chapter 30).</p>
<p>Nicardipine and isradipine are other dihydropyridine compounds with pharmacological properties and uses similar to those of nifedipine.</p>
<p>Amlodipine and felodipine, with long <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>t</mi><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">t \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord mathnormal">t</span><span class="mord">%</span></span></span></span></span> are the second generation dihydropyridine CCBs. They are potent coronary and peripheral vasodilators; bradycardia and AV block are less liable to occur with their use (Table 29.2).</p>
<p>Nisoldipine: This dihydropyridine is available as SR tablets for prophylactic therapy for chronic stable angina and hypertension.</p>
<p>Nimodipine is related to nifedipine but is claimed to have a preferential vasodilating action on the cerebral arteries in animal studies. Its use is confined to the prevention of vascular spasm and subsequent ischaemic neurological damage following subarachnoid</p>
<p>hemorrhage; its usefulness for this purpose is, however, uncertain. It is given in the dose of 60 mg every four hours for the first few days.</p>
<p>Clevidipine is a novel dihydropyridine compound available for IV administration. It has rapid action with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of 2 min . It is metabolised by esterases in the blood. It is preferentially an arteriolar dilator and is used to control BP in hypertensive emergencies.</p>
<p>Non-cardiac uses of CCB: See Chapters 24, 39 and 44 for their use in migraine, mountain sickness and as tocolytics, respectively.</p>
<p>Contraindications to CCB are:</p>
<ul>
<li>Tight aortic stenosis.</li>
<li>Severe myocardial depression, bradycardia and heart block.</li>
<li>Clinical heart failure.</li>
<li>Unstable angina; and</li>
<li>Preexisting hypotension It is unwise to use them in patients on digoxin or a beta blocker, as they may exacerbate A-V block or heart failure. They should be used in pregnancy only if absolutely necessary.
Abrupt withdrawal of CCB during long term therapy can precipitate angina and MI.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="potassium-channel-activators">Potassium Channel Activators<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#potassium-channel-activators" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These are discussed in Chapter 30.
NICORANDIL: It acts as ATP dependent myocyte potassium channel nad produces vasodilatation. In addition, it aslo act as a NO donor. Though it preferentially acts on the venous side and reduces the preload, it also acts on the arteriolar side and reduces the afterload. Given orally in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10-20 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> bid, it is equivalent to standard dose of a beta-blocker or a CCB in angina of effort. Adverse effects are mostly due to vasodilator action and include headache, dizziness and dose dependent hypotension.</p>
<p>Nicorandil is perhaps useful but expensive background therapy for patients with angina pectoris. It is particularly useful as an alternative to nitrates when tolerance is a problem. It can be used in the presence of asthma or cardiac failure.</p>
<p>Pinacidil is similar to nicorandil in its properties, adverse reactions and uses. Its duration of action is about 6 hours; the controlled release preparation ( 37.5 mg capsule) acts for about 12 hours.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antiplatelet-drugs">Antiplatelet Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antiplatelet-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>ASPIRIN: Prophylactic aspirin reduces the incidence of MI in patients with chronic stable and unstable angina (Chapter 33).</p>
<p>Dipyridamole: This drug is a coronary dilator; but unlike nitrates which dilate conductance vessels it is claimed to dilate coronary resistance vessels (Fig. 29.2). It is a weak platelet inhibitor. It is used as an antithrombotic drug (Chapter 33).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cytoprotectives">Cytoprotectives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cytoprotectives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Trimetazidine: This drug is a Partial inhibitor of Fatty acid Oxidation (PFOX) pathway in the myocardium, thereby improving its metabolism in the presence of ischemia. It is claimed to maintain normal LV function without exerting any hemodynamic effect. It has been used to treat stable angina of effort. However, its superiority over standard treatment is doubtful.</p>
<p>Ranolazine: This drug is chemically related to trimetazidine. Calcium abnormalities following cardiac ischemia are associated with disregulation of ion homeostasis, leading to increased intracellular sodium and calcium. Ranolazine is claimed to act by selective inhibition of late sodium influx and thus, prevents calcium overload via the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span> exchanger. Clinically, it produces modest improvement in exercise tolerance. Its side effects are dizziness, nausea, asthenia and constipation. It is contraindicated in hepatic impairment and in patients with preexisting Q-T prolongation.</p>
<p>Ivabradine is a pure heart rate lowering agent which acts by selectively inhibiting the sinoatrial node. It has no other hemodynamic actions. It may be useful to treat high resting heart rate in patients with Coronary Artery Disease (CAD). It is not useful in chronic stable angina.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="treatment-of-angina-pectoris">Treatment of Angina Pectoris<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment-of-angina-pectoris" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Exertional angina (angina of effort): Table 29.3 outlines the principles of treatment of angina of effort.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-29-3">Table 29.3<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-29-3" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="principles-of-treatment-of-angina-of-effort">Principles of treatment of angina of effort<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#principles-of-treatment-of-angina-of-effort" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>I General</p>
<ul>
<li>Reassurance</li>
<li>Measures to prevent progression
(a) Treatment of IHD risk factors e.g., hypertension, hyperlipidaemia, diabetes, obesity.
(b) Use of anti-atherogenic agents, e.g. statins (Chapter 40).
(c) Advise about life style modification (control of emotional excitement, alcohol and smoking and weight control).
(d) Supervised, graded, physical exercises.</li>
<li>Treatment of associated conditions which increase oxygen demand, e.g. hyperthyroidism, anaemia, valvular disease, heart failure.</li>
<li>Avoidance of preparations containing sympathomimetic amines (cold remedies, anti-asthmatic and anorectic agents), atropine, aminophylline and antidepressants II Specific</li>
<li>Drugs for acute attack e.g. a Nitrate (See Table 29.1).</li>
<li>Chronic prophylaxis (prevention of MI and improved survival) (See text).
(a) Aspirin
(b) Use of nitrates, beta blockers, CCB</li>
</ul>
<p>III Surgical revascularisation</p>
<p>Relief and prevention of individual attacks: Nitroglycerine (NTG) is the drug of choice in all types of angina. The patient is advised to carry the tablets, and to put one sublingually as soon as premonitory symptoms develop. He should be advised to use NTG while sitting, to avoid possible syncope. If symptoms are not relieved immediately, additional tablets may be used at 5 minute intervals, but not more than three tablets should be used in a 15 minute interval. The remnant of the tablet should be discarded soon after pain relief as excessive absorption of the drug would lead to hypotension. One may use as many tablets per day as needed.</p>
<p>NTG or isosorbide dinitrate, used sublingually 10-15 minutes before a period of increased activity such as walking, climbing or sexual intercourse, can frequently prevent the attack. This is the preferred method of using these drugs for prophylaxis. The acute prophylactic effect of sublingual NTG and isosorbide dinitrate persists for about 30 minutes and 2 hours respectively. Longer prophylactic effect (upto 4 hours) is obtained with NTG cutaneous ointment as NTG is absorbed slowly and bypasses the liver. Generally, isosorbide dinitrate causes less headache than NTG.</p>
<p>Chronic prophylaxis: This comprises of:</p>
<ul>
<li>Nitrates: Large oral doses of organic nitrates decrease the frequency of anginal attacks and increase the exercise tolerance. They, however, increase the risk of hypotension, tachycardia and tolerance. Small oral doses are of doubtful value for this purpose. Nitrates may be combined with beta-blockers or diltiazem but not with nifedipine or verapamil.</li>
<li>Beta blockers: All beta blockers seem to be equally effective and reasonably safe as anti-</li>
</ul>
<p>anginal drugs. They are the drugs of choice for chronic prophylaxis of angina of effort (IHD). They can be combined, if necessary, with nitrates for this purpose. They are particularly preferred for the treatment of asymptomatic (silent) myocardiac ischemia. Generally, propranolol is started in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mn>3</mn><mo>−</mo><mn>4</mn></mrow><annotation encoding="application/x-tex">10 \mathrm{mg} 3-4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4</span></span></span></span></span> times a day. The daily dose is gradually increased by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20-30 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> once in 3-4 days until the resting pulse rate is lowered to about 60 /minute and the symptoms are relieved without the development of CHF. Weight gain is a useful early indicator of the latter. The average, effective, daily dose of propranolol is about 100-200 mg. But some patients may require larger doses. Alternatively, a selective beta blocker such as metoprolol ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50-100 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> twice a day) or atenolol ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50-100 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> once a day) can be used.
Beta blockers are the drugs of choice in cardiac syndrome <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>X</mi></mrow><annotation encoding="application/x-tex">X</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07847em;">X</span></span></span></span></span> but are not particularly effective against angina at rest or on minimal exercise since their beneficial effect in the absence of sympathetic overactivity is small.</p>
<ul>
<li>Calcium channel blockers: Variant angina is generally relieved rapidly by NTG. CCB are to be preferred for its prophylaxis. In patients with angina of effort, these drugs appear to be as effective as beta-blockers as prophylactics but they are less well tolerated. Further, they do not improve life expectancy after MI. They are mainly used in patients not responding to a combination of beta blockers and nitrates; wherein dihydropyridines can be combined with beta blocker. They can be used in patients with COPD, asthma and AV conduction disturbances. Verapamil can be used instead of a beta blocker to control tachycardia in thyrotoxic patients with asthma.
In patients with stable angina, the dose of nifedipine needs to be titrated very finely. If a patient benefits from 10 mg tid, he is likely to deteriorate on a higher dose. Calcium channel blockers have no beneficial effect, and may even be detrimental, in acute MI.</li>
<li>Combination of a beta blocker and a CCB is additive but not synergistic. Verapamil should not be combined with betablockers. Diltiazem may be combined with betablockers only in patients with normal cardiac function and without conduction defects.
Nifedipine or amlodipine and betablockers have complimentary actions on the coronary blood supply and myocardial oxygen demand. The former dilate the coronaries and decrease the BP whereas the latter slow the heart rate and reduce the myocardial contractility. The second generation dihydropyridines (e.g. amlodipine) are particularly useful in patients with angina associated with hypertension.
Table 29.4 outlines a step-wise approach to the drug treatment of angina.</li>
</ul>
<p>Table 29.4
Stepwise approach to drug therapy of angina</p>
<table><thead><tr><th style="text-align: left;">All patients are prescribed aspirin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mo>−</mo><mn>150</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">75-150 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">75</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">150</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day orally and glyceryl trinitrate sublingually, whenever needed.</th><th style="text-align: left;"></th></tr></thead><tbody><tr><td style="text-align: left;">- Control risk factors</td><td style="text-align: left;">Obesity, hyperlipidemia, hypertension, diabetes, smoking. Consider using a statin.</td></tr><tr><td style="text-align: left;">- Treat concomitant diseases</td><td style="text-align: left;">Anemia, thyrotoxicosis, valvular disease, heart failure.</td></tr><tr><td style="text-align: left;">- Mild to moderate symptoms</td><td style="text-align: left;">Beta blockers; if contraindicated, CCB.</td></tr><tr><td style="text-align: left;"></td><td style="text-align: left;">If both are not tolerated, use prophylactic isosorbide dinitrate/mononitrate, or nicorandil.</td></tr><tr><td style="text-align: left;">- If symptoms persist</td><td style="text-align: left;">Combine beta blockers with a CCB</td></tr><tr><td style="text-align: left;">- If severe and not responding</td><td style="text-align: left;">Refer for revascularisation.</td></tr></tbody></table>
<ul>
<li>Advice about the life style: Excitement and emotional upset can precipitate anginal attacks. A patient who suspects that he has 'heart pain' is worried, and reassurance can give much relief. Rest, choice of occupation not involving heavy manual work and mental relaxation are important. In fact, the value of change in 'life style' is more than that of any known drug. A placebo can diminish the severity of the symptoms in many patients; hence, one should be wary of accepting a cleverly advertised anti-anginal drug or manoeuvre which has helped "many" patients.
The patient should be advised to avoid overeating, exercise after eating, and extremes of heat, cold and humidity. He should avoid any type, amount or pace of activity known to precipitate anginal attack; if it is unavoidable the prophylactic use of NTG or isosorbide dinitrate sublingually 10-15 minutes before commencing the activity is recommended. Sexual activity can be permitted in most patients.
Alcohol should be avoided by patients with angina. It is not a coronary vasodilator. By removing the higher inhibitory controls in the CNS, it may induce an individual to ignore the anginal pain, leading to more exertion and an aggravation of the cardiac ischemia. A further disadvantage is the liberation of catecholamines by acetaldehyde, a metabolite of alcohol. Alcohol has a negative inotropic action on the heart damaged by CAD. However, in alcohol addicts, its abrupt withdrawal may precipitate undesirable effects, and small amounts of alcohol may be permitted.</li>
<li>Cessation of smoking: Patients with angina must be advised to give up smoking which increases the heart rate and oxygen consumption of the myocardium. Further, absorption of carbon monoxide from the inhaled smoke increases the concentration of carboxyhemoglobin; this reduces the oxygen carrying capacity of blood.</li>
<li>Treatment of associated diseases: Weight reduction in obese patients and treatment of associated hyperlipidemia, anemia, hypertension or thyrotoxicosis help in prophylaxis of angina. Vasodilator anti-hypertensive drugs can aggravate angina by causing tachycardia; but this can be countered by using a beta-blocker.</li>
<li>Supervised, graded, exercise training improves exercise tolerance in anginal patients probably by increasing oxygen extraction in the peripheral circulation. This allows more physical activity with less increase in heart rate and in cardiac output. Isometric physical activity of any type may, however, be harmful.
Variant angina of Prinzmetal: The treatment of this condition comprises (a) NTG sublingually or nifedipine first chewed and then swallowed, for rapid onset of action in acute attacks; and (b) long acting nitrates or CCB for prophylaxis. Beta-blockers are to be avoided.</li>
</ul>
<p>Unstable angina: It requires aggressive treatment in an ICCU to prevent MI or sudden death. The patient is treated with aspirin ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>150</mn><mo>−</mo><mn>300</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">150-300 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">150</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">300</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> ); sublingual NTG or IV isosorbide dinitrate/NTG, continued till the patient remains pain-free for 24 hours. A beta blocker is administered to lower the heart rate to 50-60/minute. The combined use of aspirin and clopidogrel is synergistic. Routine anticoagulation with heparin is helpful. A CCB such as diltiazem is substituted in patients in whom beta blockers are contraindicated; but, it does not reduce the risk of MI. Thrombolytic therapy (Chapter 33) is not indicated in these patients as it may worsen the condition.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="acute-myocardial-infarction-management">Acute Myocardial Infarction: Management<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#acute-myocardial-infarction-management" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Acute MI is a medical emergency and needs immediate attention. The symptomatology varies from very mild (silent infarct) to severe presentation (with cardiogenic shock).</p>
<p>Rise in creatinine kinase-myocardial band (CK-MB) and troponin indicates degree of myocardial necrosis and are used as biochemical markers. They are always elevated in STEMI. In patients with NSTEMI, they are usually elevated but may be normal. In unstable angina they are not elevated indicating absence of necrosis. STEMI is precipitated when a coranary artery thrombus develops rapidly.</p>
<p>Table 29.5 summarises the treatment of acute myocardial infarction.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-29-5">Table 29.5<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-29-5" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="principles-of-treatment-of-acute-myocardial-infarction">Principles of treatment of acute myocardial infarction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#principles-of-treatment-of-acute-myocardial-infarction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="before-hospitalisation">Before hospitalisation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#before-hospitalisation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>For promptrelief of pain
(a) Sublingual nitroglycerine 0.4 mg every 5 minutes till pain is relieved (max. 3 doses) in mild cases and in the absence of hypotension (systolic BP <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>90</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">&lt;90 \mathrm{~mm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">90</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span></span></span></span></span> ).
(b) IV morphine, 1 mg per minute, titrated to a maximum total dose of 10 mg , together with IV metoclopramide 10 mg (antiemetic).
(c) Oxygen.</li>
<li>Aspirin 75 to 150 mg (antiplatelet action).</li>
</ul>
<p>After hospitalisation</p>
<ul>
<li>Bed rest</li>
<li>Treatment of hypotension</li>
<li>IV betablocker</li>
<li>ACE inhibitor</li>
<li>Thrombolytic therapy and/or anti-coagulants (See text)</li>
<li>Treatment of complications</li>
<li>General measures (sedation, diet, bowel care, activity)</li>
</ul>
<p>Discharge and rehabilitation</p>
<ul>
<li>Coaded increase in physical activity, including exercise therapy</li>
<li>Aspirin</li>
<li>ACE inhibitors</li>
<li>Betablockers</li>
<li>Statin</li>
<li>Modification of cardiac risk factors smoking (including nicotine substitution), alcohol, hypertension, diabetesmellitus, hyperlipidemia, obesity</li>
<li>Relief of pain: In mild cases, sublingual nitroglycerine may suffice. Transdermal or IV nitrate therapy is helpful in relieving persistent pain. In patients with severe pain, the slow IV administration of 10 mg of morphine hydrochloride over 10 minutes ensures rapid relief from pain and thereby minimises the shock. Morphine SC is less useful in such cases because of peripheral circulatory collapse which delays its absorption.
Morphine may be repeated, if necessary, after 30 minutes. Pethidine hydrochloride 25 to 50 mg may be given IV, particularly in the presence of bradycardia. Both, morphine and pethidine can produce hypotension. This can be corrected by elevating the lower limbs. Morphine may cause sinus bradycardia and respiratory depression. Alternatively buprenorphine 0.4 mg SC or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.3</mn><mo>−</mo><mn>0.6</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.3-0.6 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">0.6</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> IM may be used and repeated if necessary 6-8 hrly.</li>
<li>Oxygen and rest: The patient should be confined to bed and made to breathe 100% oxygen by means of a face mask. Even a slight increase in activity could worsen the condition.</li>
<li>Antiplatelet therapy: Aspirin 150-300 mg is chewed as soon as the diagnosis of MI is made. It is continued once daily throughout convalescence and after recovery and has</li>
</ul>
<p>shown to reduce the mortality significantly.</p>
<ul>
<li>Thrombolytic therapy (Chapter 33). This is most useful in patients with STEMI.</li>
<li>Maintenance of effective blood volume: In presence of cardiogenic shock the effective circulating volume is reduced which can be corrected by:
(i) Elevating the lower limbs and thus increasing the venous return to the heart and,
(ii) Infusing 5% dextrose. Excessive infusion, however, may cause pulmonary edema. This can be averted by a careful monitoring of CVP or PAOP and arterial blood pressure.</li>
<li>Inotropic drugs: Dopamine and dobutamine are the drugs of choice for regulating BP. Dobutamine is less likely to cause arrhythmias and sinus tachycardia. If they are not available, NA may be used (Chapter 18).</li>
<li>Prevention and treatment of arrhythmias: Prophylactic therapy with Class I antiarrhythmic drugs is not recommended in patients without an arrhythmia. It is best not to give drugs empirically for a paroxysmal tachyarrhythmia or rapid irregularity of the pulse until an ECG is recorded. Ventricular ectopic beats at a frequency of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">5 / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>., herald the possibility of serious ventricular arrhythmia and should be treated with:
(a) Lignocaine, IV infusion given at a rate of 1 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">2 \mathrm{mg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>, or
(b) Procainamide, 100 mg IV every 5 minutes, to a total dose of not more than 1 gm , or alternatively
(c) Lignocaine IM in the dose of 400 mg and repeated if necessary.</li>
</ul>
<p>Ventricular tachycardia is a serious complication needing immediate therapy with IV infusion of lignocaine or DC shock. Atrial fibrillation and flutter may need digitalisation or DC shock. Sinus or nodal bradycardia is treated with IV atropine sulfate 0.3 to 2 mg , or isoprenaline 0.05 mg , respectively Digoxin may be given if CHF develops.</p>
<ul>
<li>Beta blockers: Given IV within 4-6 hours of the onset of symptoms, propranolol, atenolol and metoprolol may limit the infarct size and reduce early mortality. They are of maximum benefit in patients with continued pain, evidence of sympathetic overactivity and absence of heart failure. The contraindications to the use of these drugs are: bronchospasm, resting bradycardia (less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>55</mn><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">55 / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">55/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span> ), low systolic BP (less than 95 mm Hg ) and heart block. Propranolol IV has been used in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.1 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> divided into three doses at 5-10 minutes, followed by 20-40 mg orally every 6-8 hours. Atenolol has been used in the IV dose of 5-10 mg, followed by 100 mg orally once daily. Metoprolol has been used in the IV dose of 5 mg over 2 minutes, repeated every 5 minutes (total 3 doses), followed by 50-100 mg orally every 12 hours. Currently, it is recommended that a betablocker should be given to all patients who do not have a contraindication (Chapter 18). Intravenous therapy should be commenced as soon as possible after hospitalisation, at least within 24 hours of onset of symptoms; oral therapy should be given in patients who are admitted late. For long term use of beta-blockers has been shown to be beneficial (See below).</li>
<li>ACE inhibitors (ACEI): They should be administered to all patients within 24 hours of the onset of symptoms, if important contra-indications (hypotension, bilateral renal artery stenosis, renal failure or history of intolerance to these drugs) are absent. ACEI reduce LV dysfunction and slow the progression of CHF. They should be used, in the first instance, for 5-6 weeks.</li>
<li>Anticoagulants: Anticoagulants may be given to all patients with STEMI, and NSTEMI. They prevent venous thrombosis, pulmonary embolism, and stroke in patients with</li>
</ul>
<p>severe LV dysfunction after MI. Heparin, especially LMWH, is the preferred drug for this purpose (Chapter 33). The risk of bleeding is higher in patients who receive fibrinolytics.</p>
<ul>
<li>General measures: Sedation with a benzodiazepine is useful in the initial days of illness to allay anxiety. The diet should be liquid on the first day; subsequently, it should be soft, with no added salt and low in calories. Caffeinated beverages and very hot or very cold liquids should be avoided. A stool softener is administered routinely as straining at stool can precipitate cardiac arrhythmias.</li>
<li>Rehabilitation and long term drug therapy: Modification of cardiac risk factors (see Table 29.3) is a must. Every effort must be made to persuade the patient to give up smoking (Chapter 21). Lifelong continuation of low dose aspirin is valuable to reduce the reinfarction rate. For patients with large infarcts and severe left ventricular dysfunction, long term anticoagulant therapy should be considered to reduce the risk of systemic embolisation.
Beta adrenergic blockers (atenolol, 100 mg OD or metoprolol 100 mg bid) have been shown to reduce mortality, sudden deaths and reinfarction after MI. This therapy should be used for at least 2-3 years after acute infarction.</li>
</ul>
<p>ACE inhibitors reduce mortality, incidence of heart failure and re-infarction. They can be stopped after 1-2 years in many patients but must be continued lifelong in patients with left ventricular dysfunction, with or without symptoms.</p>
<p>Glucocorticoids and NSAID (except low dose aspirin) should be avoided in patients with MI as they interfere with infarct healing.</p>
<p>Calcium channel blockers have no place in the treatment of acute MI. Antioxidant and/or vitamin therapy after MI has not been shown to be useful in reducing mortality.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-used-in-the-treatment-of-peripheral-vascular-disorders">Drugs Used in the Treatment of Peripheral Vascular Disorders<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-used-in-the-treatment-of-peripheral-vascular-disorders" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Peripheral vascular disease may be:
I Obstructive: Atherosclerosis or thrombo-angiitis obliterans (TAO) with large vessel involvement, or diabetes with small vessel involvement); or
II Vasospastic: Raynaud's syndrome.
I Obstructive peripheral vascular disease:
In these patients vasodilator drugs are of little avail as they fail to increase the blood flow to ischemic areas with blocked arteries/arterioles. Further, the associated generalised vasodilatation can produce severe adverse reactions. Such patients may benefit from</p>
<ul>
<li>Correction of remediable underlying factors such as CHF, anemia or diabetes mellitus. - Cessation of smoking.</li>
<li>Daily physical exercise (such as walking) which can increase the walking distance.</li>
<li>Foot care (cleanliness, avoidance of any injury and prompt treatment of infection).</li>
<li>Drugs: Low dose aspirin (antiplatelet action), statins (cholesterol lowering action) and pentoxyphylline (hemorheologic action) have been used with variable success, (Chapter 33).</li>
</ul>
<p>Naftidofuryl oxalate (Praxilene) 100 mg orally 2-3 times a day alleviates symptoms and increases pain-free walking distance in moderate peripheral obstructive vascular disease. It is not a direct vasodilator but may increase the supply of ATP and reduce lactate level in muscles. It activates the enzyme succinate dehydrogenase. It is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">5 \mathrm{HT}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord">5</span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> antagonist and it inhibits 5HT induced vasoconstriction and platelet aggregation.
PENTOXIFYLLINE: This analogue of xanthines is claimed to increase the deformability of the RBCs in circulation and thus improve the microcirculation (hemorheological action). It has been claimed to be useful in patients with cerebrovascular disease, especially those getting transient ischemic attacks; in those with intermittent claudication and in subjects with ischemic legs ulcers. The clinical results, however, have been variable and difficult to predict. The drug may reduce plasma fibrinogen level and inhibit platelet aggregation. It causes mild GI upset and CNS adverse effects. It is available as 400 mg sustained release tablets. Dose is one tablet bid after food.
Cilostazol is a PDE3 inhibitor which inhibits platelets and dilates vessels. Given as 100 mg bid ( 30 minutes before or 2 hrs after food), it may be useful in patients without rest pain and no peripheral tissue necrosis.</p>
<ul>
<li>Endarterectomy or peripheral arterial bypass surgery in selected cases may be helpful. It is important to note that intermittent claudication can be of vascular origin (e.g. Burger's disease) or neurological origin. The former is only partially helped by vasodilators while they are not at all useful in the latter group.
II Vasospastic diseases: Drugs useful in these conditions are:</li>
<li>Calcium channel blockers, e.g., Nifedipine and Diltiazem are preferred.</li>
<li>Beta adrenergic stimulants: Nylidrin and Isoxsuprine (Chapter 18).</li>
<li>Alpha adrenergic blockers: Tolazoline and Prazosin (Chapter 18).</li>
<li>Anticoagulants: Heparin and Warfarin, discussed in Chapter 33.</li>
</ul>
<p>In Raynaud's syndrome, prazosin is used in the dose of 0.5 mg bid (first dose at bed time); the maintenance dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1-2 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> bid. Nifedipine is used in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5-20 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> tid.</p>
<p>Other drugs claimed to be useful are nicotinic acid derivatives, cyclandelate (Cyclospasmol), pentoxifylline, ketanserin (Chapter 24) and prostacyclin.</p>
<p>The drug therapy must always be combined with non-pharmacological measures such as exercise, avoidance of exposure to cold and cessation of smoking.</p>
<p>30</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacotherapy-of-hypertension-pulmonary-hypertension-and-orthostatic-hypotension">Pharmacotherapy of Hypertension, Pulmonary Hypertension and Orthostatic Hypotension<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacotherapy-of-hypertension-pulmonary-hypertension-and-orthostatic-hypotension" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Hypertension, which affects over one billion adults worldwide is a major risk factor for cardiovascular and renal diseases. Clinically it can be divided into two major divisions: I Primary or essential hypertension, where definite cause for the rise in blood pressure (BP) is not known; and
II Secondary hypertension, secondary to renal (e.g. chronic diffuse glomerulonephritis, pyelonephritis, polycystic kidneys), endocrine (e.g. Cushing's syndrome, pheochromocytoma, primary hyperaldosteronism) and vascular (e.g. renal artery disease, coarctation of aorta) lesions.</p>
<p>The syndrome of essential hypertension is characterised by elevation of the diastolic BP, a normal cardiac output (in most cases) and increased peripheral vascular resistance, with documented natural history and with characteristic pathologic changes in the arterioles.</p>
<p>The 'Normal' BP in adults is defined as below 120/80 mm Hg (day time); and 'High Normal' BP (prehypertension) as 130 to 139 mmHg systolic and 80 to 89 mmHg diastolic. BP above 139 mm Hg systolic or above 89 mm Hg diastolic on several occasions qualifies as hypertension, at all ages. Systolic BP above 140 mm Hg plus diastolic BP of below 90 mm Hg in the elderly is termed isolated systolic hypertension.</p>
<p>Hypertension, if untreated, leads to a variety of disabling cardiac, cerebrovascular, and renal complications, with shortened life expectancy, regardless of its etiology. Further, the risk of morbidity and mortality rises with BP and there is no clearly defined cut-off point for increased risk.</p>
<p>Physiologically, the BP is controlled by two main types of systems (Fig. 30.1).</p>
<p><img src="assets/images/image-20251214-fb5d50d6.jpeg" alt="img-21.jpeg"></p>
<p>PGANE <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span></span></span></span></span> Postganglionic adrenergic nerve ending
(a) The adrenergic nervous system which operates through the baroreceptors and is mainly responsible for the counteracting acute changes in the BP. Baroreceptor reflexes protect the circulation against stresses that alter arterial pressure acutely. When one stands up from the lying down position, the cardiac output tends to fall due to reduced venous return to the heart. This may lead to a fall in BP and fainting. Normally, it is prevented by a reflex increase in heart rate and in peripheral resistance through the baroreceptor mechanism.
(b) The humoral renin-angiotensin- aldos-teronal system, which has a slow response, is important in long term regulation of BP. It operates through the kidneys and involves various humoral agents (Fig. 30.1).</p>
<p>Renin, a proteolytic enzyme, is produced and stored in the kidneys. It is released in response to:
(a) reduction in renal perfusion pressure,
(b) reduction in sodium delivery to the macula densa,
(c) increase in the sympathetic activity, and
(d) certain humoral factors.</p>
<p>Renin cleaves the serum globulin angiotensinogen to an inactive decapeptide, 'angiotensin I.' The latter, during its passage through the lungs, is converted into an active octapeptide, 'angiotension II' by the action of enzyme Angiotensin Converting Enzyme (ACE). Angiotensin II is the most potent direct vasoconstrictor agent, effective in as small a dose as 0.1 mcg per kg body weight. Angiotensin II also stimulates the synthesis and release of aldosterone from the adrenal cortex and thus regulates the ECF volume. In the circulation, angiotensin II is converted into a heptapeptide Angiotensin III which is as potent as angiotensin II in its action on the adrenal cortex but is weaker in its other actions. "The kidney thus plays an important role in determining the BP level, doing so via renin-angiotensin- aldosterone system (RAAS) activity, which presides over both vasoconstriction and volume, the two major determinants of BP and of tissue flow."</p>
<p>Renin and angiotensin are also produced locally in many tissues including blood vessels,</p>
<p>brain, kidney, heart and adrenal glands. It is likely that these tissue angiotensin-generating systems are involved in the local control of cardiac, renal and vascular function, and cardiovascular damage.</p>
<p>The etiology of primary hypertension is not clear. The factors implicated in its genesis are:</p>
<ul>
<li>In adult populations, the BP rises with age. However, the rise in BP with age in a population is not uniform. This is due to the development of hypertension in a discrete group of individuals with advancement of age. Such individuals are presumed to differ qualitatively from the remainder population in their BP regulation.</li>
<li>There is a strong familial clustering of essential hypertension and the inheritance is polygenic.</li>
<li>The arterial pressure is a function of the cardiac output and the peripheral resistance. Both can be readily affected by various factors. Resistance to the blood flow resides chiefly in the arterioles. Changes in their calibre produce enormous changes in the peripheral resistance.
Arteriolar walls have very reactive smooth muscle. Factors which tend to diminish their radius augment the total peripheral resistance and consequently, the BP.</li>
<li>The renin-angiotensin system is involved in the pathogenesis of some forms of secondary hypertension such as the renovascular hypertension. It is also believed to play a role in the pathogenesis of essential hypertension. In man, procedures that increase sympathetic nervous activity are associated with increased plasma renin activity (PRA). On the basis of renin activity, patients with high BP can be divided into (1) those with high renin activity or (2) those with low renin activity.
The adrenergic blockers, methyldopa, reserpine and propranolol reduce PRA whereas, vasodilator antihypertensives such as hydralazine, diazoxide, sodium nitroprusside and the thiazides increase PRA in hypertensive patients.</li>
<li>There is deficient vascular synthesis and release of nitric oxide (NO) in hypertensives.</li>
<li>There is a positive correlation between total body sodium and BP, and a negative one between total body potassium and BP, in hypertensive patients. Essential hypertension and agerelated increase in BP are virtually absent in populations where less than 50 mmol of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>3.00</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">&lt;3.00 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">3.00</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> of salt) is consumed daily. It appears that both excess of body sodium and deficit of body potassium contribute to the development of hypertension. Increase in intracellular <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> stimulates <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>exchange pump, driving <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>into the cell. Increased cytosolic <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span> triggers vascular smooth muscle contraction. Further, sodium retention in the cell decreases NO synthesis by endothelial cells whereas high potassium diet causes endothelium-dependent vasodilatation. Clinically, salt restriction reduces BP in many hypertensive patients.</li>
<li>The other endocrine abnormalities that have been demonstrated in some patients with "essential hypertension" are: (a) insulin resistance with resultant hyperinsulinemia; (b) secretion of a structurally abnormal steroid (a hybrid between cortisol and aldosterone) by the adrenal cortex; this heritable condition is called glucocorticoid-remediable aldosteronism (GRA) and (c) an inherited defect in the modulation by salt of the local renin-angiotensin system in the kidney and the adrenals; these subjects have a salt sensitive form of hypertension.
Experimental evaluation of anti-hypertensive drugs: Although many techniques exist</li>
</ul>
<p>for causing a sustained rise in the BP in various species, none has duplicated, in every detail, the picture of human essential hypertension. The important experimental models for evaluating antihypertensive drugs are:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="nephrogenic-hypertension">- Nephrogenic hypertension:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nephrogenic-hypertension" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(a) Dogs can be made hypertensive by partial constriction of one renal artery, accompanied by removal of the other kidney (Goldblatt).
(b) Similar hypertension can be produced in the rat without removing the other kidney.</p>
<ul>
<li>Neurogenic hypertension:
(a) Sectioning of the carotid sinus and the aortic arch nerves produces hypertension in dogs.
(b) Other methods include subjecting rats to intermittent loud noise and injection of kaolin into the cisterna magna of dogs.</li>
<li>Hormonal hypertension: The methods used include:
(a) Prolonged administration of deoxycorticosterone acetate (DOCA) or aldosterone together with sodium chloride in chicks and rats;
(b) Severe hypertension can be produced in uninephrectomised and uniadrenalectomised, salt treated rats during regeneration of the enucleated adrenal cortex.</li>
<li>Spontaneously hypertensive rats (SHR) are available. They would seem to come closest to human essential hypertension.
In many animal models, ingestion of salt is necessary for the development of hypertension. Drugs like methyldopa and beta blockers have little hypotensive effect in animals; but they are effective in hypertensive patients. Hence, the final evaluation has to be done in hypertensive human subjects.
Antihypertensives, classification: The drugs used in the treatment of hypertension act by reducing the
(1) cardiac output and/or
(2) the total peripheral resistance, without correcting the cause. They can be classified according to site of action: (Fig. 30.1).
I Drugs acting centrally:
(a) Alpha <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> adrenergic receptor stimulants, e.g., Clonidine and Alpha methyldopa.
(b) Selective imidazole receptor (IR) stimulants, e.g., Moxonidine.</li>
</ul>
<p>II Drugs acting on the autonomic ganglia:
Ganglion blocking agents, eg., Trimethaphan.
III Drugs acting on the postganglionic sympathetic nerve endings:
(a) Adrenergic neuron blockers: Guanethidine, Bethanidine, Debrisoquine, Bretylium.
(b) Catecholamine depletors: Reserpine.</p>
<p>IV Drugs acting on adrenergic receptors:
(a) Alpha-adrenergic blocking agents: Phentolamine, Phenoxybenzamine, Prazosin, Indoramin.
(b) Beta-adrenergic blocking agents: Propranolol, Atenolol, Metoprolol.
(c) Both alpha and beta adrenergic blocking drugs: Labetalol.</p>
<p>V Drugs acting directly on the vascular smooth muscle (Vasodilators):
(a) Arteriolar vasodilators: CCB, Hydralazine, Diazoxide, Minoxidil.</p>
<p>(b) Arteriolar-venular vasodilators: Sodium nitroprusside.</p>
<p>VI Potassium channel activators:
Diazoxide, Minoxidil, Pinacidil, Nicorandil.
VII Drugs which block renin-angiotensin-aldosterone axis:
(a) Those which block renin release: Beta-adrenergic blockers.
(b) Those that inhibit PRA e.g. Aliskiren.
(c) Those which block the conversion of angiotensin I to angiotensin II by inhibiting the ACE: Captopril, Enalapril (ACEI).
(d) Those which competitively block angiotensin II vascular receptors (ARB): Losartan.
(e) Those which counter the action of aldosterone (Aldosterone antagonist): Spironolactone.
VIII Oral diuretics: Thiazides.
IX Miscellaneous: Metyrosine.
Various antihypertensive drugs may ultimately reduce BP by more than one mechanism.
Further, the hemodynamic alterations produced by a single parenteral dose of a given drug may differ from those resulting from its prolonged oral use.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-acting-centrally">Drugs Acting Centrally<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-acting-centrally" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>CLONIDINE: This imidazoline derivative (Fig 30.2) has a potent antihypertensive action.
<img src="assets/images/image-20251214-0ade9bc4.jpeg" alt="img-22.jpeg"></p>
<p>Mechanism of action: Clonidine mainly acts centrally as agonist at postsynaptic adrenergic alpha <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors in the vasomotor centre and the hypothalamus. Activation of these receptors suppresses the sympathetic outflow and decreases the release of NA from the neuronal terminals, leading to lowering of BP. Almost all the central effects of clonidine can be blocked by the alpha <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor blocker yohimbine.</p>
<p>Larger doses stimulates the peripheral inhibitory presynaptic alpha <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> adrenoreceptors (autoreceptors). This reduces the peripheral NA release. Clonidine also reduces the PRA.</p>
<p>Since alpha adrenoreceptors are widely distributed, their interaction with clonidine can produce other effects such as increase in the level of plasma growth hormone. It potentiates the analgesic action of opioids.</p>
<p>Clonidine also binds to CNS non-adreno-receptor sites (imidazoline receptor), which may contribute to its antihypertensive effect.</p>
<p>Pharmacological actions: Given IV it produces a transient hypertensive response followed by a prolonged fall in both systolic and diastolic BP accompanied by bradycardia. Initial hypertensive effect is not seen after its oral administration.</p>
<p>Chronic administration of 0.3 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">1.5 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day:</p>
<ul>
<li>Reduces both supine and standing BP without affecting the cardiovascular reflexes.</li>
<li>Diminishes heart rate.</li>
<li>Does not cause postural hypotension.</li>
<li>Does not affect the renal blood flow and the GFR; hence, the drug is valuable in patients with compromised renal function.</li>
<li>The hypotensive effect is associated with a reduction in cardiac output, total peripheral resistance, or both. With time, this reduction in cardiac output becomes less apparent.</li>
<li>Its hypotensive effect is enhanced by simultaneous use of a thiazide diuretic.</li>
</ul>
<p>Tolerance to antihypertensive effect develops on prolonged use.
Absorption, fate and excretion: Being highly lipid soluble, it is well absorbed from the gut and has a high volume of distribution. Its <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is about 12 hours. About half of the drug is excreted unchanged in the urine.</p>
<p>Preparations: Clonidine hydrochloride 0.1 mg tablets. A transdermal preparation is also available; its effect lasts for 7 days.</p>
<p>Adverse reactions: It commonly causes drowsiness (central sedative action) and oral dryness due to central inhibition of salivation. Vertigo, constipation, parotid pain, impotence, GI disturbances, allergic reactions and hallucinations may occur. Toxic doses</p>
<p>cause marked bradycardia, miosis and hypotension.
Abrupt cessation of clonidine therapy can cause hyperirritability and a dangerous and sometimes lethal rebound rise of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi><mi>P</mi></mrow><annotation encoding="application/x-tex">B P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">BP</span></span></span></span></span>. The treatment of such rebound hypertension is either reinstitution of clonidine or use of a combined <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> adrenergic blocking agent e.g. labetalol. Therefore, when clonidine must be withdrawn, gradual tapering is recommended.</p>
<p>Clonidine produces sodium and fluid retention and rapid development of tolerance to its antihypertensive effect. Combination of clonidine and a beta-blocker can cause severe drowsiness. TCA like desipramine may impair the hypotensive action of clonidine.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic Uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Hypertension: It is now rarely used.</li>
<li>Menopausal hot flushes (Chapter 67).</li>
<li>Opiate, alcohol and nicotine withdrawal, to control adrenergic symptoms.</li>
<li>Miscellaneous: Diagnosis of growth hormone deficiency (Chapter 63) and prophylaxis of migraine.
Guanfacine and Guanabenz are related to clonidine and have actions similar to clonidine. Their duration of action, however, is prolonged.</li>
</ul>
<p>ALPHA METHYLDOPA: This isomer of methyldopa (Fig 30.3) which bears a close similarity to dihydroxy-phenylalanine (DOPA). It is a prodrug.
<img src="assets/images/image-20251214-e5e5bec0.jpeg" alt="img-23.jpeg"></p>
<p>Mechanism of action: It is metabolised in the adrenergic neurons to an active metabolite, alphamethyl-noradrenaline which cannot be metabolised by MAO and, like clonidine, acts centrally by activating the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-adrenergic receptors in the vasomotor centre. Methyldopa also inhibits renin release by the kidneys.</p>
<p>Pharmacological actions: After oral or IV administration, the hypotensive effect appears after a latent period of 3-6 hours and 1-2 hours, respectively. Its pharmacological effects are similar to that of clonidine (see earlier).</p>
<p>Absorption, fate and excretion: Given orally, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of the drug is absorbed and is carried into the brain via aromatic amino acid transporters. As the drug metabolite gets stored in the neuronal endings the effect lasts longer ( 24 hours), though its <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is 1.5 hrs . The drug is almost completely excreted in urine in 12 hours. In patients with severely impaired renal function, the drug may accumulate during chronic administration.</p>
<p>Adverse reactions: Commonly, it produces sedation, Other CNS effects are diminished intellectual drive, forgetfulness, nightmares, mental depression and parkinsonism. It causes hyperprolactinemia and gynecomastia. The drug may also cause retention of sodium and water. GI upset, constipation, failure of ejaculation, arthralgia and skin rashes can occur. Tolerance to the antihypertensive effect may occur.</p>
<p>Alpha methyldopa produces fever accompanied by abnormal liver function tests, and</p>
<p>parenchymal/cholestatic jaundice in a few cases. Rarely it causes thrombocytopenia. Methyldopa produces positive direct antibody (Coomb's) test in upto 25% of patients. Rarely it causes SLE and leucopenia.</p>
<p>Preparations: Alpha methyldopa hydrochloride 250 mg tablets; injection 50 mg per ml .
MOXONIDINE: This is claimed to be a selective imidazole receptor ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>I</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">I_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.07847em;">I</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0785em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ) agonist. Discharge at central sympathetic neurons in the rostroventral medulla maintains arteriolar smooth muscle tone, and hence peripheral vascular resistance. Moxonidine activates <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">R</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{IR}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">IR</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> in the medulla, thereby reducing central sympathetic drive and peripheral vascular resistance. It has similar hypotensive action as clonidine and methyldopa. However, its clinical superiority over clonidine needs confirmation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ganglionic-blocking-agents">Ganglionic Blocking Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ganglionic-blocking-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These drugs competitively block the nicotinic receptors in both sympathetic and parasympathetic ganglia.</p>
<p>Pharmacological actions: Hexamethonium blocks the cholinergic receptors on the postganglionic neurons in the both, sympathetic and parasympathetic ganglia. This blockade reduces the amount of NA released from the postganglionic sympathetic nerve endings leading, to a reduction in the peripheral sympathetic tone and a fall in BP. The normal protective vasomotor reflexes mediated through the baroreceptors and the sympathetic nervous system are blocked, which causes marked postural hypotension.</p>
<p>The ganglion blocking drugs, once used to treat hypertension, are now obsolete because of the high incidence of ADR due to blockade of both sympathetic and parasympathetic ganglia. (Chapter 21).</p>
<p>Trimethaphan camphor sulfonate (Arfonad): Because of its extremely transient action, it is used by IV infusion to produce controlled hypotension for short periods, during surgery and is considered as the drug of choice in the treatment of dissection of the aorta.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adrenergic-neuron-blockers">Adrenergic Neuron Blockers<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adrenergic-neuron-blockers" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Adrenergic neuron blocking agents are the drugs that block release of NA from the postganglionic adrenergic neurons in response to impulses or nerve stimulation. The ganglionic transmission is unaffected and the effector organs are fully responsive to injected NA. Guanethidine is the prototype of this group.</p>
<p>GUANETHIDINE was employed in the treatment of resistant severe hypertension.
Mechanism of action: The drug is selectively taken up by adrenergic neuron, the uptake mechanism being same as uptake of NA (uptake <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ). It is concentrated in the vesicle where it replaces NA and thus causes adrenergic neuron blockade because of:</p>
<ul>
<li>Inhibition of the release of NA at the adrenergic nerve terminals. This is its main action.</li>
<li>Blockade of re-uptake of NA by the adrenergic nerve endings, following higher doses (Fig. 17.4). This effect may account for the transient sympathomimetic overactivity following IV guanethidine in animals.</li>
<li>Depletion of vesicular NA stores at the adrenergic nerve endings and tissues such as the heart and the aorta.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacological-actions">Pharmacological actions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-actions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Following oral administration: The antihypertensive action of guanethidine is usually delayed for 48-72 hours. It:</p>
<ul>
<li>Ensures prolonged fall of BP.</li>
<li>Abolishes baroreceptors reflex and thus produces severe postural hypotension.</li>
<li>Impairs cardiovascular responses to exercise and the cold pressor response.</li>
<li>Diminishes the renal blood flow markedly.</li>
<li>Augments the pressor response to exogenous adrenaline and NA and</li>
<li>Usually diminishes the heart rate and pulse pressure.</li>
</ul>
<p>On IV administration in animals, guanethidine exerts a triphasic response: an initial, transient fall in BP due to membrane stabilising action on the heart; followed by a transient rise in BP (sympathomimetic action); and finally a marked and prolonged fall in BP. This is accompanied by an increased heart rate.</p>
<p>Adverse reaction: These are due to marked sympathetic blockade (postural hypotension, failure to ejaculate) and consequent predominance of cholinergic system (diarrhoea, parotid pain). It causes fluid retention. TCA inhibit the entry of guanethidine into the adrenergic neuron and can antagonise its anti-hypertensive action.</p>
<p>It is no more recommended. Other drugs in this group, Bethanidine and Debrisoquine, are now obsolete.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="catecholamine-depletors">Catecholamine Depletors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#catecholamine-depletors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>RESERPINE: The root of the plant Rauwolfia serpentina has been in medicinal use in India since ancient times. It was considered useful for such diverse conditions as insomnia, snake bite and insanity. The root contains alkaloids reserpine, rescinnamine, deserpidine and ajmaline. Reserpine (Chapter 13) is by far the most potent of all hypotensive alkaloids whereas ajmaline has quinidine-like properties (Chapter 28).</p>
<p>Mechanism of action: Reserpine depletes the catecholamines, adrenaline, NA and dopamine, from the various storage sites in the body. This is accompanied by depletion of 5-HT as well, particularly from the CNS. The depletion of NA stores in the peripheral sympathetic nerve endings, including those of heart, explains the antihypertensive action of reserpine.</p>
<p>Normally, the NA released at the sympathetic nerve endings is metabolised partly by COMT, but is largely taken up by the adrenergic neuronal endings (Chapter 17) and is stored in the intracellular granules or vesicles. Reserpine binds to storage vesicles in adrenergic neurons. This binding persists for a long time, and causes inhibition of both granular uptake and storage of catecholamines. Thus, the reserpine action leads to depletion of the transmitter and consequently to peripheral sympathetic blockade. The transmitter which 'leaks out' from the storage granules is inactivated by the mitochondrial MAO. It is for this reason that reserpine does not exhibit any sympathomimetic activity; however, if the enzyme MAO is inhibited by an MAO inhibitor, the subsequent reserpine administration produces a rise in BP (reserpine reversal). It also interferes with the granular uptake and storage of adrenaline, DA and 5HT.</p>
<p>The drug also inhibits the release of renin.
Pharmacological actions: These are due to depletion of NA, 5HT and DA.
Cardiovascular system:</p>
<ul>
<li>The hypotensive effect appears 30 minutes after IV administration of a single dose, whereas, the maximum effect develops after 2 to 4 weeks of repeated oral medication. Hypotension is usually accompanied by bradycardia. Hypotensive action of reserpine lasts longer even after missing a daily pill. There is no rebound.</li>
<li>In therapeutic doses, reserpine has less action on the homeostatic reflexes in man and postural hypotension is not a problem.</li>
<li>Renal and muscle blood flow is not much affected.</li>
<li>It acts synergistically with other hypotensive agents, particularly the diuretics.</li>
</ul>
<p>Reserpine pretreatment causes upgradation of post-synaptic receptors and enhances the pressor response to sympathomimetic amines like adrenaline and NA, and this must be kept in mind when the sympathomimetic amines have to be employed in individuals on reserpine therapy.
CNS: Reserpine has sedative and antipsychotic actions due to depletion of 5-HT and DA from the CNS (Chapter 13).
GI system: It causes increased gastric acid secretion and augmentation of peristalsis. The drug has been used to induce experimental peptic ulceration in animals.
Absorption, fate and excretion: On oral or parenteral administration it gets widely distributed in the various parts of the CNS. The metabolic pathway of reserpine is not known. The central and the peripheral effects of oral reserpine are established slowly and maintained for a long time even after complete elimination of the drug (Hit and run drug).</p>
<p>Adverse reactions: These usually develop as an extension of its pharmacological actions and are dose dependent.</p>
<ul>
<li>Parasympathetic predominance due to peripheral sympathetic blockade causes salivation, cutaneous vasodilatation, nasal congestion, increased motility of the gut and increased gastric acidity. Reserpine should be avoided in individuals with history of hyperacidity and/or peptic ulcer. It can prolong A-V conduction time, particularly if administered along with digitalis.</li>
<li>Orthostatic hypotension as a result of sympathetic blockade may occur infrequently.</li>
<li>Mental depression is by far the most serious but uncommon, dose-related adverse effect. It may assume serious proportions resulting in nightmares, insomnia and suicidal tendencies in some cases. Hence, it is contraindicated in the presence of depression. Further, reserpine-induced depression lasts for a long time after stopping the drug and is resistant to treatment with TCA. Reserpine may also exacerbate epilepsy.</li>
<li>Weight gain is due to an increased appetite and retention of sodium and water. Release of ADH by the central action of reserpine probably plays some part in water retention. The use of diuretics with reserpine reduces the danger of salt and water retention.</li>
<li>Parkinsonism can occur due to depletion of DA following large doses of reserpine. This is reversible.</li>
<li>Endocrine disturbances such as gynecomastia and impotence in males and reduction in fertility in females can occur with relatively large doses of reserpine.</li>
<li>Allergic manifestations are rare. These include thrombocytopenia and purpura.</li>
<li>Hypotension and death during induction of anaesthesia have been reported in patients taking reserpine. Surgery should, therefore, be done in such patients with full access to resuscitative procedures.
Not withstanding the above listed ADR, they are uncommon with therapeutic doses (less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">0.25 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day). In general, reserpine is well tolerated even in elderly, was used extensively in the past, and is cost-effective. However, its use has declined. It has been suggested that "reserpine is a tragic victim of myth, marketing and fashionable prescribing."</li>
</ul>
<p>Preparations and dosage:
(i) Rauwolfia tablet containing powdered root-bark standardised to contain 4 mg . of total alkaloids. The daily dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2-4 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>.
(ii) Reserpine tablet 0.25 mg . Dose: 0.25 mg or less OD. As little as 0.05 mg per day may be effective when used in combination with a diuretic.
(iii) Reserpine injection, 2 and 10 ml ampoules containing 2.5 mg per ml .</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adrenergic-receptor-blockers">Adrenergic Receptor Blockers<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adrenergic-receptor-blockers" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>I Alpha adrenergic blocking agents: Peripheral vascular alpha-receptors are of two types (Chapter 18):</p>
<ul>
<li>Postsynaptic <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors which are stimulatory in nature; their activation causes vasoconstriction and</li>
<li>Presynaptic <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors (auto-receptors), which are inhibitory in nature; their activation inhibits NA release.
Blockade of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> causes fall in BP. However, simultaneous blocking of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> results in enhanced output of NA that acts on cardiac beta receptors leading to tachycardia. The nonselective alpha adrenergic blocking agents like phentolamine are of relatively little value in the treatment of essential hypertension because their use leads to preponderance of the beta adrenergic activity, palpitation and tachycardia.</li>
</ul>
<p>PHENTOLAMINE: Phentolamine, a nonselective competitive blocker with a short duration of action. It can be administered IV in the dose of 2.5 to 10 mg to prevent or treat severe hypertension due to release of catecholamines during removal of pheochromocytoma. It may also be used to treat the severe hypertension induced by abrupt clonidine withdrawal (Chapter 18).</p>
<p>PHENOXYBENZAMINE: This long acting non-competitive blocker is used in the preoperative management of pheochromocytoma. Its use controls hypertension and causes an expansion of plasma volume; intraoperative hypertensive episodes are prevented. It is also used for long term management of inoperable cases of pheochromocytoma, where it is combined with a beta-adrenergic blocker.</p>
<p>PRAZOSIN: This quina-zoline derivative is a peripheral vasodilator (Chapter 18). It acts by selective <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> adrenergic receptor blockade. The drug is relatively ineffective in blocking presynaptic <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors which are inhibitory. Prazosin, thus does not cause reflex tachycardia. Though it has a short plasma half life (2.5-4 hours), its effect lasts much longer (10 hours).</p>
<ul>
<li>It controls both supine and standing BP with minimum of postural hypotension.</li>
<li>Tachycardia is minimal or absent.</li>
<li>It does not affect renal function, cardiac output or the RAAS.</li>
<li>It is effective in all grades of severity of hypertension but its main use is for the treatment of moderate to severe hypertension as an adjunct to diuretics and beta-blockers.
Selective <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> antagonists may decrease total and LDL cholesterol, and TG and increase HDL cholesterol levels.</li>
</ul>
<p>Adverse reactions: These are giddiness, drowsiness, tiredness, nausea, diarrhoea, and fluid retention. The first dose should be 0.5 mg or less and should be taken on retiring to bed at night, as some patients may have adverse reactions such as palpitation, postural hypotension and even collapse following the first dose (First dose effect). In females it may cause urinary incontinence.</p>
<p>The therapy is started with 1-3 mg/day in divided doses. The maintenance dose is 3 to 7.5 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">\mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day. A sustained release preparation (Minipres XL) is also available.</p>
<p>Other uses: It is also used to treat CHF (Chapter 30), benign prostatic hyperplasia and prostatism with obstructive symptoms (Chapter 69).</p>
<p>Terazosin, doxazosin and alfuzosin are the other analogues of prazosin. Doxazosin has <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">t</mi><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">\mathrm{t} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord mathrm">t</span><span class="mord">%</span></span></span></span></span> of eight hours. The initial dose is 1 mg daily, doubled at 1-2 weeks intervals, according to response, upto a maximum of 8 mg daily; the usual maintenance dose is 2-4 mg daily. All these drugs are metabolised in the liver.</p>
<p>INDORAMIN: This selective alpha-1 adrenergic blocker lowers the BP in a manner similar to that of prazosin.</p>
<p>For other uses of alpha blockers, see Chapter 18.
Dihydrogenated ergot alkaloids: A mixture of three alkaloids of ergot, namely ergocornine, ergocristine and ergocryptine (chapter 44), is no more used as an antihypertensive.
II Beta-adrenergic blocking agents: Their detailed pharmacology is discussed in Chapter 18. Only their antihypertensive effects are discussed below.</p>
<p>Mechanism of action: The exact mechanism of antihypertensive action is not clear. However, the antihypertensive effect correlates best with their <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blocking action. Peripheral resistance is lowered during chronic administration. Reduction in cardiac output and lowering of plasma renin are variable during long term therapy. They also increase the natriuretic peptide secretion 2-3 fold. The lipid soluble agents (e.g. propranolol) have some central effect on catecholaminergic neurons, and reduce sympathetic outflow.</p>
<p>Beta blockers also reduce the tyrosine hydroxylase and dopamine beta hydroxylase activities in the peripheral sympathetic nervous system. The relative role of these actions in producing the therapeutic effect is not clear.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacological-actions">Pharmacological actions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-actions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>All of them seem to be equal in their ability to control hypertension and if one drug fails to control the BP in the maximally tolerated doses, a change to another one generally does not help.</li>
<li>Systolic and diastolic BP are moderately lowered, both in the supine and standing positions.</li>
<li>There is no accompanying tachycardia and in fact tachycardia caused by vasodilators is prevented by a beta-blocker.</li>
<li>They protect against stress-induced hypertension.</li>
<li>They do not block baroreceptor mechanisms and postural hypotension is not a problem. Protective, alpha receptor constrictor mechanisms remain intact.</li>
<li>They are cardioprotective and are especially valuable in patients with concurrent IHD (Chapter 29).</li>
<li>They do not impair the kidney function.</li>
<li>They are generally safe, and cost-effective.</li>
</ul>
<p>Absorption, fate and excretion: See Chapter 18 for details. The clinical hypotensive effect of a single dose lasts longer than the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> (2-5 hours) would suggest and hence, most of these drugs can be used on a twice a day basis. Longer acting drugs such as atenolol can be used on a once a day basis. The onset of anti-hypertensive effect is dose-related but generally takes takes 5-7 days to become manifest. Highly lipid soluble agents such as propranolol, metaprolol and oxprenolol are metabolised in the liver while highly water soluble atenolol and nadolol are excreted by kidney.</p>
<p>Adverse reactions: Generally, these drugs are well tolerated and cause minimal ADR. Commonly they cause bradycardia. Because beta receptor density increases during chronic</p>
<p>administration, their abrupt withdrawal can result in potentially dangerous tachycardia, rebound rise in BP and angina pectoris. Cardiac enlargement is a relative contraindication to their use. In a patient with pheochromocytoma, their use alone can cause a dangerous rise of BP unless it is combined with an alpha-blocker. Deterioration of renal function in some patients with established renal disease may occur.</p>
<p>Most NSAIDs reduce the antipypertensive effect of beta blocker, and cause sodium retention probably because of inhibition of formation of renal prostacyclin. Highly lipid soluble beta blockers such as propranolol are likely to cause CNS adverse effects.</p>
<p>Preparations and Dose: See Chapter 18.
Therapeutic uses: Beta blockers are used to treat all grades of hypertension. Relatively selective <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blockers (e.g. Atenolol) are preferred.
III Alpha <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mi>α</mi><mn>1</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\alpha_{1}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> and beta <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mi>β</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\left(\beta_{1}\right.</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ) adrenergic blockers:
LABETALOL: For details see Chapter 18. It is given orally in the dose of 100 mg twice daily an increased gradually upto <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>400</mn><mo>−</mo><mn>800</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">400-800 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">400</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">800</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily. The evidence that labetalol has an important advantage over other beta blockers is lacking. However, it can be given IV to treat hypertensive emergencies (see later).</p>
<p>Carvedilol ( 6.25 mg bid) has similar actions as labetalol. It is also used in CHF (Chapter 31).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="vasodilator-drugs">Vasodilator Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vasodilator-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>HYDRALAZINE: Hydralazine (Fig 30.4) was first synthesised and tested for antihistaminic activity. However, subsequent investigations demonstrated its hypotensive action instead of antihistaminic activity.
<img src="assets/images/image-20251214-1b2fadcf.jpeg" alt="img-24.jpeg"></p>
<p>Pharmacological actions:</p>
<ul>
<li>Hydralazine lowers the BP by causing a direct relaxation of the arteriolar wall.</li>
<li>The effect is slow in onset but prolonged. Even on its IV administration, the BP falls only after 15-20 minutes.</li>
<li>The fall in BP is accompanied by a decrease in the total peripheral resistance, and by a compensatory tachycardia, increase in stroke volume and in cardiac output. Orthostatic hypotension is rare.</li>
<li>The splanchnic, coronary, cerebral and renal blood flow may increase.</li>
<li>It causes increase in plasma renin activity and fluid retention.</li>
</ul>
<p>Absorption, fate and excretion: It is well absorbed after oral and parenteral administration. Maximal blood levels are reached within 3 to 4 hours after oral administration. The drug is acetylated in the liver and there may be 'fast acetylators' and 'slow acetylators'. Elimination of the drug is almost complete within 24 hours. Less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> of an oral dose is excreted unchanged in urine. Hence, it can be used even in the presence of renal damage.</p>
<p>Adverse reactions: The high incidence of ADR is the main drawback of hydralazine therapy. The manifestations are:</p>
<ul>
<li>Gastrointestinal irritation producing nausea, vomiting, gastric hypersecretion, anorexia and diarrhoea.</li>
<li>Cardiac effects: These include palpitation, tachycardia and anginal attacks.</li>
<li>Others like headache, nasal congestion, flushing, tremors and dizziness. It causes secondary salt and water retention.</li>
<li>Intolerance: The manifestations are fever, skin rash and polyneuritis. GI haemorrhage and pancytopenia are serious manifestations.</li>
<li>Acute rheumatoid arthritis or SLE like syndrome may develop with large doses (over 600 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">\mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day) given for prolonged periods.
Preparations and dosage:
(i) Hydralazine hydrochloride tablets 10, 25, and 50 mg . Maximum dose 100 mg daily.
(ii) Dihydralazine sulphate 25 mg tablet.
(iii) Injection 20 mg for IM/IV use.</li>
</ul>
<p>SODIUM NITROPRUSSIDE: This drug, known since 1850, has been used as a colour indicator for acetone and aldehydes. It was regarded as a poison because of its cyanide</p>
<p>group.
Given by IV infusion, it is metabolised to active compound NO which causes relaxation of arterioles and veins.</p>
<ul>
<li>This results in the reduction in peripheral resistance and venous tone, lowering the after load and the preload, respectively.</li>
<li>The myocardial oxygen consumption is reduced with improvement in myocardial function in low output states.</li>
<li>Heart rate and the regional blood flow are little affected.</li>
<li>It increases plasma renin activity.</li>
<li>It is rapidly metabolised to thiocyanate.</li>
<li>The action is of rapid onset but of very short duration.</li>
</ul>
<p>Sodium nitroprusside is supplied as 50 mg powder to be dissolved in 500 ml of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> dextrose in water, just prior to administration. When it is exposed to light, it is converted to cyanide; hence a brown or black paper bag over the IV fluid container is necessary. Translucent plastic tubing may need taping. Only freshly prepared solution should be used.</p>
<p>Adverse reactions: Hepatic dysfunction may result in excessive accumulation of toxic cyanide which may cause metabolic acidosis, arrhythmia, hypotension and death.</p>
<p>Prolonged administration of sodium nitroprusside either in high doses or in the presence of renal insufficiency may precipitate thiocyanate toxicity. This results in fatigue, anorexia, nausea, vomiting, sweating, disorientation, psychotic behavior and muscle twitching. Larger doses may cause ataxia, rigidity, convulsions and metabolic acidosis.</p>
<p>Therapeutic Uses: It is mainly used in hypertensive emergencies. It has also been used to produce controlled hypotension during surgery and to improve left ventricular function in acute MI and low output states. It is infused IV slowly in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">0.5-5 \mathrm{mcg} / \mathrm{kg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>. In the treatment of severe hypertension, if the BP is not adequately controlled after 10 minutes of infusion at the maximal rate, the drug should be stopped immediately for fear of toxicity. On the other hand, nitroprusside must not be stopped abruptly during treatment of heart failure because of the danger of rebound hypertension.</p>
<p>CALCIUM CHANNEL BLOCKERS (CCB): Their properties and uses are discussed in detail in Chapter 29.</p>
<ul>
<li>They are used in the long term treatment of hypertension. Nifedipine has also been used in the management of hypertensive emergencies.</li>
<li>CCB are particularly preferred in patients with impaired renal function or asthma, and in acute hypertension during pregnancy.</li>
<li>They are often used as a monotherapy particularly in moderately hypertensive patients with diabetes mellitus.</li>
<li>CCB have no significant CNS effects. Edema of feet may be observed.</li>
<li>As these drugs are metabolised by liver, dose adjustment in patients with renal disease is less critical.
There is some concern about the long term safety of the short acting dihydropyridines. Hence, the standard formulations (used for immediate relief) of nifedipine and other short half-life dihydropyridines are not recommended for long term treatment of hypertension. Diltiazem and amlodipine are as effective as diuretics, beta-blockers or their combination, in the long term treatment of essential hypertension.</li>
</ul>
<p>Nitrates have a synergistic effect with the vasodilator drugs and, therefore, the use of</p>
<p>nitroglycerine by a patient receiving a peripheral vasodilator drug e.g. a CCB can lead to sudden fall of BP and collapse.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="potassium-channel-activators">Potassium Channel Activators<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#potassium-channel-activators" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The group includes: diazoxide and minoxidil (Fig 30.5) used in hypertension; and nicorandil and pinacidil used in angina (Chapter 29).
<img src="assets/images/image-20251214-6b9b6e1c.jpeg" alt="img-25.jpeg"></p>
<p>Mechanism of action: Potassium channels play an important role in the regulation of membrane potential and excitability of cells. Potassium channel activators combine with ATP modulated potassium channels; opening these channels causes potassium ions to leak out from the cell. This action hyperpolarises and stabilises the cell membrane of the vascular smooth muscle. This reduces <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>entry and prevents vasoconstriction, leading to relaxation. Thus, they act as arterial vasodilators. Nicorandil, in addition, also activates cGMP to produce NO.</p>
<p>The drugs reduce the excitability of the myocytes. They may have a role in the management of IHD because the ATP modulated potassium channels are believed to be crucial in myocardial adaptation to ischemic injury via 'preconditioning'.</p>
<p>DIAZOXIDE: It is a compound structurally related to the diuretic chlorothiazide but has no diuretic activity. It is a potent, direct arteriolar vasodilator with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of 36 hour. As with hydralazine, compensatory reactions include tachycardia, increased cardiac contractility and sodium retention. It is highly protein bound. When injected by IV bolus, it lowers the BP within 3-5 minutes. It also raises blood sugar levels and is used to treat hypoglycemia due to insulinoma (Chapter 65).</p>
<p>MINOXIDIL a prodrug, is used orally as a peripheral vasodilator. Its active metabolite minoxidil N-O sulfate acts similar to hydralazine, but is more potent and more toxic. It causes compensatory tachycardia, increased cardiac contractility, palpitation, angina and sodium retention. It can also cause pulmonary hypertension, hypertrichosis and headache. Pericardial effusion and cardiac tamponade have been reported. Its effective dose range is wide, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">5-40 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day. Because of its toxicity, the drug is reserved for resistant cases.</p>
<p>See Chapter 71 for its use in alopecia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="renin-inhibitors">Renin Inhibitors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#renin-inhibitors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Aliskiren: Renin cleaves angoitensinogen from the liver to form angiotensin I, which is then converted to angiotensin II (Fig. 30.1). Oral, nonpeptide, renin inhibitor, aliskiren, causes dose-dependent, direct inhibition of the plasma renin activity and thereby reduces both angiotensin I and II levels, and produces fall in BP. Reduction in angiotensin II due to aliskiren lead to increase in plasma renin levels. In contrast to ACEI and ARB, which increase both plasma renin levels and PRA (estimated by angiotensin I levels), aliskiren increases only renin levels. The drug needs further evalvation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="angiotensin-converting-enzyme-inhibitors-acei">Angiotensin Converting Enzyme Inhibitors (ACEI)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#angiotensin-converting-enzyme-inhibitors-acei" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Introduction of this new class of drugs distinctly improved the management of hypertension. Several ACEI are now available (Table 30.1) Captopril was the first ACEI introduced in 1981.</p>
<p>Table 30.1
ACE inhibitors in current use</p>
<table><thead><tr><th style="text-align: left;">Drug</th><th style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">t</mi><mn>1</mn><mi mathvariant="normal">/</mi><msup><mn>2</mn><mo lspace="0em" rspace="0em">∘</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{t} 1 / 2^{\circ}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathrm">t</span><span class="mord">1/</span><span class="mord"><span class="mord">2</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span></span></span></span></span> (hrs)</th><th style="text-align: left;">Usual dosage (mg) in hypertension</th></tr></thead><tbody><tr><td style="text-align: left;">Captopril</td><td style="text-align: left;">1.9</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12.5</mn><mo>−</mo><mn>50</mn></mrow><annotation encoding="application/x-tex">12.5-50</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">12.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">50</span></span></span></span></span> bid</td></tr><tr><td style="text-align: left;">Lisinopril</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>11</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">11-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">11</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span></td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>40</mn><mrow><mi mathvariant="normal">o</mi><mi mathvariant="normal">d</mi></mrow></mrow><annotation encoding="application/x-tex">5-40 \mathrm{od}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm">od</span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Enalapril</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>11</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">11-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">11</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span></td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">o</mi><mi mathvariant="normal">d</mi></mrow></mrow><annotation encoding="application/x-tex">5-20 \mathrm{od}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm">od</span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Ramipril</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>13</mn><mo>−</mo><mn>17</mn></mrow><annotation encoding="application/x-tex">13-17</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">13</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">17</span></span></span></span></span></td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">o</mi><mi mathvariant="normal">d</mi></mrow></mrow><annotation encoding="application/x-tex">2.5-20 \mathrm{od}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm">od</span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Benazepril</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>11</mn></mrow><annotation encoding="application/x-tex">10-11</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">11</span></span></span></span></span></td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>40</mn><mrow><mi mathvariant="normal">o</mi><mi mathvariant="normal">d</mi></mrow></mrow><annotation encoding="application/x-tex">10-40 \mathrm{od}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm">od</span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Fosinopril</td><td style="text-align: left;">12</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>40</mn><mrow><mi mathvariant="normal">o</mi><mi mathvariant="normal">d</mi></mrow></mrow><annotation encoding="application/x-tex">10-40 \mathrm{od}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm">od</span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Quinapril</td><td style="text-align: left;">3</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>80</mn><mrow><mi mathvariant="normal">o</mi><mi mathvariant="normal">d</mi></mrow></mrow><annotation encoding="application/x-tex">10-80 \mathrm{od}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">80</span><span class="mord"><span class="mord mathrm">od</span></span></span></span></span></span></td></tr></tbody></table>
<p>Drugs other than Captopril and lisinopril are prodrugs.
*Of active drug/metabolite
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>3</mn></msup></mrow><annotation encoding="application/x-tex">{ }^{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span></span></span></span></span></span></span></span></span> Smaller doses in patients on diuretics, in CHF and with renal insufficiency.
Mechanism of action: ACEI competitively inhibit ACE and thus blocks the conversion of angiotensin I to angiotensin II (Fig 30.1). Thus it prevents:
(a) The pressor effect of angiotensin II; and
(b) Stimulation of aldosterone synthesis and release. As a consequence, the plasma levels of renin and angiotensin I show a marked compensatory rise.
(c) As ACE also metabolises bradykinin (See Chapter 25), its inhibition of ACE raises the levels of bradykinin, a potent vasodilator, which may also contribute to its antihypertensive and cardioprotective effects. Blockade of angiotensin II synthesis in the tissues (vascular, cardiac and renal) by ACEI may be responsible for their other beneficial effects.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacological-actions">Pharmacological actions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-actions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In healthy, sodium replete humans, a single oral dose of ACEI lowers the systemic BP only slightly; the effect is more marked on repeated administration. By contrast, a single dose of ACEI causes substantial lowering of BP in salt depleted subjects.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="in-hypertensive-subjects">In hypertensive subjects:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#in-hypertensive-subjects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>ACEI cause vasodilation, lower systemic arterial resistance, as well as both systolic and diastolic BP.</li>
<li>There is no reflex tachycardia.</li>
<li>The antihypertensive effect is seen in all varieties of hypertension except that due to primary aldosteronism; it is most marked in patients with renovascular hypertension. Concurrent use of a diuretic potentiates its action.</li>
<li>Renal, cerebral and coronary blood flow is increased.</li>
<li>Baroreceptor function is reset, cardiovascular reflexes are not compromised and responses to posture and exercise are not impaired. Postural hypotension is not a problem.</li>
<li>Secretion of aldosterone is reduced but adequate levels are maintained by other secretogogues, ACTH and potassium. As these secretogogues need a permissive level of angiotensin II for their action, the inhibition of ACE is not complete.</li>
</ul>
<p>In patients with chronic CHF: ACEI produce several beneficial effects:</p>
<ul>
<li>They reduce the afterload and preload. The cardiac output increases and the heart rate diminishes. BP is not much affected.</li>
<li>They cause natriuresis (diuretic sparing) following hemodynamic changes and reduction in aldosterone secretion. The venous return to the heart diminishes, decreasing the preload.</li>
<li>Pulmonary arterial pressure, pulmonary capillary wedge pressure and of left atrial and left ventricular filling pressure (preload) are reduced.</li>
<li>Exercise tolerance increases.</li>
<li>They prolong survival in these patients.</li>
</ul>
<p>In diabetic patients, ACEI improve kidney function and reduce microalbuminuria. (renoprotection).</p>
<p>In patients with acute MI (See Chapter 29).
Absorption, fate and excretion: Various ACEI differ in their pharmacokinetic properties (Table 30.1). Captopril (Fig. 30.6) is rapidly absorbed from the gut with a bioavailability of about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>65</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">65 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">65%</span></span></span></span></span>. Its absorption is reduced by food and so it is given 1 hour before a meal. It is cleared rapidly from the body by renal excretion ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span> ); about half is excreted as captopril and the other half as metabolites.
<img src="assets/images/image-20251214-1b918ee3.jpeg" alt="img-26.jpeg"></p>
<p>Adverse reactions: ACEI are generally well tolerated. Most adverse effects are the result of the specific inhibition of ACE. Relatively common adverse effect is persistent dry cough. It is believed to be due to raised bradykinin. A steep fall in BP may occur after the first dose in subjects with severe hypertension who are on multidrug regimes including a diuretic, and generally in all salt depleted patients. In such cases, ACEI should be started in very small doses, preferably after stopping the diuretic.</p>
<p>Aldosterone synthesis inhibition by ACEI causes hyperkalemia, particularly in patients with renal insufficiency and in those taking a potassium sparing diuretic. It should be used with caution in patients on an NSAID or a beta blocker.</p>
<p>The other adverse effects are skin rashes, disturbances of the sense of taste, vitiligo, headache, GI disturbances, muscle cramps and rarely leucopenia. Proteinuria ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">&gt;1 \mathrm{~g} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span></span></span></span></span> day) has been described. Rarely it causes serious angioedema. The drug causes foetal toxicity in animals and should be avoided in pregnancy.</p>
<p>Preparation and dosage: See Table 30.1. Because of reduced clearance, smaller doses are indicated in patients with impaired renal function.</p>
<p>Therapeutic uses:</p>
<ul>
<li>Hypertension: These are useful in hypertension of all grades, including malignant hypertension. Combined with a thiazide they can reduce thiazide-induced hypokalemia, hypercholesterolemia, hyperglycemia and hyperuricemia. They can be used safely in asthmatics and diabetics. There is no rebound hypertension on stopping the drugs abruptly. They can be combined with an antihypertensive from any other class and are generally well tolerated by the elderly. Sexual function is not affected.</li>
<li>Chronic congestive heart failure: ACEI are indicated in all clinical manifestations of heart failure and in individuals with asymptomatic LV dysfunction (Chapter 31). Addition of ACEI to conventional treatment in patients with severe CHF can reduce mortality and improve symptoms.</li>
<li>Diabetic nephropathy: ACEI protect kidneys and decrease microalbuminuria in patients with insulin dependent diabetes mellitus and nephropathy.</li>
<li>Acute MI: They reduce LV dysfunction and mortality (Chapter 29).</li>
</ul>
<p>ENALAPRIL: This congener of captopril is without an SH group.
It differs from captopril in that:</p>
<ul>
<li>It is a prodrug and is converted in the body to the active metabolite enalaprilat.</li>
<li>Food does not interfere with its absorption.</li>
<li>It is more potent.</li>
<li>Its action is slower but lasts longer.</li>
<li>It is less liable to cause taste disturbances, leucopenia and glomerulopathy.</li>
</ul>
<p>In patients with CHF, the starting dose should be <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">2.5 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day in subjects over 60 years of age and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">5 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day in subjects younger than 60 . It is given once daily. Usual maintenance dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10-20 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> per day.</p>
<p>Contraindication for ACEI:
(1) Severe bilateral renal artery stenosis as they reduce GFR and may cause renal failure,
(2) Aortic stenosis,
(3) Coarctation of the aorta; and
(4) Pregnancy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="angiotensin-receptor-blockers-arb">Angiotensin Receptor Blockers (ARB)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#angiotensin-receptor-blockers-arb" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>ACEI inhibit ACE which is not a specific enzyme, and has other substrates (bradykinin, substance <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span> and neurokinins); inhibition of which may cause ADR such as cough and angioedema. Hence specific angiotensin receptor blockers have been developed (Table 30.2).</p>
<p>Table 30.2</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="angiotensin-receptor-blockers">Angiotensin receptor blockers<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#angiotensin-receptor-blockers" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<table><thead><tr><th style="text-align: left;">Drug</th><th style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">t</mi><mi mathvariant="normal">t</mi><mi mathvariant="normal">/</mi><msup><mi mathvariant="normal">s</mi><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{t} \mathrm{t} / \mathrm{s}^{\prime}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0019em; vertical-align: -0.25em;"></span><span class="mord mathrm">tt</span><span class="mord">/</span><span class="mord"><span class="mord mathrm">s</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7519em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span></span></span></span></span> (hrs)</th><th style="text-align: left;">Dosage (mg/day) in hypertension</th></tr></thead><tbody><tr><td style="text-align: left;">Losartan</td><td style="text-align: left;">2</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>100</mn></mrow><annotation encoding="application/x-tex">25-100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span></span></span></span></span> od or bid</td></tr><tr><td style="text-align: left;">Valsartan</td><td style="text-align: left;">6</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>320</mn></mrow><annotation encoding="application/x-tex">40-320</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">320</span></span></span></span></span> od</td></tr><tr><td style="text-align: left;">Candesartan</td><td style="text-align: left;">9</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>32</mn></mrow><annotation encoding="application/x-tex">4-32</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">32</span></span></span></span></span> od</td></tr><tr><td style="text-align: left;">Irbesartan</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>11</mn><mo>−</mo><mn>15</mn></mrow><annotation encoding="application/x-tex">11-15</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">11</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">15</span></span></span></span></span></td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mo>−</mo><mn>300</mn></mrow><annotation encoding="application/x-tex">75-300</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">75</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">300</span></span></span></span></span> od</td></tr><tr><td style="text-align: left;">Eprosartan</td><td style="text-align: left;">5</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>400</mn><mo>−</mo><mn>800</mn></mrow><annotation encoding="application/x-tex">400-800</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">400</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">800</span></span></span></span></span> od or bid</td></tr><tr><td style="text-align: left;">Telmisartan</td><td style="text-align: left;">24</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>80</mn></mrow><annotation encoding="application/x-tex">20-80</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">80</span></span></span></span></span> od</td></tr><tr><td style="text-align: left;">Olmesartan</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>14</mn><mo>−</mo><mn>16</mn></mrow><annotation encoding="application/x-tex">14-16</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">14</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">16</span></span></span></span></span></td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>40</mn></mrow><annotation encoding="application/x-tex">10-40</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">40</span></span></span></span></span> od</td></tr></tbody></table>
<p>SARALASIN: This synthetic analogue of angiotensin II is a competitive inhibitor of angiotensin II; however, it has significant partial agonist properties. Infused IV, it lowers the BP in patients with angiotensin dependent hypertension. It was used as a diagnostic agent.</p>
<p>LOSARTAN: This phenyl tetrazole substituted imidazole compound acts as a selective, competitive blocker of angiotensin II receptor type <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mo fence="true">(</mo><msub><mi>A</mi><mn>1</mn></msub><mo fence="true">)</mo></mrow></mrow><annotation encoding="application/x-tex">1\left(A_{1}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathnormal">A</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> and decreases peripheral vascular resistance. However, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AT}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blockade can activate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AT}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and may increase bradykinin. Clinically this effect is short lasting. It has some uricosuric action.</p>
<p>Given orally, it is well absorbed and undergoes hepatic first pass metabolism, being partly converted to a more active metabolite. Its effect on the cardio-vascular hemodynamics are similar to those of ACEI.</p>
<p>Adverse reactions: Like the ACEI it can cause fetotoxicity and should not be used during pregnancy. It can precipitate renal failure in patients with bilateral renal artery stenosis and in those with low, fixed renal blood flow. It can cause skin rashes and neuropsychiatric disturbances such as insomnia, confusion, nightmares, agitation and depression. Even cough and angioedema can occur rarely.</p>
<p>Valsartan, Irbesartan, Eprosartan, Telmisartan, Candesartan, Olmesartan and Azilsartan are the other analogues of losartan.</p>
<p>Therapeutically ACEI and ARB are equally effective for treatment of hypertension. The choice between them depends upon familiarity and cost. Whether ARBs offer the same degree of cardioprotection as ACEI is not known. ARB have similar contraindications as ACEI.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="aldosterone-antagonist">Aldosterone Antagonist<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#aldosterone-antagonist" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>SPIRONOLACTONE: This aldosterone antagonist is discussed in Chapter 39. By itself it is not an antihypertensive agent. As an add-on drug, it may be particularly useful in hypertensive patients with significant hyperuricemia, hypokalemia, or glucose intolerance. It is the drug of choice in primary hyperaldosteronism. It is now also recommended in small doses as an add-on drug in congestive heart failure (Chapter 31).</p>
<p>Eplerenone: See Chapter 39.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="thiazides-as-antihypertensives">Thiazides as Antihypertensives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#thiazides-as-antihypertensives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The thiazide group and related compound chlorthalidone (Chapter 39) have proved extremely valuable in the treatment of mild to moderate hyper-tension. In addition, they enhance the effect of other antihypertensive agents.</p>
<p>Mechanism of action: The thiazides probably reduce the BP by several mechanisms. The sodium depletion and consequent reduction in plasma volume and cardiac output produced by them are important in the initial days of treatment of essential hypertension. Severe dietary restriction of sodium can produce a similar fall in BP.</p>
<p>After a few weeks of thiazide therapy, the plasma volume and the cardiac output, return to the pre-treatment level. From then on, decreased systemic vascular resistance, probably due to changes in the ionic composition of the vascular wall, is important in maintaining the antihypertensive effect. Diuretics may produce cellular sodium loss and increased entry of potassium into the vascular cells, thereby reducing their responsiveness to endogenous vasoconstrictors, mainly NA. Activation of the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>channels may also contribute to thiazide-induced vasodilatation.</p>
<p>When GFR is reduced by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> or more, thiazides lose most of their diuretic and antihypertensive effects. Thiazides also increase the PRA which may contribute to the development of tolerance.</p>
<p>Pharmacological actions: The anti-hypertensive effect develops slowly. There is a reduction in both, the systolic and the diastolic BP. The hypotensive action is moderate. The maximum effect is obtained with 50 mg of hydrochlorothiazide or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12.5</mn><mo>−</mo><mn>25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">12.5-25 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">12.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> of chlorthalidone once a day. Increase in the dose does not enhance the hypotensive effect and there appears little difference in their antihypertensive action with equivalent doses of thiazides. Differences do exist, however, in their duration of action. (Chapter 39). The very potent diuretic furosemide is not recommended for the long term management of hypertension because of its short duration of action and the serious electrolyte disturbances. However, it can be valuable in patients with chronic kidney disease who do not respond to thiazides.</p>
<p>However, tolerance may develop after prolonged use. Thiazides are not useful in patients with markedly decreased GFR. Further, they are less effective than ACEI in reducing left ventricular hypertrophy.</p>
<p>Adverse reactions: These include hypokalemia, hyperuricemia and hyperglycemia (Chapter 39). With the recommended low doses, hypokalemia and other metabolic changes are generally not a problem. Data indicate that:
(a) In the absence of digitalis and possibly overt heart disease, hypokalemia is not associated with increased occurrence of ventricular arrhythmias; and
(b) Although serum LDL cholesterol levels do rise modestly after thiazide the levels usually revert to the pre-treatment levels during long term use.</p>
<p>Routine potassium supplementation during thiazides use is not necessary. Those at high risk of developing hypokalemia (patients with IHD, arrhythmias, diabetes, severe hepatic disease as well as those on digitalis or glucocorticoids) should receive prophylactic potassium supplements or potassium sparing diuretics.</p>
<p>Thiazides and chlorthalidone used in small doses have several advantages:</p>
<ul>
<li>
<p>Their efficacy in mild to moderate hypertension is similar to other antihypertensive agents (see text).</p>
</li>
<li>
<p>Postural hypotension is rare.</p>
</li>
<li>
<p>Blood flow to vital organs such as kidney and brain is not compromised.</p>
</li>
<li>
<p>They do not cause reflex tachycardia or reduce the cardiac output.</p>
</li>
<li>
<p>Unlike vasodilators, they do not cause compensatory volume overload and edema.</p>
</li>
<li>
<p>They have substantial residual effects and BP rises slowly after discontinuation. Hence, missing a dose occasionally carries no risk of sudden rebound rise.</p>
</li>
<li>
<p>With doses recommended, they are well tolerated, with minimal acceptable side effects. They have been in use for several years and their long term toxicity profile is well known. They reduce calcium excretion and these may prevent hip fractures and osteoporosis in postmenopausal women.</p>
</li>
<li>
<p>Clinically relevant drug interactions are few.</p>
</li>
<li>
<p>They can be combined with several other antihypertensives with synergistic effect.</p>
</li>
<li>
<p>They are convenient to take, remain effective for long time.</p>
</li>
</ul>
<p>In general, the oral thiazides still remain the most valuable, safe and highly cost-effective antihypertensive drugs.</p>
<p>As large proportion of hypertensive patients eventually need more than one drug to achieve satisfactory BP control, the discussion regarding their use to start with or later as "an add on" drug is academic. That their use has been declining is not because they lack virtues, but is due to "absence of corporate promotion" and "aggressive marketing" of newer but more expensive agents.</p>
<p>INDAPAMIDE: This compound, an indole derivative of chlorosulphonamide, is chemically related to chlorthalidone. Like the latter drug, it has a long duration of action with a plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of about 18 hours. Given orally in the dose of 2.5 mg once daily, it reduces the BP in mild and moderate hypertension. Larger doses cause diuresis. It has similar therapeutic activity as chlorthalidone and is available as 2.5 mg tablets. A sustained release (SR) preparation is available.</p>
<p>XIPAMIDE: This is 4-chloro-5-sulfamoyl-2'- 6' salicyloxlidide. The drug has diuretic and hypotensive effects as well as adverse effects similar to thiazides. It also resembles furosemide in that it is an effective diuretic in patients with renal failure. It is administered in a single daily dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20-40 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="miscellaneous-drugs">Miscellaneous Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#miscellaneous-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>METYROSINE (Alpha methyl tyrosine): This drug blocks the synthesis of catecholamines by inhibiting tyrosine hydroxylase. It is useful in the treatment of patients with pheochromocytoma, The ADR include sedation, GI symptoms, extrapyramidal effects, crystalluria, nasal congestion, gynecomastia, galactorrhoea and peripheral edema. It is not indicated in essential hypertension.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="hypertension-therapy">Hypertension - Therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hypertension-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Effective treatment of hypertension is an important part of any programme to reduce the toll of cardiovascular disease, viz end-organ damage and mortality, in the society. This is so because any elevation of BP significantly increases morbidity and mortality which are directly related to the level of the BP.</p>
<p>The drug treatment of essential hypertension is still 'empiric', as these drugs reduce the BP without correcting the cause. However, the reduction of BP (even suboptimally) prevents or postpones renal, cardiac and cerebral complications and prolongs life. The control of hypertension in diabetics also helps to delay the onset of retinal and renal damage. Complications arising from associated atherosclerosis are now the chief cause of death. Therefore, control of the other modifiable cardiovascular risk factors such as smoking and obesity is an essential part of the treatment of hypertension.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pretreatment-evaluation-includes">Pretreatment evaluation includes:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pretreatment-evaluation-includes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Multiple BP readings in supine and standing positions after sufficient rest.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="assessment-for-target-organ-damage">- Assessment for target organ damage<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#assessment-for-target-organ-damage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(a) Detailed history and physical examination: Dyspnoea; polyuria; nocturia; edema; cardiomegaly.
(b) Kidneys: Urine examination; serum creatinine; serum electrolytes.
(c) Heart: ECG, X-ray chest, 2 D-Echo.
(d) Fundoscopy: The condition of the retinal vessels reflects that of the cerebral vessels.</p>
<ul>
<li>Assessment for other cardiovascular risk factors: Salt intake; alcohol consumption; smoking; obesity; diabetes; hyperlipidemia; premature CV death in close relatives.</li>
<li>Special investigations to identify the cause of hypertensions: USG of the urinary tract/renal blood vessels; renal angiography; tests for pheochromocytoma, aldosteronoma, etc. These are done if indications exist; or if the hypertension is drug-resistant. It should be noted that:
(a) Every patient who knows that his/her BP is elevated requires treatment, though not necessarily with antihypertensive drugs.
(b) Systolic hypertension is as damaging as diastolic hypertension.
(c) Treatment with antihypertensives, once started, will generally have to be continued for life.
(d) Success of the treatment depends upon the care and the time spent by the doctor upon educating and counseling the patient; and the patient's compliance.</li>
</ul>
<p>Reassurance by a physician and lifestyle modifications (Table 30.3) are necessary in all hypertensive patients, including the prehypertensives. In addition, they are essential for normotensives with diabetes, those with history of CVS disease or with coronary risk factors. In fact, they may suffice in those with uncomplicated, mild hypertension and should be given a trial for 6-10 weeks.</p>
<p>Table 30.3
Lifestyle modification in hypertensives</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>• Weight reduction in obese persons.
</span>    • Restriction of salt consumption to 4-6 g, (about 2-3 g, of sodium) a day
    • Increase in dietary potassium (fruits and vegetables) consumption.
    • Restriction of fat consumption (Chapter 40).
    • Physical exercise such as brisk walking; and mental relaxation.
    • Reduction in alcohol and caffeine consumption.
    • Cessation of smoking.
    • Better adjustment at work and in family life.</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="• Weight reduction in obese persons.
    • Restriction of salt consumption to 4-6 g, (about 2-3 g, of sodium) a day
    • Increase in dietary potassium (fruits and vegetables) consumption.
    • Restriction of fat consumption (Chapter 40).
    • Physical exercise such as brisk walking; and mental relaxation.
    • Reduction in alcohol and caffeine consumption.
    • Cessation of smoking.
    • Better adjustment at work and in family life." style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>'Increased salt intake is a necessary but not sufficient cause for hypertension. Reduction in salt intake reduces BP in hypertensives as well as those with high normal BP. It may also prevent a recurrence in those who were previously normotensive on drugs. Salt restriction needs to be at least moderate (a reduction of salt intake to 4 g or less/day), sustained, and may take several weeks to be effective. Salt restriction also minimises the age-related rise in BP. Chloride is as important as sodium in elevating BP, and their effect is additive; other salts such as sodium citrate are less liable to elevate the BP. Liability for BP to be elevated by salt (salt sensitivity) is partly genetic. It is also seen in insulin resistance, hyperlipidemia and microalbuminuria. It is alleviated by increased postassium intake. Extreme salt restriction has been reported to be harmful.</p>
<p>Clinically, hypertension can be divided into mild, moderate, severe and very severe grades (Table 30.4).</p>
<p>Table 30.4
Classification of hypertension</p>
<table><thead><tr><th style="text-align: left;">Category</th><th style="text-align: left;">Systolic BP (mm Hg)</th><th style="text-align: left;"></th><th style="text-align: left;">Diastolic BP (mm Hg)</th><th style="text-align: left;">Recommendation</th></tr></thead><tbody><tr><td style="text-align: left;">Normal</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>120</mn></mrow><annotation encoding="application/x-tex">&lt;120</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">120</span></span></span></span></span></td><td style="text-align: left;">and</td><td style="text-align: left;"></td><td style="text-align: left;">Recheck in 2 years</td></tr><tr><td style="text-align: left;">High Normal (prehypertension)</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>120</mn><mo>−</mo><mn>139</mn></mrow><annotation encoding="application/x-tex">120-139</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">120</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">139</span></span></span></span></span></td><td style="text-align: left;">or</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mo>−</mo><mn>89</mn></mrow><annotation encoding="application/x-tex">80-89</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">80</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">89</span></span></span></span></span></td><td style="text-align: left;">Recheck in 6 months.</td></tr><tr><td style="text-align: left;">Hypertension</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr><td style="text-align: left;">Mild</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>140</mn><mo>−</mo><mn>159</mn></mrow><annotation encoding="application/x-tex">140-159</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">140</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">159</span></span></span></span></span></td><td style="text-align: left;">or</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mo>−</mo><mn>99</mn></mrow><annotation encoding="application/x-tex">90-99</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">90</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">99</span></span></span></span></span></td><td style="text-align: left;">Confirm and treat within 2 months.</td></tr><tr><td style="text-align: left;">Moderate</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>160</mn><mo>−</mo><mn>179</mn></mrow><annotation encoding="application/x-tex">160-179</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">160</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">179</span></span></span></span></span></td><td style="text-align: left;">or</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>109</mn></mrow><annotation encoding="application/x-tex">100-109</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">109</span></span></span></span></span></td><td style="text-align: left;">Treat within 1 month.</td></tr><tr><td style="text-align: left;">Severe</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>180</mn><mo>−</mo><mn>209</mn></mrow><annotation encoding="application/x-tex">180-209</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">180</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">209</span></span></span></span></span></td><td style="text-align: left;">or</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>110</mn><mo>−</mo><mn>119</mn></mrow><annotation encoding="application/x-tex">110-119</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">110</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">119</span></span></span></span></span></td><td style="text-align: left;">Treat within 1 week.</td></tr><tr><td style="text-align: left;">Very severe</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>≥</mo><mn>210</mn></mrow><annotation encoding="application/x-tex">\geq 210</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7719em; vertical-align: -0.136em;"></span><span class="mrel">≥</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">210</span></span></span></span></span></td><td style="text-align: left;">or</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>≥</mo><mn>120</mn></mrow><annotation encoding="application/x-tex">\geq 120</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7719em; vertical-align: -0.136em;"></span><span class="mrel">≥</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">120</span></span></span></span></span></td><td style="text-align: left;">Treat immediately.</td></tr></tbody></table>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mo lspace="0em" rspace="0em">∗</mo></msup><mo>=</mo></mrow><annotation encoding="application/x-tex">{ }^{*}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6887em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6887em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∗</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Stage 1.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mo lspace="0em" rspace="0em">∼</mo></msup><mo>=</mo></mrow><annotation encoding="application/x-tex">{ }^{\sim}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6198em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6198em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mrel mtight">∼</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Stage 2 .</p>
<ul>
<li>Patients with very severe hypertension are at grave risk of developing 'hypertensive complications' such as cerebral hemorrhage, hypertensive encephalopathy, acute LVF, renal failure or dissection of the aorta. These patients and those with papilloedema (malignant hypertension) need urgent and aggressive treatment.</li>
<li>Patients with severe hypertension are also at risk of developing the same 'hypertensive complications', especially if they are old or have long-standing high BP. Although the risk of a fatal complication is less in young patients, they are more liable to suddenly develop malignant hypertension. Prompt treatment of such patients can ward off a 'hypertensive complication' but unfortunately does not slow down the accelerated rate of atherosclerosis.</li>
<li>Patients with moderate hypertension are also at risk if they have a bad family history (a near relative has had a 'hypertensive complication'), or if they have cardiomegaly, fundus changes or ECG abnormalities. They too require energetic treatment.</li>
<li>If the hypertension is mild, the need for drug treatment is determined by the patient's</li>
</ul>
<p>age. Studies by the Veterans' Administration have shown that young patients in this group definitely benefit from aggressive treatment of their hypertension. Aggressive reduction of BP is, however, likely to prove dangerous in elderly, arteriosclerotic individuals with elevated systolic but normal diastolic BP.
In mild hypertension along with nonpharmacological treatment drug therapy is also indicated.</p>
<ul>
<li>In patients with hypertension and renal failure, there may be an initial deterioration of renal function following aggressive therapy. In the long run, however, control of BP halts the progress of renal failure and prolongs life. In CKD the target BP to be achieved is SBP <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>140</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">&lt;140 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">140</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">D</mi><mi mathvariant="normal">B</mi><mi mathvariant="normal">P</mi></mrow><mo>&lt;</mo><mn>90</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{DBP}&lt;90 \mathrm{~mmHg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7224em; vertical-align: -0.0391em;"></span><span class="mord"><span class="mord mathrm">DBP</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">90</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">mmHg</span></span></span></span></span></span>.</li>
<li>In patients with diabetes mellitus, the target BP should be the same as in CKD.</li>
</ul>
<p>Antihypertensive drugs should be used cautiously in patients who have had a recent MI or a stroke, as a rapid lowering of BP can worsen their condition.</p>
<p>The duration of drug treatment is lifelong in most patients. An occasional patient may be able to give up the treatment and remain normotensive thereafter. How often this happens is not known; but it is rare.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="principles-of-drug-therapy">Principles of Drug Therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#principles-of-drug-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The aims of treatment of hypertension are:
(a) Maintaining the BP, including the early morning BP, as near normal as possible (less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>140</mn><mi mathvariant="normal">/</mi><mn>90</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">140 / 90 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">140/90</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span> ) without undue side effects
(b) Maintaining/improving the quality of life, including the intellectual and sexual functions.
(c) Reduction in left ventricular mass.
(d) Prevention of cardiac arrhythmias, heart failure and other complications.
(e) Control of other CHD risk factors; and
(f) Doing all this in a cost-effective manner.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="principles-of-drug-therapy">Principles of drug therapy:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#principles-of-drug-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>In the long run, one aims at keeping the BP in the erect posture as near normal as possible- a systolic BP of less than 140 mm Hg and a diastolic BP of less than 90 mm Hg . However, a higher level of BP may have to be accepted in elderly patients, in patients with impaired renal function and in those with IHD or cerebrovascular disease. This is done in order to avoid the unpleasant symptoms and the possible complications (including myocardial and cerebral ischemia) of postural hypotension.</li>
<li>Antihypertensive drugs are started in small doses, increased gradually (start low, go slow) and only infrequently (every 3-4 weeks) as the maximum effect of a drug or drug combination at a given dose level may take some days or weeks.
However, in severe and very severe hypertension, one generally initiates the treatment with full doses of drugs, often using more than one drug from the start.</li>
<li>Having found a regimen that controls BP in the best possible manner, it is wrong to change the schedule unless there is a good reason to do so. However, in hot weather the patient may be asked to reduce the doses of antihypertensive drugs slightly in order to avoid postural hypotension. The fall in standing pressure may be exaggerated by exercise, or salt deficiency and sudden change of position. The patient should be warned of the possibility of fainting.</li>
<li>With drugs such as thiazide, ACEI, ARB and CCB, which do not cause significant postural hypotension, it is possible to maintain both standing and supine BP normal or near normal in many patients. If this can be done safely and continuously, then this is almost ideal antihypertensive therapy.</li>
<li>In patients with severe and very severe hypertension (see Table 30.3), the diastolic BP should be lowered to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>110</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">100-110 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">110</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span> in the first 24 hours; further lowering to target levels should be carried out over the next 2-3 days.</li>
<li>During chronic therapy, adjustments occur in homeostatic mechanisms including the reflex cardiovascular responses and in the end organ receptor concentration; for example, the number of beta adrenergic receptors increases (up-regulation) during chronic beta-blocker therapy. The reaction of the patient to the abrupt cessation of drug therapy depends upon the dose and its duration of action, and the readjustment time for the homeostatic mechanisms activated during drug therapy. If the former is much shorter than the latter (as is the case with propranolol and clonidine) rebound rise in BP is likely to occur, with serious consequences such as cerebral hemorrhage. If, on the other hand, the duration of action is prolonged (as is the case of reserpine) no such</li>
</ul>
<p>rebound occurs.</p>
<ul>
<li>In practice, it is difficult to be familiar with more than a few preparations and hence, it is wise to continue using the one or two preparations which one knows best, and change them only if they are ineffective or adverse effects are troublesome.</li>
<li>Patients should be educated about the drugs they are receiving and their possible adverse effects. Impress upon the patient the hazards of uncontrolled or intermittently controlled hypertension and the rewards of keeping the BP under check continuously and lifelong.</li>
<li>The patient must be given a card bearing the names and doses of the drugs he is receiving.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="choice-of-drug-therapy">Choice of Drug Therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#choice-of-drug-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>With the availability of many effective and reasonably safe antihypertensives, greater flexibility can be exerted in choosing the initial drug. What is most important is to reduce BP to the goal level. How that is done is less important.</p>
<p>Long term studies indicate that there are no important differences as regards efficacy, adverse effects or quality of life among patients who receive thiazides, calcium channel antagonists, ACEI or ARB. Although the responses to different groups of drugs are known to be similar in heterogeneous population, individual responses vary strikingly, even to same drug. Hence, the drug therapy has to be "tailor-made" for each patient. Currently, drugs used for the initial therapy of hypertension belong to any one of the 4 groupsACEI, ARB, CCB and Thiazide like diuretics.</p>
<p>Generally thiazides/CCB are preferable for elderly people ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>60</mn></mrow><annotation encoding="application/x-tex">&gt;60</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">60</span></span></span></span></span> years) and those of black ethnic origin at any age including those with DM, while younger patients who have more responsive RAAS than older subjects may be more benefited by ACEI or ARB. The latter should be preferred for patients aged 18yr or mor having CKD <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span> DM for their beneficial effects on kidney function. In all CKD patients they also remain the first choice regardless of age, race or diabetes.</p>
<p>Analysis of many clinical trials reconfirms that the low-dose thiazide/thiazide-type diuretics alone or in combination (depending upon the severity) remain the first line therapy in majority of the patients. The 'diabetogenic' and 'hyperlipidemic' effects of the thiazides are often overstressed. An ACEI or CCB is considered a reasonable, but more expensive, alternative first choice. Patients with special problems (Table 30.5) benefit from a non-diuretic as a first line drug eg. ACEI in patients with LV dysfunction or diabetes mellitus; or a beta-blocker/CCB in patient with stable angina pectoris. Half the patients, however, in long term, would need a minimum of two drugs for controlling their BP.</p>
<p>Table 30.5
Symptom profiling of antihypertensive drugs</p>
<table><thead><tr><th style="text-align: center;">Associated Problem</th><th style="text-align: center;">Recommended</th><th style="text-align: center;">Not Recommended</th></tr></thead><tbody><tr><td style="text-align: center;">Migraine</td><td style="text-align: center;">BB</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Depression</td><td style="text-align: center;">Diuretics &lt;br&gt; ACE inhibitors &lt;br&gt; CCB &lt;br&gt; Vasodilators <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blockers</td><td style="text-align: center;">Reserpine &lt;br&gt; Clonidine &lt;br&gt; Methyldopa &lt;br&gt; BB</td></tr><tr><td style="text-align: center;">Bronchospasm</td><td style="text-align: center;">CCB &lt;br&gt; Vasodilators</td><td style="text-align: center;">BB esp. propranolol</td></tr><tr><td style="text-align: center;">Palpitation</td><td style="text-align: center;">BB &lt;br&gt; Diltiazem</td><td style="text-align: center;">Vasodilators</td></tr><tr><td style="text-align: center;">Angina pectoris</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mrow><mi mathvariant="normal">B</mi><mi mathvariant="normal">B</mi></mrow></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">B</mi></mrow></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; \mathrm{BB} \\ &amp; \mathrm{CCB} \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord"><span class="mord mathrm">BB</span></span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord"><span class="mord mathrm">CCB</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Vasodilators like hydralazine</td></tr><tr><td style="text-align: center;">Old MI</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mrow><mi mathvariant="normal">B</mi><mi mathvariant="normal">B</mi></mrow></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">I</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">R</mi><mi mathvariant="normal">B</mi></mrow></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">A</mi></mrow></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; \mathrm{BB} \\ &amp; \mathrm{ACEI} / \mathrm{ARB} \\ &amp; \mathrm{AA} \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 4.5em; vertical-align: -2em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 2.5em;"><span style="top: -4.5em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -3em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -1.5em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 2em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 2.5em;"><span style="top: -4.66em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord"><span class="mord mathrm">BB</span></span></span></span><span style="top: -3.16em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord"><span class="mord mathrm">ACEI</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ARB</span></span></span></span><span style="top: -1.66em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord"><span class="mord mathrm">AA</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 2em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">CCB</td></tr><tr><td style="text-align: center;">Congestive heart failure</td><td style="text-align: center;">ACEI/ARB &lt;br&gt; Diuretics, AA &lt;br&gt; Vasodilators</td><td style="text-align: center;">CCB</td></tr><tr><td style="text-align: center;">Bradycardia</td><td style="text-align: center;"></td><td style="text-align: center;">BB, Verapamil Diltiazem</td></tr><tr><td style="text-align: center;">Mitral valve prolapse syndrome</td><td style="text-align: center;">BB</td><td style="text-align: center;">Drugs causing tachycardia or orthostatic hypotension</td></tr><tr><td style="text-align: center;">Left ventricular hypertrophy</td><td style="text-align: center;">ACE inhibitors</td><td style="text-align: center;">Direct acting vasodilators</td></tr><tr><td style="text-align: center;">Raynaud's phenomenon</td><td style="text-align: center;">CCB <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blockers</td><td style="text-align: center;">BB</td></tr><tr><td style="text-align: center;">Fluid retention</td><td style="text-align: center;">Diuretics</td><td style="text-align: center;">Vasodilators Clonidine BB</td></tr><tr><td style="text-align: center;">Thyrotoxicosis</td><td style="text-align: center;">BB</td><td style="text-align: center;">Drugs causing tachycardia</td></tr><tr><td style="text-align: center;">Recurrent</td><td style="text-align: center;">ACEI/ARB</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">TIA</td><td style="text-align: center;">Diuretics &lt;br&gt; CCB</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Hyperlipidemia</td><td style="text-align: center;">Low dose thiazides, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blockers, ACEI</td><td style="text-align: center;">High dose thiazides BB</td></tr><tr><td style="text-align: center;">Essential tremor</td><td style="text-align: center;">Propranolol</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Open angle glaucoma</td><td style="text-align: center;">BB</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Diabetes mellitus</td><td style="text-align: center;">ACEI, ARB CCB</td><td style="text-align: center;">Potassium sparing diuretics</td></tr><tr><td style="text-align: center;">Azotemia</td><td style="text-align: center;">Loop diuretics &lt;br&gt; Direct acting vasodilators &lt;br&gt; CCB, BB &lt;br&gt; Alpha methyl dopa <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blockers</td><td style="text-align: center;">ACEI &lt;br&gt; Potassium sparing diuretics</td></tr><tr><td style="text-align: center;">History of sexual dysfunction</td><td style="text-align: center;">Gradual reduction of blood pressure (CCB, ACEI, and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blockers are preferred)</td><td style="text-align: center;">Rapid reduction of blood pressure</td></tr><tr><td style="text-align: center;">Benign prostatic hyperplasia</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blockers (relieve prostatism)</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Osteoporosis</td><td style="text-align: center;">Thiazides</td><td style="text-align: center;">Loop diuretics</td></tr><tr><td style="text-align: center;">Renal calculi</td><td style="text-align: center;">Thiazides</td><td style="text-align: center;">Loop diuretics</td></tr><tr><td style="text-align: center;">Chronic renal disease</td><td style="text-align: center;">Loop diuretics &lt;br&gt; ACEI/ARB+ &lt;br&gt; CCB</td><td style="text-align: center;">BB</td></tr></tbody></table>
<p>BB - Beta blockers;
CCB - Calcium channel blockers;
AA-Aldosterone antagonist.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="use-of-drug-combinations">Use of Drug Combinations<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#use-of-drug-combinations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>An appropriate combination of anti-hypertensive drugs can produce beneficial effects on:</p>
<ul>
<li>Blood pressure</li>
<li>Adverse reactions; and</li>
<li>Hemodynamic effects</li>
</ul>
<p>Combinations not only help to achieve better BP control but also reduce the incidence of ADR from individual drugs because of reduction in their doses as well as by pharmacological means. Fixed-dose combinations ensure better compliance. They however, should be chosen by the physician with the full knowledge of the clinical pharmacology of the drugs.</p>
<p>It is rational to combine antihypertensive drugs with different pharmacodynamic actions or with different anatomical sites of action, e.g., a diuretic can be combined with a beta-blocker, a vasodilator, methyldopa or ACEI. Drugs with similar adverse effects should not be combined. e.g. methyldopa and clonidine. Extra care should be taken in patients who are at risk for postural hypotension.</p>
<p>The drugs which interfere with the adrenergic system tend to produce fluid retention with consequent diminution in their therapeutic effect (pseudotolerance). Addition of a thiazide effectively counteracts fluid retention, enhances the therapeutic effect and permits the use of smaller doses of other drugs.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="management-with-drugs">Management with Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#management-with-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The major factors in hypertension are:</p>
<ul>
<li>Peripheral vasoconstriction</li>
<li>Expansion of plasma volume; and</li>
<li>Hyperdynamic heart action, particularly in the young.</li>
</ul>
<p>Since the majority of hypertensive subjects will have BP reduction no matter what drug is used, the initial choice of the drug should depend upon such factors as safety, cost, likely patient compliance and associated medical problems. Such symptom drug profiling (Table 30.5) is very useful in practice.</p>
<p>Generally, a stepped-care approach is recommended.
(1) Start the therapy with low dose of an agent (monotherapy), appropriate for a given patient, depending upon the age, race, and the co-morbid conditions such as diabetes mellitus, angina, pregnancy and so on (Table 30.5). If the BP is not controlled within a month of treatment, the dose should be increased in small increments (start low, go slow), till the desired BP level is achieved without undue ADR or the maximum recommended dose is reached.
(2) If the BP is still not controlled, another drug from a different class may be added which is likely to be well tolerated, as the compliance and the long term efficacy of drugs depend upon their long term tolerability. The second drug can be added without achieving maximum recommended dose of the initial drug.
(3) When two agents are used, one of them should be a diuretic, preferably a low dose of a thiazide e.g. hydrochlorthiazide 25 mg or less/day, or its equivalent, in nearly all cases.
(4) Use low dose combination therapy, if indicated, as initial therapy e.g. A thiazide (hydrochlorthiazide) with
(a) long acting CCB (amlodipine) or
(b) an ACEI or
(c) an ARB.</p>
<p>CCB can be combined with ACEI/ARB but never ACEI with ARB.
(5) A two drug combination will control BP in almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> of patients. If this is not achieved, the primary agent should be increased to the full dose e.g. enalapril 20 mg , atenolol 50 mg or diltiazem 360 mg . This may be combined with reduction in salt intake to less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">m</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">4 \mathrm{gm} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm">gm</span></span><span class="mord">/</span></span></span></span></span> day and increased intake of potassium in the form of fresh vegetables and fruits, (the latter not in combination with ACEI or ARB).
(6) In resistant cases, the primary agent other than thiazide should be replaced by a drug from another class. Triple drug therapy with a thiazide + an ACEI/ARB + CCB may also be effective. In still resistant cases, the patient should be investigated in detail for a possible cause of secondary hypertension.
(7) Once the BP is controlled and maintained consistently, an attempt should be made to reduce the dose step-wise and possibly omit one of the drugs, to determine the minimal therapeutic regimen that will maintain the BP less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>140</mn><mi mathvariant="normal">/</mi><mn>90</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">140 / 90 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">140/90</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span> or less, without any inconvenient, adverse effects.</p>
<p>Mild hypertension: The basic drug is a thiazide such as hydrochlorothiazide ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25-50 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> ) or chlorthalidone ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12.5</mn><mo>−</mo><mn>25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">12.5-25 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">12.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> ) once daily unless a specific contraindication exists. Increasing the dose of hydrochlorothiazide beyond 50 mg OD usually does not produce any further</p>
<p>therapeutic benefit. The antihypertensive effect is usually established within 2 to 3 weeks. Subsequently, smaller doses ( 12.5 mg OD) can be administered for maintenance therapy. If the BP is not adequately controlled by thiazides, the therapy can be intensified with the addition of a CCB or ACEI/ARB.</p>
<p>If the patient is younger than 50 years of age and has evidence of tachycardia and hyperdynamic cardiac action, a beta-blocker may be initial drug of choice, especially if there is no evidence of peripheral vascular disease. Beta-blockers are also preferred in hypertensive patients with IHD. Atenolol 12.5-50 mg per day is usually preferred. In patients with diabetes mellitus, ACEI would be the first drug of choice.</p>
<p>Alpha blockers should not be used as first line therapy.
In patients with repeated BP readings of more than 160/100 mm Hg it is justifiable to start the therapy with two drugs, one of which preferably should be a thiazide diuretic.</p>
<p>Moderate hypertension: In moderate hypertension, thiazide or chlorthalidone with a beta-blocker may not be able to control the BP effectively. In such patients, a long acting CCB or an ACEI/ARB is substituted for (mono therapy) or added to the thiazide.</p>
<p>CCB such as diltiazem or amlodipine are effective anti-hypertensive agents. Diltiazem is contraindicated if congestive heart failure or AV block is present and in patients on digitalis or a beta blocker. Short acting nifedipine formulations are considered not suitable for long term use.</p>
<p>An ACEI such as enalapril may be a good drug to add to thiazide, especially if the patient is also in congestive heart failure. ACEI is the preferred drug in hypertensive patients with diabetic nephropathy for several reasons:</p>
<ul>
<li>It does not alter or may even improve glucose tolerance.</li>
<li>It does not mask the symptoms and signs of, nor interfere with recovery from hypoglycemia.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ace-inhibitors-protect-the-kidney-in-the-long-term">- ACE inhibitors protect the kidney in the long term.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ace-inhibitors-protect-the-kidney-in-the-long-term" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Severe and very severe hypertension: These patients usually have damaged target organs such as kidneys and heart. A sudden reduction in BP may produce azotemia or coronary insufficiency. If, however, the diastolic BP is above 120 mm Hg and there is no evidence of target organ damage, vigorous therapy is advocated.</p>
<p>Treatment of severe hypertension may need combination with additional drugs such as an alpha adrenergic blocker (prazosin), a centrally acting drug (alpha methyl dopa) or a direct acting peripheral vasodilator such as hydralazine.</p>
<p>An <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blocker e.g. prazosin is especially useful in patients having concurrent symptomatic benign prostatic hyperplasia.</p>
<p>Alpha methyldopa may be used along with a thiazide. Initial dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>250</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mn>2</mn><mo>−</mo><mn>4</mn></mrow><annotation encoding="application/x-tex">250 \mathrm{mg} 2-4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">250</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4</span></span></span></span></span> times a day and it is increased by 250 mg at intervals of 2 to 7 days to a maintenance level. Doses of methyldopa larger than 1.5 g daily should be avoided as it can cause mental apathy.</p>
<p>Hydralazine is usually started in a small dose, 10 mg bid, which is then gradually increased to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50-100 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> bid. The upper limit of 400 mg should not be exceeded for fear of toxicity. Hydralazine is particularly useful in the presence of kidney damage as it dilates the renal vessels. It is contraindicated in patients with arteriosclerotic hypertension, angina, MI or peptic ulcer.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="hypertension-in-the-elderly">Hypertension in the Elderly<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hypertension-in-the-elderly" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Both diastolic and isolated systolic high BP are cardiovascular risk factors in the elderly. The beta adrenergic responses of vascular smooth muscle and plasma renin levels decline with age. The most consistent cardiovascular physiologic change in elderly patients is increased peripheral resistance.</p>
<p>Not all hypertensive old people need drug treatment; this is especially so in patients over 60 years of age. Treatment should be considered for those elderly patients whose BP exceeds 150/90 mm Hg. Rapid lowering of BP and postural hypotension can be dangerous. The low dose thiazides/CCB would appear to be relatively safe in these patients. ACEI/ARB are also well tolerated. Doses of diuretic larger than the equivalent of 25 mg of hydrochlorothiazide per day should be avoided and even mild hypokalemia treated.</p>
<p>As per ALLHAT trial in elderly high risk patients over 55 years, chlorthalidone 12.5-25 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">\mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day alone or in combination was found as effective as ACEI or CCB in preventing the CVS events. Chlorthalidone is twice as potent as hydrochlorothiazide and has a longer duration of action. Hence, low dose thiazides or chlorthalidone <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span> atenolol (12.5-25 mg) appears to be suitable first line therapy in the vast majority of elderly hypertensive subjects. Amlodipine ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo>−</mo><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2.5-5 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> ), a CCB, can be substitued for atenolol.</p>
<p>Complex, multiple-drug regimes are best avoided in the elderly as they may be confusing. Hypertension which persists after cardiac failure is corrected, needs treatment with an antihypertensive drug whereas a patient with an established stroke in old age does not benefit from such therapy. In fact, some patients of the latter group may show an intellectual deterioration on lowering of the BP.</p>
<p>The aim of therapy in the elderly should be to lower the BP as much below 180/100 mm Hg as the patient can tolerate comfortably, preferably to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>150</mn><mi mathvariant="normal">/</mi><mn>90</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">150 / 90 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">150/90</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span> or less. No attempt should be made to make the BP 'normal' (&lt;J40mm Hg).</p>
<p>However, in case an elderly attains <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">B</mi><mi mathvariant="normal">P</mi></mrow><mo>&lt;</mo><mn>140</mn><mi mathvariant="normal">/</mi><mn>90</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{BP}&lt;140 / 90 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7224em; vertical-align: -0.0391em;"></span><span class="mord"><span class="mord mathrm">BP</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">140/90</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span> and tolerates drug/s well with no adverse effects on health and quality of life, no adjustment should be made in doses or drugs.</p>
<p>Isolated systolic hypertension (defined as systolic BP over 140 mm Hg and diastolic BP less than 90 mm Hg ) is often resistant to treatment; attempts to treat it aggressively lowers the diastolic BP to such an extent as to compromise blood flow to vital organs such as brain. It may be treated with a low dose thiazide or a beta blocker, (or both), or with low of dose amlodipine alone.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="hypertension-in-pregnancy">Hypertension in Pregnancy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hypertension-in-pregnancy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Hypertension in pregnant women may be diagnosed when the systolic BP is 135 mm Hg or more and the diastolic BP is 85 mm Hg or more. Hypertension during pregnancy may be:</p>
<ul>
<li>Chronic hypertension, either essential or secondary, dating from before the pregnancy.</li>
<li>Transient hypertension developing after midpregnancy; this is usually mild and the BP returns to normal postpartum. Such women are liable to develop hypertension subsequently; or</li>
<li>Pre-eclampsia with moderate to severe hypertension, edema, proteinuria and disturbances of liver function and coagulation. It can lead to eclampsia with generalised convulsions and fetal death.
Chronic hypertension dating from before pregnancy, especially when secondary, long standing and associated with organ damage, predisposes to pre-eclampsia. However, more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>85</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">85 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">85%</span></span></span></span></span> of women with mild pre-existing chronic, essential hypertension have uncomplicated pregnancies. Hypertension during pregnancy needs treatment in order to possibly prevent preeclampsia; however, no treatment guaranteedly prevents pre-eclampsia.</li>
</ul>
<p>Women with secondary hypertension and those with diastolic BP of 95 mm Hg or higher need aggressive treatment. Women with risk factors such as renal disease or end organ damage should be treated even at lower levels of diastolic BP. Methyldopa is effective, and is considered safe for the mother and the baby; it is the preferred drug in pregnant women. The alternative is beta blockers (like atenolol); they are safe in the third trimester of pregnancy but may cause intrauterine growth retardation when prescribed earlier. However, by causing fetal bradycardia, beta blockers mask an important index of fetal distress, viz. fetal bradycardia. In acute episodes of hypertension during pregnancy, nifedipine may be used safely.</p>
<p>Labetalol may be hepatotoxic whereas the use of ACE inhibitors is associated with oligohydramnios and neonatal renal failure. ACE inhibitors and ARBs are absolutely contraindicated during pregnancy. Diuretics should not be used as first-line agents to treat hypertension in pregnancy as they can deplete maternal intravascular volume, and may rarely cause neonatal thrombocytopenia. However, they may be useful in patients with edema. Clonidine and hydralazine are not considered desirable in pregnant women.</p>
<p>Severe hypertension may develop near term or during labour. When such is the case or when preeclampsia is suspected at any time during the pregnancy, the patient should be hospitalised and put to complete bed rest. The urgent need is to lower the diastolic BP to between 90 and 100 mm Hg . For this purpose, IV labetalol or sublingual/oral nifedipine (see later) given every 30 min as needed is the treatment of choice. Magnesium sulfate IV is the drug of choice for prevention and treatment of eclamptic convulsions. However, its anti-hypertensive action is slight and unpredictable. Simultaneous use of magnesium sulfate and nifedipine can cause precipitous fall of BP. Sodium nitroprusside is used only if other agents fail. If the patient's condition deteriorates or if eclampsia supervenes, the pregnancy is terminated regardless of its duration.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="supportive-treatment-of-hypertension">Supportive Treatment of Hypertension<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#supportive-treatment-of-hypertension" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>General treatment: Adequate rest, relaxation and sleep are desirable. Ambitions may have to be curbed or sacrificed for reasons of health. Reassurance and a benzodiazepine could benefit the patient. The patient should be explained in detail what 'moderation in all things' actually means. Yoga, meditation and relaxation exercises are helpful. Very strict restrictions are, however, often unnecessary, as Page has aptly remarked, "I firmly believe that those who follow directions minutely do better than the careless. But there are important areas of living in which we physicians know no more than others. Often when we don't know what to do, we proscribe instead of prescribing - we forbid this or that of the things people often most enjoy. I suppose this characteristic is a hangover from the days when anything that was pleasurable was sinful. Whether we forbid smoking, alcohol and such, may make a good deal of difference as to whether people will think life worth living. I should therefore remind you that smoke and alcohol were the oldest known preservatives and that Winston Churchill was 100 proof of this observation."</p>
<p>Weight reduction by diet control in obese patients is beneficial. Although sodium restriction is known to help the reduction in BP, with the present day diuretic drug treatment rigid restriction of salt intake is rarely necessary.</p>
<p>Prevention of cardiovascular disease: Aspirin in daily dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mo>−</mo><mn>150</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">75-150 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">75</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">150</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> can reduce major cardiovascular events in hypertensive patients. Hence, for primary prevention it is recommended in patients aged 50 years or over, only after BP is controlled.</p>
<p>In patients under the age of 70 years, who have total serum cholesterol of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>180</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">d</mi><mn>1</mn></mrow><annotation encoding="application/x-tex">&gt;180 \mathrm{mg} / \mathrm{d} 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">180</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord mathrm">d</span><span class="mord">1</span></span></span></span></span>, a statin may be used on long term basis (Chapter 40). Use of aspirin and statin should be considered in all high risk patients irrespective of age.</p>
<p>Resistant hypertension may be defined as BP persistently higher than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>140</mn><mi mathvariant="normal">/</mi><mn>90</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">140 / 90 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">140/90</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span> in most hypertensive patients, and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>130</mn><mi mathvariant="normal">/</mi><mn>80</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">130 / 80 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">130/80</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span> or more in diabetics and subjects with renal disease, despite prescription of three drugs including a diuretic. The common causes of inadequate response to antihypertensive treatment (resistant hypertension) are listed in Table 30.6. The commonest cause is noncompliance, probably present in 50-70% of patients. Apparent resistance is commonly due to faulty BP apparatus and/or faulty technique employed for measurement.</p>
<p>Table 30.6
Common causes of inadequate response to antihypertensive treatment</p>
<p><sup><a href="#user-content-fn-0" id="user-content-fnref-0-3" data-footnote-ref="true" aria-describedby="footnote-label">1</a></sup></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="treatment-of-hypertensive-crises">Treatment of Hypertensive Crises<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment-of-hypertensive-crises" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>High DBP ( 120 mm Hg or higher DBP) may sometimes be found in completely asymptomatic patients. Long term treatment with gradual reduction of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi><mi>P</mi></mrow><annotation encoding="application/x-tex">B P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">BP</span></span></span></span></span> is sufficient in such cases to prevent severe organ damage.</p>
<p>On the other hand, in many situations <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi><mi>P</mi></mrow><annotation encoding="application/x-tex">B P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">BP</span></span></span></span></span> must be reduced in several hours or even within one hour to prevent death or severe damage to vital organ functions; they constitute hypertensive crises (Table 30.7). It usually occurs in patients with known hypertension, but may occur in previously normotensive persons. It is characterised by some or all of the following:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-30-7">Table 30.7<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-30-7" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="hypertensive-crises">Hypertensive crises<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hypertensive-crises" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(A) Hypertensive urgencies: These may be defined as sudden or severe elevation of BP, usually with DBP of 120 mm Hg or higher with an impending complication. Such patients need immediate treatment, preferably in an ICU. The DBP needs to be reduced to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>110</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">100-110 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">110</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span> within <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>24</mn><mo>−</mo><mn>48</mn></mrow><annotation encoding="application/x-tex">24-48</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">24</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">48</span></span></span></span></span> hours without the use a loading dose. The BP may then be reduced further, gradually, over the next several days. Urgencies include:</p>
<ul>
<li>Severe epistaxis</li>
<li>Severe perioperative hypertension</li>
<li>Unstable angina pectoris</li>
<li>Diabetic retinopathy</li>
<li>Pre-eclampsia</li>
<li>Tyramine ingestion during MAOI therapy</li>
<li>Amphetamine or cocaine intoxication</li>
<li>Hypertension with papilledema
(B) Hypertensive emergencies: These may be defined as severe elevation of BP to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>210</mn><mi mathvariant="normal">/</mi><mn>120</mn><mo>−</mo><mn>130</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">210 / 120-130 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">210/120</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">130</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span>, with evidence of target organ damage or dysfunction. Such patients also require admission into an ICU and rapid, but not too rapid, lowering of BP to 150-160/100-110 within thour; the BP should be maintained at that level for a few days, before lowering it, slowly, still further. Examples of emergencies are:</li>
<li>Hypertensive encephalopathy</li>
<li>Intracranial hemorrhage</li>
<li>Acute myocardial infarction</li>
<li>Acute LVF with pulmonary edema</li>
<li>Eclampsia</li>
</ul>
<p>Most bypertensive emergencies are characterised by vasoconstriction and normal or reduced plasma volume. Therefore, drugs which do not cause reduction in renal blood flow (CCBs, fenoldopam and sodium nitroprusside) are preferred.</p>
<ul>
<li>Sudden or sustained rise of DBP to 120 mm Hg or higher and/or SBP <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>180</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">&gt;180 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">180</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span>.</li>
<li>Papilledema (not always present)</li>
<li>Decrease in renal function</li>
<li>Epistaxis</li>
<li>Neurological dysfunction (encephalopathy, intracranial haemorrhage); and</li>
<li>Acute LVF, Unstable angina or MI.</li>
</ul>
<p>The severity of a hypertensive crisis depends not only upon the absolute BP but also on the rapidity of its rise to the present level.</p>
<p>Hypertensive crises should be treated in a hospital ICU with facilities for invasive BP monitoring. In its absence, IV antihypertensives should be avoided. Drugs which reduce the perfusion of vital organs minimally are preferred. Patients should be treated in a strictly supine position to avoid orthostatic complications. If renal function is greatly impaired, even a small reduction in GFR may worsen it.</p>
<p>Drastic lowering of BP in a few minutes is hazardous. Such an immediate fall of BP to below the autoregulatory range of cerebral blood flow (which in hypertensives can be as high as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>120</mn><mo>−</mo><mn>160</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">120-160 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">120</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">160</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span> systolic) can cause cerebral ischaemia and severe brain damage and may precipitate MI, blindness and stroke. The initial reduction in DBP should be about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span>; further reduction of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> every two to four hours till the diastolic pressure</p>
<p>reaches <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mo>−</mo><mn>100</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">90-100 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">90</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span> is desirable. Drugs with long plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi>t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">t^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathnormal">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> may cause extended hypotension with its attendant complications. Close monitoring by frequent BP measurements is, therefore, mandatory.</p>
<p>The drugs used to reduce BP in hypertension crisis are given in Table 30.8:
Table 30.8
Some parenteral/oral drugs in hypertensive emergencies</p>
<table><thead><tr><th style="text-align: center;">Drug</th><th style="text-align: center;">Dose</th><th style="text-align: center;">Onset</th><th style="text-align: center;">Duration</th><th style="text-align: center;">Remarks</th></tr></thead><tbody><tr><td style="text-align: center;">Arteriolar and venous dilator:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Sodium nitroprusside</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.25</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">0.25-10 \mathrm{mcg} / \mathrm{kg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>, IV infusion</td><td style="text-align: center;">Immediate</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>3</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">2-3 \mathrm{~min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6679em;"></span><span class="mord">3</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span></span></span></td><td style="text-align: center;">Thiocyanate toxicity</td></tr><tr><td style="text-align: center;">Nitroglycerine</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow><mo separator="true">,</mo><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">V</mi></mrow></mrow><annotation encoding="application/x-tex">5-100 \mathrm{mcg} / \mathrm{min}, \mathrm{IV}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">IV</span></span></span></span></span></span> infusion</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">2-5 \mathrm{~min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6679em;"></span><span class="mord">5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>5</mn><mo>−</mo><mn>10</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;min&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 5-10 \\ &amp; \text { min } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">10</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;min&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Preferred in patients with IHD</td></tr><tr><td style="text-align: center;">Arteriolar dilator:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Hydralazine</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5-10 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> IV bolus every 30 min or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10-50 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> IM</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="center" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mn>10</mn><mo>−</mo><mn>20</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mi>min</mi><mo>⁡</mo></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{gathered} 10-20 \\ \min \end{gathered}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-c"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">20</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mop">min</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>4</mn><mrow><mi mathvariant="normal">h</mi><mi mathvariant="normal">r</mi><mi mathvariant="normal">s</mi></mrow></mrow><annotation encoding="application/x-tex">2-4 \mathrm{hrs}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm">hrs</span></span></span></span></span></span></td><td style="text-align: center;">May ppt. angina, MI, Used in pregnancy</td></tr><tr><td style="text-align: center;">D, receptor agonist:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Fenoldopam</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mo>−</mo><mn>0.6</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">0.1-0.6 \mathrm{mcg} / \mathrm{kg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.6</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span> IV infusion</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">3-5 \mathrm{~min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6679em;"></span><span class="mord">5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="center" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mn>10</mn><mo>−</mo><mn>30</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mtext>&nbsp;min&nbsp;</mtext></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{gathered} 10-30 \\ \text { min } \end{gathered}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-c"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">30</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">&nbsp;min&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Maintains renal perfusion</td></tr><tr><td style="text-align: center;">Alpha and beta adrenergic blocker:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Labetalol</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>80</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20-80 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">80</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>, IV bolus every 10 min to max. total dose of 300 mg or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow><mo separator="true">,</mo><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">V</mi></mrow></mrow><annotation encoding="application/x-tex">2 \mathrm{mg} / \mathrm{min}, \mathrm{IV}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">IV</span></span></span></span></span></span> infusion</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>10</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">5-10 \mathrm{~min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6679em;"></span><span class="mord">10</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">3-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> hrs</td><td style="text-align: center;">Avoid in pts with cardiogenic shock or marked bradycardia</td></tr><tr><td style="text-align: center;">Nonselective alpha blocker:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Phentolamine</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5-15 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> IV</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">1-2 \mathrm{~min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6679em;"></span><span class="mord">2</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>3</mn><mo>−</mo><mn>10</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;min&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 3-10 \\ &amp; \text { min } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">10</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;min&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">For pheochromocytoma and MAOI interactions</td></tr><tr><td style="text-align: center;">Beta adrenergic blocker:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Esmolol</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>250</mn><mo>−</mo><mn>500</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">250-500 \mathrm{mcg} / \mathrm{kg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">250</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">500</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span> for 1 min ; then <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>300</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50-300 \mathrm{mcg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">300</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span></span></span></span></span> for 1 min ; then <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>300</mn></mrow><annotation encoding="application/x-tex">50-300</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">300</span></span></span></span></span> <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{mcg} / \mathrm{kg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span> for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">4-5 \mathrm{~min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6679em;"></span><span class="mord">5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">3-5 \mathrm{~min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6679em;"></span><span class="mord">5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="center" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mn>10</mn><mo>−</mo><mn>20</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mtext>&nbsp;min&nbsp;</mtext></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{gathered} 10-20 \\ \text { min } \end{gathered}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-c"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">20</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">&nbsp;min&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">For post-operative hypertension</td></tr><tr><td style="text-align: center;">CCB:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Nifedipine</td><td style="text-align: center;">SL 10 mg , then 10 mg PO 6 hry.</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>3</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">2-3 \mathrm{~min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6679em;"></span><span class="mord">3</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>3</mn></mrow><annotation encoding="application/x-tex">2-3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">3</span></span></span></span></span> hrs</td><td style="text-align: center;">May cause fluctuation in BP</td></tr><tr><td style="text-align: center;">Nicardipine</td><td style="text-align: center;">5 mg IV bolus, repeated every <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>15</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">10-15 \mathrm{~min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6679em;"></span><span class="mord">15</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span></span></span>, max <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">h</mi><mi mathvariant="normal">r</mi></mrow></mrow><annotation encoding="application/x-tex">15 \mathrm{mg} / \mathrm{hr}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">hr</span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">1-5 \mathrm{~min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6679em;"></span><span class="mord">5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">3-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> hrs</td><td style="text-align: center;">Can cause reflex tachycardia</td></tr><tr><td style="text-align: center;">ACE blockers:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Enalaprilat</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.25</mn><mo>−</mo><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1.25-5 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1.25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> IV bolus 6 hrly</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="center" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mn>15</mn><mo>−</mo><mn>30</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mi>min</mi><mo>⁡</mo></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{gathered} 15-30 \\ \min \end{gathered}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-c"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">30</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mop">min</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">6 hrs</td><td style="text-align: center;"></td></tr></tbody></table>
<p>Sodium nitroprusside: It has almost instantaneous onset of action and is most consistently effective. Since it can cause a precipitous fall in BP, the infusion should be titrated very carefully. It is the drug of choice in the presence of MI or pulmonary edema.</p>
<p>Nitroglycerine (NTG): It reduces BP in a few minutes. It is the preferred agent in advanced renal or hepatic insufficiency where nitroprusside is contraindicated. Since it reduces the preload more than the afterload, it should be avoided in patients with inferior wall MI with RV involvement. It can also be administered sublingually.</p>
<p>Fenoldopam: This drug is a peripheral, dopamine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mi mathvariant="normal">D</mi><mn>1</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{D}_{1}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathrm">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> receptor agonist with a short action. It causes peripheral and renal vasodilatation, and natriuresis. It is as effective as sodium nitroprusside. It can cause headache, flushing and raised intra-ocular pressure.</p>
<p>Labetalol, IV, reduces BP in a dose-dependent manner. It affects the heart rate and cardiac output minimally. Since its <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi>t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">t^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathnormal">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>8</mn></mrow><annotation encoding="application/x-tex">5-8</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">8</span></span></span></span></span> hours, the IV infusion should be discontinued before starting oral therapy with 200 mg ; oral labetalol is continued as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>200</mn><mo>−</mo><mn>400</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mn>6</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">200-400 \mathrm{mg} 6-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">200</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">400</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span></p>
<p>hourly. Labetalol IV (infusion or bolus doses) is preferred in hypertensive crisis in pregnancy.</p>
<p>Esmolol: This beta-1 selective blocker gets rapidly metabolised by blood esterases and has a very short <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of 9 minutes. Given by IV infusion, the effects begin almost immediately and last for 30 minutes. The therapy may be stopped abruptly, if necessary.</p>
<p>Nifedipine: Sublingual nifedipine is effective in lowering the BP rapidly. Given in the dose of 10 mg , it acts within 2-3 minutes and the action lasts for 2-3 hours. In less urgent cases, it is given orally in the dose of 10 mg 6 hourly. If a sublingual preparation is not available, the patient can chew a 10 mg tablet for immediate local absorption and should swallow a second 10 mg tablet at the same time. Nifedipine is the drug least liable to aggravate regional blood flow imbalances and to cause ischemia of the brain, eyes or kidney; but it can cause undesirable fluctuations in BP. Although not an ideal drug, given under supervision, it is the preferred drug when intensive care facilities are not available. Nifedipine should be avoided in patients with CAD or with ECG evidence of LVH.</p>
<p>Enalaprilat: This active metabolite of enalapril has a rapid onset and long duration of action. Peak effect may not be seen for 4 hours. It is contraindicated in renal artery stenosis.</p>
<p>Diuretics should be used only to treat salt retention or acute LVF with pulmonary edema.
Although parenteral drugs are administered with precaution and care, an occasional patient may develop excessive hypotension. Hence, noradrenaline should be kept ready to treat drug induced hypotension. Similarly, if diuretics are used, attention must be given for maintaining adequate hydration to avoid oligemia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-induced-hypertension">Drug Induced Hypertension<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-induced-hypertension" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Some drugs used in therapeutics may cause a rise in BP as their adverse effect (Table 30.9).</p>
<p>Table 30.9
Some drugs causing hypertension</p>
<ul>
<li>Hormones: Glucocorticoids, fludrocortisone, testosterone, ethinyl estradiol.</li>
<li>Vasoconstrictors: Adrenergic agents, ergot alkaloids, anorexiants, decongestants.</li>
<li>MAO inhibitors.</li>
<li>Salt retaining drugs: NSAID, liquorice.</li>
<li>Miscellaneous: Bromocriptine, Alcohol, Caffeine in excess, Epoeitin alpha, Cyclosporine.</li>
</ul>
<p>Further, some dietary supplements such as bitter orange have been reported to increase BP. It is imperative, therefore, to enquire whether the patient is taking any such drug or herbal remedies while evaluating a hypertensive subject.</p>
<p>Many proprietary 'cold cures' and 'cough mixtures' contain adrenergic drugs e.g. ephedrine, phenylephrine, phenteramine or phenylpropanolamine. Hence, it is best to warn the patients on antihypertensives to avoid such preparations as they may cause a sudden rise of BP. Their enquiry should form a part of history taking.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pulmonary-hypertension">Pulmonary Hypertension<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pulmonary-hypertension" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Pulmonary hypertension (PH) is an abnormal increase of BP in the lung vasculature arising from diverse etiology- cardiac, pulmonary or intrinsic vascular disease. It is associated with shortness of breath, dizziness, edema and markedly decreased exercise tolerance. It results in heart failure.</p>
<p>Increase in PH with normal pulmonary capillary wedge pressure is termed as pulmonary arterial hypertension (PAH), which is a progressive disease. PAH is associated with abnormalities of pulmonary vascular endothelium and smooth muscle cells, resulting in smooth muscle proliferation and remodeling leading to obliteration of vascular lumen and increase pulmonary vascular resistance. This results in right ventricular failure and death. PAH is also common in advanced cases of idiopathic pulmonary fibrosis. Pulmonary perfusion is regulated by local production of NO and prostacycline, which are vasodilators and endothelin, a vasoconstrictor in the lung and their impaired release is reported in PAH. Though, there is no cure, drugs are now available which can prolong life and improve its quality.</p>
<p>ENDOTHELIN (ET): This 21 residue polypeptide, originally isolated from cultured vascular endothelium, is present in several tissues (brain, kidney, intestine, adrenal glands). It is a potent endogenous vasoconstrictor that also has proliferative, pro-fibrotic and pro-inflammatory effects. It also stimulates secretion of many hormones.</p>
<p>Three types of ETs have been identified so far: ET-1, ET-2 and ET-3. Of these ET-1 is the most potent, long acting vasoconstrictor which is continuously formed in the cells of resistance vessels and contributes to peripheral vascular resistance. It controls the uteroplacental blood flow and is involved in the development of cardiorespiratory system. Patients with PAH have raised plasma and lung levels of ET-1. It is also present in thyroid follicles and is involved in thyroglobulin synthesis.</p>
<p>Role of ET-2 and ET-3 remains to be elucidated.
There are two types of ET receptors: ETA and ETB. ETA is expressed on vascular smooth muscles, heart, lung and kidney. ET-1 preferentially activates ETA which, results in vasoconstriction, bronchoconstriction, aldosterone release and smooth muscle proliferation.</p>
<p>ETB is mainly expressed in brain, but moderate expression is observed in vessels, heart, lungs, kidney and adrenals. In contrast to ETA, ETB is highly expressed on the endothelial cells (ETB1); its activation causes vasodilatation by stimulating NO and PGI2 synthesis. ETB found on smooth muscles (ETB2) is responsible for vasoconstrictor effects.</p>
<p>Endothelin receptor antagonists can be classified as: I. Nonselective - Bosentan and Macitentan II. Selective - Ambrisentan.</p>
<p>BOSENTAN: This substituted pyrimidine derivative acts as a nonselective competitive antagonist of ET1. It binds to both ETA receptors in vascular smooth muscles and ETB receptors in the brain, smooth muscles, and endothelium. In patients with PAH, it reduces the pulmonary vascular resistance and lowers the pulmonary arterial pressure.</p>
<p>The drug is well absorbed orally. It is highly ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>98</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">98 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">98%</span></span></span></span></span> ) protein bound and has a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of 3 hours. It is metabolised in the liver, and the metabolites excreted in the bile. Inhibition of hepatic microsomal enzymes by ketoconazole and fl uvastatin can increase its plasma levels. Bosentan can cause decrease in the serum levels of warfarin and oral contraceptives.</p>
<p>Cyclosporin-A increases its plasma concentration.
Adverse reactions: These include nausea, anemia and liver damage. It is teratogenic and carcinogenic in mice and rats, and is contraindicated during pregnancy.</p>
<p>Therapeutic uses: It has been used to treat severe PAH, in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>62.5</mn><mo>−</mo><mn>125</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">62.5-125 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">62.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">125</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> bid.
Macitentan, a derivative of bosentan has similar properties but risk of liver toxicity may be lesser.</p>
<p>Ambrisentan, is a selective, newer analogue of bosentan and used for similar purpose.
Other drugs used in PAH are:
(i) Prostacyclin analogues e.g. epoprostenol, iloprost, treprostinil by IV infusion (Chapter 25);
(ii) Nitric oxide inhalation;
(iii) PDE5 inhibitors (which) such as sildenafil or tadalafil orally (Chapter 69), which maintain cGMP and thereby NO levels;
(iv) Furosemide; and
(v) Warfarin to counter the tendency to thrombosis (Chapter 33).</p>
<p>Pirfenidone, a pyridine immunosuppressant, has been recently introduced as antifibrotic drug for therapy of advanced pulmonary fibrosis. It reduces production of fibrosis associated proteins and cytokines response to growth factors such as TGF-beta and platelet-derived growth factor (PDGF). It has shown some marginal benefits. ADR include mild GI symptoms, dizziness, photosensitivity and rash.</p>
<p>Riociguat is recently approved as an oral soluble guanylate cyclase (sGC) stimulator for PAH. sGC binds to NO, forming an enzyme that promotes the synthesis of cGMP. In PAH, there is an impaired synthesis of NO and insufficient stimulation of the NO-sGC-cGMP pathway. Riociguat acts directly by stimulating sGC and also indirectly by increasing sensitivity of sGC to NO.</p>
<p>The adverse effects include headache, gastritis, dizziness, hypotension, diarrhea, vomiting anemia and rarely fatal hemorrhage. Riociguat is contraindicated for use with nitrates and PDE inhibitors.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="orthostatic-hypotension">Orthostatic hypotension<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#orthostatic-hypotension" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Orthostatic hypotension is defined as a reduction in systolic blood pressure of at least 20 mm Hg or diastolic blood pressure of at least 10 mm Hg within 3 minutes of standing from a supine or sitting position. It is often most troublesome on rising in the morning and after meals, especially breakfast. Severe orthostatic hypotension can be disabling and its management is unsatisfactory.</p>
<p>The first step is to establish that the condition is persistent and find out whether there is a remediable cause. Drug therapy (diuretics, nitrates, phenothiazines, antiparkinsonian drugs, tricyclic antidepressants and antihypertensives) is by far the commonest correctable cause. Often, chronic orthostatic hypotension is due to autonomic failure secondary to diseases such as diabetes mellitus. It is important to treat the symptomatic orthostatic hypotension and not just the blood pressure reading alone. Patients with starting systolic BP as low as 70 mm Hg may be completely symptom-free. It should be remembered that treatment of orthostatic hypotension may lead to supine hypertension.</p>
<p>In mild cases, non-pharmacological measures should be tried: advice to rise slowly, high salt diet, sleeping with the head of the bed elevated 10 cm and use of 'support tights'. Drug therapy is used for those who remain disabled or have severe faintness, syncopeal episodes or inability to stand. The patient is advised to drink two cups of coffee ( 250 mg of caffeine) before breakfast. Midodrine, an <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonist, in a dose of 2.5 mg tid may be helpful. The dose may be increased gradually to the maximum of 10 mg tid if required. The last dose of the day is to be given at least 4 hr before bedtime to reduce potential for supine hypertension. The alternatives are pseudoephedrine ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>60</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">30-60 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">60</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> tid) and phenylephrine ( 10 mg every 4 hourly).</p>
<p>In severe cases, fludrocortisone is the drug of choice despite its shortcomings (Chapter 66). The main problem with this drug is the occurrence of supine hypertension.</p>
<p>31</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacotherapy-of-heart-failure">Pharmacotherapy of Heart Failure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacotherapy-of-heart-failure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Heart failure is a common and serious condition with high morbidity and mortality. Since the introduction of digitalis (in 1776) the pharmacotherapy of heart failure has made spectacular advances, resulting in better prognosis.</p>
<p>The normal heart is capable of increasing the cardiac output (CO) upto 3-4 times the resting value during exercise and in other states of increased need. Heart failure may be defined as the inability of the heart to maintain the cardiac output adequate to meet the metabolic demands of the body at all times. It manifests as :
(1) Acute heart failure (as after MI); or
(2) Chronic heart failure.</p>
<p>For rational therapy of heart failure, it is necessary to understand the physiology of cardiac contraction and the pathophysiology of failure of the heart as a pump.</p>
<p>Physiology of cardiac contraction: The structural and functional unit of the cardiac muscle (myocyte) is a sarcomere. It is made up of two interdigitating myofilaments: the thicker filament made of the protein myosin and the thinner one made of the protein actin. Myosin has intrinsic enzymatic (ATPase) activity sites. Actin possesses the ability to combine reversibly with myosin in the presence of ATPase and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>. Calcium ions activate myosin ATPase, which in turn breaks down ATP, the energy source for excitationcontraction coupling in cardiac muscle.</p>
<p>The principal mediator for the inotropic state of the heart is increased intracytoplasmic <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>. Cardiac contraction and relaxation result from the changing concentration of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>in the myocyte cytosol. During depolarisation, calcium ions enter the myocyte via the calcium channels and trigger the release of more <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>from the sarcoplasmic reticulum, and thereby initiate the cardiac contraction-relaxation cycle (Chapter 28). According to Starling's law, "the force of contraction of the cardiac muscle is a function of the enddiastolic length of the muscle fibre", which in turn closely relates to the ventricular enddiastolic volume. Upto a limit, increase in the muscle fibre length increases the force of contraction, resulting in increased cardiac output.</p>
<p>Among the neurohumoral influences that affect the cardiac contractility, the most important is the adrenergic system which acts via the neurotransmitter noradrenaline that stimulates the cardiac beta <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors.</p>
<p>Cardiac output depends upon rate of cardiac contraction (heart rate) and the stroke volume ejected by the ventricle with each beat. Thus,
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{CO}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord mathrm">CO</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> heart rate x stroke volume (SV) Stroke volume is regulated by:
(1) Preload, the length of the ventricular muscle fibre at the onset of contraction, which reflects the ventricular and diastolic pressure. It depends upon the amount of blood received into the left ventricle from the left atrium at the end of ventricular diastole.
(2) Myocardial contractility, the ability of the heart to contract in response to given preload and after load; and
(3) Afterload, defined as the tension or stress developed in the ventricular wall during ejection of blood into the arteriolar system. It is dependent on aortic pressure as well as the volume of the ventricular cavity and the thickness of the ventricular wall. The aortic</p>
<p>pressure in turn is regulated by the peripheral resistance and the condition of the arterial wall.</p>
<p>When myocardial contractility is impaired and the ventricle dilates, the cardiac output diminishes. The resultant neural (ANS) and humoral stimuli following decrease in cardiac output causes peripheral vasoconstriction and increase in the afterload. This reduces the cardiac output further while increasing the myocardiac oxygen requirement, thus establishing a vicious cycle.</p>
<p>Among the techniques used to assess the global cardiac function, the most clinically convenient is the evaluation of left ventricular ejection fraction (LVEF), the ratio of the stroke volume to the end-diastolic volume of the left ventricle (normal value about 65%).</p>
<p>Pathophysiology of heart failure (HF): A failing heart is characterised by inability to provide a cardiac output sufficient for the body's metabolic needs, initially during exercise, but later even at rest. Basically, heart failure is failure of the heart as a pump, the left ventricle more often than and earlier than the right ventricle. This can arise in several ways:
(a) Pressure overload as in hypertension and stenosis of cardiac valves (mitral or aortic).
(b) Volume overload as in congenital heart disease and in regurgitant lesions of the mitral and aortic valves.
(c) Loss of cardiac muscle due to infarction or chronic ischemic damage.
(d) Impaired cardiac contractility due to causes such as myocarditis; and
(e) Restriction of cardiac filling as in constrictive pericarditis (diastolic heart failure).</p>
<p>The syndrome of heart failure is worsened by
(a) factors which increase the need for a higher cardiac output such as, e.g., fever, anemia or thyrotoxicosis; and
(b) hypoxia, acidosis and cardiac arrhythmias which impair contractility.</p>
<p>The diminished cardiac output causes fatigue, diminution in exercise tolerance and a variety of compensatory circulatory changes. LVEF may be as low as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> in patients with severe cardiac failure. The increased venous pressure behind the failing ventricle causes:
(a) Pulmonary venous congestion, pulmonary edema and dyspnoea of left ventricular failure, and
(b) Systemic venous congestion, liver enlargement and peripheral edema of right ventricular failure.</p>
<p>The important event in heart failure is the loss of functioning cardiac tissue. To compensate for this loss, both hemodynamic and neurohumoral adaptive mechanisms are activated to improve the force of ventricular contraction (Fig 31.1). The compensatory mechanisms involved are:</p>
<p><img src="assets/images/image-20251214-6f621351.jpeg" alt="img-27.jpeg"></p>
<ul>
<li>Increase in diastolic tension (preload) which in early stages enhances the force of contraction according to Frank-Starling principle.</li>
<li>Activation of adrenergic nervous system, leading to increase in the circulating NA; chronic stimulation of the adrenergic system, however, causes increased afterload.</li>
<li>Activation of renin-angiotensin-aldosterone system;</li>
<li>Atrial stretch, stimulating secretion of Atrial Natriuretic Peptide - ANP (Chapter 37);</li>
<li>Release of endothelin</li>
</ul>
<p>In response to these mechanisms, ventricular remodeling occurs: the ventricle hypertrophies, and in severe cases there is loss of myocytes with interstitial fibrosis. The atrial stretch stimulates the baroreceptors to produce bradycardia which counteracts the effects of sympathetic outflow. The atrial distention stimulates the release of ANP, which causes vasodilatation, and natriuresis, thus opposing the actions of angiotensin II and aldosterone (Chapter 37). Thus, the cardiac output is maintained and the cardiac tissue is protected to a certain extent from the adverse effects of ventricular dilatation and sympathetic activation. However, prolonged ventricular distension leads to progressive dilatation of the ventricles and to a gradual loss of inhibitory control over the adrenergic stimulation leading to decompensated heart failure. The failing heart is not able to maintain the cardiac output. Further, activation of adrenergic system causes peripheral vasoconstriction, which increases the load on the ventricles (afterload).</p>
<p>When the cardiac output falls, systemic perfusion pressure is maintained by two mechanisms:
(a) Peripheral vasoconstriction caused by activation of adrenergic system early in the disease, and
(b) Sodium retention caused by activation of renin-angiotensin-aldosterone system which causes increase in aldosterone production. In the terminal phases of cardiac disease, vasopressin is also released (decompensated heart failure). Thus, the heart failure is not only a disease of the heart (a systolic dysfunction of the left ventricle), but is also a disorder of the circulation, involving both hemodynamic and neurohumoral factors.</p>
<p>Heart failure (HF) is a complex clinical syndrome, which arises from abnormalities of cardiac structure, function or both that impair the ability of the heart to fill or eject blood. The major symptoms of HF are dyspnoea, decreased exercise tolerance, fatigue and fluid retention, which may result in pulmonary and/or systemic congestion. Some patients, however, do not show signs and symptoms of overload (congestion). Hence the term congestive heart failure is now replaced by the term heart failure.</p>
<p>Patients with HF show wide variation in LV functional abnormalities of both systolic and diastolic functions. Clinical LV dysfunction can occur with normal heart size and preserved EF or dilated heart and/or markedly reduced ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&lt;40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> ) EF. Hence, HF can be clinically classified as
(1) HF with preserved <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">E</mi><mi mathvariant="normal">F</mi></mrow><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">F</mi></mrow><mi mathvariant="normal">P</mi></msub><mrow><mi mathvariant="normal">E</mi><mi mathvariant="normal">F</mi></mrow><mo fence="true">)</mo></mrow></mrow><annotation encoding="application/x-tex">\mathrm{EF}\left(\mathrm{HF}_{\mathrm{P}} \mathrm{EF}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">EF</span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">HF</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">P</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">EF</span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> or
(2) HF with reduced <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">E</mi><mi mathvariant="normal">F</mi></mrow><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">F</mi></mrow><mi mathvariant="normal">R</mi></msub><mrow><mi mathvariant="normal">E</mi><mi mathvariant="normal">F</mi></mrow><mo fence="true">)</mo></mrow></mrow><annotation encoding="application/x-tex">\mathrm{EF}\left(\mathrm{HF}_{\mathrm{R}} \mathrm{EF}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">EF</span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">HF</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">R</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">EF</span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span>. Patients with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">F</mi></mrow><mi mathvariant="normal">R</mi></msub><mrow><mi mathvariant="normal">E</mi><mi mathvariant="normal">F</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{HF}_{\mathrm{R}} \mathrm{EF}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HF</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">R</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">EF</span></span></span></span></span></span> have evidence of abnormal LV systolic dysfunction and marked reduction in LVEF ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&gt;40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> ).</p>
<p>Patients with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">F</mi></mrow><mi mathvariant="normal">P</mi></msub><mrow><mi mathvariant="normal">E</mi><mi mathvariant="normal">F</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{HF}_{\mathrm{P}} \mathrm{EF}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HF</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">P</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">EF</span></span></span></span></span></span>, on the other hand, have evidence of abnormal LV diastolic dysfunction and near normal EF ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&gt;50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> ). Commonly it is caused by disorders that chronically increase the cardiac workload e.g, previous history of MI, high blood pressure. The myocardial responses to such stresses involve remodeling of cardio-myocytes and the non-myocytes. Such responses are initially adaptive and beneficial but later progress to contractile dysfunction, ventricular dilatation and arrhythmias.</p>
<p>Diastolic cardiac dysfunction involves an abnormality of diastolic distensibility, filling or relaxation of the left ventricle. The patient may be symptomatic or asymptomatic. Doppler echocardiography plays a critical diagnostic role in such patients, partly because the physical examination, chest X-ray and ECG do not provide definite information. It is more prevalent in elderly patients and may be associated with hypertension, IHD and diabetes mellitus. The management primarily comprises the treatment of the specific underlying cause. Digitalis, diuretics and vasodilators are less effective than in systolic heart failure and must be used with great caution. Unlike systolic heart failure, verapamil and diltiazem may improve diastolic function.</p>
<p>Three important pathophysiological factors that contribute to the ventricular wall stress are:</p>
<ul>
<li>Reduced cardiac contractility.</li>
<li>Peripheral vasoconstriction due to activation of sympathetic and renin-angiotensin aldosterone systems; and</li>
<li>Sodium and water retention.</li>
</ul>
<p>In acute heart failure reduction of load (elevated LV filling pressure) and maintenance of cardiac output as well as optimal blood pressure are the immediate aims of therapy.</p>
<p>In chronic heart failure, the long term aims include:</p>
<ul>
<li>Relief of symptoms and signs;</li>
<li>Stabilisation of hemodynamics;</li>
<li>Prevention of disease progress;</li>
<li>Treatment of risk factors; and</li>
<li>Improvement in quality of life and reduction in mortality</li>
</ul>
<p>The principles of rational therapy of chronic heart failure are outlined in Table 31.1. Risk factors should be treated in all patients. Restriction of sodium intake is beneficial to all.</p>
<p>Table 31.1
Rational therapy of chronic heart failure</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>Reduction in ventricular wall stress by
</span>    - Bed rest
    - Vasodilators
    Reduction in neurohumoral activation by
    - ACE inhibitors
    - Beta blockers
    Countering sodium and fluid retention by
    - Restriction of sodiumintake (&lt;2 g/day).
    - Restriction of fluid to &lt; 1.5 L/day.
    - Promotion of sodium excretion by using a diuretic, furosemide 20-40 mg.
    Treatment of the cause e.g. hypertension, arrhythmias, anemia, thyrotoxicosis.
    Use of aldosterone antagonist: Spironolactone
    Use of an inotropic drug, e.g., Digoxin.
    Use of low dose aspirin, if evidence of ischaemic heart disease</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="Reduction in ventricular wall stress by
    - Bed rest
    - Vasodilators
    Reduction in neurohumoral activation by
    - ACE inhibitors
    - Beta blockers
    Countering sodium and fluid retention by
    - Restriction of sodiumintake (&lt;2 g/day).
    - Restriction of fluid to &lt; 1.5 L/day.
    - Promotion of sodium excretion by using a diuretic, furosemide 20-40 mg.
    Treatment of the cause e.g. hypertension, arrhythmias, anemia, thyrotoxicosis.
    Use of aldosterone antagonist: Spironolactone
    Use of an inotropic drug, e.g., Digoxin.
    Use of low dose aspirin, if evidence of ischaemic heart disease" style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="acei-and-vasodilators-in-heart-failure">ACEI and Vasodilators in Heart Failure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#acei-and-vasodilators-in-heart-failure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Activation of the neurohumoral mechanisms in CHF increases the systemic vascular resistance and venous return. Thus, the body tries to maintain an adequate pressure-head to perfuse the vital organs such as brain and kidneys. However, such vasoconstriction of arterioles causes increased impedence (afterload) to left ventricular ejection and further increases the cardiac work load. Increase in venous return increases the end diastolic ventricular filling pressure (preload), which also increases the cardiac work. A reduction in either the afterload or in the preload increases the cardiac output. Hence, vasodilators, particularly ACEI, are now considered the cornerstone of the therapy of patients with heart failure.</p>
<p>Vasodilator drugs are of three types (Table 31.2):</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-31-2">Table 31.2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-31-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="beneficial-effects-of-vasodilators-in-cardiac-failure">Beneficial effects of vasodilators in cardiac failure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#beneficial-effects-of-vasodilators-in-cardiac-failure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<table><thead><tr><th style="text-align: left;">Vasodilator type</th><th style="text-align: left;">Preload</th><th style="text-align: left;">Afterload</th><th style="text-align: left;">VEDV</th><th style="text-align: left;">Stroke volume</th></tr></thead><tbody><tr><td style="text-align: left;">Arterial (hydralazine)</td><td style="text-align: left;">No change</td><td style="text-align: left;">Reduced</td><td style="text-align: left;">No change</td><td style="text-align: left;">Increased</td></tr><tr><td style="text-align: left;">Venous (nitrates)</td><td style="text-align: left;">Reduced</td><td style="text-align: left;">No change</td><td style="text-align: left;">Reduced</td><td style="text-align: left;">No change</td></tr><tr><td style="text-align: left;">Combined (ACEI)</td><td style="text-align: left;">Reduced</td><td style="text-align: left;">Reduced</td><td style="text-align: left;">Reduced</td><td style="text-align: left;">Increased</td></tr></tbody></table>
<p>VEDV = Ventricular end diastolic volume.</p>
<ul>
<li>Arterial e.g. Hydralazine. It reduces the afterload on the heart.</li>
<li>Venous e.g. Nitrates. They reduce the preload on the heart.</li>
<li>Combined, balanced arteriolar plus venous e.g. Prazosin; ACEI, ARB, Sodium nitroprusside. They reduce both preload and afterload.
The vasodilator drugs currently used in chronic CHF are shown in Table 31.3.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-31-3">Table 31.3<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-31-3" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="vasodilators-used-in-chronic-congestive-heart-failure">Vasodilators used in chronic congestive heart failure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vasodilators-used-in-chronic-congestive-heart-failure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Captopril ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6.25</mn><mo>−</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">6.25-50 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">6.25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> tid), enalapril ( 10 mg bid), lisinopril 5 mg od.</li>
<li>Isosorbide dinitrate ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20-40 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> orally or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2.5-10 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> sublingually, 6 hourly) or nitroglycerine ointment.</li>
<li>Hydralazine ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>75</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mn>6</mn></mrow><annotation encoding="application/x-tex">50-75 \mathrm{mg} 6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">75</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">6</span></span></span></span></span> hourly).</li>
<li>Prazosin ( 5 mg 8 hourly).</li>
</ul>
<p>Many clinicians presently treat heart failure with sinus rhythm, at least initially, with bed rest and ACEI (Chapter 30; Table 31.4)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-31-4">Table 31.4<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-31-4" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Use of ACEI in heart failure</p>
<ul>
<li>Start with small doses (captopril 6.25 mg , enalapril 2.5 mg , lisinopril 2.5 mg or ramipril 2.5 mg a day)</li>
<li>Maximum doses are captopril 50 mg tid, enalapril 10 mg bid, lisinopril 30 mg od, or ramipril 5 mg bid.</li>
<li>Stop potassium supplements and potassium sparing diuretics before starting ACEI.</li>
<li>Stop other diuretics 24 hours before the first dose of ACEI. They may be restarted the next day.</li>
<li>Patient should be sitting or lying down for 2-4 hours, depending on the drug used, after the first dose of ACEI.</li>
</ul>
<p>ACEI has several advantages:</p>
<ul>
<li>They are beneficial clinically and hemodynamically even in resistant heart failure.</li>
<li>They control hypertension which is an important risk factor.</li>
<li>They prolong survival in CHE</li>
<li>Tolerance is rare.</li>
<li>By blocking the local generation of angiotensin II, they reduce its direct toxic effects on the myocardium (cardiac remodeling) and reduce the risk of coronary ischemic events.</li>
<li>They reduce the mortality rate and the risk of hemodynamic and clinical progression in asymptomatic patient with left ventricular dysfunction following acute MI.
All patients with asymptomatic or symptomatic LV dysfunction or LV enlargement should be treated with ACEI as a first line therapy. Patients who do not tolerate ACEI or remain symptomatic may be treated with ARB or combination of hydralazine + isosorbide dinitrate as these drugs improve exercise tolerance and increase life expectancy. Nitrates decrease the preload by venodilatation without causing decrease in blood volume and are helpful if ischaemia is also present.</li>
</ul>
<p>In the management of acute congestive heart failure due to MI, the therapy of choice is an infusion of sodium nitroprusside or nitroglycerine (Chapter 30). The use of such infusions requires the facilities of an ICCU. In their absence, NTG ointment may be used.</p>
<p>The other indications for vasodilator therapy are:</p>
<ul>
<li>Hypertensive crisis especially malignant hypertension and dissecting aortic aneurysm; and</li>
<li>Acute or chronic mitral or aortic regurgitation, and ventricular septal defect, in patients awaiting surgery.
Vasopeptidase inhibitors: These drugs inhibit both ACE and neutral endopeptidase (NEP). NEP is found mainly in the renal tubules but is also present in other tissues such as lungs, intestines, brain, heart and blood vessels. It catalyses the breakdown of atrial natriuretic peptide (ANP) and some other peptide hormones including bradykinin. Its inhibition by vasopeptidase inhibitors prevents the breakdown of ANP and causes vasodilation and sodium excretion (Fig 31.2). They also inhibit the production of angiotensin II. Thus, they may be useful in the treatment of CHF and hypertension.
<img src="assets/images/image-20251214-68373eee.jpeg" alt="img-28.jpeg"></li>
</ul>
<p>FIG. 31.2 Mechanism of action of vasopeptidase inhibitors ACE = Angiotensin converting enzyme; NEP = Neutral endopeptidase</p>
<p>OMAPATRILAT: This vasopeptidase inhibitor drug, given orally, is rapidly absorbed with plasma half life of 14-19 hrs. It causes both arterial and venous dilatation and natriuresis. It inhibits the serum ACE activity and increases the renal excretion of natriuretic peptide in a dose dependant manner. Toxicity reported includes dizziness, cough and angioedema.</p>
<p>NESIRITIDE: This, recombinant human B type natriuretic peptide (BNP), given IV binds to surface receptors on the vascular smooth muscle and endothelial cells and activates cGMP. It causes both arterial and venous vasodilatation and mild natriuresis. It also suppresses the renin-angiotensin-aldosterone system. However, it causes dose-dependant hypotension and hence should not be used routinely to treat severely decompensated heart failure.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="beta-adrenergic-blocking-agents-in-heart-failure">Beta-adrenergic Blocking Agents in Heart Failure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#beta-adrenergic-blocking-agents-in-heart-failure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Although the beta-adrenergic blockers can block the adverse cardiac effects of catecholamines, their use in large doses can worsen the heart failure owing to their negative inotropic action. However, the use of gradually increasing doses (start low, go slow) of metoprolol/carvedilol/bisoprolol over long term improve the symptoms and reduces the all-cause mortality substantially in heart failure.</p>
<p>They attenuate the adverse effects of the activated sympathetic drive (including apoptosis) on the heart, upregulate the beta receptors and reduce the LV remodeling. They are recommended in all patients in a stable condition, in whom LVEF is less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>35</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">35 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">35%</span></span></span></span></span>, without substantial salt and water retention and without recent exacerbation of heart failure requiring digoxin. Their long term effects are uniformly beneficial. Combination of an ACEI and a beta blocker is currently the cornerstone of the treatment of patients with left ventricular systolic dysfunction. Once started, they should not be stopped abruptly.</p>
<p>Beta blockers are not indicated in heart failure after acute MI nor in those with heart failure and normal LVEF (i.e. diastolic heart failure). They are also not indicated in patients with heart rate less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow><mo separator="true">,</mo><mi mathvariant="normal">A</mi><mo>−</mo><mi mathvariant="normal">V</mi></mrow><annotation encoding="application/x-tex">60 / \mathrm{min}, \mathrm{A}-\mathrm{V}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">60/</span><span class="mord"><span class="mord mathrm">min</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord mathrm">A</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm" style="margin-right: 0.01389em;">V</span></span></span></span></span> block, asthma or COPD and severe or unstable heart failure. The therapy is initiated with very small doses, increased every 2 weeks. As beta blockers and ACEI can worsen the fluid retention, it is necessary to optimise the diuretic drugs before starting beta blockers.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="diuretics-in-heart-failure">Diuretics in Heart Failure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#diuretics-in-heart-failure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Diuretics are used in heart failure to relieve sodium and water accumulation (volume overload) and thus reduce peripheral edema, and dyspnoea due to pulmonary congestion. This gives quick symptomatic relief. But, their use alone has limitations:
(a) They do not increase cardiac output nor do they improve ventricular function.
(b) With the excessive use of diuretics, cardiac output and renal perfusion may diminish, with resultant fatigue, hypotension and impairment of renal function.
(c) They do not improve the survival rate.
(d) They can cause electrolyte disturbances.</p>
<p>Therefore, diuretics alone are not recomended; they are combined with either ACEI or digoxin. Diuretics have no place in the absence of overt heart failure. Table 31.5 outlines the principles of safe diuretic therapy of heart failure. For pharmacology of diuretics, see Chapter 39.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-31-5">Table 31.5<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-31-5" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="diuretic-therapy-of-chronic-heart-failure">Diuretic therapy of Chronic heart failure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#diuretic-therapy-of-chronic-heart-failure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><sup><a href="#user-content-fn-0" id="user-content-fnref-0-4" data-footnote-ref="true" aria-describedby="footnote-label">1</a></sup></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="aldosterone-antagonists-in-heart-failure">Aldosterone Antagonists in Heart Failure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#aldosterone-antagonists-in-heart-failure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>It is known that ACEI in therapeutic doses do not completely abolish the secretion of aldosterone. In addition to its classic mineralocorticoid properties, excess aldosterone causes coronary and renovascular remodeling, endothelial cell and baroreceptor dysfunction, potassium excretion and inhibition of myocardial noradrenaline uptake (Chapter 66). Morphological studies indicate that chronic excess of aldosterone and salt loading cause fibrosis in the atria, ventricles, kidney and other organs. The aldosterone antagonist spironolactone (Chapter 39) in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12.5</mn><mo>−</mo><mn>25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">12.5-25 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">12.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> OD has been shown to decrease the hospitalisation and mortality rates in patients with severe CHF who are already on the drugs discussed earlier. Further, the risk of hyperkalemia is very low when such small doses of spironolactone are used in combination with ACEI. It also probably helps to conserve magnesium and thus prevent arrythmias. Monitoring of renal function and serum <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>is mandatory. For eplerenone, see Chapter 39.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="digitalis-and-other-inotropic-agents-in-heart-failure">Digitalis and Other Inotropic Agents in Heart Failure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#digitalis-and-other-inotropic-agents-in-heart-failure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>In 1776, William Withering, the master physician and botanist from Birmingham, identified digitalis as the active ingredient from a mixture of twenty different herbs used by an old woman in Shropshire for the treatment of dropsy. In 1785, Withering published his treatise entitled 'An Account of the Foxglove and Some of its Medical Uses: with Practical Remarks on Dropsy and other Diseases', which remains a classic even today. He, however, thought it to be a diuretic. Later a number of active glycosides were identified and shown to possess potent inotropic actions on the heart (cardiac glycosides).</p>
<p>Chemistry of the cardiac glycosides: Besides the plant Digitalis purpurea or foxglove, many other plants also serve as a source of cardiac glycosides. The glycoside strophanthin is obtained from the seeds of Strophanthus kombe or hispidus and another glycoside ouabain is derived from the seeds of Strophanthus gratus. Other less important and less prevalent sources include squill, the dried fleshy bulb of the 'sea onion' and the plants Convallaria majalis and Thevetia neriifolia (yellow oleander).</p>
<p>The cardiac glycosides exist in plants as precursors, which have to be hydrolysed for the release of the active glycosides. The seeds of Strophanthus gratus, however, yield the glycosides directly. Each glycoside represents the combination of an aglycone or genin, with a sugar (Table 31.6). If the sugar is glucose, the glycoside is called as a glucoside, e.g., strophanthin. Structurally, the aglycone has a steroid nucleus (CPP ring) with an attached lactone ring (Fig. 31.3). Acid hydrolysis of the glycoside results in separation of the aglycone and the sugar. The pharmacological activity is contained in the aglycone and the sugars ensure increased water solubility, cell penetrability and potency of the aglycones.</p>
<p>Table 31.6
Important cardiac glycosides</p>
<table><thead><tr><th style="text-align: left;">Source</th><th style="text-align: center;">Glycoside</th><th style="text-align: center;">Aglycone or Genin</th></tr></thead><tbody><tr><td style="text-align: left;">Digitalis purpurea</td><td style="text-align: center;">Digitoxin</td><td style="text-align: center;">Digitoxigenin</td></tr><tr><td style="text-align: left;"></td><td style="text-align: center;">Gitoxin</td><td style="text-align: center;">Gitoxigenin</td></tr><tr><td style="text-align: left;"></td><td style="text-align: center;">Gitalin</td><td style="text-align: center;">Gitaligenin</td></tr><tr><td style="text-align: left;">Digitalis lanata</td><td style="text-align: center;">Digitoxin</td><td style="text-align: center;">Digitoxigenin</td></tr><tr><td style="text-align: left;"></td><td style="text-align: center;">Gitoxin</td><td style="text-align: center;">Gitoxigenin</td></tr><tr><td style="text-align: left;"></td><td style="text-align: center;">Digoxin</td><td style="text-align: center;">Digoxigenin</td></tr></tbody></table>
<p><img src="assets/images/image-20251214-e8cd1ca1.jpeg" alt="img-29.jpeg"></p>
<p>FIG. 31.3 Structure of digitalis aglycone, digitoxigenin</p>
<p>Mechanism of action: Sarcolemmal membrane structures that regulate calcium entry into the cell include the slow (L type) calcium channel, the sodium-calcium exchanger, calcium ATPase, and (indirectly) the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>activated ATPase, and the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{H}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>exchanger. Digitalis acts as a potent positive inotropic agent by directly inhibiting the membrane bound <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mord">−</span></span></span></span></span> <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi>K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">K^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.07153em;">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ATPase which acts as a digitalis receptor (direct action). This prevents extrusion of sodium and hastens the entry of sodium into the cell during the resting phase (diastolic depolarisation). Along with sodium, some calcium also moves in and remains intracellularly because of the depressed function of the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>exchange pump. The accumulated intracellular sodium exchanges for the extracellular calcium thus increasing the cytoplasmic calcium concentration. The increased calcium is stored within the sarcoplasmic reticulum sacs. This permits faster release and dispersal of calcium from these sacs into the cytoplasm. Increase in intracellular calcium activates the light chain of myosin, which combines with actin to form actomyosin, and the muscle contracts. Digitalis thus enhances the contractility, automaticity and ectopic pacemaker activity in the heart.</p>
<p>As inhibition of the sodium pump also prevents reentry of potassium into the cell after repolarisation is complete, digitalis causes depletion of intracellular potassium. This potassium depleting action is not confined to the cardiac muscle but also involves the skeletal muscle and the liver.</p>
<p>Digitalis also exerts indirect action on the heart, mainly by enhancing the vagal activity and thus influencing the activity of the SA node, the atria and the AV node (see below).</p>
<p>Pharmacological actions of digitalis: These can be divided into
I Cardiovascular actions; and
II Extracardiac actions
Cardiovascular actions: These are explained by an indirect and a direct actions of digitalis on the heart.</p>
<p>In the presence of CHF, digitalis has the following actions:</p>
<ul>
<li>Contractility: By direct action, it:
(i) Increases the force of contraction thus increasing the stroke output.
(ii) Shortens the duration of the systole, allowing greater time for both ventricular filling. and cardiac rest; and
(iii) Reduces diastolic size of the heart. Since the oxygen consumption is a function of the initial diastolic fibre length, such a reduction in size diminishes the oxygen consumption for a given work output. The digitalised heart, thus, can do the same work with less energy expenditure (oxygen utilisation) or more work for the same energy expenditure, than before digitalisation. Digitalis, therefore, is called a 'cardiotonic' (and not merely a cardiac stimulant like adrenaline). Such increase in the cardiac output following digoxin also occurs in cases with 'latent' (asymptomatic) heart failure.</li>
<li>Heart rate (HR): In an individual with CHF the heart rate diminishes. However, digitalis is not effective in tachycardia without cardiac decompensation as in sinus tachycardia due to fever or thyrotoxicosis.
Small doses of digitalis reduce the HR predominantly by stimulation of the vagus (the vagal effect), which can be abolished by atropine and exercise.
Full digitalising dose reduces the HR by direct cardiac action; this effect cannot be abolished by exercise or atropine. In an individual with CHF, an increased sympathetic</li>
</ul>
<p>activity causes tachycardia and increased venous pressure. Digitalis, by improving the circulation, decreases the sympathetic tone and thus, helps to reduce the heart rate and venous pressure.</p>
<ul>
<li>Refractory period (RP): Digitalis exerts varying effects on the RP of different cardiac tissues.
(a) It shortens the atrial RP with small doses (vagal action) and prolongs it with larger doses (direct action).
(b) It prolongs the effective RP of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi><mi>V</mi></mrow><annotation encoding="application/x-tex">A V</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span><span class="mord mathnormal" style="margin-right: 0.22222em;">V</span></span></span></span></span> node through the vagus and directly. This leads to a decrease in the transmission of the number of stimuli arising from the supraventricular pacemakers to the ventricle. This action is of major importance in slowing the rapid ventricular rate in a patient with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi><mi>F</mi></mrow><annotation encoding="application/x-tex">A F</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span><span class="mord mathnormal" style="margin-right: 0.13889em;">F</span></span></span></span></span>.
(c) In contrast, digitalis shortens the ventricular RP by direct action, as observed in ECG as a shortening in the Q-T interval.</li>
<li>Conduction velocity: The resultant effects of the 'vagal' and the direct cardiac actions on conduction are:
(a) The conduction velocity is slightly increased in the atria and the ventricles by small doses of digitalis (vagal action) while therapeutic doses depress the conduction velocity (direct action).
(b) Conduction through the AV node is depressed by both vagal and direct actions, this effect being therapeutically useful. The action of digitalis on A-V conduction and refractory period is mainly due to increased vagal tone and only to a minimal extent due to its direct effect.
(c) Conduction through the Purkinje fibre system of the ventricles is depressed by the direct action.</li>
<li>Automaticity: Digitalis increases the ability of the Purkinje cells and the ventricular muscle to initiate impulses. This leads to the development of ventricular extrasystoles, bigeminy, and if accompanied by depression of the conduction velocity, even to VF.</li>
<li>Blood pressure: IV injection of a digitalis glycoside in normal humans increases the mean arterial pressure while persons with CHF show no such increase. The effects of oral digitalis upon arterial pressure in patients with failure are secondary to improvement in the circulation.</li>
<li>Coronary circulation: Improvement in coronary flow is secondary to the improvement in cardiac output and slowing of the heart.</li>
<li>Venous system: The decrease in venous pressure in individuals with CHF is secondary to the improvement of circulation.</li>
<li>Digitalis and potassium: Discussed later.</li>
<li>Digitalis and calcium: Calcium ions increase the force of cardiac contraction. Digitalis acts synergistically with calcium. Its toxicity is enhanced by excess of calcium ions. IV calcium should be avoided in individuals on digoxin.</li>
<li>Effect of digitalis on the electrocardiogram (ECG): The characteristic ECG changes are:
(a) Changes in the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>T</mi></mrow><annotation encoding="application/x-tex">T</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">T</span></span></span></span></span> wave and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>S</mi><mi>T</mi></mrow><annotation encoding="application/x-tex">S T</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">ST</span></span></span></span></span> segments. These include depression or 'scooping out' of ST segment, and inversion of the first portion of T wave. The changes, however, are no guide to its adequacy or toxicity.
(b) The PR interval is prolonged.
(c) The Q-T interval is shortened by digitalis, an indication that the drug shortens</li>
</ul>
<p>ventricular systole. Large doses may produce extrasystoles, various degrees of A-V block and ventricular fibrillation as the terminal event.
Almost every type of ECG abnormality associated with cardiac disease has been seen in patients on digitalis. However, QRS widening in the presence of sinus rhythm is not caused by digitalis; it is due to the concurrent heart disease.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="extracardiac-actions">Extracardiac actions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#extracardiac-actions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Kidney: The increased urinary output observed following digitalis in edematous patients is due to:
(a) Decrease in the venous pressure bringing about shifting of the edema fluid into the circulation.
(b) Improvement in renal circulation and increased excretion of sodium; and
(c) Inhibition of renin release from the kidney because of the decreased activity of the renal sodium pump.</li>
<li>Gastrointestinal tract: Digitalis, can produce anorexia, nausea, vomiting and diarrhoea.</li>
</ul>
<p>The nausea and vomiting are of central origin due to stimulation of the CTZ.
Absorption, fate and excretion: There are no qualitative differences among the digitalis glycosides in their effects on heart; the dissimilarities encountered are quantitative and related to the differences in pharmacokinetics. These drugs are usually administered orally or IV. Absorption is mostly from the small intestine. Absorption after SC or IM administration is unreliable.</p>
<p>The pharmacokinetics of the two digitalis glycosides is summarised in Table 31.7. Digitoxin, a non polar compound, is absorbed almost completely and rapidly from the gut whereas the more polar digoxin is absorbed to the extent of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mo>−</mo><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70-80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">70</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span>. Further, absorption of digoxin is slowed by the presence of food in the GI tract and by malabsorption syndrome.</p>
<p>Table 31.7
Pharmacokinetics of oral digoxin and digitoxin</p>
<table><thead><tr><th style="text-align: left;"></th><th style="text-align: left;">Digoxin</th><th style="text-align: left;">Digitoxin</th></tr></thead><tbody><tr><td style="text-align: left;">Absorption</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mo>−</mo><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70-80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">70</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span></td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mo>−</mo><mn>100</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90-100 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">90</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">100%</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Plasma Protein binding</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span></td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> or more</td></tr><tr><td style="text-align: left;">Disposal</td><td style="text-align: left;">Renal excretion of unchanged drug 50-75%</td><td style="text-align: left;">Metabolised in liver</td></tr><tr><td style="text-align: left;">Enterophepatic recycling</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mo>−</mo><mn>8</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">6-8 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">8%</span></span></span></span></span></td><td style="text-align: left;">Extensive</td></tr><tr><td style="text-align: left;">Plasma half-life</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>24</mn><mo>−</mo><mn>48</mn></mrow><annotation encoding="application/x-tex">24-48</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">24</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">48</span></span></span></span></span> hours</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>7</mn></mrow><annotation encoding="application/x-tex">5-7</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">7</span></span></span></span></span> days</td></tr><tr><td style="text-align: left;">Therapeutic plasma concentration</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>2</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">0.5-2 \mathrm{ng} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">ng</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span></td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>35</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">10-35 \mathrm{ng} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">35</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">ng</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Time for max. effect of a single dose</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">4-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> hours</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">6-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span> hours</td></tr><tr><td style="text-align: left;">Persistence of effect after stopping drug</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">3-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> days</td><td style="text-align: left;">18 days</td></tr><tr><td style="text-align: left;">Time for digitalisation without loading dose</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>7</mn></mrow><annotation encoding="application/x-tex">5-7</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">7</span></span></span></span></span> days</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>30</mn></mrow><annotation encoding="application/x-tex">25-30</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">30</span></span></span></span></span> days</td></tr></tbody></table>
<p>Liquid filled capsules of digoxin (Lanoxicaps) have higher bioavailability.
One of the metabolites is digoxin.
Corresponding figures after IV dose are 1.5-3 hours (digoxin) and 4-8 hours (digitoxin).
As about 50-75% of digoxin is excreted by the kidneys, its excretion is prolonged in renal insufficiency and needs dose adjustment.</p>
<p>The body eliminates per day not a fixed quantity of digoxin and digitoxin but a fixed proportion of that present in the body at the beginning of the day (exponential elimination). The figure is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> in the case of digoxin and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> in the case of digitoxin. Therefore, on repeated daily administration, these compounds accumulate in the body until the daily dose equals the amount eliminated by the body per day. After this, a steady</p>
<p>state is reached. It is reached much faster if initial loading dose is employed but is eventually reached even with the use of a daily maintenance dose right from the first day without any initial loading dose; only it takes longer. Thus, a patient can be digitalised without using any loading dose.</p>
<p>Adverse reactions: Digoxin can cause cardiac and extracardiac adverse effects:
Cardiac toxicity: Digoxin produces cardiac arrhythmias either due to:</p>
<ul>
<li>Disturbed impulse formation</li>
<li>Disturbed impulse conduction; or</li>
<li>Both</li>
</ul>
<p>The disorders of impulse formation are due to ectopic pacemaker activity. The commonest are multifocal extrasystoles and bigeminy, followed by partial or complete A-V block. Less common are A-V dissociation, sinoatrial block, paroxysmal atrial tachycardia with block (PATB), sinoatrial arrest, ventricular tachycardia and VF. Any arrhythmia occurring in a patient receiving digoxin should be assumed to be due to drug toxicity until proved otherwise.</p>
<p>Pre-existing extrasystoles in themselves, however, do not constitute a contraindication to digoxin.</p>
<p>Several factors can modify the of digitalis cardiotoxicity. Recent MI, hypoxemia and acidosis increase the liability to digoxin induced arrhythmias.</p>
<p>Hypokalemia enhances digoxin toxicity. The serum potassium level, however, is not a reliable guide to the severity of depletion of myocardial potassium.</p>
<p>Vigorous therapy of cor pulmonale with digoxin without correction of the other abnormalities with measures such as diuretics, bronchodilators, oxygen and antibiotics can precipitate cardiac toxicity. Cor pulmonale produces hypoxia which results in tachycardia and an increased blood volume due to compensatory polycythemia. Hypoxia also produces pulmonary vasoconstriction resulting in pulmonary hypertension. The right ventricle has to force an increased volume of blood against an increased vascular resistance (because of pulmonary hypertension)into a grossly reduced pulmonary vascular bed (due to emphysema). Inability of the right ventricle to achieve this results in right ventricular failure. Such patients might become worse following the administration of digoxin, as increase in the right ventricular stroke volume may further increase the load on the already compromised pulmonary circulation.</p>
<p>In patients with AF and CHF, slowing down of the ventricular rate provides a good guide to digoxin therapy. But, this is not so in patients with sinus rhythm, in whom improvement in the cardiac status can occur without much reduction in the heart rate; increasing the dose of digoxin in order to slow down the heart rate to an arbitrary level in such patients can lead to digoxin toxicity. Persistence of tachycardia and cardiac failure can be due to such factors as myocarditis, pulmonary infarcts or emboli, or a mechanical problem such as very tight mitral stenosis. Increasing digoxin dose in such cases may lead to toxicity.</p>
<p>Adrenergic drugs enhance the digoxin cardiotoxicity.
A common cause of digoxin toxicity is the use of increasing doses of digoxin for noncardiac dyspnoea.</p>
<p>Gastrointestinal toxicity: Although anorexia, nausea and vomiting are generally the earliest toxic effects, cardiotoxicity can occur without them. It is necessary to distinguish vomiting due to digoxin from that due to CHF.</p>
<p>Neurological toxicity: Vertigo, visual disturbances including blurring, photophobia and disturbances of colour vision and headache are fairly common. Lassitude, confusion, disorientation, delirium, neuralgic pains, and psychotic behaviour may appear.</p>
<p>Miscellaneous toxicity: Includes skin rashes and gynecomastia; cardiac glycosides have a structural resemblance to estrogens.</p>
<p>Digoxin crosses the placental barrier, producing foetal concentration higher than the maternal concentration. Large doses to the mother, therefore, may lead to premature delivery, and the newborn may present with ECG abnormalities.</p>
<p>Drug interactions: See Table 31.8. About 10% of patients convert large amounts of digoxin to inactive metabolites in the gut; in such patients oral antibiotics can cause a sudden increase in serum digoxin level.</p>
<p>Table 31.8</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interactions-of-digoxin">Drug interactions of digoxin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interactions-of-digoxin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(a) Drugs which increase serum digoxin levels: Quinidine; Verapamil; Methyldopa; Indomethacin. Antibiotics (see text); Amiodarone.
(b) Drugs which reduce serum digoxin levels:</p>
<ul>
<li>By induction of hepatic microsomal enzymes: Rifampicin.</li>
<li>By reducing the bioavailability: Antacids; Kaolin-pectin preparations; Neomycin; Cholestyramine</li>
<li>Drugs acting indirectly by interfering with serum <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>levels, e.g., diuretics and IV calcium.</li>
</ul>
<p>Recognition of overdigitalisation: Over-digitalisation is to be suspected when any of the aforementioned symptoms or signs arise in a patient on digitalis therapy. The usual symptoms and signs of digoxin toxicity are:
(a) Anorexia, nausea and vomiting.
(b) Decrease in the pulse rate below 60 per minute, presence of extrasystoles, especially bigeminy or any other arrhythmia.</p>
<p>A detailed analysis of the clinical situation, with special reference to past digitalisation, the amount and the speed of digoxin administration during the present illness, the nature of the disease process, and the patient's electrolyte and renal status, is necessary because the ECG may not be of help in diagnosing digoxin toxicity.</p>
<p>Determination of plasma digoxin level is valuable in
(a) Pharmacokinetic studies;
(b) Adjusting the maintenance dose of digoxin; and
(c) Detecting such unsuspected factors as poor patient compliance or poor bioavailability.</p>
<p>Higher than expected levels suggest renal failure. Therapeutic serum levels of digoxin generally range from 0.5 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.0</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">2.0 \mathrm{ng} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2.0</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">ng</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>. Although levels are higher in patients showing toxicity than in those without it, plasma level alone for the diagnosis of digoxin toxicity is unreliable.</p>
<p>Treatment of digoxin toxicity: See Table 31.9. Tachyarrhythmias and ectopic impulse generation caused by digoxin are associated with intracellular loss of potassium and can be corrected by potassium administration.</p>
<p>Table 31.9
Principles of treatment of digoxin toxicity</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>- Stop digoxin
</span>    - Stop diuretics
    - Estimate serum potassium
    - Bradycardia: atropine
    - Mildtoxicity: oral potassium
    - Supraventricular tachyarrhythmiaes oral/IV propranolol. Verapamil is contraindicated as it elevatesserum digoxin concentration
    - Ventricular tachycardia: lignocaine or phenytoin, IV
    - Severe toxicity: antidi goxin antibodies.
    - Potassium is contraindicated in the presence of A-V block, hyperkalemia or severe renal insufficiency.</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="- Stop digoxin
    - Stop diuretics
    - Estimate serum potassium
    - Bradycardia: atropine
    - Mildtoxicity: oral potassium
    - Supraventricular tachyarrhythmiaes oral/IV propranolol. Verapamil is contraindicated as it elevatesserum digoxin concentration
    - Ventricular tachycardia: lignocaine or phenytoin, IV
    - Severe toxicity: antidi goxin antibodies.
    - Potassium is contraindicated in the presence of A-V block, hyperkalemia or severe renal insufficiency." style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>Mild toxicity (stable, ventricular premature beats especially bigemini) can be treated by administration of potassium salts, 5 to 7.5 g of potassium chloride orally, daily, in divided doses. In more serious arrhythmias a solution containing 40 mEq of potassium chloride in 500 ml . of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> glucose can be administered IV over 2-4 hours with ECG as a guide.</p>
<p>Potassium loss does not appear to be related to the other cardiac toxic actions of digoxin. Potassium has little effect on the myocardial binding of digoxin that has already occurred; it can only reduce further uptake of the glycoside by the heart. Since <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>itself prolongs the refractory period of the AV node, it is contraindicated in the presence of A-V block. It is usually preferred, even in the presence of normal serum potassium level, when there is an evidence of ventricular irritability. However, it should be avoided in the presence of severe renal impairment. The administration of a potassium salt for treating digoxin toxicity does not counteract the positive inotropic properties of the glycoside.</p>
<p>The supraventricular tachyarrhythmias complicating digoxin therapy are best treated with a beta adrenergic blocking drug. Propranolol is used orally in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10-40 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> every 6 hours or 0.5 to 1 mg IV.</p>
<p>Ventricular tachycardia is best treated with either lignocaine hydrochloride or phenytoin sodium IV. In the case of lignocaine, an initial dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1-2 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> is followed either by similar doses at 20-30 minute intervals or by drip at the rate of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1-2 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> per minute. Phenytoin sodium is injected IV in the dose of 250 mg well diluted, over 3-5 minutes. Phenytoin sodium has the added advantage of countering the depression of A-V conduction by digitalis.</p>
<p>In severe digoxin toxicity (which usually involves suicidal overdose), hyperkalemia is commonly present and administration of an antiarrhythmic agent may cause cardiac arrest. Such patients are best treated with antidigoxin specific antibodies (Digibind).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations">Preparations:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Digoxin tablet (Lanoxin) 0.125 or 0.25 mg
(ii) Digoxin injection 0.25 mg per ml .
(iii) Digitoxin tablet 0.1 mg . Digitoxin injection 0.2 mg per ml .
(iv) Liquid-filled capsules of digoxin (Lanoxicaps) 100 mcg and 200 mcg .
(v) Elixir Digoxin 1 ml equivalent to 0.05 mg of digoxin.</p>
<p>Therapeutic uses:</p>
<ul>
<li>Heart failure: see below and</li>
<li>Cardiac arrythmias for its action on the conducting system of the heart. Larger doses of digoxin are required to control arrhythmias than CHF.
Table 31.10 summarises the therapeutic usefulness of digoxin in various cardiac</li>
</ul>
<p>conditions.</p>
<p>Table 31.10
Therapeutic usefulness of digoxin</p>
<ul>
<li>Very useful in heart failure associated with atrial fibrillation and rapid ventricular rate.</li>
<li>Useful in low output failure in valvular, hypertensive, ischemic and congenital heart disease.</li>
<li>Of limited value in high output failure in anemia, thyrotoxicosis, beriberi and arterio-venous fistula; and in heart failure due to myocarditis and cor pulmonale.</li>
<li>Not effective in mitral stenosis, constrictive pericarditis and restrictive cardiomyopathy.</li>
<li>Contraindicated in patients with A-V block and in those with dynamic outflow block such as hypertrophic cardiomyopathy. (Refer text for details).
(1) Congestive heart failure (CHF): Digoxin, by increasing the cardiac output, brings about more complete emptying of the ventricles during systole. This reduces pulmonary congestion and edema (relief from orthopnea, disappearance of basal rales) and reduces systemic venous pressure (disappearance of hepatojugular reflux). As a result of improved cardiac output, the compensatory circulation changes abate, providing further clinical relief. Thus, tachycardia improves and diuresis is established as a result of diminution in the augmented sympathetic drive and reduction in various hormonal levels in the blood.</li>
</ul>
<p>Digoxin has no place in treatment of acute heart failure associated with acute MI, acute onset mitral regurgitation and papillary muscle dysfunction. These conditions are best treated by reduction of afterload.</p>
<p>Studies have reconfirmed that although digoxin is not the first drug of choice in CHF, it is useful in improving the clinical status and LV dysfunction. The consensus is that:</p>
<ul>
<li>Digoxin (in maintenance doses <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.125</mn><mo>−</mo><mn>0.25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">0.125-0.25 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.125</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day) is an effective, generally safe and inexpensive drug for the relief of symptoms of CHE It prevents worsening of heart failure, improves exercise tolerance and reduces the repeated hospitalisation.</li>
<li>However, it does not alter the natural history of the disease nor does it substantially increase survival, in contrast to ACEI; and</li>
<li>Maintenance of lower serum digoxin level ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1.0</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">0.5-1.0 \mathrm{mg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.0</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> ) is as effective as and much safer than higher levels.
Digoxin may be prescribed particularly in patients with persistent symptoms even after the ACEI, therapy.
(2) Left ventricular failure (LVF): Digoxin is helpful in the treatment of chronic, pure, left ventricular failure in patients with hypertensive or ischemic heart disease and aortic valve disease. It relieves orthopnoea. Hypertension if present, is treated with an antihypertensive drug. For acute LVF, see later.
(3) Atrial fibrillation (AF): Digoxin is indicated in (a) patients of AF with rapid ventricular rate; and (b) those with AF and cardiac failure, even if the heart rate is not rapid.</li>
</ul>
<p>The aim of digoxin therapy in patients with AF is to reduce the ventricular rate. If failure is present, digoxin relieves it. In the absence of failure, digoxin can protect the ventricles from too rapid atrial impulses by depressing conduction across the AV node and the AV bundle. The dosage should be adjusted to maintain a ventricular rate of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>80</mn><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">60-80 / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">80/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span> at rest and less than 100/min during physical activity. Verapamil or diltiazem IV is now preferred to digoxin in the absence of heart failure (28).</p>
<p>Electrical cardioversion is dangerous in patients with overt digoxin toxicity, who can develop fatal ventricular arrhythmias.</p>
<p>Digoxin is not indicated in patients with AF with normal ventricular rate. In such patients, warfarin is indicated to prevent stroke particularly in presence of risk factors</p>
<p>such as history of transient ischemic attacks, clinical heart failure, enlarged left atrium or impaired left ventricular function (Chapter 28).
(4) Atrial flutter: Digoxin corrects any associated cardiac failure and slows the ventricular rate. Propranolol can be added in patients resistant to digoxin. Atrial flutter is often converted into atrial fibrillation by digoxin, and its withdrawal at this stage may restore sinus rhythm.
(5) Paroxysmal atrial tachycardia (PAT): Digoxin is the drug of choice in the treatment of PAT - associated with heart failure. In patients without heart failure, other drugs such as verapamil/diltiazem/adenosine is preferred (Chapter 28). Physical measures such as pressure on the carotid sinus may occasionally be helpful. Digoxin terminates PAT probably by its indirect (vagal) action. It should be noted that digoxin therapy itself sometimes converts AF into PATB and hence, it is imperative to enquire about previous digitalisation before the institution of therapy. Spontaneous PAT without obvious cause could be benign but PATB induced by digoxin is a serious complication.</p>
<p>Digitalisation: The patient should be digitalised, avoiding even the mildest digoxin toxicity. This, however, may not always be possible. The important determinant of daily digoxin dose is the renal function. The therapeutic benefit, though proportionately smaller, comes even from partial digitalisation, because there is a linear dose-response relationship in the case of digoxin and there is no threshold for the positive inotropic effect of digoxin. Hence, except in special circumstances, the use of initial, large loading dose of digoxin should be avoided.</p>
<p>The recommended schedules for digoxin therapy are summarised in Table 31.11.</p>
<p>Table 31.11
Digoxin dosage (mg) in adults in heart failure</p>
<p>For routine, oral digitalisation: 0.25 mg once in 24 hours (maintenance dose); smaller doses in the the elderly and in those in renal failure; digitalisation occurs in 5-7 days. For rapid, oral digitalisation: Loading dose of 0.75 mg in 24 hours, followed by maintenance dose.
For IV digitalisation: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1.0</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.5-1.0 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1.0</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>.</p>
<p>In a patient with mild cardiac failure, especially when he is treated on an out-patient or domiciliary basis, digoxin should be administered in maintenance dose from the first day. Estimation of serum level may be useful for dose adjustment in renal failure.</p>
<p>A loading dose should be used only when it is necessary to digitalise a patient rapidly (in 24-36 hours) as in:</p>
<ul>
<li>Severe LVF; or</li>
<li>Acute heart failure due to paroxysmal atrial fibrillation with rapid ventricular rate.</li>
</ul>
<p>The loading dose, if used, should be three times the expected maintenance dose and should be given in divided doses in the first 24 hours. History of digoxin therapy should be enquired into before using the loading dose. A baseline ECG should be recorded.</p>
<p>IV digitalisation is a potentially dangerous procedure, to be employed only in emergency. The preparation to be administered should be diluted with normal saline and injected slowly over 10-15 min.</p>
<p>Bioavailability of digoxin may vary among different brands of tablets because of differences in the dissolution rates. Change to a different brand may suddenly increase the plasma level of digoxin and precipitate toxicity.</p>
<p>Once started, digoxin therapy is generally required for life in most patients.</p>
<p>Contraindications to digoxin therapy: The only absolute contraindication to digoxin therapy is digoxin toxicity. Except for partial and complete heart block and perhaps paroxysmal ventricular tachycardia, no other cardiac arrhythmia, unless digoxin induced, is a contraindication to digoxin therapy, and even in these cases, it may be used if CHF is present.</p>
<p>Ouabain (Strophanthin - G): Ouabain is a pure crystalline glycoside derived from the plant Strophanthus gratus. It is now rarely used.</p>
<p>Other inotropic agents: These agents stimulate the myocardium either by stimulating the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors or inhibiting the breakdown of cAMP by phosphodiesterase (aminophylline). Their usefulness is limited.</p>
<p>Beta-adrenergic agonists, dopamine and dobutamine increase myocardial contractility, particularly in selected patients with severe heart failure (Chapter 32).</p>
<p>AMRINONE: This bipyridine derivative is a non-adrenergic, positive inotropic agent. It acts by inhibiting cardiac phosphodiesterase activity. It increases the force of contraction and rate of shortening of the cardiac muscle. It is a vasodilator and, reduces peripheral resistance (ionodilator effect). It has been used in patients with refractory HF. A common adverse effect is dose related thrombocytopenia. The drug has no clear benefits over digoxin.</p>
<p>Milrinone has similar action as amrinone.
The inotropes such as dobutamine, dopamine and milrinone improve myocardial contractility by raising cardiac myocyte intracellular calcium. The heart rate and myocardial <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">O</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{O}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> consumption increased, which can exacerbate cardiac ischemia in CHF and may precipitate cardiac arrhythmias. Although, these agents increase the velocity and force of contraction, they do not increase but often shorten the duration of systole. Hence a new inotropic agent with novel mechanism of action has been developed.</p>
<p>Omecamtiv mecarbil: This new sarcomere directed drug, is a selective cardiac myosin activator. It increases myocardial contractility and stroke volume without increasing the calcium transit in myocytes and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">O</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{O}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> consumption, thereby improving myocardial efficiency. The effect is dose dependent. The duration of left ventricular systole is increased. As the heart rate is decreased, the duration of diastole is not much altered. As a result, the coronary flow and left ventricular filling is not much altered. Thus, omecamtiv mecarbil may be an useful inotropic agent in the treatment of chronic HF caused by left ventricular dysfunction. It is under evaluation.</p>
<p>Table 31.12 describes one of the proposed protocols for the management of heart failure. The effectiveness of therapy can be monitored by observing the following:</p>
<p>Table 31.12
Protocol for management of heart failure</p>
<table><thead><tr><th style="text-align: center;">Stage <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">§</mi></mrow><annotation encoding="application/x-tex">\S</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">§</span></span></span></span></span></th><th style="text-align: center;">Risk factors for heart failure*</th><th style="text-align: center;">Symptoms of heart failure**</th><th style="text-align: center;">Structural abnormalities in the heart <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mrow><mo>∗</mo><mo>∗</mo><mo>∗</mo></mrow></msup></mrow><annotation encoding="application/x-tex">{ }^{* * *}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6887em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6887em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∗∗∗</span></span></span></span></span></span></span></span></span></span></span></span></span></th><th style="text-align: center;">Treatment recommended</th></tr></thead><tbody><tr><td style="text-align: center;">A: High risk only</td><td style="text-align: center;">Present</td><td style="text-align: center;">Never</td><td style="text-align: center;">None</td><td style="text-align: center;">Treat risk factors &lt;br&gt; Patient education. ACEI or ARB in some patients</td></tr><tr><td style="text-align: center;">B: Asymptomatic LV dysfunction</td><td style="text-align: center;"></td><td style="text-align: center;">Never</td><td style="text-align: center;">Detectable</td><td style="text-align: center;">ACEI/ARB &lt;br&gt; + beta blockers for all.</td></tr><tr><td style="text-align: center;">C: Symptomatic heart failure</td><td style="text-align: center;"></td><td style="text-align: center;">Currently present or H/O such symptoms</td><td style="text-align: center;">Detectable</td><td style="text-align: center;">ACEI + beta blockers in all <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mi mathvariant="normal">/</mi><mo>−</mo></mrow><annotation encoding="application/x-tex">+/-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">+</span><span class="mord">/</span><span class="mord">−</span></span></span></span></span> Diuretics <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mi mathvariant="normal">/</mi><mo>−</mo></mrow><annotation encoding="application/x-tex">+/-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">+</span><span class="mord">/</span><span class="mord">−</span></span></span></span></span> Digoxin, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mi mathvariant="normal">/</mi><mo>−</mo></mrow><annotation encoding="application/x-tex">+/-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">+</span><span class="mord">/</span><span class="mord">−</span></span></span></span></span> ARB <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mi mathvariant="normal">/</mi><mo>−</mo></mrow><annotation encoding="application/x-tex">+/-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">+</span><span class="mord">/</span><span class="mord">−</span></span></span></span></span> Aldosterone antagonist <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mi mathvariant="normal">/</mi><mo>−</mo></mrow><annotation encoding="application/x-tex">+/-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">+</span><span class="mord">/</span><span class="mord">−</span></span></span></span></span> Vasodilator</td></tr><tr><td style="text-align: center;">D: End stage heart failure Advanced (HF)</td><td style="text-align: center;"></td><td style="text-align: center;">Refractory heart failure with marked symptoms at rest ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">E</mi><mi mathvariant="normal">F</mi></mrow><mo>&lt;</mo></mrow><annotation encoding="application/x-tex">\mathrm{EF}&lt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7224em; vertical-align: -0.0391em;"></span><span class="mord"><span class="mord mathrm">EF</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&lt;</span></span></span></span></span> <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> ) resistant to maximal therapy</td><td style="text-align: center;">Obvious</td><td style="text-align: center;">Difficult to treat &lt;br&gt; No beta blockers &lt;br&gt; May use inotropes &lt;br&gt; Ventricular assist device/Surgery</td></tr></tbody></table>
<p>Risk factor treatment and patient education is for all (A-D) groups.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo><mover><mo><mo>=</mo></mo><mn>5</mn></mover></mo><mo>=</mo></mrow><annotation encoding="application/x-tex">\stackrel{5}{=}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.118em;"></span><span class="mrel"><span class="mop op-limits"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 1.118em;"><span style="top: -3em;"><span class="pstrut" style="height: 3em;"></span><span><span class="mop">=</span></span></span><span style="top: -3.5669em; margin-left: 0em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">5</span></span></span></span></span></span></span></span></span></span><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span></span></span></span></span> Stages as per the guidelines of the American College of Cardiology and The American Heart Assocition.
*= Hypertension; Diabetes mellitus; Ischemic heart disease; Chronic lung disease; Heavy smoking/alcohol consumption; H/O rheumatic fever.
" <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span></span></span></span></span> Symptoms (current or past) of either left or right sided heart failure.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mrow><mo>∗</mo><mo>∗</mo></mrow></msup><mo>=</mo></mrow><annotation encoding="application/x-tex">{ }^{* *}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6887em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6887em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∗∗</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Cardiac chamber enlargement; Valvular heart disease; H/O myocardial infarction; Signs of left or right ventricular hypertrophy/failure.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="symptoms-and-signs-of-improvement">Symptoms and signs of improvement:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#symptoms-and-signs-of-improvement" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(a) Increased urinary output.
(b) Relief from fatigue, insomnia, orthopnoea and disappearance of basal rates.
(c) Improved exercise tolerance.
(d) Diminution in jugular venous pressure, hepatojugular reflux and in liver size.
(e) Disappearance of tachycardia and ventricular gallop; and
(f) Change of dry and paper like skin to normal, moist and elastic type.</p>
<p>Table 31.13 lists important points to remember in the management of systolic LV dysfunction.</p>
<p>Table 31.13
Points to remember in management of left ventricular systolic dysfunction</p>
<p><sup><a href="#user-content-fn-0" id="user-content-fnref-0-5" data-footnote-ref="true" aria-describedby="footnote-label">1</a></sup></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="management-of-acute-lvf">Management of Acute LVF<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#management-of-acute-lvf" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Acute left ventricular failure with pulmonary edema is a medical emergency and is treated with IV furosemide, nitrate and ACEI (Table 31.14). Management of acute HF has to be tailor-made guided by several factors such as concomitant diseases, left ventricular filling pressure and cardiac output and hence is better left to specialist.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-31-14">Table 31.14<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-31-14" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Management of acute LVF with pulmonary edema
<img src="assets/images/image-20251214-6bbb11d0.jpeg" alt="img-30.jpeg">
(a) The patient without hypotension is made to lie in a semi-upright position either by raising the head end of the bed or by using a back-rest, preferably with the legs hanging over the edge of the bed. Application of tourniquets to three limbs at a time, with rotation of the free limb every 15-20 minutes. This helps to pool the blood in the limbs to reduce venous return and the preload.
(b) Oxygen is administered at the rate of 6-8 litres a minute.
(c) Furosemide is injected IV in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>60</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">40-60 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">60</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>, repeated every 30 minutes until diuresis sets in. It acts by causing venodilatation, in addition to diuresis.
(d) Morphine IV 2 to 4 mg every 15 mins to a total of 15 mg is used. In addition to allaying anxiety and improving patient comfort, morphine also brings about peripheral pooling of blood by central reduction in sympathetic activity (Chapter 10).
(e) If the patient has associated bronchospasm, aminophylline is given IV in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>250</mn><mo>−</mo><mn>500</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">250-500 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">250</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">500</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> over 15 minutes, followed by an infusion.
(f) Sublingual NTG <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>0.4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(0.4 \mathrm{mg})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">0.4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mclose">)</span></span></span></span></span> is a first line therapy in acute HF. It temporarily reduces the pulmonary capillary pressure by producing venodilatation and may be repeated every 5 minutes three times. As NTG may cause severe hypotension in some patients BP, must be monitored regularly. In resistant cases, IV NTG (5-10 mcg/min) is administered provided there is no hypotension. Careful use of sodium nitroprusside infusion (as a balanced preload and afterload reducer) may be helpful in these patients but it requires the facilities of an intensive care unit.
(g) Low dose of short acting ACEI is initiated in hypertensive patients and those with acute MI with HF.
(h) If inotropic effect is desired, drugs such as dopamine or dobutamine may be preferred to digoxin. However, IV digoxin, 0.5 mg injected over 15 minutes, can be valuable in patients with atrial fibrillation or supraventricular tachycardia.</p>
<p>After resolution of acute heart failure, the patient should be investigated for possible cause of heart failure and treated accordingly.</p>
<p>Table 31.15 lists drugs to be avoided/used cautiously in CHF.</p>
<p>Table 31.15
Drugs to be avoided in CHF</p>
<ul>
<li>Antiarrhythmics except beta blockers and antiodarone</li>
<li>Calciumchannel blockers</li>
<li>NSAID</li>
<li>Glucocorticoids</li>
<li>Glitazones</li>
<li>Metformin</li>
<li>Cilostazol</li>
<li>Sildenafil</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="nonpharmacological-treatment-of-heart-failure">Nonpharmacological Treatment of Heart Failure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nonpharmacological-treatment-of-heart-failure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>This is outlined in Table 31.16.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-31-16">Table 31.16<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-31-16" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Nonpharmacological treatment of heart failure</p>
<ul>
<li>Salt and water restriction: advise sodium intake less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>3</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">2-3 \mathrm{~g} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span></span></span></span></span> day.</li>
<li>Weight reduction in the obese.</li>
<li>Cessation of smoking and alcohol consumption.</li>
<li>Limit physical activity in the acute phase of illness.</li>
<li>Stop any drug contributing to heart failure,
(Table 31.15).</li>
<li>Influenza and pneumococcal vaccination has been recommended.</li>
<li>Supervised rehabilitation therapy including regular graded physical exercise which improves peak exercise capacity and the quality of life.</li>
<li>Surgical treatment, when appropriate.</li>
</ul>
<p>Chronic heart failure in many cases is preventable by:</p>
<ul>
<li>Controlling risk factors such as hypertension, DM and correcting the structural anomalies like valve damage/stenosis</li>
<li>Controlling body weight and the sodium intake</li>
<li>Use of ACEI after MI and in patients with asymptomatic LV dysfunction</li>
<li>Avoidance of certain drugs</li>
</ul>
<p>32</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacotherapy-of-shock">Pharmacotherapy of Shock<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacotherapy-of-shock" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Shock may be defined as complex acute systemic circulatory failure associated with hypoperfusion of tissues, which is incompatible with life if untreated and persisting for more than a short time. It may be initiated by trauma, acute blood loss, depletion of body fluids, severe infection or acute myocardiac dysfunction. In these conditions, it may be mediated by one or more of the following mechanisms; of these, hypovolemia is the most important.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanisms-of-shock">Mechanisms of shock:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanisms-of-shock" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Hypovolemic: This may be defined as a reduction in the circulating blood volume, and can arise in many different ways. It evokes, through the baroreceptors, a generalised, compensatory sympatho-adrenal discharge and peripheral vasoconstriction. The latter is responsible for many of the clinical manifestations of shock. Though it helps to maintain the cardiac output and is important in short-term survival, it aggravates the hypovolemia by making the microcirculation very sluggish, pooling the blood in the periphery and thus reducing the effective intravascular volume.
The excessive sympatho-adrenal discharge causes a redistribution of the cardiac output with reduction in the blood flow to the skin, the intestines and the kidneys. The BP is stabilised but the tissue perfusion is impaired. Excessive vasoconstriction results in slowing of the blood flow, local hemoconcentration from loss of fluid from the capillaries into the tissues and in local formation of thrombi in the microcirculation. This causes tissue hypoxia leading to acidosis and to liberation of substances such as histamine, kinins, prostaglandins and cardiodepressant peptides into the circulation. Tissue hypoxia damages intracellular structures. The coronary filling is mainly diastolic and excessive fall in diastolic BP (together with cardiodepressant peptides) adds a cardiogenic element to any other variety of shock. Inadequate cerebral blood flow causes mental changes. Microcirculatory changes in the lungs lead to pulmonary odema (shock lung); this is abetted by neurogenic and mechanical factors leading to ventilatory failure and multiorgan dysfunction. Oligemic acute renal shut down completes the devastating picture.</li>
<li>Cardiogenic: This is due to failure of the heart as a pump as in acute myocardial infarction (MI). Rarely, in some cases, there is complete failure of the compensatory sympathoadrenal discharge.</li>
<li>Obstructive: Extracardiac obstructive diseases impair cardiac filling.</li>
<li>Distributive: In shock due to sepsis and burns, the peripheral resistance is initially low (warm shock); the cardiac output is elevated but is maldistributed exactly as in shock with low cardiac output, with all the disastrous consequences detailed above. In the later stages, the cardiac output falls and the peripheral resistance rises markedly.
The septic shock is initiated by the toxins released by the micro-organisms: exotoxins (as in the case of Toxic Shock Syndrome (TSS) due to staphylococci or streptococci); or endotoxins (as with Gram-negative bacilli). These toxins cause the release of tumour necrosis factor alpha (TNF alpha) and a variety of interleukins especially IL-1 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>, and the platelet activating factor (PAF) from the mononuclear phagocytes and the endothelial cells. These cytokines cause a further cascade of synthesis and release of substances</li>
</ul>
<p>such as leukotrienes, PGs and thromboxane <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">A</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{A}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">A</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. They injure the vascular endothelium, increase its permeability, and cause fluid loss from the circulation leading to
hypovolemia. They also depress the myocardium. Diffuse cell injury results in multiple organ failure. Many patients with septic shock have partial adrenocortical insufficiency. Distributive shock may also occur following anaphylaxis and spinal cord or neurologic injury.
The clinical picture of shock is variable but generally consists of pallor, sweating, cold extremities, rapid and thready pulse and air hunger, all due to the sympatho-adrenal discharge. Cyanosis of the extremities may be present. Rarely, the extremities are warm (even in the absence of fever) whereas the circulation to the vital organs may be critically compromised. Oliguria (urine output less than 25 ml per hour for 4 hours or less than 500 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mn>24</mn></mrow><annotation encoding="application/x-tex">\mathrm{ml} / 24</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/24</span></span></span></span></span> hours in adults), mental changes (somnolence, confusion, restlessness), acidosis and a marked difference in the temperature between the rectum and the skin are all indicators of reduced cardiac output and reduced tissue perfusion. Central venous pressure (CVP) is the best guide to hypovolemia. If it is low to begin with and fails to rise during intravenous infusion of fluid at the rate of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">10-20 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> per minute for 10-15 minutes, hypovolemia can be diagnosed. If during such infusion, the CVP exceeds 15 cm of water or rises more than 5 cm of water over the basal level, pump failure is a major component of the shock. In patients with chronic lung disease and after acute MI, CVP does not truthfully reflect left ventricular filling pressure. In such patients monitoring of pulmonary artery occlusive pressure (PAOP) is a better index of left ventricular filling pressure.</p>
<p>By the time the BP falls, there is already a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> deficit in the effective intravascular volume and hence an attempt should be made to diagnose and treat shock before the BP falls significantly. The femoral pulses are the best guide to the level of arterial pressure, since they are weak in hypotension but bounding in the presence of peripheral vasoconstriction with adequate arterial pressure. On the other hand, thready or absent radial or brachial pulses may be due to either severe hypotension or to reduction in extremity blood flow due to peripheral vasoconstriction. A low BP recorded by means of a blood pressure cuff has the same significance as weak brachial or radial pulses.</p>
<p>Arterial hypoxemia (reduced <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PaO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PaO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ), lactic acidosis and acidemia are the biochemical reflections of severe tissue hypoxia. It is customary to talk about 'irreversible' shock when the latter does not respond easily to treatment. It may be better to give up this term which admits defeat and call it 'refractory'.</p>
<p>Successful management of circulatory failure aims at:</p>
<ul>
<li>Early recognition of the shock state.</li>
<li>Correction of the initiating insult (defibrillation, antibiotics, hemostasis, IV fluids, surgical removal of necrotic tissue).</li>
<li>Treatment of secondary consequences of shock (e.g., acidosis, hypoxemia).</li>
<li>Maintenance of function of vital organs (e.g., cardiac output, B.P., urine output); and</li>
<li>Identification and treatment of aggravating factors.</li>
</ul>
<p>All the five factors must be handled concurrently.
Hemodynamic and biochemical monitoring of the patients response to treatment is critical to success of the treatment and need repeated monitoring.</p>
<p>Restoration of blood volume: Since increased blood flow to vital organs increases the likelihood of survival, therapy should augment cardiac output. This is best achieved by</p>
<p>restoring the intravascular blood volume as quickly as possible and may be the only treatment necessary, except in shock due to MI where the function of the heart itself is impaired. Fluid administration should be monitored by measurement of CVP and mean arterial BP. Rise in CVP without a corresponding rise in arterial blood pressure during IV fluid therapy denotes an overloading of the circulation. To avoid such overloading, CVP should be maintained below 15 cm of water.</p>
<p>Fluids used for volume replacement are:
I Whole blood and plasma
II Colloidal plasma substitutes: Dextran, Hydroxyethyl starches, Polyvinylpyrrolidone and Oxypolygelatin.
III Crystalloid plasma substitutes: Normal saline (sodium chloride solution) and 5% Dextrose solution.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="whole-blood-plasma-and-plasma-fractions">Whole Blood, Plasma and Plasma Fractions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#whole-blood-plasma-and-plasma-fractions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>BLOOD obtained from donors by aseptic technique, is preserved with either CPD (citrate-phosphate-dextrose) or CPDA (citrate-phosphate-dextrose-adenine) solution. Blood is stored at a constant temperature between <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>2</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">2^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord">2</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>6</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">6^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord">6</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span>; storage below <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>2</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">2^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord">2</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> damages the RBC. It is vital to maintain the temperature constantly below <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>6</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">6^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord">6</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> to prevent the multiplication of bacterial contaminants. However, some bacilli can multiply even at a temperature below <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>6</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">6^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord">6</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> if they have previously been stimulated by exposure to a higher temperature. As the degree of hemolysis produced by such organisms is too insignificant for detection, a bottle once taken out from the refrigerator and exposed to room temperature for 30 minutes or more should be discarded.</p>
<p>The straw colour of the supernatant plasma serves as a convenient indicator to judge the suitability of blood sample for use. Pink or red stained plasma indicates hemolysis.</p>
<p>The expiry date for blood preserved in CPD solution is 21 days and that for blood stored in CPDA solution is 35 days; however, the local FDA regulations must be followed in this matter. Blood should not be used after the stipulated period as the fragility of the erythrocytes increases after that period. Supernatant plasma, however, is stable and can be used. In the absence of an unusual hemolytic state or factor, the transfused erythrocytes have an average life of 4 months.</p>
<p>While transfusing whole blood, care must be taken to use only blood belonging to the same ABO blood group but preferably not from a genetically related donor (see GVHD below). While using packed red blood cells, it is permissible to transfuse cells from an O group person (universal donor) into a person with any ABO group; similarly a person with AB group may receive packed RBCs from a donor of any ABO group. Rh positive blood should not be given to Rh negative individual if it can be avoided; at least, it should not be repeated in a Rh negative individual who has received Rh positive blood transfusion previously.</p>
<p>Autologous blood transfusion: Blood collected from a patient awaiting elective surgery which is likely to require a blood transfusion, can be infused back into the donor, when the need arises. The main advantages of this procedure are avoidance of immunological mismatch and/or disease transmission; and conservation of the available blood resources. The disadvantages are reinfusion of contaminants, dilutional coagulopathy and undesired infusion of anticoagulants; further, hemolysed red cells in the blood may cause renal insufficiency.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="indications-for-blood-transfusion">Indications for blood transfusion:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#indications-for-blood-transfusion" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(1) Acute hemorrhage: Assessment of blood loss is relatively easy in case of external injuries or gynaecological emergencies. Many times, however, one has to rely mainly on clinical signs such as pallor, tachycardia and hypotension to gauge the degree of blood loss.</p>
<p>While treating acute blood loss, an attempt should be made to maintain:
(a) Blood volume at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> or more of normal;
(b) Hemoglobin level of at least <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">10 \mathrm{~g} / \mathrm{dl}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">dl</span></span></span></span></span></span>;
(c) Total serum proteins level of at least <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> of normal;
(d) Platelets above 50,000/cu mm; and
(e) Plasma coagulation factors above <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>35</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">35 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">35%</span></span></span></span></span> of normal. When the blood loss is mild ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> or less of the total blood volume) a crystalloid solution (see later) should be infused in</p>
<p>amounts 3-4 times the estimated blood loss. For moderate blood loss (26-50% of the total blood volume), colloid plasma expanders may be adequate. For larger estimated blood losses, either packed blood cells or whole blood are needed to achieve adequate tissue oxygenation; this may be in addition to crystalloid and colloid solutions.
Adequacy of transfusion can be judged clinically from the reappearance of colour and warmth in the patient, filling of veins and the improvement in pulse and BP.
(2) To provide leucocytes in cases of agranulocytosis: Fresh blood is preferred as the leucocytes deteriorate on storage.
(3) Anaemia: See later
(4) Intrauterine transfusion: To reduce mortality in erythroblastosis foetalis.</p>
<p>In the past, whole blood transfusions were used to provide RBCs, platelets and clotting factors as indicated e.g. anaemia, thrombocytopenia or bleeding disorders. However, all these uses have been superseded by use of multiple components like packed red cells, platelet concentrates and clotting factors isolated from whole blood. Thus the donated blood can be used optimally on fractionation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="complications-of-blood-transfusion">Complications of blood transfusion:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#complications-of-blood-transfusion" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Nonhemolytic pyrexial reaction: Rigor, a common manifestation, is mostly due to imperfect sterilisation of the apparatus. In the event of a rigor, the transfusion should be stopped. The patient is covered with blankets. In severe cases aspirin, anti-histaminics and glucocorticoids are employed. Usually, it is due to pyrogens but occasionally it can be caused by antibodies against antigens on donor leucocytes or platelets, stimulated by a previous transfusion or pregnancy.</li>
<li>Allergy: It is mandatory to enquire about previous history of urticaria in the donor to prevent this complication. Antihistaminics and adrenaline are used to treat this manifestation.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="air-embolism">- Air embolism.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#air-embolism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>
<p>Heart failure due to hypervolemia and circulatory overload.</p>
</li>
<li>
<p>Transmission of disease: (i) Acute viral hepatitis B or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="bold">C</mi></mrow><annotation encoding="application/x-tex">\mathbf{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6861em;"></span><span class="mord mathbf">C</span></span></span></span></span> is one of the most serious adverse reactions. Type C virus is the infective agent most frequently transmitted by blood. (ii) Acquired immuno-deficiency syndrome (AIDS) due to HIV. (iii) Syphilis. Treponema pallidum does not survive refrigeration for more than three days. In an emergency, prophylactic use of penicillin can prevent this complication. (iv) Malaria.
There is also the possibility of the recipient being harmed if the donor has received certain medications in recent or remote past. Blood for homologous transfusion should not be collected if the prospective donor has been given:
(a) A blood transfusion or a blood product or any hormone derived from the human pituitary, ever in the past;
(b) Isotretinoin or etretinate (Chapter 71) in the past 3 years;
(c) Rabies vaccine in the past one year;
(d) Any other vaccine in the past 4 weeks;
(e) An antiplatelet agent such as aspirin or another NSAID (Chapter 11), clopidogrel or ticlopidine (Chapter 33), in the past 7 days, especially if the recipient requires platelets;
(f) An androgen or a antiandrogen, especially one with long half life (danazol or cyproterone acetate); or
(g) Is currently taking any drug.</p>
</li>
<li>
<p>Hemolytic reaction due to mismatched transfusion is characterised by rigor, pain in loins, jaundice, hemoglobinuria, oliguria, bleeding and coma. The treatment of an acute hemolytic reaction is aimed at prevention of acute renal shut down. Mannitol 20 g (20%) should be administered rapidly, to initiate diuresis. If diuresis occurs, it should be maintained at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">100 \mathrm{ml} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span></span></span></span></span> hour by giving normal saline, and IV furosemide, and by maintaining BP above 100 mm systolic. Alkalinising the urine with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi></mrow></mrow><annotation encoding="application/x-tex">40-50 \mathrm{mE}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm">mE</span></span></span></span></span></span> moles of sodium bicarbonate, given IV, helps to hasten the excretion of free hemoglobin. If diuresis fails to occur, patient is treated for acute renal failure.</p>
</li>
<li>
<p>Hyperkalemia: Storing of blood at a temperature below <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>6</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">6^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord">6</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> causes an efflux of potassium from erythrocytes into the plasma. When the blood is brought back to room temperature, potassium re-enters the erythrocytes. Failure to re-warm the blood to room temperature may lead to hyperkalemia.</p>
</li>
<li>
<p>Graft-versus-host disease (GVHD) in which the donor lymphocytes attack and damage the host immune system. The mortality rate is high. It may be prevented either by avoiding transfusing blood from a genetically related donor or by irradiating such blood before transfusing it.</p>
</li>
<li>
<p>Iron overload can occur in an adult after he/she has received 60-210 (mean 120) units of blood. It is successfully treated by iron chelation (Chapter 34).</p>
</li>
<li>
<p>Citrate intoxication leading to cardiac irregularities and metabolic alkalosis due to metabolic conversion of citrate to bicarbonate, is a rare complication seen only after massive blood transfusions (more than 5 units of blood).
Other complications after massive blood transfusion are: hypocalcemia; hyperkalemia; pulmonary insufficiency with adult respiratory distress syndrome (due to debris comprising of platelets, leucocytes and fibrin, in the stored blood); hypothermia (if blood is transfused without warming it to body temperature); and hemorrhagic diathesis (due to dilution of platelets and clotting factors in patient's own blood or due to disseminated intravascular coagulation).
Due to these complications of whole blood transfusion, when oxygen replacement is required, RBC replacement is always preferable to whole blood.
PACKED RED CELLS can be transfused when it is desired to increase the oxygen carrying capacity of blood without increasing its volume. A packed red cell preparation is made by removal of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> of the supernatant plasma. The red cell content of the remaining packed cells should be at least 5.5 million cmm . Concentrated red cells have to be infused within twelve hours of preparation. There are less blood group antibodies in packed cells, so non-group specific blood i.e. O negative blood can be given to patients with other groups. In addition, chances of anaphylactic reactions are less.
Indications for packed red cell transfusion:</p>
</li>
<li>
<p>Anaemia:
(a) Symptomatic anaemia with haemoglobin below <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>8</mn><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">m</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&lt;8 \mathrm{gm} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">8</span><span class="mord"><span class="mord mathrm">gm</span></span><span class="mord">%</span></span></span></span></span> )
(b) Aplastic and refractory anemias.
(c) Thalassemia and other haemolytic anemias.
(d) Cases of dyshaemopoiesis.
(e) As a pre-operative measure.</p>
</li>
</ul>
<p>One unit of packed red cells has haematocrit of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>65</mn><mo>−</mo><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">65-70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">65</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> which raises haematocrit of the recipient by approx. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">3 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">3%</span></span></span></span></span> and and Hb by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">m</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \mathrm{gm} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm">gm</span></span><span class="mord">%</span></span></span></span></span>. The amount of packed cells administered</p>
<p>should not exceed 500 ml at a time. In chronic severe anemia and in sepsis, the myocardium is on the verge of ischemia, and the rate of transfusion should not exceed 1015 drops per minute. Failure to observe this precaution may result in heart failure. The amount administered in children under 25 kg is usually <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">15 \mathrm{ml} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> of body weight while 10 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{ml} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> are administered in premature infants.</p>
<p>When selective component replacement is necessary then plasma fractions are preferred; however, plasma also can be used.</p>
<p>PLASMA: Fresh plasma is prepared by separating a single unit ( 350 ml ) of blood immediately after collection, for immediate infusion; and fresh-frozen plasma (FFP) is prepared by separating a single unit of blood within 6 hours of collection and then storing the plasma at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><msup><mn>30</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">-30^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord">−</span><span class="mord">3</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> or lower. Fresh plasma and FFP contain all the stable proteins (albumin, globulin) and the coagulation factors including Factor VIII, factor IX and vWF; their main use is to treat/prevent bleeding due to deficiencies of coagulation factors.</p>
<p>FFP is administered as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mo>−</mo><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">12-15 \mathrm{ml} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">12</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>. It should be transfused immediately after thawing or else it should be stored at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><msup><mn>6</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">1-6^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord">6</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> after thawing but should be used within 24 hours. Ideally, ABO compatibility of FFP should be matched with the recipient. However, Group AB plasma is a neutral plasma and hence is considered as universal for all the blood groups. Prothrombin time or partial thromboplastin time should be monitored and should not be allowed to go beyond 1.5 times the normal.</p>
<p>Plasma can also be prepared by separating stored blood within five days after its expiry date; it may be prepared by separating single units of blood individually; or by first mixing together blood of many donors (preferably small in number, say 10-12), and then separating that mixture. Such plasma may then be freeze dried and stored. Plasma prepared in this last manner lacks the labile coagulation factors but has the advantage of easy and prolonged storage upto 5 years. The use of pooled plasma is, however, discouraged because of the statutory requirement of sterilising it free of viruses. The use of plasma merely to maintain blood volume is not recommended.</p>
<p>NORMAL HUMAN SERUM ALBUMIN: This sterile preparation is obtained from human whole blood. It is used to raise the serum protein and reduce edema level in hypoproteinemia, in hypovolemic shock, and as a vehicle for transfusing packed red cells. It is usually non-toxic and does not interfere with normal coagulation. The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> solution is given undiluted usually at a rate of 2 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">4 \mathrm{ml} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>. The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> solution can be administered undiluted or diluted with sterile saline or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> dextrose. Undiluted solution is used to treat the presence of edema. In patients with low cardiac reserve, the rate of administration should be slow, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(1 \mathrm{ml} / \mathrm{min})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">1</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span><span class="mclose">)</span></span></span></span></span>.</p>
<p>PLASMA FRACTIONS: Plasma may also be used, by fractionating it, to prepare:</p>
<ul>
<li>Individual coagulation factor concentrates, such as prothrombin complex concentrate, Factor VIII concentrate, to treat deficiencies of specific factors;</li>
<li>Human gamma globulin;</li>
<li>Fibrinogen;</li>
<li>Human and bovine thrombin, and</li>
<li>Human fibrin foam</li>
</ul>
<p>These are discussed elsewhere.</p>
<ul>
<li>Platelet concentrates are discussed in Chapter 35.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="colloidal-plasma-expanders">Colloidal Plasma Expanders<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#colloidal-plasma-expanders" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Colloidal plasma expanders are substances of relatively high molecular weight, which, when infused, remain in circulation and augment the blood volume by increasing its oncotic pressure.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="requirements-of-an-ideal-plasma-expander">Requirements of an ideal plasma expander:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#requirements-of-an-ideal-plasma-expander" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(a) It should have an oncotic pressure comparable to that of plasma.
(b) It should remain in the circulation for an adequate period and yet be eventually disposed of by metabolic degradation/excretion.
(c) It should not affect any visceral function adversely and should not have antigenic, allergenic or pyrogenic effects.
(d) It should not interfere with blood grouping or cross-matching.
(e) It should remain stable over a long period and at usual variations in environmental temperature. It should be easily sterilised and have a viscosity suitable for infusion. (f) It should be easily available.</p>
<p>The plasma expanders are used to treat oligemic shock when blood and plasma are not available immediately. The colloidal plasma expanders are:</p>
<p>DEXTRAN: Dextran is isolated from beet root, where it is formed by the action of a contaminating bacterium Leuconstoc mesenteroides. Native dextran has a very high molecular weight ( 40 million) and from it can be prepared low molecular weight dextrans. Those used in therapeutics are Dextran 70 (Macrodex, M.W. 70,000) and Dextran 40 (Lomodex, M.W. 40,000). Dextran 70 is available as a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">6 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">6%</span></span></span></span></span> solution and Dextran 40 as a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> solution, in either isotonic saline or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> dextrose. They are infused in the dose of 10 ml per kg body weight.</p>
<p>The oncotic pressure of dextrans is similar to that of plasma proteins and they persist in the plasma with an effective half life of about 24 hours. The dextrans also inhibit rouleaux formation by RBCs and have an antisludging effect on blood; they are claimed to improve the microcirculation independently of volume expansion. They may not interfere with typing, crossmatching or Rh determination. However, they coat the platelets and coagulation factors, and interfere with their function. In large doses, dextrans can cause widespread hemorrhages.</p>
<p>Dextran 70 tends to be retained in the body especially in the liver and the reticuloendothelial system. Dextran 40 is rapidly excreted by the kidneys; as much as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> is excreted in 24 hours and the remainder in 4-7 days. Dextran molecules not excreted are slowly degraded enzymatically to glucose over a period of weeks. Dextrans are potent antigens especially when administered SC in small doses. However, administration of massive doses IV does not induce antibody formation, probably because of immunological paralysis. Allergic reactions including fatal shock are seen in about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> of persons, including those who have never received it in the past.</p>
<p>During its excretion through the renal tubules, dextran 40 can clog them and is known to precipitate acute oliguric renal failure which is gradual in onset (3-6 days) and hence may be missed initially. In order to guard against such possibility; dextran should not be used: (a) In quantities larger than 1 litre <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(20 \mathrm{ml} / \mathrm{kg})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">20</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mclose">)</span></span></span></span></span> on day one and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">10 \mathrm{ml} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day on subsequent days.
(b) If the urine output is less than 1500 ml per day or the blood urea is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">60 \mathrm{mg} / \mathrm{dl}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">60</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">dl</span></span></span></span></span></span> or higher.</p>
<p>(c) If the urine output drops further or the specific gravity of the urine rises above 1045 during its administration; in such cases an attempt may be made to keep the urine output high with the use of diuretics and a high fluid intake; and
(d) For more than 5 days.</p>
<p>They are contraindicated in those who are known to be allergic to them; in patients in heart failure; in existing or threatened acute oliguric renal failure; and in patients with hypofibrino-genemia or marked thrombocytopenia.</p>
<p>Dextrans can be easily sterilised by either filtration or autoclaving. They can be stored without any special precautions for upto 10 years and thus can be stockpiled for emergency use.</p>
<p>HYDROXYETHYL STARCHES: Addition of hydroxyethyl groups to starch molecules makes them resistant to hydrolysis by amylase and prolongs their intravascular half-life. One preparation (Hetastarch, Expan, MW 450,000) of hydroxyethyl starch has been extensively tried in treating shock. Compared to dextrans, hetastarch:</p>
<ul>
<li>Maintains blood volume longer</li>
<li>Is non-allergenic; and</li>
<li>Does not cause acute renal failure or coagulation disturbances</li>
</ul>
<p>POLYVINYLPYRROLIDONE (PVP): This is a synthetic, water soluble, hydrophilic polymer of heterogenous molecular sizes with a molecular weight between 35,000 and 40,000. It is given IV, as a clear, amber coloured, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> solution in buffered normal saline.</p>
<p>It is rapidly excreted; 50 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">75 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">75%</span></span></span></span></span> of the dose is recovered from the urine within 48 to 72 hours. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> is excreted in bile. The remainder (fraction of molecular weight above 120,000 ) is not metabolised and is stored in the skin, skeletal muscle and the reticuloendothelial system.</p>
<p>PVP may interfere with antibody formation. It can bind to drugs like penicillin and insulin and has a tendency to produce agglutination of erythrocytes. Hence, it interferes with blood grouping. It is now less used.</p>
<p>GELATIN POLYMERS: Various gelatin polymers have been investigated as plasma substitutes. One such polymer of degraded gelatin available commercially (Haemaccel) is a polypeptide with molecular weight of about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo separator="true">,</mo><mn>000</mn><mo>−</mo><mn>35</mn><mo separator="true">,</mo><mn>000</mn></mrow><annotation encoding="application/x-tex">30,000-35,000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">30</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">35</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000</span></span></span></span></span>. It is dissolved in an electrolyte solution with the final pH of the infusion 7.2-7.3. In this state, it can remain stable for 3 years at room temperature. Given IV, its mean serum half life is 4 to 5 hours. Approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60-80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> of the gelatin is excreted unchanged by the kidneys. The preparation exerts osmotic activity similar to that of albumin.</p>
<p>It does not interfere with coagulation, blood grouping and cross matching and is nonantigenic. Occasionally, it may cause flushing, urticaria and rigors. Bronchospasm and hypotension can occur. It is available as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">3.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">3.5%</span></span></span></span></span> gelatin polymer in 500 ml .</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="crystalloid-plasma-expanders">Crystalloid Plasma Expanders<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#crystalloid-plasma-expanders" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Crystalloids are solutions containing salts or other water-miscible agents. They can freely cross biological barriers to enter interstitial tissue and hence, their effects are not restricted within vessels.</p>
<p>NORMAL SALINE, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.9</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.9 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.9%</span></span></span></span></span>, is the most widely used IV preparation. As its osmolality (308 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">O</mi><mi mathvariant="normal">s</mi><mi mathvariant="normal">m</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{mOsm} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">mOsm</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> ) matches that of serum, it is an excellent fluid for volume replacement. It distributes itself in the extracellular space, and infusion of 1 litre of normal saline raises the blood volume by about 300 ml . It is mainly useful to replace lost sodium, chloride and water, particularly in cases of dehydration for emergency correction of hypovolemia e.g. hemorrhage, burns, diarrhoea. It is also used as a vehicle for giving IV drugs by drip. Though it is adequate to raise the effective blood volume and BP in emergencies, it leaves the blood rapidly and hence, has a short duration of effect. Too rapid administration of large amounts can produce pulmonary edema. The febrile reaction that occur is usually due to the presence of pyrogens.</p>
<p>It is important to note that noradrenaline is unstable at the neutral pH of normal saline but is stable at the acidic pH of dextrose solution.</p>
<p>Hypertonic Saline: see Chapter 37
Hypotonic Saline ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.45</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.45 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.45%</span></span></span></span></span> ): it is used to treat:
(a) Hypernatremia with extracellular volume depletion and
(b) Hyperosmolar state with severe hyperglycemia ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.45</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.45 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.45%</span></span></span></span></span> saline with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> dextrose).</p>
<p>DEXTROSE 5% in water: When the glucose metabolism is normal, this solution is equivalent to administration of water alone. As its osmolality is lower than that of serum, it is not optimum for volume replacement. Water distributes itself in the total body water, and infusion of 1 litre of dextrose in water raises the blood volume by about 100 ml only. It is particularly useful when the kidney function is impaired. It supplies nutrition. It can be used as a vehicle for drugs, especially noradrenaline. However, phenytoin should not be infused in glucose-containing fluids.</p>
<p>In general, colloids are superior to crystalloids in maintaining blood volume. But they are expensive and they may not always be available. Hence <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.9</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.9 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.9%</span></span></span></span></span> sodium chloride or Ringerlactate is used commonly.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cardiovascular-drugs-in-shock">Cardiovascular Drugs in Shock<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cardiovascular-drugs-in-shock" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The major cardiovascular drugs used in shock are summarised in Tables 32.1 and 32.2.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-32-1">Table 32.1<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-32-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="actions-of-drugs-used-in-shock">Actions of drugs used in shock<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#actions-of-drugs-used-in-shock" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<table><thead><tr><th style="text-align: center;">Drug</th><th style="text-align: center;">Receptors</th><th style="text-align: center;"></th><th style="text-align: center;"></th><th style="text-align: center;"></th></tr></thead><tbody><tr><td style="text-align: center;"></td><td style="text-align: center;">Dopamine</td><td style="text-align: center;">Beta,</td><td style="text-align: center;">Beta,</td><td style="text-align: center;">Alpha</td></tr><tr><td style="text-align: center;">Adrenaline <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi>a</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{a}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6644em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6644em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">a</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">-</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Noradrenaline <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>a&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {a }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6644em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6644em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">a&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">-</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">-</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;">(small doses)</td><td style="text-align: center;"></td><td style="text-align: center;">(large doses)</td></tr><tr><td style="text-align: center;">Dopamine</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">-</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Dobutamine</td><td style="text-align: center;">-</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mrow><mo fence="true">∣</mo><mtext> </mtext><mfrac><mn>101</mn><mn>2</mn></mfrac></mrow></mrow><annotation encoding="application/x-tex">++\left\lvert\, \frac{101}{2}\right.</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1.2em; vertical-align: -0.35em;"></span><span class="minner"><span class="mopen"><span class="delimsizing mult"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.85em;"><span style="top: -2.85em;"><span class="pstrut" style="height: 3.2em;"></span><span style="width: 0.333em; height: 1.2em;"><svg xmlns="http://www.w3.org/2000/svg" width="0.333em" height="1.200em" viewBox="0 0 333 1200"><path d="M145 15 v585 v0 v585 c2.667,10,9.667,15,21,15
c10,0,16.667,-5,20,-15 v-585 v0 v-585 c-2.667,-10,-9.667,-15,-21,-15
c-10,0,-16.667,5,-20,15z M188 15 H145 v585 v0 v585 h43z"></path></svg></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.35em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.8451em;"><span style="top: -2.655em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.394em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">101</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.345em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Phenylephrine</td><td style="text-align: center;">-</td><td style="text-align: center;">-</td><td style="text-align: center;">-</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Isoprenaline</td><td style="text-align: center;">-</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">-</td></tr><tr><td style="text-align: center;">Glucagon: Positive inotropic and chronotropic action independent of beta-adrenergic receptors.</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr></tbody></table>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi>a</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{a}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6644em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6644em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">a</span></span></span></span></span></span></span></span></span></span></span></span></span> Low doses elevate systolic and decrease diastolic pressure; higher doses elevate both.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>a&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {a }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6644em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6644em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">a&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> Both systolic and diastolic pressures elevated.
The action of dopamine varies with the dose. See Table 18.6 in Chapter 17.
Dobutamine is a more potent ionotropic agent than isoprenaline.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-32-2">Table 32.2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-32-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="principles-of-management-of-shock">Principles of management of shock<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#principles-of-management-of-shock" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<table><thead><tr><th style="text-align: center;">Treatment</th><th style="text-align: center;">Hypovolemic shock</th><th style="text-align: center;">Endotonic shock</th><th style="text-align: center;">Cardiogenic shock</th><th style="text-align: center;">Anaphylactic shock</th></tr></thead><tbody><tr><td style="text-align: center;">Volume replacement</td><td style="text-align: center;">Yes</td><td style="text-align: center;">Yes</td><td style="text-align: center;">Usually no</td><td style="text-align: center;">Possibly</td></tr><tr><td style="text-align: center;">Dopamine</td><td style="text-align: center;">Yes</td><td style="text-align: center;">Yes</td><td style="text-align: center;">Yes</td><td style="text-align: center;">Possibly</td></tr><tr><td style="text-align: center;">Dobutamine</td><td style="text-align: center;">Possibly</td><td style="text-align: center;">Yes</td><td style="text-align: center;">Yes</td><td style="text-align: center;">No</td></tr><tr><td style="text-align: center;">Noradrenaline (only if severely hypotensive)</td><td style="text-align: center;">Yes</td><td style="text-align: center;">Yes</td><td style="text-align: center;">Yes</td><td style="text-align: center;">Yes</td></tr><tr><td style="text-align: center;">Adrenaline</td><td style="text-align: center;">No</td><td style="text-align: center;">No</td><td style="text-align: center;">No</td><td style="text-align: center;">Drug of choice</td></tr><tr><td style="text-align: center;">Vasodilators (Sodium nitroprusside, nitroglycerine)</td><td style="text-align: center;">Possibly</td><td style="text-align: center;">No</td><td style="text-align: center;">Possibly</td><td style="text-align: center;">No</td></tr><tr><td style="text-align: center;">Phenylephrine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mo lspace="0em" rspace="0em">∗</mo></msup></mrow><annotation encoding="application/x-tex">{ }^{*}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6887em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6887em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∗</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">No</td><td style="text-align: center;">Sometimes</td><td style="text-align: center;">No</td><td style="text-align: center;">Sometimes</td></tr><tr><td style="text-align: center;">Glucocorticoids</td><td style="text-align: center;">In Addison's disease</td><td style="text-align: center;">Yes</td><td style="text-align: center;">No</td><td style="text-align: center;">Yes</td></tr><tr><td style="text-align: center;">Antihistaminics</td><td style="text-align: center;">No</td><td style="text-align: center;">No</td><td style="text-align: center;">No</td><td style="text-align: center;">Yes</td></tr></tbody></table>
<p>Isoprenaline is useful in toxicity due to beta blockers if bradycardia is the main problem (atropine may also be used for the same purpose); glucagon, dopamine and dobutamine are useful if hypotension is the main problem.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>7</mn></msup></mrow><annotation encoding="application/x-tex">{ }^{7}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">7</span></span></span></span></span></span></span></span></span></span></span></span></span> May also be used along with dopamine.
"Also useful in spinal shock.
Dopamine is indicated for reversing hypotension following MI, trauma, sepsis, kidney failure, overt heart failure and chronic CHF, when volume resuscitation is unsuccessful. For dobutamine, see Chapter 18. Noradrenaline may be required for severe hypotension. The other drugs used are mephentermine, metara-minol and methoxamine (Chapter 18).</p>
<p>Mephentermine acts chiefly by increasing the cardiac output. Metaraminol acts like NA but is less potent. As it acts by releasing NA from the nerve endings, prior treatment with reserpine (which depletes catecholamine stores) makes the patient unresponsive to this drug. Methoxamine, being a pure alpha adrenergic stimulant, is useful only in neurogenic shock. Correction of acidosis restores sensitivity to the sympathomimetics.</p>
<p>The main problem with sympathomimetics is the loss of responsiveness to them, apparently due to downregulation of adrenergic receptors, which may become evident within 8 hours of continuous infusion. Therefore, some workers recommend their intermittent use in shock.</p>
<p>Except as a desperate resuscitative measure, the use of vasopressors should be preceded by expansion of intravascular volume. The systolic blood pressure should be maintained around <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mo>−</mo><mn>100</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">90-100 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">90</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span> (or in previously hypertensive patients, 30 mm Hg below their usual pressure) during vasopressor infusion, as at infusion rates needed to raise the pressure higher, peripheral resistance rises disproportionately and compromises tissue perfusion. Use of isoprenaline should be monitored by PAOP measurement and measurement of arterial BP; heart rate over 120/minute may cause cardiac arrhythmias and should be avoided.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="treatment-of-shock">Treatment of Shock<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment-of-shock" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Clinically, shock can be classified as:
I Hypovolemic or oligemic shock due to
(a) Acute loss of plasma or blood as in burns and hemorrhage; or
(b) Due to dehydration and sodium depletion as in excessive vomiting, diarrhoea, diabetic ketoacidosis and Addison's disease.
II Bacteremic endotoxic or septic shock produced as a result of severe infection usually with gram negative bacteria like E. coli. Gram positive organisms, particularly resistant staphylococci, can also produce shock by releasing an exotoxin called toxic shock syndrome toxin-1 (TSST-1) into the circulation. Deficiency of adrenal gland function and vasopressin production occurs in about half and one-third patients respectively. The mortality is still <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40-60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span>.
III Cardiogenic shock due to acute heart failure e.g., myocardial infarction, acute myocarditis or severe paroxysmal tachycardia.
IV Anaphylactic shock which is due to release of histamine and other mediators (Chapters 2 and 23).
V Neurogenic shock due to pooling of blood in post-capillary capacitance blood vessels, e.g. shock encountered with spinal anaesthesia, spinal cord injury, abdominal and testicular trauma and perforation of a hollow viscus. In fact, it is a form of distributive shock.
VI Haemo-obstructive shock produced as a result of obstruction of a main vascular channel, e.g. shock due to massive pulmonary embolism.
I Hypovolemic shock:</p>
<ul>
<li>Immediate treatment is directed towards restoration of effective blood volume by suitable fluids given IV. Hypovolemic shock is usually associated with metabolic acidosis as tissue hypoxia increases the production of lactic acid. This can be corrected by administration of sodium bicarbonate. Associated diseases such as diabetes or Addison's disease must be treated.</li>
<li>Abnormalities of electrolyte balance should be corrected.</li>
<li>As soon as the clinical state of the patient permits, the causative factor should be corrected, if possible.</li>
<li>Morphine is administered IV to relieve pain if shock is not associated with head injury or suspected acute abdomen.</li>
<li>Vasopressor agents (DA or NA see Table 32.2) may be employed to correct hypotension. However, fluid deficit must be corrected before using vasopressors. Without such correction, the use of vasopressor agents may worsen the patient's condition by reducing renal and cerebral blood flow and by increasing the oxygen consumption of the myocardium.</li>
<li>Oxygen administration to correct arterial hypoxemia. Central venous <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">O</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{O}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> saturation should be maintained at more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span>.
II Bacteremic shock (Endotoxic shock): This is caused by severe infection and tissue hypoperfusion, leading to organ dysfunction. Emergency treatment comprises the use of appropriate antibiotic, surgical intervention (if necessary), correction of acidosis, blood volume expansion, and therapy for hypotension and for associated hypoglycemia. As active lung injury often complicates severe sepsis, lung-protective ventilation, meaning the</li>
</ul>
<p>use of relatively low tidal volumes ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">6 \mathrm{ml} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">6</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> of ideal body weight), is reported to be beneficial in reducing mortality. Excessive tidal volume causes lung injury. Use of antiendotoxin and monoclonal antibodies to TNF- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> are under evaluation for the treatment of endotoxic shock.
III Shock due to acute myocardial infarction (MI): see Chapter 29.
IV Anaphylactic shock: See Chapters 2 and 23.
V Neurogenic shock: This should be treated like hypovolemic shock. Use of a vasopressor IV (Tables 32.1 and 32.2) is indicated. Alternatively, ephedrine hydrochloride 0.5 to 1 ml of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>45</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">45 \mathrm{mg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">45</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> solution may be injected IM prophylactically.
VI Hemo-obstructive shock: This should be treated like cardiogenic shock.
Vasodilators in shock: Their use is restricted to the treatment of continued ischemic pain or cardiogenic shock in acute MI. Nitroglycerin IV infusion, along with dobutamine infusion is the preferred regimen.</p>
<p>Glucocorticoids in shock: Glucocorticoids are of definite value in shock due to adrenocortical insufficiency and anaphylaxis. As many patients in septic shock may have partial, adrenocortical insufficiency, early administration of low doses of a glucocorticoid ( 200 mg hydrocortisone per 24 hours by continuous IV infusion, or equivalent doses IM of methylprednisolone, betamethasone, or dexamethasone) for 5-7 days may be helpful. The first dose should be administered as soon as septic shock is suspected. Treatment of septic shock with corticosteroids is, however, not accepted by all experts. It is of no value in cardiogenic, hypovolemic and traumatic shock.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="section-viii-drugs-acting-on-blood-and-blood-forming-organs">SECTION VIII Drugs Acting on Blood and Blood Forming Organs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#section-viii-drugs-acting-on-blood-and-blood-forming-organs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="outline">OUTLINE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#outline" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Chapter 33: Drugs and Blood Coagulation
Chapter 34: Drugs Effective in Iron Deficiency and Other Related Anemias
Chapter 35: Drugs Effective in Megaloblastic Anemias and Neutropenia
Chapter 36: Drug-Induced Blood Dyscrasias</p>
<p>33</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-and-blood-coagulation">Drugs and Blood Coagulation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-and-blood-coagulation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Drugs are often used in therapeutics to prevent blood coagulation and to arrest blood loss. They do that by acting on various stages of coagulation:</p>
<ul>
<li>Platelet aggregation</li>
<li>Clot or fibrin formation; or</li>
<li>Fibrinolysis</li>
</ul>
<p>Hemostasis is the spontaneous arrest of bleeding from damaged blood vessels. When cut, the precapillary vessels constrict. Platelets adhere (platelet adhesion) to the exposed collagen fibrils in the subendothelium of the injured vessel via a specific, platelet-collagen receptor, glycoprotein Ia/IIa. This causes platelet activation and release of preformed platelet granule constituents ( 5 HT ) and de novo generation of mediators of coagulation including adenosine diphosphate (ADP). This promotes platelet aggregation (more platelets sticking to each other), thus forming a primary hemostatic plug. Activated platelets lose their individual membranes, form a viscous mass and promote the assembly of clotting factors, thereby amplifying thrombin formation. Activated platelets generate thromboxane <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">A</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{A}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">A</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, a potent platelet agonist that also stimulates additional platelets. The other platelet agonists include collagen, ADP, adrenaline and thrombin. ADP elicits its effects on the platelet through <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">P</mi><mn>2</mn></msub><msub><mi mathvariant="normal">Y</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{P}_{2} \mathrm{Y}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">P</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.025em;">Y</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.025em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">P</mi><mn>2</mn></msub><msub><mi mathvariant="normal">Y</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{P}_{2} \mathrm{Y}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">P</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.025em;">Y</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.025em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors while thrombin interacts with protease activated receptors PAR -1 and -4 .</p>
<p>Circulating fibrinogen binds to an activated platelet receptor glycoprotein IIb/IIIa (Integrin) and is converted to fibrin. The process of deposition of fibrin is called coagulation.</p>
<p>The process of coagulation involves a series of interactions among various protein factors and other substances (Kallekrein, calcium, platelet factor) present in the plasma. The clotting factors (Table 33.1) are synthesised by the liver. Some of the factors (II or prothrombin; VII, IX and X) are vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>K</mi></mrow><annotation encoding="application/x-tex">K</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">K</span></span></span></span></span> dependent for their synthesis. During the process of clotting, each factor undergoes partial proteolysis to form an enzyme (activated factor labelled by the subscript ' <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>a</mi></mrow><annotation encoding="application/x-tex">a</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal">a</span></span></span></span></span> ' after the Roman number indicating the factor e.g. Xa). The activated factor then brings about similar proteolysis of the next factor in the cascade of coagulation, leading ultimately to conversion of fibrinogen into soluble fibrin (friable clot) and finally, conversion of soluble fibrin into insoluble fibrin (firm clot). Figure 33.1.</p>
<p>Table 33.1
Blood clotting factors</p>
<table><thead><tr><th style="text-align: center;">Factor No.</th><th style="text-align: left;">Common name</th></tr></thead><tbody><tr><td style="text-align: center;">I</td><td style="text-align: left;">Fibrinogen</td></tr><tr><td style="text-align: center;">II</td><td style="text-align: left;">Prothrombin</td></tr><tr><td style="text-align: center;">III</td><td style="text-align: left;">Thromboplastin</td></tr><tr><td style="text-align: center;">IV</td><td style="text-align: left;">Ionic calcium</td></tr><tr><td style="text-align: center;">V</td><td style="text-align: left;">Hereditary labile factor, Activator (AC) globulin, Proaccelerin.</td></tr><tr><td style="text-align: center;">VI</td><td style="text-align: left;">Accelerin, supposed to be active form of Factor V</td></tr><tr><td style="text-align: center;">VII</td><td style="text-align: left;">Proconvertin; Serum prothrombin conversion accelerator (SPCA)</td></tr><tr><td style="text-align: center;">VIII</td><td style="text-align: left;">Antihemophilic factor (AHF)</td></tr><tr><td style="text-align: center;">IX</td><td style="text-align: left;">Plasma thromboplastin component (PTC; Christmas factor)</td></tr><tr><td style="text-align: center;">X</td><td style="text-align: left;">Stuart-Prower factor</td></tr><tr><td style="text-align: center;">XI</td><td style="text-align: left;">Plasma thromboplastin antecedent (PTA)</td></tr><tr><td style="text-align: center;">XII</td><td style="text-align: left;">Hageman factor</td></tr><tr><td style="text-align: center;">XIII</td><td style="text-align: left;">Fibrin stabilising factor, Fibrinase</td></tr><tr><td style="text-align: center;">XIV</td><td style="text-align: left;">Prekallekrein</td></tr><tr><td style="text-align: center;">XV</td><td style="text-align: left;">Kallekrein</td></tr><tr><td style="text-align: center;">XVI</td><td style="text-align: left;">Platelet factor</td></tr></tbody></table>
<p><img src="assets/images/image-20251214-f3d8d949.jpeg" alt="img-31.jpeg"></p>
<p>FIG. 33.1 Clotting factors and blood clotting</p>
<ul>
<li>Inhibited by warfarin ** Inhibited by heparin</li>
</ul>
<p>The coagulation is initiated in vitro by the intrinsic pathway whereas it is initiated in vivo by the extrinsic pathway (Fig. 33.1). These pathways merge with the generation of factor Xa. All the reactants necessary for the intrinsic pathway are already present in the blood in an inactive form.</p>
<p>The initial event in the intrinsic pathway appears to be the activation of factor XII to factor XIIa following a contact with a foreign surface such as glass. The initiators of the extrinsic pathway are not normally present in the blood; they are added following tissue injury; in their presence, factor VII converts factors IX and X to active factors IXa and Xa respectively. The two pathways have the common objective of generating factor Xa from factor X . The intrinsic pathway is slow requiring minutes for the formation of activated factor X (factor Xa ); the extrinsic pathway takes only seconds for the same.</p>
<p>Normally, the blood is kept fluid by:</p>
<ul>
<li>The rapid flow of blood, which keeps the local concentration of clotting factors low.</li>
<li>Antithrombin III which inactivates all the clotting factors in the blood as well as any thrombin formed in the circulation; and</li>
<li>Removal by fibrinolysis of traces of fibrin formed in the circulation.</li>
</ul>
<p>Disturbances in hemostasis include hypercoagulability and excessive bleeding. The latter may be due to deficiency of platelets or clotting factors. Hypercoagulability is due to:</p>
<ul>
<li>Stasis within the venous system</li>
<li>Injury to or disease of the vessel wall; and</li>
<li>A hypercoagulable state of blood</li>
</ul>
<p>Thrombogenesis is a pathological process, leading to an intravascular thrombus formation. It is normally prevented by several regulatory mechanisms such as normal vascular endothelium, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, antithrombin, protein C and heparan sulfate proteoglycans synthesised by the vascular endothelium.</p>
<p>There are two types of thrombi: (1) arterial (white thrombus); and (2) venous (red thrombus). The process of formation of an arterial thrombus is an extension of the processes of platelet adhesion, granule release and platelet aggregation. The arterial thrombus is predominantly made up of aggregated platelets and contains little thrombin. The arterial thrombus via platelet receptor glycoprotein IIb/IIIa (GpIIb/IIIa) may occlude the artery or, by disintegrating, embolise the distal arterial tree. It may lead to ischemic necrosis of the tissue such as heart. By contrast, a venous thrombus forms in an area of venous stasis (slow blood flow). It is largely a mass of fibrin with RBCs entangled in its mesh and resembles a clot formed in a test tube. It has few platelets.</p>
<p>Figure 33.2 depicts the steps in thrombosis and their inhibitors. Drugs used in the prevention and treatment of thrombosis are:
<img src="assets/images/image-20251214-abca99d3.jpeg" alt="img-32.jpeg"></p>
<p>FIG. 33.2 Mechanism of thrombosis and its inhibition by drugs (1) Aspirin; (2) Clopidogrel; and (3) Glycoprotein llb/llla antagonists. Prostacyclin is a physiological inhibitor (see text).</p>
<ul>
<li>Antiplatelet agents</li>
<li>Anticoagulants</li>
<li>Fibrinolytic agents; and</li>
<li>Hemorrheological agents (Chapter 28).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antiplatelet-agents">Antiplatelet Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antiplatelet-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Intravascular thrombosis is initiated by platelet adhesion and aggregation and is completed by the formation of fibrin.</p>
<p>Prostacyclin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{PGI}_{2}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> and thromboxane <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">X</mi><mi mathvariant="normal">A</mi></mrow><mn>2</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{TXA}_{2}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">TXA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> are both derived from arachidonic acid (Chapter 25). Unlike <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> which is formed by the vascular endothelium, TXA2, mostly generated by the platelets, is a potent vasoconstrictor, and promotes platelet aggregation. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> plays a major role in the natural resistance to intra-arterial thrombosis. A balance between platelet <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">X</mi><mi mathvariant="normal">A</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{TXA}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">TXA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and vascular <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> regulates the platelet aggregability. Circulating platelets normally do not adhere to the healthy endothelium, mainly because of the adequate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> formed locally.</p>
<p>Platelet cyclic AMP plays an important role in platelet adhesion/aggregation. Endothelial <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> stimulates adenylyl cyclase and the formation of cAMP. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">X</mi><mi mathvariant="normal">A</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{TXA}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">TXA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> within the platelets, on the other hand, inhibits adenylyl cyclase and lowers cAMP concentration. High concentration of intraplatelet cAMP inhibits, whereas low concentration accelerates, platelet aggregation. Platelet adhesion and thrombosis seen in atheromatous plaques are due to failure of local generation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> by the vascular endothelial cells (Endothelial dysfunction).</p>
<p>Apart from <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, the endothelial cells also produce NO which increases the platelet cAMP resulting in inhibition of platelet aggregation. Exposed collagen from the subendothelial matrix of damaged vessel wall initiates platelet attachment and simultaneously the release of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">X</mi><mi mathvariant="normal">A</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{TXA}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">TXA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and ADP from the platelets. Additional platelets are then recruited. Antagonists of platelet <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">P</mi><mn>2</mn></msub><msub><mi mathvariant="normal">Y</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{P}_{2} \mathrm{Y}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">P</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.025em;">Y</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.025em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ADP receptors prevent activation of platelets, their recruitment to the site of injury, and aggregation. Prevention of platelet aggregation can prevent thrombosis.</p>
<p>Antiplatelet agents-classification:
I Prostacyclin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>.
II Inhibitors of TXA <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> formation e.g., Aspirin.
III ADP receptor ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">P</mi><mn>2</mn></msub><msub><mi mathvariant="normal">Y</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{P}_{2} \mathrm{Y}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">P</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.025em;">Y</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.025em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ) antagonists e.g., Ticlopidine, Clopidogrel, Prasugrel.
IV Phosphodiesterase inhibitors e.g., Dipyridamole.
V Glycoprotein IIb/IIIa antagonists e.g., Abciximab; and
VI Protease activated receptor (PAR-1) antagonist e.g., Vorapaxar
PROSTACYCLIN <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{PGI}_{2}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> is naturally produced by the endothelial cells lining the blood vessels. It is also present in other tissues such as the brain, the gut and the kidney. It is formed from PG-endoperoxide (Chapter 25).</p>
<p>In man, prostacyclin infusion, in addition to inhibiting platelet aggregation, causes vasodilatation, resulting in hypotension, tachycardia, headache and intense facial flushing. It causes renin release. The compound is very unstable with a short half life of 3 minutes.</p>
<p>Epoprostanol, an analogue of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, is available for preventing platelet aggregation during hemodialysis and to treat primary pulmonary hypertension (Chapter 25).</p>
<p>ASPIRIN: Aspirin selectively acetylates platelet cyclo-oxygenase irreversibly (Chapter 11). The enzyme of vessel walls is less sensitive to aspirin than is that of platelets. Hence, small doses of aspirin selectively inhibit the synthesis of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>T</mi><mi>X</mi><msub><mi>A</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">T X A_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord mathnormal" style="margin-right: 0.07847em;">TX</span><span class="mord"><span class="mord mathnormal">A</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> by platelets whereas higher doses</p>
<p>also inhibit <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> formation in the vessel. Aspirin in the oral dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mo>−</mo><mn>150</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">75-150 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">75</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">150</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily is useful in:</p>
<ul>
<li>Decreasing the incidence of CHD in adults with high risk factors (Primary prevention).</li>
<li>Preventing MI in patients with angina.</li>
<li>Acute coronary syndromes (ACS) such as unstable angina. As immediate platelet inhibition is desirable, the dose of aspirin should be 150-300 mg.</li>
<li>Patients undergoing coronary bypass surgery or angioplasty, or other revascularization procedures.</li>
<li>Preventing stroke in patients with cerebrovascular disease and history of transient ischemic attacks (TIA).</li>
<li>Preventing ischemic limb complications in patients with atherosclerotic peripheral vascular disease.</li>
<li>Preventing re-infarction in patients with MI and ischemic heart disease.</li>
<li>Preventing the development of preeclampsia in pregnant women at high risk of developing that condition; for this purpose, it is started between the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>12</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">12^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord">1</span><span class="mord"><span class="mord">2</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>16</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">16^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord">1</span><span class="mord"><span class="mord">6</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> weeks of pregnancy. Its routine use in all pregnant women to prevent pre-eclampsia is, however, not recommended. It does not prevent the development of eclampsia if started after the onset of pre-eclampsia.
In hypertensive patients, aspirin therapy should not be initiated until the BP is controlled.
The low dose aspirin therapy can cause adverse effects including GI bleeding, and intracranial hemorrhage, though rarely.</li>
</ul>
<p>Dazoxiben is a substituted imidazole which selectively blocks production of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">X</mi><mi mathvariant="normal">A</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{TXA}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">TXA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> without affecting the production of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. However, aspirin is safer and far superior.</p>
<p>Ticlopidine, a thienopyridine derivative, is a prodrug. Its active metabolites act as ADP receptor <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mi mathvariant="normal">P</mi><mn>2</mn></msub><msub><mi mathvariant="normal">Y</mi><mn>12</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{P}_{2} \mathrm{Y}_{12}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathrm">P</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.025em;">Y</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.025em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> antagonists and inhibit platelet aggregation. Orally, the onset of action is delayed for hours to days and the effect lasts for a few days after its discontinuation. Adverse effects include neutropenia, thrombocytopenia, thrombotic thrombocytopenic purpura (TTP), rash, diarrhoea and liver dysfunction.</p>
<p>Therapeutically, it is only slightly more effective but more toxic than aspirin.
CLOPIDOGREL: This prodrug, related chemically to ticlopidine, has slow onset of action ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mn>8</mn><mrow><mi mathvariant="normal">h</mi><mi mathvariant="normal">r</mi><mi mathvariant="normal">s</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2} 8 \mathrm{hrs}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mord">8</span><span class="mord"><span class="mord mathrm">hrs</span></span></span></span></span></span> ). It gets metabolised to its active form by CYP2C19 which irreversibly blocks above-mentioned ADP receptors. Its antiplatelet effect lasts for the life of the platelets (5-7 days). The usual dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">75 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">75</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day. Given alone, it is equivalent to aspirin but is much more expensive. Its superiority over aspirin remains to be established. Substitution of clopidogrel for aspirin may provide marginal benefit for the secondary prevention of serious vascular events.</p>
<p>Combination of aspirin and clopidogrel is synergistic. Such combination offers no advantage over aspirin for primary prevention of CV disease. The combination is usually used in patients with ACS (unstable angina, NSTEMI, acute MI [STEMI]), during percutaneous coronary intervention (PCI) and other vascularisation procedures. Excessive bleeding is a clear hazard of this combination.</p>
<p>Clopidogrel has several drawbacks such as delayed onset of action, large inter-individual variability in platelet response, irreversibility of its inhibitory effect on platelets, genetic polymorphisms (CYP2C19) and drug-drug interactions with CYP3A4 inhibitors like</p>
<p>atorvastatin.
Low dose aspirin still remains the relatively safe, efficacious and cost-effective antiplatelet regimen for routine use.</p>
<p>Prasugrel, a theinopyridine, is also a prodrug with properties similar to clopidogrel but with greater risk of bleeding. It is claimed to be less susceptible to genetic polymorphism. It is contraindicated in patients with history of stroke of TIA. It should be avoided in elderly <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>75</mn></mrow><annotation encoding="application/x-tex">&gt;75</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">75</span></span></span></span></span> years of age.</p>
<p>TICAGRELOR: This cyclopentine triazolopyrimidine reversibly inhibits <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">P</mi><mn>2</mn></msub><msub><mi mathvariant="normal">Y</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{P}_{2} \mathrm{Y}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">P</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.025em;">Y</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.025em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ADP receptors. Its action is more rapid and more complete and it is effective in patients not responding to Clopidogrel. The recovery after stoppage is rapid. The drug is metabolised by CYP3A4. Adverse effects include dyspnoea, bradyarrhythmia and increase serum uric acid and creatinine level.</p>
<p>Combinations of newer antiplatelet agents with aspirin are more effective than that with clopidogrel. However, they may have higher risk of bleeding</p>
<p>DIPYRIDAMOLE: This vasodilator reversibly inhibits platelet phosphodiesterase enzyme and thus, increases cAMP. It has a weak therapeutic effect. Its main use is as an adjunct to warfarin in patients with artificial heart valves. It is used orally in the dose of 100 mg qid. By itself, it is hardly of any benefit.</p>
<p>Cilostazol (See Chapter 29)
Glycoprotein IIb/IIIa antagonists: These are:
(1) A monoclonal antibody against the platelet receptor, e.g., Abciximab.
(2) Synthetic inhibitors of glycoprotein IIb/IIIa e.g., Tirofiban - a non-peptide;</p>
<p>Eptifibatide - a cyclic heptapeptide. These agents compete with fibrinogen to occupy the glycoprotein IIb/IIIa receptors. They inhibit the final common pathway of platelet aggregation. Thus, they are effective against any platelet aggregating agent and are more potent than other anti-platelet drugs. Onset of action is rapid.</p>
<p>ABCIXIMAB: This monoclonal antibody blocks platelet receptors and inhibits platelet aggregation. Given as IV bolus, followed by infusion for 12 hours, it produces an immediate effect which lasts for 18-24 hours after stopping the infusion. Small amounts of the drug can be detected on circulating platelets for 7-14 days. It is an effective antithrombotic agent in ACS that requires percutaneous coronary intervention. It acts synergistically with aspirin and heparin. The drug is effective in refractory unstable angina and has also been used in ischemic stroke. The major adverse effect is thrombocytopenia, which is reversed by platelet transfusion; monitoring of platelet count is necessary.</p>
<p>Tirofiban and Eptifibatide are competitive inhibitors of the GpIIb/IIIa complex, with a plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of 2-2.5 hrs. Their effect disappears within 4-6 hours after stopping the infusion.</p>
<p>Vorapaxar: Thrombin activates the platelets by acting on protease activated receptors (PAR-1) on platelets. Vorapaxar selectively inhibits PAR-1 and thus blocks the cellular action of thrombin and serves as modestly effective antiplatelet agent. Although it may help in the secondary prevention of thrombotic events in addition to standard care (aspirin and/or clopidogrel), it also increases the risk of bleeding.</p>
<p>The use of antiplatelet drugs may unmask an underlying defect in hemostasis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anticoagulants-classification">Anticoagulants - classification:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anticoagulants-classification" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>I Those used for preventing clotting of blood inside the intact vasculature.</p>
<ul>
<li>
<p>Fast acting, e.g., Heparin, Bivalirudin, Dabigatran.</p>
</li>
<li>
<p>Slow acting, e.g., (i) Coumarin derivatives e.g. Bishydroxycoumarin, Ethyl biscoumacetate and Warfarin sodium. (ii) Indandione derivatives e.g. Phenindione. II Those used to prevent clotting of blood in vitro. (See later).
The division is necessarily arbitrary as certain drugs can be used both in vivo as well as in vitro.</p>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="fast-acting-anticoagulants">Fast Acting Anticoagulants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#fast-acting-anticoagulants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>HEPARIN: Heparin was discovered in 1916 by McLean, a medical student, who was looking for a coagulant in the liver. It is a naturally occurring anticoagulant substance of marked molecular heterogeneity (mol. wt 5000-30,000 daltons), found in the metachromatically staining granules of mast cells. These cells are abundant in the liver (hence the name heparin), and in the lung. When released, it is rapidly degraded by macrophages and cannot be detected in normal plasma. Commercial heparin is obtained from the lung and the intestinal mucosa of pigs and cattle.</p>
<p>Purified, unfractionated (native) heparin preparations from different animals have different activities. The bioassay of heparin depends upon the capacity of heparin to prevent clotting of sheep or cattle plasma under standardized conditions. This activity is compared with that of the standard heparin powder; 1 mg of dry material obtained from the cattle lung equals 150 USP units.</p>
<p>Heparin is a mucopolysaccharide composed of a number of sulfated D-glucosamine and D-glucuronic acid units linked through an oxygen bridge (glucosaminoglycans) with more than 40-45 saccharides per chain. The content of esterified sulfuric acid is very high, which makes heparin a strongly electronegative compound. It is thus the strongest organic acid occurring in the body. The anticoagulant activity is attributed to its strong electronegative charge. It is used as the sodium salt.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacological-actions-of-heparin">Pharmacological actions of heparin:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-actions-of-heparin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Blood coagulation: Heparin prevents the clotting of blood both, in vivo and in vitro. Heparin binds to and activates antithrombin III which then inactivates factor IXa, Xa, and thrombin. The heparin binding changes conformation of antithrombin and the complex becomes almost 1000 fold more active inhibitor than antithrombin alone, producing instantaneous action.
At least 5 saccharide units of heparin are needed to bind to antithrombin. This facilitates binding of the complex to serine protease of factor Xa. Attachment of heparinantithrombin complex to thrombin (factor II) requires at least 18 saccharide units. These units serve as a template on which both, antithrombin and thrombin bind. Antifactor Xa: antifactor IIa activity of unfractionated heparin is 1:1. Even small doses of heparin that have much less antithrombin activity inhibit factor Xa which is a critical moiety in coagulation system. This may explain the usefulness of small dose heparin given SC for prophylaxis. It has no action on thrombin bound to fibrin.
The therapeutic doses prolongs the clotting time ( 2 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>2</mn><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">2^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord">2</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> times the control) and activated partial thromboplastin time (aPTT) to 1.5 to 2 times the control. Because of its varied distribution, its elimination from plasma involves both first and zero order kinetic. Thus clinically, the dose-response relation is not linear; instead, the anticoagulant respons increases disproportionately in intensity and duration with increasing doses.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="heparin-and-lipoprotein-lipase">- Heparin and lipoprotein lipase:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#heparin-and-lipoprotein-lipase" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Heparin abolishes the cloudiness of the hyperlipemic plasma (Tyndall effect) within minutes after its administration. This action occurs only in vivo and is attributed to an enzyme called lipoprotein lipase activated by heparin.</p>
<ul>
<li>Miscellaneous actions: Heparin inhibits aldosterone secretion and causes hyperkalemia. Heparin inhibits the growth of many cells such as vascular muscle and endothelium in</li>
</ul>
<p>culture. It also has some antiinflammatory action.
Absorption, fate and excretion: Heparin is poorly absorbed orally. It is well absorbed after SC injection. Usually, it is given IV. It circulates bound to plasma proteins. The mast cells take up heparin in their granules and act as a storage depot for exogenously administered heparin. It is also taken up by the endothelial cells.
The onset of anticoagulant action with an IV dose is almost immediate and reaches peak within 5 to 10 minutes; whereas after SC administration, it is delayed upto 1 hour. The clotting time returns to normal within 2 to 4 hours with a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of about 60 minutes. The aqueous preparation is, therefore, administered at 2 to 4 hourly interval.
Heparin is metabolised mainly by a liver enzyme termed heparinase. Following IV administration, 25 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of a single dose may appear in the urine in active form. Heparin does not cross the placental barrier and is not secreted in the milk.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-reactions">Adverse reactions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Allergic and anaphylactoid reactions are rare and include asthma, urticaria, rhinitis, and fever. It is advisable to give a trial dose of 1000 units of heparin.</li>
<li>Bleeding: Excessive or injudicious use of heparin may produce hemorrhage from various sites such as peptic ulcer, kidneys and hemorrhoids, and may cause hemarthrosis or wound hematoma. Patients can bleed with even normal aPTT value. It is advisable to avoid aspirin and other drugs which interfere with platelet function during heparin therapy.</li>
<li>Thrombocytopenia: Heparin causes transient, mild thrombocytopenia in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> of patients and severe thrombocytopenia in a few. The mild reaction results from heparin induced platelet aggregation. The severe form, which occurs on <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>8</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">8^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">8</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>12</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">12^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord">1</span><span class="mord"><span class="mord">2</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> day of treatment, is due to the formation of heparin dependent antiplatelet antibodies; this can result in tolerance to its anticoagulant action and recurrent thromboembolic disease. The thrombocytopenia improves after its discontinuation. The incidence is less with low molecular weight (LMW) heparins which interact less readily with platelets than unfractionated heparin. It is recommended that a platelet count should be obtained before starting the therapy and frequently during the therapy. Heparin should be discontinued if platelet count falls below 1,00,000/cu mm.</li>
<li>Alopecia: Transient alopecia may occur after prolonged heparin therapy.</li>
<li>Osteoporosis: Use of heparin in the dose of 15,000 units daily for a period of 6 months or more has been reported to cause osteoporosis.</li>
<li>Miscellaneous: SGOT and SGPT levels may rise during therapy with heparin.</li>
</ul>
<p>Preparations and dosage: Heparin is available as sodium or calcium heparin. Since the commercial preparations of heparin vary in their potency (as units <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">/ \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> ), the dosage of heparin must be prescribed in units.</p>
<p>Small fixed doses of heparin are given deep SC to prevent venous thromboembolism. Larger doses are needed either SC or IV to prevent the propagation of an established thrombus; still larger doses may be necessary in acute pulmonary embolism. When large doses are used, they must be adjusted according to the results of clotting time and activated partial thromboplastin time (aPTT) (see below).</p>
<p>Heparin is not injected IM as it can cause a hematoma.
(i) Low fixed dose, SC regimen (Prophylactic): 5,000 U given every 8-12 hours, starting 1-2 hours before the operation and continuing till the patient is discharged. Injection is given</p>
<p>with a small needle and the smallest possible volume is employed, to prevent local hematoma. Determination of aPTT is not needed.
(ii) Dose adjusted SC regimen (Therapeutic): This regimen employs either 8000-10,000 U hourly or 15,000-20,000 U 12 hourly, the actual dose being adjusted in either instance according to the results of aPTT.
(iii) IV Intermittent regimen (Therapeutic): 10,000 U initially (in a 70 kg man) followed by 5000 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo separator="true">,</mo><mn>000</mn><mi mathvariant="normal">U</mi></mrow><annotation encoding="application/x-tex">10,000 \mathrm{U}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000</span><span class="mord mathrm">U</span></span></span></span></span> every <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">4-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> hours. In children, the dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>100</mn><mi mathvariant="normal">U</mi><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50-100 \mathrm{U} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord mathrm">U</span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> initially, followed by a similar dose every 4 hours.
(iv) IV infusion (Therapeutic): Initially, 5000 U into the tubing of infusion, followed by 20,000 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo separator="true">,</mo><mn>000</mn><mi mathvariant="normal">U</mi></mrow><annotation encoding="application/x-tex">30,000 \mathrm{U}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">30</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000</span><span class="mord mathrm">U</span></span></span></span></span> daily at the rate of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mi mathvariant="normal">U</mi><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">0.5 \mathrm{U} / \mathrm{kg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.5</span><span class="mord mathrm">U</span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span> ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1000</mn><mi mathvariant="normal">U</mi><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">1000 \mathrm{U} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1000</span><span class="mord mathrm">U</span><span class="mord">/</span></span></span></span></span> hour in a 70 kg man) in isotonic saline. Not more than 25,000 units of heparin should be added to one bag for IV infusion.</p>
<p>Low molecular weight heparins (LMWH) are prepared by fractionation of native heparin; they are more homogeneous molecularly with molecular weight between 4000 and 6500 and have 15-17 saccharide chains. Given SC once or twice daily, these compounds have at least as much antithrombotic activity as native heparin. Their advantages are that, they:</p>
<ul>
<li>Are absorbed more uniformly than the native heparin after SC administration.</li>
<li>Have a longer duration of action ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mn>4</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">h</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2} 4 \mathrm{~h}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mord">4</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">h</span></span></span></span></span></span> ).</li>
<li>Inactivate factor Xa selectively; their action against thrombin is minimal. (ratio of anti-Xa to anti-IIa activity is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>:</mo><mn>1</mn></mrow><annotation encoding="application/x-tex">2: 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span></span></span></span></span> to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>:</mo><mn>1</mn></mrow><annotation encoding="application/x-tex">4: 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span></span></span></span></span> )</li>
<li>Have a predictable anticoagulant effect because they bind less avidly to cells and to heparin binding proteins.</li>
<li>Interact relatively less with platelets and lead to fewer bleeding episodes; and</li>
<li>Are less antigenic and cause thrombocytopenia and osteoporosis less frequently.</li>
</ul>
<p>These properties would make their use attractive for outpatient and domiciliary use. However, they are expensive and their routine post-operative use in all cases is not recommended.</p>
<p>Examples of LMW heparins are enoxaparin, dalteparin sodium, tinzaparin, pamaparin and reviparin. They vary in their pharmacokinetic properties and dose. Their uses are similar to those of native heparin. (Table 33.2). However, native heparin still remains the parenteral anticogualant of choice in cardiopulmonary bypass and DIC.</p>
<p>Table 33.2
Doses of commonly used LMWH</p>
<table><thead><tr><th style="text-align: left;">Preparation For prophylaxis of deep vein thrombosis (DVT)</th><th style="text-align: left;">For treatment of DVT and pulmonary embolism</th></tr></thead><tbody><tr><td style="text-align: left;">Enoxaparin 2000 units SC 2 hrs before surgery; then 2000 units every 24 hrs for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7</mn><mo>−</mo><mn>10</mn></mrow><annotation encoding="application/x-tex">7-10</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">7</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">10</span></span></span></span></span> days</td><td style="text-align: left;">100 units <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">/ \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> SC every 12 hrs for 5 days</td></tr><tr><td style="text-align: left;">Dalteparin 2500 units SC 1-2 hrs before surgery; then 2500 units every 24 hrs for 5-7 days</td><td style="text-align: left;">100 units <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">/ \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> SC twice daily for 5 days</td></tr><tr><td style="text-align: left;">Tinzaparin 3500 units SC 2 hrs before surgery; then 3500 units every 24 hrs for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7</mn><mo>−</mo><mn>10</mn></mrow><annotation encoding="application/x-tex">7-10</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">7</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">10</span></span></span></span></span> days</td><td style="text-align: left;">175 units <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">/ \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> SC once daily for 6 days</td></tr></tbody></table>
<p>Table 33.3 lists the methods of monitoring heparin therapy. Small doses of heparin SC, for prophylaxis, and LMWH do not generally require monitoring of blood samples.</p>
<p>Table 33.3
Monitoring heparin therapy</p>
<ul>
<li>Whole blood clotting time (Lee-White), which should be kept at 2-3 times the normal; and</li>
<li>Activated partial thromboplastin time (aPTT) which should be kept at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>11</mn><mi mathvariant="normal">/</mi><mn>2</mn><mo>−</mo><mn>2</mn></mrow><annotation encoding="application/x-tex">11 / 2-2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">11/2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span></span></span></span></span> times the normal.</li>
</ul>
<p>FONDAPARINUX is a synthetic pentasaccharide unit of heparin that binds to antithrombin and enhances inactivation of Factor Xa. Its <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi>t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">t^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathnormal">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is 17 hrs . It is excreted by the kidney. It does not cause heparin induced thrombocytopenia. It is not neutralised by protamine. It is given as 2.5 mg SC once daily.</p>
<p>Heparin antagonists: The anticoagulant effects of heparin can be promptly arrested by the administration of strongly basic compounds which react with the strongly acidic groups of heparin, thereby abolishing the anticoagulant activity e.g. protamine sulfate.</p>
<p>PROTAMINE SULFATE: Protamine is a mixture of simple, low molecular weight polypeptides, found in the sperms of certain fish. It binds firmly to heparin and inactivates it. Protamine sulfate as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> solution, is administered slowly, IV, not more than 50 mg over a 10 minute period. One mg of protamine sulfate neutralises the anti-coagulant effect of 100 units of heparin activity. If more than 30 minutes have elapsed after heparin administration half of this dosage is required. A patient given protamine should be observed for recurrence of bleeding as protamine sulfate itself has anticoagulant activity and the action of heparin lasts longer than that of protamine.</p>
<p>It is considered unsafe to exceed the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50-100 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> over a short period. Protamine IV injection may cause a sudden fall in BP, bradycardia, dyspnoea and transitory flushing. Protamine only partially neutralises LMWH.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="other-factor-xa-inhibitors">Other Factor Xa inhibitors:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#other-factor-xa-inhibitors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>RIVAROXABAN: It is an orally acting, direct, reversible selective Factor Xa inhibitor used for prevention and treatment of arterial and venous thromboembolism. It does not require monitoring. There is no specific antidote (Table 33.6). Others are, Apixaban and Edoxaban.</p>
<p>Table 33.6
Advantages and disadvantages of different classes of oral anticoagulants</p>
<table><thead><tr><th style="text-align: center;">Drug class</th><th style="text-align: center;">Advantages</th><th style="text-align: center;">Disadvantages</th></tr></thead><tbody><tr><td style="text-align: center;">Vit. K antagonists (Warfarin)</td><td style="text-align: center;">- Large data on therapeutic utility and adverse effects &lt;br&gt; - Once daily dosing &lt;br&gt; - Antidote available &lt;br&gt; - Cost effective</td><td style="text-align: center;">- Marked variability in dose requirements &lt;br&gt; - Dietary restrictions &lt;br&gt; - INR monitoring required &lt;br&gt; - Numeous drug interactions</td></tr><tr><td style="text-align: center;">Factor Xa inhibitors (Rivaroxaban)</td><td style="text-align: center;">- INR monitoring not required &lt;br&gt; - Once daily dosing &lt;br&gt; - Appeas to have lessincidence of intraconial and fatal bleeding &lt;br&gt; - No dietary restrictions</td><td style="text-align: center;">- No specific antidote &lt;br&gt; - Missing a dose can predispose to thrombotic risk. &lt;br&gt; - No method to evaluate extent of anticoagulant effect &lt;br&gt; - Dose adjustment required in renal impairment &lt;br&gt; - Non dialyzable</td></tr><tr><td style="text-align: center;">Thrombin inhibitors (Dabigatran)</td><td style="text-align: center;">- INR monitoring not required &lt;br&gt; - Dialyzable &lt;br&gt; - Appeas to have lessincidence of intraconial and fatal bleeding</td><td style="text-align: center;">- No specific antidote &lt;br&gt; - No method to evaluate extent of anticoagulant effect &lt;br&gt; - Dose adjustment required in renal impairment &lt;br&gt; - Twice daily dosing and must be stored in original container</td></tr></tbody></table>
<p>Danaparoid: This heparinoid, obtained from porcine intestinal mucosa, is a mixture of glucosaminoglycans. It inhibits Xa. It is given SC twice a day, for prophylaxis. It does not</p>
<p>cause thrombocytopenia. It has no antidote.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="direct-thrombin-inhibitors">Direct Thrombin Inhibitors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#direct-thrombin-inhibitors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>HIRUDIN: This is a potent antithrombin polypeptide obtained from the leech Hirudo medicinalis. It has now been synthesised by recombinant DNA technique (lepirudin,). Unlike heparin, it binds irreversibly to thrombin and inactivate free as well as fibrin-bound thrombin. Its effect does not require antithrombin or other co-factors. It not only prevents conversion of fibrinogen to fibrin, but also blocks thrombin-catalysed platelet aggregation, and activation of other clotting factors. Its activity is monitored by the same tests as that of heparin. It has a short duration of action and hence it is given by IV infusion. There is no antidote. It inhibits disseminated intravascular coagulation, and venous and arterial thrombosis.</p>
<p>Bivalirudin is a synthetic analogue of hirudin, with rapid onset and offset of action (due to reversible binding; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mn>25</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2} 25 \mathrm{~min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mord">25</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span></span></span> ). It does not form antihirudin antibodies. Desirudin is also an analogue of hirudin.</p>
<p>Argatroban: is also a reversible direct thrombin inhibitor, given as IV infusion. Its <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is 45 min . It is used as an alternative to lepirudin.</p>
<p>DABIGATRAN: Dabigatran etexilate is a prodrug. Given orally, it is converted to the active agent dabigatran which is a direct inhibitor of thrombin. Given once daily, it is claimed to be as effective as enoxaparin for the treatment and prevention of venous thromboembolism. The drug appears to have an ADR profile similar to that of enoxaparin. The major advantage of this drug is that it is effective orally without the need for coagulation monitoring.</p>
<p>All the direct thrombin inhibitors are used in patients with or at risk of developing heparin induced thrombocytopenia.</p>
<p>HUMAN ANTITHROMBIN CONCENTRATE: This is prepared from pooled human plasma or by recombinant technology. It is used either alone or along with heparin to treat patients with a rare hereditary disorder, antithrombin III deficiency.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="slow-acting-anticoagulants">Slow Acting Anticoagulants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#slow-acting-anticoagulants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These drugs are known as oral anticoagulants because, in contrast to heparin, they are effective orally. They have a slow onset of action.</p>
<p>COUMARIN DERIVATIVES: Bishydroxycoumarin or dicoumarol, the first coumarin compound (Fig 33.3), was isolated from spoilt sweet clover in 1943-1944 and was proved to be the causative factor in a cattle disease termed 'Sweet Clover Disease', characterised by a severe haemorrhagic tendency. The most commonly used drug is warfarin sodium.
<img src="assets/images/image-20251214-51ef5f7a.jpeg" alt="img-33.jpeg"></p>
<p>FIG. 33.3 Coumarin ring
Pharmacological actions: The various coumarin drugs exert qualitatively similar pharmacological actions (Fig 33.4).
<img src="assets/images/image-20251214-26bbb17e.jpeg" alt="img-34.jpeg"></p>
<p>FIG. 33.4 Vitamin K cycle and site of action of Coumarin anticoagulants</p>
<ul>
<li>Anticoagulant action: Coagulation factors prothrombin, VII, IX and X are synthesised in the liver but are biologically inactive until they are carboxylated. Carboxylation is directly coupled to the oxidation of vitamin K to its epoxide. To sustain the carboxylation, the epoxide is converted back to the reduced form of vitamin K by the enzymes vitamin K epoxide reductase and vitamin K reductase (Fig. 33.4). Coumarin being structurally similar to vitamin K, competitively inhibits vitamin K epoxide reductase. This prevents regeneration of reduced form of vitamin K and therefore to inhibition of carboxylation. Thus coumarins inhibit vitamin K dependent synthesis of coagulation factors. In contrast to heparin, there is a considerable lag (usually 24 to 48 hours) between the</li>
</ul>
<p>time of peak plasma level of coumarins and the therapeutic response. This is because they prevent the formation of active essential clotting factors by the liver but do not destroy the circulating ones. It takes 3-7 days for prothrombin time to return to normal after cessation of therapy. As coumarins have no direct action on coagulation factors they are not effective in vitro.
Coumarin therapy is controlled by estimating prothrombin time which is expressed as International Normalised Ratio (INR). Bleeding time is unaltered.
Absorption, fate and excretion: The intestinal absorption of coumarin is slow and incomplete. The drugs are extensively bound to plasma proteins. They cross the placental barrier and are also secreted in milk. They are mainly metabolised in the liver. There is a considerable individual variation (as much as 14 fold) in the rate of detoxification.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-reactions">Adverse reactions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Bleeding: The incidence of hemorrhage is 5-6%. There is no correlation between the onset and degree of hemorrhage and the dose, or the prothrombin, levels. In fact, similar degree of hypoprothrombinemia may be found in patients who bleed and those who do not.
The hemorrhage induced by coumarins can be treated by large doses of vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">K</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{K}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> which enables the liver to synthesise active clotting factors. However, even the IV administration of vitamin K is associated with a latent period of several hours. Therefore, in the immediate treatment of severe hemorrhage, prompt administration of fresh whole blood is necessary. Menadione (synthetic Vitamin K, Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">K</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{K}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ) is ineffective in countering the bleeding caused by coumarins.</li>
<li>Fetal toxicity: Coumarin anticoagulants may cause fatal hemorrhage in the fetus; further they are teratogenic (Chapter 80).</li>
<li>Cutaneous gangrene: Petechiae that coalesce to painful ecchymoses, hemorrhagic bullae and finally to necrosis/gangrene occur occasionally within 3-8 days after starting treatment with large doses of warfarin. The lesions affect women more often than men and involve the adipose tissue of breasts, buttocks, thighs and the distal lower extremities.</li>
<li>Miscellaneous: Rarely, coumarins may cause urticaria, anorexia, vomiting and diarrhoea. WARFARIN SODIUM: This coumarin (Fig 33.5), originally employed as a rodent poison, is the most widely used coumarin anticoagulant and is considered to be the drug of choice. It is a racemic mixture of two isomers, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>S</mi></mrow><annotation encoding="application/x-tex">S</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">S</span></span></span></span></span> ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">t</mi><mn>1</mn><mi mathvariant="normal">/</mi><mn>235</mn></mrow><annotation encoding="application/x-tex">\mathrm{t} 1 / 235</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathrm">t</span><span class="mord">1/235</span></span></span></span></span> hours) and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>R</mi></mrow><annotation encoding="application/x-tex">R</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.00773em;">R</span></span></span></span></span> ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">t</mi><mn>1</mn><mi mathvariant="normal">/</mi><mn>250</mn></mrow><annotation encoding="application/x-tex">\mathrm{t} 1 / 250</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathrm">t</span><span class="mord">1/250</span></span></span></span></span> hours), in almost equal proportions. After initiating therapy with the maintenance dose <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">5-10 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day (no loading dose is used), therapeutic INR level is usually achieved in 36 hours but clinical effect is seen within 4-5 days. Its advantages are:</li>
</ul>
<p><img src="assets/images/image-20251214-8a686a79.jpeg" alt="img-35.jpeg"></p>
<ul>
<li>It is almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>99</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">99 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">99%</span></span></span></span></span> absorbed and gives more steady plasma levels; approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>97</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">97 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">97%</span></span></span></span></span> of the drug is bound to plasma albumin.</li>
<li>It has rapid onset and predictable duration of action; therefore, the therapy is easier to regulate; and</li>
<li>It is water soluble and can be given parenterally. Parenteral administration, however, does not accelerate the speed of anticoagulation.
If warfarin is employed for long-term anticoagulant therapy, it takes about 3 days for the prothrombin time to return to normal after drug discontinuation.</li>
</ul>
<p>Adverse reactions: Comparatively few toxic effects other than haemorrhage have been reported. These include alopecia, urticaria and dermatitis. It can cross the placenta but is not secreted in the milk. It is contraindicated during pregnancy. Women on long term warfarin therapy should avoid pregnancy. The major drawback of this drug is the possibility of multiple drug interactions (Table 33.4).</p>
<p>Table 33.4
Drug interactions of coumarin anticoagulants</p>
<ul>
<li>Drugs which prolong prothrombin time and may cause bleeding: Aspirin, phenylbutazone, other NSAID, heparin, clofibrate, thyroxine, amiodarone, anabolic steroids, cimetidine, omeprazole, metronidazole, co-trimoxazole, high doses of penicillins, erythromycin, some cephalosporins, moxalactam.</li>
<li>Drugs which shorten prothrombin time: Barbiturates, chloral hydrate, meprobamate, rifampicin, griseofulvin, cholestyramine, carbamazepine. When these drugs are stopped, bleeding may occur in a patient on oral anticoagulants.</li>
</ul>
<p>The action of warfarin can be antagonised by vitamin K (see later).
Other preparations used are: Fresh frozen plasma, recombinant factor VIIa and prothrombin complex concentrate, which act more rapidly than vitamin K.</p>
<p>Preparation and dosage: Warfarin sodium 5 mg . It is used once a day in the dose of 2.510 mg . It has a cumulative action and the maintenance dose may have to be gradually decreased after the first week or so. No loading dose is used to initiate therapy. Its haemostatic effect varies within individuals depending upon the vitamin K intake and polymorphism of vitamin K reductase and liver CYP2C9.</p>
<p>The dose of warfarin is adjusted by measuring INR, which is generally maintained between 2.0 and 3.5 .</p>
<p>Drug interactions: See Table 33.4. Coumarins can cause drug interactions by:</p>
<ul>
<li>Inhibiting the platelet function (aspirin, NSAID).</li>
<li>Stimulating hepatic microsomal catabolism of warfarin (barbiturates, rifampicin, griseofulvin, carbamazepine).</li>
<li>Displacing warfarin from protein binding (sulfonamides, phenylbutazone, chlorpropamide); or</li>
<li>Inhibiting the metabolic clearance of warfarin (cimetidine, omeprazole, amiodarone). Drugs like tolbutamide and phenytoin may accumulate in the body following coumarins</li>
</ul>
<p>and hence, doses of these drugs must be reduced.
Indandione Derivatives: Such as phenindione have anticoagulant activity similar to the coumarin compounds. Because of their toxicity, they are now almost obsolete.</p>
<p>Factors affecting the dosage and activity of the oral anticoagulants are listed in Table 33.5 .</p>
<p>Table 33.5
Factors affecting the dosage of oral anticoagulants</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>* Genetic differences in the rate of drug metabolism.
</span>* Age and ses.
* Vitamin K deficiency caused by poordiet, bowel disease or biliary disease enhances the response to oral anticoagulants
* Chronic alcoholism, liver disease, kidney disease and vitamin C deficiency enhance the response.
* Hypermetabolic states.</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="* Genetic differences in the rate of drug metabolism.
* Age and ses.
* Vitamin K deficiency caused by poordiet, bowel disease or biliary disease enhances the response to oral anticoagulants
* Chronic alcoholism, liver disease, kidney disease and vitamin C deficiency enhance the response.
* Hypermetabolic states." style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>Advantages and disadvantages of different classes of oral anticoagulants is presented in Table 33.6.</p>
<p>Table 33.7 summarises the main actions of anticoagulant drugs.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-33-7">Table 33.7<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-33-7" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="main-actions-of-anticoagulant-drugs">Main actions of anticoagulant drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#main-actions-of-anticoagulant-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>* Heparin accelerates inactivation of thrombin by antithrombin III.
</span>* LMWHs, mainly, inactivate factor Xa (activated factor X).
* Rivaroxaban inhibits factor Xa
* Hirudin, Lepuridin and Dabigatran inactivate thrombin.
* Warfarin inhibits the synthesis of several active coagulation factors, including prothrombin.</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="* Heparin accelerates inactivation of thrombin by antithrombin III.
* LMWHs, mainly, inactivate factor Xa (activated factor X).
* Rivaroxaban inhibits factor Xa
* Hirudin, Lepuridin and Dabigatran inactivate thrombin.
* Warfarin inhibits the synthesis of several active coagulation factors, including prothrombin." style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>Therapeutic uses of anticoagulants: Arterial and venous thrombosis differ in their causes, pathologic effects and management. To understand the usefulness of anticoagulants it is essential to differentiate between a thrombus (White thrombus) and a clot (Red thrombus). Platelet aggregation is the more important event in the initiation of arterial thrombus. In contrast, a typical clot has a much smaller platelet- leucocyte element than the red cells entangled in fibrin (see earlier). In venous 'thrombosis' and pulmonary embolism the structure responsible for the clinical state is usually a clot, and not a 'thrombus'. The drugs which interfere with the clotting mechanism may not necessarily modify the arterial thrombus formation unless they affect the platelet behaviour. Although such drugs may satisfy the conventional definition of an 'anticoagulant' they are not 'antithrombotic' agents.</p>
<p>Conventional anticoagulant therapy can prevent the extension of an existing venous thrombus and the development of emboli additional thrombi in the vascular bed (Venous thromboembolism). It does not influence the established arterial thrombus, nor can it reverse ischemic tissue damage.</p>
<p>Heparin is the drug of choice when rapid induction of anticoagulation is desired. It can be used safely during late pregnancy. The disadvantages of heparin are its narrow therapeutic window, high cost, the need for parenteral administration, and the frequency of reactions at the site of injection.</p>
<p>The disadvantages of oral anti-coagulants are:</p>
<p>(i) Delayed onset of action,
(ii) Variable therapeutic effect and
(iii) Need for an elaborate laboratory control.</p>
<p>The maximum therapeutic response to oral warfarin is achieved 3-5 days after the initial dose. Hence, in order to obtain immediate therapeutic response, heparin is given IV, intermittently at 4-8 hour interval. Combined IV heparin and oral warfarin therapy gives the patients the advantage of immediate and prolonged anticoagulation.</p>
<p>Invasive procedures and intramuscular injections should be minimised and antiplatelet drugs (aspirin and NSAID) should be avoided in patients on anticoagulants. Further, if a patient on anticoagulant therapy bleeds it should not automatically be attributed to the anticoagulant therapy, but an effort should be made to rule out an underlying lesion such as a malignancy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="indications-for-anticoagulant-therapy">Indications for anticoagulant therapy:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#indications-for-anticoagulant-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Prevention and treatment of deep venous thrombosis (DVT) and pulmonary embolism: Anticoagulants are most useful in this condition and are used prophylactically.
Low fixed dose heparin considerably reduces the incidence of pulmonary embolism, if used prophylactically in post-operative therapy and in patients with acute MI. It is given SC in doses of 5000 units every 8-12 hours; the first dose being given 2 hours before surgery. Laboratory monitoring is not necessary and risk of hemorrhage is minimal. A highly concentrated solution of heparin should be used. Pressure over the injection site minimises local bleeding into the tissues.
Such prophylactic use of heparin in low doses is also justified for prevention of DVT particularly in patients confined to prolonged bed rest. Other agents currently used for thromboprophylaxis are listed in Table 33.8.</li>
</ul>
<p>Table 33.8
Drugs for Thromboprophylaxis</p>
<table><thead><tr><th style="text-align: left;">Drug (Dose)</th><th style="text-align: left;">Mechanism of action</th><th style="text-align: left;">Antidote</th></tr></thead><tbody><tr><td style="text-align: left;">Warfarin (2-10 mg orally OD) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>a&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {a }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6644em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6644em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">a&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: left;">Vink dependent clotting factors synthesis inhibitor</td><td style="text-align: left;">Vitamin K</td></tr><tr><td style="text-align: left;">Enoxaparin (40 mg SC OD)</td><td style="text-align: left;">Antithrombin mediated inhibitor of factor Xa</td><td style="text-align: left;">Protamine sulfate</td></tr><tr><td style="text-align: left;">Fondaparinux (2.5 mg SC OD) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>a&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {a }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6644em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6644em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">a&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: left;">Antithrombin mediated inhibition of factor Xa</td><td style="text-align: left;">None</td></tr><tr><td style="text-align: left;">Desirudin (15 mg SC 12 hrly) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>b&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {b }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">b&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: left;">Direct inhibitor of thrombin</td><td style="text-align: left;">Antibodies</td></tr><tr><td style="text-align: left;">Dabigatran (150 mg bid)</td><td style="text-align: left;">Direct inhibitor of thrombin</td><td style="text-align: left;">None</td></tr><tr><td style="text-align: left;">Rivaroxaban (10 mg orally OD)</td><td style="text-align: left;">Direct inhibitor of factor Xa</td><td style="text-align: left;">None</td></tr><tr><td style="text-align: left;">Aspirin/Clopidogrel</td><td style="text-align: left;">Anti-platelet action</td><td style="text-align: left;">None</td></tr></tbody></table>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>1</mn></msup></mrow><annotation encoding="application/x-tex">{ }^{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span></span></span></span></span></span></span></span></span> Needs monitoring;
"Is avoided, if creatinine is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">&lt;30 \mathrm{ml} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>;
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>2</mn></msup></mrow><annotation encoding="application/x-tex">{ }^{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span></span></span></span></span></span></span></span></span> Only in presence of heparin induced thrombocytopenia
Patients with recurrent venous thromboembolism and those with chronic AF usually need long term, perhaps indefinite, anticoagulant therapy. In AF prior anticoagulation for three weeks is indicated before conversion to sinus rhythm in such patients. For patients who have confirmed acute proximal DVT or pulmonary embolism, immediate anticoagulation with both, full dose IV heparin (LMWH/fondaparinux and oral warfarin is recommended). Heparin SC takes 12 hours to exert full anticoag-lant effect while warfarin requires 5-7 days. After 7 days warfarin is continued for 3-6 months. Patients with calf vein thrombosis without proximal extension are less liable to develop pulmonary</p>
<p>embolism and hence 6-8 week therapy is adequate.</p>
<ul>
<li>Myocardial infarction: Chapter 29.</li>
<li>Mitral valve disease with AE</li>
<li>Cerebrovascular disease: As a rule, anticoagulants are not indicated in cerebrovascular disease for fear of causing cerebral hemorrhage. Their usefulness is doubtful, except perhaps in the intermittent insufficiency syndromes, and stroke due to emboli from the heart; the possibility of hemorrhage should be ruled out.</li>
<li>Miscellaneous: They are also used in case of artificial heart valves in order to prevent emboli and during cardiac bypass surgery.
Contraindications to anticoagulants: See Table 33.9
Table 33.9
Contraindications to anticoagulant therapy</li>
<li>Haemorrhagic tendency and blood dyscrasias.</li>
<li>Benign or malignant ulcera, such as in the gut, colitis, diverticulitis, recent operation upon the CNS, eye or prostate gland.</li>
<li>In subacute bacterial endocarditis, anticoagulants may cause detachment of the bacterial vegetations from the damaged valves into general circulation.</li>
<li>Threatened abortion, injury to the brain the spinal cord and stroke.</li>
<li>Regional and lumbar block anaesthesia.</li>
<li>Prothrombin deficiency, severe hepatic, renal impairment and severe uncontrolled hypertension.</li>
<li>An uncooperative patient, inadequate laboratory facility and uninformed or casual medical supervision.</li>
<li>Pregnancy</li>
</ul>
<p>Long acting oral anticoagulants such as di-phenindione, pindone and broadifacum are used as rodenticides.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="in-vitro-anticoagulants">In Vitro Anticoagulants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#in-vitro-anticoagulants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Physical methods: Clotting can be delayed by cooling the blood or by collecting it in coated vessels so that platelets are not broken up. The coating used is paraffin, collodion or silicone.</p>
<p>Oxalates and citrates: These act by removal of calcium ions. Potassium oxalate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.1%</span></span></span></span></span> precipitates serum calcium as calcium oxalate. Sodium citrate combines with calcium and forms calcium sodium citrate. The anticoagulant solution (B.P.) contains <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2.5%</span></span></span></span></span> of sodium citrate in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.9</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.9 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.9%</span></span></span></span></span> saline. Citrate is usually employed as an anticoagulant for blood to be transfused. The final strength of citrate is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3.8</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">3.8 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">3.8%</span></span></span></span></span>. Potassium oxalate produces convulsions and hence is not employed in vivo.</p>
<p>EDTA (Ethylenediamine tetraacetic acid) a chelating agent, has a great affinity for calcium and its sodium salt has been used as an anticoagulant (see also Chapter 76).</p>
<p>Heparin: discussed earlier.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="fibrinolytic-agents">Fibrinolytic Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#fibrinolytic-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The process of fibrinolysis or dissolution of blood clot is schematically represented in Fig. 33.6.
<img src="assets/images/image-20251214-907b5254.jpeg" alt="img-36.jpeg"></p>
<p>The euglobulin fraction of the plasma contains the inactive preursor plasminogen. An activator substances (tPA, Urokinase), present in tissues, converts plasminogen to fibrinolytic enzyme plasmin. The plasmin breaks down fibrin clots. It is relatively nonspecific in action and it can also act on proteins and clotting factors.</p>
<p>Plasminogen, the inactive proteolytic enzyme of plasma, binds to fibrin during the formation of a thrombus. The fibrin-bound plasminogen is more susceptible to the activation than the plasminogen in circulation.</p>
<p>All fibrinolytic agents in use act directly or indirectly as plasminogen activators. These are:</p>
<ul>
<li>Streptokinase.</li>
<li>Recombinant tissue-type plasminogen activators, Alteplase Reteplase, Tenecteplase.</li>
<li>Urokinase.</li>
<li>Acylated plasminogen-streptokinase activator (APSAC) complex (Anistreplase).</li>
</ul>
<p>STREPTOKINASE: It is used in the treatment of DVT in the dose of 250,000 units IV in 30 minutes, followed by 100,000 units every hour for 24-72 hours (Chapter 78). A loading dose is given to neutralise the antibodies following any previous dose.</p>
<p>ALTEPLASE, rtPA (Recombinant tissue-type plasminogen activator), a natural protein in man, is now prepared by recombinant DNA technology. It preferentially activates plasminogen bound to fibrin clot and thus avoids systemic activation of plasminogen; fibrinogen depletion and bleeding are thus minimised. It is as effective as streptokinase. It has a short <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of 8 min . It is metabolised by the liver. Patients weighing <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>67</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">&lt;67 \mathrm{~kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">67</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> should receive a total dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1.5 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> Heparin 5000 U is given IV bolus prior to administration of rt-PA.</p>
<p>Reteplase ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mn>1.6</mn><mrow><mi mathvariant="normal">h</mi><mi mathvariant="normal">r</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2} 1.6 \mathrm{hr}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mord">1.6</span><span class="mord"><span class="mord mathrm">hr</span></span></span></span></span></span> ) and tenecteplase ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mn>2</mn><mrow><mi mathvariant="normal">h</mi><mi mathvariant="normal">r</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2} 2 \mathrm{hr}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mord">2</span><span class="mord"><span class="mord mathrm">hr</span></span></span></span></span></span> ) are the other recombinant analogues of human rt-PA. They have long plasma half lives and can be given as bolus injection.</p>
<p>UROKINASE: This enzyme, originally isolated from human urine, is now obtained from cultured human renal cells. It is a potent direct plasminogen activator. Unlike</p>
<p>streptokinase, it is non-antigenic, non-pyrogenic and does not cause allergic reactions. However, it lacks fibrin specificity. and is very expensive (Table 33.10). Its use is followed by administration of heparin. It is also used to lyse fibrin or blood deposits in the anterior chamber of the eye. For this purpose, 5000 units of the enzyme in 2 ml of sterile physiological saline at pH 7.2 to 7.6 are usually instilled into the anterior chamber.</p>
<p>Table 33.10</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="properties-of-thrombolytic-agents">Properties of thrombolytic agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#properties-of-thrombolytic-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<table><thead><tr><th style="text-align: center;">Characteristic</th><th style="text-align: center;">Streptokinase</th><th style="text-align: center;">Urokinase</th><th style="text-align: center;">Alteplase*</th></tr></thead><tbody><tr><td style="text-align: center;">Plasma half life ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> min.)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>25</mn></mrow><annotation encoding="application/x-tex">15-25</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">25</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>20</mn></mrow><annotation encoding="application/x-tex">15-20</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">20</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>8</mn></mrow><annotation encoding="application/x-tex">4-8</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">8</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Fibrin specificity</td><td style="text-align: center;">Minimal</td><td style="text-align: center;">Moderate</td><td style="text-align: center;">Maximum</td></tr><tr><td style="text-align: center;">Plasminogen binding</td><td style="text-align: center;">Indirect</td><td style="text-align: center;">Direct</td><td style="text-align: center;">Direct</td></tr><tr><td style="text-align: center;">Potential for allergic reaction/hypotension</td><td style="text-align: center;">Yes</td><td style="text-align: center;">No</td><td style="text-align: center;">No</td></tr><tr><td style="text-align: center;">Total dose</td><td style="text-align: center;">1.5 million units</td><td style="text-align: center;">3-4 million units</td><td style="text-align: center;">100 mg</td></tr><tr><td style="text-align: center;">Administration for MI</td><td style="text-align: center;">1.5 million units</td><td style="text-align: center;">3 lacs IV in 10 min , then 3 lacs/hr for 12 hrs .</td><td style="text-align: center;">15 mg IV bolus, then 50 mg over 30 min , then 35 mg over 1 hr</td></tr></tbody></table>
<p>*Appears to result in a higher rate of early coronary reperfusion compared to streptokinase.
Alteplase, reteplase and tenecteplase are more fibrin-specific. They bind strongly to fibrin and are capable of dissolving resistant thrombi better than fibrin-nonspecific agents, streptokinase, anistreplase and urokinase as they are not well absorbed by fibrin thrombi. Streptokinase indirectly activates plasminogen while others are direct activators of plasminogen in circulation. With the doses used in the treatment of acute MI, the lytic activity is greatest with streptokinase, intermediate with urokinase and least with rt-PA. Given IV, the plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of these agents differs (Table 33.10). Thus, differences in pharmacokinetics and patient's tolerance and the disease state dictate the duration of administration necessary to achieve an appropriate thrombolytic effect.</p>
<p>Therapeutically, when treatment is begun within the first 6 hours of the onset of chest pain in MI, a similar incidence of reperfusion is provided by all the agents, but there are considerable differences in the ease with which they can be administered (see later). Rethrombosis, after reperfusion, occurs in roughly inverse proportion to the length of the plasma halflife of the drug used, with the lowest incidence with urokinase and streptokinase, and the highest with rt-PA. Hence, heparin is administered simultaneously with rt-PA, primarily to enhance re-perfusion and decrease the rate of re-thrombosis. Since streptokinase and urokinase produce more prolonged and extensive anticoagulant effect, simultaneous administration of heparin is not required.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="adverse-reactions">Adverse reactions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>
<p>Bleeding is the commonest adverse effect with all these agents. It is probably much less with fibrin-specific agents. In case of bleeding the drug should be stopped and fresh frozen plasma may be given.</p>
</li>
<li>
<p>Multiple microemboli can occur following disintegration of existing thrombus.</p>
</li>
<li>
<p>Allergic reactions: Streptokinase, being a bacterial protein, is antigenic. Hence, it may cause allergic and febrile reactions and rarely ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.1%</span></span></span></span></span> ) anaphylactoid reaction; therapy with urokinase and other tPAs does not provoke allergic reaction.</p>
</li>
<li>
<p>Hypotension may occur more often with rapid administration of streptokinase.</p>
</li>
<li>
<p>Hemorrhagic stroke is a dreaded complication of thrombolytic therapy. IM injections are contraindicated during thrombolytic therapy.
The therapeutic goal is to re-establish the blood flow through the occluded vessel within a short time, so as to prevent organ damage. The optimal dose to achieve this with the lowest incidence of bleeding and rethrombosis is difficult to decide precisely. Because thrombolytic agents do not distinguish between the fibrin of a thrombus and the fibrin of a hemostatic plug; they are double edged weapons. From the experience with heparin, it appears that a hypocoagulable state is itself well tolerated and an unlikely initiator of bleeding in patients with an intact vascular system and in the absence of risk factors such as recent surgery, DU, thrombocytopenia or administration of other antithrombotic agents. Vascular injury, rather than changes in blood coagulation is the main cause of bleeding. The important contraindications to fibrinolytic therapy are listed in Table 33.11.</p>
</li>
</ul>
<p>Table 33.11
Contraindications to thrombolytic therapy</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>- Active bleeding, bleeding tendency.
</span>- Recent major trauma.
- Invasive or surgical procedure in the past 10 days.
- GI or genitourinary bleeding in the past 10 days.
- Recent prolonged cardiopulmonary resuscitation.
- Neurosurgical procedure in the past 2 months.
- Stroke or transient cerebral ischemic attack in the past 12 months.
- History of cerebral tumour, aneurysm or arteriovenous malformation.
- Active peptic ulcer disease.
- Hypertension (severe, uncontrolled).
- Diabetes mellitus with proliferative retinopathy.
- Pregnancy.</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="- Active bleeding, bleeding tendency.
- Recent major trauma.
- Invasive or surgical procedure in the past 10 days.
- GI or genitourinary bleeding in the past 10 days.
- Recent prolonged cardiopulmonary resuscitation.
- Neurosurgical procedure in the past 2 months.
- Stroke or transient cerebral ischemic attack in the past 12 months.
- History of cerebral tumour, aneurysm or arteriovenous malformation.
- Active peptic ulcer disease.
- Hypertension (severe, uncontrolled).
- Diabetes mellitus with proliferative retinopathy.
- Pregnancy." style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>Probably 10-20% of reperfused arteries undergo re-thrombosis. The ideal antithrombotic regimen to sustain reperfusion has not been established; but heparin in the dose of 5000 units (IV bolus) followed by 1000 units hourly (by IV infusion) for 3-5 days and aspirin (150 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">\mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day) have been recommended. Rethrombosis of veins is probably most often related to incomplete lysis of the original thrombus, and the present management emphasizes adequate anti-coagulation with heparin as the best approach to preventing rethrombosis.</p>
<p>Therapeutic uses: Fibrinolytic agent by accelerating the rate of vascular reperfusion, improves rapidly the manifestations of vessel occlusion.</p>
<ul>
<li>Myocardial infarction (MI): Fibrinolytic therapy is most useful in patients with STEMI (Chapter 29). Patients without ST elevation or those with unstable angina are only marginally benefitted.
As progression of ischemia and infarction from the subendocardium to the epicardium occurs in about 6 hours, fibrinolytic therapy, begun within 6 hours of the onset of MI reduces mortality and preserves LV function.
Among various fibrinolytic agents, streptokinase (SK) and rt-PA (Altepase) are commonly used. The classical indications for fibrinolytic therapy in acute MI are chest pain characteristic of infarction, lasting for at least 30 minutes but not more than 6 hours, with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">V</mi></mrow><mo stretchy="false">(</mo><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">0.1 \mathrm{mV}(1 \mathrm{~mm})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mV</span></span><span class="mopen">(</span><span class="mord">1</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mclose">)</span></span></span></span></span> or more ST-segment elevation in at least two contiguous leads in the ECG, in a patient younger than 75 years. Although such therapy is useful, it rarely prevents the subsequent ECG and enzymatic changes indicating infarction, even when used within the first hour after MI.</li>
</ul>
<p>Streptokinase is given IV in the dose of 1.5 million units over 60 min .; rt-PA (Alteplase) is given IV in the dose of 100 mg over <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>11</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">11 / 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">11/2</span></span></span></span></span> hours. This is followed by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mo>−</mo><mn>150</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">75-150 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">75</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">150</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> of aspirin daily, for 4 weeks. There appears to be little difference in left ventricular function or predischarge patency rates whether SK or alteplase is used. SK sometimes aggravates hypotension and this should be watched for. Patients are not routinely treated with fibrinolytics later than six hours after infarction unless they are at high risk; they can, however, be given aspirin.</p>
<ul>
<li>Ischemic stroke: Because of the risk of conversion of a non-hemorrhagic stroke into a hemorrhagic one, such therapy is highly controversial in ischemic strokes. IV Altepase has been used within <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>4.5</mn></mrow><annotation encoding="application/x-tex">3-4.5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4.5</span></span></span></span></span> hours <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>0.9</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">(0.9 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">0.9</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> to maximum of 90 mg<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mclose">)</span></span></span></span></span> to treat acute ischemic stroke. However, in such cases occlusion by clot must be demonstrated by MRI.</li>
<li>Pulmonary embolism: Heparin is the mainstay of treatment of pulmonary embolism. A thrombolytic therapy is useful adjunct in patients with severe (massive) pulmonary embolism and right ventricular dysfunction.</li>
<li>Acute peripheral arterial occlusion: It is used especially for dissolving occlusion of small arteries that cannot be surgically treated. Further, it may serve as a prelude to vascular surgery. Thrombolytic therapy for arterial thrombi in locations other than the limbs or the coronary arteries has been reported for virtually all organs. For this, the drug may be administered systemically or by regional infusion.</li>
<li>Deep venous thrombosis (DVT): Anticoagulation is the treatment of choice (see earlier). Fibrinolytic therapy may be used to treat those with high risk of pulmonary embolism and those with axillary vein thrombosis.
All the plasminogen activators are effective fibrinolytic agents when given in proper dosage and duration, within stipulated time. SK and urokinase can be administered by bolus injection, or short infusion without heparin. In contrast, rt-PA must be infused for 3 or more hours concurrently with heparin, in order to provide a continuous supply of fresh agent to the thrombus to prevent rethrombosis. SK and anistreplase induce the formation of antibodies, which may limit the response to future administration of these agents.</li>
</ul>
<p>Clinically, no large differences are seen between SK and rtPA, though experimentally rtPA, being selective, appears to be superior. But, it needs heparin supplementation to prevent early re-closure of the vessels, whereas the incidence of stroke is higher than with SK. SK is more cost-effective than rtPA. If the patient has received SK even 4 days earlier, rtPA is preferred.</p>
<p>Aspirin is administered as soon as the thrombolytic therapy is begun and continued as described earlier.</p>
<p>Administration of heparin and aspirin remains the mainstay of treatment in unstable angina. Thrombolytics are not useful and are not recommended.</p>
<p>ARVIN: Arvin is a purified enzyme obtained from the venom of the Malayan Pit Viper, Agkistroden rhodostoma. The enzyme:</p>
<ul>
<li>Converts fibrinogen to an imperfect fibrin polymer that breaks up easily in the circulation and is lysed.</li>
<li>Produces fibrinogen depletion independently of the coagulation and fibrinolytic enzyme systems.
The therapy is controlled by measuring plasma fibrinogen.
The enzyme has been used to treat venous thrombosis. It is administered IV. It reduces</li>
</ul>
<p>the fibrinogen levels, the peak anticoagulant activity occurring 8 to 12 hours after its administration, and fibrinogen levels return to normal within 3 weeks after cessation of therapy. It can also be used IM/SC.</p>
<p>Unlike the conventional anticoagulants. it does not cause a hemorrhagic tendency. However. bleeding may occur from a silent peptic ulcer or a surgical wound. Hemolytic anemia. urticaria and unilateral impairment of vision have been reported. Specific antivenom antidote is available to treat the toxicity. Resistance to the enzyme may occur due to antibody formation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="hemostatic-agents">Hemostatic Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hemostatic-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Bleeding can be controlled by physical methods such as application of direct pressure. tourniquet. cold and use of cautery. Drugs like desmopressin and adrenaline can be used to produce vasoconstriction (see later). Adrenaline is used in the form of nasal pack to control epistaxis after ruling out any systemic cause such as hypertension.</p>
<p>When bleeding is the consequence of a specific defect in hemostasis such as hemophilia, the ideal treatment is to correct the defect. Such specific treatment, however, may not be possible because the bleeding may be due to multiple defects or no specific cause can be identified. Major blood loss commonly occurs during surgery, trauma and some medical conditions. In such cases nonspecific hemostatic therapy has to be employed.</p>
<p>Drugs used for hemostatic therapy are:
I Agents acting locally
II Transfusional agents such as specific coagulation factors
III Nontransfusional agents, e.g., Vitamin K and antifibrinolytic agents e.g. Epsilon aminocaproic acid and Tranexamic acid.
I Agents acting locally: These agents control oozing of blood from minute vessels but are not effective in controlling bleeding from large vessels. They are:</p>
<p>THROMBIN: Thrombin is obtained from bovine/human plasma. It is stable as a dry powder stored between <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>2</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">2^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord">2</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>8</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">8^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord">8</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span>. It is, however, inactive below pH 5 . Thrombin therapy is restricted to local application in oozing of blood. It has also been used, mixed with plasma, to anchor skin grafts.</p>
<p>THROMBOPLASTIN: Thromboplastin is a powder prepared from the acetone extracts of brain and/or lung tissue of freshly killed rabbits. It is used for determination of prothrombin time and as a local haemostatic in surgery.</p>
<p>FIBRIN: Fibrin obtained from human plasma is used in the dehydrated form as sheets to cover bleeding surfaces. When used in combination with a thrombin solution, it also acts as a mechanical barrier and holds thrombin in position over the bleeding area.</p>
<p>GEL FOAM: Gel foam is a porous, pressed form of gelatin sponge used in conjunction with thrombin to control oozing of blood from surface wounds. Gel foam is moistened with isotonic saline before use. It is completely absorbed within 4 to 6 weeks and hence, may be left in place after suturing of a wound. It is available as cones, packs, sponges and powder.</p>
<p>OXIDISED CELLULOSE, Oxycel, is surgical gauze treated with nitrogen dioxide. It promotes clotting by a reaction between hemoglobin and cellulosic acid. Oxycel, when wet with tissue fluid, becomes sticky and gummy and exerts its haemostatic effect by mechanical blockage. Oxycel is usually absorbed completely within 2 to 10 days. It interferes with bone regeneration.</p>
<p>MICROFIBRILLAR COLLAGEN: This hemostatic material is prepared from purified, bovine corium collagen. When applied to a bleeding surface, it attracts platelets to initiate formation of a platelet plug followed by a natural clot. Used along with manual pressure, it is effective in controlling capillary bleeding, even in patients on heparin or oral anticoagulants, and in hemophiliacs. It is non-allergenic but can promote local infection and abscess formation. It may conceal deep hemorrhage/hematoma in a penetrating wound. The residual unused material should be discarded. Care should be taken to avoid</p>
<p>spillage over nonbleeding surfaces, especially abdominal or thoracic viscera. As it is inactivated by autoclaving, it should not be sterilised.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-transfusional-agents">II Transfusional agents:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-transfusional-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>HUMAN FIBRINOGEN: Fibrinogen, a sterile fraction from human plasma, is used for restoring normal fibrinogen levels in haemorrhagic complications caused by acute afibrinogenemia. Fibrinogen and thrombin may be employed together for local haemostasis.</p>
<p>ANTIHAEMOPHILIC GLOBULIN (AHG): Haemophilia A and Christmas disease (haemophilia B) are the two commonest hereditary haemorrhagic states, due to deficiency of specific clotting factors VIII and IX respectively. Antihaemophilic globulin or concentrate of factor VIII (AHG) is highly effective in the treatment of classical haemophilia-A. High potency human AHG is prepared from pooled, normal, human plasma; it is now prepared by recombinant DNA technique. It is given in the dose of 15-60 units/kg daily. Simultaneous use of fibrinolytic inhibitors like EACA can reduce the dose of AHG required. The half-life of injected factor VIII in a haemophiliac, is about 12 hours. In case of non-availability of AHG, fresh plasma or blood transfusion is used. Desmopressin (Chapter 39), which causes release of AHG from its stores, transiently increases its blood level and may be helpful in mild-moderate hemophilic bleeding.</p>
<p>Pure recombinant factor VIII, factor IX and activated factor VII (rFVIIa) are available. They are very expensive and may be associated with a greater risk of inducing IgG antibodies to factor VIII, thus reducing the efficacy of specific therapy. rFVIIa has also been used in major bleeding from surgery, trauma and other medical causes. Treatment should be guided by the physician experienced in the case of hemophilia.</p>
<p>In patients with Christmas disease, fresh or stored plasma infusion is indicated to replenish the factor IX which is stable on storage.</p>
<p>PLASMA or BLOOD: Fresh frozen plasma is suitable for the treatment of most coagulation disorders, since it provides all the clotting factors. Concentrate of factor VIII (purified) and a partially purified preparation containing factors II, VII, IX and X are also available for specific deficiencies. Whole blood for replacement of coagulation factors may not be ideal as large volumes required carry the risk of transfusion reactions.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-non-transfusional-agents">III Non-transfusional agents:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-non-transfusional-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>VITAMIN K: Vitamin K comprises three distinct fat soluble, naphthoquinone compounds which participate in the biosynthesis of several clotting factors:
(i) Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">K</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{K}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">K</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (phytonadione) is found in several foods and also prepared synthetically.
(ii) Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">K</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{K}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">K</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, produced by the bacteria in the GI tract and supplies almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of the human requirements.
(iii) Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">K</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{K}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">K</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (menadione) a synthetic compound used for therapeutic purposes. The diphosphate salt of menadione is water soluble.
Pharmacological actions: Vitamin K in its reduced form is essential for the biosynthesis of 'active' coagulation related proteins (coagulation factors). It participates in the carboxylation of the glutamic acid residues of prothrombin and factors VII, IX and X in the final stage of their synthesis (see earlier). Vitamin K is also shown to be involved in electron transport (coenzyme) and oxidative phosphorylation.</p>
<p>Absorption, fate and excretion: Vitamin K is produced by the flora of the human intestine. The fat soluble vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">K</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{K}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">K</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{K}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> are absorbed in the presence of bile salts, while</p>
<p>the water soluble menadione salts can be absorbed even in their absence. The exact daily requirement of vitamin K is not known. Both the lipid and water soluble preparations are satisfactorily absorbed on parenteral administration.</p>
<p>Adverse reactions: These are rare after oral administration. However, serious anaphylactoid reactions can occur after IV use. Large doses of synthetic menadione have produced haemolytic anaemia, hyper-bilirubinemia and kernicterus in newborn, especially in premature infants. Menadione competes with bile salts for glucuronide detoxification mechanism causing the accumulation of bile salts in the blood and this results in jaundice. Haemolysis with menadione is usually seen in infants, whose RBC lack the enzyme G6PD. Patients with liver disease should not be given repeated, large doses of vitamin K.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Adult vitamin K deficiency which may be produced by (a) Malabsorption syndrome or obstructive jaundice. (b) Long term intravenous feeding (prophylactic use). (c) Prolonged periods of malnutrition. Menadione may be used.</li>
<li>Vitamin K deficiency in infants during acute diarrhoea. Menadione may be used.</li>
<li>Neonatal vitamin K deficiency, for prevention and treatment.</li>
<li>Bleeding state during coumarin anticoagulant (warfarin) therapy.</li>
</ul>
<p>Vitamin K can generally be given orally but being fat soluble requires the presence of bile salts for its absorption. It can also be given SC, IM or IV.</p>
<p>Menadione preparations are NOT useful in treating oral anticoagulant induced bleeding, and may cause adverse reactions in neonates with vitamin K deficiency. They should not be used in the last weeks of pregnancy to avoid neonatal hemorrhagic disease.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="preparations">Preparations:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">K</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{K}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> tablets and injection for IV use. Dose: 20 mg orally; 10 mg IV over 30 min to reduce the risk of anaphylactoid reaction.
(ii) Menadione 5 mg tablets. Dose <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5-10 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily. It is water soluble
(iii) Menadione sodium diphosphate injection, 5 and 10 mg per ml . Dose <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5-15 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> once or twice daily, SC, IM or IV.</p>
<p>EPSILON AMINOCAPROIC ACID (EACA): This is a water soluble analogue of the amino acid lysine (Fig 33.7).
<img src="assets/images/image-20251214-01da52e6.jpeg" alt="img-37.jpeg"></p>
<p>Mechanism of action: Lysine analogues reversibly occupy the lysine binding sites on plasminogen and inhibits fibrin binding to plasminogen. Activation of plasminogen to plasmin is thus inhibited. This impairs fibrinolysis with consequent stabilisation of clot.</p>
<p>Orally, it is rapidly absorbed; the peak level after a single dose is achieved in about 2 hours. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60-90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> of the dose is excreted in the urine within 24 hours. A blood level of 13 mg per 100 ml is required for plasminogen inhibition, whereas 130 mg per 100 ml inhibits plasmin activity.</p>
<p>Adverse reactions: The drug has been reported to produce mild side effects such as</p>
<p>nasal stuffiness, abdominal discomfort, dyspepsia, hypotension, conjunctival erythema, nausea, vomiting, diarrhoea and skin rash. A rare, lethal complication is disseminated intravascular thrombosis.</p>
<p>Preparation and dosage: See below.
Therapeutic uses: The drug has been found to be useful in preventing the hyperplasminaemic bleeding state following the damage to tissues rich in plasminogen activator, e.g.</p>
<ul>
<li>Primary menorrhagia (Chapter 67).</li>
<li>During prostatic surgery.</li>
<li>Major trauma with risk of bleeding</li>
<li>Upper GI bleeding.</li>
<li>Bleeding following dental extraction in patients with coagulation disorders; and</li>
<li>Bleeding associated with thrombocytopenia and postpartum hemorrhage.</li>
</ul>
<p>It is given in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">100 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> loading dose (upto 10 g ), and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> (upto 5 g ) 6 hourly for 2-3 days. No more than 30 g should be given in 24 hours. It is also given IV during surgery. Although the drug has been employed to control bleeding during prostatectomy, it is contraindicated in the event of hematuria because of the risk of ureteral occlusion by unlysed clot.</p>
<p>TRANEXAMIC ACID (TA), also a derivative of lysine, is about 10 times more potent than EACA and has a longer duration of action. It is clinically preferred and is used in the dose of 1-1.5 g 3-4 times daily. Adverse reactions are mild and include nausea, diarrhoea and hypotension.</p>
<p>Both EACA and TA are contraindicated in patients with subarachnoid haemorrhage because they may induce vasospasm and ischemic stroke.</p>
<p>Ethamsylate is used for similar indications as EACA and TA. It probably acts by correcting abnormal platelet adhesion. It does not stabilise fibrin. The oral dose is 500 mg four times a day.</p>
<p>Aprotinin: It is a polypeptide obtained from bovine lung. It inhibits the action of several proteases such as plasmin, trypsin, chymotrypsin and kallikrein by formation of reversible enzyme-inhibitor complex. Hence, aprotinin inhibits the initiation of both coagulation and fibrinolysis. The drug was used mainly during cardiac surgery to reduce blood loss. Because of cardiovascular toxicity, stroke and renal failure, it has been withdrawn.</p>
<p>Ecallantide, a Kallikrein inhibitor is now used in cardiothoracic surgery to prevent blood loss (Chapter 23).</p>
<p>DESMOPRESSIN: This analogue of arginine vasopressin (Chapter 39), given IV or SC, increases for a short time the plasma concentration of factor VIII in hemophiliacs, and of von Willebrand factor, the adhesive protein that is deficient or defective, in patients with von Willebrand disease. Demopressin is considered a treatment of choice for patients with mild hemophillia-A or type I von Willebrand disease. It shortens or normalises the bleeding time in patients with congenital defects of platelet function. It has also been found of some use in acquired bleeding disorders such as during uremia, and following drugs like aspirin. Desmopressin is also used for acute variceal bleeding (see below). Adverse effects are mild and include headache, water retention and hyponatremia.</p>
<p>The major risk involved in using agents that potentiate hemostasis is thrombotic complications.</p>
<p>CONJUGATED ESTROGENS (Refer Chapter 67 for menorrhagia): Given IV in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.6</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.6 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.6</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>, daily, they improve platelet function, shorten the prolonged bleeding time, and reduce or stop bleeding in uremic patients. Compared to desmopressin, they have a delayed onset but much longer duration of action on bleeding time. They can be combined with desmopressin for synergistic effect. They have been used daily for 5-7 days with hardly any adverse reaction.</p>
<p>Vitamin C: Vitamin C (50-100 mg tid) specifically controls bleeding due to scurvy.
Snake Venoms: Snake venoms, especially Russel Viper and Copper Head snake venoms, enhance coagulation by stimulating thrombokinase.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="management-of-acute-variceal-bleeding">Management of Acute Variceal Bleeding<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#management-of-acute-variceal-bleeding" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Bleeding from esophageal varices is a common complication of advanced cirrhosis of the liver. Esophageal varices are dilated anastomoses between systemic veins and portal venous system, which help to decompress the increased portal venous pressure. In cirrhosis, increased cardiac output and splanchnic vasodilatation causes increased blood flow to the liver. This along with increased portal venous resistance leads to dilation of esophageal/gastric varices, which tend to rupture and cause hematemesis.</p>
<p>Acute bleeding can be controlled by reducing the portal pressure by using</p>
<ul>
<li>l-arginine vasopressin, desmopressin or long acting analogue terlipressin (triglycyl-lysine-vasopressin) which act by constricting mainly the splanchnic blood vessels decrease the blood flow in portal venous system and they reduce variceal bleeding. Vasopressin is given as 20 units IV infusion. Terlipressin is given IV as bolus, 4 hrly usually for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>48</mn><mo>−</mo><mn>72</mn></mrow><annotation encoding="application/x-tex">48-72</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">48</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">72</span></span></span></span></span> hrs.</li>
<li>Somatostatin/octreotide also decreases splanchnic blood flow (Chapter 62).</li>
<li>Prophylactically, non-selective beta-adrenergic blockers such as propranolol or nadolol may be useful. Because of the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonism, they reduce the cardiac output while the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> antagonism allows unopposed <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> adrenergic vasoconstriction. In practice, their dose can be regulated by monitoring the reduction in pulse ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> ), although direct measurement of the portal/systemic venous pressure gradient is to be preferred.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="sclerosing-agents">Sclerosing Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sclerosing-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Sclerosing agents are irritating substances employed to obliterate varicose veins and uncomplicated piles. They act locally.</p>
<p>The important preparations are:</p>
<ul>
<li>Sodium tetradecyl sulfate is an anionic detergent, marketed as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>3.0</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5-3.0 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">3.0%</span></span></span></span></span> solution: given IV as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1.0</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">0.5-1.0 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">1.0</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> at upto 4 sites.</li>
<li>Ethoxy scleral (3%) in 5% aqueous ethanol (Polidocanol), a nonionic detergent.</li>
<li>Phenol, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> in vegetable oil, in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>3</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">2-3 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">3</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>, given into the submucosal layer at the base of each pile; maximum total dose 10 ml at any one time.</li>
<li>Sodium linoleate. The dose varies from 0.5 to 5 ml by intravenous route, locally.</li>
<li>Ethanolamine oleate 5%. Dose: 2-5 ml divided between 3-4 sites.</li>
<li>Sodium morrhuate 1-2 ml of 5% solution per site. Total 15-25 ml at one sitting.</li>
</ul>
<p>34</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-effective-in-iron-deficiency-and-other-related-anemias">Drugs Effective in Iron Deficiency and Other Related Anemias<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-effective-in-iron-deficiency-and-other-related-anemias" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Anemia is one of the most common disorder in clinical practice. It is characterised by a decrease in the oxygen carrying capacity of the blood which is determined by the haemoglobin content of the erythrocytes. A reduction in the blood haemoglobin level and in the number of circulating erythrocytes are the hallmarks of anemia.</p>
<p>Erythropoiesis: The erythrocytes are produced in the bone marrow and are destroyed by the reticuloendothelial system. The maturation of erythrocytes occurs through several stages. The precursor cell in the bone marrow is the proerythroblast or haemocytoblast, which is subsequently converted to early, intermediate and late normoblast. The nucleus of the late normoblast becomes pyknotic along with the appearance of a reticulum in the cytoplasm, resulting in the formation of a reticulocyte. It takes the reticulocyte approximately 4 days to mature into a normal erythrocyte. The normal life span of a human erythrocyte is roughly 110 to 120 days.</p>
<p>Various factors such as lack of oxygen, vitamin C, growth hormone and thyroxine stimulate erythropoiesis. The red cell mass is continually adjusted to the optimum quantity for its function as an oxygen carrier by messages transmitted to the bone marrow from an oxygen sensor in the kidneys. These messages are mediated by a glycoprotein hormone, erythropoietin (EPO), produced by the kidneys.</p>
<p>Deficiency of dietary factors such as iron, folic acid and vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, and of EPO disturbs the normal erythropoiesis resulting in anemia.</p>
<p>Anemias may be classified according to their etiology:
I Anemias due to increased requirement of essential nutrients e.g. in pregnancy, growing children, lactating women.</p>
<p>II Anemias due to nutritional deficiency or malabsorption of factors essential for blood formation, e.g. Iron, Folic acid, Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, Vitamin C, and Pyridoxine.</p>
<p>III Anemias due to blood loss such as menorrhagia, GI loss and hookworm infestation.
IV Anemias due to excessive hemolysis, e.g. thalassemia, sickle cell anemia, malaria and autoimmune haemolytic anemia.</p>
<p>V Anemias due to aplasia or hypoplasia of the bone marrow, such as idiopathic or following certain drugs such as anticancer drugs and chloramphenicol.</p>
<p>VI Anemia due to deficiencies of erythropoietin as in chronic renal disease.
VII Anemias of uncertain origin, e.g. due to chronic infections, rheumatoid arthritis, liver disease and cancer.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iron-metabolism">Iron Metabolism<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iron-metabolism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Iron deficiency anemia is caused by deficient synthesis of hemoglobin of which iron is an essential constituent. Iron is present in every cell in the body. The total iron content of the body varies between 2 and 3 gm depending upon the body weight and hemoglobin level. In adult males the iron content is estimated to be about 50 mg per kg body weight as compared to only 35 mg per kg body weight in adult females. The body iron is distributed as:</p>
<ul>
<li>Heme, in hemoglobin, myoglobin, and in cytochrome oxidase and other enzymes.</li>
<li>Iron bound to protein, without heme formation, as the storage compounds, water soluble ferritin and insoluble hemosiderin; and</li>
<li>Transport iron bound to transferrin.</li>
</ul>
<p>Hemoglobin has an iron-containing moiety, metalloporphyrin or heme, combined with the protein globin. The molecular weight of hemoglobin is 64,500 . Porphyrin consisting of 4 pyrrole rings and the protein globin are both synthesised in the body. About 2/3rds of the total body iron is in the form of hemoglobin.</p>
<p>Myoglobin is the heme protein of skeletal and cardiac muscle with molecular weight 16,800 .</p>
<p>Parenchymal iron exists as a component of various cellular enzymes either concerned with tissue respiration or linked to cellular metabolism.</p>
<p>Iron absorption: The amount of iron available from food depends upon its iron content as well as absorbability which differs with different foods. Iron from animal foods is better absorbed than that from vegetable foods. Heme iron is by far the most available (20-40%) and its absorption is independent of the food composition. It gets absorbed intact. However, non-heme fraction represents by far the largest amount in a vegetarian diet. This form needs reduction to ferrous iron <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msup><mrow><mi mathvariant="normal">F</mi><mi mathvariant="normal">e</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{Fe}^{++}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.2em; vertical-align: -0.35em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;"><span class="delimsizing size1">(</span></span><span class="mord"><span class="mord"><span class="mord mathrm">Fe</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;"><span class="delimsizing size1">)</span></span></span></span></span></span></span>prior to absorption.</p>
<p>The mean absorption of iron from vegetable foods ranges from <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> for rice, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> for wheat to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">6 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">6%</span></span></span></span></span> for soyabeans, while for animal foods it ranges from <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>11</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">11 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">11%</span></span></span></span></span> for fish, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">12 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">12%</span></span></span></span></span> for meat hemoglobin to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>13</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">13 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">13%</span></span></span></span></span> for liver. Milk and milk products are a poor source of iron. Use of iron cooking utensils increases the iron content of food. Absorption of inorganic iron salts can occur from any part of the GI tract; however, there exists an absorption gradient, decreasing from the duodenum to colon. Maximum iron absorption occurs in the duodenum.</p>
<p>Mechanism of iron absorption: The iron is absorbed via the brush borders of the intestinal lining cells. The absorption depends as much on its form as on its absolute amount. Two mechanisms for iron absorption have been postulated. These are:</p>
<ul>
<li>An active transport process which actively transports ferrous iron from intestinal lumen into mucosal cells with the help of a carrier protein. The absorption of iron is probably controlled by the availability of apoferritin, a protein present in the mucosal cells. The absorbed iron combines with apoferritin to form ferritin and is stored. Iron is actively released into blood as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">F</mi><mi mathvariant="normal">e</mi></mrow><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Fe}^{+++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Fe</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+++</span></span></span></span></span></span></span></span></span></span></span></span></span>from basolateral side by ferroproteins as per body needs. When apoferritin gets fully saturated to ferritin, no more iron is absorbed. Thus, in normal individuals the body is protected from possible excessive absorption of the metal. This regulation by the mucosa, however, is relative and partial. In iron deficiency, however, the amount of apoferritin synthesised is reduced and iron passes through the cells into the blood.</li>
</ul>
<p>Iron deficiency, decreased iron stores and accelerated erythropoiesis due to any cause increase iron absorption. It is less influenced by plasma iron level.
Within the mucosal cells, iron exists as:
(1) Mobile iron <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><msup><mrow><mi mathvariant="normal">F</mi><mi mathvariant="normal">e</mi></mrow><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">-\mathrm{Fe}^{+++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord">−</span><span class="mord"><span class="mord"><span class="mord mathrm">Fe</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+++</span></span></span></span></span></span></span></span></span></span></span></span></span>, and
(2) Storage iron - ferritin.</p>
<p>This intracellular ferritin is eventually excreted during desquamation of the epithelial cells, as a part of the regular shedding of the intestinal mucosa.</p>
<ul>
<li>A passive transport process, by which iron diffuses across the intestinal villi, perhaps in combination with amino acids such as glycine and serine, has been described. This mechanism probably operates primarily at doses of iron exceeding the amounts in a normal diet.
Hepcidin, an iron-regulatory peptide, plays an important negative role in iron absorption. It is 'an acute phase protein', and its synthesis by the liver is increased in acute and chronic inflammatory diseases and cancer. It:
(i) Inhibits iron transport across the cell membranes, and reduces the GI absorption of dietary iron and
(ii) Blocks the release of stored iron from hepatocytes and macrophages.</li>
</ul>
<p>Normally, hepcidin production is regulated by iron stores and erythropoietic activity. Hepcidin mediated iron sequestration is a common cause of iron deficiency anaemia in chronic inflammation. High levels of hepcidin have been observed in several inflammatory diseases such as RA, IBD, chronic infection and malignancy. It causes retention of iron in macrophages and enterocytes leading to hypoferreamia and decreased iron dependent erythropoeisis. Such patients are unresponsive to oral iron and might need intravenous iron.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="factors-affecting-iron-absorption">Factors affecting iron absorption:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#factors-affecting-iron-absorption" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Type of iron: Iron is reduced from ferric to ferrous form before it is absorbed in the small intestine. Food iron is ionised in the stomach under the influence of gastric acid. Hypochlorhydria may thus reduce the amount of iron absorbed from the food. Heme iron present in animal foods is absorbed better than non-heme iron. Ferric hydroxide iron complexes present in the vegetarian foods are absorbed poorly.</li>
<li>Reducing agents present in the diet, such as ascorbate, succinate, and the SH groups of amino acids like cysteine, and proteins convert ferric iron to ferrous form and help the iron absorption.</li>
<li>A diet poor in phosphorus enhances iron absorption, while phytates and organic phosphates (as in vegetarian foods) interfere with iron absorption by forming insoluble and unabsorbable complexes. Wheat is rich in phytates; only about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> of wheat iron is absorbed, which increases to only about 7% during iron deficiency. Egg iron is strongly complexed to the phosphate of yolk phosphoproteins and is poorly absorbed.</li>
<li>Antacids such as calcium carbonate, aluminium hydroxide and magnesium hydroxide reduce iron absorption.</li>
<li>Other drugs like tetracycline, levodopa, fluroquinolones, captopril, bisphosphonates and thyroxine interfere with iron absorption.</li>
<li>Administration of iron along with or after food reduces its absorption. However, in practice, ferrous salts are usually administered after food to minimise gastric irritation.</li>
<li>Pancreatic secretion has an inhibitory effect on iron absorption and prevents iron overload. In severe chronic pancreatitis and liver cirrhosis, iron absorption is greatly</li>
</ul>
<p>increased. Pyridoxine deficiency also enhances iron absorption despite elevated plasma iron levels.</p>
<ul>
<li>Iron deficiency accelerates iron absorption. Individuals with iron deficiency absorb 20 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> of the food iron (compared to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5-10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> in normals), while the absorption of iron in organic form (vegetables and meat) is approximately doubled, and that of inorganic iron is increased 5 to 6 fold.</li>
<li>Pica: Iron deficiency can promote appetite for bizarre foods (pica). If clay is consumed (geophagia), there occurs chelation of iron in the gut, worsening the iron deficiency.</li>
<li>GI Disorders: Partial gastrectomy and extensive bowel surgery reduce absorption of food iron. Absorption of inorganic iron salts, however, is less impaired. Cachexia, infectious diseases and malabsorption syndrome reduce iron absorption.
Iron transport and utilisation: After absorption or after release from storage site, iron circulates in the blood bound to a beta globulin fraction, siderophilin or transferrin to reach the sites of its intracellular utilisation. In iron deficiency, increased number of transferrin receptors increase the cellular iron uptake. The liver parenchymal cells are the major site of transferrin synthesis. Transferrin is normally one-third saturated with iron.</li>
</ul>
<p>Plasma iron is normally in equilibrium with iron stores. The normal plasma iron level varies between <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>66</mn><mo>−</mo><mn>146</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">66-146 \mathrm{mcg} / 100 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">66</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">146</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/100</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>. The plasma iron level and plasma unsaturated binding capacity are modified by:
(a) Iron deficiency which is associated with a reduction in serum iron levels and an increase in iron binding capacity.
(b) Haemochromatosis which is associated with high serum iron levels and reduced binding capacity. A similar picture is seen in pernicious and aplastic anemias; and
(c) Acute and chronic infections which are generally associated with reduced serum iron due to sequestration and decreased binding capacity (see later).</p>
<p>The daily iron turnover has been estimated to be approximately 35 mg . The major contribution to this, 21 mg , comes from the normal red cell destruction; iron thus released is reutilised. About 11 mg of iron is contributed by that fraction which is not used for hemoglobin production during its stay in the marrow while the remaining 2-3 mg comes from the storage sites, intestinal absorption and the ECF.</p>
<p>From these 35 mg of iron, about 32 mg enter the 'erythropoietic labile pool', a poorly defined compartment, primarily in the bone, for erythropoiesis. Approximately 1 mg of iron goes for storage and into the ECF each, and about 1 mg is excreted.</p>
<p>The labile iron pool is that part of body iron which is readily available for utilisation for haemoglobin synthesis. Iron quickly enters this pool after absorption from the intestine, after release from the RBC breakdown and following an iron injection. If the amount entering this labile pool is in excess of needs, then it is transferred into storage pool.</p>
<p>Iron transfer to maturing erythrocytes (erythron) occurs mainly by binding transferrin to specific receptor sites on the membrane of the erythrocyte precursors. The iron released and inserted into the porphyrin ring to form heme is now considered to be controlled by enzymes situated in the cell mitochondria. Failure of this process causes 'sideroachrestic anemias'. The anemias of lead poisoning and of thalassemia are of this type. In such cases iron granules are seen in the cytoplasm of erythroblasts.</p>
<p>Iron storage: About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> of the total body iron is in the form of storage iron; iron deficiency anemia does not appear until the stores are largely depleted. Iron is stored</p>
<p>predominantly in the form of ferritin and hemosiderin in bone marrow, liver, spleen and other areas with prominent reticuloendothelial components. Hemosiderin is probably a polymer of ferritin but unlike ferritin, it is not soluble in water. Conversion of iron to ferritin in the body is rapid, the normal stores being 0.5 to 1.5 g . Both ferritin and hemosiderin are available for heme synthesis.</p>
<p>The concentration of serum ferritin is normally in equilibrium with body iron stores. Serum ferritin measurement, therefore, can be used to evaluate body iron stores. Usually <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mn>1</mn></mrow><annotation encoding="application/x-tex">1 \mathrm{mcg} / 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/1</span></span></span></span></span> of serum ferritin corresponds to 8 mg of storage iron.</p>
<p>Iron excretion: Iron is tenaciously conserved. The body iron is regulated mostly by regulation of iron absorption by the gut. The total iron excreted daily is 0.5 to 1 mg via:</p>
<ul>
<li>Intestine: Iron is excreted in the faeces with the exfoliation of the villous cells. Iron is also lost by desquamation of the skin and hair.</li>
<li>Bile and sweat: Traces of iron are lost in bile and sweat. However, in tropical climate like in India, sweat may be a major channel of iron loss and amounts as high as 2 to 3 mg may be excreted daily in sweat.</li>
<li>Urine: Urinary iron excretion is 0.1 mg daily.</li>
<li>Menstrual blood: One ml of blood contains 0.5 mg of iron and the iron loss due to menstruation, spread evenly over the 28 days of the cycle, is 0.3 to 0.6 mg per day.</li>
<li>Milk: Upto 1.5 mg appears in milk daily during lactation.</li>
</ul>
<p>Iron requirements and sources: Table 34.1 gives the daily iron requirements. Vegetable foods rich in iron (containing 10 mg of iron per 100 g ) include cereals like bajra, rice bran, whole wheat flour, pulses like Bengal gram, many leafy vegetables like spinach, peas and beans, condiments like turmeric and tamarind pulp, bananas and jaggery. The iron content of milk is so poor <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>0.2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">(0.2 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">0.2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span> ) that an infant fed on cow's milk alone would need 10 litres daily to get its daily requirement of iron! Among the non-vegetarian foods, egg yolk, crab muscle, meat, liver and heart are rich in iron.</p>
<p>Table 34.1
Daily dietary iron requirements*</p>
<p><sup><a href="#user-content-fn-0" id="user-content-fnref-0-6" data-footnote-ref="true" aria-describedby="footnote-label">1</a></sup>Based on 5-10% absorption of food iron.
"Based on the monthly loss of 50 ml of blood ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo><mn>25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">=25 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> of iron).
"Based on the fetal accumulation of 200-400 mg of iron and loss during child birth.
Preparations and dosage: Table 34.2 lists the commonly used iron salts for oral use:</p>
<p>Table 34.2
Iron preparations for oral therapy</p>
<table><thead><tr><th style="text-align: left;">Preparation</th><th style="text-align: center;">Therapeutic <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>d&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {d }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">d&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> dose mg/day</th><th style="text-align: center;">Total iron content mg</th><th style="text-align: center;">Percent utilisation of iron</th></tr></thead><tbody><tr><td style="text-align: left;">- Exsiccated ferrous sulfate</td><td style="text-align: center;">600</td><td style="text-align: center;">180</td><td style="text-align: center;">15</td></tr><tr><td style="text-align: left;">- Ferrous gluconate</td><td style="text-align: center;">900</td><td style="text-align: center;">108</td><td style="text-align: center;">11</td></tr><tr><td style="text-align: left;">- Ferrous fumarate</td><td style="text-align: center;">600</td><td style="text-align: center;">198</td><td style="text-align: center;">15</td></tr><tr><td style="text-align: left;">- Iron and ammonium citrate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi>c</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{c}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6644em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6644em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">c</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">6000</td><td style="text-align: center;">1200</td><td style="text-align: center;">1.5 to 3</td></tr><tr><td style="text-align: left;">- Ferrous succinate</td><td style="text-align: center;">300</td><td style="text-align: center;">105</td><td style="text-align: center;">-</td></tr></tbody></table>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>8</mn></msup></mrow><annotation encoding="application/x-tex">{ }^{8}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">8</span></span></span></span></span></span></span></span></span></span></span></span></span> Given only in liquid form; the rest either as tablets or in liquid form.
'Prophylactic dose <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">1 / 3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0991em; vertical-align: -0.25em;"></span><span class="mord">1/</span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> or less.
(i) Dried ferrous sulfate tablet 200 mg .
(ii) Ferrous sulfate syrup. 60 mg of ferrous sulfate ( 12 mg of iron) in 5 millilitres.
(iii) Ferrous sulfate paediatric drops for infants contain 125 mg of ferrous sulfate ( 25 mg of iron) in each millilitre.
(iv) Ferrous gluconate 300 mg tablets. Elixir of ferrous gluconate 36 mg of iron per 5 ml .
(v) Ferrous fumarate: 200 mg tablets.
(vi) Iron and ammonium citrate is a scaly ferric preparation soluble in water and is administered in the form of a mixture in the dose of 2 g tid.
(vii) Ferric hydroxide polymaltose complex ( 100 mg of elemental iron per tablet). This is an expensive preparation which offers hardly any advantage. Therapeutic failures have been reported with this preparation.</p>
<p>Therapeutic uses: Iron deficiency anaemia can occur due to:
(1) Absolute iron deficiency
(2) Functional iron deficiency as in erythro-poeitin stimulated erythropoeisis; and
(3) Sequestration of iron as in anaemia of chronic diseases.</p>
<p>Iron should generally be administered orally. Many iron preparations are marketed but there is little to recommend them over the cost effective ferrous sulfate. Sustained release and enteric coated iron preparations are generally poorly dissolved in the gastric and intestinal secretions, and may be lost in the feces.</p>
<p>Indications for iron therapy are summarised in Table 34.3.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-34-3">Table 34.3<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-34-3" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Indications for iron therapy</p>
<p>Prophylactic: Pregnancy; infancy; rapidly growing children; menstruating wo men; elderly, professional blood donors; following partial gastrectomy.
Therapeutic: i. e. to treat existing iron deficiency anemia.</p>
<ul>
<li>Nutritional deficiency due to deficient intake or decreased absorption.</li>
<li>Anemia of pregnancy, infancy, prematurity and prolonged breast feeding.</li>
<li>Anemia due to acute or chronic blood loss as in menorrhagia, peptic ulcer and hook-worm infestation. (Blood loss of 100 ml corresponds to a loss of 50 mg of iron)</li>
<li>Chronic kidney disease.</li>
<li>Chronic inflammatory disease</li>
</ul>
<p>As iron deficiency develops, iron stores diminish, as reflected by reduced and later absent stainable iron, hemosiderin. The most sensitive diagnostic test for detection of early or mild iron deficiency is the iron staining of the bone marrow. In fact, prelatent iron</p>
<p>deficiency is characterised by the absence of stainable iron in the bone marrow, increased iron absorption but no decrease in either serum iron or hemoglobin concentration.</p>
<p>The iron deficiency anemia is characterised by the presence of small erythrocytes (microcytosis) poorly filled with hemoglobin (hypochromia) and many cells of bizarre shapes (poikilocytosis) and variable sizes (anisocytosis). All hypochromic anemias, however, are not due to iron deficiency. Currently evidence indicates that the metabolic importance of iron extends far beyond the red cell. Even in the absence of anemia, iron deficiency can produce adverse effects on brain function and abnormalities in behaviour; mental performance in children with iron deficiency improves after iron therapy. Rule out thalassemia trait before starting long term iron therapy unless the cause of iron deficiency (e.g. bleeding) is obvious.</p>
<p>The aims of treatment of iron deficiency anemia are:</p>
<ul>
<li>Correction of hemoglobin.</li>
<li>Correction of the underlying cause; and</li>
<li>Building up body iron stores.</li>
</ul>
<p>Routinely any cost effective preparation such as ferrous sulphate or ferrous gluconate is preferred. Tablets are more convenient than fluid preparations; further, they do not blacken the teeth and the tongue. The fluid preparations, however, are preferred in children and in the presence of dysphagia and peptic ulcer.</p>
<p>The great majority of patients do not experience any significant adverse effects with 150200 mg of dry ferrous sulfate three times daily after food. Absorption of ferrous sulfate in the usual therapeutic dose varies from 20 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> in iron deficient patients and every day <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50-100 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> of iron gets incorporated in haemoglobin. Dose should be increased at weekly intervals to reduce GI disturbances. If it is not tolerated, the dose should be reduced or other preparations such as ferrous gluconate or ferrous fumarate may be substituted.</p>
<p>During pregnancy, women should receive oral iron supplements (equivalent to 100 mg of elemental iron daily) prophylactically from the fourth month onwards and this should be continued during the lactation period.</p>
<p>Prophylactic iron therapy is also advocated for infants and children, more so in those with low birth weights, the average daily dose of ferrous sulfate varies from 100 to 200 mg .</p>
<p>Professional blood donors should receive routinely 300 mg of ferrous sulfate daily for 1 month after each donation of 500 ml .</p>
<p>Following oral iron, normal hemoglobin level is usually attained within 1 to 3 months, depending mainly on the initial hemoglobin level. It is important, however, to continue with the therapy for 12-20 weeks after the hemoglobin level has returned to normal, in order to replenish the depleted iron stores.</p>
<p>The response to iron therapy is quite predictable. The reticulocyte count in the peripheral blood begins to rise within a week, reaches a peak at 10 to 14 days and returns to normal after about 3 weeks. Reticulocyte response is more striking in children than in adults; however, in children with hemoglobin more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7.5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">7.5 \mathrm{~g} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">7.5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">%</span></span></span></span></span> and in adults, the rise in hemoglobin level may be the only indication of response to iron therapy.</p>
<p>The response to oral iron is considered satisfactory when the hemoglobin level increases by about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">1.5 \mathrm{~g} / 100 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/100</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> of blood within three weeks. Most patients respond to oral therapy satisfactorily if iron is taken regularly and it is absorbed. Table 34.4 lists the causes of failure of oral iron therapy.</p>
<p>Table 34.4
Causes of failure of oral iron therapy</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>- Incorrect diagnosis
</span>- Non-compliance
- Continued loss of blood
- Defective iron absorption
- Superimposed infection or inflammation;
- Severe protein deficiency
- Underlying uremia or malignancy</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="- Incorrect diagnosis
- Non-compliance
- Continued loss of blood
- Defective iron absorption
- Superimposed infection or inflammation;
- Severe protein deficiency
- Underlying uremia or malignancy" style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>Adverse reactions to oral iron: All iron preparations are probably equally toxic per unit mass of soluble iron. They produce mild GI disturbances characterised by colicky pain, nausea, vomiting, diarrhoea or constipation, and gastric distress in about 6 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">12 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">12%</span></span></span></span></span> of individuals. These disturbances can be minimised by giving iron with food and by a gradual increase in the dosage. The daily dose should not exceed six 200 mg tablets of exsiccated ferrous sulfate ( 180 mg of elementary iron). Iron administered in liquid form may combine with sulfide ions in the mouth forming black iron sulfide which causes blackening of teeth; this can be avoided by using a straw for drinking. Oral iron invariably makes the faeces black due to iron sulfide; this may interfere with detection of occult blood in the stools with old tests, but not by newer tests.</p>
<p>Acute iron poisoning is rare in adults but is not uncommon in children and infants. Doses of 1 g or more of ferrous sulfate are considered toxic in children. Ingestion of large doses of iron is associated with severe GI irritation, hematemesis, vomiting, diarrhoea, cardiovascular collapse and shock. Death may occur within 12 to 48 hours. Some may develop jaundice, hypoglycemia and convulsions. Even if recovery occurs, sequelae such as GI obstruction may prove troublesome. Every patient should be warned to keep the tablets away from children who may mistake them for sweets.</p>
<p>Indications for parenteral iron: Response to oral or parenteral iron preparations is essentially similar, with average daily hemoglobin rise of about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.2 \mathrm{~g} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">0.2</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">%</span></span></span></span></span>. Hence, parenteral therapy is used only under special circumstances (Table 34.5).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-34-5">Table 34.5<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-34-5" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Indications for parenteral iron therapy</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>- Failure to absorb adequate amounts of oral iron e.g. malabsorption or extensive bowel resection.
</span>- Inability to tolerate oral iron
- Ulcerative colitis, colostomy and intestinal shunts.
- Depleted iron stores as in patients with chronic bleeding, in whom the average daily ironlosesqualsorexceedsabsorption of iron fromoral iron preparations.
- When the patient cannot be relied upon to take oral iron medication.
- Patients with advanced kidney disease requiring erythropoietin.
- Chronic inflammatory diseases</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="- Failure to absorb adequate amounts of oral iron e.g. malabsorption or extensive bowel resection.
- Inability to tolerate oral iron
- Ulcerative colitis, colostomy and intestinal shunts.
- Depleted iron stores as in patients with chronic bleeding, in whom the average daily ironlosesqualsorexceedsabsorption of iron fromoral iron preparations.
- When the patient cannot be relied upon to take oral iron medication.
- Patients with advanced kidney disease requiring erythropoietin.
- Chronic inflammatory diseases" style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="parenteral-iron-releases-inorganic-ferric-iron-preparations-and-dosage">Parenteral iron releases inorganic ferric iron. Preparations and dosage<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#parenteral-iron-releases-inorganic-ferric-iron-preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="for-im-use">For IM use:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#for-im-use" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Iron-dextran: 15 ml vial, 50 mg of elemental iron <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">/ \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>.
(ii) Iron-Sorbitol-Citric acid complex: 1.5 ml vial, 50 mg of iron <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">/ \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>.</p>
<p>For IV use:
(i) High molecular weight iron dextran, 1-2 ml vial, 50 mg iron <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">/ \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>.</p>
<p>(ii) Low molecular iron dextran 2 ml vial, 50 mg of iron <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">/ \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>
(iii) Iron saccharate (Ferric hydroxide complexed with sucrose), 5 ml vial, 20 mg of iron <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">/ \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>. (iv) Ferric gluconate, 5 ml vial, 12.5 mg iron <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">/ \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>.
(v) ferric carboxymaltose, 15 ml single use vial, 50 mg iron <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">/ \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>, given as 2 doses separated by at least 7 days.
(vi) Ferumoxytol, 17 ml single use vial, 30 mg iron <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">/ \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>, given as 2 doses separated by 2-8 days.</p>
<p>The dose is calculated on the basis that 25 mg of elemental iron are needed to correct <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> deficit of hemoglobin by Sahli's method. To this dose is added half of the calculated amount for replenishing body iron stores.</p>
<p>Iron dextran and iron sorbitol citric acid complex are the two commonly used preparations. They are injected deep into the upper and outer quadrant of the buttock. The injection is made by ' <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>Z</mi></mrow><annotation encoding="application/x-tex">Z</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">Z</span></span></span></span></span> ' technique, pulling the skin and subcutaneous tissue to one side before entering the muscle to avoid leakage and skin staining. After an initial test dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo separator="true">,</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25 \mathrm{mg}, 100 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> are given daily or every few days till the total calculated dose is administered. A single dose should not exceed 25 mg for infants, 50 mg for children and 100 mg for adults.</p>
<p>Iron sorbitol is rapidly absorbed into the blood, and saturates transferrin. It is mostly stored in the liver and bone marrow.</p>
<p>Mobilisation of iron dextran from IM injection site varies from 50-90%. Iron dextran, unlike iron sorbitol citric acid, does not saturate transferrin rapidly. It is absorbed from the muscle via the lymphatics and is converted by hepatic parenchymal cells into ferritin which in turn releases iron.</p>
<p>Utilisation of IV iron is 70 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">100 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">100%</span></span></span></span></span>. The initial dose of IV iron preparations is usually 20 to 30 mg of iron ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>1.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">1-1.5 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">1.5</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> ). It is gradually increased to 100 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">(</mo><mn>5</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">200 \mathrm{mg}(5-10 \mathrm{ml})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">200</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mopen">(</span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mclose">)</span></span></span></span></span> and repeated daily, till the total dose is given.</p>
<p>Intravenous infusion of total dose of iron dextran in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>500</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">500 \mathrm{ml} 5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">500</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">5%</span></span></span></span></span> glucose or normal saline, given over 3-4 hours has been reported; the drug concentration in the infusion must not exceed <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span>. The initial rate of the infusion is 10 drops per minute. If no ill effects are seen over 30 minutes, the rate may be increased to 30-40 drops. The IV administration of prednisolone before and after the infusion decreases the incidence of myalgias and arthralgias. Although a satisfactory response is obtained, there is no evidence to indicate that the response is more rapid than that obtained by other conventional methods. The incidence of severe adverse reactions varies from 1 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">6 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">6%</span></span></span></span></span> and hospitalisation is essential. The incidence is claimed to be much less with low molecular weight dextran-iron preparations. The merit of IV therapy is that the patient gets the required iron in one dose and the iron stores may be rapidly restored, which would take months to achieve by the oral route.</p>
<p>As there are reports of abnormalities in the offspring of animals given large single doses of iron dextran parenterally, the preparation is contraindicated in early pregnancy. However, IV iron dextran seems to be safe during late pregnancy.</p>
<p>Alternatively, ferric gluconate or iron saccharose is used in repeated IV boluses in the dose of 100-200 mg of elemental iron. Doses larger than 100 mg may be diluted in normal saline and infused over 30 minutes. Lower doses can be injected slowly over 2-3 minutes. Prior test dose or medication is not needed. These preparations are not preferred for total</p>
<p>dose infusion because they may cause dose-dependent GI or vasoactive reactions at doses above 200 mg .</p>
<p>Parenteral and oral iron preparations should not be administered concomitantly.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-reactions-to-parenteral-iron">Adverse reactions to parenteral iron:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reactions-to-parenteral-iron" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>IM preparations cause local pain, permanent skin discoloration and local inflammation and regional lymphadenopathy. The systemic toxicity which may develop within 10 minutes of injection includes headache, fever, myalgia, arthralgia, backache, tachycardia, flushing, haemolysis and circulatory collapse. These effects are probably due to excessive amounts of free iron in the plasma. Iron sorbitol, in addition, may cause disorientation and temporary loss of taste.</li>
<li>With IV therapy, the systemic reactions are similar to those observed following IM iron. Anaphylactoid reactions can occur within the first few minutes of administration. Severe chest pain, respiratory distress and circulatory collapse have been reported. In general, local inflammatory reactions are much less frequent with IV than with IM iron. Extravasation into the subcutaneous tissue can cause abscess.</li>
<li>The urine of a person on iron sorbitol therapy turns black on standing, probably due to conversion of excreted iron into iron sulfide and the patient should be warned about this effect.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="treatment-of-iron-poisoning">Treatment of Iron Poisoning<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment-of-iron-poisoning" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="acute-oral-iron-poisoning">Acute Oral Iron Poisoning:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#acute-oral-iron-poisoning" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(a) Milk and egg yolk mixture is administered to bind the iron.
(b) Desferrioxamine 1-2 g IM is administered.
(c) Gastric lavage with water containing desferrioxamine is given initially, followed by 5-10 g of the same in 100 ml of water being left in the stomach to adsorb any more iron. If desferrioxamine is not available, calcium disodium edetate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>35</mn><mo>−</mo><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">35-40 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">35</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> may be used.
(d) An IV infusion of desferrioxamine (see below).
(e) Early replacement of body fluids and electrolytes using isotonic saline, correction of metabolic acidosis and hypotension by using ringer lactate and vasopressor agents, respectively, are indicated.
(f) Diazepam to control convulsions.</p>
<p>DESFERRIOXAMINE MESYLATE: This compound, obtained from Streptomyces pilosus, is a potent and specific chelator of iron. It readily binds ferric iron to form ferrioxamine, a stable and water soluble chelate. Ferrioxamine is excreted <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">/</mi><mn>3</mn></mrow><annotation encoding="application/x-tex">2 / 3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2/3</span></span></span></span></span> in the urine and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>3</mn></mrow><annotation encoding="application/x-tex">1 / 3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/3</span></span></span></span></span> in the bile. It colours the urine reddish brown. Desferrioxamine also removes iron from hemosiderin except that in the bone marrow; desferrioxamine 100 mg . binds 8.5 mg of iron.</p>
<p>The drug is generally well tolerated. Rapid IV injection can produce hypotension, tachycardia and anaphylactoid reactions and urticaria. Allergic reactions and cataract formation are known to occur during its chronic administration for iron storage diseases. It is contraindicated in patients with severe renal disease or anuria, and in pregnant women. It is available as lyophilised powder ( 500 mg ) and is administered by IV infusion or IM.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Acute iron intoxication: In severe cases (in shock), the drug is administered by IV infusion: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">10-15 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> hour to a maximum of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">80 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">80</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> in 24 hours. In less severe cases (without shock), it is given in the dose of 1-2 g every 3-12 hours; maximum dose 6 g in 24 hours. In less severe cases (without shock), it is given IM in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">40 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> every 412 hours.</li>
<li>Hemochromatosis: Desferrioxamine is useful in the prevention and treatment of iron overload in patients with chronic anemia such as in thalassemia major treated with multiple transfusions. In these patients, it is administered by SC infusion 40-50 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day over <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>8</mn><mo>−</mo><mn>12</mn><mrow><mi mathvariant="normal">h</mi><mi mathvariant="normal">r</mi><mi mathvariant="normal">s</mi></mrow></mrow><annotation encoding="application/x-tex">8-12 \mathrm{hrs}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">12</span><span class="mord"><span class="mord mathrm">hrs</span></span></span></span></span></span> for 5-7 days a week. Concomitant oral administration of ascorbic acid ( 0.5 g twice a day) improves its action.
Deferiprone: This is an orally effective iron chelator. It is less effective than desferrioxamine. It causes nausea, vomiting abdominal pain, arthralgia and nutropenia. It is excreted mainly in urine as metabolite. The dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25-30 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> tid.</li>
</ul>
<p>Deferasirox: This oral, selective iron chelator is given once daily. The drug-iron complex is excreted in the feces. Its uses are similar to those of desferrioxime. The dose is 20-30 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> once a day.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adjuvants-to-iron-therapy">Adjuvants to Iron Therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adjuvants-to-iron-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Various substances claimed to enhance the efficacy of iron are vitamin C, cobalt, copper, zinc and manganese. Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi></mrow><annotation encoding="application/x-tex">C</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span></span></span></span></span> may increase the iron absorption but it is not necessary to use costly iron preparations incorporating vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi></mrow><annotation encoding="application/x-tex">C</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span></span></span></span></span> to achieve this effect. Copper is said to mobilise iron from storage, while cobalt is claimed to stimulate erythropoietin production. Cobalt is potentially toxic. Angina, goitre and CHF are some of the adverse effects reported with the use of cobaltous chloride. The therapeutic value of these supplements in the treatment of iron deficiency anemia is doubtful. However, nutritional iron deficiency is commonly associated with folate deficiency and folic acid is combined with iron with beneficial effects. The use of expensive pills containing several minerals and vitamins along with iron is unnecessary and wasteful.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="erythropoietin-epo-and-anemia">Erythropoietin (EPO) and Anemia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#erythropoietin-epo-and-anemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Anemia is an almost invariable feature of chronic renal failure. The critical defect is inadequate secretion of erythropoietin, the major hormonal regulator of RBC production, produced by the kidney. Recombinant human erythropoietin is now available.</p>
<p>ERYTHROPOIETIN (Epoetin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> ) has molecular weight about 36,000 . It is a glycoprotein hormone mainly synthesised by the kidney in response to hypoxemia. Some amount is also produced by the liver, which is its important source to maintain erythropoiesis in patients with degenerated kidneys.</p>
<p>Thyroxine, growth hormone, prolactin, testosterone, beta <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> adrenergic agonists, PG's and angiotensin II stimulate erythropoietin production, while alkylating agents, estrogens and beta-adrenergic blocking drugs inhibit it.</p>
<p>Commercial recombinant rHuEPO, epoetin alfa, has the same amino acid sequence as the natural human erythropoietin. Given IV, it has a plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of 6-8 hours. The target cell for erythropoietin is the early erythroid colony forming unit. It is metabolised in the liver.</p>
<p>Adverse reactions are aggravation of hypertension, associated with a too-rapid rise in hematocrit, increased viscosity, higher rate of thrombosis and stroke. The drug appears to be non-immunogenic and causes no significant allergic reaction.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Anaemia of end stage renal failure: It is a normochromic, normocytic, hypoproliferative anaemia. The IV or SC administration of erythropoietin causes dose dependent rise in the hematocrit and eliminates the need for transfusions. Most patients respond to a dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>35</mn><mo>−</mo><mn>80</mn><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">U</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">35-80 \mathrm{IU} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">35</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">80</span><span class="mord"><span class="mord mathrm">IU</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> three times a week, which is needed to maintain the lowest hemoglobin level required to avoid blood transfusion. Correction of co-existing iron deficiency should be done before erythropoietin therapy.</li>
<li>Anemia in premature babies.</li>
<li>To permit the autologous blood transfusion: Injection of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>600</mn><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">U</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">600 \mathrm{IU} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">600</span><span class="mord"><span class="mord mathrm">IU</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> of erythropoietin thrice a week makes it possible both to donate more blood and to maintain higher hematocrit at the time of elective surgery in an individual.
Patients with aplastic anemia, hematologic cancers and severe hemolytic anemia usually have high erythropoietin levels and are unlikely to be benefited by exogenous erythropoietin.</li>
</ul>
<p>Darbepoietin alfa is a long acting, synthetic analogue of epoietin. Its properties and uses are similar to those of epoietin. It can be injected once a week.</p>
<p>Methoxy polyethylene glycol epoetin beta is an isoform of EPO which is longer acting and given IV/SC at 2-4 weeks interval.</p>
<p>35</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-effective-in-megaloblastic-anemias-and-neutropenia">Drugs Effective in Megaloblastic Anemias and Neutropenia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-effective-in-megaloblastic-anemias-and-neutropenia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The story of megaloblastic anemias really began in the middle of the nineteenth century when Thomson Addison, a physician from Guy's Hospital, London, described pernicious (deadly) anemia, so designated because of its fatal outcome. The brilliant discovery by Minot and Murphy in 1926, demonstrating the dramatic effectiveness of liver preparations in pernicious anemia, forms one of the landmarks in the history of therapeutics. This was followed by the work of Castle (1932) who postulated the hypothesis that 'an intrinsic factor (IF)' from the normal human gastric juice reacts with 'an extrinsic factor' in the food to produce 'antipernicious anemia principle'. Crystalline vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> was isolated from the liver in 1948 and soon after, the 'extrinsic' factor in Castle's hypothesis was shown to be vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. Another anti-anemic factor from the liver, useful in macrocytic anemia of pregnancy, was isolated in 1943 and identified as pteroyl-monoglutamic acid, which turned out to be the same as 'folic acid' described by Mitchel and co-workers in 1941 and so named because of its isolation from the leafy vegetable, spinach.</p>
<p>Megaloblastic anemia: Megaloblastic anemias are characterised by the presence of abnormally large, nucleated, red cell precursors, known as megaloblasts, in the bone marrow. A megaloblast is viewed as an example of the unbalanced growth between the cytoplasm and the nucleus due to defective synthesis of nucleoproteins. In almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span> of the cases with megaloblastic bone marrow, vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and/or folic acid deficiency is present.</p>
<p>Although folic acid and vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> influence different metabolic pathways in the synthesis of nucleoproteins, the final result of deficiency of either of these is defective DNA (deoxyribonucleic acid) synthesis. Since DNA is present in every cell, the basic abnormality affects all proliferating cells such as those in buccal cavity, tongue and GI tract leading to glossitis, stomatitis and intestinal malabsorption. Other organs affected include the cervical and vaginal squamous epithelium, the ovary and testes. The precursors of white cells (giant metamyelocytes) and those of platelets show abnormal mitotic activity. These abnormally large cells give rise to abnormally large offsprings that appear in the peripheral blood, which shows fully hemoglobinised (hyperchromic), large, red cells called macrocytes, polymorphonuclear leucocytes with hypersegmented nuclei and giant platelets. The anemia is thus described as 'macrocytic hyperchromic'. Such abnormal cells have a shortened life span and may undergo early hemolysis, which sometimes gives rise to associated jaundice. The anemia is also associated with pancytopenia (leucopenia, neutropenia and thrombocytopenia). Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> deficiency causes damage to myelin in peripheral nerves, spinal cord and brain. With folate deficiency, the loss of body weight is much more marked and nervous instability may be present; but, the damage to the myelin is doubtful.</p>
<p>All the macrocytic anemias, however, are not megaloblastic. Thus, the macrocytic anemias due to liver disease, myxedema, following certain hemolytic states, and leukemias usually have normoblastic bone marrow.</p>
<p>Physiological role of Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and folic acid: Physiologically, both these vitamins play an important role in the synthesis of DNA and RNA. The deficiency picture produced by both is clinically indistinguishable except that the neurological disturbances are commoner with vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> deficiency than with folic acid deficiency; the peripheral blood picture and bone marrow changes are also similar and only certain special tests give the correct clue about the precise diagnosis.</p>
<p>Small 'physiological' doses of either folic acid or vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> will selectively improve the blood picture only in those persons suffering from a deficiency of the particular vitamin being administered; large 'pharmacologic' doses of either vitamin, however, will cause a hematological response irrespective of the type of deficiency, vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> or folic acid or both.</p>
<p>Although it is believed that folate deficiency may lead directly to megaloblastic anemia, such a direct effect is doubted in case of vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. Since the deficiency of one vitamin is known to affect the metabolism and utilisation of the other, it is believed that vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> produces its actions indirectly by influencing folate metabolism and megaloblastic anemia produced by vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> deficiency is partly due to deranged folate metabolism (see below).</p>
<p>COBALAMINS: Chemically, vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> belongs to the family of cobalamins which are cobalt containing carrinoid compounds. Cobalamins are dark red crystalline hygroscopic powders, readily soluble in water. The solution is stable at room temperature. These compounds differ from each other in the groups attached to the cobalt atom. In case of cyanocobalamin, a cyanide group is attached to the cobalt atom. A cobalamin with hydroxy <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">H</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(\mathrm{OH})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">OH</span></span><span class="mclose">)</span></span></span></span></span> group is known as hydroxocobalamin. Cyanocobalamin, on exposure to light, is converted to hydroxocobalamin, while hydroxocobalamin in the presence of cyanide gets changed into cyanocobalamin. Other cobalamins of physiological importance are aquacobalamin, nitrocobalamin, methyl-cobalamin and 5' deoxyadenosylcobalamin.</p>
<p>Cyanocobalamin and hydroxocobalamin are commonly used therapeutically. They are discussed below under the general heading 'Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> '.</p>
<p>VITAMIN <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> : Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is synthesised solely by micro-organisms in soil, water and animal intestine or rumen. It is almost absent in plant products. In man, as in animals, it is synthesised in the colon by micro-organisms; however, it is hardly absorbed from this site and hence, is excreted (about 3-5 mcg daily) in feces. Some of the animals like rabbits and rats eat their own feces (coprophagy) and hence, they have very high serum <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> levels. Nonvegetarian foods like muscle, liver, kidney, oysters, fish and egg yolk are rich in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>; dairy food contains smaller amounts. The vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> content of cow's milk is considerably more than that of human milk.</p>
<p>The daily dietary intake of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> varies considerably and is high in non-vegetarians and likely to be very low in vegetarians, some of whom may not even consume sufficient amount of milk or milk products; however, vegetarians may obtain enough vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> from contaminated water and in the form of co-enzyme <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> by ingesting legumes and nodules of root vegetable in which vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is synthesised by micro-organisms.</p>
<p>The minimum daily requirement of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> in adults is not exactly known but is believed to</p>
<p>be extremely small, about 1 mcg per day. Taking into consideration the incomplete absorption of the food <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, the recommended daily dietary intake is 2 mcg for adults, 3 mcg in pregnancy and lactation and 0.3 mcg for infants.</p>
<p>Absorption of vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> : The cobalamins in food exist in a bound form and are metabolically inactive until they are released by heat (cooking) and by proteolysis in the stomach. The gastric juice contains cobalamin binding protein, called R-type protein (cobalophilin, haptocoin). This protein binds cobalamin with higher affinity than does intrinsic factor (IF). Thus, at acidic pH the dietary cobalamin enters the duodenum bound to R-type protein.</p>
<p>Pancreatic proteases degrade this complex in the jejunum, whereafter cobalamin is presented to the IF. The latter, is a glycoprotein, produced by the parietal cells of the fundus and the body of the stomach. IF-cobalamin complex binds specifically to cubulin receptors on terminal ileum with high affinity. Finally <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> released from lysosomes is transported into the blood.</p>
<p>Thus, very little or none of the dietary cobalamin is absorbed in cases with pernicious anemia, gastric diseases and after gastrectomy as the IF is absent. IF is antigenic and antibodies against intrinsic factor are known. Ionic calcium is necessary for the initial binding of the intrinsic factor - <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> complex to the ileal receptor site. Low ionic calcium concentration and a low pH as observed in chronic pancreatitis may cause vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> malabsorption.</p>
<p>Many naturally occurring substances can also bind <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> but they are not IF.
The maximum absorption of vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> occurs within 8-12 hours following a physiological dose ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1-5 \mathrm{mcg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span></span></span></span></span> ), uninfluenced by the concentration of vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> in the blood.</p>
<p>Given SC or IM, cyanocobalamin is rapidly absorbed and the plasma level reaches the peak in 1 hour. Cyanocobalamin can also get absorbed without the help of intrinsic factor, but the dose needed is much higher (500-1000 mcg). This type of absorption occurs by simple diffusion, probably by mass action, although such absorption is inefficient.</p>
<p>Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> transport and storage: Almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> of absorbed vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is transported in the plasma, bound to beta <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> globulin called transcobalamin II, which is a cellular delivery protein. Only 1-10% circulates as a free fraction. The transcobalamin II is taken up by cells by endocytosis. During the process, the transcobalamin is degraded and the released cobalamin is converted to two coenzymes, viz., methylcobalamin and adenosyl cobalamin. The major form of vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> in the serum is methylcobalamin attached to a globulin. The total body stores of cobalamin in normal adult are estimated at about 3-5 mg, of which a large portion is present in the liver. Not all of this, however, is available for hemopoesis.</p>
<p>Turnover of vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is very slow and only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.2</mn><mo>−</mo><mn>0.3</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.2-0.3 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.3%</span></span></span></span></span> of the total <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> contained in the body is excreted per day. Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is excreted in the bile but most of it is reabsorbed, so that there is a closed enterohepatic circulation. This is how the body conserves <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and this would explain partly why even strict vegans with a very low intake of this vitamin rarely develop clinical vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> deficiency syndrome. The lack of IF or defective absorption due to intestinal pathology in such cases, however, will lead to a rapid depletion of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> stores.</p>
<p>Excretion: The daily urinary loss of vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is very small, less than 0.25 mcg . Only the cobalamin not bound to proteins is capable of being excreted by glomerular filtration. Conservation of the vitamin by enterohepatic circulation and its very slow excretion explain why it takes a long time, perhaps 10 years, for deficiency to develop in the presence of deficient intake or absorption. The half life of a tracer dose of radioactive vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> in the liver is about 12 months.</p>
<p>If vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is injected, only the amount necessary for the saturation of the binding sites is retained; the remaining excess is excreted in the urine. It is calculated that 80-95% of a 50 mcg dose of injected vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is retained. As the dose exceeds 100 mcg , large proportions ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> ) of the injected dose appear in the urine within 48 hours.</p>
<p>Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> crosses the placental barrier and the cord blood level of vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is significantly higher than the maternal blood levels.</p>
<p>Metabolic actions of vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> : Cyano-cobalamin itself has no metabolic activity in man. After absorption it is converted by cellular enzymes in tissues to the coenzyme forms which are active. Cobalamin functions as an essential cofactor for two enzymes in the human cells: (1) methionine synthetase (methyl transferase); and (2) l-methyl-malonyl coenzyme-A transmutase (Fig. 35.1 and 35.2).
<img src="assets/images/image-20251214-f95062cd.jpeg" alt="img-38.jpeg"></p>
<p>FIG. 35.1 Important metabolic actions of vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub><mi mathvariant="normal">.</mi><msub><mrow><mi mathvariant="normal">F</mi><mi mathvariant="normal">H</mi></mrow><mn>4</mn></msub><mo>=</mo></mrow><annotation encoding="application/x-tex">B_{12} . \mathrm{FH}_{4}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">.</span><span class="mord"><span class="mord"><span class="mord mathrm">FH</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Tetrahydrofolate</p>
<p><img src="assets/images/image-20251214-84805c5b.jpeg" alt="img-39.jpeg"></p>
<p>FIG. 35.2 Interrelation between <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and folate actions.
PGA = Pteroyl glutamic acid; DHFR= Dihydrofolate reductase
(1) On entry into the cell, methyl group from <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">N</mi><mn>5</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{N}_{5}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">N</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">5</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-methyl tetrahydrofolic acid <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">M</mi><mi mathvariant="normal">e</mi><mi mathvariant="normal">F</mi><mi mathvariant="normal">H</mi></mrow><mn>4</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{MeFH}_{4}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">MeFH</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> is transferred to cobalamin to form methyl cobalamin. The methyl group from methyl cobalamin is transferred to homocysteine to form methyl-homocysteine also called methionine (Fig. 35.1). In the absence of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, the conversion of dietary and stored folate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">M</mi><mi mathvariant="normal">e</mi><mi mathvariant="normal">F</mi><mi mathvariant="normal">H</mi></mrow><mn>4</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{MeFH}_{4}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">MeFH</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">F</mi><mi mathvariant="normal">H</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{FH}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">FH</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is blocked (Fig. 35.2), resulting in deficiency of essential folate co-factors and accumulation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">M</mi><mi mathvariant="normal">e</mi><mi mathvariant="normal">F</mi><mi mathvariant="normal">H</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{MeFH}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">MeFH</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ('methyltetrahydrofolate trap'). As a result biochemical reactions requiring folate co-factors will suffer. This may explain the similarity of GI lesions and peripheral blood picture seen in megaloblastic anemia due to deficiency of either vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> or folic acid.
(2) Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is needed for the development and myelination of CNS and its function. Because the neurons do not divide, impaired DNA synthesis cannot explain the demyelination that occurs in vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> deficiency. Various hypotheses have been proposed to explain the neurological damage. It is suggested that tissue deficiency of deoxyadenosyl cobalamin and failure of transmethylation reactions are important in causing deficiency of myelin synthesis. The major pathway of propionic acid utilisation in animal tissues involves the conversion of propionyl co-enzyme A (CoA) to succinyl CoA. Thus, propionyl CoA is first converted to methyl malonyl CoA. It is necessary for the conversion of methyl malonyl CoA to succinyl CoA. (Fig. 35.1). Lack of adenosyl cobalamin cause accumulation of methylmalonyl CoA. Deficiency of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> thus interferes with the production of lipoprotein in myelin tissue and may explain the neurological complications</p>
<p>such as peripheral neuritis, optic atrophy, subacute combined degeneration of the spinal cord and brain atrophy.
(3) Purine biosynthesis is reduced in cobalamin deficiency and this abnormality may also contribute to defective DNA synthesis. Both methyl tetrahydrofolate trapping and lack of deoxyadenosyl <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> contribute to impairment of purine synthesis.</p>
<p>Human red blood cells show low folate stores in the presence of vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> deficiency, which rises after <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> therapy, suggesting that <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> plays some role in folate uptake and storage.
(4) It has been demonstrated in animals that supplementing the diet with vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> has a growth promoting effect. It is used in poultry farming for increasing the bird weight and for fattening the pigs. No such growth promoting effect, however, has been observed in normal or premature human infants.</p>
<p>Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> does not seem to have any other significant pharmacological actions, even in large doses.</p>
<p>Serum vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> levels: The serum level in normals consuming non-vegetarian food varies between 140 and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>750</mn><mrow><mi mathvariant="normal">p</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">750 \mathrm{pg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">750</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">pg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> (means <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>205</mn><mrow><mi mathvariant="normal">p</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">205 \mathrm{pg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">205</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">pg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> ). The levels in healthy subjects consuming vegetarian food are considerably lower, some of them even below <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mrow><mi mathvariant="normal">p</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">100 \mathrm{pg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">pg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>.; they may not, however, show any clinical or hematological evidence of deficiency. Although <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> deficiency anemia is accompanied by low serum levels, it is doubtful whether a low serum level of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> by itself signifies tissue deficiency in otherwise healthy vegetarians.</p>
<p>Only characteristic peripheral blood picture and estimation of serum methylmalonic acid and total homocysteine (both of which are markedly increased) will help in correct diagnosis. With currently employed auto-measured assays for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, both false positive and false negative results are common up to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span>. Further, the results obtained differ from laboratory to laboratory and hence could be unreliable.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Cyanocobalamin, pink coloured injection, contains 100 mcg per ml . It should be administered either IM or SC.
(ii) Hydroxocobalamin injection, 100, 500 or 1000 mcg per ml.
(iii) Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> for oral administration is available as a part of multivitamin formulations. Such preparations may be helpful in treating dietary deficiency of vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> but are ineffective in patients with deficiency.</p>
<p>Oral formulations of vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> are not recommended to treat established <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> deficiency in the initial period; however, after parenteral therapy, 1-2 mg/day of oral hydroxocobalamin can be given as maintenance doses. Large oral doses get absorbed using another transport system which does not require IF or functional terminal ileum but has a lower efficiency.</p>
<p>Adverse reactions: Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> given orally is very safe. Cyanocobalamin IV has been reported to cause anaphylactoid reactions very rarely; it should never be injected IV. The use of hydroxocobalamin can lead to the development of antibodies to the transcobalamin-vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> complex. Hence, cyanocobalamin, IM or SC is the treatment of choice in vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> deficiency.</p>
<p>Therapeutic uses:
(1) Megaloblastic anemia due to vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> deficiency due to:</p>
<ul>
<li>Deficient intake in nutritional megaloblastic anemia as seen in strict vegans who do not take even dairy products. As the daily <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> requirement is extremely small, selective <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> deficiency is uncommon even among the vegetarians in India. Majority of the nutritional megaloblastic anemias observed in India are mainly due to folate deficiency. The nutritional <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> deficiency can be corrected by parenteral administration of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. Exclusively breast fed infants of mothers with the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> deficiency, could develop severe <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> deficiency.</li>
<li>Impaired absorption of Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> as observed in pernicious anemia (due to lack of intrinsic factor), after gastrectomy or resection of small bowel, in malabsorption syndromes and in GI diseases involving stomach and intestine such as malignancy, and chronic pancreatitis. Long term use of biguanides, antacids, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors blockers and proton pump inhibitors can impair <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> absorption and cause <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> deficiency. Correction of absorption defect by simultaneous administration of IF suggests its absence as observed in patients with pernicious anemia. This forms the basis for Schilling's test using radioactive <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. In all these cases, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> should be given parenterally.
Cyanocobalamin is the drug of choice. Initially, it is given in the dose of 1000 mcg IM or deep SC daily for 1-2 weeks to replenish the body stores. Then, a similar dose may be given IM every week for 4 weeks and then monthly. The reticulocyte response occurs on <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>4</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">4^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">4</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> day and reaches the peak by 5 to 8 days. In patients with pernicious anemia and in cases with incurable GI lesions, the treatment has to be continued lifelong.</li>
<li>Infestation with the fish tapeworm also causes megaloblastic anemia due to preferential uptake of dietary <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> by the worm. This is not common in India but heavy worm infestation may contribute to such a deficiency.</li>
<li>Inadequate utilisation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> which may occur in infants who inherit the deficiency of certain enzymes necessary for conversion of vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> to its co-enzyme forms.
Hereditary deficiency of transcobalamine II may also cause cobalamin deficiency. (2) Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> deficiency neuropathies such as tropical neuropathy, subacute combined degeneration, tobacco and tropical amblyopia, which sometimes occur without clearcut megaloblastic anemia, respond to parenteral <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> therapy. The sensory component inproves much less than the motor component. There is some evidence to suggest that certain well defined neurological and ophthalmic syndrome (tobacco amblyopia) may represent the chronic neurotoxic effects of cyanide, and that hydroxocobalamin may help in the detoxication of cyanide by binding it (See Chapter 77).</li>
</ul>
<p>Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, given in massive doses, has been claimed to be useful in such varied conditions as infective hepatitis, infertility, herpes zoster, toxic amblyopia, trigeminal neuralgia etc; there is no evidence to suggest that this vitamin is of any value in such conditions. Nor there is any conclusive evidence to suggest its usefulness in patients with mental disorders. Its use as general 'tonic' is irrational.</p>
<p>HYDROXOCOBALAMIN: Hydroxocobalamin, when injected, is absorbed slowly and is more protein bound than cyanocobalamin. It is excreted slowly and hence, higher blood levels are maintained over a longer period than with cyanocobalamin. It is given initially in the dose of 1 mg IM every 2-3 days for five doses. Maintenance dose is 1 mg every three months.</p>
<p>Methylcobalamin: There is no evidence for superiority of this expensive analogue over cyanocobalamin and hydroxocobalamin, which are cost-effective.</p>
<p>FOLIC ACID (PTEROYLMONO-GLUTAMIC ACID): Folic acid occurs as yellow, spear shaped crystals. Its disodium salt is soluble in water in the concentration of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1.5 \mathrm{mcg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">1.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">%</span></span></span></span></span>. Chemically, folic acid molecule contains pteridine, para-aminobenzoic acid and glutamic acid. It is named folic acid because it is commonly present in green leaves. The term 'folate' is used in the generic sense and includes other chemical forms.</p>
<p>Folate is present in abundance in green vegetables, liver and yeast. Moderate amounts are present in eggs, meat, fish and dairy foods. Most of the folic acid in vegetables is in conjugated form, usually as triglutamic and heptaglutamic acid conjugates. Prolonged boiling during cooking destroys most of the folate in the food.</p>
<p>Vitamin C protects the reduced product, tetrahydrofolic acid, from oxidative destruction. It also protects the folate in the food. Hence, food poor in vitamin C content is generally low in folate content as well. There is no evidence, however, that vitamin C in any way potentiates the therapeutic effects of folic acid in man.</p>
<p>As in the case of vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> many microorganisms including those in the colon synthesise folic acid. It is doubtful, however, whether it is available for utilisation in man.</p>
<p>Absorption: Folic acid conjugates, present in vegetable and mammalian tissues, are hydrolysed to pteroylmonoglutamic acid by enzymes, conjugases. A conjugase is found throughout the GI mucosa and in pancreas, the highest level being in the duodenum and jejunum. Pteroylmonoglutamic acid is absorbed almost completely in the small intestine, particularly in the jejunum. Physiological doses ( 1 mg ) are absorbed by an active process by binding to folate receptors while large doses can get absorbed by diffusion. Absorption of food folate as such, however, is incomplete. Further, inhibition of conjugase by certain drugs or its decreased concentration due to intestinal pathology may cause malabsorption of polyglutamates in the diet.</p>
<p>Transport, storage and fate: Given orally, folic acid appears in the blood within 30 mins. It circulates in the plasma mainly as N-methyl tetrahydrofolate. The majority is loosely bound to albumin, from which it is readily taken up by the cells. Inside the cells, it is converted to tetrahydrofolate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">F</mi><mi mathvariant="normal">H</mi></mrow><mn>4</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{FH}_{4}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">FH</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> by the cobalamine dependent enzyme, methionine synthetase.</p>
<p>The amount of folic acid excreted in the urine is dependent on the dose. Only a small amount appears in the urine following ingestion of 0.1 mg of folic acid, while almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> is excreted after 15 mg dose. Folate appears in the urine within 6 hours after ingestion, and excretion is complete within 24 hours.</p>
<p>The total body stores of folate is estimated to be in the range of 5-10 mg of which almost one-third is present in the liver mostly as methylfolate. Unlike vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, folate gets selectively concentrated in the spinal fluid.</p>
<p>Folate is incorporated in red cells during erythropoiesis and the amount decreases only slightly during their life span. Red cell folate is, therefore a useful indicator of body folate status.</p>
<p>The exact daily requirement of folate in man is not known; but it appears to be about 200 mcg in adults, 100 mcg for children and 300-400 mcg in pregnancy and lactation. Since the net folate losses from the body appear to be about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of the amount ingested, the recommended daily intake is 400 mcg for adults, 200 mcg for children and 600-800 mcg in</p>
<p>pregnancy.
Metabolic actions of folate: Like vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, folic acid by itself is inactive. Folate functions to transfer one carbon units such as methyl and formyl groups to various substrates in enzymatic reactions. Folate co-enzymes are involved in various metabolic reactions.</p>
<ul>
<li>Biosynthesis of purine and pyrimidine nucleotides; and</li>
<li><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">F</mi><mi mathvariant="normal">H</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{FH}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">FH</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is able to accept one carbon fragment such as methyl, formyl and methylene groups; the folate co-enzymes participate in reactions in which one carbon fragment is transferred from one molecule to another. The important reactions of this type are conversion of homocysteine to methionine (see earlier) and of serine to glycine.
These reactions are necessary for the biosynthesis of DNA and RNA and hence, for cell division. In folate deficiency, homocysteine accumulates in the blood due to lack of 5methyl tetrahydrofolate. Figure 35.2 depicts the interrelation between actions of vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and folic acid.</li>
</ul>
<p>Serum levels of folic acid: Low blood level of folic acid, in itself, cannot be considered as a definite indication of folic acid deficiency. Various other tests (eg. Serum homocysteine level) have been proposed for diagnosing folic acid deficiency but none of these is without fallacies.</p>
<p>Adverse reactions: Folic acid is non-toxic in man and no adverse effects have been reported.</p>
<p>Preparations and dosage: Folic acid tablet contains 5 mg of the drug. Dose 1-5 mg. It can also be given parenterally.</p>
<p>Therapeutic uses: Folic acid is used in the treatment of megaloblastic anemias due to folate deficiency. These are:</p>
<ul>
<li>Dietary deficiency: Nutritional megaloblastic anemia is the commonest type of megaloblastic anemia in India and other tropical countries, and is mainly due to dietary deficiency because of undernutrition. Megaloblastic anemia of protein caloric undernutrition of infancy and childhood is mostly due to folic acid deficiency. Cooking habits involving prolonged boiling of food with spices, which destroys folic acid, and possibly loss of folate in sweat contribute further to the development of its deficiency. It must be realised that wherever there is deficiency of folate there is also a lack of other nutrients and the ideal treatment lies in correcting the diet. Supplementation with folic acid orally can, however, avoid and correct this deficiency.</li>
<li>Anemia due to increased requirements: The commonest type of megaloblastic anemia in pregnancy is due to folate deficiency caused by the increased requirement both by the foetus and the mother. Folate deficiency during pregnancy is so common that prophylactic use of folic acid along with iron from conception till the end of lactation is justified. Daily prophylactic dose of 600 to 800 mcg of folic acid with about 100-200 mg of elemental iron is all that is needed. In the treatment of established anemia, folic acid is given orally in the dose of 5 mg daily. It can also be administered IM.
Increased demand for folic acid has also been observed in various pathological states like hyperthyroidism, rheumatoid arthritis, leukemia, hemolytic anemia, chronic infections, exfoliative skin disease, myelofibrosis and in cancer; this is probably due to rapid cell synthesis. This may aggravate the already existing anemia.</li>
<li>Anemia due to impaired absorption: This is observed in malabsorption syndrome</li>
</ul>
<p>associated with tropical sprue, extensive organic disease of the jejunum and in blind loop syndrome.
In other types of malabsorptive states such as idiopathic steatorrhoea, adult celiac disease and nontropical sprue, sensitivity to the gluten fraction of wheat protein is often the offending cause. In such cases and in gluten enteropathy in children, administration of gluten-free diet gives dramatic results; many patients in this group, however, also suffer from folic acid deficiency. In such conditions folic acid is given IM in a dose of 5 mg daily, followed by oral therapy as soon as the diarrhoea ceases.</p>
<ul>
<li>Anemia due to drug induced folate deficiency: Certain anti-epileptic drugs like phenobarbitone, phenytoin and primidone may cause folic acid deficiency anemia by impairing its absorption and/or its utilisation. Drugs like methotrexate, the anti-malarial pyrimethamine and the antibacterial drug trimethoprim can also cause folate deficiency by blocking the conversion of folic acid to tetrahydrofolate. A supplement of folic acid, 1 mg daily, orally, can correct this deficiency. The antiepileptic treatment need not be stopped.</li>
<li>Certain other megaloblastic anemias as in liver disease, chronic alcoholism and scurvy are usually associated with folate deficiency.</li>
<li>Prevention of neural tube defects (NTD): Any woman who can become pregnant should be prescribed 400 mcg of folic acid daily, as otherwise the conceptus might develop NTD which are liable to occur during the first week of gestation, even before the subject knows that she is pregnant. Further, if the woman is at high risk for NTD (has past/family history of NTD, or is taking carbamazepine or valproate), she should be prescribed 5 mg of a folic acid daily atleast 1 month before planned conception. However, as many pregnancies may be unplanned, it is recommended for all women with child bearing potential.</li>
<li>Folate deficiency of ageing may be associated with elevated serum homocysteine levels and degenerating vascular disease in the elderly. Folate supplementation (400-1000 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">\mathrm{mcg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span></span></span></span></span> day) given prophylactically, may be useful.
Folate deficiency is also observed in those who are exposed to excessive UV light e.g. after skin tanning. The UV rays penetrate the skin and destroy folates in the cutaneous circulation and can cause deficiency.
Folate deficiency as a cause of neuropathy is not universally accepted, although cases of encephalopathy giving rise to a confusional state, usually diagnosed as senile dementia and/or myelopathy, responding to folic acid have been reported. Hence, folic acid may be tried empirically in obscure chronic neurological disorder not responding to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> therapy.</li>
</ul>
<p>Administration of folic acid alone is contraindicated in pernicious anemia as, although it may correct the hematological abnormality, it can precipitate or worsen the neurological complications. It has been postulated that folic acid accelerates the utilisation of the meagre vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> stores (Pathway 2 in Fig. 35.2) in an already deficient subject and may thus aggravate deficiency of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> which is essential for maintaining the integrity of the nervous system (Pathway 1 in Fig. 35.2). In a few cases of pernicious anemia, however, the folate stores are so low that there is only little response to vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> therapy unless folic acid is also administered.</p>
<p>Following initiation of treatment with folic acid, subjective improvement such as feeling of well being and decrease in the soreness in the mouth occur early. Objective responses</p>
<p>including disappearance of megaloblasts from the peripheral blood occur within 48 hours, with reticulocyte peak within 7 days. Rise in hemoglobin is observed in 10-15 days.</p>
<p>FOLINIC ACID (Citrovorum factor): This is the term used for N5 formyl tetrahydrofolinic acid. It was originally found in the liver and was demonstrated to have a growth promoting effect on the organism Leuconostoc citrovorum. It is available in 1 ml ampoules for injection. Its only use is in the treatment of toxicity due to folic acid antagonists like methotrexate.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-used-in-neutropenia">Drugs Used in Neutropenia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-used-in-neutropenia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Recombinant preparations of human granulocyte colony stimulating factor (G-CSF) and granulocyte/macrophage colony stimulating factor (GM-CSF) are available for the treatment of neutropenia.</p>
<p>MOLGRAMOSTIM stimulates proliferation and differentiation of partially committed hemopoietic progenitor cells to produce end cells of granulocyte and monocyte/macrophage lineages. It also activates some of the functions of the fully differentiated cells. Its administration stimulates myelopoiesis.</p>
<p>FILGRASTIM is a glycoprotein which is not glycosylated unlike the natural G-CSF. It stimulates neutrophil progenitors to produce mature neutrophils, stimulates their release from bone marrow storage pool and also increases their phagocytic and cytotoxic capacity.</p>
<p>These agents are given SC or slow IV infusion. Filgrastim is infused at a dose of 1-20 microgm/kg/day over 30 min while molgramostim is given as 125-500 microgm/m²/day over 3-6 hours. Half life of filgrastim is 3.5 hrs and that of molgramostim is 2-3 hours. Dosages are adjusted based on the blood counts and duration. Generally 7-14 days therapy is needed. Higher doses of molgramostim causes monocytosis and eosinophilia.</p>
<p>Adverse reactions: Both are well tolerated but bone pain, fever, myalgia and lethargy, pain and reddening at the site of injection, hypersensitivity reactions including skin rashes can occur. Hypotension, flushing, nausea, vomiting and dyspnoea (especially after IV infusion) have also been reported. Prolonged administration can lead to capillary leak syndrome with peripheral edema and pleural and pericardial effusion. Supraventricular arrhythmia, and elevation of serum creatinine and hepatic enzymes are also reported. Filgrastim rarely causes splenomegaly and reversible abnormalities in liver function. These agents stimulate growth of tumour cells with myeloid characters.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(a) To reduce severity and duration of neutropenia induced by cytotoxic cancer chemotherapy.
(b) To shorten duration of neutropenia in patients undergoing bone marrow transplantation.
(c) To stimulate release of progenitor cells in circulation and to reduce number of collections of peripheral blood stem cells (PBSC) necessary for transplant in patient undergoing PBSC transplantation.
(d) To expand number of harvested progenitor cells ex vivo before infusing them.
(e) To increase peripheral blood neutrophils in prospective donors.
(f) For persistent neutropenia in patients with AIDS.</p>
<p>It may be used in patients with aplastic anaemia and myelodysplasia.
Lenograstim is the glycosylated analog of filgrastim. It has similar properties, adverse reactions and uses.</p>
<p>Pegfilgrastim is filgrastim conjugated to polyethylene glycol (PEG), which minimises its glomerular filtration. Its half life is 5-8 hrs and requires to be given as a single injection (6 mg SC) per chemotherapy cycle.</p>
<p>Some drugs causing neutropenia are given in Chapter 36.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-used-in-thrombocytopenia">Drugs used in Thrombocytopenia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-used-in-thrombocytopenia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Recombinant human IL-11 (Oprelvekin) is available for cancer-chemotherapy-induced severe thrombocytopenia. Given SC, it leads to thrombopoietic response within 5-9 days. Two forms of r-thrombopoietin are also available. However, platelet transfusions are commonly used to treat thrombocytopenia. Considering immunogenicity of recombinant preparations, smaller molecular weight thrombopoeitin-mimetics viz. Romiplostim (for SC use) and Eltrombopag (for oral use) have been developed. These agents promote megakaryocyte growth and maturation by binding to thrombopoietin receptors. They are used in the treatment of idiopathic thrombocytopenia (IIP) and that in hepatitis C and viral infection, in cancer chemotherapy and myelodysplastic syndromes. They are under evaluation.</p>
<p>36</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-induced-blood-dyscrasias">Drug-Induced Blood Dyscrasias<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-induced-blood-dyscrasias" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>In addition to blood loss caused by NSAID and anticoagulants, various types of blood dyscrasias may occur following the use of certain drugs in toxic doses or sometimes even in therapeutic doses. These reactions can be grouped into:</p>
<ul>
<li>Those due to impaired production of blood cells e.g. aplastic anemia.</li>
<li>Those due to increased destruction of blood cells e.g. hemolytic anemias, and</li>
<li>Those due to derangement of blood cell functions e.g. methaemoglobinemia.</li>
</ul>
<p>The important drug-induced blood dyscrasias are as follows :
Drug induced anemias: Megaloblastic anemias following certain drugs have already been discussed in Chapter 35. Drugs responsible for this can be grouped as follows: I Folic acid inhibitors:</p>
<ul>
<li>DHF reductase inhibitors or folic acid antagonists: Methotrexate, Pyrimethamine, Triamterene, Trimethoprim and Diamidine compounds.</li>
<li>Associated with impaired absorption and/or utilisation of folic acid: Phenytoin, Primidone, Barbiturates, Cycloserine, Alcohol and probably Oral contraceptive agents. II Those which cause vitamin B12 malabsorption: PAS, Colchicine, Neomycin and Alcohol.</li>
</ul>
<p>Blood loss induced by anti-inflammatory drugs and anticoagulants can cause iron deficiency anemia.</p>
<p>Pyridoxine responsive anemia in humans is a hypochromic microcytic anemia with normal serum iron, and bone marrow showing normoblastic, erythroid hyperplasia. The anemia is probably due to inability of iron to get incorporated into hemoglobin.</p>
<p>The anti-tubercular drug isoniazide (INH) causes such a type of anemia, which responds to the oral administration of pyridoxine.</p>
<p>Aplastic anemia: This is the most severe type of blood dyscrasia; fortunately, it is rare. The evidence that a given drug is responsible for aplastic anemia in a given patient is largely circumstantial and in many cases toxicity may occur 2 weeks to 6 months after cessation of therapy. It is associated with pancytopenia and hypocellular bone marrow. The mortality is very high (more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> ) and recovery, if it takes place, occurs only after illness for many months. The important offenders in this group are phenylbutazone, oxyphenbutazone, amidopyrine, indomethacin, antineoplastic drugs and the antibiotic chloramphenicol. Other agents reported to produce aplastic anemia are mephenytoin, gold salts, potassium perchlorate, benzene, insecticides like DDT, gamma benzene hexachloride, antithyroid drugs, sulfonamides and sulfonylureas. This reaction is probably not dose related and may represent some form of idiosyncratic phenomenon.</p>
<p>Cytotoxic drugs used in cancer chemotherapy may cause aplastic anemia as an extension of their pharmacological action.</p>
<p>The choice of therapy depends on the cause and the severity of the anemia, and the age of the patient. Apart from good supportive and nursing therapy, and blood transfusions, the main therapeutic choice is between allogenic bone marrow transplantation and immunosuppression with horse antithymocytic globulin (ATG), rabbit antilymphocytic globulin (ALG) or cyclosporine. Immunosuppression may be effective in 70-80% of the patients. ATG and ALG may cause anaphylaxis, serum sickness and temporary exacerbation of cytopenia. Immunosuppression is usually recommended in subjects for</p>
<p>whom bone marrow transplantation is not available. Additional use of GCSF, erythropoietin and large doses of androgen may help some patients. Although glucocorticoids such as prednisolone ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">20-40 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day) do not induce a remission, they may control the hemorrhage.</p>
<p>Haemolytic reactions occur generally with the drugs which oxidise hemoglobin. Normally, the RBCs contain the enzyme glucose 6-phosphate dehydrogenase (G-6-PD). Normal functioning of G-6-PD is necessary for maintaining glutathione in its reduced form, which in turn protects the red blood cells from the damage by oxidising agents. The drug-damaged red cells show precipitated denatured hemoglobin, identified as Heinz bodies in an appropriate blood smear preparation.</p>
<p>Individuals whose RBCs are deficient in G-6-PD, reduced glutathione (GSH) or glutathione reductase are more susceptible to drug induced hemolysis. Such deficiency is hereditary. It is known to occur predominantly in Negros, and is relatively rare in white population. Its presence has also been noted in Indians.</p>
<p>A hemolytic reaction with oxidant drugs can occur even in normal individuals without G-6-PD deficiency, if the concentration of the drug is sufficiently high. Drugs which are known to cause hemolytic reactions in G-6-PD deficiency are listed in Table 36.1. Similar reactions can also occur due to improper functioning of phosphogluconate dehydrogenase and glutathione reductase.</p>
<p>Table 36.1
Some drugs causing hemolysis in G-6-PD deficiency
Sulfonamides, Furazolidone, Nitrofurantoin, Chloramphenicol, Fluoroquinolones
Antileprosy drugs (sulfones):
Diaminodiphenyl sulfone, Sulfoxone
Antimalarials:
Primaquine, Quinine
Miscellaneous drugs:
Acetanilid, Salicylates, Phenacetin, Naphthalene, Water soluble analogues of vitamin K, Methylene blue, Niridazole
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><mo>−</mo><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">--&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span><span class="mord">−</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&gt;</span></span></span></span></span></p>
<p><sup><a href="#user-content-fn-0" id="user-content-fnref-0-7" data-footnote-ref="true" aria-describedby="footnote-label">1</a></sup>Drugs can also cause hemolysis by an immune mechanism, where the RBC destruction</p>
<p>is caused by circulating antibodies. Drugs which can cause immune hemolytic anemia are methyldopa, quinine, quinidine, stibophen and phenacetin. Patients with abnormal hemoglobins may develop hemolysis if they are given sulfonamides or 8 -aminoquinoline drugs. The treatment of hemolytic reactions is essentially symptomatic. Glucocorticoids such as hydrocortisone may produce beneficial effects in blood dyscrasias caused by immune mechanisms.</p>
<p>Methemoglobinemia: The oxygen carriage by red cell hemoglobin is dependent on the availability of haemoglobin iron in the ferrous form. Drugs such as phenacetin, sulfonamides, bismuth subnitrate, ammonium nitrate and nitrites are known to oxidise the hemoglobin iron from ferrous to ferric state and thus cause methemoglobinemia. Infants below 6 months are more susceptible to this reaction, probably on account of a low concentration of the erythrocyte enzyme nicotinamide adenine dinucleotide hydrogen (NADH) which normally reduces methemoglobin to hemoglobin. This enzyme is also genetically deficient in certain subjects who are more prone to develop drug induced methemoglobinemia.</p>
<p>Treatment consists of stoppage of the drug and the administration of methylene blue, an effective antidote. 50 ml of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> solution is administered intravenously.</p>
<p>Neutropenia: In this condition, specific depression of leucocytes, particularly granulocytes, occurs. Drugs known to produce this condition do so relatively frequently, in 1 in 1000 to 1 in 100 of patients. Certain drugs like amidopyrine and dipyrone produce neutropenia by an immune mechanism, where patient's serum with specific antibodies lyses granulocytes in the presence of the drug. However, with drugs like phenothiazines and antithyroid compounds the exact mechanism is not known. Drugs that are commonly known to produce neutropenia are listed in Table 36.2.</p>
<p>Table 36.2
Some drugs causing neutropenia and agranulocytosis
Chlorpromazine and related drugs, Meprobamate</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="analgesics">Analgesics:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#analgesics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Amidopyrine, Phenylbutazone, Oxyphen-butazone, Analgin, Indomethacin</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="antibacterial-agents">Antibacterial agents:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antibacterial-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Chloramphenicol, Sulfonamides, Strepto-mycin, Cotrimoxazole Antithyroid drugs:</p>
<p>Propylthiouracil, Methimazole, Potassium perchlorate Miscellaneous:</p>
<p>Troxidone, Procainamide, Thiacetazone, Gold preparations, Imipramine.</p>
<table><thead><tr><th style="text-align: left;">Tranquillizers:</th></tr></thead><tbody><tr><td style="text-align: left;">Chlorpromazine and related drugs, Meprobamate</td></tr><tr><td style="text-align: left;">Analgesics:</td></tr><tr><td style="text-align: left;">Amidopyrine, Phenylbutazone, Oxyphen-butazone, Analgin, Indomethacin</td></tr><tr><td style="text-align: left;">Antibacterial agents:</td></tr><tr><td style="text-align: left;">Chloramphenicol, Sulfonamides, Strepto-my cin, Cotrimoxazole</td></tr><tr><td style="text-align: left;">Antithyroid drugs:</td></tr><tr><td style="text-align: left;">Propylthiouracil, Methimazole, Potassium perchlorate</td></tr><tr><td style="text-align: left;">Miscellaneous:</td></tr><tr><td style="text-align: left;">Troxidone, Procainamide, Thiacetazone, Gold preparations, Imipramine.</td></tr></tbody></table>
<p>Periodic blood counts may not necessarily predict impending neutropenia. Patients taking such drugs, therefore, should be warned about unexplained fever, or sore throat with ulceration, and should be instructed to report immediately. The mortality rate is more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span>, mainly as a result of infection, which needs prompt treatment. Blood transfusion may be necessary. Treatment with human granulocyte colony stimulating factor is discussed in Chapter 35.</p>
<p>Thrombocytopenia: This is a less frequent complication and in most cases is due to immune mechanisms. This can be demonstrated by mixing fresh normal blood with the patient's serum containing an appropriate concentration of the drugs, where clot retraction is prevented. Drugs known to cause thrombocytopenia are listed in Table 36.3. Quinidine is most commonly involved in causing this reaction. In addition, all drugs causing aplastic anemia also cause thrombocytopenia.</p>
<p>Table 36.3
Some drugs causing thrombocytopenia</p>
<p><sup><a href="#user-content-fn-0" id="user-content-fnref-0-8" data-footnote-ref="true" aria-describedby="footnote-label">1</a></sup></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="section-ix-water-electrolytes-and-drugs-affecting-renal-functions">SECTION IX Water, Electrolytes and Drugs Affecting Renal Functions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#section-ix-water-electrolytes-and-drugs-affecting-renal-functions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="outline">OUTLINE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#outline" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Chapter 37: Water, Sodium, Potassium and Hydrion Metabolism
Chapter 38: Nutritional Supplementation Therapy
Chapter 39: Diuretic and Anti-Diuretic Drugs</p>
<p>37</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="water-sodium-potassium-and-hydrion-metabolism">Water, Sodium, Potassium and Hydrion Metabolism<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#water-sodium-potassium-and-hydrion-metabolism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Correction of body water and electrolytes forms an important aspect of therapy in clinical practice, and on many occasions it is a life saving measure. The most important determinants of the amount of body water ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">%</span></span></span></span></span> of body weight) are age and gender. The water content of the newborn, the middle aged adult and the elderly are <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mi mathvariant="normal">%</mi><mo separator="true">,</mo><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">75 \%, 60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">75%</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">60%</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span>, respectively. The females, because of their higher fat percentage, have lower water content. The gender differences develop after puberty.</p>
<p>Distribution of body fluids: Body fluid is broadly divided into:</p>
<ul>
<li>Extracellular fluid (ECF); and</li>
<li>Intracellular fluid (ICF).</li>
</ul>
<p>As pointed out by Robinson and McCance (1952), ECF is like the continuous phase while ICF is like the dispersed phase of an emulsion. ECF, being continuous, plays an important role as a transport medium for various substances moving into and from the cells, while the confinement of ICF in the cells provides the basis for individual cellular functions.</p>
<p>The extracellular compartment is divided anatomically, by the traversing blood vessels, into intravascular (plasma) and extravascular (or interstitial) moieties. Physiologically, however, these compartments are continuous in respect of their electrolyte composition, as small molecules and ions can easily cross the capillary walls, the main difference being their protein content which is lower in the interstitial fluid.</p>
<p>The fluid present in the CSF, tracheobronchial tree, aqueous humor, the lumen of the GI tract and certain glands, sometimes designated as the transcellular fluid, constitutes about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2.5%</span></span></span></span></span> of total body water.</p>
<p>In a healthy, 70 kg man, total body water (TBW) comprises about 40 litres. Table 37.1 gives the distribution of the body water in various body compartments in a young man.</p>
<p>Table 37.1
Distribution of body water (percent of body weight)</p>
<table><thead><tr><th style="text-align: center;">Intracellular (ICF)</th><th style="text-align: center;"></th><th style="text-align: center;">33.0</th></tr></thead><tbody><tr><td style="text-align: center;">Interstitial</td><td style="text-align: center;"></td><td style="text-align: center;">20.5</td></tr><tr><td style="text-align: center;">Intravascular</td><td style="text-align: center;">(ECF)</td><td style="text-align: center;">4.0</td></tr><tr><td style="text-align: center;">Transcellular</td><td style="text-align: center;"></td><td style="text-align: center;">2.5</td></tr><tr><td style="text-align: center;">Total</td><td style="text-align: center;"></td><td style="text-align: center;">60.0</td></tr></tbody></table>
<p>Body fluids contain various substances, some of which are vital for normal functioning of life. Some of these exist as ionised particles carrying a positive or a negative charge. When placed in an electrical field, they migrate to the cathode (cation) or the anode (anion); hence they are known as electrolytes. The electrolyte composition of ECF is different from that of ICF. Thus, sodium, chloride and bicarbonate are mainly extracellular while potassium, magnesium, phosphate and sulfate are essentially intracellular.</p>
<p>The electrolyte composition of plasma and ICF is given in Table 37.2.</p>
<p>Table 37.2
Electrolyte composition of plasma and ICF (mMol/l)</p>
<table><thead><tr><th style="text-align: center;">Plasma ICF</th><th style="text-align: center;"></th><th style="text-align: center;"></th></tr></thead><tbody><tr><td style="text-align: center;">Cations</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Na</td><td style="text-align: center;">142</td><td style="text-align: center;">14</td></tr><tr><td style="text-align: center;">K</td><td style="text-align: center;">4.2</td><td style="text-align: center;">140</td></tr><tr><td style="text-align: center;">Ca</td><td style="text-align: center;">1.2</td><td style="text-align: center;">Negligible</td></tr><tr><td style="text-align: center;">Mg</td><td style="text-align: center;">0.8</td><td style="text-align: center;">20</td></tr><tr><td style="text-align: center;">Anions</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Cl</td><td style="text-align: center;">108</td><td style="text-align: center;">4</td></tr><tr><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{HCO}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">24</td><td style="text-align: center;">10</td></tr><tr><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">O</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PO}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">2</td><td style="text-align: center;">11</td></tr><tr><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">S</mi><mi mathvariant="normal">O</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{SO}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">SO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">0.5</td><td style="text-align: center;">1</td></tr><tr><td style="text-align: center;">Protein</td><td style="text-align: center;">1.2</td><td style="text-align: center;">4</td></tr></tbody></table>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mo lspace="0em" rspace="0em">∘</mo></msup></mrow><annotation encoding="application/x-tex">{ }^{\circ}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6741em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span></span></span></span></span> ICF contains 10,000 times less Ca than plasma.
The biological functions of the electrolytes will be better understood, not by noting their concentration in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">\mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span> but by some other unit which express the concentration in terms of molecules per unit weight of the solvent (i.e. molality). Molal solution is one which contains one mole of solute per 1000 g of the solvent. One millimolal solution is also one milliosmolal. The particle concentration of a fluid known as 'osmolality' is expressed as Milliosmoles per kg of water ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">O</mi><mi mathvariant="normal">s</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{mOsmol} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">mOsmol</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> ).</p>
<p>The higher ionic concentration of the ICF than of ECF does not result in higher ICF osmolality, because <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> of the IC ions are bound to proteins and other cellular components, rendering them osmotically inactive. Thus, the osmolalities of both compartments are nearly identical despite their different total ionic contents.</p>
<p>There are, however, certain similarities between the ECF and the ICF. Thus, in each compartment the total cation concentration in milliequivalents ( mEq ) is almost same as the total anion concentrations in mEq . Both fluids are, therefore, very nearly electrically neutral.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="functions-of-electrolytes">Functions of electrolytes:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#functions-of-electrolytes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Maintenance of osmotic pressure: The amount of water present in a given compartment is determined by the number of particles present, exerting an osmotic effect. Electrolytes play a major role in maintaining osmotic pressure. It is the number of molecules and ions per kg of water and not the mass of a solute per unit volume of fluid that determines its osmotic pressure. Substances with low molecular weight possess a larger number of molecules per unit mass than substances with high molecular weight. Hence, although the plasma protein mass is very much larger than the plasma sodium mass, the latter contributes far more to the osmotic pressure of plasma than the proteins. The osmotic balance between the ICF and the ECF is largely maintained by the electrolytes, whereas that between the ECF and the intravascular compartment is largely determined by the osmotic effect of the plasma proteins.
Normally, the volume, the total electrolyte concentration and the osmolality of ECF are maintained within narrow limits. The normal osmolality of the plasma is mostly due to</li>
</ul>
<p>the sodium and is maintained constant by the kidneys. A rise in blood urea or glucose in some diseases, however, may increase the plasma osmolality significantly. Potassium is mainly responsible for maintaining intracellular osmolality.</p>
<ul>
<li>Maintenance of electroneutrality: Electroneutrality of the body fluids is maintained by the concentrations of cations and anions being nearly equal. In order to emphasise the concept of electroneutrality of the body fluids, it is customary to express the concentrations of electrolytes in terms of their chemically reactive units expressed as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mn>1</mn></mrow><annotation encoding="application/x-tex">\mathrm{mMol} / 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/1</span></span></span></span></span>.</li>
<li>Production of energy: Energy at the cellular level is produced by anaerobic and aerobic glycolysis and is stored in available form in high energy phosphate bonds. Intracellular potassium and magnesium are essential for the function of various enzymes necessary for this process. Inorganic phosphorus is necessary for ATP synthesis. Potassium depletion affects various metabolic processes such as utilisation of carbohydrates and synthesis of proteins. Weakness in chronic diarrhoea is attributed partly to potassium depletion.</li>
<li>In impulse transmission: The neuronal and the muscle activities are associated with transmembrane shift of the electrolytes, with reversal of these during recovery period. Some drugs like phenytoin sodium, quinidine and digitalis modify these shifts of electrolytes and thus alter the cell signalling.</li>
<li>Miscellaneous: Electrolytes also have certain specialised functions to perform, e.g., calcium in blood clotting and bone formation.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="water-metabolism">Water Metabolism<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#water-metabolism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>In health, the TBW content is usually maintained within normal limits, although the water and electrolyte output varies from day to day. Water intake varies widely in subjects from different climates and even among the individuals from the same region. The daily water intake includes that taken as water and beverages ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>≈</mo><mn>1200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">\approx 1200 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4831em;"></span><span class="mrel">≈</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">1200</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> ), and that in food ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>≈</mo><mn>500</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">\approx 500 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4831em;"></span><span class="mrel">≈</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">500</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> ). Nearly 300 ml is produced daily in the body during oxidation of food. The output (about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1500</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">1500 \mathrm{ml} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1500</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span></span></span></span></span> day) is mainly in the urine; in addition, about 100 ml is lost in feces and about 1000 ml (insensible loss) in the expired air and through sweating. Considerable loss of water in sweat can occur in tropical countries like India. Under basal conditions, water balance can be calculated as follows: ( 24 hours intake +400 ml produced by oxidation of food) - ( 24 hours urinary volume +1000 ml lost from skin and lungs). This obviously gives only a gross assessment but is useful in clinical practice. In normal subjects, the water balance is zero.</p>
<p>In individuals from the tropics, the TBW on body weight basis and the water turnover are more than in those from the temperate zones. The amount of water lost by insensible perspiration is also more, particularly in hot and dry climate where the heat loss occurs mainly by evaporation of water from the skin. Water lost in hot but humid climate is less because of less evaporation from the skin.</p>
<p>The rate of sweating in terms of body mass is greater in children upto age of 9 months than in adults, owing to higher metabolic rate.</p>
<p>Acclimatisation to heat reduces the volume of sweat produced at a given temperature, probably increases the threshold for the onset of sweating and also reduces the volume of sweat produced for a given heat load. The local inhabitants of tropics, therefore, produce <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> less sweat from a unit skin area in a saturated hot environment than unacclimatised Europeans.</p>
<p>In health, water balance is maintained by:</p>
<ul>
<li>Intake as regulated by thirst; and</li>
<li>Output in the urine as regulated mainly by antidiuretic hormone (ADH).</li>
</ul>
<p>The exact stimulus for the production of thirst is not known. However, thirst can be induced by:
(a) Increase in ECF effective osmolality, leading to cellular dehydration;
(b) Decrease in ECF volume; and
(c) Increase in the CNS angiotensin II, a potent stimulus to thirst.</p>
<p>It is known that one feels thirsty after eating excessively sweet or salty food. An increase in extracellular solute concentration, following water depletion causes extraction of water from the cells. Thus, the cellular dehydration caused by water deficit or an increase in extracellular solute concentration acts as an effective stimulus to thirst. Osmoreceptors responding to changes in the plasma osmolality are present in the basal forebrain and the hypothalamus. Hypovolemia stimulates stretch/volume receptors which elicit thirst through vagal afferents reaching the hypothalamus. Hypovolemia also increases angiotensin II levels.</p>
<p>The output of water in the urine is controlled mainly by the ADH. Increased plasma osmolality caused by water depletion activates the osmoreceptors, which in turn stimulates the release of ADH . The threshold for ADH secretion is a plasma osmolality of about 280</p>
<p>mOsmol/kg of plasma water; below this level, such secretion is shut off. ADH promotes water absorption in the distal tubules and the collecting ducts of the kidney, thus reducing the urine volume and increasing its osmolality. The body thus tries to conserve water. Other stimuli like pain, decreased blood volume, mental stress, hypoglycemia and drugs like morphine, nicotine and barbiturates also increase ADH release, mediated by the baroreceptors in the carotid sinus.</p>
<p>Both the mechanisms, thirst and ADH activity, are very sensitive even to small changes in the osmolality of body fluids. They are, however, less influenced by changes in the volume alone. In the natural stress of water deprivation, these two mechanisms act synergistically and protect the body from water depletion. Water excess is countered by inhibition of ADH release, resulting in a decrease in renal water resorption and water diuresis.</p>
<p>Water metabolism is intimately connected with the changes in solute content of the body. Thus, an increased intake of solutes necessitates increased water intake, and increased retention of sodium is associated with retention of water causing edema. Similarly, an excessive loss of solutes in the urine causes an increased water loss (osmotic diuresis).</p>
<p>Aldosterone, the mineralocorticoid hormone, influences the water balance by modifying the sodium metabolism. Physiologically, hydrocortisone, another hormone of the adrenal cortex, is essential for eliminating an extra load of water from the body. In its absence as in case of Addison's disease, patients are unable to excrete the water load adequately.</p>
<p>Water depletion: The clinical syndrome of water depletion is usually associated with disturbances of electrolyte metabolism as well; selective water deficiency is uncommon. Relative water deficiency can occur:</p>
<ul>
<li>Due to reduced water intake in patients with extreme lethargy or coma.</li>
<li>In GI disorders with defective water absorption.</li>
<li>Due to excessive sweating as in fever; hypotonicity of the sweat causes a greater loss of water than of sodium.</li>
<li>In certain cases of chronic renal failure.</li>
<li>Due to osmotic diuresis as in diabetes mellitus</li>
<li>In diabetes insipidus; and</li>
<li>After damage to thirst centre.</li>
</ul>
<p>Infants, in general, are more prone to develop water depletion than adults, as the kidneys of infants are unable to concentrate the urine adequately. This is also partly due to inadequate body water stores.</p>
<p>In mild water depletion, the osmolality of body fluids increases as their volume is decreased. This decrease in the volume is initially spread evenly over all the fluid compartments. Marked ECF contraction however, stimulates the secretion of aldosterone causing sodium retention which conserves the ECF volume in preference to ICF (Fig. 37.2).</p>
<p><img src="assets/images/image-20251214-b3ca5e50.jpeg" alt="img-40.jpeg"></p>
<p>FIG. 37.2 Effect of sodium depletion and of mild and severe water depletion on the partition of fluid between ECF and ICF (Black D.AK., Essentials of Fluid Balance, 4th ed. 1967, Blackwell scientific Publications. The figure is reproduced by the courtesy of the author and the publishers)</p>
<p>Clinical history helps to suspect water depletion. Such a patient is usually apathetic and confused. The urine volume is markedly reduced except in conditions like diabetes insipidus or chronic renal failure. The plasma sodium, proteins and blood urea levels are raised; but as the loss of fluid from the plasma is associated with a corresponding loss of fluid from the erythrocytes the hematocrit is not significantly raised. A conscious patient usually complains of thirst, dryness of mouth and difficulty in swallowing. Severe water depletion causes unconsciousness and finally even respiratory failure. In practice, the clinical picture of water depletion is usually complicated by the associated sodium depletion (dehydration).</p>
<p>The treatment is to give enough water, which, in the presence of normal kidney function, is well tolerated. In patients who are vomiting or unconscious, water in the form of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> glucose is given IV. This also supplies calories and prevents ketosis. Associated disturbances in electrolyte concentrations should be corrected. Patients with fever and polyuria, and those on high protein intake need higher water intake.</p>
<p>In the absence of thirst, the water requirement can be judged by noting the 24 hour urinary volume and plasma sodium concentration. Free water deficit can be calculated by:</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mtext>&nbsp;Water&nbsp;deficit&nbsp;</mtext><mo>=</mo><mrow><mo fence="true">{</mo><mfrac><mrow><mtext>&nbsp;PlasmaNa+&nbsp;</mtext><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mo stretchy="false">)</mo><mo>−</mo><mn>140</mn></mrow><mn>140</mn></mfrac><mo fence="true">}</mo></mrow><mo>×</mo><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">B</mi><mi mathvariant="normal">W</mi></mrow><mo stretchy="false">(</mo><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">L</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">\text { Water deficit }=\left\{\frac{\text { PlasmaNa+ }(\mathrm{mEq})-140}{140}\right\} \times \mathrm{TBW}(\mathrm{~L})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord text"><span class="mord">&nbsp;Water&nbsp;deficit&nbsp;</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 2.4em; vertical-align: -0.95em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;"><span class="delimsizing size3">{</span></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.427em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">140</span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">&nbsp;PlasmaNa+&nbsp;</span></span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mclose">)</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">140</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.686em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mclose delimcenter" style="top: 0em;"><span class="delimsizing size3">}</span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">TBW</span></span><span class="mopen">(</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">L</span></span><span class="mclose">)</span></span></span></span></span></div>
<p>Total body water (TBW) is appromixately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of lean body mass in men and women respectively.</p>
<p>After adequate water supplementation, the plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>concentration decreases to normal levels.</p>
<p>Water excess: This is uncommon but can occur following unrestricted administration of fluids in the presence of inadequate urinary output and in patients with cortisol deficiency. In mild cases, the patient may develop headache, nausea, vomiting and mental confusion.</p>
<p>Body weight increases and edema may occur. Severe water intoxication can produce convulsions and coma. The plantar response may be extensor and pupils unequal. The symptomatology is probably due to hypotonicity of body fluids with resultant cerebral edema.</p>
<p>The presence of oliguria, in spite of adequate hydration of subcutaneous tissues, low serum sodium level, and an awareness on the part of physician that such a possibility may exist, help to diagnose the water excess.</p>
<p>The treatment of water intoxication consists of restriction of intake of non-saline fluid. In severe cases with convulsions and coma, 50 to 100 ml of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> saline is given IV, repeatedly, till the plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>is raised to about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>130</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mn>1</mn></mrow><annotation encoding="application/x-tex">130 \mathrm{mMol} / 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">130</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/1</span></span></span></span></span>. Isotonic saline is not useful in water intoxication as it does not help to raise the plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>level. In patients with renal disease with oliguria, water intoxication must be avoided by restricting the water intake as guided by the urinary output.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="sodium-metabolism">Sodium Metabolism<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sodium-metabolism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The study of sodium metabolism is fundamental to the understanding of electrolyte physiology and ECF volume regulation.</p>
<p>Sodium distribution: The distribution of body sodium is shown in Fig. 37.1. Sodium is present principally in ECF, though this is not its only location. There is a considerable amount of sodium in bones, which act as a sodium reservoir. The total body sodium can be measured by (i) direct carcass analysis and (ii) isotope dilution technique using radioactive sodium. The radioactive sodium, injected IV, gets uniformly distributed in all the body fluids and tissues containing stable sodium, except some portion of the bone. The distribution is proportional to the sodium content of various body compartments and tissues. This process is known as 'sodium exchange'. Since plasma represents the ECF, by noting the dilution of injected radiosodium, total body exchangeable sodium can be calculated.
<img src="assets/images/image-20251214-45bcf02c.jpeg" alt="img-41.jpeg"></p>
<p>FIG. 37.1 Distribution of body sodium. Note that a considerable amount of sodium is in the bone and is not exchangeable with radiosodium within 24 hours of equilibrium <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mi mathvariant="normal">e</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{Na}_{\mathrm{e}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.1514em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">e</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> : Exchangeable Na; T.C.:
Trans-cellular; I.C.: Intracellular; CART: Cartilage. INT: Intestinal
Body sodium calculated by the isotope dilution method is approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>45</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">45 \mathrm{mMol} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">45</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> in Indian males and about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>43</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">43 \mathrm{mMol} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">43</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> in Indian females. Thus, an average Indian male weighing 60 kg will have 2700 mMol of exchangeable sodium. This value, however, is less than 'actual total body sodium', as part of the bone sodium is not estimated by isotope dilution technique, using 24 hours equilibrium period. Although the exchangeable sodium may vary over a wide range, the serum sodium level is maintained remarkably constant at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>140.9</mn><mo>±</mo><mn>4.8</mn><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">S</mi><mi mathvariant="normal">D</mi></mrow><mo stretchy="false">)</mo><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">140.9 \pm 4.8(\mathrm{SD}) \mathrm{mMol} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">140.9</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">±</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4.8</span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">SD</span></span><span class="mclose">)</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span></span></span></span></span> litre.</p>
<p>Body content of sodium over a long period depends on the balance between intake and output. The daily intake of sodium varies considerably between 50 and 500 mMol . Unlike the phenomenon of thirst, no craving for salt is generally observed in sodium depletion;</p>
<p>and hence, excessive sweating in tropics can easily cause salt depletion producing the symptoms of 'heat exhaustion'. Sodium loss in stools is very small. This may, however, be very marked in watery diarrhoea. The major output of sodium occurs in the urine. In tropical countries, the loss of sodium in sweat can be considerable, particularly with occupations that involve heavy labour. Sweat contains less sodium per litre than plasma. The sodium content of sweat in infants is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">2.5 \mathrm{mMol} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2.5</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span>, while in adults, not acclimatised to hot weather, it could be as much as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">90 \mathrm{mMol} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">90</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span>. With acclimatisation, it is reduced to 10-15 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">\mathrm{mMol} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span>. Excessive sweating thus causes proportionately more water loss than sodium loss.</p>
<p>Sodium absorption: The rate of absorption of sodium and water from isotonic saline solutions is though very similar in the human jejunum and ileum, there are important differences. The sodium absorption in the jejunum occurs mainly by passive process. Experiments with human proximal jejunum suggest that:</p>
<ul>
<li>Concurrent glucose or fructose absorption stimulates water absorption and that water movement across the mucosa stimulates passive absorption of sodium by 'solvent drag'.</li>
<li>Glucose also stimulates active sodium absorption.</li>
<li>Fructose, unlike glucose, stimulates active potassium absorption.</li>
<li>The sodium absorption increases with rising intraluminal sodium concentration; and</li>
<li>Bicarbonate absorption is an active process and increases with increasing intraluminal bicarbonate concentration; however, it is minimally affected by concurrent glucose or fructose absorption.
In contrast to jejunum, in the ileum sodium can be absorbed against large concentration gradients and it is not affected by water flow nor by the addition of glucose or bicarbonate. Thus, sodium absorption in the ileum occurs mainly by active transport process. These findings have an important clinical application in oral fluid therapy (see management of dehydration).</li>
</ul>
<p>About 1000 mMoles of sodium are secreted daily into the GI tract. This is totally reabsorbed. Aldosterone promotes the sodium absorption from the intestines and the colon.</p>
<p>Urinary excretion of sodium: Normally, about 13-20 mMoles of sodium is filtered out every minute at the glomeruli. Of this, over <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>98</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">98 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">98%</span></span></span></span></span> is reabsorbed by the renal tubules and only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> is excreted in the urine. Hence, even a slight interference with the tubular reabsorption can produce a marked increase in the urinary sodium loss. Increasing the amount of sodium filtered at the glomeruli has a less marked effect on urinary sodium. A decrease in the filtered load of sodium as in CHF, however, leads to sodium retention and edema. On the other hand, failure of the tubules to reabsorb sodium due to lack of aldosterone causes marked sodium loss as in Addison's disease.</p>
<p>Urinary excretion of sodium is regulated by:</p>
<ul>
<li>Renal blood flow, which depends upon cardiac output, local condition of the kidney vessels, and plasma and ECF volumes; and</li>
<li>Hormonal control particularly by aldosterone, which influences tubular reabsorption of sodium.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="hormonal-control-of-sodium-metabolism">Hormonal control of sodium metabolism:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hormonal-control-of-sodium-metabolism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The bulk of sodium filtered by the glomeruli is reabsorbed in the proximal tubules independently of hormonal control. However, the adrenal salt retaining steroid, aldosterone, promotes sodium reabsorption and potassium excretion, by acting on distal</p>
<p>renal tubule. It also modifies the sodium concentration of sweat, saliva and intestinal juices and the movement of sodium and potassium across the cell membrane (Chapter 66). The aldosterone secretion is regulated by:</p>
<ul>
<li>A reflex pathway with a regulatory centre in the brain which responds to changes in serum electrolytes such as sodium depletion, potassium loading and to ECF volume contraction due to blood loss or reduction in body water. With respect to volume receptors, stimulation of either the right atrial wall or the juxta-glomerular apparatus in the kidneys can alter the secretion of aldosterone; and</li>
<li>A humoral mechanism related to renin-angiotensin-aldosterone system (RAAS) with its trigger in the kidney plays an important role in the maintenance of salt and water homeostasis through the formation of angiotensin II and aldosterone (Chapter 66).
In normal man, sodium depletion increases while sodium loading decreases the plasma renin levels. The Yanomamo Indians inhabiting the tropical rain forests of Brazil, who do not use salt in their diet and thus have life-long very low levels of sodium intake have raised plasma aldosterone and renin levels. Interestingly, their BP does not rise with age unlike in the developed world consuming a lot of salt. Chronic elevation of renin without hypertension indicates the importance of the level of body sodium in affecting BP in man. Total body exchangeable sodium is increased in hypertensive subjects, and it correlates positively with BP. Conversely, the exchangeable potassium correlates negatively with BP in essential hypertension. Sodium retention decreases the synthesis of NO, a potent vasodilator, by the endothelial cells. The RAAS, however, does not fully account for the physiological mechanisms involved in the renal handling of sodium.</li>
</ul>
<p>NATRIURETIC PEPTIDE (NP): This vasoactive natriuretic peptide hormone, released from the myocardium and the brain, plays an important role in sodium homeostasis. Three NPs have been identified :
(1) Atrial NP (ANP), released mainly from the atrium.
(2) Brain NP (BNP), originally isolated from porcine brain but released mainly from the ventricles of the heart; and
(3) C-type NP (CNP), released mainly from the brain and the vascular tissue.</p>
<p>ANP and BNP are released from the myocardiac tissue following atrial/ventricular myocyte stretch. Their synthesis is also increased by glucocorticoids, tachycardia, thyroxine, angiotensin II and endothelin I. They have similar chemical structures.</p>
<p>Three NP receptors have been identified. ANP and BNP bind to specific receptors situated on the surface of target cells and cause generation of cyclic guanosine monophosphate (cGMP). CNP binds to the third specific receptor (the clearance receptor) to block the clearance of ANP and BNP, thus prolonging their action. These peptides are inactivated by the enzyme neutral peptidase (vasopeptidase) present on the surface of endothelial cells, cardiac myocytes, smooth muscle cells, kidney epithelium and in the brain. It is nonspecific and also catalyses the breakdown of peptides such as bradykinin and angiotensin II.</p>
<p>Both, ANP and BNP exert almost identical actions. They act on:</p>
<ul>
<li>
<p>Kidneys to increase the renal blood flow and GFR, and decrease sodium reabsorption, causing natriuresis.</p>
</li>
<li>
<p>Renin-angiotensin-aldosterone system, which they inhibit by direct action, reducing the release of angiotensin II and aldosterone.</p>
</li>
<li>
<p>Vascular smooth muscle, causing vasodilatation, and reduce blood pressure and ventricular preload.</p>
</li>
<li>
<p>Vascular endothelium, inhibiting the production of the vasoconstrictor endothelin.</p>
</li>
<li>
<p>Vascular tissue, possibly to exert, antiproliferative and antifibrotic actions.</p>
</li>
<li>
<p>ANS, decreasing the activity of the sympathetic nervous system; and</p>
</li>
</ul>
<p>The blood concentration of BNP is consistently raised in patients with cardiac dysfunction and is of diagnostic and prognostic significance in heart failure. Unlike ANP and BNP, CNP acts locally as a vasodilator; it does not function as a circulating hormone.</p>
<p>Recombinant human BNP (Nesiritide) and vasopeptidase inhibitors which inhibit the metabolic degradation of BNP have been used in CHF (Chapter 31).</p>
<p>Centrally released ANP suppresses pituitary ADH release and angiotensin II mediated thirst.</p>
<p>Other hormones such as hydrocortisone, estrogens and testosterone can produce sodium retention. Adrenaline and noradrenaline may affect sodium metabolism indirectly by their actions on blood vessels. ADH has no direct effect on sodium metabolism. However, in the Syndrome of Inappropriate ADH secretion (SIADH), expansion of plasma volume leads to natriuresis, probably through inhibition of aldosterone secretion. The marked sodium loss that occurs in diabetic ketoacidosis is due to hyperglycemia with resultant polyuria.</p>
<p>The usual salt intake in humans (100-400 mMoles of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0946em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mord">/</span></span></span></span></span>day) is generally not a true reflection of salt requirement. The customary quantities of salt in contemporary diets far exceed the amount necessary to maintain sodium balance in health.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="sodium-depletion">Sodium Depletion<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sodium-depletion" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>True sodium depletion is one in which there is actual loss of sodium from the body. This must not be confused with the 'low salt syndrome' characterised by low plasma sodium concentration (hyponatremia), wherein the total body sodium may not necessarily be low.</p>
<p>The effects of pure sodium depletion are distinctly different from those of pure water depletion. During the early stages of sodium depletion, the filtered sodium is almost completely reabsorbed. In addition, an excess of water is excreted by the kidneys, producing dilute urine. The body, thus, conserves sodium concentration at the cost of ECF volume which contracts. Bones release some sodium which helps to maintain the serum sodium level; such release is more marked in younger and sodium depleted acidotic individuals. With further losses of sodium, the serum sodium level falls. This causes further loss of ECF water, partly into urine and partly by a shift of water into the cells resulting in increased volume and decreased osmolality of ICF. This is in contrast to changes in severe water depletion, where the ECF and plasma volumes are maintained at the cost of ICF volume, which diminishes (Fig. 37.2).</p>
<p>Sodium depletion thus causes decrease in ECF and plasma volumes resulting in a rise in the hematocrit and the serum protein concentration.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="causes-of-sodium-loss">Causes of sodium loss:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#causes-of-sodium-loss" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>GI loss: as in diarrhoea and discharge from fistulae. Sodium loss can be severe in watery diarrhoea eg. in cholera or acute bacillary dysentery. In such cases, it is also associated with loss of bicarbonate causing acidosis.</li>
<li>Renal loss: Urinary loss of sodium is observed following diuretics, in diabetic coma, and during starvation or increased catabolism of proteins. A primary renal disease like acute tubular necrosis during its recovery phase and salt losing nephritis may produce marked sodium loss. Sodium loss is not directly linked with the urine volume. It can occur even in the absence of polyuria (e.g. Addison's disease); however, sodium excretion may be normal in the presence of polyuria (e.g. diabetes insipidus).</li>
<li>Cutaneous loss: Considerable cutaneous losses of sodium can occur in people working in hot climate like deserts and in patients with burns.</li>
<li>Miscellaneous: Draining of ascitic fluid can also produce marked sodium loss.</li>
</ul>
<p>Symptomatology of sodium depletion: The clinical findings depend on:</p>
<ul>
<li>Amount of volume loss</li>
<li>Rate of volume loss</li>
<li>Nature of the fluid lost (blood or water); and</li>
<li>Response of the vasculature to volume loss</li>
</ul>
<p>Mild sodium depletion (100-200 mMoles) is common in tropical countries. Patients usually complain of loss of appetite, lethargy and cramps and have tachycardia. Since sweat is hypotonic, drinking water without correcting the sodium loss would cause body fluid dilution, which is partly responsible for these symptoms.</p>
<p>Massive sodium loss such as 1000-1500 mMoles causes extrarenal uremia accompanied by shock:
(a) Limbs are cold. Cardiac output is low and pulse rate is increased. There is a fall in BP, with marked vasoconstriction in the skin and kidney vessels.
(b) Loss of tissue elasticity and turgor is characteristic of sodium depletion and is due to a</p>
<p>decrease in the interstitial fluid content.
(c) Eyeballs appear 'sunken'.
(d) Symptoms like muscle cramps, anorexia and vomiting are probably due to relative body fluid dilution, as these are also seen in water intoxication.</p>
<p>It is vitally important to distinguish the extrarenal uremia from that due to renal tubular necrosis and acute renal failure secondary to acute severe sodium depletion with volume contraction. The former is reversible with proper treatment. In case of doubt, a therapeutic trial with saline infusion is justified. Primary sodium depletion can cause albuminuria but the presence of hematuria and casts suggests intrinsic renal disease.</p>
<p>In sodium depletion, the serum sodium may be low but presence of normal serum sodium level does not rule out sodium depletion. Blood urea rises out of proportion to serum creatinine. The urine volume decreases, the urine sodium falls and the specific gravity rises. Sodium depletion following GI losses is obvious. In other conditions, history and symptoms help to suspect it. The possibility of sodium loss from the kidney itself should be borne in mind.</p>
<p>Sodium depletion and kidneys: A variety of mechanisms in the body operate to protect the body against the deleterious effects of sodium depletion and the resulting extra cellular volume (ECV) contraction.</p>
<ul>
<li>ECV contraction is sensed by extrarenal baroceptors located in the high (carotid body and aortic arch) and low (atria and thoracic veins) pressure areas of the circulation. Their activation results in increased sympathetic nerve activity, leading to tachycardia and rise in BP due to increased peripheral arteriolar resistance.</li>
<li>Within the kidney, increased arteriolar resistance brings about renal hypoperfusion; this and the direct stimulation of the renal sympathetic nerves causes more complete sodium reabsorption by the proximal tubules.</li>
<li>Activation of the extrarenal baroceptors also causes non-osmotic release of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi><mi>D</mi><mi>H</mi></mrow><annotation encoding="application/x-tex">A D H</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span><span class="mord mathnormal" style="margin-right: 0.08125em;">DH</span></span></span></span></span> which in turn causes renal water conservation, and reduces renal perfusion by vasoconstriction.</li>
<li>Sympathetic nerve stimulation of the juxta-glomerular (JG) apparatus within the kidney (an intrarenal baroceptor) enhances renin release. Renin, in turn, accelerates the formation of angiotensin II.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="angiotensin-ii">- Angiotensin II<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#angiotensin-ii" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Is a potent pressor agent;
(ii) Causes release of aldosterone, which stimulates sodium reabsorption by the distal renal tubules;
(iii) Is a potent stimulus to thirst and
(iv) In low concentrations, it has a selective constrictive effect on efferent renal glomerular arterioles, and thus maintains GFR.
In higher concentrations, however, it constricts afferent renal glomerular arterioles as well, leading to decrease GFR and renal ischemia.</p>
<ul>
<li>In mild to moderate ECV contraction, beneficial peripheral vasoconstriction and renal sodium conservation occur. Renal blood flow, GFR and osmoregulation are less affected.</li>
<li>When ECV contraction becomes severe, high levels of noradrenaline and angiotensin II cause marked reduction in both GFR and rate of sodium excretion. Further, nonosmotic ADH release, angiotensin II mediated thirst and reduction in salt delivery to the loop of Henle, all cause hyponatremia. Finally, marked decrease in renal blood flow cause renal</li>
</ul>
<p>ischemia and precipitation of prerenal azotemia.
The other vasoconstrictors that may play a role in modulating systemic hemodynamics are endothelin 1 and thromboxane <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">A</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{A}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">A</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (Table 37.3).</p>
<p>Table 37.3
Agents which modulate renal circulation</p>
<table><thead><tr><th style="text-align: left;">Vasoconstrictors</th><th style="text-align: left;">Vasodilators</th></tr></thead><tbody><tr><td style="text-align: left;">Noradrenaline</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">ADH</td><td style="text-align: left;">Natriuretic peptide(s)</td></tr><tr><td style="text-align: left;">Angiotensin II</td><td style="text-align: left;"></td></tr><tr><td style="text-align: left;">Endothelin 1</td><td style="text-align: left;"></td></tr><tr><td style="text-align: left;">Thromboxane <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">A</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{A}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">A</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: left;"></td></tr></tbody></table>
<p>As against the vasoconstrictors, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and NP act to protect the renal hemodynamics against the onslaught of excess vasoconstrictors. They are the negative feedback elements of the renal, volume regulatory response.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is produced in the renal glomeruli, where angiotensin II activates eicosanoid production and release, as well as by the renal medullary interstitial cells. It :</p>
<ul>
<li>Is a natriuretic, causing direct inhibition of tubular sodium reabsorption;</li>
<li>Is a vasodilator and protects the kidney against the injurious effects of excessive NA and angiotensin II; and</li>
<li>Antagonises the renal tubular effect of ADH directly.</li>
</ul>
<p>Treatment of sodium depletion: The aim of therapy is to maintain the urine output at 30<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">50 \mathrm{ml} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span></span></span></span></span> hour and the BP within normal limits. The principles of treatment are shown in Table 37.4.</p>
<p>Table 37.4
Principles of treatment of sodium depletion</p>
<ul>
<li>Introduce a good IV line.</li>
<li>Start with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.9</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.9 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.9%</span></span></span></span></span> (normal) saline. This is the fluid of choice with isotonic fluid loss.</li>
<li>In severe cases, a rapid rate of infusion ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>3</mn></mrow><annotation encoding="application/x-tex">2-3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">3</span></span></span></span></span> litres <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">/</mi><mn>2</mn><mo>−</mo><mn>3</mn></mrow><annotation encoding="application/x-tex">/ 2-3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">3</span></span></span></span></span> hours) may be required.</li>
<li>Add potassium and bicarbonate, depending upon the type of fluid lost. Excessive use of normal saline alone aggravate acidosis, if present, because of its chloride content.</li>
<li>In case of diarrhoea, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">q</mi></mrow><annotation encoding="application/x-tex">40 \mathrm{ml} / \mathrm{q}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord mathrm">q</span></span></span></span></span> of potassium <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">(40 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">40</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7.5</mn><mi mathvariant="normal">%</mi><mrow><mi mathvariant="normal">K</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">7.5 \% \mathrm{KCl})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">7.5%</span><span class="mord"><span class="mord mathrm">KCl</span></span><span class="mclose">)</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>45</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">q</mi></mrow><annotation encoding="application/x-tex">45 \mathrm{ml} / \mathrm{q}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">45</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord mathrm">q</span></span></span></span></span> of bicarbonate ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mrow><mi mathvariant="normal">o</mi><mi mathvariant="normal">f</mi></mrow><mn>7</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \mathrm{ml} \mathrm{of} 7 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.07778em;">of</span></span><span class="mord">7%</span></span></span></span></span> sodium bicarbonate) may be added to each litte normal saline.</li>
<li>Monitor the therapy in severe cases by measuring the CVP, which should be maintained at 6-12 cm of water.</li>
<li>If the urine output does not rise in spite of adequate fluid replacement, renal failure should be suspected.</li>
</ul>
<p>Mild degrees of volume depletion can be corrected by giving about 10 g of sodium chloride and 2-3 litres of oral fluid daily. This can be done by administering <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.9</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.9 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.9%</span></span></span></span></span> saline.</p>
<p>Moderately depleted cases usually require about 3-4 litres of IV saline. Overfilling of the neck veins indicates overloading with saline which should be avoided as it may cause pulmonary edema. Deficiency of other electrolytes, particularly potassium and bicarbonate, if present, should be corrected.</p>
<p>In patients with acute severe sodium and water depletion, the amount of isotonic saline needed is so large that if injected quickly, it may overload the circulation. Serum sodium levels below <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>110</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">110 \mathrm{mMol} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">110</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span> may precipitate convulsions and coma. In such severe hyponatremia, slow IV infusion of hypertonic (3-5%) sodium chloride solution is used to relieve cerebral edema temporarily and prevent neurological sequale by restoring plasma volume and renal circulation, particularly in patients with extrarenal azotemia. The</p>
<p>hypertonic saline injected gets diluted by a shift of the water (which has entered into the ICF during severe sodium depletion) back to ECF. As severe sodium depletion is generally associated with acidosis, sodium bicarbonate has to be administered to correct the acidosis. Severe hyponatremia with marked sodium depletion should be corrected slowly to serum <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>125</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">125 \mathrm{mMol} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">125</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span> (no more) over 24 hours. Further rise in serum <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>to normal level should take several days.</p>
<p>For subjects working in hot environment and in diseases like Addison's disease, where continued sodium loss occurs, prophylactic addition of salt to the diet is necessary.</p>
<p>Hyponatremia: Hyponatremia, defined as serum sodium concentration of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>135</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">&lt;135 \mathrm{mMol} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">135</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span> is quite common in hospitalised patients. It is associated with high morbidity and mortality in patients with chronic heart failure, cirrhosis and neurological diseases. It must be emphasised that although serum sodium may be low in cases with sodium depletion, not all patients with low serum sodium levels are suffering from body sodium depletion. In some of these cases with hyponatremic syndrome where plasma sodium level is low, the total body sodium may be normal or even high.</p>
<p>It has been observed that serum sodium correlates well with the osmolality of serum which is related to:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="exchangeable-sodium-exchangeable-potassium-br-total-body-water">Exchangeable sodium + Exchangeable potassium &lt;br&gt; Total body water<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#exchangeable-sodium-exchangeable-potassium-br-total-body-water" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>This observation in man provides a rational basis for the classification of hyper and hyponatremic states.</p>
<p>Hyponatremia may be caused by:</p>
<ul>
<li>Primary sodium loss</li>
<li>Primary potassium loss</li>
<li>Primary water excess; or</li>
<li>Combination of these</li>
</ul>
<p>In practice, hyponatremia can be classified as hypovolemic, euvolemic and hypervolemic.</p>
<p>Hyponatremia in diarrhoea is due to loss of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>(dehydration) while that observed in CHF and cirrhosis is due to primary gain of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>, loss of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>and secondary gain in body water (edema). In these patients, water retention is mediated by vasopressin- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">V</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{V}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">V</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0139em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors in the renal collecting tubules. In some cases, it is associated with SIADH.</p>
<p>Symptoms of hyponatremia are due to osmotic water shift leading to increased ICF volume. They are mostly neurological due to swelling of brain cells.</p>
<p>Treatment: It depends upon the cause. Mild asymptomatic cases need no treatment. Serum sodium concentration can be temporarily raised by water deprivation in mild cases, by administration of saline in symptomatic patients and by promoting water loss in excess of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>in edematous patients. Recently, a selective, vasopressin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">V</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{V}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">V</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0139em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonist tolvaptan used orally and conivaptan, a nonselective <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">V</mi><mrow><mn>1</mn><mi mathvariant="normal">a</mi></mrow></msub></mrow><annotation encoding="application/x-tex">\mathrm{V}_{1 \mathrm{a}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">V</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0139em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathrm mtight">a</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">V</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{V}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">V</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0139em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonist used</p>
<p>IV have been shown to be useful in maintaining serum <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>concentration in euvolemic or hypervolemic hyponatremic patients (Chapter 39).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="sodium-excess">Sodium Excess<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sodium-excess" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Sodium retention is always associated with water retention and may manifest as pitting edema. Sodium excess due to increased intake is most unlikely in the presence of normal kidney function. The main cause of sodium retention is the failure of the kidneys to excrete the sodium load. This may be due to:</p>
<ul>
<li>Intrinsic kidney disease e.g. acute nephritis, nephrosis.</li>
<li>Decreased renal blood flow such as in CHF and acute hypotension and</li>
<li>Excessive reabsorption of sodium by the tubules e.g. in aldosteronism.</li>
<li>Iatrogenic, following certain drugs e.g. NSAID, hydrocortisone.</li>
</ul>
<p>Estimation of serum sodium levels is not of much help in the diagnosis of body sodium excess and in fact, in some cases the levels may be even subnormal.</p>
<p>Treatment: This depends upon the cause which should be corrected, if possible. Therapeutically, sodium depletion can be brought about by:</p>
<ul>
<li>Restricting the daily dietary sodium intake to 20-50 mEq.</li>
<li>Increasing the sodium output in urine by using diuretics (Chapter 39); and</li>
<li>Improving renal perfusion e.g., digoxin in CHF or IV infusions in oligemic shock.</li>
</ul>
<p>Usually, these methods are combined.
Hypernatremia or increased serum sodium level of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>145</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">&gt;145 \mathrm{mMol} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">145</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span> is a state of hyperosmolality and is due to:</p>
<ul>
<li>Primary sodium excess</li>
<li>Primary potassium excess</li>
<li>Primary water deficit; or</li>
<li>Combination of these</li>
</ul>
<p>It results in ICF volume contraction.
In practice, it is commonly due to excessive loss of total body water as in diabetes insipidus. It may cause mental impairment in the adults.</p>
<p>Hypernatremia has been reported in a patient with poisoning given 10% hypertonic saline as emetic but failed to vomit, and in infants who were given feeds prepared with salt instead of sugar by mistake; half of these infants died. The clinical picture showed pyrexia, hyperpnea, hyper-reflexia and coma. Brain damage has been reported to be associated with hypernatremia due to heat stroke. Hypernatremia can also occur following osmotic diarrhoea (carbohydrate malabsorption) or osmotic diuresis.</p>
<p>Hypernatremia treatment: It is directed towards reducing the serum sodium level. In patients with severe dehydration and contraction of blood volume, it should be corrected slowly at the rate of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mo>−</mo><mn>13</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi><mi mathvariant="normal">/</mi><mn>24</mn></mrow><annotation encoding="application/x-tex">12-13 \mathrm{mMol} / \mathrm{L} / 24</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">12</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">13</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord mathrm">L</span><span class="mord">/24</span></span></span></span></span> hours for the first 48 hours. This is best brought about by initial infusion of normal saline followed by infusion of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">1 / 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/2</span></span></span></span></span> strength saline. Infusion of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> dextrose in water in this condition has two disadvantages:
(1) It lowers the plasma osmolality too fast for the brain to keep pace; the brain which remains hypertonic then swells up by transfer of water from ECF; and
(2) It can cause hyperglycemia with osmotic diuresis; the latter can aggravate hypernatremia. In children the best solution is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2.5%</span></span></span></span></span> dextrose in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">1 / 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/2</span></span></span></span></span> normal saline.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="potassium-metabolism">Potassium Metabolism<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#potassium-metabolism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The body potassium in man, as measured by isotope dilution, amounts to about 45 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{mMol} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> in males and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>38</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">38 \mathrm{mMol} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">38</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> in females. These figures are lower than the actual total body potassium as estimated by cadaveric analysis by about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">15 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">15%</span></span></span></span></span>.</p>
<p>Distribution of potassium: Potassium is essentially a cation of the cells and hence its distribution is related to the cell mass. It is predominantly ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>98</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">98 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">98%</span></span></span></span></span> ) restricted to the IC space. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> of the total potassium is in the muscles, about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> in the brain and large viscera while <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> is present in the skin and subcutaneous tissues.</p>
<p>The mean serum level of potassium is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4.5</mn><mo>±</mo><mn>0.46</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">4.5 \pm 0.46 \mathrm{mMol} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">±</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.46</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span>. Although this is considerably lower than the mean serum sodium level, changes in serum potassium concentration can produce profound effects on body functions.</p>
<p>Potassium intake and excretion: The daily potassium intake is estimated to be about 50150 mMoles. It is likely to be more in vegetarians than in non-vegetarians as vegetables and fruits (citrus fruits, tomatoes, potatoes, bananas) contain large amounts of potassium. Processed foods are usually high in sodium and low in potassium.</p>
<p>Kidney is the major regulator of long term potassium homeostasis. The major loss ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> ) of potassium occurs in urine by tubular secretion. That which is filtered by the glomeruli is totally reabsorbed. The kidney reabsorbs sodium and, in exchange, excretes <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{H}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ions into the distal tubules. The normal urine is, thus, acidic in reaction. Because of this tubular secretion of potassium, the urinary loss of potassium would continue and may even be greater than the intake, when daily intake of potassium is markedly restricted. Increased sodium intake increases the potassium loss because it makes more <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>available for exchange with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>while low sodium intake reduces the urinary loss of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>.</p>
<p>Normally, about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> of potassium is excreted in the feces. A part of this is secreted by the colon in exchange for sodium which is reabsorbed. This potassium loss in stools continues even in subjects on very low potassium intake. This is in contrast to body sodium, which is conserved by achieving its complete reabsorption by the tubules and the intestines, when sodium intake is markedly reduced.</p>
<p>The potassium concentration of sweat in infants is 3.9 mMoles as compared to the sodium concentration of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">2.5 \mathrm{mMol} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2.5</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span>. In non-acclimatised adults it is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">10 \mathrm{mMol} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span>. Thus, proportionately more potassium is lost per unit volume of sweat than sodium, with respect to their plasma levels. Excessive sweating, as occurs during dry heat or during fevers, can cause significant potassium depletion.</p>
<p>The Institute of Medicine, USA, recommends a daily intake of 65-70 mmol of sodium (3.8 g of sodium chloride) for normal adults younger than 50 years of age and 50 mmol for those over 70 years. Their recommendation for daily intake of potassium is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>120</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">100-120 \mathrm{mmol}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">120</span><span class="mord"><span class="mord mathrm">mmol</span></span></span></span></span></span> ( 4.7 g of potassium), thus maintaining a dietary <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup><mi mathvariant="normal">/</mi><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+} / \mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0946em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mord">/</span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ratio at about 2 . As per current estimate, nations which consume lots of processed foods ingest as much as 100-400 mmol of sodium and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>70</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">50-70 \mathrm{mmol}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">70</span><span class="mord"><span class="mord mathrm">mmol</span></span></span></span></span></span> of potassium, with a dietary <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup><mi mathvariant="normal">/</mi><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+} / \mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0946em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mord">/</span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ratio of less than 0.4 .</p>
<p>Factors affecting plasma potassium: Estimation of plasma potassium gives information about ECF potassium changes.</p>
<ul>
<li>Potassium intake: With normal intake of sodium, reduction of potassium intake would cause a fall in plasma potassium on account of its continued loss in urine and feces, leading to potassium depletion. Hyperkalemia may occur in older patients with renal</li>
</ul>
<p>insufficiency. Salt substitutes which may contain as much as 200 mmoles of potassium per tablespoonful are a hidden source of ingested potassium.</p>
<ul>
<li>Total body sodium increase causes loss of body potassium. Part of the retained sodium shifts into the cells, thus displacing some of the potassium which is excreted. Conversely, in severe sodium depletion, as in diabetic coma, the serum potassium may be raised. Thus, the changes in the ECF volume may cause a rise or a fall in serum <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>levels. In CHF, where sodium retention is marked and ECF volume is increased, the serum <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>is usually low.</li>
<li>Acidosis and alkalosis: Normally, the kidney compensates for metabolic acidosis by secreting more <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{H}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ions than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ions in exchange for sodium. This leads to potassium retention. Acidosis also reduces the potassium uptake by the cells. This causes hyperkalemia. If the plasma potassium level is high to begin with, acidosis will cause further rise in plasma potassium. However, acidosis, in the presence of marked potassium depletion, will cause severe cellular derangement as it will aggravate the fall of intracellular potassium.
Alkalosis is associated with lowering of plasma potassium level.</li>
<li>Changes in the cell metabolism: Increased uptake of glucose by the cells is associated with a shift of potassium into the cell. This may cause a transient fall in serum potassium. In the presence of potassium depletion, such a shift may cause marked hypokalemia. This phenomenon occurs in patients recovering from diabetic coma where, as the tissue glycogen is repleted following insulin and glucose, potassium shifts into the cells thus causing a fall in serum potassium level. Protein anabolism is also associated with increased potassium uptake by the cells while protein catabolism would cause cellular potassium loss.</li>
<li>Hormones: Potassium is a major stimulus to aldosterone production. Aldosterone secretion is integral to potassium homeostasis, controlling its excretion in the urine, feces, sweat and saliva. The normal physiological regulators insulin and catecholamines are stimulated by the ingestion of foods containing glucose and potassium. They are essential in shifting potassium intracellularly, mainly into the liver and the muscles.</li>
<li>Drugs: See below.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="potassium-depletion-and-hypokalemia">Potassium Depletion and Hypokalemia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#potassium-depletion-and-hypokalemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Hypokalemia is usually defined as plasma potassium <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>3.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">&lt;3.5 \mathrm{mMol} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3.5</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span>. However, body potassium depletion can exist in the presence of normal serum potassium. As much as 100 to 200 mMol of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>loss is necessary in adults before the serum <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>falls below <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">3 \mathrm{mMol} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span>.</p>
<p>Causes of potassium depletion: These can be grouped as follows:</p>
<ul>
<li>Decreased Intake: Potassium deficiency due to decreased intake can occur but more so in old people who may have inadequate dietary intake (less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">1 \mathrm{~g} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span></span></span></span></span> day).</li>
<li>GI loss (urinary <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>equal to or less than 20 mMoles/day): This occurs in excessive vomiting, copious discharge from a fistula, aspiration of intestinal contents and diarrhoea. In diarrhoea, both sodium and potassium are lost. In formed bulky stools, however, sodium loss may not be much but the loss of potassium could be considerable e.g. in steatorrhea and following chronic use of purgatives.</li>
<li>Renal loss (urinary <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">30 \mathrm{mMol} / \mathrm{L} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord mathrm">L</span><span class="mord">/</span></span></span></span></span> day): Perhaps the commonest cause of hypokalemia is diuretics. Increase in plasma potassium level due to intracellular potassium loss in such conditions as sodium overload, starvation, acidosis or protein catabolism increases renal loss of potassium. In addition, renal loss of potassium also occurs in:
(a) The presence of excessive aldosterone, hydrocortisone. Hyperaldosteronism secondary to ECF volume contraction increases <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>loss in urine.
(b) Extra-renal states like diabetic acidosis.
(c) Magnesium depletion can cause severe hypokalemia by increasing <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>excretion.
(d) Primary renal diseases such as renal tubular dysfunction and nephrotic syndrome. Patients with glomerular diseases do not lose potassium; in fact, they generally retain potassium. It must also be borne in mind that potassium depletion, in itself, may cause renal tubular dysfunction.</li>
<li>Transcellular shift: Transient hypokalemia occurs in patients with diabetic ketoacidosis following treatment with insulin and glucose. Metabolic alkalosis is always associated with hypokalemia.</li>
<li>Drug induced: Apart from diuretics, laxatives, beta <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> adrenergic agonists such as salbutamol, theophylline, exogenous insulin amphotericin and rarely calcium channel blockers can cause hypokalemia.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="excessive-sweating">- Excessive sweating<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#excessive-sweating" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Clinical manifestations: Since potassium is the major intracellular cation, its depletion is expected to produce widespread dysfunction.</p>
<ul>
<li>Mild potassium depletion, (serum <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup><mn>3.0</mn><mo>−</mo><mn>3.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+} 3.0-3.5 \mathrm{mMol} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8547em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mord">3.0</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3.5</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span> ) about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> of the total body potassium, does not produce any dramatic symptoms. Many vague symptoms such as lethargy, malaise, weakness of muscular activity, anorexia and thirst have been attributed to but not definitely proved to be due to mild potassium deficiency. On average, a reduction of serum <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.3</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">0.3 \mathrm{mMol} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.3</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span> suggests a total body deficit of about 100 mMoles.</li>
<li>Marked hypokalemia (serum <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">l</mi></mrow><annotation encoding="application/x-tex">2.5 \mathrm{mEq} / \mathrm{l}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2.5</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/</span><span class="mord mathrm">l</span></span></span></span></span> ) impairs neuromuscular function leading to paralysis, causes conduction defects in the heart, intestinal dilatation and even paralytic ileus, and lowers the BP. Clinically, hypokalemia is associated with arrhythmias and tachycardia. Tetany can occur on account of ECF alkalemia.</li>
<li>Excessive potassium depletion causes reduction in the capacity of the kidneys to</li>
</ul>
<p>concentrate urine. Loss of potassium in amounts greater than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> of the total body potassium causes widespread damage to cell function.</p>
<ul>
<li>Chronic cumulative potassium loss may cause nonspecific symptoms like muscular pain, abdominal distension and nocturia. If such a deficiency is not suspected, these symptoms may lead to the erroneous diagnosis of neurosis and may even result in death, if left untreated. It must be pointed out that there is no consistency in the symptoms for any given level of plasma potassium. In general, in severe potassium depletion plasma potassium level is below <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">2.5 \mathrm{mMol} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2.5</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span> except in cases with acidosis and associated sodium depletion.
Hypokalemia in humans can cause sodium retention, phosphate reabsorption and increased renal ammonia production. By impairing renal urine concentrating mechanism, it can cause nephrogenic diabetes insipidus.</li>
</ul>
<p>Other changes: The normal activity of both skeletal and smooth muscles is impaired. The neuromuscular abnormality is probably due to alteration in the excitability. The skeletal muscle fibres may show rhabdomyolysis, and the heart muscle, degenerative changes. Excess of sodium and deficit of potassium in the diet has been correlated with the development of high BP and tissue injury in rats. Current evidence suggest that a potassium deficit has an important role in hypertension and its cardiovascular sequelae in man (Chapter 30). In moderate to severe hypokalemia, ECG changes may show prominent U wave, ST depression, prolonged QT and inversion of T wave.</p>
<p>Potassium depletion inhibits insulin secretion and is associated with glucose intolerance. Chronic potassium deficiency causes metabolic alkalosis by bringing about a shift in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{H}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ions from the extracellular space into the intracellular space in exchange for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> ions. The ability to form gastric acid and to absorb electrolytes from the bowel is impaired.</p>
<p>Treatment of potassium depletion: Normally, potassium deficiency can be prevented by taking diet rich in vegetables and fruits. Fruit juices and tender coconut water contain good amounts of potassium in palatable form; in addition, it also supplies some calories. Fresh, green, coconut water contains about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">70 \mathrm{mMol} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">70</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span> of potassium. A single orange gives <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mo>−</mo><mn>8</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">6-8 \mathrm{mMol}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">8</span><span class="mord"><span class="mord mathrm">mMol</span></span></span></span></span></span> of potassium, a tomato <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>16</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">16-20 \mathrm{mMol}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">16</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm">mMol</span></span></span></span></span></span> and a banana <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>18</mn><mo>−</mo><mn>22</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi><mi mathvariant="normal">e</mi><mi mathvariant="normal">s</mi></mrow></mrow><annotation encoding="application/x-tex">18-22 \mathrm{mMoles}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">18</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">22</span><span class="mord"><span class="mord mathrm">mMoles</span></span></span></span></span></span>. In the presence of normal kidney function, oral administration of potassium (50-100 mMoles/day) is usually effective in controlling chronic potassium depletion with low serum level.</p>
<p>Drug of choice is potassium chloride although potassium citrate is less unpalatable than potassium chloride. Potassium bicarbonate is used to prevent metabolic acidosis and may be preferred in chronic diarrhoea. Three grammes of potassium chloride gives 40 mMoles of potassium. The bad taste of the salt can be masked by adding a small quantity of ginger extract. Usually, a mixture is preferred to tablets as the latter can cause intestinal ulcerations.</p>
<p>In acute cases, potassium depletion is associated with other electrolyte disturbances such as sodium depletion and acidosis as seen in severe diarrhoea. These, along with the water depletion, should be corrected. A vigorous correction of acidosis should be avoided as potentially lethal hypokalemia may be precipitated.</p>
<p>In emergency, potassium can be given by IV infusion; 40 mMoles of potassium per litre are recommended as a safe limiting concentration, with a drip-rate of one litre in 2-3 hours. Such a concentration can be prepared by adding 20 ml of potassium chloride injection to one litre of normal saline or glucose drip. During the IV infusion, the serum potassium</p>
<p>level and ECG should be monitored as a sudden marked rise in serum potassium may cause cardiac arrest. For the same reason, potassium should never by administered as an IV bolus or injected into the tubing of an IV infusion. Further, the adequate urine output must be established before treatment.</p>
<p>Potassium salts can also be used prophylactically in patients receiving digioxin and diuretic drugs (thiazides) that cause <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>loss. A daily supplement of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi></mrow></mrow><annotation encoding="application/x-tex">25-50 \mathrm{mM}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm">mM</span></span></span></span></span></span> oles is adequate. Table 37.5 summarises the treatment of hypokalemia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-37-5">Table 37.5<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-37-5" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="treatment-of-hypokalemia">Treatment of hypokalemia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment-of-hypokalemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Potassium chloride KCl 40-100 mMol/day in divided doses.</li>
<li>Potassium phosphate in patients with concurrent hypophosphatemia.</li>
<li>Potassium bicarbonate in acidotic patients.</li>
</ul>
<p>IV Potassium chloride: This is usually reserved for patients with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>level less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.6</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">l</mi></mrow><annotation encoding="application/x-tex">2.6 \mathrm{mMol} / \mathrm{l}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2.6</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord mathrm">l</span></span></span></span></span>. It is administered under monitoring, at a rate not exceeding <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">20 \mathrm{mMol} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span></span></span></span></span> hour.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><mo>−</mo><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">--&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span><span class="mord">−</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&gt;</span></span></span></span></span></p>
<p>Oral Potassium:</p>
<ul>
<li>Potassium chloride KCl 40-100 mMol/day in divided doses.</li>
<li>Potassium phosphate in patients with concurrent hypophosphatemia.</li>
<li>Potassium bicarbonate in acidotic patients.</li>
</ul>
<p>IV Potassium chloride: This is usually reserved for patients with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>level less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.6</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">l</mi></mrow><annotation encoding="application/x-tex">2.6 \mathrm{mMol} / \mathrm{l}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2.6</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord mathrm">l</span></span></span></span></span>. It is administered under monitoring, at a rate not exceeding <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">20 \mathrm{mMol} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span></span></span></span></span> hour.
Alkalosis due to hypokalemia cannot be corrected except by potassium administration.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="hyperkalemia-and-potassium-excess">Hyperkalemia and Potassium Excess<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hyperkalemia-and-potassium-excess" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Hyperkalemia or the serum potassium more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">5 \mathrm{mMol} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span> is fairly common and may often cause fatal complications.</p>
<p>Causes of hyperkalemia: In the presence of normal kidney function, increased oral intake of potassium causes only a transient hyperkalemia. Usually, dangerous blood levels are not reached, unless potassium is injected IV, rapidly.</p>
<p>The most important cause of hyperkalemia is decreased renal excretion following acute or chronic renal insufficiency. Occasionally, it can occur following tissue injury, due to increased catabolic processes, diabetic and chronic respiratory acidosis, in patients with Addison's disease due to lack of aldosterone, and following certain drugs like spironolactone, triamterene, ACE inhibitors, NSAID and trimethoprim. Hyperkalemia due to transcellular shift of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>may be observed following insulin deficiency, acidosis and the use of beta-blockers.</p>
<p>It should be noted that the plasma potassium levels in newborn may be higher (upto 6 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">\mathrm{mMol} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span> ) without any obvious toxic effects.</p>
<p>Effects of hyperkalemia: Mild hyperkalemia (less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">5.5 \mathrm{mMol} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5.5</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span> ) is often asymptomatic. Severe hyperkalemia affects both cardiac and skeletal muscles. Muscular weakness is common. It may cause various arrhythmias, idioventricular rhythm and finally, cardiac arrest in diastole, if the serum level exceeds <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">7 \mathrm{mMol} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">7</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span>. The ECG shows peaking or tenting of T wave, depression of ST segment and widening of QRS complex. PR interval may be prolonged.</p>
<p>Skeletal muscles may show paralysis. Ascending paralysis involving respiratory muscle has been described in hyperkalemia.</p>
<p>Treatment of hyperkalemia: Hyperkalemia with ECG changes is a medical emergency and requires immediate treatment; the detailed work-up is postponed till the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>level is brought down to a safe level. The treatment is directed at:
(a) Minimising the membrane depolarisation over 2-3 minutes, thus reducing the membrane excitability:</p>
<ul>
<li>IV Calcium gluconate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi><mo separator="true">,</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">10 \%, 10 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">10%</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>, over 3-4 per minute. It can be repeated after 10 min .
(b) Promoting an intracellular shift of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span></li>
<li>Plain insulin, 5-10 units, in 25-50 g of dextrose in water, over 5 minutes.</li>
<li>A beta-adrenergic agonist e.g. Salbutamol, either parenterally or by nebulisation.
(c) Promoting <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>loss from the body</li>
<li>Dialysis in patients with chronic renal failure.</li>
<li>Cation exchange resin (Chapter 39)</li>
<li>The mineralocorticoid fludrocortisone (Chapter 66).</li>
<li>A loop diuretic in combination with a thiazide, in patients with normal renal function.
(d) Minimising the entry/retention of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>.</li>
<li>Cessation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>rich foods and drugs.</li>
<li>Cessation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>retaining drugs such as spironolactone and ACEI.
(e) Treatment of associated infection and acidosis.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="acidosis-and-alkalosis">Acidosis and Alkalosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#acidosis-and-alkalosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The regulation of the reaction of the body fluids is mainly influenced by their 'hydrogen ion' concentration designated by the term "hydrion" <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">[</mo><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup><mo fence="true">]</mo></mrow><annotation encoding="application/x-tex">\left[\mathrm{H}^{+}\right]</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0213em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">[</span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">]</span></span></span></span></span></span>.</p>
<p>An acid is a proton donor molecule or ion which provides a proton (hydrion <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{H}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>) a positively charged particle, and thus lowers the pH of a solution into which it is placed. Apart from conventional acids like HCl , other agents like ammonium ion which can split into a proton + ammonia or even water which can split to give a hydrion + a hydroxyl ion can be considered as acids. By this definition, chloride, sulfate and phosphate ions are not acids but considered as the conjugate bases of a true acid. On the other hand, a molecule or an ion which can accept a proton (hydrion) is termed as a base; it thus raises the pH of a solution into which it is placed. Thus, ammonia <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">H</mi></mrow><mn>3</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{NH}_{3}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">NH</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> and hydroxyl <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">H</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(\mathrm{OH})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">OH</span></span><span class="mclose">)</span></span></span></span></span> ions are bases as they can accept a proton <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{H}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>and produce ammonium <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msubsup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">H</mi></mrow><mn>4</mn><mo lspace="0em" rspace="0em">+</mo></msubsup><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{NH}_{4}^{+}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.2em; vertical-align: -0.35em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;"><span class="delimsizing size1">(</span></span><span class="mord"><span class="mord"><span class="mord mathrm">NH</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -2.453em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.247em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;"><span class="delimsizing size1">)</span></span></span></span></span></span></span>and water respectively.</p>
<p>Unlike the concentration of sodium and potassium, the body fluid concentration of hydrion is very small and is measured indirectly using a pH meter.</p>
<p>In the plasma, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is present as carbonic acid <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><mi mathvariant="normal">H</mi><mi mathvariant="normal">.</mi><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{H} . \mathrm{HCO}_{3}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord mathrm">H</span><span class="mord">.</span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> whereas bicarbonate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{HCO}_{3}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> is present in combination with cations as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">B</mi><mi mathvariant="normal">.</mi><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B} . \mathrm{HCO}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord mathrm">B</span><span class="mord">.</span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. Hence <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub><mi mathvariant="normal">/</mi><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CO}_{2} / \mathrm{HCO}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">/</span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ratio may also be expressed as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">.</mi><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub><mi mathvariant="normal">/</mi><mi mathvariant="normal">B</mi><mi mathvariant="normal">.</mi><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H} . \mathrm{HCO}_{3} / \mathrm{B} . \mathrm{HCO}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathrm">H</span><span class="mord">.</span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">/</span><span class="mord mathrm">B</span><span class="mord">.</span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ratio. If the concentrations of both carbonic acid and bicarbonate in the blood were fixed, the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">[</mo><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup><mo fence="true">]</mo></mrow><annotation encoding="application/x-tex">\left[\mathrm{H}^{+}\right]</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0213em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">[</span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">]</span></span></span></span></span></span>of the blood would also be fixed. Thus, in health the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">[</mo><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup><mo fence="true">]</mo></mrow><annotation encoding="application/x-tex">\left[\mathrm{H}^{+}\right]</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0213em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">[</span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">]</span></span></span></span></span></span>of blood is remarkably constant. The changes in the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">[</mo><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup><mo fence="true">]</mo></mrow><annotation encoding="application/x-tex">\left[\mathrm{H}^{+}\right]</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0213em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">[</span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">]</span></span></span></span></span></span>of the body fluids are resisted by three mechanisms:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="buffer-systems">- Buffer systems.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#buffer-systems" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Renal mechanisms; and</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="respiratory-mechanisms">- Respiratory mechanisms.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#respiratory-mechanisms" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Buffer mechanisms merely minimise disturbances when strong acids or bases are added to the blood but the blood <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">[</mo><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup><mo fence="true">]</mo></mrow><annotation encoding="application/x-tex">\left[\mathrm{H}^{+}\right]</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0213em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">[</span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">]</span></span></span></span></span></span>is maintained constant at its normal value mainly by the combined efforts of kidneys and lungs. The respiratory mechanisms fix the carbonic acid concentration in the blood at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">1.4 \mathrm{mMol} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.4</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span> and the kidneys maintain the blood bicarbonate level at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>28</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">28 \mathrm{mMol} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">28</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span>. The ratio of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">.</mi><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub><mi mathvariant="normal">/</mi><mi mathvariant="normal">B</mi><mi mathvariant="normal">.</mi><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H} . \mathrm{HCO}_{3} / \mathrm{B} . \mathrm{HCO}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathrm">H</span><span class="mord">.</span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">/</span><span class="mord mathrm">B</span><span class="mord">.</span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is thus fixed at 1.4: 28 resulting in a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">[</mo><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup><mo fence="true">]</mo></mrow><annotation encoding="application/x-tex">\left[\mathrm{H}^{+}\right]</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0213em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">[</span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">]</span></span></span></span></span></span>of 40 nanoMol/L. Normally, the arterial plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">[</mo><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup><mo fence="true">]</mo></mrow><annotation encoding="application/x-tex">\left[\mathrm{H}^{+}\right]</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0213em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">[</span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">]</span></span></span></span></span></span>varies between 36 - 44 nanoMol/L. The normal pH of arterial plasma calculated by Henderson-Hasselbalch equation is between <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7.44</mn><mo>−</mo><mn>7.36</mn></mrow><annotation encoding="application/x-tex">7.44-7.36</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">7.44</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">7.36</span></span></span></span></span>. The remainder of the buffer systems in plasma then adjust the ratios of their acids to bases in keeping with this pH .</p>
<p>Unlike with sodium and potassium one cannot measure 'hydrion balance', as hydrion does not maintain its identity in the body; it is constantly disappearing or is constantly produced during various complex reactions of energy metabolism. Major portion of the body hydrion is produced during the oxidation of food and tissue metabolism; the contribution made by the actual intake of hydrion is very little.</p>
<p>Metabolically, hydrion is produced in the body in two forms:</p>
<ul>
<li>
<p>Potential hydrion or as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, which is produced by the combustion of foods. This can normally be eliminated by the lungs. In the presence of respiratory diseases, however, retention of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> raises the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">.</mi><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub><mi mathvariant="normal">/</mi><mi mathvariant="normal">B</mi><mi mathvariant="normal">.</mi><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H} . \mathrm{HCO}_{3} / \mathrm{B} . \mathrm{HCO}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathrm">H</span><span class="mord">.</span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">/</span><span class="mord mathrm">B</span><span class="mord">.</span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ratio and hence, increases hydrion concentration in the plasma, although the total body production of hydrion is not raised; and</p>
</li>
<li>
<p>Non-volatile hydrion which is derived from:
(i) Incomplete oxidation of carbohydrates and fats, giving organic acids,
(ii) Sulfuric acid, produced following the oxidation of sulfur containing amino acids, and
(iii) Phosphoric acid, produced following the oxidation of phosphoprotein residues.</p>
</li>
</ul>
<p>The nonvolatile hydrion is normally excreted by the kidneys, mainly in the form of ammonium ion <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">H</mi></mrow><mn>4</mn></msub><mrow><mo fence="true">(</mo><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow></mrow><annotation encoding="application/x-tex">\mathrm{NH}_{4}\left(\mathrm{H}^{+}\right.</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0213em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">NH</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span>buffered by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">H</mi></mrow><mn>3</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left.\mathrm{NH}_{3}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen nulldelimiter"></span><span class="mord"><span class="mord"><span class="mord mathrm">NH</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> and titratable acidity <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\left(\mathrm{H}^{+}\right.</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0213em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span>buffered by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">P</mi><mi mathvariant="normal">O</mi></mrow><mn>4</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left.\mathrm{HPO}_{4}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen nulldelimiter"></span><span class="mord"><span class="mord"><span class="mord mathrm">HPO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span>. Very little acid is excreted as free H ions.</p>
<p>The plasma concentration of hydrion being regulated mainly by the lungs and the kidneys is proportional to the plasma ratio <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub><mi mathvariant="normal">/</mi><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CO}_{2} / \mathrm{HCO}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">/</span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>; the level of plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is regulated by the lungs and the respiratory centre while <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{HCO}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> level is regulated by renal conservation. Physiologically, effect of a sudden rise in plasma hydrion is countered by the action of blood and tissue buffers and to a certain extent by exchange of hydrion with bone cations. The renal adjustment, though important, is rather slow to occur.</p>
<p>The ratio <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">.</mi><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub><mi mathvariant="normal">/</mi><mi mathvariant="normal">B</mi><mi mathvariant="normal">.</mi><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H} . \mathrm{HCO}_{3} / \mathrm{B} . \mathrm{HCO}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathrm">H</span><span class="mord">.</span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">/</span><span class="mord mathrm">B</span><span class="mord">.</span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and thus the blood <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">[</mo><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup><mo fence="true">]</mo></mrow><annotation encoding="application/x-tex">\left[\mathrm{H}^{+}\right]</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0213em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">[</span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">]</span></span></span></span></span></span>can be disturbed by factors that change either the carbonic acid or bicarbonate levels in the blood. Thus, a fall in carbonic acid or a rise in bicarbonate level will decrease the ratio and the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">[</mo><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup><mo fence="true">]</mo></mrow><annotation encoding="application/x-tex">\left[\mathrm{H}^{+}\right]</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0213em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">[</span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">]</span></span></span></span></span></span>in the blood, leading to alkalosis. Similarly, a rise in carbonic acid or a fall in bicarbonate will increase the ratio leading to rise in the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">[</mo><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup><mo fence="true">]</mo></mrow><annotation encoding="application/x-tex">\left[\mathrm{H}^{+}\right]</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0213em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">[</span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">]</span></span></span></span></span></span>, causing acidosis. In all the cases of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">[</mo><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup><mo fence="true">]</mo></mrow><annotation encoding="application/x-tex">\left[\mathrm{H}^{+}\right]</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0213em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">[</span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">]</span></span></span></span></span></span>disturbances, when the fault is primarily respiratory the compensation is primarily renal and vice versa.</p>
<p>Table 37.6 gives the normal values of acid-base parameters in arterial blood. The pH gives a quantitative idea of the acid-base balance of the extra-cellular space but only a qualitative idea of the total body acid-base balance. To obtain the latter an additional parameter called 'bicarbonate deficit' is calculated.</p>
<p>Table 37.6
Normal values of acid base parameters in arterial blood</p>
<table><thead><tr><th style="text-align: left;">Parameter</th><th style="text-align: center;">Normal range</th></tr></thead><tbody><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="bold">p</mi><mi mathvariant="bold">H</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathbf{p H}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0418em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord mathbf">pH</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8473em;"><span style="top: -3.139em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7.38</mn><mo>−</mo><mn>7.42</mn></mrow><annotation encoding="application/x-tex">7.38-7.42</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">7.38</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">7.42</span></span></span></span></span></td></tr><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="bold">p</mi><mi mathvariant="bold">C</mi><mi mathvariant="bold">O</mi></mrow><mn>2</mn></msub><mo stretchy="false">(</mo><mrow><mi mathvariant="bold">m</mi><mi mathvariant="bold">m</mi><mi mathvariant="bold">H</mi><mi mathvariant="bold">g</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">\mathbf{p C O}_{2}(\mathbf{m m H g})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord"><span class="mord mathbf">pCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.207em;"><span style="top: -2.4559em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.2441em;"><span></span></span></span></span></span></span><span class="mopen">(</span><span class="mord"><span class="mord mathbf" style="margin-right: 0.01597em;">mmHg</span></span><span class="mclose">)</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>37</mn><mo>−</mo><mn>42</mn></mrow><annotation encoding="application/x-tex">37-42</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">37</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">42</span></span></span></span></span></td></tr><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="bold">H</mi><mi mathvariant="bold">C</mi><mi mathvariant="bold">O</mi></mrow><mn>2</mn></msub><mo stretchy="false">(</mo><mrow><mi mathvariant="bold">m</mi><mi mathvariant="bold">M</mi><mi mathvariant="bold">o</mi><mi mathvariant="bold">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="bold">l</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">\mathbf{H C O}_{2}(\mathbf{m M o l} / \mathbf{l})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord"><span class="mord mathbf">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mopen">(</span><span class="mord"><span class="mord mathbf">mMol</span></span><span class="mord">/</span><span class="mord mathbf">l</span><span class="mclose">)</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>24</mn><mo>−</mo><mn>28</mn></mrow><annotation encoding="application/x-tex">24-28</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">24</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">28</span></span></span></span></span></td></tr><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="bold">p</mi><mi mathvariant="bold">O</mi></mrow><mn>2</mn></msub><mo stretchy="false">(</mo><mrow><mi mathvariant="bold">m</mi><mi mathvariant="bold">m</mi><mi mathvariant="bold">H</mi><mi mathvariant="bold">g</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">\mathbf{p O}_{2}(\mathbf{m m H g})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord"><span class="mord mathbf">pO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.207em;"><span style="top: -2.4559em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.2441em;"><span></span></span></span></span></span></span><span class="mopen">(</span><span class="mord"><span class="mord mathbf" style="margin-right: 0.01597em;">mmHg</span></span><span class="mclose">)</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>85</mn><mo>−</mo><mn>100</mn></mrow><annotation encoding="application/x-tex">85-100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">85</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span></span></span></span></span></td></tr><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="bold">S</mi><mi mathvariant="bold">a</mi><mi mathvariant="bold">O</mi></mrow><mn>2</mn></msub><mo stretchy="false">(</mo><mi mathvariant="normal">%</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">\mathbf{S a O}_{2}(\%)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord"><span class="mord mathbf">SaO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mopen">(</span><span class="mord">%</span><span class="mclose">)</span></span></span></span></span></td><td style="text-align: center;">98</td></tr></tbody></table>
<p>Bicarbonate deficit <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo><mo stretchy="false">(</mo></mrow><annotation encoding="application/x-tex">=(</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span></span></span></span></span> body weight <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mo>×</mo><mn>0.6</mn><mo stretchy="false">)</mo><mo>×</mo><mo fence="true">(</mo></mrow><annotation encoding="application/x-tex">\mathrm{kg} \times 0.6) \times\left(\right.</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.6</span><span class="mclose">)</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mclose nulldelimiter"></span></span></span></span></span></span> Normal <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msubsup><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn><mo lspace="0em" rspace="0em">−</mo></msubsup><mo>−</mo></mrow><annotation encoding="application/x-tex">\left.\mathrm{HCO}_{3}^{-}-\right.</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0916em; vertical-align: -0.247em;"></span><span class="minner"><span class="mopen nulldelimiter"></span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -2.453em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.247em;"><span></span></span></span></span></span></span><span class="mord">−</span><span class="mclose nulldelimiter"></span></span></span></span></span></span>Actual <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msubsup><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn><mo lspace="0em" rspace="0em">−</mo></msubsup><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left.\mathrm{HCO}_{3}^{-}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.2em; vertical-align: -0.35em;"></span><span class="minner"><span class="mopen nulldelimiter"></span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -2.453em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.247em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;"><span class="delimsizing size1">)</span></span></span></span></span></span></span>
The anion gap represents anions which are not normally measured in acid-base studies: proteins, phosphate, sulfate and organic acids.</p>
<p>Anion gap <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo><mrow><mo fence="true">(</mo><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo fence="true">)</mo></mrow><mo>−</mo><mrow><mo fence="true">(</mo><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup><mo>+</mo><msubsup><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn><mo lspace="0em" rspace="0em">−</mo></msubsup><mo fence="true">)</mo></mrow></mrow><annotation encoding="application/x-tex">=\left(\mathrm{Na}^{+}\right)-\left(\mathrm{Cl}^{-}+\mathrm{HCO}_{3}^{-}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1.2em; vertical-align: -0.35em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;"><span class="delimsizing size1">(</span></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;"><span class="delimsizing size1">)</span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1.2057em; vertical-align: -0.35em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;"><span class="delimsizing size1">(</span></span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -2.453em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.247em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;"><span class="delimsizing size1">)</span></span></span></span></span></span></span>, all in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mn>1</mn></mrow><annotation encoding="application/x-tex">\mathrm{mMol} / 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/1</span></span></span></span></span>.
Normal anion gap is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>18</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mn>1</mn></mrow><annotation encoding="application/x-tex">10-18 \mathrm{mMol} / 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">18</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/1</span></span></span></span></span>.
The anion gap is used to divide metabolic acidosis into those with normal anion gap and those with widened anion gap. Metabolic acidosis with normal anion gap is due to bicarbonate loss from the Gl tract or the kidneys. Anion gap is widened in ketoacidosis, lactic acidosis, uremic acidosis and methanol, ethylene glycol and salicylate poisoning.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="acidosis">Acidosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#acidosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Acidosis is defined as an increase in either potential and/or nonvolatile hydrion content of the body. Increase in the hydrion concentration of the plasma is termed as acidemia and is manifested by a fall in blood pH . In certain instances, although excessive potential hydrion is produced in the body, the plasma level of hydrion may remain normal due to a compensatory increase in the ventilation. Such a state of acidosis without acidemia is known as 'compensated acidosis', which could become 'decompensated' if the metabolic cause remains uncorrected. Similarly in lung diseases, retention of potential hydrion CO2 can be compensated by renal conservation of bicarbonate, thus main-taining the plasma ratio of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">.</mi><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub><mi mathvariant="normal">/</mi><mi mathvariant="normal">B</mi><mi mathvariant="normal">.</mi><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H} . \mathrm{HCO}_{3} / \mathrm{B} . \mathrm{HCO}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathrm">H</span><span class="mord">.</span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">/</span><span class="mord mathrm">B</span><span class="mord">.</span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> constant. But this too would become 'uncompensated' if respiratory failure is not corrected. Acidosis can occur as:</p>
<p>Metabolic acidosis: This is due to excess production of hydrion in the body because of:</p>
<ul>
<li>Acceleration of the normal metabolic processes as during excessive catabolism in fever, starvation, dehydration and during diabetic ketoacidosis.</li>
<li>Excessive loss of alkaline fluids from the intestines, as in diarrhoea.</li>
<li>Ingestion of toxic doses of agents which are hydrion-donors e.g. salicylates and methanol.</li>
<li>Administration of large quantities of normal saline.</li>
<li>A high level of plasma potassium which results in a fall in plasma bicarbonate by interfering with the reabsorption and manufacture of bicarbonate by the kidneys; and</li>
<li>Accumulation of lactic acid. This is seen in conditions like severe circulatory failure or following extracorporeal circulation where tissue hypoxia is present. Lactic acidosis is also seen following oral hypoglycemic agent, (biguanides), which inhibit aerobic glycolysis.
The rise in hydrion and fall in blood pH in metabolic acidosis are to a certain extent compensated by the buffering action of the blood and tissues, by increased ventilation and by increased renal excretion of the hydrion. Although hyperpnea and the buffering systems reduce acidemia they do not help to eliminate the excess of hydrion, which is solely excreted by the kidneys.</li>
</ul>
<p>The net effect of metabolic acidosis is:
(1) Fall in the plasma bicarbonate and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">p</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{pCO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9275em; vertical-align: -0.2441em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">pCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.207em;"><span style="top: -2.4559em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.2441em;"><span></span></span></span></span></span></span></span></span></span></span> and
(2) Strongly acidic urine with a high ammonium content.</p>
<p>Renal acidosis: This is associated with increase in body hydrion due to its defective renal excretion, either as titratable acid or as ammonium ion. This is observed either in selective tubular disorders (renal tubular acidosis) or in diseases primarily damaging the glomeruli (glomerulonephritis and diabetic nephropathy). Renal acidosis is also seen in Addison's disease where ammonia formation is inadequate. Carbonic anhydrase inhibitor drugs like acetazolamide which interfere with tubular secretion of hydrion can cause renal acidosis.</p>
<p>In renal acidosis,
(1) The excretion of titratable acid and ammonium is impaired and
(2) The plasma bicarbonate and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">p</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{pCO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9275em; vertical-align: -0.2441em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">pCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.207em;"><span style="top: -2.4559em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.2441em;"><span></span></span></span></span></span></span></span></span></span></span> concentrations are low. The urine, however, may be alkaline.</p>
<p>Respiratory acidosis: This is due to increased retention of the potential hydrion <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{CO}_{2}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> in the blood leading to a rise in plasma carbonic acid content. It usually occurs in chronic</p>
<p>lung diseases with cor pulmonale, in diseases with respiratory muscle paralysis and following the respiratory centre depression. The associated hyperapnea may be difficult to differentiate from that due to original respiratory pathology.</p>
<p>Unlike in metabolic or renal acidosis, the plasma bicarbonate and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">p</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{pCO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9275em; vertical-align: -0.2441em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">pCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.207em;"><span style="top: -2.4559em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.2441em;"><span></span></span></span></span></span></span></span></span></span></span> are raised. The urine is strongly acidic.</p>
<p>Clinical manifestations of acidosis: The clinical picture is usually complicated by the associated electrolyte disturbances such as sodium depletion. Uncomplicated acidosis causes hyperapnea, muscle twitching and mental confusion. Patients with renal and metabolic acidosis may have Kussmaul breathing although they may not complain of dyspnoea. Ultimately, coma may result, which occurs more frequently in patients with respiratory acidosis; in such cases, the blood pH value is below 7.25. The diagnosis of acidotic coma is important as it is reversible following appropriate treatment. In patients with chronic acidosis, mental or respiratory changes may not be so prominent but the patient may complain of bone pains and tenderness due to demineralisation of bones. This is usually seen in chronic renal acidosis.</p>
<p>Treatment of acidosis: In acute cases, other electrolyte disturbances like sodium and potassium depletion should be corrected and in many cases, this, along with the treatment of the cause, is the major form of therapy, e.g., in diabetic acidosis and in diarrhoea. In severe cases ( pH 7.1 or less, or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{HCO}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">10 \mathrm{mMol} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span> ) acidosis can be corrected by a slow infusion of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">7.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">7.5%</span></span></span></span></span> sodium bicarbonate in quantities sufficient ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1 \mathrm{mMol} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> over 20-30 minutes) to raise the plasma bicarbonate concentration to about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">15-20 \mathrm{mMol} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span>. No attempts should be made to correct the acidosis rapidly or fully. When sodium bicarbonate solution for injection is available, the use of sodium lactate (1/6 molar) to correct acidosis is not justified for two reasons: (a) it depends upon the body oxidative mechanisms for conversion to bicarbonate; and (b) it can cause lactic acidosis.</p>
<p>Administration of excessive alkali in the presence of marked kidney damage may cause tetany and pulmonary edema. Acidosis associated with renal failure, therefore, may be better managed by peritoneal dialysis or by hemodialysis. Chronic renal acidosis responds to alkaline mixture containing sodium citrate and citric acid. Shohl's mixture which is commonly used contains 140 gm of citric acid and 90 gm of sodium citrate per litre of water. The adult dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">50-100 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> per day.</p>
<p>Respiratory acidosis is often a terminal event in patients with extensive lung damage or respiratory centre failure. In general, it is difficult to treat. Oral/IV sodium bicarbonate should be tried as an emergency measure. Treatment of respiratory infection, use of bronchodilators and intermittent oxygen may be useful.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="alkalosis">Alkalosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#alkalosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Alkalosis is defined as a reduction in the total hydrion content of the body. Alkalemia is a reduction in the hydrion concentration of the plasma, manifested as an increase in the blood pH . Alkalosis without alkalemia is called compensated alkalosis, that accompanied by alkalemia is called decompensated alkalosis.</p>
<p>Metabolic alkalosis: Normally, in the presence of healthy kidneys an individual can tolerate large daily doses ( 140 g ) of sodium bicarbonate for about 3 weeks, without any gross disturbances. Alkali ingestion in the presence of renal damage, however, may cause alkalosis. Excessive vomiting or gastric suction can cause a marked loss of body hydrion and chloride, producing alkalosis. Excessive milk and alkali ingestion can also cause alkalosis of the milk-alkali syndrome.</p>
<p>The blood pH and plasma bicarbonate show a rise. The urine is usually alkaline, containing excess of bicarbonate. In patients with severe electrolyte depletion, however, urine may be scanty and acidic; this is probably due to accompanying potassium depletion which leads to increased renal tubular secretion of hydrion.</p>
<p>Hypokalemic alkalosis as observed with diuretics such as thiazides (Chapter 39).
Respiratory alkalosis: Excessive ventilation, washing away large amounts of carbon dioxide, causes lowering of the arterial <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">p</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{pCO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9275em; vertical-align: -0.2441em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">pCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.207em;"><span style="top: -2.4559em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.2441em;"><span></span></span></span></span></span></span></span></span></span></span> and reduction in the ratio <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">.</mi><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub><mi mathvariant="normal">/</mi><mi mathvariant="normal">B</mi><mi mathvariant="normal">.</mi><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H} . \mathrm{HCO}_{3} / \mathrm{B} . \mathrm{HCO}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathrm">H</span><span class="mord">.</span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">/</span><span class="mord mathrm">B</span><span class="mord">.</span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> with a fall in hydrion content. This is commonly seen following hyperventilation, involuntarily carried out by certain individuals probably in response to anxiety. Physiologically, it can occur at high altitudes. A similar phenomenon can occur in fever, encephalitis, hypothalamic tumors and following drugs like salicylates.</p>
<p>Excessive washing out of potential hydrion would tend to raise the blood pH . This is initially countered by transfer of cation (B) from ECF to ICF, release of chloride into ECF by red cells and lactate from the muscles. This causes decrease in B and replacement of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{HCO}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> by chloride, resulting in correction of the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">.</mi><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub><mi mathvariant="normal">/</mi><mi mathvariant="normal">B</mi><mi mathvariant="normal">.</mi><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H} . \mathrm{HCO}_{3} / \mathrm{B} . \mathrm{HCO}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathrm">H</span><span class="mord">.</span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">/</span><span class="mord mathrm">B</span><span class="mord">.</span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ratio. Later, kidneys eliminate more cation and bicarbonate, the urine becoming alkaline. In contrast to metabolic alkalosis, the plasma bicarbonate is decreased. In later stages, the urine may become acidic, particularly in patients with marked depletion of sodium and potassium.</p>
<p>Clinical manifestations of alkalosis: In functional cases, respiratory alkalosis is episodic and is associated with feeling of tingling and muscle cramps; sometimes tetany can occur. Tetany in alkalosis is due to lowering of plasma ionised calcium and responds to IV calcium gluconate; increased neuromuscular irritability due to raised blood pH also contributes to this phenomenon. Tetany following hyperventilation needs no treatment other than reassurance about its harmless nature.</p>
<p>Chronic metabolic alkalosis causes anorexia, apathy and mental disturbances. Kidney function may be impaired and attacks of tetany can occur.</p>
<p>Treatment of alkalosis: This is aimed at removal of the cause and correction of the body fluid disturbances. Acute loss of chloride due to vomiting can be corrected by IV normal saline. In chronic cases, similar treatment given orally is adequate, except that occasionally an associated potassium loss needs to be rectified.</p>
<p>Management of dehydration due to diarrhoea: See Chapter 41.</p>
<p>38</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="nutritional-supplementation-therapy">Nutritional Supplementation Therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nutritional-supplementation-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Nutritional supplementation therapy is an important part of the total therapeutic planning, and without it, pharmacotherapy and surgery may not be optimally effective. In fact, there are diseases (e.g., phenylketonuria) in which nutritional therapy is the only treatment available. Complete coverage of nutritional therapy is, however, beyond the scope of this book. This chapter outlines the principles of nutritional supplementation in adults, mainly in acute medical and surgical illnesses.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="nutritional-requirements-in-healthy-adults">Nutritional Requirements in Healthy Adults<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nutritional-requirements-in-healthy-adults" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Energy: The total daily requirement (TDR) for energy must be met every day. Ideally, energy intake equals energy requirement unless weight gain or weight loss is desired. The best way of assessing whether a person is in energy balance (Intake - Requirement = zero) is to weigh him daily. TDR can be calculated as the sum of:</p>
<ul>
<li>Basal metabolic rate.</li>
<li>Energy expenditure on physical activity; and</li>
<li>Specific dynamic action.</li>
</ul>
<p>Basal metabolic rate (BMR) is the energy requirement at rest and is related to the body surface area.</p>
<p>Basal energy requirement in persons above the age of 20 years can be calculated by Wilmore's formula:</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mi mathvariant="normal">BMR</mi><mo>⁡</mo><mrow><mo fence="true">(</mo><mrow><mi mathvariant="normal">K</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><msup><mi mathvariant="normal">M</mi><mn>2</mn></msup><mi mathvariant="normal">/</mi><mtext>&nbsp;day&nbsp;</mtext><mo fence="true">)</mo></mrow><mo>=</mo><mn>24</mn><mo>×</mo><mrow><mo fence="true">(</mo><mn>37</mn><mo>−</mo><mfrac><mrow><mtext>&nbsp;Age&nbsp;</mtext><mo>−</mo><mn>20</mn></mrow><mn>10</mn></mfrac><mo fence="true">)</mo></mrow></mrow><annotation encoding="application/x-tex">\operatorname{BMR}\left(\mathrm{KCal} / \mathrm{M}^{2} / \text { day }\right)=24 \times\left(37-\frac{\text { Age }-20}{10}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.2141em; vertical-align: -0.35em;"></span><span class="mop"><span class="mord mathrm">BMR</span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;"><span class="delimsizing size1">(</span></span><span class="mord"><span class="mord mathrm">KCal</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">M</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8641em;"><span style="top: -3.113em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span></span></span></span></span><span class="mord">/</span><span class="mord text"><span class="mord">&nbsp;day&nbsp;</span></span><span class="mclose delimcenter" style="top: 0em;"><span class="delimsizing size1">)</span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">24</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 2.4em; vertical-align: -0.95em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;"><span class="delimsizing size3">(</span></span><span class="mord">37</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3603em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">10</span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">&nbsp;Age&nbsp;</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">20</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.686em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mclose delimcenter" style="top: 0em;"><span class="delimsizing size3">)</span></span></span></span></span></span></span></div>
<p>A more rough and ready formula is:
BMR (KCal/day) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo><mn>24</mn><mo>×</mo><mn>0.9</mn><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">=24 \times 0.9 / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">24</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.9/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> (i.e. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>22</mn><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">22 / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">22/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day) People in tropics have relatively low BMR as compared to those from the temperate climate.</p>
<p>Because the second formula does not include a term for age, it tends to overestimate the basal requirement in older people.</p>
<p>Energy expenditure on activity (EEA) values for different physical activities are available from textbooks of physiology.</p>
<p>Specific dynamic action (SDA) refers to the additional calories required to metabolise and utilise the consumed foods. It is estimated at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> of the sum of BMR and EEA.</p>
<p>Proteins: Unlike with fats and carbohydrates, the body has very little mobilisable protein store. All the proteins in the body are either structural or functional. Repair of damaged tissue and recovery from an illness are critically dependent on readily available protein. In the absence of external supply of protein, there occurs breakdown of endogenous protein and hence damage to tissues. Therefore, negative protein balance can be harmful even in the short run. The average protein requirement in adults is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.6</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">0.6 \mathrm{~g} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.6</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day, out of which at least <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25-30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> should be animal protein including milk. Protein requirement is often stated in terms of nitrogen requirement, where 1 g of nitrogen <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo><mn>6.25</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">=6.25 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">6.25</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> of protein.</p>
<p>Water: Water requirement in healthy adults is around <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">40 \mathrm{ml} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day. This will allow the excretion of about 1000 ml of urine. In hot and dry climates, upto <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>800</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">800 \mathrm{ml} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">800</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span></span></span></span></span> day should be added, especially in summer, to offset the insensible losses.</p>
<p>Minerals: Table 38.1 gives the daily mineral requirements. Various trace elements are also required, e.g., zinc, iodine, chromium, copper and manganese.</p>
<p>Table 38.1
Daily requirement of minerals</p>
<table><thead><tr><th style="text-align: left;">Mineral</th><th style="text-align: left;">Daily requirement</th></tr></thead><tbody><tr><td style="text-align: left;">Sodium</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.4</mn><mo>−</mo><mn>2.0</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1.4-2.0 \mathrm{mEq} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1.4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2.0</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Potassium</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.2</mn><mo>−</mo><mn>1.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1.2-1.5 \mathrm{mEq} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1.2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.5</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Calcium</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.2</mn><mo>−</mo><mn>0.3</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.2-0.3 \mathrm{mEq} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.3</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Magnesium</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.3</mn><mo>−</mo><mn>0.45</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.3-0.45 \mathrm{mEq} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.45</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Iron</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">10-20 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day</td></tr><tr><td style="text-align: left;">Phosphorus</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7</mn><mo>−</mo><mn>9</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">7-9 \mathrm{mmol}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">7</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">9</span><span class="mord"><span class="mord mathrm">mmol</span></span></span></span></span></span> or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>14</mn><mo>−</mo><mn>18</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi><mn>1000</mn><mrow><mi mathvariant="normal">K</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">14-18 \mathrm{mEq} / 1000 \mathrm{KCal} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">14</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">18</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/1000</span><span class="mord"><span class="mord mathrm">KCal</span></span><span class="mord">/</span></span></span></span></span> day</td></tr></tbody></table>
<p>Vitamins: Recommended daily allowances (RDA) for vitamins are given in Chapter 75. Those not mentioned in that table are: panthothenic acid <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>7</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">4-7 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">7</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>, biotin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>400</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">100-400 \mathrm{mcg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">400</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span></span></span></span></span> and vitamin K 70-140 mcg.</p>
<p>Essential fatty acids (EFA): The RDA for linoleic acid is 2-4% and that for linolenic acid <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.5%</span></span></span></span></span> of the total daily calorie intake. The polyunsaturated fatty acid (linoleic + linolenic) content of the commonly used edible fats is as follows (all figures are in g per tablespoonful i.e. 15 ml ): safflower oil 10, soyabean oil 7.4, cottonseed oil 6.8, maize (corn) oil 6.1, til oil 5.7, rice bran oil 4.7, groundnut oil 3.9, mustard oil 3.4, olive oil 1.35, palm oil 1.2, vanaspati 0.8 , ghee 0.55 and coconut oil 0.3 . Weekly ingestion of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">50-100 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> of safflower oil, soyabean oil, cotton seed oil or corn oil satisfies the requirement for EFA.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="alterations-in-nutritional-requirements-in-acute-illness">Alterations in Nutritional Requirements in Acute Illness<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#alterations-in-nutritional-requirements-in-acute-illness" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="energy">Energy:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#energy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Fasting and undernutrition decrease the BMR by about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span>.</li>
<li>Fever increases the BMR by about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>13</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">13 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">13%</span></span></span></span></span> for every degree rise of body temperature above <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>37</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">37^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">3</span><span class="mord"><span class="mord">7</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span>. Rigors raise the BMR further. Secretion of catecholamines in acute stress also elevates BMR. On the other hand, these conditions reduce the appetite and food intake (and hence SDA), as well as physical activity (and hence EEA).</li>
<li>Illness: In addition to fever and its consequences, the hormonal response of the body to physical trauma and infection, as well as the losses from the body (e.g., protein in burns), increase the TDR. In illness, the calculations of energy requirement are based on BMR; EEA and SDA are ignored. Thus, in mild illness (elective hospitalisation or mild infection) TDR=110% of BMR; in moderate illness (fracture or severe infection) TDR = <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>125</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">125 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">125%</span></span></span></span></span> of BMR; and in severe illness (severe burns or a combination of stresses) TDR=150 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>200</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">200 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">200%</span></span></span></span></span> of BMR. Thus, TDR does not exceed twice the BMR even in the most severe illness.
Protein: During acute illness, the protein requirements rise: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.6</mn><mo>−</mo><mn>0.8</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">0.6-0.8 \mathrm{~g} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.8</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day in mild illness, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.8</mn><mo>−</mo><mn>1.0</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">0.8-1.0 \mathrm{~g} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.0</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day in moderate illness and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>1.5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">1-1.5 \mathrm{~g} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day in severe illness. For optimum utilisation of protein, about 150 total KCal must be supplied per day per 6.25 g of protein consumed.</li>
</ul>
<p>Water: The water requirement increases because of insensible sweating, visible sweating, vomiting, diarrhoea, burns or fistulae. At the same time, the intake is likely to be poor because of apathy, obtundation of consciousness, or damage to the thirst centre as in head injury. Electrolyte-free water (as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> dextrose in water) must be made available to the patient parenterally under these circumstances.</p>
<p>Electrolytes: Their requirements go up if there are excessive losses from the body such as sweating, diuresis, vomiting, diarrhoea, aspiration or fistulae. They must be calculated and must be made good.</p>
<p>Iron requirements must be considered carefully in the presence of trauma and bleeding. Further, some patients may be anemic to begin with.</p>
<p>Vitamins: During acute illness, especially if it is prolonged, the requirements for vitamins go up because of the catabolic state. If the patient is unable to ingest a normal diet, water soluble vitamins should be supplemented daily and fat soluble vitamins once a week.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="sequelae-of-malnutrition">Sequelae of Malnutrition<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sequelae-of-malnutrition" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Malnutrition has several deleterious effects which may impair patient's ability to recover from an acute illness:</p>
<ul>
<li>Weight loss: Reduction in body fat and in muscle mass, and weakness.</li>
<li>Hypoproteinemia and edema.</li>
<li>Impairment of cellular and humoral immunity.</li>
<li>Delayed wound healing.</li>
<li>Deficiencies of vitamins and minerals.</li>
<li>Deficiency of EFA: This is known to arise during the course of prolonged total parenteral nutrition. The deficiency causes dry, scaly cracked skin, coarse hair, hair loss, and may impair wound healing.</li>
<li>Malaise and poor morale; and</li>
<li>Increased mortality.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="assessment-of-nutritional-status">Assessment of Nutritional Status<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#assessment-of-nutritional-status" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A detailed history and physical examination, together with selected laboratory tests, help in the nutritional assessment of the patient. Deficiencies are commonly multiple; evidence of one deficiency should make one look carefully for other deficiencies. A nutritional assessment helps in estimating the overall nutritional impact of the disease; it helps to decide whether intensive nutritional support is necessary and if so how urgently; lastly, it helps to predict organ dysfunction which may dictate that elective surgery should be postponed.</p>
<p>Table 38.2 gives a protocol for assessment for protein-calorie status. Laboratory estimations of haemoglobin and of serum <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo separator="true">,</mo><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup><mo separator="true">,</mo><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup><mo separator="true">,</mo><msup><mi mathvariant="normal">P</mi><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}, \mathrm{K}^{+}, \mathrm{Ca}^{++}, \mathrm{P}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.039em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord mathrm">P</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span>and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">M</mi><mi mathvariant="normal">g</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Mg}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.039em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Mg</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>are other helpful parameters.</p>
<p>Table 38.2
Assessment for protein-calorie status</p>
<table><thead><tr><th style="text-align: left;">Parameter</th><th style="text-align: left;">Result which suggests significant malnutrition</th></tr></thead><tbody><tr><td style="text-align: left;">Weight loss in adults*</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>5</mn></mrow><annotation encoding="application/x-tex">&gt;5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">5</span></span></span></span></span></td></tr><tr><td style="text-align: left;">% loss in past 1 month</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>10</mn></mrow><annotation encoding="application/x-tex">&gt;10</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">10</span></span></span></span></span></td></tr><tr><td style="text-align: left;">% loss in past 6 months</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>2.8</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&lt;2.8 \mathrm{~g} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">2.8</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">%</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Serum albumin</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>150</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&lt;150 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">150</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Serum transferrin from TIBC</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>1200</mn><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">&lt;1200 / \mathrm{cmm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1200/</span><span class="mord"><span class="mord mathrm">cmm</span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Total lymphocyte count</td><td style="text-align: left;"></td></tr></tbody></table>
<p>*It is necessary to distinguish between weight loss due to dehydration and that due to loss of fat or muscle.
*Transferrin (mg %) = (0.83 × TIBC) - 43 where TIBC is the total iron binding capacity.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="nutritional-supplementation-aims-and-indications">Nutritional Supplementation: Aims and Indications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nutritional-supplementation-aims-and-indications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Nutritional supplementation therapy aims at establishing or maintaining good nutritional status; establishing positive nitrogen balance and increasing weight in the malnourished; and overcoming the effects of malnutrition.</p>
<p>Nutritional intervention to prevent malnutrition or to replenish the malnourished patient improves recovery and increases survival from many diseases.</p>
<p>Indications for nutritional supplementation are listed in Table 38.3.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-38-3">Table 38.3<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-38-3" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Indications for nutritional supplementation</p>
<ul>
<li>To correct existing malnutrition.</li>
<li>To prevent malnutrition that will occur unless there is intervention (e.g., in patients in coma; in those with severe burns, serious intestinal obstruction, trauma or sepsis).</li>
<li>When bowel rest is required (as in acute symptomatic inflammatory bowel disease, acute pancreatitis, intestinal fistulae).</li>
<li>When serious GI symptoms occur during cancer chemotherapy or radiotherapy.</li>
<li>When mechanical problems exist (e.g., dysphagia, surgery of head or neck; and</li>
<li>After massive bowel resection or other disorders causing malabsorption.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="enteral-nutrition">Enteral Nutrition<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#enteral-nutrition" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Nutritional supplementation may be done:</p>
<ul>
<li>Orally.</li>
<li>By enteral tube feeding (forced enteral feeding); or</li>
<li>Parenterally: This may be partial or total (Total Parenteral Nutrition, TPN).</li>
</ul>
<p>Wherever possible, oral or enteral tube feeding is the preferred method.
Enteral feeding, advantages:</p>
<ul>
<li>Oral and enteral tube feeding use a physiological route.</li>
<li>Safe and inexpensive.</li>
<li>They can provide almost any nutrient that is required.</li>
<li>Calorie supplementation can be done easily and completely by these methods.</li>
<li>Luminal nutrition which :
(a) Maintains the structural and functional integrity of the small intestine.
(b) Is a stimulus to hormonal homeostasis, to adaptation of the gut in patients with short bowel syndrome, and for maintenance of immunocompetence of the gut. This last factor permits the gut to maintain its normal secretion of IgA into the gut lumen and to minimise bacterial translocation from the gut into the systemic circulation, as occurs during TPN.</li>
<li>They are the methods of choice, whenever possible, if supplementation is going to last for more than a week.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindications-to-enteral-nutrition">Contraindications to enteral nutrition:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-to-enteral-nutrition" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Severe malabsorption in which tube feeding is liable to cause uncontrollable diarrhoea.</li>
<li>Total bowel obstruction.</li>
<li>Persistent and uncontrolled vomiting; and</li>
<li>Tendency to aspirate, especially in the presence of serious pulmonary disease.</li>
</ul>
<p>Oral supplementation requires satisfactory appetite, intact deglutition and the conscious co-operation of a patient; it also requires that the oral supplements must be palatable; it has no disadvantages.</p>
<p>Enteral tube feeding circumvents the need for adequate appetite and deglutition; it requires less cooperation from the patient and can be carried out even in an unconscious patient. Its disadvantages are:</p>
<ul>
<li>Less acceptability than oral feeds.</li>
<li>Nasopharyngeal irritation by the tube.</li>
<li>Erosion of the esophagus.</li>
<li>Infection of the nose, paranasal sinuses and ears; and</li>
<li>Incompetence of the gastroesophageal sphincter with regurgitation of gastric contents into the esophagus followed by their aspiration into the tracheobronchial tree. To prevent the risk of regurgitation of gastric contents and pulmonary aspiration, the patient should be kept in a semi-sitting position (head of the bed elevated <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>30</mn><mo lspace="0em" rspace="0em">∘</mo></msup></mrow><annotation encoding="application/x-tex">30^{\circ}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6741em;"></span><span class="mord">3</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span></span></span></span></span> ) during feeding and for one hour thereafter. Such a position should be maintained all the time in the elderly, infants and comatose patients.
Enteral tube feeding should be done cautiously in patients with loss of gag reflex, hiccuping, a tendency to vomit or significant pulmonary dysfunction; under these circumstances bolus feeds and feeding by the nasogastric tube should be avoided; slow</li>
</ul>
<p>drip feeding by a nasoduodenal tube may be done with caution.
Types of enteral feeding:</p>
<ul>
<li>Oral supplementation with high calorie, high protein 'table foods' (milk; milk products such as cheese and ghee; meat; and groundnuts) is the most pleasant form of supplementation in patients who can tolerate it and will cooperate in consuming them. Vegetables, fruits, fruit juices, dal, cereals and a multivitamin capsule would complete the list. Medium chain triglyceride (MCT) preparations (Precision LR, Pregestimil) containing 8-10 carbon, fatty acid residues are valuable in patients with steatorrhoea; these medium chain fatty acids are absorbed directly into the portal circulation without the help of bile salts. MCT preparations, however, are expensive.
The oral route can also be used to supplement the intake of water and electrolytes.</li>
<li>Enteral tube feeding can be carried out either by nasogastric or by nasoduodenal route in patients with intact GI tract, who are unconscious or who are not sufficiently cooperative to take all the calculated daily requirement by mouth. Local irritation and erosion can be minimised by using a small diameter tube, preferably made of plastic. Larger diameter tubes, however, permit the administration of an almost normal meal, blenderized to the consistency of a thick soup.
A problem with nasogastric feeding is the gastric distension, especially when bolus feeds are used. The nasoduodenal tube is more difficult to position properly, and diarrhoea is more likely to occur with nasoduodenal feeding; however, the problem of gastroesophageal reflux and its consequences are less troublesome. The other problems with enteral tube feeding are: electrolyte disturbances, volume overload, lactose intolerance, diarrhoea and hyperosmolality syndrome. They can be minimised by:
(a) Proper adjustment of the composition of the feeds.
(b) Not using too much of milk but using buttermilk, instead; and
(c) Not being overambitious with tube feeding.</li>
</ul>
<p>Bolus feeding: This is used only with nasoduodenal tube. Begin with 50-100 ml of a half strength feed every 3-6 hours; aspirate the gastric contents before each feed; flush the tube with water after each feed; and gradually increase the volume of a feed to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>250</mn><mo>−</mo><mn>300</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">250-300 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">250</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">300</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> to be given every 3-4 hours. Finally, increase the concentration of the feed gradually to the full strength.</p>
<p>Continuous infusion: This can be employed with either nasogastric or nasoduodenal tube. The initial rate of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">25-50 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> per hour is gradually increased, once in 24 hours, to 100150 ml per hour. Additional water may be given to prevent hyperosmolality. A variety of foods can be used by this route: soups; fruit juice; milk, buttermilk, eggnog; blenderised normal meals (rice, chapatti, dal, vegetables, meat, etc.); commercially available protein powders.</p>
<p>During enteral feeding by any method, it must be remembered that some patients have lactose intolerance and may not tolerate large quantities of milk (equivalent to more than 8 g of lactose per day); others may be intolerant to sucrose.</p>
<p>Strict intake output charts must be maintained in patients on enteral tube feeding. Unfortunately, the enteral route is not available in patients with medical or surgical abdominal diseases.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="parenteral-nutrition">Parenteral Nutrition<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#parenteral-nutrition" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Partial parenteral supplementation: Maintenance therapy with water and electrolytes is indicated in a patient who is temporarily not able or not allowed to ingest food and fluids e.g. a postoperative patient. No pre-existing deficit or excess of water or electrolytes or altered renal function should be present. Such therapy should not be extended beyond 7 days, if it can be avoided. The daily maintenance requirement in an adult can be provided by 1000 ml of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.9</mn><mi mathvariant="normal">%</mi><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">0.9 \% \mathrm{NaCl}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.9%</span><span class="mord"><span class="mord mathrm">NaCl</span></span></span></span></span></span> in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> dextrose in water ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo><mn>170</mn></mrow><annotation encoding="application/x-tex">=170</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">170</span></span></span></span></span> calories); 1000 ml of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> dextrose in water with 20 mEq of KCl added; and 1000 ml of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> dextrose in water. It is customary to avoid infusing NaCl solution for 24-48 hours after surgery as the stress of surgery produces intense salt and water retention during this period. It must be remembered that even healthy postoperative patients tend to have glucose intolerance and can develop hyperglycemia while receiving 5% dextrose in water. Water soluble vitamins should be given daily, particularly thiamine as prolonged parenteral glucose supplementation without thiamine can precipitate acute thiamine deficiency and Wernicke's encephalopathy. Fat soluble vitamins should be administered once a week. Calcium, magnesium, phosphorus and protein supplements become necessary if parenteral supplementation is continued beyond 1 week. Strict intake output chart should be maintained in these patients. Table 38.4 shows the composition of some fluids for intravenous use.</p>
<p>Table 38.4
Composition of some fluids for intravenous use</p>
<table><thead><tr><th style="text-align: left;">Solution</th><th style="text-align: center;">Dextrose <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi><mo stretchy="false">)</mo><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(\mathrm{g} / \mathrm{L}) \mathrm{Na}^{+}(\mathrm{mEq} / \mathrm{L})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0946em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span><span class="mord">/</span><span class="mord mathrm">L</span><span class="mclose">)</span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/</span><span class="mord mathrm">L</span><span class="mclose">)</span></span></span></span></span></th><th style="text-align: center;"></th></tr></thead><tbody><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn mathvariant="bold">5</mn><mi mathvariant="bold">%</mi></mrow><annotation encoding="application/x-tex">\mathbf{5 \%}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord"><span class="mord mathbf">5%</span></span></span></span></span></span> Dextrose in water</td><td style="text-align: center;">50</td><td style="text-align: center;">-</td></tr><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn mathvariant="bold">5</mn><mi mathvariant="bold">%</mi></mrow><annotation encoding="application/x-tex">\mathbf{5 \%}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord"><span class="mord mathbf">5%</span></span></span></span></span></span> Dextrose in saline</td><td style="text-align: center;">50</td><td style="text-align: center;">145</td></tr><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn mathvariant="bold">0.85</mn><mi mathvariant="bold">%</mi></mrow><annotation encoding="application/x-tex">\mathbf{0 . 8 5 \%}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord"><span class="mord mathbf">0.85%</span></span></span></span></span></span> Saline (isotonic)</td><td style="text-align: center;">-</td><td style="text-align: center;">145</td></tr><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn mathvariant="bold">0.9</mn><mi mathvariant="bold">%</mi></mrow><annotation encoding="application/x-tex">\mathbf{0 . 9 \%}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord"><span class="mord mathbf">0.9%</span></span></span></span></span></span> Saline</td><td style="text-align: center;">-</td><td style="text-align: center;">154</td></tr><tr><td style="text-align: left;">Ringer lactate</td><td style="text-align: center;">-</td><td style="text-align: center;">130</td></tr><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn mathvariant="bold">5</mn><mi mathvariant="bold">%</mi></mrow><annotation encoding="application/x-tex">\mathbf{5 \%}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord"><span class="mord mathbf">5%</span></span></span></span></span></span> Saline</td><td style="text-align: center;">-</td><td style="text-align: center;">855</td></tr><tr><td style="text-align: left;">1/6th Molar lactate</td><td style="text-align: center;">-</td><td style="text-align: center;">167</td></tr></tbody></table>
<p>'Also contains potassium <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">l</mi></mrow><annotation encoding="application/x-tex">4 \mathrm{mEq} / \mathrm{l}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/</span><span class="mord mathrm">l</span></span></span></span></span>, chloride <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>109</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">l</mi></mrow><annotation encoding="application/x-tex">109 \mathrm{mEq} / \mathrm{l}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">109</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/</span><span class="mord mathrm">l</span></span></span></span></span> (as against <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>154</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">l</mi></mrow><annotation encoding="application/x-tex">154 \mathrm{mEq} / \mathrm{l}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">154</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/</span><span class="mord mathrm">l</span></span></span></span></span> of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.9</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.9 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.9%</span></span></span></span></span> saline), calcium <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">l</mi></mrow><annotation encoding="application/x-tex">3 \mathrm{mEq} / \mathrm{l}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/</span><span class="mord mathrm">l</span></span></span></span></span> and lactate 28 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">l</mi></mrow><annotation encoding="application/x-tex">\mathrm{mEq} / \mathrm{l}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/</span><span class="mord mathrm">l</span></span></span></span></span>.</p>
<p>All these solutions can be administered through a peripheral vein. Table 38.5 shows the composition of some parenteral additives.</p>
<p>Table 38.5
Composition of some parenteral additives</p>
<table><thead><tr><th style="text-align: left;">Solution</th><th style="text-align: center;">Volume ml per ampoule</th><th style="text-align: center;">Cation Anior (mEq/amp)</th><th style="text-align: center;"></th></tr></thead><tbody><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn mathvariant="bold">7.5</mn><mi mathvariant="bold">%</mi></mrow><annotation encoding="application/x-tex">\mathbf{7 . 5 \%}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord"><span class="mord mathbf">7.5%</span></span></span></span></span></span> Sodium bicarbonate</td><td style="text-align: center;">50</td><td style="text-align: center;">44.6</td><td style="text-align: center;">44.6</td></tr><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn mathvariant="bold">15</mn><mi mathvariant="bold">%</mi></mrow><annotation encoding="application/x-tex">\mathbf{1 5 \%}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord"><span class="mord mathbf">15%</span></span></span></span></span></span> Potassium chloride</td><td style="text-align: center;">30</td><td style="text-align: center;">60.0</td><td style="text-align: center;">60.0</td></tr><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn mathvariant="bold">10</mn><mi mathvariant="bold">%</mi></mrow><annotation encoding="application/x-tex">\mathbf{1 0 \%}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord"><span class="mord mathbf">10%</span></span></span></span></span></span> Calcium gluconate</td><td style="text-align: center;">10</td><td style="text-align: center;">4.6</td><td style="text-align: center;">4.6</td></tr><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn mathvariant="bold">50</mn><mi mathvariant="bold">%</mi></mrow><annotation encoding="application/x-tex">\mathbf{5 0 \%}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord"><span class="mord mathbf">50%</span></span></span></span></span></span> Magnesium sulfate</td><td style="text-align: center;">10</td><td style="text-align: center;">40.6</td><td style="text-align: center;">40.6</td></tr><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn mathvariant="bold">42</mn><mi mathvariant="bold">%</mi></mrow><annotation encoding="application/x-tex">\mathbf{4 2 \%}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord"><span class="mord mathbf">42%</span></span></span></span></span></span> Disodium hydrogen phosphate</td><td style="text-align: center;">15</td><td style="text-align: center;">36.0</td><td style="text-align: center;">36.0</td></tr><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn mathvariant="bold">46</mn><mi mathvariant="bold">%</mi></mrow><annotation encoding="application/x-tex">\mathbf{4 6 \%}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord"><span class="mord mathbf">46%</span></span></span></span></span></span> Potassium dihydrogen phosphate</td><td style="text-align: center;">15</td><td style="text-align: center;">100.0</td><td style="text-align: center;">100.0</td></tr></tbody></table>
<p>Phlebitis is a well recognised complication of intravenous infusion therapy. Such phlebitis may be either infective or noninfective. Contamination of the fluid to be infused during manufacturing process, frequent manipulations of the intravenous system, and entry of bacteria at the cannula-skin junction account for the infective phlebitis. However, most phlebitis following intravenous infusions is non-infective. Many factors contribute to it; they all seem to operate through mechanical and physicochemical interaction at the cannula-vein junction. These factors are:</p>
<ul>
<li>Type of cannula: Metal cannulae cause less phlebitis than plastic ones and short cannulae less than long ones.</li>
<li>Duration of cannulation: The longer the cannulation, the greater the risk of phlebitis.</li>
<li>Location of the cannula: Veins in the upper extremity and the large central veins are less liable to develop phlebitis than those in the lower extremity and the periphery; and</li>
<li>Type and composition of the infusate and the presence of additives in it. Certain drugs are more liable to produce phlebitis than others. Fluids with non-physiologic pH , hypertonic fluids and fluids which contain particulate matter are prone to produce phlebitis. Particulate matter is often present in solutions that appear clear to the naked eye, and comprises glass, cotton fibres, precipitated proteins, microcrystalline drug particles, and degradation products of interaction between fluids and glass, plastic or even rubber stoppers. The above list of causes of phlebitis suggests possible ways of preventing it.
Catheter sepsis can be a serious complication during prolonged intravenous infusion therapy. Methods of preventing catheter sepsis are listed in Table 38.6.</li>
</ul>
<p>Table 38.6
Prevention of catheter sepsis</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>- Insertion of the catheter under aseptic conditions.
</span>- Subcutaneoustunnelling of the catheter.
- Use of transparent polyurethane dressingsover the site of cannulation.
- Changing of dressings by experienced staff.
- Change of the infusion set every 2-3 days; and
- Administration of blood products or drugs via separate set from the one used for the main infusate.</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="- Insertion of the catheter under aseptic conditions.
- Subcutaneoustunnelling of the catheter.
- Use of transparent polyurethane dressingsover the site of cannulation.
- Changing of dressings by experienced staff.
- Change of the infusion set every 2-3 days; and
- Administration of blood products or drugs via separate set from the one used for the main infusate." style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>Catheter sepsis should be the uppermost in the physician's mind when a patient receiving an intravenous infusion develops fever or any metabolic deterioration. A special in-line filter in the infusion line is available to intercept any particulate matter in the fluid.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="total-parenteral-nutrition-tpn">Total Parenteral Nutrition (TPN)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#total-parenteral-nutrition-tpn" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>TPN is used to supply all the essential nutrients without using the gastrointestinal tract. Indications for TPN: These are given in Table 38.7.</p>
<p>Table 38.7
Indications for TPN</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>- Short bowel syndrome.
</span>    - Prolonged ileus, such as that following visceral trauma.
    - Pancreatic abscess/fistula.
    - Intestinal fistula.
    - Hypermetabolic states, such as severe burns, major sepsis.
    - Alimentary tract cancer causing mechanical obstruction.
    - Severe vomiting or anorexia, such as anorexia nervosa, hypoemesis gravidarum; and
    - Crohn's disease with malabsorption and retarded growth in children.</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="- Short bowel syndrome.
    - Prolonged ileus, such as that following visceral trauma.
    - Pancreatic abscess/fistula.
    - Intestinal fistula.
    - Hypermetabolic states, such as severe burns, major sepsis.
    - Alimentary tract cancer causing mechanical obstruction.
    - Severe vomiting or anorexia, such as anorexia nervosa, hypoemesis gravidarum; and
    - Crohn's disease with malabsorption and retarded growth in children." style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>TPN has also been used in other situations such as for routine preoperative support and as an adjunct to cancer chemo-/radio-therapy.</p>
<p>TPN has been used in the hospital setting as well as at home. It has been shown to achieve positive nitrogen balance, and to promote growth in children. One of the aims of TPN is to ensure complete bowel rest which minimises the intestinal motor and secretory activity and encourages the healing of bowel lesions.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="composition-and-requirements">Composition and requirements:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#composition-and-requirements" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>
<p>Calories: These are provided by means of 20 - <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> dextrose in water through a central vein, as it is hypertonic. Water is provided in the quantity of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">40 \mathrm{ml} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day.</p>
</li>
<li>
<p>Protein: This is supplied in the form of specially prepared mixtures of synthetic, essential amino acids. They contain <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>8</mn><mo>−</mo><mn>9</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">8-9 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">9%</span></span></span></span></span> of the amino acids in 200 ml bottles for intravenous use. The calories provided by the amino acids are not taken into account in the daily calorie calculation. These mixtures are used as a source of protein as the endogenous protein breakdown is less when some protein is made available than when only carbohydrate is supplied. Further, the protein prevents fatty infiltration of the liver which is likely to occur when only carbohydrate is supplied to the patient. Patients who are losing protein in exudates need infusion of human serum albumin in the dose of 10<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">25 \mathrm{~g} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">25</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span></span></span></span></span> day; they and anemic patients also benefit from blood transfusions. Amino acid mixtures and albumin solutions, however, are expensive.</p>
</li>
<li>
<p>Fats: Milky emulsions of soyabean oil ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> and 20%) and safflower oil ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> and 20%) in combination with glycerol and emulsifying agents are available for intravenous administration. The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> emulsions supply 1.1 calorie per ml . Both are good sources of linoleic acid; the soyabean oil preparations are a good source of linolenic acid as well. A weekly injection of 500-1000 ml of a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> emulsion is used to provide the necessary essential fatty acids to prevent the development of a deficiency syndrome. As the fat emulsions are isotonic, they can be administered by a peripheral vein. In the usual doses, intravenous fats are metabolised in the same manner as the natural chylomicrons.</p>
</li>
<li>
<p>Minerals: Mineral requirements are as per Table 37.1. In addition, trace elements are supplied as follows: zinc <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo>−</mo><mn>4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">2.5-4 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day; copper <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">0.5-1.5 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day; iodine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mo>−</mo><mn>150</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">75-150 \mathrm{mcg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">75</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">150</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span></span></span></span></span> day; manganese <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.15</mn><mo>−</mo><mn>0.8</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">0.15-0.8 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.8</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day; chromium <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">10-15 \mathrm{mcg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span></span></span></span></span> day; and selenium <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">50-200 \mathrm{mcg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">200</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span></span></span></span></span> day. They are added to the intravenous infusion.</p>
</li>
<li>
<p>Vitamins: The recommended vitamin supplements during TPN are:
(a) Daily: Thiamine 3 mg , riboflavin 3.6 mg , pantothenic acid 15 mg , pyridoxine 4 mg , niacin 40 mg , biotin 60 mg , folacin 400 mcg , cyano-cobalamin 5 mcg , ascorbic acid 100 mg ; and vitamin D 200 IU. Prolonged use of larger doses of vitamin D has been reported to cause a reversible form of metabolic bone disease.
(b) Weekly: vitamin A 3300 IU , and vitamin E 10 IU .</p>
</li>
</ul>
<p>Technique of TPN: The base solution for TPN is a mixture of an amino acid solution and dextrose solution (final concentration of dextrose 20-25%); it is prepared daily by mixing an amino acid solution and a dextrose solution in a laminar flow hood in the hospital pharmacy. The minerals and vitamins are added to this base solution. The calorie content of dextrose solution is calculated on the basis of 3.4 KCal per gramme as the dextrose used is not anhydrous <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mo>=</mo><mn>4</mn><mrow><mi mathvariant="normal">K</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">g</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(=4 \mathrm{KCal} / \mathrm{g})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm">KCal</span></span><span class="mord">/</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span><span class="mclose">)</span></span></span></span></span> but in the form of monohydrate. The calorie contribution of amino acids is ignored. The total calories supplied should bear a ratio of 125-190:1 to nitrogen (in g) supplied, in order to optimise the utilisation of the aminoacids for anabolic purposes. As the base solution is hypertonic, it must be infused through a central vein, taking all the precautions detailed above. The rate of dextrose infusion should not exceed <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>7</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">5-7 \mathrm{ml} / \mathrm{kg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">7</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span> in adults. The lipid emulsion is administered separately through a peripheral vein.</p>
<p>In order to prevent cracking, nothing should be added to the fat emulsion.
Insulin (soluble) in the dose of 10 units per 250 g of dextrose is added to the base solution to prevent hyperglycemia. Heparin may be added to the infusate to prevent fibrin plugging of the central venous catheter. If corticosteroids are required for the patient's primary condition, they (preferably those with little mineralo-corticoid activity, such a dexamethasone) may be added to the base solution.</p>
<p>TPN is generally initiated with one litre of the base solution (containing about 250 g of dextrose and about 40 g of amino acids) per 24 hours. If this amount is tolerated, the quantity infused is increased by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn><mo>−</mo><mn>1</mn></mrow><annotation encoding="application/x-tex">1 / 2-1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span></span></span></span></span> litre per day till the desired amount of calories and protein are being delivered. This concentrated glucose solution is infused in 18 hours and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> dextrose infused during the remaining 6 hours of the day; the latter helps to prevent rebound hypoglycemia. Further, when TPN is being discontinued, the amount of glucose infused should be tapered gradually for the same reason.</p>
<p>Physical therapy is a valuable adjunct for restoring muscle function and muscle mass in patients on TPN.</p>
<p>Monitoring of TPN: Patients on TPN need close clinical and laboratory monitoring. A strict intake output chart must be maintained. The daily physical examination of the patient should include weighing, looking for signs of fluid overload and for TPN related sepsis. Daily examination of urine for glucose and acetone, and daily estimation of plasma glucose, urea nitrogen, creatinine, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo separator="true">,</mo><mi mathvariant="normal">K</mi><mo separator="true">,</mo><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mo separator="true">,</mo><mrow><mi mathvariant="normal">M</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{Na}, \mathrm{K}, \mathrm{Ca}, \mathrm{Mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">Na</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord mathrm">K</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord mathrm">Ca</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Mg</span></span></span></span></span></span> and P should be done till the patient stabilises. The appearance of hyperglycemia during apparently stable TPN suggests a catabolic stress such as catheter sepsis. Serum bilirubin and liver enzymes should be done once in 3-4 days to detect hepatic dysfunction.</p>
<p>A weekly weight gain of about 1.5 kg indicates successful TPN. Improvement in muscle strength is a good indication of improved skeletal muscle function. Improvement in plasma albumin and transferrin occurs only gradually. Growth is known to be normalised in children with retarded growth due to inflammatory bowel disease and malabsorption.</p>
<p>Complications of TPN: A variety of complications can occur in a patient on TPN. An attempt should be made to prevent them; at the same time they should be carefully looked for and treated promptly and vigorously, if they occur. The complications are listed in Table 38.8 .</p>
<p>Table 38.8</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="complications-of-tpn">Complications of TPN<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#complications-of-tpn" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Hyperglycemia.</li>
<li>Rebound hypoglycemia on cessation of</li>
</ul>
<p>TPN.</p>
<ul>
<li>Electrolyte abnormalities.</li>
<li>Azotemia.</li>
<li>Liver dysfunction.</li>
<li>Volume overload.</li>
<li>Metabolic bone disease.</li>
<li>A variety of non-metabolic complications such as adverse reactions to lipid emulsions; sepsis; allergic reactions; and complications due to the physical trauma by the catheter in the vein.</li>
</ul>
<p>TPN is more expensive, and requires more careful monitoring than enteral nutrition. Therefore, it should not be instituted unless it is absolutely necessary. Further, an attempt should be made to re-establish enteral supplementation as soon as possible in all patients who are treated with TPN.</p>
<p>39</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="diuretic-and-anti-diuretic-drugs">Diuretic and Anti-Diuretic Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#diuretic-and-anti-diuretic-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The kidneys play an important role in regulating the volume and the composition of the body fluids. They also secrete erythropoietin and thus serve as an endocrine organ. They have a rich blood supply; almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> of cardiac output is received by the kidneys. Hence, several drugs and their metabolites during their passage through the kidneys cause either beneficial or adverse effects.</p>
<p>The functional unit of the kidney is termed as the nephron (Fig. 39.1). Drugs can modify the renal functions:
<img src="assets/images/image-20251214-566c41f2.jpeg" alt="img-42.jpeg"></p>
<p>FIG. 39.1 The simplified schematic diagram showing functional subdivisions of a mammalian nephron and sites of diuretic action on sodium reabsorption-(I) Proximal tubule, (II) Ascending limb of Henle's loop, (III) Early distal tubule and (IV) Distal tubular <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mi mathvariant="normal">/</mi><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+} / \mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0946em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>exchange site.</p>
<ul>
<li>Indirectly by modifying its circulation; or</li>
<li>Directly by affecting the nephron function. Most of the therapeutically useful agents act mainly by modifying various functions of the nephron.
Physiology of urine formation: The volume and composition of urine are essentially determined by:</li>
<li>Glomerular filtration.</li>
<li>Tubular reabsorption; and</li>
<li>Active tubular secretion.</li>
</ul>
<p>Urine formation begins in the glomerular capillary tufts by the process of ultrafiltration. The glomerular filtrate is a protein free ultra filtrate of the plasma. Both the renal plasma flow and glomerular filtration can be affected by factors which may cause sodium retention and edema; e.g. chronic heart failure, renal vascular disease. The GFR is directly</p>
<p>related to the cortical blood flow since <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mo>−</mo><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90-95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">90</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span> of the renal blood flow passes through the cortex. The medullary blood flow is of importance in the concentrating ability of the kidney.</p>
<p>PGE 2 synthesised in the renal medulla participates in the autoregulation of renal blood flow and glomerular filtration.</p>
<p>The transport of sodium and other solutes across the tubular epithelial cells involves several mechanisms: (1) solute movement with bulk water flow; (2) simple diffusion; (3) channel mediated diffusion; (4) carrier mediated or facilitated diffusion (uniport); (5) primary ATP mediated transport; (6) secondary ATP mediated transport which is either in the same direction (co-transport or symport) or in opposite directions (counter transport or antiport). Sodium is actively transported from the basolateral surface of tubular epithelial cells, involving <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>-ATPase pump. The type of transport in a particular nephron and its location (luminal or basolateral) determine the electrolyte transport across that segment.</p>
<p>Nearly <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60-70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> of the filtered sodium is reabsorbed in the proximal tubule.
Proportionate quantities of water are absorbed along with sodium (obligatory reabsorption), so that the tubular fluid remains isotonic with plasma. The sodium reabsorption in the proximal tubule varies with changes in ECF and GFR; it is enhanced markedly in response to contraction of ECF volume and acute reduction in GFR from any cause, whereas it is depressed following ECF expansion which causes the release of a natriuretic hormone. Reabsorption of sodium from the tubular fluid into the peritubular capillaries makes the tubular fluid electrochemically negative to the tubular cell and establishes an electrochemical gradient for passive reabsorption of chloride. This then establishes an osmotic gradient along which water is reabsorbed. Removal of water from the tubular lumen sets up a concentration gradient for urea which is then reabsorbed. Thus, reabsorption of sodium is the event of primary importance in tubular reabsorption. Bicarbonates are absorbed with the help of carbonic anhydrase enzyme.</p>
<p>Quantitatively less ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> ) of filtered sodium is absorbed from the next portion of the nephron, the loop of Henle (Fig. 39.1). Juxtaglomerular apparatus (JG) is located at the vascular pole of the glomerulus and contains modified smooth muscle cells called the myoepithelial cells, which secrete renin. The JG apparatus is responsible for tubuloglomerular feedback which regulates the glomerular hemodynamics via altering the renin secretion.</p>
<p>The loop is of considerable interest since it acts as a counter current multiplier. According to the counter current concept, the descending and the ascending limbs of the loop (Fig. 39.1) have relatively different permeabilities to water and sodium. In the thick segment of the ascending limb, sodium and chloride are actively transported (Symport) from the tubular lumen to the interstitium by ion transporter system. The tubular epithelium at this site is impermeable to water and hence, the tubular fluid becomes dilute (hypotonic) and the interstitium becomes hypertonic. In contrast, the tubular epithelium in the descending limb is permeable to water, which is absorbed readily into the hypertonic interstitium. Thus, the tubular fluid, which is isotonic with plasma at its entry into the descending limb of the loop of Henle, becomes progressively more hypertonic as it approaches the tip of the loop. From then on, its osmolality diminishes progressively because of passive reabsorption of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>from the ascending thin limb and active extrusion</p>
<p>of chloride (accompanied by sodium) from the ascending thick limb of the loop. Thus, the fluid entering the distal convoluted tubule (Site III) is hypotonic to plasma. This circular and repetitive transfer of sodium across the loop is called the 'hairpin counter-current multiplier system'. It is largely responsible for creating a hypertonic medullary interstitium. Preferential transport of sodium by the ascending limb with its low water permeability is important in the process of concentration of the urine.</p>
<p>The active reabsorption of sodium along with chloride through specific sodium channels continues in the late distal convoluted tubule and the collecting tubule. This is the driving force for secretion of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>into the lumen of the tubule. In the collecting tubules there is a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{H}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ATPase pump on the luminal site which secretes <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{H}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>into the lumen. Most of the potassium filtered by the glomeruli ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> ) is reabsorbed in the proximal tubules and the fluid presented to the distal tubule probably does not contain any potassium. The potassium that appears in the urine is, therefore, secreted by the distal tubule in exchange for sodium which is reabsorbed. The exchange of potassium with sodium in the distal tubule is largely but not completely under the influence of aldosterone, excess of which causes sodium retention and potassium depletion.</p>
<p>Most of the filtered calcium ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> ) is reabsorbed in the proximal tubule; about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> is reabsorbed in the thick descending limb. The rest is reabsorbed in the distal convoluted tubule. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> of the filtered magnesium is reabsorbed in the proximal tubule whereas <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> is reabsorbed in the thick ascending limb.</p>
<p>In the proximal tubule, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{H}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ion is transported from the tubular cell cytoplasm to the tubular lumen in exchange for the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ion which is absorbed into the tubular cell (antiport) and is pushed out into the interstitium by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{K}^{+}-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8547em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mord">−</span></span></span></span></span>ATPase pump. (Fig. 39.2). In the lumen, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{H}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>reacts with the filtered <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msubsup><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn><mo lspace="0em" rspace="0em">−</mo></msubsup></mrow><annotation encoding="application/x-tex">\mathrm{HCO}_{3}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0916em; vertical-align: -0.247em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -2.453em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.247em;"><span></span></span></span></span></span></span></span></span></span></span>to form <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2} \mathrm{CO}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> which splits into <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and water in the presence of carbonic anhydrase. Carbon dioxide <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{CO}_{2}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> diffuses across the luminal membrane into the tubular epithelial cell where it forms <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2} \mathrm{CO} 3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">CO</span></span><span class="mord">3</span></span></span></span></span>, a reaction that is catalysed by cytoplasmic carbonic anhydrase. Within the cytoplasm, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2} \mathrm{CO}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> splits into <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mrow><mo>−</mo><mn>3</mn></mrow></msub></mrow><annotation encoding="application/x-tex">\mathrm{HCO}_{-3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8917em; vertical-align: -0.2083em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.2083em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{H}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>. The hydrogen ion then repeats the above cycle and exchanges with luminal <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>which is reabsorbed into the tubular cell and again pushed out into the interstitium. The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{HCO}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span>in the tubular cell cytoplasm is also pushed out into the interstitium, where it combines with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>to form <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub><mi mathvariant="normal">.</mi><msub><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{NaHCO}_{3} . \mathrm{NaHCO}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">NaHCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">.</span><span class="mord"><span class="mord"><span class="mord mathrm">NaHCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> thus formed is reabsorbed into the systemic circulation for conservation.</p>
<p><img src="assets/images/image-20251214-98618e0d.jpeg" alt="img-43.jpeg"></p>
<p>FIG. 39.2 Carbonic anhydrase action in renal tubules
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>=</mo><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">1=\mathrm{Na}^{+} \mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ATPase. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>=</mo><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mi mathvariant="normal">/</mi><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">2=\mathrm{Na}^{+} / \mathrm{H}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1.0946em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>exchanger. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>=</mo></mrow><annotation encoding="application/x-tex">3=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Carbonic anhydrase. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>L</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">L=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">L</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Luminal cell membrane. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">B=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Basolateral cell membrane. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>L</mi><mo separator="true">,</mo><mi>B</mi></mrow><annotation encoding="application/x-tex">L, B</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">L</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span></span></span></span></span> and cytoplasm are rich in carbonic anhydrase</p>
<p>Addition of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{H}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ion to the luminal fluid in the distal tubule makes the normal urine acidic. The presence of bicarbonate and phosphate buffers in the filtrate prevents the tubular fluid from becoming excessively acidic. Renal tubular cells also produce ammonia <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">H</mi></mrow><mn>3</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{NH}_{3}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">NH</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> which diffuses and reacts, with hydrogen ion in the urine to form <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">H</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{NH}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">NH</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> which cannot be reabsorbed. The acidification of urinary buffers and formation of ammonium ion are thus necessary for the reabsorption of sodium bicarbonate.</p>
<p>The final volume and composition of the urine to be excreted are regulated by the collecting duct which runs from the relatively isosmotic cortex through the hyperosmotic renal medulla to the papilla. The urine entering the collecting tubule is isotonic with plasma. Under the influence of ADH, collecting ducts are relatively permeable to water which passes freely to hyperosmotic renal medulla, thus concentrating the urine further. In addition, collecting ducts also reabsorb sodium actively under the influence of aldosterone and secrete <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{H}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>and ammonium ions.</p>
<p>Since tubules normally absorb over 99% of the glomerular filtrate, marked diuresis can be achieved by interfering with the tubular reabsorption of sodium. The distal convoluted tubule, the collecting duct and the ascending limb of the loop have reserve capacity for sodium reabsorption. This is utilised when sodium reabsorption is decreased in the proximal tubule. Hence, a diuretic acting on the proximal tubule alone may not be so potent since its effect would be counterbalanced by increased distal reabsorption.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="diuretics">Diuretics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#diuretics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Diuretic are the drugs which increase the rate of urine formation together with natriuresis.
Only a few drugs produce diuresis by increasing the GFR; most of the diuretics used therapeutically act by interfering with sodium reabsorption by the tubules.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="classification-of-diuretics">Classification of Diuretics:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-diuretics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>I Weak diuretics:</p>
<ul>
<li>Osmotic diuretics: Sodium and Potassium salts.</li>
<li>Xanthine derivatives such as Aminophylline.</li>
<li>Carbonic anhydrase inhibitors such as Acetazolamide.</li>
</ul>
<p>II Moderately efficacious diuretics:</p>
<ul>
<li>Osmotic diuretics such as Mannitol, Isosorbide, Sucrose and Glycerol.</li>
<li>Benzothiadiazines (thiazides) and related compounds such as Chlorthalidone, Chloroxozone and Clopamide. They:
(1) Inhibit <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{Cl}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8557em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span>symport.
(2) Have a moderately rapid onset of action, lead to excretion of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5-10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> of the filtered NaCl
(3) Have a wide spectrum of duration of action (8-72 hours); and
(4) Are ineffective with GFR <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">&lt;30 \mathrm{ml} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>.</li>
</ul>
<p>III Very efficacious diuretics (High ceiling-loop diuretics) e.g. Furosemide, Mefruside, Bumetamide and Ethacrynic acid. They:
(1) Inhibit <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><mn>2</mn><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{K}^{+}-2 \mathrm{Cl}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8547em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8557em;"></span><span class="mord">2</span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span>symport.
(2) Have a rapid onset and short duration of action.
(3) Cause excretion of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">15-20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> of the filtered NaCl .
(4) Are effective even in the presence of markedly reduced GFR; and
(5) Tend to be effective when drugs from group II, given in maximum doses, fail to act. IV Potassium sparing diuretics:
(a) Aldosterone antagonists: Spironolactone, Potassium canreonate and Eplerenone.
(b) Renal epithelial sodium channel inhibitors: Triamterene and Amiloride.</p>
<p>By themselves, they are weak diuretics. But, they are useful adjuncts because of their potassium sparing effect.</p>
<p>Classification of diuretics according to the site of action is given in Table 39.1.</p>
<p>Table 39.1
Site of action of diuretics and their effects</p>
<table><thead><tr><th style="text-align: center;">Site of action</th><th style="text-align: center;">Drug group</th><th style="text-align: center;">Mechanism of action</th><th style="text-align: center;">Effect on ions</th></tr></thead><tbody><tr><td style="text-align: center;">Proximal tubule</td><td style="text-align: center;">Carbonic anhydrase inhibitors</td><td style="text-align: center;">Inhibition of carbonic anhydrase</td><td style="text-align: center;">Inhibition of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{H}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>exchange indirectly</td></tr><tr><td style="text-align: center;">Loop of Henle and Proximal tubule</td><td style="text-align: center;">Osmotic diuretics</td><td style="text-align: center;">Osmotic effect to reduce medullary tonicity</td><td style="text-align: center;">Limits passive reabsorption of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Thick ascending limb of loop of Henle</td><td style="text-align: center;">(Loop diuretics)</td><td style="text-align: center;">Inhibition of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><mn>2</mn><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{K}^{+}-2 \mathrm{Cl}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8547em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8557em;"></span><span class="mord">2</span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span>symport</td><td style="text-align: center;">Inhibition of reabsorption of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Cl}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8557em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span>and increased excretion of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Site in distal tubule before <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mi mathvariant="normal">/</mi><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+} / \mathrm{H}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0946em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>exchange</td><td style="text-align: center;">Thiazides</td><td style="text-align: center;">Inhibition of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{Cl}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8557em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span>symport</td><td style="text-align: center;">Inhibition of reabsorption of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Cl}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8557em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span>and increased excretion of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Late segment of Distal tubule (site of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mi mathvariant="normal">/</mi><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+} / \mathrm{H}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0946em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> exchange) and collecting duct</td><td style="text-align: center;">Aldosterone antagonist &lt;br&gt; Triamterene &lt;br&gt; Amiloridc</td><td style="text-align: center;">Blockade of mineralocorticoid receptors &lt;br&gt; Inhibition of renal epithelial sodium channels</td><td style="text-align: center;">Inhibition of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>reabsorption and reduced excretion of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span></td></tr></tbody></table>
<p>Water, given in excess, acts as a physiological diuretic. During water diuresis the ADH remains inhibited and the ADH responsive portion of the nephron becomes impermeable to water. The urine consists of water that is excreted along with the electrolytes (osmolar clearance) as well as the solute free portion (free water clearance). In edema, the basic problem is sodium retention, the water retention being secondary. In such cases, water does not act as a diuretic. Conversely, in patients with sodium retention, there need not be a rigid restriction of water intake when sodium intake is restricted. Water diuresis is used to wash out drugs which irritate the urinary tract or are of limited solubility in the urine, e.g. salicylates or sulfonamides. It is also useful in UTI.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="osmotic-diuretics">Osmotic Diuretics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#osmotic-diuretics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Osmotic diuretics are solutes with the following properties. They are:</p>
<ul>
<li>Pharmacologically inert.</li>
<li>Generally non-metabolisable.</li>
<li>Increase osmolality of plasma and tubular fluid.</li>
<li>Freely filtered at the glomerulus; and</li>
<li>Not significantly reabsorbed by the renal tubules.</li>
</ul>
<p>Mechanism of action: In the proximal tubule, sodium is actively absorbed from tubular lumen, dragging water passively along with it. In the presence of a non-absorbable solute such as mannitol, diffusion of water is reduced relative to that of sodium. As a consequence the net absorption of sodium diminishes. There is an enhanced urine flow with a relatively smaller increase in the sodium excretion. However, this action is of secondary importance; the main site of action of the osmotic diuretics is the loop. They expand the ECF and increase the renal blood flow, thereby reducing the medullary tonicity, which inhibits water extraction from the descending limb. This limits the passive reabsorption of sodium from the thick ascending limb of the loop.</p>
<p>The other osmotically active solutes are urea, glucose, isosorbide, and urographic and angiographic contrast agents. In case of glucose, this mechanism becomes operative when the tubular maximum for reabsorption of glucose is exceeded because of hyperglycemia.</p>
<p>When GFR is acutely reduced (as in hypotension or dehydration), solutes undergo more complete reabsorption in the proximal tubule, so that there is a marked fall in the urine flow and solute excretion. In such circumstances, diuretics that act by directly inhibiting tubular reabsorption may be ineffective. However, the osmotic diuretics retain their effectiveness. Although the GFR is reduced, a substance like mannitol is filtered at the glomerulus and is excreted in the voided urine, dragging water (and sodium) with it, causing diuresis.</p>
<p>MANNITOL: It is a sugar (polyhydroxy aliphatic alcohol) which, when injected IV, is not metabolised and is rapidly filtered by the glomeruli causing osmotic diuresis. It increases excretion of all the electrolytes including magnesium and calcium.</p>
<p>To be effective, mannitol has to be administered in sufficiently large doses. It is not a suitable diuretic to treat cardiac edema, because it increases the ECF volume by extracting water from the cells, thus increasing further the load on the heart. When the renal tubules are damaged, in addition to reduction in GFR (as happens with nephrotoxic agents or with prolonged, severe, renal ischemia), they become permeable to mannitol, which then loses its capacity to induce diuresis.</p>
<p>Adverse reactions: It can cause headache, nausea, chills, polydipsia, confusion and pain in the chest. Excessive amounts or rapid infusion of mannitol can cause cellular dehydration; pulmonary edema in patients with CHF and hyponatremia. Extravasation of mannitol may cause thrombophlebitis. It can cross the BBB, though less readily than urea, and may occasionally cause rise in intracranial tension. Mannitol should not be mixed with whole blood because agglutination and irreversible crenation of RBCs may occur.</p>
<p>It is supplied as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> solution in ampoules of 50 ml for IV use. Contraindications to mannitol are given in Table 39.2.</p>
<p>Table 39.2
Contraindications to mannitol</p>
<ul>
<li>Pulmonary congestion/edema.</li>
<li>Intracranial bleeding, except during craniotomy.</li>
<li>Congestive heart failure.</li>
<li>Metabolic edema with abnormal capillary fragility; and</li>
<li>Established acute renal failure with anuria.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Barbiturate poisoning: It is useful in barbiturate poisoning to increase the urinary elimination of barbiturate. In such cases, it is infused as a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5-25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> solution. However, the loop diuretic furosemide is preferred.</li>
<li>Threatened acute renal failure: It is also useful in any condition of threatened acute oliguric renal failure from pre-renal causes (e.g. severe gastroenteritis) which result in hypovolemia and hypotension. In such cases, after initial correction of hypovolemia with adequate IV fluids, 200 mg of mannitol per kg may be infused rapidly in 10-15 minutes. If the urine flow rate increases to 100 ml per hour further mannitol is given to maintain the high urine flow rate. This may prevent the establishment of acute renal failure. If no diuresis occurs after the initial infusion, established acute renal failure is diagnosed and no more mannitol is given.
Mannitol is also used pre-operatively during certain surgical procedures (aortic surgery or surgery in a deeply jaundiced patient) which are known to increase the risk of acute renal failure. It is also useful in preventing acute oliguric renal failure after severe trauma and hemolytic transfusion reactions.</li>
<li>Raised intraocular pressure (IOP): Mannitol infusion is used in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.5</mn><mo>−</mo><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1.5-2 \mathrm{~g} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> (in 30-60 minutes) to reduce IOP in acute congestive glaucoma (see Chapter 72).</li>
<li>Cerebral edema: See later.</li>
<li>During rapid dialysis, to maintain osmolality of ECF.</li>
</ul>
<p>GLYCEROL: Glycerol is used orally in the dose of 1 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1.5 \mathrm{~g} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> (maximum dose 120 g per day), as a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>75</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50-75 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">75%</span></span></span></span></span> solution, prior to ophthalmological procedures. Palatability is increased by chilling the solution and adding either lemon juice or instant coffee. Glycerol 10% in normal saline or in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> dextrose, given IV in the dose of 1.2 gm per kg body weight, has been claimed to avoid the 'rebound edema', which may occur after mannitol. Moreover, it can be used in the presence of dehydration and cardiac failure where mannitol cannot be used. It has been used in the treatment of acute cerebral infarction, given IV daily <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> in 500 ml saline for 6 days. Rapid infusion of high concentrations ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> ) can cause hemolysis. It also causes hyperglycemia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="xanthines-as-diuretics">Xanthines as Diuretics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#xanthines-as-diuretics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Xanthines (Chapter 12) act by increasing the renal blood flow by both cardiac and vascular action, as well as by inhibiting the tubular reabsorption of sodium. However, its diuretic action is weak. Theophylline is the most effective xanthine diuretic and is used as theophylline ethylene diamine (aminophylline). To be effective, it must be given IV, slowly, over 20 minutes, in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.25</mn><mo>−</mo><mn>0.5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.25-0.5 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">0.5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span>, diluted in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">10-20 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> glucose. The drug may cause marked diuresis when given 3-4 hours after a thiazide or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">1 / 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/2</span></span></span></span></span> hour after furosemide in a previously refractory patient.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="carbonic-anhydrase-inhibitors">Carbonic Anhydrase Inhibitors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#carbonic-anhydrase-inhibitors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>ACETAZOLAMIDE: This drug (Fig. 39.3), a weak diuretic, is unique because of its mechanism of action.</p>
<p>FIG. 39.3 Acetazolamide
Mechanism of Action: The enzyme carbonic anhydrase is present in the kidney, gastric mucosa, pancreas, eyes, CNS and RBC. It catalyses the reactions:</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub><mi mathvariant="normal">O</mi><mo>+</mo><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub><mo>⇆</mo><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2} \mathrm{O}+\mathrm{CO}_{2} \leftrightarrows \mathrm{H}_{2} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord mathrm">O</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8641em; vertical-align: -0.1808em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel amsrm">⇆</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2} \mathrm{CO}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is then split into <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{H}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{HCO}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span>making <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{H}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>available for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>reabsorption.</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub><mo>+</mo><mo>⇆</mo><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup><mo>+</mo><msubsup><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn><mo lspace="0em" rspace="0em">−</mo></msubsup></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2} \mathrm{CO}_{3}+\leftrightarrows \mathrm{H}^{+}+\mathrm{HCO}_{3}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8641em; vertical-align: -0.1808em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel amsrm">⇆</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.9047em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8213em;"><span style="top: -3.113em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1.0916em; vertical-align: -0.247em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -2.453em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.247em;"><span></span></span></span></span></span></span></span></span></span></span></div>
<p>Acetazolamide inhibits the enzyme carbonic anhydrase. Thus, carbonic acid is not formed, resulting in unavailability of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{H}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>for luminal <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>exchange (Fig. 39.2).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacological-actions">Pharmacological actions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-actions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Kidney and electrolytes: The enzyme carbonic anhydrase plays an important role in the tubular reabsorption of sodium and bicarbonate (Fig. 39.2). Normally, the secreted H ion combines with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{HCO}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ion provided by the glomerular filtrate to form <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2} \mathrm{CO}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. This is converted to water and carbon dioxide. Carbon dioxide diffuses into the tubular cell.</li>
</ul>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mtable rowspacing="0.25em" columnalign="center" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup><mo>+</mo><msubsup><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn><mo lspace="0em" rspace="0em">−</mo></msubsup><mo>→</mo><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub><mo>+</mo><mo>→</mo><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub><mi mathvariant="normal">O</mi><mo>+</mo><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{gathered}
\mathrm{H}^{+}+\mathrm{HCO}_{3}^{-} \rightarrow \mathrm{H}_{2} \mathrm{CO}_{3} \\
\mathrm{H}_{2} \mathrm{CO}_{3}+\rightarrow \mathrm{H}_{2} \mathrm{O}+\mathrm{CO}_{2}
\end{gathered}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3.0046em; vertical-align: -1.2523em;"></span><span class="mord"><span class="mtable"><span class="col-align-c"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.7523em;"><span style="top: -3.9077em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8213em;"><span style="top: -3.113em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -2.453em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.247em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">→</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span><span style="top: -2.4077em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">→</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord mathrm">O</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.2523em;"><span></span></span></span></span></span></span></span></span></span></span></span></div>
<p>Acetazolamide inhibits both membrane bound and cytoplasmic carbonic anhydrase so that (a) carbonic acid <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{H}_{2} \mathrm{CO}_{3}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> is not formed; and (b) hydrogen ion is not made available for sodium exchange, leading to excretion of luminal sodium along with water.
It must be noted that major portion of the sodium in the distal tubule is reabsorbed by an active process and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup><mo separator="true">,</mo><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup><mi mathvariant="normal">/</mi><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}, \mathrm{H}^{+} / \mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0946em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mord">/</span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>exchange mechanisms control only a small amount of sodium that accompanies a less diffusible anion, bicarbonate. Following acetazolamide, due to lack of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{H}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ion, bicarbonate will remain in the poorly diffusible form and hence excreted in large amounts. The urine becomes alkaline. Since exchange of potassium and hydrogen ions with sodium occurs along the same pathway, the decrease in available hydrogen ion may promote more loss of potassium. Acetazolamide, therefore, causes loss of sodium,</p>
<p>potassium, bicarbonate and phosphate ions. The resulting decrease in the ECF base may cause metabolic acidosis which is accompanied by the loss of diuretic activity. Acetazolamide is thus a self-limiting diuretic. Its action is markedly decreased by acidifying salts while it is enhanced in the presence of metabolic alkalosis.</p>
<ul>
<li>Eye: Carbonic anhydrase present in the ciliary processes is important in the production of aqueous humor, which has a high bicarbonate content. Acetazolamide reduces the intraocular pressure by inhibiting this enzyme.</li>
<li>CNS: Acetazolamide decreases the CSF formation. For its antiepileptic action, see Chapter 9 .</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="absorption-fate-and-excretion">Absorption, fate and excretion:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#absorption-fate-and-excretion" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Acetazolamide, given orally, is well absorbed. It is not metabolised but is actively secreted into the urine by the proximal tubular cells through the organic acid pathway.</p>
<p>Adverse reactions: It can cause excessive potassium loss (hypokalemia) and metabolic acidosis. Occasionally, it may cause drowsiness and paraesthesiae. It can lead to renal calcium and phosphorus calculi formation. Being structurally related to sulfonamides, rarely, it causes skin rashes, blood dyscrasias, and kidney damage. Salicylates enhance its toxicity by inhibiting its plasma protein binding and by interfering with its renal tubular secretion.</p>
<p>Preparation and dosage: Acetazolamide 0.25 g tablet; dose: 1-2 tablets daily in divided doses. Sodium acetazolamide can be given parenterally.</p>
<p>Therapeutic uses: It is no more used as a diuretic. Its use is restricted to:</p>
<ul>
<li>Prophylaxis and treatment of high altitude illness: This term is used to describe the cerebral and pulmonary syndromes that can develop in unacclimatised persons after ascent to high altitude. The cerebral syndrome comprises acute mountain sickness and cerebral edema; the pulmonary syndrome is due to high altitude non cardiogenic pulmonary edema. These conditions are caused by rapid ascent to heights of 8000 feet or more. At these heights, the low partial pressure of atmospheric oxygen causes marked hypoxemia, resulting in tissue hypoxia. Resulting neurohumoral and hemodynamic responses lead to hyperperfusion of microvascular beds, capillary leakage and consequent local edema.</li>
</ul>
<p>Early symptoms of the cerebral syndrome are headache, and impairment of memory, judgement and ability to perform complex calculations. More advanced manifestations are anorexia, malaise and insomnia.
The early symptoms of the pulmonary syndrome are decreased performance and dry cough. Later manifestations are respiratory distress, resting tachycardia, tachypnoea, fever, and pink or frankly bloody sputum. The most serious symptoms are due to cerebral edema, noncardiogenic pulmonary edema with pulmonary arterial hypertension and retinal hemorrhages. Coma and death can occur.
The principles of prevention and treatment of these conditions are:
(a) For acute mountain sickness and cerebral edema:
(i) Gradual ascent to high altitude to promote acclimatisation.
(ii) Avoidance of over exertion.
(iii) Descent to lower altitude at the first appearance of symptoms. Descent may be simulated by stay in a portable hyperbaric oxygen chamber (Chapter 77).
(iv) Supplementary oxygen.
(v) Drugs: Prophylactic acetazolamide is the drug of choice. It is given in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>125</mn><mo>−</mo><mn>250</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mn>12</mn></mrow><annotation encoding="application/x-tex">125-250 \mathrm{mg} 12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">125</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">250</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">12</span></span></span></span></span> hourly, the day before, during and for 5 days after the ascent. Lower doses may not be effective. Acetazolamide probably helps by causing mild metabolic acidosis, which increases the respiratory drive, prevents</p>
<p>hypoxemia and produces a pharmacological response resembling an acclimatisation response. Acetazolamide ameliorates symptoms but does not reduce the risk of cerebral edema, pulmonary edema or retinal hemorrhages. Hence, acetazolamide is no substitute for slow ascent.
Dexamethasone, in the dose of 4 mg every 8-12 hours, begun on the day of the ascent, continued for 3 days at high altitude, and then tapered quickly, may be useful in reducing the incidence and early symptoms of acute mountain sickness. Acetazolamide and dexamethasone are useful for both prevention and treatment.
Adjunct drugs used are NSAID and antiemetics, when necessary.
(b) For pulmonary syndrome: The non-pharmacological measures are the same as those for the cerebral manifestations. Nifedipine is the preferred drug for prevention and treatment of pulmonary manifestations of high altitude illness. It probably acts by lowering pulmonary arterial pressure, which is critical in the development of pulmonary edema. The other drugs recommended are beta adrenergic agonists which clear the fluid from the alveolar space and may lower pulmonary arterial pressure. Dexamethasone is indicated if cerebral symptoms develop. Prophylactic nifedipine should be considered before a future ascent in a person with a history of high altitude pulmonary edema.</p>
<ul>
<li>Treatment of glaucoma (Chapter 72)</li>
<li>Treatment of resistant epilepsy (Chapter 9).</li>
<li>Prevention of attacks of periodic paralysis.</li>
</ul>
<p>DICHLORPHENAMIDE and METHAZOLAMIDE are the other carbonic anhydrase inhibitors, related to acetazolamide, used orally in the treatment of glaucoma (Chapter 72).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="benzothiadiazines-thiazides">Benzothiadiazines (Thiazides)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#benzothiadiazines-thiazides" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Introduction of thiazide diuretics (Fig. 39.4) revolutionised the oral diuretic therapy. Synthesis of thiazides stems from the original observation by Southworth (1937) that sulfanilamide, an antibacterial drug, possesses a mild diuretic activity. This was later shown to be related to its carbonic anhydrase inhibiting action. Interestingly, chlorothiazide, synthesised as one of the carbonic anhydrase inhibitor, revealed marked diuretic activity in doses that did not significantly inhibit the carbonic anhydrase. Since then, several thiazide-like diuretics have been introduced.
<img src="assets/images/image-20251214-9094ff8b.jpeg" alt="img-44.jpeg"></p>
<p>Mechanism of Action: Like acetazolamide, these drugs are secreted into the tubular fluid and block the electroneutral <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{Cl}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8557em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span>symport in the distal convoluted tubule by competing with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Cl}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8557em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span>for the binding sites. Thiazides primarily act on the site proximal to the sodium and potassium exchange region in the distal tubule (site III, Fig. 39.1). Hence, they are sometimes known as early distal diuretics. The GFR is not affected.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacological-action">Pharmacological action:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="a-diuretic-action">(a) Diuretic action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-diuretic-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Thiazides increase <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Cl}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8557em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span>excretion but as almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> of the filtered load of sodium is reabsorbed before reaching the distal tubules, they exert only a moderate diuretic effect.</li>
<li>Chlorothiazide has a weak carbonic anhydrase inhibitory activity and it causes some loss of bicarbonate. The newer thiazides, however, do not significantly increase the bicarbonate loss.</li>
<li>Because of the marked inhibitory action on sodium reabsorption, a large amount of sodium is made available to the distal segment where exchange of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>takes place. This may cause increased potassium loss.</li>
<li>Excessive renal loss of sodium and chloride may cause hyponatremia and hypochloremia; excessive potassium loss can cause hypokalemia, thus leading to hypokalemic hypochloremic alkalosis. Long term use causes hypomagnesemia.</li>
<li>Initially, the drug causes a diminution in sodium reabsorption in the distal tubule and a gradual reduction in the ECF volume. When the ECF volume falls to slightly below normal, the reabsorption of sodium from the proximal tubule is stimulated, resulting in diminished amount of sodium delivered into the distal tubule. This decreases its diuretic activity and causes resistance. Thiazides are less effective when GFR falls below <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">30-40 \mathrm{ml} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>.
(b) Antihypertensive action: Thiazides produce a mild antihypertensive effect partly due to their action on sodium metabolism and partly due to their direct action on blood vessels</li>
</ul>
<p>(Chapter 30).
(c) Metabolic actions: Thiazide may cause:</p>
<ul>
<li>Hyperglycemia</li>
<li>Hyperuricemia</li>
<li>Hypercalcemia</li>
<li>Hyperlipidemia</li>
</ul>
<p>The mechanism by which thiazides cause hyperglycemia is not known. These drugs can unmask or aggravate the pre existing diabetes mellitus. Diazoxide, a thiazide derivative with potent hyperglycemic action, has been used in the treatment of hypoglycemia.</p>
<p>However, during long-term therapy of hypertension, thiazides do not significantly increase the incidence of diabetes mellitus.</p>
<p>Thiazides also decrease the reabsorption of uric acid from proximal tubule, thus raising plasma uric acid level. In addition, they compete with uric acid for urate transporter causing uric acid retention. Usually, this is asymptomatic but, occasionally, it can precipitate gout.</p>
<p>Unlike loop diuretics (see later), thiazides reduces urinary calcium loss by acting on distal convoluted tubules and promote calcium retention; they are useful in treating idiopathic hypercalciuria.</p>
<p>Serum cholesterol and triglycerides may increase slightly; however, this has hardly any significance as the elevation is not persistent beyond 6-12 months of treatment.
(d) In patients with nephrogenic type diabetes insipidus, thiazides decrease urinary volume (See later).</p>
<p>Absorption, fate and excretion: Thiazides are well absorbed from the intestine and the effect starts within one hour. They are distributed throughout the ECF and are relatively concentrated in the kidney. They can cross the placental barrier. Like other organic acids, thiazides are secreted into the tubules and excreted in urine. The slowly excreted compounds like polythiazide and bendro -flumethiazide have prolonged action.</p>
<p>The long acting thiazides are long acting because of greater plasma protein binding and greater lipid solubility. Bendroflumethiazide, polythiazide and indapamide are primarily metabolised in the liver; whereas chlorothiazide, hydrochlorothiazide, hydroflumethiazide and chlorthalidone are excreted in the urine. Plasma half life of thiazides is sufficient to permit their use once or twice daily.</p>
<p>Adverse reactions: Apart from electrolyte disturbances such as hypokalemic and hypochloremic alkalosis, these drugs have few serious toxic effects. Hypokalemia increases the risk of fatal toxicity of certain arrhythmias (Chapter 28) and drugs like digoxin (Chapter 31). They may cause dilutional hyponatremia. Because of structural similarity to sulfonamide, allergic reactions such as dermatitis and thrombocytopenia may occur.</p>
<p>In the presence of renal and hepatic insufficiency, these drugs may precipitate renal failure or hepatic coma.</p>
<p>Preparations and dosage: Table 39.3.</p>
<p>Table 39.3
Commonly used benzothiadiazine and related diuretics</p>
<table><thead><tr><th style="text-align: left;">Name</th><th style="text-align: center;">Tablet mg Daily dose as antihypertensive mg</th><th style="text-align: center;"></th><th style="text-align: center;">Daily dose as diuretic mg</th><th style="text-align: center;">Duration of diuretic action hours</th></tr></thead><tbody><tr><td style="text-align: left;">Chlorothiazide</td><td style="text-align: center;">250,500</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>125</mn><mo>−</mo><mn>250</mn></mrow><annotation encoding="application/x-tex">125-250</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">125</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">250</span></span></span></span></span></td><td style="text-align: center;">500 to 1000 Children: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span></td><td style="text-align: center;">6 to 12</td></tr><tr><td style="text-align: left;">Hydrochlorothiazide</td><td style="text-align: center;">25,50</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12.5</mn><mo>−</mo><mn>25</mn></mrow><annotation encoding="application/x-tex">12.5-25</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">12.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">25</span></span></span></span></span></td><td style="text-align: center;">25 to 200 Children: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span></td><td style="text-align: center;">12 or more</td></tr><tr><td style="text-align: left;">Hydroflumethiazide</td><td style="text-align: center;">50</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12.5</mn><mo>−</mo><mn>25</mn></mrow><annotation encoding="application/x-tex">12.5-25</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">12.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">25</span></span></span></span></span></td><td style="text-align: center;">25 to 200</td><td style="text-align: center;">18 to 24</td></tr><tr><td style="text-align: left;">Benzthiazide</td><td style="text-align: center;">25</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12.5</mn><mo>−</mo><mn>25</mn></mrow><annotation encoding="application/x-tex">12.5-25</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">12.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">25</span></span></span></span></span></td><td style="text-align: center;">50 to 200</td><td style="text-align: center;">12 to 18</td></tr><tr><td style="text-align: left;">Cyclopenthiazide</td><td style="text-align: center;">0.5</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.25</mn><mo>−</mo><mn>0.5</mn></mrow><annotation encoding="application/x-tex">0.25-0.5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">0.5</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1</mn></mrow><annotation encoding="application/x-tex">0.5-1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span></span></span></span></span></td><td style="text-align: center;">18 to 24</td></tr><tr><td style="text-align: left;">Bendroflumethiazide</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo separator="true">,</mo><mn>5</mn></mrow><annotation encoding="application/x-tex">2.5,5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">2.5</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">5</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.25</mn><mo>−</mo><mn>2.5</mn></mrow><annotation encoding="application/x-tex">1.25-2.5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1.25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2.5</span></span></span></span></span></td><td style="text-align: center;">2.5 to 5</td><td style="text-align: center;">18 to 24</td></tr><tr><td style="text-align: left;">Polythiazide</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo separator="true">,</mo><mn>2</mn><mo separator="true">,</mo><mn>4</mn></mrow><annotation encoding="application/x-tex">1,2,4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">2</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">4</span></span></span></span></span></td><td style="text-align: center;">2</td><td style="text-align: center;">1 to 4</td><td style="text-align: center;">24 to 48</td></tr><tr><td style="text-align: left;">Chlorthalidone</td><td style="text-align: center;">100</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12.5</mn><mo>−</mo><mn>25</mn></mrow><annotation encoding="application/x-tex">12.5-25</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">12.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">25</span></span></span></span></span></td><td style="text-align: center;">50 to 200</td><td style="text-align: center;">48 to 72</td></tr><tr><td style="text-align: left;">Quinethazone</td><td style="text-align: center;">50</td><td style="text-align: center;">25</td><td style="text-align: center;">50 to 200</td><td style="text-align: center;">18 to 24</td></tr><tr><td style="text-align: left;">Metolazone</td><td style="text-align: center;">5</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.25</mn><mo>−</mo><mn>2.5</mn></mrow><annotation encoding="application/x-tex">1.25-2.5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1.25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2.5</span></span></span></span></span></td><td style="text-align: center;">5 to 10</td><td style="text-align: center;">18 to 24</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>As diuretics: Thiazides produce effective diuresis in most of the patients with sodium retention and edema. There is no special advantage in using any particular preparation; hydrochlorthiazide is usually preffered. Dosage has to be adjusted in individual cases depending upon the response. Occasionally, patients may develop resistance to these drugs. In majority of such cases, hypokalemia may be present which needs correction. Excessive potassium loss can be prevented by combining thiazide drugs with spironolactone or triameterene (see later).
As the maximum diuretic effect of all thiazides is similar, a patient resistant to the maximum dose of one thiazide is unlikely to respond to another.</li>
<li>As antihypertensives: See Chapter 30.</li>
<li>In the prevention of recurrent renal calculi: In patients with idiopathichypercalciuria, hydrochlorthiazide ( 50 mg twice a day) reduces the frequency of stone formation.</li>
<li>In nephrogenic diabetes insipidus: See later.</li>
</ul>
<p>Thiazide-like diuretics: These drugs, structurally similar to thiazides, have similar mechanism but longer duration of action. As diuretics, they offer limited advantage over thiazides.</p>
<p>CHLORTHALIDONE: This phthalimidine derivative is absorbed slowly, and is not significantly metabolised. Itremains preferentially bound to renal tissue for prolonged periods. Hence, its duration of action is longer, upto 48 hours. It may be preferred in the treatment of hypertension and can be given on alternate days. It is more liable to cause hypokalemia than the thiazides. It has been reported to be useful in the treatment of hypoparathyroidism where it corrects hypocalcemia without the danger of causing hypercalcemia which is inherent in vitamin D therapy of this condition.</p>
<p>Chlorexolone: This long action phthalimidine derivative is claimed to be more effective than chlorothiazide on weight basis.</p>
<p>Indapamide and xipamide are used in the treatment of hypertension (Chapter 30).
Clopamide is administered in a single daily dose of 20 to 60 mg in the morning, on alternate days. It has longer duration of action (18-24 hr).</p>
<p>QUINAZOLINONES: Quinethazone and Metolazone belong to this group. These</p>
<p>compounds have diuretic characteristics similar to those of thiazides.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="loop-diuretics">Loop Diuretics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#loop-diuretics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>FUROSEMIDE (Frusemide): It is a potent, oral, diuretic, possessing a halogenated sulfamoyl benzene ring common to thiazide diuretics (Fig. 39.5).
<img src="assets/images/image-20251214-00f6b426.jpeg" alt="img-45.jpeg"></p>
<p>Note the sulfamoyl benzene ring.
Mechanism of action: Like thiazides, the loop diuretics are secreted into the tubular fluid via the organic acid pathway. The drug acts along the entire nephron (sites II and III in Fig. 39.1), primarily on the thick ascending limb of the loop of Henle with the exception only of the distal site where <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>is exchanged for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{H}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>. It blocks the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><mn>2</mn><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{K}^{+}-2 \mathrm{Cl}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8547em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8557em;"></span><span class="mord">2</span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span> symport. Hence, it is more efficacious and unlike thiazides, urinary excretion of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>may continue uninterruptedly even when the patient's ECF volume has been severely depleted. It also inhibits the reabsorption of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">M</mi><mi mathvariant="normal">g</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Mg}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.039em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Mg</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>.</p>
<p>Given IV bolus, it is a venodilator and increases the renal blood flow. Further, it increases <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> synthesis in the kidneys, which has a locally protective, vasodilator effect.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacological-actions">Pharmacological actions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-actions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(a) Kidneys:</p>
<ul>
<li>Intense diuretic action starts within an hour of oral administration and is completed in 46 hours. It has a steep dose-response curve without a ceiling effect. Because of its short duration of action, furosemide is administered twice a day when sustained diuresis is desired.</li>
<li>It causes marked sodium, potassium, chloride and phosphate loss. The bicarbonate loss is not marked.</li>
<li>Excessive chloride loss can cause hypochloremic alkalosis. The associated potassium loss leads to hypokalemia. However, the free water clearance is larger and the hypokalemia less marked with furosemide than with thiazides.</li>
<li>Furosemide causes little change in the urinary pH and its diuretic action does not appear to be particularly limited by the prevailing state of electrolyte or acid-base balance.</li>
<li>Loop diuretics, in general, are potent renin releasers.</li>
<li>GFR is not affected.
(b) Blood vessels and blood pressure: Intravenous furosemide dilates the peripheral vasculature, lowers the arterial BP, and causes rapid venous pooling of blood, thus reducing the cardiac preload and afterload. This action of bringing about a re-distribution of blood from the congested pulmonary circulation into the systemic, capacitance vessels is more rapid than its diuretic effect and is perhaps more important than the latter in the treatment of acute LVF with pulmonary edema.</li>
</ul>
<p>Its effects on the BP on oral administration are comparable to those of thiazide diuretics.</p>
<p>(c) Metabolic actions: Like thiazides, furosemide can cause hyperglycemia, hyperuricemia and rise in blood urea. Calcium and magnesium excretion is increased.</p>
<p>Absorption, fate and excretion: The drug is rapidly absorbed (60-100%) from the GI tract. Food reduces its bioavailability. The onset of action is quick and the duration short. It is excreted within 4 hours by glomerular filtration and tubular secretion. Given IV, the diuresis begins within 2 minutes and lasts for 2-3 hours. It is best given in a single dose. Fifty per cent of the dose is excreted unchanged in urine; the rest is conjugated with glucuronide in the kidney. Hence, in patients with renal insufficiency the plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is prolonged.</p>
<p>Adverse reactions: Generally it is well tolerated. As it is a potent diuretic, it can precipitate serious hypovolemia and excessive loss of sodium, potassium and chloride. A patient may complain of weakness, fatigue, dizziness, and cramps; orthostatic hypotension can occur. Excessively rapid diuresis in elderly may precipitate acute urinary retention. Rapid diuresis with excessive <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>loss can precipitate hepatic coma in the presence of liver disease. Other less common reactions include skin rashes, nausea, diarrhoea and rarely acute pancreatitis, thrombocytopenia and neutropenia. It can unmask latent diabetes mellitus. It increases plasma triglycerides, total and LDL cholesterol.</p>
<p>Hearing loss, usually transient, with or without tinnitus, has been reported following very large doses in patients with renal failure. Furosemide can enhance the toxicity of lithium, aminoglycosides and cephalosporins. Its action is inhibited by NSAID such as indomethacin.</p>
<p>It should be avoided in pregnancy.
Preparations and dosage: Furosemide tablet 40 mg . Furosemide injection, 20 mg in 2 ml Dose: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">40-100 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>As a diuretic: Furosemide is a very effective, potent and usually safe diuretic. However, it has no distinct advantage over thiazides, in the treatment of moderate edema. It is more useful in severe edema.</li>
<li>Pulmonary edema: Given IV, it can be life saving in patients with pulmonary edema.</li>
<li>Acute renal failure: See later.</li>
<li>Chronic renal failure: The dose response curve with furosemide shows a steep rise and very large single doses ( 1000 mg ) have been used in patients with advanced renal failure. It is sometimes effective in the presence of marked decrease in GFR (as low as 2 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">\mathrm{ml} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span></span></span></span></span> minute). Since the drug continues to act even in the presence of electrolyte and acid-base disturbances, close monitoring of the therapeutic response and blood chemistry is very essential.</li>
<li>Barbiturate poisoning: It is used to induce forced diuresis (Chapter 8).</li>
<li>Hypercalcemia: Intravenous furosemide, together with normal saline infusion, is valuable in the emergency management of hypercalcemia (Chapter 70).</li>
<li>As an antihypertensive: Furosemide cannot be recommended for long term antihypertensive therapy because of high dose requirements, short duration of action and its high diuretic potential.
TORSEMIDE: This congener is as active as furosemide in similar doses. However, it is absorbed completely and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> of the drug is metabolised in the liver.</li>
</ul>
<p>BUMETANIDE: This diuretic is chemically 3-n-butylamino-4-phenoxy-sulphamoyl benzoic acid. Its diuretic action is similar to those of furosemide. One mg of bumetanide</p>
<p>equals 40 mg of furosemide in its diuretic potency. Its absorption is nearly <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> and is metabolised in the liver. Its half life is not prolonged in renal insufficiency.</p>
<p>Axosemide, tripamide, piretanide are the other diuretics belonging to the furosemide group.</p>
<p>ETHACRYNIC ACID: Ethacrynic acid, an unsaturated ketone derivative of phenoxyacetic acid, is a potent oral diuretic like furosemide. Chemically, it is unrelated to other diuretics.</p>
<p>The diuretic and metabolic effects of ethacrynic acid are similar to those of furosemide. Like furosemide, it can be used in edematous states, especially in patients allergic to sulfonamides. However, it is more prone to cause adverse effects particularly, nausea and deafness.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="potassium-sparing-diuretics">Potassium Sparing Diuretics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#potassium-sparing-diuretics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These agents inhibit <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>absorption in the later part of distal tubule, collecting ducts and concomitantly, indirectly suppress the secretion of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{H}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>, thus preventing potassium loss. They are:
(1) Aldosterone antagonist: Spironolactone
(2) Direct inhibitors of renal epithelial sodium channels: Triamterene and Amiloride.</p>
<p>Both drugs can cause hyperkalemic, hyperchloremic, metabolic acidosis. However, they do not affect renal hemodynamics.</p>
<p>SPIRONOLACTONE: Spironolactone, with structural similarity to aldosterone (Fig. 39.6), is a commonly employed aldosterone antagonist. It does not require access to lumen but enters the tubular cells from basolateral surface.
<img src="assets/images/image-20251214-ae83f670.jpeg" alt="img-46.jpeg"></p>
<p>FIG. 39.6 Spironolactone
It acts by competitive antagonism of aldosterone, in the distal part of the nephron, (late distal diuretic) and prevents potassium secretion and thus decreases sodium reabsorption. By itself, it does not produce significant natriuresis in normal individuals. Even in edema associated with an excess of aldosterone, its natriuretic action is weak.</p>
<p>Given orally, its full response is observed after 3-5 days. It has a short <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>11</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">11 / 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">11/2</span></span></span></span></span> of 1.6 hrs. Its major action is due to an active metabolite, canrenone ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mn>17</mn><mrow><mi mathvariant="normal">h</mi><mi mathvariant="normal">r</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2} 17 \mathrm{hr}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mord">17</span><span class="mord"><span class="mord mathrm">hr</span></span></span></span></span></span> ). When combined with thiazide or loop diuretics it prevents loss ofpotassium. It is metabolised to several inactive compounds.</p>
<p>Adverse reactions: No serious toxic effects have been reported even after long term use.</p>
<ul>
<li>Hyperkalemia: In the presence of renal insufficiency, it can cause dangerous hyperkalemia and metabolic acidosis. Simultaneous use of ACEI or a beta blocker with it increases the risk of hyperkalemia.</li>
<li>Endocrine effects: The drug has affinity for progesterone and androgenic receptors and has been shown to block gonadal and adrenal steroidogenesis. Occasionally, it may cause decreased libido, gynecomastia, impotence and menstrual irregularity.</li>
<li>Miscellaneous effects: Spironolactone may cause lethargy and drowsiness. It may increase blood urea nitrogen and serum uric acid levels. It can cause gastritis and is avoided in patients with acid-peptic disease. NSAIDS may inhibit the excretion of this drug.
Preparation and dosage: Spironolactone is supplied as a microcrystalline preparation, 25</li>
</ul>
<p>mg tablet. Dose : 100-200 mg per day (maximum 400 mg ) in divided doses.
Therapeutic uses: It is used:</p>
<ul>
<li>In the treatment of edema particularly cirrhotic edema. (See later)</li>
<li>In severe congestive heart failure (Chapter 31).</li>
<li>In the treatment of hypertension, as an adjunct to thiazide diuretics (Chapter 30).</li>
<li>In patients with hirsutism due to polycystic ovarian disease (Chapter 69); and</li>
<li>In the treatment of primary hyperaldosteronism (Conn syndrome): It corrects the electrolyte abnormalities and lowers the BP.
POTASSIUM CANREONATE: This prodrug gets converted to canrenone in the body, and has similar uses as spironolactone but it can be given parenterally. It is available as injections containing <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">20 \mathrm{mg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> in 10 ml ampoules and is given IV, slowly, upto 400 mg per day, in divided doses.</li>
</ul>
<p>EPLERENONE blocks the mineralocorticoid receptors in the kidney, heart, blood vessels and brain more selectively than spironolactone; it has lower affinity for the androgen and progesterone receptors.</p>
<p>It is metabolised by the liver and has a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">4-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> hours. Its adverse reactions include GI intolerance, dizziness, hyperkalemia and hypertriglyceridemia. Its probable advantage over spironolactone is the lower incidence of endocrine side effects.</p>
<p>It is used to treat:
(a) Hypertension, in the dose of 50 mg OD, increased to 100 mg OD (maximum dose) within 4 weeks, as required,
(b) Post MI CHF, in one half of the above dosage.
(c) It is also used in the combined oral contraceptive pill, Yasmin.</p>
<p>TRIAMTERENE: This drug (Fig. 39.7), increases the excretion of water, sodium, chloride and bicarbonate but it depresses the excretion of potassium. In this respect, it resembles the aldosterone antagonist spironolactone.
<img src="assets/images/image-20251214-73ab6cad.jpeg" alt="img-47.jpeg"></p>
<p>Mechanism of action: It acts on the late distal tubule and collecting duct. It blocks renal epithelial <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>channels competitively. Combination of triamterene and spironolactone produces more marked natriuretic effect than the maximally effective dose of triamterene given alone. It also spares magnesium loss. Triamterene has no antihypertensive action.</p>
<p>It is administered orally in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">100-200 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">200</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>. After administration, it is secreted by proximal tubules. Its peak effect is reached in about 2 hours and the action is over in about 10 hours. It has an active metabolite.</p>
<p>Adverse reactions: No serious toxic effects have been noted. Besides causing hyperkalemia, the drug may cause troublesome diarrhoea. Occasionally, skin rash and dryness of mouth have been noted. It may cause a decrease in glucose tolerance and a rise</p>
<p>in blood urea level. Chronic administration decreases the uric acid excretion and may cause renal calculi.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Potassium sparing diuretic: Triamterene itself is a weak diuretic. However, It is usually combined with a thiazide or loop diuretic to prevent the potassium loss.</li>
<li>Pseudo-aldosteronism: The drug has also been used in 'pseudo-aldosteronism', a familial renal disorder characterised by hypertension, and hypokalemia but without increased aldosterone secretion. In such patients, spironolactone is not of much use as the aldosterone secretion is subnormal.
AMILORIDE HYDROCHLORIDE: This compound, a guanidine derivative, has a weak diuretic activity, and is given orally. Its action is similar to that of triamterene. It prevents potassium loss. It has <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of 6 hours and is excreted unchanged in the urine. It is reported to cause photosensitivity. It is used:</li>
<li>As a diuretic, in the dose of 10-20 mg daily, in combination with other diuretics. On weight basis, it is more potent than triamterene.</li>
<li>In lithium-induced diabetes insipidus as it blocks lithium reabsorption from the collecting tubules.</li>
<li>In cystic fibrosis: An aerosolised preparation facilitates mucociliary clearance by blocking bronchial epithelial sodium channels. Reduced reabsorption of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>increases the hydration of bronchial secretions.
Electrolyte excretion pattern following various diuretics is given in Table 39.4.</li>
</ul>
<p>Table 39.4
Electrolyte excretion pattern following diuretics</p>
<table><thead><tr><th style="text-align: center;">Drug</th><th style="text-align: center;">Urinary electrolytes</th><th style="text-align: center;"></th><th style="text-align: center;"></th><th style="text-align: center;"></th><th style="text-align: center;">Urine pH</th></tr></thead><tbody><tr><td style="text-align: center;"></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Cl}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8557em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub><msup><mrow></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{HCO}_{3}{ }^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9213em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Acetazolamide</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">-</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">8.2</td></tr><tr><td style="text-align: center;">Thiazides</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span></td><td style="text-align: center;">7.4</td></tr><tr><td style="text-align: center;">Furosemide</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span></td><td style="text-align: center;">6.0</td></tr><tr><td style="text-align: center;">Spironolactone</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">-</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span></td><td style="text-align: center;">7.2</td></tr><tr><td style="text-align: center;">Triamterene</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">-</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">7.2</td></tr><tr><td style="text-align: center;">Mannitol</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">6.5</td></tr></tbody></table>
<ul>
<li>denotes no change.
*denotes potassium retention.
Indications for diuretic therapy are given in Table 39.5. The non-diuretic uses of diuretic drugs are given in Table 39.6. These are discussed in the respective chapters.</li>
</ul>
<p>Table 39.5
Indications for diuretic therapy</p>
<ul>
<li>Edema associated with sodium retention such as cardiac, hepatic and renal edema.</li>
<li>Pulmonary and cerebral edema.</li>
<li>Drug poisoning such as due to barbiturates or salicylates.</li>
<li>Acute oliguric renal failure.</li>
<li>Edema of pregnancy and idiopathic edema.</li>
</ul>
<p>Table 39.6
Nondiuretic uses of diuretic drugs</p>
<ul>
<li>Hypertension (hydrochlorothiazide).</li>
<li>Idiopathic calcium urolithiasis (hydrochlorothiazide).</li>
<li>Diabetes insipidus (hydrochlorothiazide, amiloride).</li>
<li>Hypercalcemia (furosemide).</li>
<li>Hyponatremic states due to water retention (furosemide).</li>
<li>Glaucoma (acetazolamide, mannitol).</li>
<li>Mountain sickness (acetazolamide).</li>
<li>Cystic fibrosis (amiloride).</li>
<li>Acute LVF (furosemide).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="management-of-edema">Management of Edema<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#management-of-edema" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Increase in extracellular sodium and fluid volume leads to the development of "pitting" edema. This could occur due to either an excessive intake or decreased renal excretion of sodium and/or water. The edematous states observed in practice are mostly due to decreased rate of renal excretion of sodium and water.</p>
<p>Factors involved in promoting excessive sodium retention are:
(a) Decreased cardiac output and GFR as in CHF.
(b) Increased levels of aldosterone as in edema due to hepatic cirrhosis.
(c) Intrinsic renal disease such as acute nephritis; and</p>
<p>Edema can also occur due to reduction in plasma colloids as in hypoproteinemic states (nutritional edema and nephrotic syndrome).</p>
<p>Although the treatment of underlying pathology is important in all such cases, great relief can be obtained by using proper diuretics.</p>
<p>Edema due to sodium retention can be treated by:</p>
<ul>
<li>Restricting sodium intake</li>
<li>Ensuring adequate renal perfusion, by improving cardiac efficiency, as in cardiac edema.</li>
<li>Promoting sodium and water excretion by using diuretics and aldosterone antagonists.</li>
</ul>
<p>Usually, these approaches are combined. Some pitting edemas like postural and drug induced edema need no treatment with drugs.</p>
<p>CATION EXCHANGE RESINS: Cation exchange resins are insoluble macromolecular compounds with fixed negative charges which loosely hold cations such as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>. Administered orally, depending on affinity and concentration, these ions exchange with cations in the intestinal fluid. Thus, the sodium or calcium containing resins exchange their cations with potassium cation in the fluids to form an insoluble complex which is excreted in the faeces. The released <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>is absorbed. Such resins are used to promote loss of potassium in the treatment of hyperkalemia. Cation exchange resin to promote sodium loss is no more used.</p>
<p>In practice, the dose of such resin is bulky and unpalatable. The resin often causes nausea, vomiting and diarrhoea. Calcium containing resin can cause hypercalcemia.</p>
<p>The cation exchange resin available is:
(i) Sodium polystyrene sulfonate, used for removal of potassium, dose 15 to 60 g daily.</p>
<p>Cardiac edema: This is due to the failure of the heart as a pump, leading to a fall in the cardiac output and an inadequate renal perfusion. Hence, unless the cardiac function is improved and adequate renal perfusion is restored, diuretics cannot cause worthwhile diuresis (Chapter 31). Adequate GFR is ensured by:</p>
<ul>
<li>Complete rest</li>
<li>Improving the cardiac output; and by</li>
<li>Treating the underlying cause such as anemia, hypertension, or hyperthyroidism.</li>
</ul>
<p>Restriction of sodium intake and induction of diuresis are usually combined with the primary therapy of the cause.</p>
<p>In mild CHF, one should aim at diuresis which causes a weight reduction of less than 1 kg per day, and a thiazide is preferred to a loop diuretic for this purpose. The latter causes abrupt diuresis with contraction of plasma volume. This results in secondary hyperaldosteronism. For the same reason, intermittent use of a diuretic (2-3 times a week)</p>
<p>is preferred to daily administration. When planning continuous diuretic therapy, ACEI <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span> spironolactone is combined with the primary diuretic right from the beginning with advantage, instead of waiting for development of diuretic resistance due to hyperaldosteronism. Diuretics, however, are not the first choice in such cases (Chapter 31).</p>
<p>As the disease progresses, the use of furosemide is inevitable. With single-daily-dose of furosemide, intense sodium retention post-diuresis can limit the efficacy of the drug. This can be overcome by increasing the daily dose of furosemide and administering it in 2-3 divided doses per day. Patients with severe CHF may need larger oral/parenteral dose of furosemide.</p>
<p>The routine use of diuretics in all cases of cardiac failure from the beginning is not recommended (Chapter 31).</p>
<p>Cirrhotic edema and ascites: This is due to:</p>
<ul>
<li>Increased portal venous pressure.</li>
<li>Decreased plasma colloid osmotic pressure following hypoalbuminemia; and</li>
<li>Secondary rise in aldosterone secretion.</li>
</ul>
<p>The treatment, therefore, would be bed rest, salt restriction, use of spironolactone and, use of diuretics only in severe cases.</p>
<p>Compared to cardiac edema, the danger of precipitating hypokalemia and azotemia (volume contraction) with diuretic therapy is higher in cirrhotic edema; the chances of precipitating hepatic encephalopathy are also high. Hence, the diuretic therapy in a cirrhotic edema should be undertaken under supervision with checks on serum electrolytes. The dose used should be the smallest possible one and oral potassium supplements should be given. The regime recommended is as follows:
(1) Begin with bed rest, restriction of sodium intake (to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">20 \mathrm{mEq} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/</span></span></span></span></span> day) and provided the blood urea is normal, oral potassium supplements in large doses ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">100 \mathrm{mEq} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/</span></span></span></span></span> day).
(2) After 4-5 days, spironolactone is added. Unlike in edema from other causes, potassium supplement is continued in cirrhotic patients.
(3) If adequate diuresis does not occur in 5 days, furosemide in doses <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>80</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">40-80 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">80</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day is added.</p>
<p>Seriously ill cirrhotic patients with ascites should not be treated too vigorously, as this may precipitate hepatic coma, azotemia and death.</p>
<p>Renal edema: Diuretics are ineffective in treating edema due to acute glomerulonephritis.</p>
<p>The treatment of nephrotic syndrome depends on the underlying cause; in patients with diabetic nephrotic syndrome, furosemide is the diuretic of choice. In the 'idiopathic' nephrotic syndrome due to 'minimal change disease' in children, the treatment comprises (1) salt restriction; (2) dietary protein supplementation, unless concurrent renal insufficiency is present; (3) prednisolone (a glucocorticoid) in adequate doses (2 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day); and (4) judicious use of diuretics; furosemide is the drug of choice. The response in children is very satisfactory, and remission without any permanent renal damage occurs in a high proportion of patients. The same disease in adults is less responsive to treatment. It must be remembered that the concurrent use of large doses of furosemide and a glucocorticoid in a nephrotic child who has secondary hyperaldosteronism may cause severe hypokalemia. In such circumstances spironolactone is added.</p>
<p>Edema in patients with chronic renal failure may be due to salt loading or to CHF. In</p>
<p>either case, the thiazide diuretics are ineffective in the presence of elevated serum creatinine. Furosemide is effective but increasingly large doses, sometimes given IV as a bolus ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">100-200 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">200</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> ) are required. Concurrent salt restriction is necessary.</p>
<p>Pulmonary edema: It is a medical emergency and needs immediate treatment. The treatment depends upon etiology (Chapter 31). Attention is paid to circulation, gas exchange and lung mechanics. Infection, acidaemia, anaemia and renal failure, when present, must be treated.</p>
<p>Cerebral edema: See Table 39.7.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-39-7">Table 39.7<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-39-7" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="treatment-of-cerebral-edema">Treatment of cerebral edema<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment-of-cerebral-edema" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Mannitol 25-50 g IV every 3-5 hours to a maximum of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">2 \mathrm{~g} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day.</li>
<li>Furosemide IV in doses of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>80</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20-80 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">80</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> every <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">4-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span> hours to supplement the effect of mannitol.</li>
<li>Replacement of fluids to maintain serum osmolality.</li>
<li>Glucocorticoids (dexamethasone 8 mg by injection every 6-8 hours) in intracranial neoplasms. Also see Chapter 65.</li>
<li>Mechanical hyperventilation to achieve a CO, partial pressure of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>30</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25-30 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">30</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span>.</li>
<li>Oral glycerine 30 ml tid</li>
<li>Magnesiumsulfate, saturated solution, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">50-200 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">200</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> sectally.</li>
<li>Surgical decompression if all above measures fail.</li>
</ul>
<p>Nutritional edema: This is due to hypoalbuminemia and it responds to increased protein intake. Diuretics are usually not indicated. In severe cases, weak diuretics may be used to obtain temporary relief from the edema; vigorous diuretic therapy is, however, dangerous and should be avoided.</p>
<p>Table 39.8 lists the drugs that can cause fluid retention and edema. In majority of the cases, it is mild, dose related and reversible without requiring any drug therapy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-39-8">Table 39.8<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-39-8" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="drugs-causing-fluid-retention">Drugs causing fluid retention<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-causing-fluid-retention" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>NSAIDs
Fludrocortisone
Cortisone and hydrocortisone
Calcium channel blockers and vasodilators
Testosterone and estrogen
Danazol
Glitazones</p>
<p>Choice of a diuretic: The choice of a diuretic in the treatment of edema would depend on:</p>
<ul>
<li>Nature of the disease.</li>
<li>Potency of the drug.</li>
<li>Electrolyte changes associated with its use.</li>
<li>Possibility of development of tolerance.</li>
<li>Convenience of administration.</li>
</ul>
<p>Majority of the patients with edema respond satisfactorily to relatively small doses of any moderately effective diuretic, and thiazides, being orally effective, safe and cheap, are to be preferred for routine use. Only when quick and vigorous response is needed, loop diuretic like furosemide is employed. The thiazide diuretics are ineffective once the GFR</p>
<p>has fallen below <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">30 \mathrm{ml} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>. Loop diuretics remain effective until the GFR falls below 3 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{ml} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>, but they often have to be used in very large doses. Vigorous treatment with potent diuretics, coupled with strict restriction of sodium intake to clear the edema, may lead to rapid development of serious electrolyte disturbances, volume depletion and even death.</p>
<p>Combination of diuretics: There is no advantage in routinely combining diuretics. In majority of cases, a single drug given in adequate doses is all that is necessary. However, sequential nephron blocking is an important principle in diuretic therapy, and the addition of diuretic drugs acting at different sites in the nephron in resistant cases is logical. Thus, (a) A potassium sparing diuretic is commonly added to a thiazide or to furosemide, to prevent hypokalemia.
(b) When fluid retention is refractory to furosemide, the addition of a thiazide may promote diuresis (see below).
(c) The concurrent use of furosemide and mannitol, both given by separate IV infusions, is effective in minimising the dose of furosemide in patients with acute oliguric renal failure.</p>
<p>Diuretic tolerance/resistance: This can occur in two ways:
(a) A short term form may occur from second dose onwards (early braking). The decrease in the response can be prevented by restoring the diuretic -induced loss of volume. Its mechanism is not clear.
(b) Sometimes, long term administration of loop diuretics is followed by tolerance (resistance). In that case, the solute that escapes the loop of Henle floods the more distal segments of the nephron. The increased exposure to the solute causes hypertrophy of the distal nephron segments. This leads to reabsorption of sodium at more distal sites, decreasing the overall diuretic effect. Thiazides block the nephron sites at which hypertrophy occurs; this explains the synergistic effect of the combination of a thiazide and a loop diuretic.</p>
<p>In practice, when diuretic resistance occurs it can be due to:</p>
<ul>
<li>Drug related factors such as the choice of the diuretic; its dose; or interfering drugs such as NSAID, lithium or probenecid.</li>
<li>Patient related factors such as non-compliance with instructions about bed rest or salt and fluid intake.</li>
<li>Disease related factors such as markedly low GFR; severe hypokalemia, hyponatremia, hypovolemia, or hypomagnesemia; or severe CHF.
Correction of the underlying factors often restores the response.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="complications-of-diuretic-therapy">Complications of Diuretic Therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#complications-of-diuretic-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Diuretic therapy, no doubt, is very effective and many times life saving. However, it can produce various complications. These are:
(1) Allergic reactions: These include various types of skin eruptions, uriticaria, occasional blood dyscrasias and rarely interstitial nephritis. Such reactions are usually confined to a single drug or class of drugs. In such circumstances, a drug from another group may be substituted.
(2) Disturbances of electrolyte balance: These occur more commonly and are usually predictable. These include:</p>
<ul>
<li>Acute sodium depletion and hypovolemia: This is a relatively common complication especially following the loop diuretics particularly, in patients on sodium restriction and in those with undetected renal disease. The patient who improves dramatically initially, suddenly becomes lethargic and sleepy. Signs of dehydration are present. Increasing the sodium intake reverses this condition. In severe cases, IV sodium chloride may be necessary (Chapter 37).</li>
<li>Chronic sodium depletion: This is less common and is characterised by lethargy, weakness and disorientation. Absence of demonstrable edema along with a low serum sodium is the cardinal requirement for its diagnosis. This condition should be distinguished from the more severe condition of dilutional hyponatremia.</li>
<li>Potassium depletion and hypokalemia: This occurs during long term use of thiazides and loop diuretics. It is especially liable to occur (a) when these drugs are used in large doses continuously rather than in small doses, intermittently; (b) when the diuresis is very brisk and the resultant contraction of plasma volume causes secondary hyperaldosteronism; (c) when the patient receives glucocorticoids at the same time; (d) in diabetics; (e) in elderly patients and the chronically sick who may have anorexia and may not eat properly; and (f) in states (such as cirrhosis of liver) with high circulating levels of aldosterone to begin with.</li>
</ul>
<p>By itself hypokalemia can impair renal function and is dangerous to patients receiving digitalis. Diuretic induced hypokalemia can cause life threatening arrhythmias in patients taking drugs which prolong QT interval.
Hypokalemia can be prevented/corrected by:
(a) Increased dietary intake of potassium; (see Chapter 37).
(b) Potassium chloride supplement; this is an effective method and 20-40 mMol of potassium should be given per day. Patients with liver cirrhosis need <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">100 \mathrm{mMol} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span></span></span></span></span> day as they lose much of the potassium supplement in the urine; it can benefits from concurrent administration of spironolactone. Routine administration of supplemental potassium is not necessary when thiazides are used to treat hypertension and in young, ambulatory patients with good appetite.
(c) Potassium sparing diuretics; They are valuable but when they are given, potassium supplements should be omitted except in cirrhotic patients to avoid hyperkalemia.</p>
<ul>
<li>Hyperkalemia: This is less common. It occurs in cases with uremia and with drugs like triamterene. It is sometimes seen following massive diuresis with any potent drug; this is probably due to failure of potassium secretion by kidney tubules because of less availability of sodium at potassium secretory sites, after initial marked loss of sodium.</li>
</ul>
<p>(Chapter 37).</p>
<ul>
<li>Hypochloremic alkalosis: This occurs following thiazides and loop diuretics.</li>
<li>Metabolic acidosis: This is seen following carbonic anhydrase inhibition (acetazolamide), and is discussed earlier.</li>
<li>Chronic dilutional hyponatremia: This state is sometimes seen in patients with CHF where serum sodium is persistently low in spite of severe edema. This is because there is relatively more water retention than sodium retention by the kidneys resulting in extreme dilution of ECF; its mechanism is not clear. Although it is not a direct consequence of diuretic therapy, it may be aggravated following diuretics. Such patients usually have severe myocardiac impairment and are unresponsive to the diuretics. The treatment is difficult and replacement therapy with salt to correct hyponatremia is seldom successful. Rigid restriction of water intake (less than 700-800 ml daily) is recommended. Glucocorticoids may be useful in some cases.
(3) Selective adverse effects: These are discussed under each individual drug. Thiazides and loop diuretics can cause magnesium deficiency which can give rise to ventricular arrhythmias. It can be corrected by 4 ml of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> magnesium sulfate given IV infusion over 10 - 15 min followed by a small maintenance dose of 72 mmol over next 24 hrs .</li>
</ul>
<p>With proper use of diuretics, there would be only a few patients who show refractioriness. In many such cases, correction of underlying electrolyte disturbances restores the responsiveness. Treatment of extra-renal factors such as pulmonary infection, adequate bed rest and proper use of other drugs like steroids/NSAID may help in some patients.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="acute-renal-failure-arf">Acute Renal Failure (ARF)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#acute-renal-failure-arf" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Acute renal failure (ARF) may be defined as a state in which the kidney's ability to maintain homeostasis has declined suddenly, with resultant retention of metabolic waste products as well as electrolyte, acid-base and volume disturbances.</p>
<p>The causes of ARF are prerenal, intra-renal and postrenal (obstructive). It is important to distinguish among these three types as:</p>
<ul>
<li>Prerenal ARF is largely due to a reduction in effective blood volume with resultant in reduction in glomerular filtration; it is totally reversible with restoration of the effective blood volume; if unrecognised and untreated, it can deteriorate into the intra renal type.</li>
<li>Intra-renal type of ARF due to intrinsic renal damage poses the maximum challenge to the clinician. Further, ARF may be (i) oliguric (urine output less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>500</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">500 \mathrm{ml} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">500</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span></span></span></span></span> day in adults) or (ii) non-oliguric. The distinction between oliguric and non-oliguric ARF is important because the larger urine output and diuretic-responsiveness in the latter permit more liberal administration of fluids, and thus improving the prognosis.</li>
<li>Postrenal ARF is reversible with the relief of obstruction.</li>
</ul>
<p>The aims of therapy are (i) to treat the cause (if possible); (ii) to maintain the urine output at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">30-50 \mathrm{ml} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span></span></span></span></span> hour in adults without causing fluid overload; (iii) to maintain the BP normal; nutritional care; and (iv) prevention and treatment of infection, hyperkalemia, metabolic acidosis, hyperphosphatemia and other complications; all this while awaiting spontaneous recovery of renal function.</p>
<p>The principles of management, when ARF is suspected, are presented in Table 39.9. These are as follows:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-39-9">Table 39.9<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-39-9" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Principles of management of established ARF</p>
<ul>
<li>Isolation and barrier nursing to prevent infection.</li>
<li>Clinical monitoring (weight; B.P.; urine output; signs of dehydration or over hydration).</li>
<li>Laboratory monitoring for anemia; electrolyte and acid base balance.</li>
<li>Ensuring an intake of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>50</mn><mrow><mi mathvariant="normal">K</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">30-50 \mathrm{Kcal} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm">Kcal</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day.</li>
<li>Restriction of protein intake.</li>
<li>Restricting fluid intake to (urine output + insensible losses from the skin and the lungs + visible losses such as sweat, vomit, stool) -300 ml .</li>
<li>Restricting sodium chloride intake to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>4</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">2-4 \mathrm{~g} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span></span></span></span></span> day.</li>
<li>Restricting potassium intake to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">40 \mathrm{ml} / \mathrm{g} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span><span class="mord">/</span></span></span></span></span> day.</li>
<li>Restriction of phosphorus intake to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>800</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">800 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">800</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day.</li>
<li>Phosphorus-binding antacidssuch aluminium hydroxide.</li>
<li>Avoid magnesium containing drugs.</li>
<li>Adjusting doses of drugs to renal status.</li>
<li>Maintain blood pressure.</li>
<li>Detection and treatment of acidosis, hyperkalemia and hypo or hyper natremia.</li>
<li>Treatment of infection, anemia and GI bleeding.</li>
<li>Hemodialysis.</li>
<li>Fluid challenge in oliguric patients, if the patient is not volume overloaded; typically 5001000 ml of normal saline is infused over 30-60 minutes while watching for signs of fluid overload. If the urine output increases, prerenal ARF is diagnosed and appropriate fluid administration is continued.</li>
<li>IV furosemide: If there is no increase in the urine output in response to the fluid challenge, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>400</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">100-400 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">400</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> of furosemide is infused to promote diuresis; this may accompanied by an infusion of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> mannitol at the rate of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">h</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">u</mi><mi mathvariant="normal">r</mi></mrow></mrow><annotation encoding="application/x-tex">10-20 \mathrm{ml} / \mathrm{hour}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">hour</span></span></span></span></span></span>, in order to minimize the dose of furosemide needed. If these manoeuvres are successful, they are</li>
</ul>
<p>continued in order to maintain the high rate of urine flow.
If these manoeuvres fail, an established ARF is diagnosed; hemodialysis may be needed and is often life-saving (Table 39.9).</p>
<p>Usefulness of furosemide in established ARF is doubtful.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anti-diuretic-agents">Anti-diuretic Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anti-diuretic-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>ANTI-DIURETIC HORMONE (ADH, Vasopressin): The antidiuretic hormone is released from the posterior lobe of the pituitary along with oxytocin. Given in pharmacological doses, it also has a vasopressor action and hence, is also called vasopressin.</p>
<p>The hormone is formed by the supraoptic and paraventricular nuclei of the hypothalamus and travels to the posterior pituitary where it is stored. The rate of secretion of ADH is mainly determined by the plasma osmolality. Thus, dehydration stimulates whereas hydration inhibits ADH secretion. An increase or a decrease in the circulating blood volume may also influence the secretion through ill- defined 'volume receptors' found in the heart and the pulmonary veins and postulated in the hypothalamus. In addition, pain, nausea, hypoxia and some hormones and neurotransmitters can modify its secretion. Angiotensin is a potent stimulator of vasopressin release. Some drugs can also stimulate or inhibit its release (Table 39.10).</p>
<p>Table 39.10
Drugs and vasopressin release</p>
<table><thead><tr><th style="text-align: left;">Stimulants</th><th style="text-align: left;">Inhibitors</th></tr></thead><tbody><tr><td style="text-align: left;">Tricyclic anti-depressants</td><td style="text-align: left;">Alcohol</td></tr><tr><td style="text-align: left;">Nicotine</td><td style="text-align: left;">Phenytoin</td></tr><tr><td style="text-align: left;">Adrenaline</td><td style="text-align: left;">Chlorpromazine</td></tr><tr><td style="text-align: left;">Morphine(high doses)</td><td style="text-align: left;">Haloperidol</td></tr><tr><td style="text-align: left;">Barbiturates</td><td style="text-align: left;">Promethazine</td></tr><tr><td style="text-align: left;">Cyclophposphamide</td><td style="text-align: left;">Morphine(low dose)</td></tr><tr><td style="text-align: left;">Vincristine</td><td style="text-align: left;">Butorphanol</td></tr><tr><td style="text-align: left;"></td><td style="text-align: left;">Glucocorticoids</td></tr></tbody></table>
<p>Chemically, vasopressin is a polypeptide. The amino acid sequence of the hormone varies from animal to animal. Human antidiuretic hormone is arginine vasopressin (AVP).</p>
<p>Mechanism of action: Vasopressin acts on two receptors, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">V</mi><mn>1</mn></msub><mrow><mo fence="true">(</mo><msub><mi mathvariant="bold">V</mi><mrow><mn>1</mn><mi mathvariant="normal">a</mi></mrow></msub></mrow></mrow><annotation encoding="application/x-tex">\mathbf{V}_{1}\left(\mathbf{V}_{1 \mathrm{a}}\right.</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathbf" style="margin-right: 0.01597em;">V</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.016em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathbf" style="margin-right: 0.01597em;">V</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.016em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathrm mtight">a</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">V</mi><mrow><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">b</mi></mrow></mrow></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left.\mathbf{V}_{1 \mathrm{~b}}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen nulldelimiter"></span><span class="mord"><span class="mord mathbf" style="margin-right: 0.01597em;">V</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3361em;"><span style="top: -2.55em; margin-left: -0.016em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mtight"><span class="mspace nobreak mtight"><span class="mtight">&nbsp;</span></span><span class="mord mathrm mtight">b</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">V</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{V}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf" style="margin-right: 0.01597em;">V</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.016em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>.
Receptors <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">V</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{V}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf" style="margin-right: 0.01597em;">V</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.016em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> are located in the vascular smooth muscle, the bladder and uterine smooth muscle, the platelets and the CNS.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">V</mi><mrow><mn>1</mn><mi mathvariant="normal">a</mi></mrow></msub></mrow><annotation encoding="application/x-tex">\mathrm{V}_{1 \mathrm{a}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">V</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0139em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathrm mtight">a</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> usually are not stimulated by physiological concentrations of the hormone. Activation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>V</mi><mrow><mn>1</mn><mi>a</mi></mrow></msub></mrow><annotation encoding="application/x-tex">V_{1 a}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.22222em;">V</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.2222em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathnormal mtight">a</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> increases intracellular calcium and causes vasoconstriction, including that of the coronary vessels. Vasopressin acts directly on the cardiac myocytes which hypertrophy. It may also potentiate the synthesis of endothelin. In patients with CHF plasma vasopressin may rise early during the disease. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>V</mi><mrow><mn>1</mn><mi>b</mi></mrow></msub></mrow><annotation encoding="application/x-tex">V_{1 b}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.22222em;">V</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3361em;"><span style="top: -2.55em; margin-left: -0.2222em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathnormal mtight">b</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors are involved in vasopressin-stimulated secretion of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi><mi>C</mi><mi>T</mi><mi>H</mi></mrow><annotation encoding="application/x-tex">A C T H</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span><span class="mord mathnormal" style="margin-right: 0.13889em;">CT</span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span></span></span></span></span>.</p>
<p>Receptors <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">V</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{V}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf" style="margin-right: 0.01597em;">V</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.016em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> are found predominantly in the renal collecting duct where they promote the reabsorption of water (Anti-diuretic action). <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>V</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">V_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.22222em;">V</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.2222em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor activation may also increase the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Cl}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8557em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span>transport in the thick ascending limb. Their effects are mediated by activation of adenylyl cyclase.</p>
<p>Physiological and pharmacological actions:</p>
<ul>
<li>Kidney: Under the influence of vasopressin, the distal tubule and the collecting duct become permeable to water, leading to water reabsorption and reduced urine volume. In</li>
</ul>
<p>addition, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">V</mi><mrow><mn>1</mn><mi mathvariant="normal">a</mi></mrow></msub></mrow><annotation encoding="application/x-tex">\mathrm{V}_{1 \mathrm{a}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">V</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0139em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathrm mtight">a</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor activation reduces the renal medullary blood flow. Production of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is stimulated. Absence of vasopressin causes pituitary (central) diabetes insipidus. The anti-diuretic response to vasopressin is enhanced by NSAID, chlorpropamide and carbamazepine; it is inhibited by lithium and demeclocycline.</p>
<ul>
<li>Cardiovascular system: In large doses, ADH raises the BP by direct stimulation of the vascular smooth muscle. It also constricts the coronary and cerebral blood vessels. The hormone causes an initial tachycardia, probably secondary to coronary insufficiency and resultant hypotension, followed by bradycardia.</li>
<li>Other smooth muscles: Vasopressin stimulates the GI smooth muscle.</li>
<li>CNS: ADH is believed to play a role as a neuromodulator/neurotransmitter.</li>
<li>Miscellaneous: Stimulation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">V</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{V}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf" style="margin-right: 0.01597em;">V</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.016em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors increases the level of coagulation factor VII and von Willebrand factor. Vasopressin, stored in the platelets, plays a role in platelet aggregation.
Absorption, fate and excretion: It is given parenterally. When administered SC or IM, the drug remains in the body for a few hours; given IV, it is rapidly metabolised. However, vasopressin tannate in oil, administered SC or IM, produces an effect lasting for 24 to 48 hours.</li>
</ul>
<p>Vasopressin is rapidly metabolised in the body, largely during passage through the liver and the kidney. Its plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is 20 minutes or less.</p>
<p>Adverse reactions: It may produce nausea, biliary colic and abdominal cramps due to increased peristaltic activity. Hypotension and shock are serious adverse effects.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Vasopressin injection 20 units per ml; dose 5-10 units every <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>6</mn><mrow><mi mathvariant="normal">h</mi><mi mathvariant="normal">r</mi></mrow></mrow><annotation encoding="application/x-tex">4-6 \mathrm{hr}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">6</span><span class="mord"><span class="mord mathrm">hr</span></span></span></span></span></span> SC or IM.
(ii) Vasopressin tannate injection an oily suspension contains 5 pressor units per ml. Dose 0.5 to 1 ml once in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>24</mn><mo>−</mo><mn>72</mn></mrow><annotation encoding="application/x-tex">24-72</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">24</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">72</span></span></span></span></span> hours. On standing, the drug settles down at the bottom of the ampoules as a yellow residue. The ampoule, therefore, should be warmed gently and shaken vigorously before administration.
(iii) Synthetic vasopressin analogue, DDAVP (1-deamino -8 -D -arginine -vasopressin, Desmopressin), administered intranasally 5-10 mcg bid, is a preparation with greater antidiuretic and decreased pressor activity. Its action lasts for 13-22 hours. It can also be given by SC or IM (dose 1-4 mcg/day) and orally (300-600 mcg/day as tablets).
(iv) Lysine -8 -vasopressin is more stable and has activity of 50 units per 0.185 mg (per ml). It is used intranasally by spray. Each squeeze delivers about 2 units. The dose is 1-4 squeezes 3-7 times a day.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>I Those related to vascular and smooth muscle ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">V</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{V}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">V</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0139em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor) actions, where AVP is used:</p>
<ul>
<li>Postoperative ileus and abdominal distension.</li>
<li>Esophageal varices due to portal hypertension: Vasopressin infusion was used earlier to cause a marked splanchnic vasoconstriction, reducing thereby the portal flow and venous pressure. Triglycyl lysine vasopressin (Glypressin), an analogue, has practically no activity by itself on smooth muscle but in vivo it results in a slow release of active hormone. The effect, therefore, lasts for 10 hours after a single bolus injection as compared to the vasopressin which is active only for 30-40 minutes (Chapter 33).</li>
<li>Acute hemorrhagic gastritis.</li>
<li>Vasopressin IV has been found effective in the treatment of asystolic cardiac arrest. It</li>
</ul>
<p>may be given in a single dose of 40 IU, IM.
II Those related to antidiuretic action and release of blood coagulation factors ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">V</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{V}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">V</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0139em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors), where desmopressin is useful.</p>
<ul>
<li>Diabetes insipidus: Desmopressin is the treatment of choice. It is administered intranasally or by SC/IM injection. If desmopressin is not available, AVP may be used. As this is replacement therapy, it is lifelong in most cases. It is effective in central (pituitary) but not in nephrogenic diabetes insipidus.</li>
<li>Nocturnal enuresis: Desmopressin intranasally or orally (as tablet) at bedtime has been used for its short term treatment.</li>
<li>Bleeding disorders, Hemophilia A (factor VIII deficiency) and von Willebrand's disease (Chapter 33).
BENZOTHIADIAZINES: Surprisingly, benzothiadiazines are effective in controlling central as well as nephrogenic diabetes insipidus. The mechanism of action is not known. Various possibilities have been suggested; they probably act by causing a negative sodium balance and reducing the GFR. This leads to a decrease in volume and an increase in concentration of urine. A long acting drug such as polythiazide is usually preferred. Since symptomless hypokalemia is commonly associated with this therapy, a potassium sparing diuretic may be added to this regimen.</li>
</ul>
<p>In nephrogenic diabetes insipidus, where there is renal unresponsiveness to the action of desmopressin, thiazides are the most effective form of therapy. They are combined with low sodium diet and PG synthesis inhibitors such as indomethacin.</p>
<p>In both idiopathic and nephrogenic diabetes insipidus, the beneficial effect of benzothiadiazines is reduced by liberal salt intake.</p>
<p>CHLORPROPAMIDE: This drug, used in the treatment of diabetes mellitus (Chapter 65), is effective in the treatment of diabetes insipidus. Interestingly the closely related compounds tolbutamide and glibenclamide are not effective. It probably acts by increasing the sensitivity of renal tubules to low and otherwise ineffective concentrations of vasopressin. Unlike thiazide diuretics, the response to chlorpropamide is not reduced by high sodium intake or steroid administration. It is not useful in nephrogenic diabetes insipidus. It is usually given in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>250</mn><mo>−</mo><mn>500</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">250-500 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">250</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">500</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> once daily orally.</p>
<p>Carbamazepine ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>400</mn><mo>−</mo><mn>600</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">400-600 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">400</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">600</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day) is effective in patients with partial diabetes insipidus. It probably acts by stimulating vasopressin release from the neurohypophysis. Action of carbamazepine and chlorpropamide is overcome by ethanol, which inhibits the release of ADH.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="vasopressin-receptor-antagonists">Vasopressin Receptor Antagonists<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vasopressin-receptor-antagonists" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>CONIVAPTAN: This is a nonselective vasopressin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><msub><mi mathvariant="bold">V</mi><mn>1</mn></msub><mi mathvariant="normal">/</mi><msub><mi mathvariant="bold">V</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">-\mathbf{V}_{1} / \mathbf{V}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">−</span><span class="mord"><span class="mord mathbf" style="margin-right: 0.01597em;">V</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.016em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">/</span><span class="mord"><span class="mord mathbf" style="margin-right: 0.01597em;">V</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.016em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonist which causes decreased permeability of the renal collecting ducts to water, leading to excretion of free water (aquaresis). It is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>99</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">99 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">99%</span></span></span></span></span> protein bound and is metabolised in the liver. It has been used for short term treatment of euvolemic hyponatremia, usually caused by SIADH, hypothyroidism and adrenocortical insufficiency. In general, the drug is well tolerated but may cause headache, thirst, dry mouth hypokalemia, orthostatic hypotension, vomiting or diarrhoea in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> of cases. It is not recommended during pregnancy.</p>
<p>Tolvaptan, another benzazepine derivative, has selective <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">V</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{V}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf" style="margin-right: 0.01597em;">V</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.016em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> antagonistic action. It is effective orally and has been used to treat hyponatremia in patients with CHF, cirrhosis and SIADH. Adverse effects reported are similar to those of conivaptan.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-and-nephrotoxicity">Drugs and Nephrotoxicity<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-and-nephrotoxicity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Kidney has a rich blood supply and further, it can concentrate the drugs and their polar metabolites locally, thus exposing the renal tubules to very high concentrations of the drugs, which may cause renal damage resulting into acute renal failure, chronic nephropathy or functional impairment. The latter is observed following diuretics and lithium.</p>
<p>Drugs can cause nephrotoxicity:</p>
<ul>
<li>Directly, e.g. NSAID, aminoglycosides, heavy metals, chemicals such as ethylene glycol.</li>
<li>Indirectly, e.g., Vitamin D causing hypercalcemia leading to the formation of renal calculi; diuretics causing hypokalemia may cause renal tubular damage and cytotoxic drugs causing hyperuricaemia.</li>
<li>By immunological mechanisms. Many drugs can produce variety of damages such as glomerulolitis, interstitial nephritis, vasculitis and SLE. Examples are sulfonamides, INH, rifampicin, gold, phenytoin, hydralazine, procainamide etc.
Nephrotoxicity can be 'acute' leading to acute renal failure or may be 'chronic' and responsible for chronic renal disease. Drugs can damage the kidney at various sites from renal arteries to the ureters. They can also cause the renal damage by crystal or calculi formation. From among the many compounds incriminated in producing such renal damage, only some of the better known nephrotoxic agents are included in Table 39.11. These drugs are discussed elsewhere.</li>
</ul>
<p>Table 39.11
Drugs causing nephrotoxicity</p>
<table><thead><tr><th style="text-align: center;">Site of action</th><th style="text-align: center;">Drugs</th><th style="text-align: center;">Nature of Toxicity</th></tr></thead><tbody><tr><td style="text-align: center;">Extra-renal</td><td style="text-align: center;">Tetracyclines, Corticosteroids.</td><td style="text-align: center;">Aggravation of azotaemia probably via increased protein breakdown.</td></tr><tr><td style="text-align: center;">Arteries and arterioles</td><td style="text-align: center;">Heavy metals e.g. Arsenic, Bismuth and Gold salts, Long acting sulfonamides, Iodides, Thiazides, Bevacizumab.</td><td style="text-align: center;">Vasculitis, thrombotic microangiopathy</td></tr><tr><td style="text-align: center;">Glomeruli</td><td style="text-align: center;">Hydralazine, Long acting sulfonamides. Interferons</td><td style="text-align: center;">Nephrotic syndrome, podocytopathy, glomerulopathy</td></tr><tr><td style="text-align: center;">Convoluted tubules</td><td style="text-align: center;">Aminoglycoside antibiotics, e.g. Kanamycin, Gentamicin, Colistin, Amphotericin B, Polymyxin B, Vancomycin, Cephaloridine Cisplatin</td><td style="text-align: center;">Necrosis of proximal and/or distal tubular epithelium</td></tr><tr><td style="text-align: center;">Interstitium</td><td style="text-align: center;">NSAID, Phenytoin, Sulfonamides, Cyclosporin</td><td style="text-align: center;">Interstitial nephritis with papillary necrosis. May cause acute renal failure or chronic nephropathy</td></tr><tr><td style="text-align: center;">Collecting ducts</td><td style="text-align: center;">Acetazolamide, Sulfonamides, Antineoplastic drugs - Methotrexate</td><td style="text-align: center;">Crystalluria, Calculi, Hyperuricaemia</td></tr><tr><td style="text-align: center;">Ureters</td><td style="text-align: center;">Methysergide</td><td style="text-align: center;">Obstruction due to retroperitoneal fibrosis</td></tr></tbody></table>
<p>Chronic nephropathy due to prolonged ingestion of NSAID has received considerable attention. Patients suffering from this syndrome may present with hematuria, renal colic, urinary infection and finally hypertension and renal failure. The lesions are reversible if the syndrome is detected early and the offending drug stopped (see Chapter 11).</p>
<p>Drug-induced nephrotic syndrome has been observed following therapeutic use of drugs like tolbutamide, probenecid, penicillamine, perchlorate and gold salts. It is characterised by marked proteinuria.</p>
<p>Compounds like antiepileptic drugs, sulfonamides, phenylbutazone, tetracyclines, antihypertensive agents like hydralazine; and methyl-dopa can induce systemic lupus erythematosus (SLE) and affect the kidney. The damage may be reversible on discontinuation of the drug.</p>
<p>Apart from the therapeutic agents, many chemicals also cause nephrotoxicity. These</p>
<p>include such compounds as aniline, carbon tetrachloride, phenol, ethylene glycol, phosphorus, arsenic, cadmium and mercuric chloride.</p>
<p>In the presence of kidney damage, the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of drugs that are mainly excreted by kidney is prolonged e.g. beta lactams, fluoroquinolones, aminoglycosides, atenolol, ACEI, digoxin etc. In such patients, it is necessary to reduce the doses of such drugs to avoid toxicity. In general, the serum creatinine is a useful rough guide to the severity of impairment of renal function. In mild failure, with a GFR of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">25-50 \mathrm{ml} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>., it is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.8</mn><mo>−</mo><mn>2.8</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1.8-2.8 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1.8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">2.8</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span>. With GFR of 10-25 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{ml} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>., it is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.9</mn><mo>−</mo><mn>7.9</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2.9-7.9 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.9</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">7.9</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span> while in severe renal failure when the GFR is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">&lt;10 \mathrm{ml} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>, serum creatinine is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>8</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">8 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">8</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span> or higher.</p>
<p>Renal function deteriorates with age but this reduction, until marked, is not reflected in the serum creatinine level. It should be noted that many apparently healthy elderly subjects also may have a GFR of less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">50 \mathrm{ml} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>. and therefore, caution is needed in prescribing certain drugs in the elderly.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="section-x-br-drugs-used-in-disorders-of-the-gastrointestinal-tract">SECTION X &lt;br&gt; Drugs Used in Disorders of the Gastrointestinal Tract<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#section-x-br-drugs-used-in-disorders-of-the-gastrointestinal-tract" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="outline">OUTLINE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#outline" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Chapter 40: Appetite Stimulants, Digestants, Antiflatulents, Appetite Suppressants and Hypolipidemic Agents
Chapter 41: Emetics, Drug Therapy of Vomiting, Vertigo and Diarrhoea
Chapter 42: Pharmacotherapy of Constipation
Chapter 43: Pharmacotherapy of Peptic Ulcer Disease</p>
<p>40</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="appetite-stimulants-digestants-antiflatulents-appetite-suppressants-and-hypolipidemic-agents">Appetite Stimulants, Digestants, Antiflatulents, Appetite Suppressants and Hypolipidemic Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#appetite-stimulants-digestants-antiflatulents-appetite-suppressants-and-hypolipidemic-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Appetite, a desire to eat or drink, is a complex phenomenon influenced by several factors. The final outcome is achieved by the release of various hypothalamic peptides which are integrated with catecholaminergic, serotoninergic and opioid signaling pathways. Dopamine and 5-HT mediated processes in the CNS, and ghrelin, a gut-brain peptide, probably play an important role in appetite control.</p>
<p>Loss of appetite (anorexia) is a common complaint in clinical practice. Its etiology varies from prolonged, debilitating illnesses to purely psychological disturbances such as depression. It is common in patients with widespread cancer. It is imperative, therefore, to investigate thoroughly an individual complaining of anorexia for the underlying cause.</p>
<p>Temporary anorexia due to short illnesses usually needs no treatment. Symptomatically, appetite can often be improved by varying the diet and by use of such simple preparations as lemon pickles, bitters such as bitter orange peel and soups. The aromatic bitter appetite stimulants combine the property of bitterness with that of an aromatic volatile oil e.g. orange, ginger and cardamom. Use of costly appetite stimulants and 'tonics' for this purpose is unnecessary.</p>
<p>Alcohol: In small quantities ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> ), given before a meal it can augment the gastric secretion both reflexly by stimulation of the taste buds and by a direct action (Chapter 6). It is a major constituent of popular 'tonics'. Many tonics dispensed in fancy bottles contain 10-15% of alcohol. Repeated ingestion of alcohol, however, causes chronic gastritis and a diminution in appetite. The use of alcohol containing 'tonics' in children is to be condemned. Their prolonged use even in adults is to be discouraged.</p>
<p>Megestrol acetate and glucocorticoids are useful in increasing the appetite but not necessarily weight in patients with cancer-induced cachexia. Insulin and oral hypoglycemics augment gastric secretion by producing hypoglycemia; however, their use is irrational and hazardous. Similar claims have been advanced for vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and anabolic steroids but whether appetite stimulation is their primary action or secondary to their metabolic effects remains to be established. The 5-HT antagonist cyproheptadine, has also some appetite stimulating property; however, used in large doses, it inhibits the release of ACTH and depresses the circulating cortisol level (Chapter 24). Thus there is no safe and reliable appetite stimulant.</p>
<p>Anorexia nervosa is a chronic disorder characterised by loss of appetite and self induced weight loss, accompanied by psychological and physiological alterations such as amenorrhoea. Hypothalamic abnormalities are believed to play a role in its pathogenesis. Currently, no pharmacological agent of proven value is available for its treatment. Olanzapine, an atypical antipsychotic acting on multiple receptors, and reboxitine, an antidepressant, have been tried as adjuncts (Chapter 14).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="digestants">Digestants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#digestants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The digestants are the drugs that are claimed to aid digestion in the gastrointestinal tract. The commonly used digestants are:</p>
<p>PEPSIN: This is a proteolytic enzyme, obtained from the glandular layer of the fresh stomach of the hog. It is administered orally in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.5-1 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span>. It is of doubtful value except perhaps in patients with gastric achylia, a condition characterised by defective acid and pepsin secretion.</p>
<p>Enzyme, papain, obtained from vegetable source (papaya), also has proteolytic properties.</p>
<p>RENNIN: This is a partially purified milk-curdling enzyme, obtained from the glandular layer of calf stomach. It is used in the preparation of cheese.</p>
<p>PANCREATIN: This contains the enzymes amylase, trypsin and lipase and is obtained from hog or ox pancreas. It has been employed as a replacement therapy in chronic pancreatitis, obstruction caused by the cancer of the head of pancreas, cystic fibrosis, and after total gastrectomy and pancreatectomy. It is not useful in GI disorders unrelated to pancreatic enzyme insufficiency. It is administered orally in enteric coated capsules, to prevent its gastric inactivation. However, this preparation contains very small amounts of enzymatic activity per tablet or capsule, compared to quantities necessary for efficient digestion. Hence, even with large doses, total correction of steatorrhoea may not occur. It may be used only as an adjunct to reduction in dietary fat intake. Prolonged use of pancreatin may cause fibrosing colonopathy.</p>
<p>BILE AND BILE ACIDS: Normally, about 1000 ml of bile is secreted by the liver per day. It contains bile acids, cholesterol and bilirubin. Bile acids are important in emulsifying the fats in the intestine. Cholecystokinin (CCK), the polypeptide secreted by the duodenal mucosa, is the main stimulant to biliary secretion. Bile salts and bile acids increase the flow as well as the concentration of bile and are termed choleretics.</p>
<p>The bile salt preparations have been employed to facilitate surgical drainage, as replacement therapy in biliary fistulae, and for their choleretic effect in conditions like liver cirrhosis and functional hepatic insufficiency. Their usefulness, however, is doubtful.</p>
<p>The preparations are:
(i) Dehydrocholic acid as 250 mg tablet. Dose: 500 mg thrice daily, and
(ii) Sodium dehydrocholate injection, as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> solution in 3 and 10 ml ampoules. Dose: 3 to 5 ml IV.</p>
<p>CHENODEOXYCHOLIC ACID (CDCA, Chenodiol): This normal constituent of bile reduces biliary cholesterol concentration by depressing hepatic cholesterol secretion and improves solubility of cholesterol in bile. It dissolves radiolucent gallstones but is ineffective with the radioopaque (calcified) ones. The results are poor in the presence of a nonfunctioning gall bladder. The drug causes diarrhoea, increase in the LDL cholesterol and rarely hepatotoxicity. It has been replaced by ursodeoxycholic acid.</p>
<p>URSODEOXYCHOLIC ACID, (Ursodiol) an analogue of CDCA is formed from chenodiol by colonic bacteria. It has similar actions but unlike chenodiol, it does not increase the secretion of bile acids into bile. Given orally, it is absorbed rapidly and taken up by the liver. It is better tolerated than chenodiol.</p>
<p>Ursodiol, given orally in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>8</mn><mo>−</mo><mn>12</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">8-12 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">12</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day, in divided doses, has been reported</p>
<p>to cause clinical, biochemical and histological improvement in primary biliary cirrhosis. It acts by modifying the composition of bile acids in the liver, thereby hindering the progression of the pathological process. It lowers the serum cholesterol levels in these patients.</p>
<p>Gallstones are common, and although they are blamed for many digestive symptoms they are probably innocent in most cases. Asymptomatic gallstones are often an incidental finding on ultrasonography. In most cases, they need little treatment. True symptoms of gallstone disease include acute cholecystitis, biliary colic, jaundice and acute pancreatitis. When they are proved to be the cause of severe symptoms, cholecystectomy is the best treatment. However, this may not guarantee improvement in all digestive symptoms of the patient. Bile acid therapy may be considered as another option for radiolucent cholesterol stones, 5 mm or less in diameter. Ursodeoxycholic acid, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>750</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">750 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">750</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day needs to be administered for prolonged time, even upto 2 years. This therapy, however, is unsuitable in patients with (1) non-cholesterol stones; (2) non-functioning gall bladder; or (3) severe recurrent symptoms. Gallstones in the bile duct are more serious and need surgical treatment.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antiflatulents-and-carminatives">Antiflatulents and Carminatives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antiflatulents-and-carminatives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These are the drugs used to expel gas from the stomach or the intestines in the treatment of flatulence and colics. Most of these drugs are aromatic volatile oils. They act by mild stimulation thereby increasing the GI motility and causing relaxation of sphincters. They produce a feeling of warmth in the stomach. They do not affect the gastric acid secretion significantly. Indian food contains enough carminatives in the form of various spices and condiments. The common ones are cardamom seeds, ginger, fennel seeds, asafoetida, cinnamon bark, cloves, coriander and anise. Along with sodium bicarbonate, they form important constituents of various 'gripe water' mixtures commonly used in infants to relieve griping.</p>
<p>Although carminatives may afford some quick symptomatic relief and audible satisfaction, it must be remembered that flatulent dyspepsia may be associated with disorders such as peptic ulcer, biliary tract disease, the irritable bowel syndrome, alimentary tumours and even IHD.</p>
<p>DIMETHYLPOLYSILOXANE: This silicone derivative has been advocated in symptomatic treatment of postprandial and postoperative flatulence and abdominal distension. It is believed to act as a defoaming agent, allowing the gas to escape from the GI tract, providing comfort to the patient with 'gases.' However, evidence to support these claims is not convincing. It eliminates mucus-embedded bubbles that interfere with visualisation during gastroscopy, but is not particularly effective in reducing gas that may interfere with radiologic or ultrasound examination of the abdomen. It is available as 40 mg tablets. Simethicone is a mixture of dimethylpolysiloxane and silicagel.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anorexiants-and-treatment-of-obesity">Anorexiants and Treatment of Obesity<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anorexiants-and-treatment-of-obesity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Obesity is defined as "a condition of abnormal or excessive accumulation of adipose tissue, to the extent that health may be impaired." People with abdominal fat distribution or android obesity are at greater risk to its consequences than those with the less serious gynoid fat distribution where fat is more evenly and peripherally distributed around the body.</p>
<p>Sedentary lifestyle of modern living, combined with the abundant availability of tempting, high-fat (junk) foods has caused almost an epidemic of obesity in the affluent nations. The current estimate indicates that the number of 'overweight' individuals in the world is almost the same as that of 'underweight' ones. However, not everyone who partakes of such foods becomes obese. The tendency to become obese is definitely inherited. The mortality rises exponentially with increasing bodyweight and the incidence of heart disease, hypertension, diabetes, sleep apnoea, osteoarthritis and bowel cancer is higher in the obese than in the non-obese.</p>
<p>Regulation of energy balance: Obesity is a disorder of energy balance. Hypothalamus is a major centre that regulates food consumption by modulating hunger and satiety. It integrates neural, hormonal and nutrient messages from elsewhere and sends signals to the higher centres, leading to the feeling of hunger or satiety. Hypothalamus also controls the energy expenditure via the adrenergic nervous system and the pituitary hormones.</p>
<p>The central control of the bodyweight is a complex phenomenon, not well understood, regulated by multiple brain nuclei and many neurotransmitters (Table 40.1). Of these, neuropeptide <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="bold">Y</mi></mrow><annotation encoding="application/x-tex">\mathbf{Y}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6861em;"></span><span class="mord mathbf" style="margin-right: 0.02875em;">Y</span></span></span></span></span> is the most potent appetite stimulant and is abundantly present in the hypothalamus. It also suppresses sympathetic activity and thus reduces energy expenditure.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-40-1">Table 40.1<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-40-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Neuropeptides affecting energy balance
Noradrenaline, GHRH Neuropeptide Y, Ghrelin, Opioids, Endogenous Cannabinoids</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="inhibit-food-intake">- Inhibit food intake:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#inhibit-food-intake" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>5-HT, Dopamine Cholecystokinin (CCK), CRH Neurotensin, Bombesin and Glucagon-like peptide, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> MSH</p>
<ul>
<li>Increase food intake:</li>
</ul>
<p>Noradrenaline, GHRH Neuropeptide Y, Ghrelin, Opioids, Endogenous Cannabinoids</p>
<ul>
<li>Inhibit food intake:</li>
</ul>
<p>5-HT, Dopamine Cholecystokinin (CCK), CRH Neurotensin, Bombesin and Glucagon-like peptide, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> MSH
Ghrelin, a 28 amino acid, gut-brain peptide which is a potent inducer of growth hormone release has also powerful appetite stimulating (orexigenic) properties. It is produced mainly by neuroendocrine cells in the gastric fundus and acts on the hypothalamus. Given in human volunteers, it stimulates appetite, induces hunger and</p>
<p>increases food consumption. Reduction in ghrelin secretion is one of the mechanisms of appetite reduction after gastric surgery for weight reduction.</p>
<p>Leptin is another peptide hormone synthesised in the fat cells. It acts on the hypothalamus to signal adequacy of body fat stores, suppress food intake and increase the calorie expenditure through inhibition of neuropeptide Y. Plasma leptin concentration is high in the obese persons and falls with weight reduction, which probably indicates resistance to the central effects of leptin in obese subjects.</p>
<p>Leptin acts as a signal from the adipose tissue to the CNS that the body is ready/mature enough for reproductive functions such as entering into puberty in adolescents, and fertility in adults. It is not a trigger but a permissive factor for LHRH release in both the situations. Leptin has been used successfully in overcoming amenorrhoea in females with anorexia nervosa and those participating in vigorous sports.</p>
<p>Normally, body weight is tightly regulated and a small excess of food consumption over burning of calories is all that is required to cause weight gain. Daily excess of 100 Kcal (a small chocolate bar or one chapati) would result in 4-5 kg weight gain in one year! Even modest weight loss of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> improves physical performance and glucose tolerance. What is most important, however, is maintenance of the reduced weight for long term benefit.</p>
<p>Clinically, overweight and obesity are assessed in terms of Body Mass Index (BMI = Body weight in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">K</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">\mathrm{Kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Kg</span></span><span class="mord">/</span></span></span></span></span> Height in meter <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>2</mn></msup></mrow><annotation encoding="application/x-tex">{ }^{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span></span></span></span></span></span></span></span></span> ) and waist circumferences. The normal value in adults is 18.5 to 24.9 ; overweight is BMI of 25 to 29.9 ; and obesity is 30 or higher. BMI of 35 or more means severe obesity. Asians develop hypertension, IHD and type 2 diabetes mellitus at lower level of BMI than their western counterparts if their waist circumference is higher than normal. Thus according to the new Asian criteria, a person with a BMI <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>23</mn></mrow><annotation encoding="application/x-tex">&gt;23</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">23</span></span></span></span></span> is considered as obese. The perils of obesity, diabetes, hypertension and hyperlipidemia increase from a BMI of 23.</p>
<p>Alternatively, obesity is diagnosed even with normal BMI if the waist circumference exceeds 102 cm in men and 88 cm in women in the western countries; for Asians, the corresponding figures are 90 cm and 80 cm , respectively.</p>
<p>Many of the co-morbidities of obesity present themselves in the form of the so-called metabolic syndrome. The latter is related to an excess of intra-abdominal rather than subcutaneous fat. (Chapter 65).</p>
<p>Many obese individuals show psychological disturbances and a compulsive desire to eat, though such individuals may not derive satisfaction from the act of eating.</p>
<p>Treatment of obesity is essentially medical. Surgical treatment (on the GI tract) may be useful only in severe, resistant cases. The general principles of treatment are outlined in Table 40.2. In an obese individual, if an organic cause such as an endocrine disease is present, it should be treated. Commonly, obesity is due to excessive eating and lack of adequate exercise. The patient must be made to appreciate this at the beginning of the treatment and explained that diet is the mainstay of the treatment of obesity; he/she must be adequately motivated by the concept of 'positive health'. It must also be emphasised that dietary treatment of obesity consists of a lifelong reorientation of his eating habits (and often those of his family) and not merely of a 'course' of dieting. Those who look upon dieting as a course of treatment are bound to regain the lost weight.</p>
<p>Table 40.2
Principles of treatment of obesity</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>- Nutritionally adequate, low calorie diet, containing at least 1 gm of protein/kg of desirable body weight.
</span>    - Fat intake below 25% of total calories prescribed.
    - Liberal use of fibre-containing foods.
    - Regular exercise.
    - Behavioural therapy for change in life-style.
    - Restriction of alcohol.
    - Anorectic drugs- as adjunctive therapy.</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="- Nutritionally adequate, low calorie diet, containing at least 1 gm of protein/kg of desirable body weight.
    - Fat intake below 25% of total calories prescribed.
    - Liberal use of fibre-containing foods.
    - Regular exercise.
    - Behavioural therapy for change in life-style.
    - Restriction of alcohol.
    - Anorectic drugs- as adjunctive therapy." style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>There are many diets for obesity. It has, however, been established that nothing about the diet matters except its calorie content. Hence, the best diet is one which is low in calorie content (1000-1500 per day), contains all the essential nutrients, provides a variety and is simple for the patient to follow for prolonged periods. Drastic one-step calorie reduction may not be tolerated by patients; it is better to reduce the daily calorie intake progressively in steps of 500 calories. The diet should also conform to the patient's pocket. "It is prudent to avoid well advertised, fancy and expensive nutritional supplements."</p>
<p>Diet rich in fruits, vegetables and whole grain, especially pulses, is to be preferred. Excessive intake of fat (butter, eggs, oil) and sweets (chocolate, pastries) should be avoided. Proprietary slimming foods are expensive and ineffective, though many patients believe that they can lose weight by consuming them in addition to their normal diet. Prolonged fasting is a drastic measure to be used rarely, only in resistant cases and that too under medical supervision. The age-old Indian religious custom of fasting on certain days of the month has, however, much to recommend it, as it can atone for the minor sins of the palate indulged in at other times and thus, help to keep good health. If the patient realises the importance of dieting and exercise and if he has the necessary will, then the treatment of obesity is not that difficult and can easily be carried out at home without the help of expensive 'obesity clinics', and fashionable 'health clubs'. The most simple and cost-effective moderate exercise recommended is 'brisk' walking (during which subject finds speaking difficult but not impossible). Other exercises recommended are stair climbing, cycling, jogging or swimming. Physical activity should be carried out for 30-60 min/day.</p>
<p>The results of therapy are likely to be more satisfactory in hypertrophic obesity (enlarged, distended fat cells, with usual onset in adult life) than in the hyperplastic variety (more numerous fat cells, with usual onset in childhood).</p>
<p>The patient should be told at the onset of therapy that an average weekly loss of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>0.8</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.5-0.8 \mathrm{~kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">0.8</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> is adequate and would result in annual loss of about 25 kg . This can be achieved by consuming 500-1000 fewer calories per day.</p>
<p>Sometimes, even with the best of motivation, drastic reduction in the customary food intake is initially a trying experience. In such cases, appetite suppressants (anorexiants) may help the patient to adjust to the prescribed diet. However, these drugs only supplement and are not a substitute for the dietary restrictions.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="classification-of-drugs-used-for-obesity">Classification of drugs used for obesity:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-drugs-used-for-obesity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>I Centrally acting, appetite suppressants (Anorexiants)</p>
<ul>
<li>
<p>Adrenergic agents e.g. Benzamphetamine, Phentermine, Mazindol, Phendimetrazine, Diethylpropion.</p>
</li>
<li>
<p>5-HT agonists e.g. Fenfluramine, Dexfenfluramine, Fluoxetine, Lorcaserin.</p>
</li>
<li>
<p>Drugs acting on both adrenergic and 5-HT systems e.g. Sibutramine</p>
</li>
<li>
<p>Cannabinoid receptor antagonists e. g. Rimonabant. II Drugs acting in the GI tract</p>
</li>
<li>
<p>Bulk anorexiants e.g. Dietary fibre, Methylcellulose, Guar gum.</p>
</li>
<li>
<p>Non-absorbable fat substitutes e.g. Olestra</p>
</li>
<li>
<p>Lipase inhibitors e.g. Orlistat</p>
</li>
</ul>
<p>III Drug combinations: e.g. Phenteramine + Topiramate, Bupropion + Naltrexone IV Miscellaneous e.g. Metformin I Anorexiants:</p>
<p>Amphetamine and related compounds:
Their anorexiant effect appears to be related to the central release of DA and NA from the adrenergic cells. They also inhibit the reuptake of NA and DA. Their major drawbacks are drug dependence and sympathomimetic ADR like hypertension, tachycardia, insomnia and nervousness. Hence, sympathomimetics are rarely recommended in the treatment of obesity (Chapter 18). Methylamphetamine is highly addictive and is extensively abused.</p>
<p>Other related drugs are phenteramine, phendimetrazine, mazindol and diethylpropion.
Of these, the first two are suspected to produce dependence and could be abused. Mazindol is chemically unrelated to amphetamine, and probably acts through dopaminergic mediators. None of these drugs is safe for long term use.</p>
<p>Fenfluramine: This drug, once used extensively, acts by increasing the brain synaptic 5HT by accelerating its release and reducing its re-uptake. However, it was found to cause cardiac valvular injury and primary pulmonary hypertension. It has been withdrawn from the market.</p>
<p>Fluoxetine: This 5-HT reuptake inhibitor antidepressant, in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">60 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">60</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day, is associated with weight loss; but its long term use should be avoided in view of the experience with fenfluramine (Chapter 14).</p>
<p>Lorcaserin: This is a selective central <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>2</mn><mi>C</mi></mrow></msub></mrow><annotation encoding="application/x-tex">5 \mathrm{HT}_{2 C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord">5</span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mathnormal mtight" style="margin-right: 0.07153em;">C</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor agonist. It suppreses the appetite. It has a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of 11 hours and is extensively metabolised by the liver. Headache, nausea, dizziness and euphoria (at doses <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">&gt;40 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> ) are the frequently reported adverse effects. Lorcaserin inhibits CYP 2D6 and hence increases the concentration of other drugs metabolised by this enzyme (e.g. dextromethorphan).</p>
<p>It took over 30 years to detect the serious adverse reaction to fenfluramine. This emphasises the vital importance of continued and vigilant post-marketing adverse drug reaction surveillance. Similar long term toxicity is likely to occur following the use of other drugs acting as 5-HT agonists.</p>
<p>Sibutramine and rimonabant are no more used because of their cardiovascular and neuropsychiatric toxicity respectively.</p>
<p>Table 40.3 summarises the limitations of the centrally acting anorexiants. None of these drugs are both, effective and safe for long term therapy.</p>
<p>Table 40.3
Limitations of centrally acting anorexiants</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>- Short termefficacy.
</span>    - Relapse of weight gain.
    - Possible toxicity during long term therapy;
    - Weight cycling as a result of drug holiday, leading to adverse outcomes such as coronary heart disease; and
    - Inability to prevent obesity-related illnesses and to prolong life.
    - Poor compliance</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="- Short termefficacy.
    - Relapse of weight gain.
    - Possible toxicity during long term therapy;
    - Weight cycling as a result of drug holiday, leading to adverse outcomes such as coronary heart disease; and
    - Inability to prevent obesity-related illnesses and to prolong life.
    - Poor compliance" style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-drugs-acting-in-the-gi-tract">II Drugs acting in the GI tract:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-drugs-acting-in-the-gi-tract" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="bulk-anorexiants">Bulk anorexiants:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bulk-anorexiants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Methylcellulose, a non-digestible polysaccharide, when ingested, swells and adds to the bulk in the diet. Though used as an appetite satiator, it is no more effective than the high residue low caloric diet for the obvious reason that an obese person is interested in eating good food and not something that would merely distend the stomach. It forms an important, cheap constituent of many 'costly', commercial preparations advertised for the treatment of obesity. Guar gum, karaya gum (Sterculia gum, Kanormal) and glucomannan are the other bulking agents.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="digestion-inhibitors">Digestion inhibitors:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#digestion-inhibitors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>OLESTRA: This is a mixture of sucrose-fatty-acid esters that is neither digested nor absorbed from the GI tract. When used as a component of diet, it increases the bowel function and stool bulk. It is recommended as a fat substitute in cooking. Long term effects on the health are yet not fully known. It is expensive.</p>
<p>ORLISTAT: Orlistat (Tetrahydrolipostatin) is related to a lipase inhibitor, lipostatin produced by the mould, Streptomyces toxytricini. It acts by inhibiting pancreatic and other lipases including phospholipase <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">A</mi><mn>2</mn></msup></mrow><annotation encoding="application/x-tex">\mathrm{A}^{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord mathrm">A</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span></span></span></span></span></span></span></span></span>. It is not absorbed and the effects are confined to the GI tract, where it prevents the lipase-catalysed breakdown (GI lipase inhibition) of TG and subsequent absorption of about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">1 / 3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0991em; vertical-align: -0.25em;"></span><span class="mord">1/</span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> of the dietary fat. The additional benefit is a modest reduction in the plasma levels of total cholesterol and LDL cholesterol but not of TG. It is modestly effective and causes weight loss over 1-4 years. It is almost completely excreted unchanged in feces. The common adverse effects are abdominal pain, flatulence, increased defecation of oily/fatty stools with anal leaking, which can be inconvenient and socially embarrassing. Rarely hepatotoxicity has been reported. It is used in the dose of 120 mg 2-3 times daily, with meals, for a maximum of two years.</p>
<p>Isn't it better to eat less fat, rather than eating it and then preventing its absorption by a "pill"?
III Drug combinations:
(a) Phenteramine in combination with topiramate, an antiepileptic, given as OD causes dose dependent weight loss. However because of ADR, the discontinuation rate is nearly <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span>. Topiramate is also a carbonic anhydrase inhibitor and can cause metabolic acidosis.
(b) Bupropion, a weak antidepressant, also stimulates hypothalamic neurons to produce anorexigenic effects. However, these neurons also secrete beta endorphin, an endogenous opioid, which counters this action. Hence, bupropion is combined with naltrexone, an opioid antagonist. The combination is reported to cause weight loss but the effect may not be sustained. Moreover, its neuropsychiatric toxicity including</p>
<p>possible suicidal thoughts limit its usefulness (Chapter 14)
IV Miscellaneous: The antidiabetic, metformin induces weight loss in diabetic and some nondiabetic obese subjects (Chapter 65).</p>
<p>Experts recommend that drugs may be considered in adults with a BMI of over 27 in the presence of an obesity-related complication and in those with a BMI of over 30 even in the absence of such a complication. For persons with a BMI of over 40, bariatric surgery may be considered. As obesity is a chronic disease and as relapse is common after cessation of drug therapy, prolonged, lifelong, drug therapy may be desirable. However, none of the available drugs is safe enough for prolonged use. They also fail to maintain weight loss over <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> in a year. Evidence suggests that combined drug therapy is no better than drug monotherapy. Irrespective of the drugs used, if significant weight loss does not occur within 4-6 months of therapy, the drug is discontinued. Drug should not be used simply for cosmetic weight control.</p>
<p>Thus the treatment of obesity mainly depends on permanent lifestyle modifications such as change in eating habits and regular physical exercise, supported by behavioural therapy.</p>
<p>In practice, many drugs may cause some degree of anorexia as their side effect. Common among these are listed in Table 40.4.</p>
<p>Table 40.4
Some drugs causing anorexia</p>
<ul>
<li>Aminophylline</li>
<li>Amphetamines and related drugs</li>
<li>Antimicrobials: Metronidazole, Fluoroquinolones, Erythromycin, Nitrofurantoin, Tetracycline</li>
<li>Antimalarials</li>
<li>Metformin</li>
<li>Digitalis</li>
<li>Levodopa</li>
</ul>
<p>Table 40.5 lists the drugs commonly used, which may cause weight gain as a side effect.</p>
<p>Table 40.5
Drugs which may cause weight gain</p>
<ul>
<li>Antipsychotics, especially Olanzapine</li>
<li>Antidepressants: Tricyclics, SSRI, MAOI, Mirtazapine</li>
<li>Hormones: Glucocorticoids, Insulin Progestogens, Oral contraceptives and Danazol</li>
<li>Beta blockers</li>
<li>Oral hypoglycemic agents: Sulfonylureas, Glitazones</li>
<li>Anticonvulsants: Phenytoin, Sodiumvalproate</li>
<li>Antihistaminics, especially the first generation agents</li>
<li>Pizotifen</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="atherosclerosis-and-hyperlipidemia">Atherosclerosis and Hyperlipidemia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#atherosclerosis-and-hyperlipidemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The plasma lipids are water insoluble and transported in several classes of lipoproteins. These classes are:</p>
<ul>
<li>Chylomicrons</li>
<li>Chylomicron remnants</li>
<li>Very low density lipoproteins (VLDL)</li>
<li>Intermediate density lipoproteins (IDL)</li>
<li>Low density lipoproteins (LDL)</li>
<li>High density lipoproteins (HDL); and</li>
<li>Lipoprotein (a)</li>
</ul>
<p>The lipoproteins contain a non-polar core of triglycerides (TG) and cholesterol esters, surrounded by a polar coat made up of phospholipids, unesterified cholesterol and apoproteins. The lipid in the chylomicrons and VLDL is mostly TG whereas that in the LDL is mostly cholesterol. High serum LDL and VLDL levels are considered as atherogenic whereas high HDL (over <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">60 \mathrm{mg} / \mathrm{dl}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">60</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">dl</span></span></span></span></span></span> ) has a protective effect. Asians commonly have low HDL levels ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>35</mn></mrow><annotation encoding="application/x-tex">&lt;35</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">35</span></span></span></span></span> <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{dl}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">dl</span></span></span></span></span></span> ), probably because of high carbohydrate diet. The normal fasting plasma is clear and contains about 700 mg of total lipids, comprising TG, cholesterol and phospholipids. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> of cholesterol is in ester form. Lipoproteins play a major role in distribution and recycling of cholesterol. Body derives cholesterol from:
(1) Diet absorbed from the intestine and
(2) Large amount by de novo synthesis by the liver and peripheral tissues.</p>
<p>In health the plasma cholesterol and TG levels are regulated by several factors such as age, sex, race, genetics, diet, exercise and stress.</p>
<p>Atherosclerosis, a disease which affects large and medium sized arteries, is now a leading cause of death in many developed countries. The atherosclerotic lesion is a localised plaque in the intima and is composed of cholesterol esters, proliferation of smooth muscle, deposition of fibrous proteins (predominantly collagen) and calcification. Such plaques:</p>
<ul>
<li>Narrow the arterial lumen causing distal ischemia.</li>
<li>Ulcerate into the arterial lumen, with thrombosis of the artery and distal embolisation; or,</li>
<li>Weaken the arterial wall, leading to formation of aneurysms.</li>
</ul>
<p>The coronary and the cerebral vessels are common sites of atherosclerosis.
The cause of atherosclerosis is not known.
Experimental and epidemiological evidence suggests a relationship between atherosclerosis and elevated levels of plasma lipids (cholesterol and TG). Although there is no diagnostic abnormal pattern of the plasma lipids in atherosclerotic subjects, an increase in plasma LDL cholesterol and TG has been observed in them. The risk of IHD in such subjets is about thrice that in those with normal plasma cholesterol. A redution of plasma lipids by either dietetic restriction or drugs helps to prevent the progression of atherosclerosis. Studies have confirmed that a reduction in elevated plasma LDL cholesterol does reduce the risk of MI.</p>
<p>Table 40.6 shows the risk of IHD associated with different levels of serum lipids. The major risk factors include age, sex, race, BP, diabetes mellitus and smoking. Some evidence suggests that folic acid deficiency leading to elevated plasma levels of homocysteine may</p>
<p>play a role in the pathogenesis of atherosclerosis.</p>
<p>Table 40.6
Serum lipid levels ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{dl}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">dl</span></span></span></span></span></span> ) and the risk of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">H</mi><mi mathvariant="normal">D</mi></mrow><mo lspace="0em" rspace="0em">∗</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{IHD}^{*}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7619em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">IHD</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7619em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∗</span></span></span></span></span></span></span></span></span></span></span></span></span></p>
<table><thead><tr><th style="text-align: left;">Lipid</th><th style="text-align: center;">Desirable level (Low risk)</th><th style="text-align: center;">Borderline level (Moderate risk)</th><th style="text-align: center;">Abnormal level (High risk)</th></tr></thead><tbody><tr><td style="text-align: left;">Total cholesterol</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>200</mn></mrow><annotation encoding="application/x-tex">&lt;200</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">200</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>200</mn><mo>−</mo><mn>240</mn></mrow><annotation encoding="application/x-tex">200-240</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">200</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">240</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>240</mn></mrow><annotation encoding="application/x-tex">&gt;240</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">240</span></span></span></span></span></td></tr><tr><td style="text-align: left;">LDL cholesterol</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>130</mn></mrow><annotation encoding="application/x-tex">&lt;130</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">130</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>130</mn><mo>−</mo><mn>160</mn></mrow><annotation encoding="application/x-tex">130-160</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">130</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">160</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>160</mn></mrow><annotation encoding="application/x-tex">&gt;160</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">160</span></span></span></span></span></td></tr><tr><td style="text-align: left;">HDL cholesterol</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>60</mn></mrow><annotation encoding="application/x-tex">&gt;60</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">60</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>60</mn></mrow><annotation encoding="application/x-tex">40-60</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">60</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>40</mn></mrow><annotation encoding="application/x-tex">&lt;40</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">40</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Triglycerides</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>200</mn></mrow><annotation encoding="application/x-tex">&lt;200</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">200</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>200</mn><mo>−</mo><mn>400</mn></mrow><annotation encoding="application/x-tex">200-400</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">200</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">400</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>400</mn></mrow><annotation encoding="application/x-tex">&gt;400</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">400</span></span></span></span></span></td></tr></tbody></table>
<p>The risk increases further with other risk factors such as smoking, diabetes and hypertension.
Hyperlipoproteinemias which are incriminated in the pathogenesis of atherosclerosis are divided into five Fredrickson's types (I to V) depending on the class of lipoprotein(s) elevated (Table 40.7). In practice, determination of the total TG, total cholesterol and HDL cholesterol levels also allows to diagnose (a) hyperlipidemia, and (b) hyperlipoproteinemia type. The commonest hyperlipidemias are secondary to dietary excess, uncontrolled diabetes mellitus, hypothyroidism, alcoholism, chronic renal failure and drugs such as etretinate, glucocorticoids used for prolonged periods and protease inhibitors. Therefore, every patient with hyperlipidemia (defined as elevation of cholesterol and/or TG) should be investigated for such factors.</p>
<p>Table 40.7
Fredrickson's classification of hyperlipoproteinemias</p>
<table><thead><tr><th style="text-align: center;">Phenotype</th><th style="text-align: center;">I</th><th style="text-align: center;">II a</th><th style="text-align: center;">II b</th><th style="text-align: center;">III</th><th style="text-align: center;">IV</th><th style="text-align: center;">V</th></tr></thead><tbody><tr><td style="text-align: center;">Lipoprotein elevated</td><td style="text-align: center;">Chylo</td><td style="text-align: center;">LDL</td><td style="text-align: center;">LDL &amp; VLDL</td><td style="text-align: center;">IDL</td><td style="text-align: center;">VLDL</td><td style="text-align: center;">VLDL &amp; Chylo.</td></tr><tr><td style="text-align: center;">Total cholsterol mg%</td><td style="text-align: center;">N to slightly <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↑</mo></mrow><annotation encoding="application/x-tex">\uparrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↑</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>300</mn><mo>−</mo><mn>600</mn></mrow><annotation encoding="application/x-tex">300-600</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">300</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">600</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>300</mn><mo>−</mo><mn>600</mn></mrow><annotation encoding="application/x-tex">300-600</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">300</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">600</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>300</mn><mo>−</mo><mn>600</mn></mrow><annotation encoding="application/x-tex">300-600</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">300</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">600</span></span></span></span></span></td><td style="text-align: center;">N to slightly <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↑</mo></mrow><annotation encoding="application/x-tex">\uparrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↑</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>250</mn><mo>−</mo><mn>500</mn></mrow><annotation encoding="application/x-tex">250-500</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">250</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">500</span></span></span></span></span></td></tr><tr><td style="text-align: center;">LDL cholesterol</td><td style="text-align: center;">N</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↑</mo></mrow><annotation encoding="application/x-tex">\uparrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↑</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↑</mo></mrow><annotation encoding="application/x-tex">\uparrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↑</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↑</mo></mrow><annotation encoding="application/x-tex">\uparrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↑</span></span></span></span></span></td><td style="text-align: center;">N</td><td style="text-align: center;">N</td></tr><tr><td style="text-align: center;">Triglycerides mg%</td><td style="text-align: center;">Usually <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>2000</mn></mrow><annotation encoding="application/x-tex">&gt;2000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2000</span></span></span></span></span></td><td style="text-align: center;">N</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>400</mn></mrow><annotation encoding="application/x-tex">&lt;400</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">400</span></span></span></span></span></td><td style="text-align: center;">200-1000</td><td style="text-align: center;">500-1500</td><td style="text-align: center;">500-1500</td></tr><tr><td style="text-align: center;">Relative frequency %</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>1</mn></mrow><annotation encoding="application/x-tex">&lt;1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span></span></span></span></span></td><td style="text-align: center;">10</td><td style="text-align: center;">40</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>1</mn></mrow><annotation encoding="application/x-tex">&lt;1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span></span></span></span></span></td><td style="text-align: center;">45</td><td style="text-align: center;">5</td></tr><tr><td style="text-align: center;">Atherogenicity</td><td style="text-align: center;">None</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span></td></tr></tbody></table>
<p>Chylo <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span></span></span></span></span> Chylomicrons</p>
<ul>
<li><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span></span></span></span></span> Especially for peripheral vascular disease
Type I hyperlipoproteinemia is due to a defect in lipoprotein lipase and is induced by dietary fat. Type II is hereditary. Type III is due to hereditary dysbetalipoproteinemia. Types IV and V are carbohydrate induced and are associated with insulin resistance as well.</li>
</ul>
<p>Elevation of plasma LDL cholesterol, especially when combined with reduced HDL, is associated with increased risk of atherosclerotic arterial disease. Raised concentration of TG and VLDL may also contribute. Extreme elevation of plasma TG can lead to pancreatitis.</p>
<p>Management: Stress reduction, weight reduction, modification of diet, abstinence from alcohol and smoking and treatment of the causative disease, if any, such as hypothyroidism and diabetes mellitus, are more important than lipid-lowering drugs. The cornerstone of</p>
<p>the current therapy is improvement in the lifestyle for the primary and secondary prevention of CAD. It is claimed that existing CAD can be reversed by appropriate nonsurgical and even non-pharmacological regimens (such that of Dean Ornish), which comprises:</p>
<ul>
<li>Dietary modification</li>
<li>Increased physical activity</li>
<li>Elimination of associated risk factors, e.g. smoking, alcohol.</li>
<li>Stress control</li>
</ul>
<p>Dietary modification implies:</p>
<ul>
<li>Decrease the consumption of foods rich in saturated fats (restrict up <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> of total calories). The dietary cholesterol appears to contributes relatively insignificantly to serum cholesterol level. However, processed products rich in cholesterol may be harmful as they contain trans-fat.</li>
<li>Reduce intake of salt and sugars</li>
<li>Increasing the consumption of poultry, low fat fish ans skimmed milk, together with large helpings of vegetables, fruits and mixed nuts. In fact, the traditional Indian vegetarian diet, which contains lot of fibres andd pulses with limited fat has much to recommend in this respect.
The principles of dietary modification for treatment hyperlipidemia are outlined in Table 40.8. Basically, a single type of dietary modification is appropriate for the prevention and treatment of all types of hyperlipidemia, except primary chylomicronemia (Type I). In this last condition, the dietary fat needs to be reduced to the lowest possible level ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> of the total daily calories), and medium chain fats substituted for other types in the diet. In all other varieties, the diet recommendation is as follows:</li>
</ul>
<p>Table 40.8
Principles of diet therapy in hyperlipoproteinemia</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>- Restriction of fat calories to less than 20% of total calories.
</span>- Saturated, monounsaturated and polyunsaturated fats should form 1/3" each of the total dietary fat. Avoid trans fatty acids.
- Increased consumption of vegetables, fresh fruit, cereals, nuts especially walnuts and almonds (in moderation) and whole grain products.
- Increased consumption of fish, where possible/permitted.
- Drastic reduction in alcohol consumption and smoking.</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="- Restriction of fat calories to less than 20% of total calories.
- Saturated, monounsaturated and polyunsaturated fats should form 1/3&quot; each of the total dietary fat. Avoid trans fatty acids.
- Increased consumption of vegetables, fresh fruit, cereals, nuts especially walnuts and almonds (in moderation) and whole grain products.
- Increased consumption of fish, where possible/permitted.
- Drastic reduction in alcohol consumption and smoking." style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>The above principles may need to be modified in the case of children, pregnant women and old people.</p>
<ul>
<li>Reduce the body weight to the ideal level.</li>
<li>Decrease the consumption of total fats to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">15-20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> of the daily caloric intake. Only one third of these fat calories should be supplied by saturated fats (fats of animal origin and coconut oil), one third by mono-unsaturated fats (olive oil, mustard oil, til oil and groundunt oil), and the rest one third by polyunsaturated fats (sunflower, corn and safflower oils).
Saturated fally acids (SFA) are straight chained and vary in the chain length. Unsaturated fatty acids (UFA), on the other hand, also vary in the number and the position of their double bonds. In natural products, the double bonds are in cis form; while in the case of commercial products, they are converted into trans form (TFA) following partial hydrogenation. The trans forms:
(1) Are more stable and have higher melting points.</li>
</ul>
<p>(2) Though unsaturated, they decrease HDL cholesterol and increase LDL cholesterol, triglycerides and lipoproteins.
(3) Can also cause endothelial dysfunction,
(4) Promote abdominal fat accumulation, and insulin resistance in animals and
(5) Their consumption is associated with increased risk of IHD in humans.</p>
<p>As deep-fried and bakery food products are the major dietary sources of TFA, these should be avoided. In fact, some countries have made it mandatory to keep the TFA content of all commercial food products to less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> of the total fat present.</p>
<p>Excessive use of polyunsaturated fats in diet is also no longer recommended as they are known to lower the protective HDL cholesterol levels; further, they are susceptible to hydroperoxidation, thus leading to the generation of the issue damaging free radicals in the body. Hydrogenated fats and prolonged heating of facts, also have deleterious effects similar to those of saturated fats and should be avoided.</p>
<p>With the reduction in the total fat content of the diet, carbohydrates become a major source of calories. Use of complex carbohydrates such as starchy foods (cereals, beans, pulses) should be encouraged. Provided the excessive use of simple sugars (not to exceed <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> of the total daily calories) is avoided, the fear of hypertriglyceridemia with liberal carbohydrate consumption ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>65</mn><mo>−</mo><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">65-70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">65</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> of the daily calorie intake) in unfounded.</p>
<p>Traditional approaches to prophylaxis of atherosclerosis have focused on one aspect of its pathogenesis viz. platelet function or blood lipids. Coastal Eskimos who eat a traditional diet of fish and seals have a low incidence of cardiovascular diseases, chronic inflammatory diseases such as psoriasis, and asthma. This is believed to be due to consumption of fatty fish rich in two omega-3-fatty acids-eicosapentaenoic acid and docosahexaenoic acid, as against omega-6 fatty acids (linoleic acid), present in vegetable oils, which is converted to arachidonic acid (Chapter 25). Studies indicate that the administration of omega-3-polyunsaturated fatty acids in the form of salmon or cod liver oil results in reduction in platelet responsiveness, lowering of blood lipids and improvement of blood flow. Long term intake of cod liver oil promotes the formation of the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. Further, exogenous eicosapentaenoic acid dose-dependently suppresses formation of leukotriene-B4. Omega-3-fatty-acid-rich fish oil reduces the blood TG levels; it has little effect on cholesterol levels. Vegetarians get omega-3 fatty acids from linseed oil, flaxseed oil or powder, pumpkin seed oil, soyabean oil, canola and sunflower oil, but to a smallar extent. Omega-3-fatty acids cannot be synthesised in humans and deficiency syndromes have been described. These fatty acids may play a role in the prophylaxis of atherosclerosis (Chapter 25).</p>
<p>Drug therapy is indicated in those:</p>
<ul>
<li>In whom the dietary measures are not successful.</li>
<li>Who find the dietary restrictions irksome; and</li>
<li>Who are at risk of pancreatitis because of very high TG levels ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1000</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1000 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">1000</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span> ).</li>
</ul>
<p>Drug therapy should be started with the understanding that it will have to be continued life-long. The drugs do not cure the basic disorder of lipoprotein metabolism but symptomatically control only one aspect of the disease process.</p>
<p>Antihyperlipidemic drugs are also beneficial to those with symptomatic atherosclerotic disease such as angina and many cardiovascular risk factors. Used judiciously these drugs are capable of retarding the atheroscelerotic process and prolonging life. In all patients, a life style</p>
<p>modification is very important and should be monitored regularly. Lipid levels are retested at an interval of 12 months for adjusting the drug dose while other laboratory parameters like CPK or LFT are estimated as per the clinical needs.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antihyperlipidemic-drugs">Antihyperlipidemic Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antihyperlipidemic-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These drugs act predominantly on:</p>
<ul>
<li>Elevated cholesterol, e.g., HMG-CoA reductase inhibitors (Statins), Cholestyramine resin, Ezetimibe, Fibre;</li>
<li>Elevated triglycerides, e.g., Fibric acid derivatives (fibrates), Fish oil or,</li>
<li>Both, e.g., Nicotinic acid.</li>
</ul>
<p>STATINS (HMG-CoA-reductase inhibitors):
Drugs belonging to this class are structural analogues of HMG-CoA. They are listed in Table 40.9.</p>
<p>Table 40.9
Statins and the doses recommended</p>
<table><thead><tr><th style="text-align: left;">Statins</th><th style="text-align: center;">High intensity statin therapy (mg/day)</th><th style="text-align: center;">Moderate intensity statin therapy (mg/day)</th></tr></thead><tbody><tr><td style="text-align: left;">Atorvastatin</td><td style="text-align: center;">40 to 80</td><td style="text-align: center;">10 to 20</td></tr><tr><td style="text-align: left;">Rosuvastatin</td><td style="text-align: center;">20 to 40</td><td style="text-align: center;">5 to 10</td></tr><tr><td style="text-align: left;">Simvastatin</td><td style="text-align: center;">-</td><td style="text-align: center;">20 to 40</td></tr><tr><td style="text-align: left;">Pravastatin</td><td style="text-align: center;">-</td><td style="text-align: center;">40 to 80</td></tr><tr><td style="text-align: left;">Lovastatin</td><td style="text-align: center;">-</td><td style="text-align: center;">40</td></tr><tr><td style="text-align: left;">Fluvastatin</td><td style="text-align: center;">-</td><td style="text-align: center;">extended-release: 80 &lt;br&gt; 40 twice a day</td></tr><tr><td style="text-align: left;">Pitavastatin</td><td style="text-align: center;">-</td><td style="text-align: center;">2 to 4</td></tr></tbody></table>
<p>Mechanism of action: Normally, about 70-75% of plasma LDL is removed by hepatocytes, by receptor-mediated endocytosis. Cholesterol esters from LDL molecules are hydrolysed in the liver to free cholesterol. The liver also produces cholesterol by de novo synthesis by a pathway involving formation of mevalonic acid by the enzyme Hydroxy Methyl Glutaryl Co-enzyme A reductase (HMG-CoA reductase). Statins inhibit this rate-limiting enzyme. This decreases hepatic cholesterol synthesis, which leads to increased synthesis of high affinity LDL receptors (up-regulation) on the surface of liver cells. This results into increased clearance (uptake) of cholesterol-rich plasma LDL with subsequent reduction in plasma LDL cholesterol (Fig. 40.1). This action is dose dependent and is observed in 10 days. Full effect is generally seen within 6 weeks. Effect of statins on HDL-C is variable.</p>
<p><img src="assets/images/image-20251214-94d72225.jpeg" alt="img-48.jpeg"></p>
<p>FIG. 40.1 Hepatic regulation of synthesis of cholesterol and bile acids. (I) Site of action of statins; (II) Site of action of resins and ezetimibe</p>
<p>Absorption, fate and excretion: Given orally, the absorption of all the statins (except fluvastatin) varies between <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span>. Fluvastatin is absorbed almost completely. Lovastatin and simvastatin are prodrugs and are hydrolysed in the GI tract to the active metabolites. Atorvastatin, fluvastatin and rosuvastatin are fluorinated compounds that are active as such. All undergo first-pass metabolism and most of the dose is excreted in the bile; only about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5-20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> is excreted in the urine.</p>
<p>Adverse reactions: Generally statins are well tolerated. ADR are mostly mild and dose dependent. They may cause reversible rise in hepatic aminotransferase levels. Small rise in the plasma creatine kinase level is not uncommon. Rarely, it may be marked, and accompanied by muscular pains (myositis) and even myopathy. Rhabdomyolysis is rare.</p>
<p>Rarely, statins may cause impotence, gynecomastia, peripheral neuropathy, memory loss, insomnia, mood changes and depression.</p>
<p>Clinical trials demonstrate that statins may increase the risk of new-onset diabetes but incidence is not as much as they reduce the cardiovascular risk.</p>
<p>Statins are contraindicated in pregnancy and in a woman planning to become pregnant, during breast-feeding, in children and in patients with severe liver disease.</p>
<p>Drug interactions: Combination of a statin with a fibric acid derivative and nicotinic acid potentiates the rise in plasma CPK level.</p>
<p>Lovastatin, simvastatin and atorvastatin undergo extensive first-pass metabolism by CYP3A4 and their toxicity can be increased by the concurrent use of hepatic microsomal enzyme inhibitors such as ketoconazole, isoniazid, erythromycin, cyclosporine and HIV protease inhibitors. Fluvastatin and rosuvastatin are metabolised by hepatic CYP2C9. Inhibitors of this enzyme such as ketoconazole, metronidazole and cimetidine can increase the plasma levels of these statins.</p>
<p>Maximum dose of simvastatin recommended is 10 mg in patients taking amiodarone, diltiazem or verapamil and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">20 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day in those on amlodipine and ranolazine.</p>
<p>Therapeutic uses: Statins are useful in both primary and secondary prophylaxis of hypercholesterolemia. Their main indications are:</p>
<ul>
<li>MI or any cardiovascular event.</li>
<li>Patients less than 70 years with known IHD.</li>
<li>Familial hypercholesterolemia.</li>
<li>Diabetes mellitus.</li>
<li>Subjects with strong family history of premature cardiovascular disease.</li>
</ul>
<p>Statins, used alone in maximum doses, can lower LDL level by 30-50%. Statin therapy can reduce the 5 year incidence of major coronary events, and stroke significantly, largely irrespective of the initial lipid level.</p>
<p>In general, statins are more effective in subjects with high risk factors than a particular LDL cholesterol level. Currently they are indicated in:
(i) Individuals with clinical evidence of atherosclerotic cardiovascular disease (ASCVD) IHD, MI.
(ii) Subjects with primary elevation of LDL cholesterol <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>190</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&gt;190 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">190</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span>
(iii) Subjects with age 40-75 years with diabetes mellitus and LDL cholesterol between 70<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>189</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">189 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">189</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span> without clinical evedence of ASCVD
(iv) Subjects with age 40-75 years, having LDL cholesterol between <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mo>−</mo><mn>189</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70-189 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">70</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">189</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span> with no evidence of diabetes mellitus or ASCVD but having estimated 10-years ASCVD risk of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">7.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">7.5%</span></span></span></span></span> or higher. This risk is calculated based on the presence of risk factors in a given patient.</p>
<p>Patients with clinical evidence of ASCVD and those with LDL-cholesterol <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>190</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&gt;190 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">190</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span> are treated with high intensity statin therapy, which reduces LDL-cholesterol by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&gt;50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span>. Others are treated with moderate intensity, wherein a decrease by 30 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&lt;50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> is expected (Table 40.9). Considering that low doses are required in Asian polulations (Table 40.10), there is a need for studies in Indians to establish appropriate dose range.</p>
<p>Table 40.10
Doses of commonly used statins in Asian population</p>
<table><thead><tr><th style="text-align: left;">Drug</th><th style="text-align: center;">Starting/Max. dose (mg/day)</th></tr></thead><tbody><tr><td style="text-align: left;">Lovastatin</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">/</mi><mn>80</mn></mrow><annotation encoding="application/x-tex">10 / 80</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10/80</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Pravastatin</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">/</mi><mn>20</mn></mrow><annotation encoding="application/x-tex">10 / 20</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10/20</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Simvastatin</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">/</mi><mn>20</mn></mrow><annotation encoding="application/x-tex">5 / 20</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5/20</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Fluvastatin</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">/</mi><mn>60</mn></mrow><annotation encoding="application/x-tex">20 / 60</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20/60</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Atorvastatin</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">/</mi><mn>40</mn></mrow><annotation encoding="application/x-tex">10 / 40</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10/40</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Rosuvastatin</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mi mathvariant="normal">/</mi><mn>20</mn></mrow><annotation encoding="application/x-tex">2.5 / 20</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2.5/20</span></span></span></span></span></td></tr></tbody></table>
<p>Atorvastatin may be given at any time of the day; pravastatin and fluvastatin at bedtime; others with evening meal.
There is no unanimity about what can be considered as an "ideal" level of serum cholesterol and hence currently importance is given to the clinically relevant risk factors rather than chasing a particular target level for LDL cholesterol. Routine use of statin in subject with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>75</mn></mrow><annotation encoding="application/x-tex">&lt;75</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">75</span></span></span></span></span> years and without evidence of ASCVD and those with NYHA class II, III, and IV HF (see Chapter 31) do not seem to be benefitted.</p>
<p>Statins also possess other lipid-independent effects. These are:</p>
<ul>
<li>
<p>Decrease in platelet aggregation and in fibrinogen levels.</p>
</li>
<li>
<p>Improvement in endothelial function and increase in local NO production.</p>
</li>
<li>
<p>Decrease in macrophage infiltration into the vessel wall.</p>
</li>
<li>
<p>Decrease in the arterial muscle proliferation.</p>
</li>
<li>
<p>Retardation of the progression of hypertrophy of the vessel wall; and</p>
</li>
<li>
<p>Decrease LDL oxidation in the vessel wall.</p>
</li>
</ul>
<p>These effect contribute to anti-inflammatory potential of statins.
However, how far they contribute to the over all beneficial effects in the patient is not clear.</p>
<p>Choice of statin: Therapeutically there are no clear differences among various statins. Hence the choice of the statin depends upon the degree of LDL elevation, drug pharmacokinetics, drug interactions, presence of hepatic/renal disease and cost. Atorvastatin and simvastatin are more efficacious than others, and therefore may be preferred. Atorvastatin and fluvastatin need no dose adjustment in patients with renal impairment. Pravastatin and fluvastatin are not metabolised by CYP3A4 and are likely to cause few drug interactions. Atorvastatin and rosuvastatin have long <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> ( 14 and 19 hours, respectively) and can be taken at any time of the day.</p>
<p>Since most cholesterol synthesis occurs during the night, the short <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi>t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">t^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathnormal">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> compounds are best administered at night as a single dose.</p>
<p>EZETIMIBE: This prodrug, 2-azetidinone, is converted in intestine to an active metabolite ezetimibe glucuronide ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mn>22</mn><mrow><mi mathvariant="normal">h</mi><mi mathvariant="normal">r</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2} 22 \mathrm{hr}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mord">22</span><span class="mord"><span class="mord mathrm">hr</span></span></span></span></span></span> ). It binds to a intestinal mucosal transporter, and decreases delivery of dietary and biliary cholesterol to the liver. Thus, it inhibits absorption of cholesterol by the small intestine. Reduction of hepatic cholesterol stores causes increase in LDL receptors on the hepatocytes (up-regulation) and an increased LDL cholesterol clearance from the circulation. The plasma total and LDL cholesterol decreases with minimal increase in HDL-C (Table 40.10). It also interrupts the entero-hepatic cycling of cholesterol. It is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> bound to plasma proteins and is largely excreted in the faeces.</p>
<p>Adverse reactions are fatigue, dizziness, headache, abdominal discomfort, diarrhoea, arthralgia and hypersensitivity reactions.</p>
<p>Therapeutic uses: It can be used as monotherapy in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">5-10 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day. However, it acts synergistically when combined with statins, and is particularly useful in patients who do not tolerate large doses of statins. However, this decrease in cholesterol level has not shown to decrease the progress of atherosclerosis. It should be avoided in children and in pregnant/lactating women.</p>
<p>CHOLESTYRAMINE RESIN: This insoluble chloride salt of a basic anion exchange resin, has a strong affinity for bile salts (cholates) in the intestine. It binds the cholates into an insoluble complex which is excreted in faeces (Fig. 40.1). The result is decreased absorption of exogenous cholesterol and increased metabolism of endogenous cholesterol into bile acids in the liver. This leads to increased LDL receptors on liver cells and increased removal of LDL from the circulation. The drug, however, does not significantly lower the plasma levels of triglycerides. The dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mo>−</mo><mn>24</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">12-24 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">12</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">24</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> per day in a single or divided doses.</p>
<p>Adverse reactions: These include nausea, vomiting, heartburn and constipation. Large doses may interfere with absorption of fats and fat-soluble vitamins, causing steatorrhoea. It also interferes with the absorption of thyroid hormones, tetracyclines, warfarin, digoxin and phenobarbitone.</p>
<p>It is now rarely used to treat hyperlipidemia. It may be useful in relieving pruritus associated with biliary cirrhosis and cholestatic jaundice.</p>
<p>Colestipol, and Colesevalam like cholestyramine, are bile acid sequestrants.
GUGULIPID: This is the steroidal fraction derived from the plant Commiphora mukul</p>
<p>and has moderate and variable hypocholesterolemic activity. It is well tolerated. It is available as 25 mg tablets.</p>
<p>FIBRE: Soluble fibres (pectins in citrus fruits, mucilages in psyllium seeds, gums in oat products and in beans) have a modest effect in lowering serum cholesterol. Psyllium seeds (Isapgol) is administered in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo>−</mo><mn>5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2.5-5 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> twice a day; oat bran is used in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>150</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50-150 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">150</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> a day. Insoluble fibre such as is present in wheat bran is not effective in lowering serum cholesterol (Chapter 42).</p>
<p>FIBRATES are the derivatives of fibric (isobutyric) acid (Fig. 40.2) and include gemfibrozil, bezafibrate and fenofibrate. Clofibrate is no more used.
<img src="assets/images/image-20251214-2c1f6014.jpeg" alt="img-49.jpeg"></p>
<p>Mechanism of action: These drugs stimulate the nuclear transcription receptor, Peroxisome Proliferator Activated Receptor-alpha (PPAR- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> ) that controls the expression of genes, which mediate TG metabolism. They increase lipoprotein lipase (lpL) activity and the hydrolysis of TG and promote HDL production. They reduce the incorporation of fatty acids into VLDL in the liver, thus inhibiting its synthesis and secretion. The plasma TG declines by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span>, and cholesterol by 10-15%. HDL increases by 20% (Table 40.11). They are claimed to reduce plasma fibrinogen levels, to increase fibrinolysis and to reduce abnormal platelet stickiness.</p>
<p>Table 40.11
Effects of lipid lowering agents on lipid fractions</p>
<table><thead><tr><th style="text-align: left;">Drug</th><th style="text-align: center;">Total cholesterol</th><th style="text-align: center;">LDL cholesterol</th><th style="text-align: center;">HDL cholesterol</th><th style="text-align: center;">Triglycerides (TG)</th></tr></thead><tbody><tr><td style="text-align: left;">Statins</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↓</mo></mrow><annotation encoding="application/x-tex">\downarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↓</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↓</mo><mo>↓</mo></mrow><annotation encoding="application/x-tex">\downarrow \downarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↓↓</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↑</mo></mrow><annotation encoding="application/x-tex">\uparrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↑</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↓</mo></mrow><annotation encoding="application/x-tex">\downarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↓</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Ezetimibe</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↓</mo></mrow><annotation encoding="application/x-tex">\downarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↓</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↓</mo></mrow><annotation encoding="application/x-tex">\downarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↓</span></span></span></span></span></td><td style="text-align: center;">-</td><td style="text-align: center;">-</td></tr><tr><td style="text-align: left;">Fibrates</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↓</mo></mrow><annotation encoding="application/x-tex">\downarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↓</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↑</mo></mrow><annotation encoding="application/x-tex">\uparrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↑</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↑</mo></mrow><annotation encoding="application/x-tex">\uparrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↑</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↓</mo><mo>↓</mo></mrow><annotation encoding="application/x-tex">\downarrow \downarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↓↓</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Nicotinic acid (NA)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↓</mo></mrow><annotation encoding="application/x-tex">\downarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↓</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↓</mo></mrow><annotation encoding="application/x-tex">\downarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↓</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↑</mo><mo>↑</mo></mrow><annotation encoding="application/x-tex">\uparrow \uparrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↑↑</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↓</mo></mrow><annotation encoding="application/x-tex">\downarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↓</span></span></span></span></span></td></tr></tbody></table>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↑</mo><mi mathvariant="normal">/</mi><mo>↑</mo><mo>↑</mo><mo>=</mo></mrow><annotation encoding="application/x-tex">\uparrow / \uparrow \uparrow=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↑</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">↑↑=</span></span></span></span></span> Increases; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↓</mo><mi mathvariant="normal">/</mi><mo>↓</mo><mo>↓</mo><mo>=</mo></mrow><annotation encoding="application/x-tex">\downarrow / \downarrow \downarrow=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↓</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">↓↓=</span></span></span></span></span> Decreases.
Absorption, fate and excretion: They are almost completely absorbed from the gut, are highly protein bound (more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> ). They are largely excreted unchanged in the urine.</p>
<p>Adverse reactions: Fibrates are generally well tolerated although, they occasionally produce allergic reactions, nausea and diarrhoea. Though rare, potentially serious effects on the skeletal (myositis) and cardiac muscle have been reported. Fibrates should be avoided in patients with renal or hepatic damage and in alcoholics (with hypertriglyceridemia) who are predisposed to myositis. Long term therapy is associated with an increase in gallstone formation. The combination of a fibrate and a statin increases the chance of rhabdomyolysis and myopathy. These drugs displace acidic drugs from their plasma protein binding and may enhance the action of warfarin and sulfonylureas.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Fenofibrate: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>67</mn><mo separator="true">,</mo><mn>134</mn><mo separator="true">,</mo><mn>200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">67,134,200 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">67</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">134</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">200</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> single dose capsules. Dose: One capsule OD with a meal.
(ii) Gemfibrozil 300 mg capsules. Dose: 600 mg twice a day 30 minutes before meals.
(iii) Bezafibrate: 200 mg tablets. Doses: 200 mg three times a day with meals.</p>
<p>Therapeutic uses: These drugs are effective in reducing mainly plasma TG. Fenofibrate is preferred to gemfibrozil.</p>
<p>Fish oil: Epidemiological evidence suggests that fatty-fish-eating communities have a lower incidence of IHD than non-fish-eaters. Omega-3 PUFA in the fish oil decreases hepatic production of TG and increases its clearance. Thus they reduce plasma TG but have little effect on HDL and LDL cholesterol and can sometimes increase total cholesterol upto <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span>. They also lead to synthesis of leukotrienes and prostaglandins of series 1 and 3, which are less pro-inflammatory than those of series 2 (Chapter 25). Unlike gemfibrozil and niacin, omega-3 PUFAs do not interact with statins to enhance the incidence of myositis. They may decrease the risk of cardiac death in recent MI. But, in chronic IHD there is a possibility of a proarrhythmic effect.</p>
<p>Adverse effects: These include eructions, dyspepsia and unpleasant after taste. Large doses of Omega 3- PUFA can inhibit platelet aggregation and may worsen glycemic control in diabetes.</p>
<p>Eating fatty fish may be beneficial in healthy people but there is no convincing evidence supporting the prevention of cardiovascular disease in the general population. The drug is contraindicated in patients with type IIa hyperlipidemia. The dose is five 1 g capsules bid.</p>
<p>Omega-3 fatty acids are also present in nuts (especially walnuts), dark green leafy vegetables, soya beans, flax seeds and flax seed oil, and hemp seeds.</p>
<p>Icosapent ethyl, the ethyl ester of eicosapentanoic acid is available as 1 gm capsule. A dose, 2 gm bid with food can lower serum TG without increasing LDL-cholesterol.</p>
<p>NICOTINIC ACID: This vitamin in large doses effectively and rapidly reduce plasma TG by lowering VLDL levels; LDL levels diminish more slowly, whereas HDL levels rise during therapy. Nicotinamide lacks these actions.</p>
<p>Mechanism of action: In the adipose tissue, nicotinic acid inhibits adenylyl cyclase, and prevents lipolysis by hormone sensitive lipase. This reduces the transport of fatty acids to the liver. In the liver, it reduces both synthesis and esterification of fatty acids. The end result is reduction in the hepatic production of VLDL and in plasma TG, VLDL cholesterol and LDL cholesterol. (Table 40.11).</p>
<p>Adverse reactions: In pharmacological doses, nicotinic acid produces intense cutaneous flushing and pruritus by increasing the local prostaglandin levels. This can be minimized by starting with a small dose and gradually building it up to the full dose, and by taking the drug with meals; further, one tablet of aspirin, taken 30 minutes earlier, markedly reduces the flush. Other adverse reactions are nausea, vomiting, diarrhoea; abnormalities of liver function, clinical jaundice; hyperuricemia, hyperglycemia; and potentiation of hypotension caused by antihypertensives.</p>
<p>Therapeutic uses: Nicotinic acid is useful in all forms of hyperlipoproteinemias except type I and is drug of choice in type V hyper-lipoproteinemia. The usual dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>8</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">2-8 \mathrm{~g} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">8</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span></span></span></span></span> day, in divided doses, with meals. It is advisable to start with 100 mg tid with meals and to build up the dose in 2-4 weeks.</p>
<p>Folic acid supplements are used to prevent homocysteinemia (Chapter 35).</p>
<p>Choice of lipid lowering drugs: This is outlined in Table 40.12. The current evidence indicates that the statins are the lipid lowering drugs of choice for most patients at risk of coronary artery disease. No evidence has been observed to support use of non-statin drugs for prevention of atherosclerotic cardiovascular risk.</p>
<p>Table 40.12
Choice of lipid lowering drugs</p>
<table><thead><tr><th style="text-align: center;">Drug</th><th style="text-align: center;">Hypercholesterolemia (Elevated LDL-C + TG &lt; 200 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">l</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{dl})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">dl</span></span><span class="mclose">)</span></span></span></span></span></th><th style="text-align: center;">Combined hyperlipidemia (Elevated LDL-C + TG 200-400 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">l</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{dl})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">dl</span></span><span class="mclose">)</span></span></span></span></span></th><th style="text-align: center;">Hypertriglyceridemia (TG &gt; 400 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">l</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{dl})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">dl</span></span><span class="mclose">)</span></span></span></span></span></th></tr></thead><tbody><tr><td style="text-align: center;">Statins</td><td style="text-align: center;">Drugs of choice</td><td style="text-align: center;">Effective</td><td style="text-align: center;">-</td></tr><tr><td style="text-align: center;">Fibrates</td><td style="text-align: center;">-</td><td style="text-align: center;">Effective in high doses</td><td style="text-align: center;">Drugs of choice</td></tr><tr><td style="text-align: center;">Nicotinic acid</td><td style="text-align: center;">Effective; usefulness limited by adverse effects of full doses</td><td style="text-align: center;">Drug of choice</td><td style="text-align: center;">Effective but poorly tolerated</td></tr></tbody></table>
<p>Statins can be combined with (a) nicotinic acid, or (b) a fibrate, in resistant cases.</p>
<p>41</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="emetics-drug-therapy-of-vomiting-vertigo-and-diarrhoea">Emetics, Drug Therapy of Vomiting, Vertigo and Diarrhoea<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#emetics-drug-therapy-of-vomiting-vertigo-and-diarrhoea" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Vomiting, though unpleasant, is a protective reflex which helps to rid the stomach of noxious material. Vomiting also occurs in physiological situations such as pregnancy, but often it is an indication of ill health and needs to be treated.</p>
<p>Physiology of vomiting: The act of vomiting is accompanied by a complex series of movements, controlled by the vomiting centre. It receives afferent impulses from:</p>
<ul>
<li>Higher centres in the brain</li>
<li>Chemoreceptor trigger zone (CTZ)</li>
<li>Vestibular apparatus; and</li>
<li>Peripheral structures including the GI tract and nucleus tractus solitarius</li>
</ul>
<p>Figure 41.1 shows the mechanism of vomiting and the receptors involved.
<img src="assets/images/image-20251214-7517d6aa.jpeg" alt="img-50.jpeg"></p>
<p>NTS = Nucleus Tractus Solitarius; CTZ = Chemoreceptor trigger zone; AMI = Acute Myocardial infarction; NK = Neurokinin receptor; M = Muscarinic receptors; H = Histamine receptors</p>
<p>A major sensory relay station in the afferent vomiting pathway is the chemoreceptor trigger zone (CTZ), situated in the lateral border of the area postrema of the medulla oblongata. Histologically, CTZ resembles the carotid body and is not a part of the brain. It is in direct contact with the circulating blood and is outside the BBB. A variety of drugs like morphine, apomorphine, alkylating agents and digitalis stimulate the CTZ while the phenothiazines and certain antihistaminics depress it. However, the CTZ being a purely sensory relay station, is incapable of initiating vomiting in the absence of vomiting centre, while direct stimulation of the latter evokes vomiting irrespective of the CTZ. Vomiting</p>
<p>due to irritation or overdistension of the GI tract and delayed gastric emptying does not involve the CTZ but is directly mediated by stimulation of the vomiting centre via visceral vagal afferents. Similarly, it is likely that vomiting of central origin due to emotions, nauseous odours, and similar factors does not involve the CTZ but is due to impulses directly reaching the vomiting centre. On the other hand, vomiting of vestibular origin is mediated by the pathway - vestibular nuclei, cerebellum, CTZ and the vomiting centre.</p>
<p>Gastroesophageal reflux (GER) is not true vomiting; it occurs as a result of failed normal esophageal function. GER is effortless and generally not associated with autonomic symptoms.</p>
<p>Apart from 5-HT, other NT such as DA, neurokinins (NK) and histamine probably play an important role in the process of vomiting. Three different NKs have been identified: substance <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>, neurokinin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi></mrow><annotation encoding="application/x-tex">A</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span></span></span></span></span> and neurokinin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi></mrow><annotation encoding="application/x-tex">B</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span></span></span></span></span> which are believed to act as neurotransmitters/neuromodulators. Substance <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span> has been identified in the nucleus tractus solitarius and the area postrema of the brainstem, and also with 5-HT within the enterochromaffin cells of the GI tract. It is excitatory in nature and can induce vomiting.</p>
<p>Vomiting is usually preceded by the feeling of nausea and increased secretion of saliva, bronchial fluid and sweat. The muscles involved in the act of coughing also take part in the act of vomiting, and the vagal, vomiting, and cough centres have a close functional relationship. Vomiting can also be induced voluntarily.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="emetics">Emetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#emetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The drugs that produce vomiting are termed emetics. These can be classified as: I Centrally acting, by stimulation of the CTZ e.g. Apomorphine and Morphine. II Peripherally acting e.g. Mustard, Antimony-potassium tartrate (tartar emetic) and Hypertonic sodium chloride.
III Both peripherally and centrally acting e.g. Ipecacuanha.
I Centrally acting emetics:
APOMORPHINE: This drug (Chapters 10 and 15), given SC, causes vomiting within 15 minutes. In hypersensitive individuals, however, even a subtherapeutic dose may elicit severe emesis. Vomiting is often accompanied by sedation. Apomorphine induced vomiting is effectively suppressed by chlorpromazine. Large doses often produce restlessness, tremors, occasionally convulsions, and respiratory depression. The drug may cause hypotension, syncope and coma. The adverse effects can be treated by a specific antidote, nalorphine, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5-10 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> IV.</p>
<p>Although apomorphine is a highly effective emetic, it is not used as an emetic. II Peripherally acting emetics: These cause vomiting reflexly by irritating the gastric mucosa. The drugs are:</p>
<p>MUSTARD: This acts by virtue of its volatile oil which is formed as a result of a reaction between a glycoside and an enzyme, in the presence of water. Although it is uncertain in action, it is safe and easily available. Hence, it forms one of the common household remedies. Dose: 1 teaspoonful in 300 ml water.</p>
<p>SODIUM CHLORIDE (hypertonic): Given orally, it withdraws fluid from the gastric cell lining. This causes irritation with reflex emesis.
III Both peripherally and centrally acting emetics: Ipecacuanha syrup which contains, an alkaloid emetine is a safe emetic. It can be administered relatively safely in older children. It should be avoided in infants. The drug can evoke emesis in poisoning with drugs that depress the CTZ e.g. chlorpromazine. The usual adult dose is 15 ml by mouth and may be repeated after 20 minutes if the individual fails to vomit.</p>
<p>Therapeutic uses of emetics: The therapeutic use of emetics is limited to certain cases of poisoning, especially where facilities for gastric lavage are not available. Aspiration of the gastric contents into the respiratory passage may occur during emesis. In case of a caustic poison, emesis may cause gastric perforation. Severe emesis causes collapse.</p>
<p>Emetics should generally be avoided in:</p>
<ul>
<li>Children and the elderly.</li>
<li>Pregnant women; and</li>
<li>Patients with cardiac decompensation, hypertension, hernia, peptic ulcer and pulmonary tuberculosis.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-vomiting">Drug Therapy of Vomiting<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-vomiting" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Similar stimuli in progressively increasing intensity produce successively anorexia, nausea, and vomiting. In many situations nausea and vomiting seem to serve no discernibly useful purpose and need treatment.</p>
<p>There appear to be wide differences in individual susceptibility to 'become sick' e.g. infants are less susceptible to motion sickness than older children and adults (among whom again there are wide individual differences); women are more susceptible than men and the aged are less susceptible than young adults to postanaesthetic vomiting. Estrogens are believed to lower the threshold of the CTZ, thus possibly explaining the vomiting of pregnancy and the nausea during combination OC therapy.</p>
<p>Vomiting may be psychic in origin and initiated by sights or bad smells. Secondly, it may arise reflexly following GI irritation, MI, biliary and renal colic; the impulses being conveyed (probably directly to the vomiting centre) by both the vagus and the sympathetic nerves. Thirdly, impulses arising from the vestibular apparatus are the primary cause of motion sickness though sight of others vomiting, odours and the expectation of vomiting may all contribute to it. Fourthly, drugs (Table 41.1), metabolites (as in uremia) and raised intracranial tension act on the CTZ to produce vomiting. Finally, any severe pain may make a person 'sick'.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-41-1">Table 41.1<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-41-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Some drugs which cause vomiting</p>
<ul>
<li>Antimicrobials Erythromycin, Tetracyclines, Fluoroquinolones, Metronidazole</li>
<li>Anticancer drugs</li>
<li>Amiodarone</li>
<li>Opioids</li>
<li>Chloroquine; Quinine</li>
<li>Diltiazem</li>
<li>Emetine</li>
<li>Ergot alkaloids</li>
</ul>
<p>The treatment of vomiting consists of:</p>
<ul>
<li>Treatment of the cause, e.g., relief of pain, treatment of intestinal obstruction and colic, reduction in the intracranial tension or correction of metabolic acidosis.</li>
<li>Symptomatic treatment with antiemetics.</li>
<li>Supportive therapy, e.g., correction of dehydration and electrolyte disturbances.</li>
</ul>
<p>Antiemetic are drugs which specifically prevent or relieve nausea and vomiting. They can be classified as:
I Antidopaminergic ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">D</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{D}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors) e.g., Chlorpromazine and related drugs (Chapter 13) Metoclopramide, Domperidone;
II Antihistaminic, e.g., Cyclizine, Meclizine, Promethazine, Dimenhydrinate (Chapter 23); III Anti-5HT <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> e.g., Ondansetron, Granisetron, Dolasetron and Palonosetron (Chapter 24); and Ginger;
IV Antimuscarinic, e.g., Scopolamine;
V Antagonist of the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="bold">N</mi><mi mathvariant="bold">K</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{N K}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathbf">NK</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors for substance <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="bold">P</mi></mrow><annotation encoding="application/x-tex">\mathbf{P}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6861em;"></span><span class="mord mathbf">P</span></span></span></span></span> : Aprepitant.
VI Miscellaneous such as Nabilone (a cannabinoid), Trimethobenzamide, Benzquinamide Clinically, the antiemetics are grouped according to their potency as:</p>
<ul>
<li>Most potent: Ondansetron, Granisetron and high dose Metoclopramide.</li>
<li>Moderately potent: Low dose Metoclopramide, Phenothiazines (Prochlorperazine), Butyrophenones (Droperidol), and Cannabinoids.</li>
<li>Weak: Anticholinergics, Antihistaminics and Benzodiazepines (Lorazepam).</li>
<li>Glucocorticoids such as dexamethasone given parenterally in large doses, are used as adjuncts in the management of resistant nausea and vomiting induced by cancer chemotherapeutic agents.
Antihistaminic-antiemetic drugs like dimenhydrinate, cyclizine, promethazine and meclizine act on the vomiting centre and also have mild sedative effect. They are effective in motion sickness, in vomiting due to labyrinthine disorders (vestibular neuronitis, Meniere's disease) and in vomiting during pregnancy. Vomiting due to gastroenteritis does not respond well to antihistaminic antiemetics.</li>
</ul>
<p>Phenothiazines like chlorpromazine, dopamine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>D</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">D_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0278em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> antagonists or prochlorperazine, selectively depress the CTZ but have no action on the vomiting centre. Hence, they are ineffective in motion sickness. They are however, the drugs of choice in nausea and vomiting due to uremia, carcinomatosis, radiation sickness and that due to drugs. Among the phenothiazines, triflupromazine and the piperazine phenothiazines are more effective than others. However, they can cause extrapyramidal adverse effects.</p>
<p>In general, the phenothiazines are preferred when vomiting is severe and hazardous but is of short duration e.g. postoperative vomiting. On the other hand, the antihistaminic antiemetics, though less effective than the phenothiazines, are safer and preferred for long term use.</p>
<p>Dopamine present peripherally in the upper GI tract has inhibitory effect on the GI motility and intragastric pressure. These effects are believed to be due to the suppression of ACh release from the primary motor neurons in the myenteric plexus, the activity of which is modulated by inhibitory dopaminergic- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">D</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{D}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> neurons. The drugs that promote coordinated GI motility maintaining physiological pattern and rhythm are known as prokinetic drugs. Thus <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">D</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{D}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> antagonists metoclopramide and domperidone (Table 41.2) are prokinetics. By acting as dopamine antagonists in the CTZ, they also act as central antiemetics. Since 5-HT plays an important role in GI motility and is present in the neurons of the myenteric plexus, prokinetic action can also be achieved by the action of 5<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="bold">H</mi><mi mathvariant="bold">T</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{H T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathbf">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor agonists, on the excitatory interneurons e.g. cisapride and metoclopramide (Chapter 24).</p>
<p>Table 41.2
Actions of prokinetic drugs</p>
<table><thead><tr><th style="text-align: left;">Action</th><th style="text-align: center;">Metoclopramide</th><th style="text-align: center;">Domperidone</th><th style="text-align: center;">Cisapride</th></tr></thead><tbody><tr><td style="text-align: left;">- 5-HT <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonist</td><td style="text-align: center;">+++</td><td style="text-align: center;">-</td><td style="text-align: center;">+++</td></tr><tr><td style="text-align: left;">- Antidopaminergic <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mi mathvariant="normal">D</mi><mn>2</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{D}_{2}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathrm">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span></td><td style="text-align: center;">++</td><td style="text-align: center;">+++</td><td style="text-align: center;">-</td></tr><tr><td style="text-align: left;">- CNS</td><td style="text-align: center;">++</td><td style="text-align: center;">+</td><td style="text-align: center;">-</td></tr><tr><td style="text-align: left;">- Hyperprolactinemia</td><td style="text-align: center;">++</td><td style="text-align: center;">+++</td><td style="text-align: center;">-</td></tr><tr><td style="text-align: left;">- Antiemetic</td><td style="text-align: center;">++</td><td style="text-align: center;">++</td><td style="text-align: center;">-</td></tr><tr><td style="text-align: left;">- Prokinetic</td><td style="text-align: center;">Upper Gl tract</td><td style="text-align: center;">Upper Gl tract</td><td style="text-align: center;">Upper Gl tract and colon</td></tr></tbody></table>
<p>METOCLOPRAMIDE: This antiemetic, chemically related to procainamide, acts predominantly as a dopamine antagonist. It also has <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonist properties. Its antiemetic effect has two components:</p>
<ul>
<li>Promotion of forward propulsion of the contents of the upper GI tract, particularly the stomach (prokinetic action) due to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> action. The cholinomimetic effect of metoclopramide is restricted to the proximal gut and is due to enhancement of the action of ACh at the muscarinic receptor; and</li>
<li>Central inhibition of vomiting due to the blockade of DA receptors in the CTZ.</li>
</ul>
<p>Pharmacological actions: The drug increases the resting tone of the gastroesophageal sphincter and stimulates coordinated gastric motility. An injection of 20 mg produces gastric emptying within 90 minutes in most patients. It also increases the activity of the pyloric antrum and duodenal peristalsis, and accelerates transit along the small bowel. It has no significant action on the biliary tract and the large bowel motility.</p>
<p>By its central action, metoclopramide reduces post-operative vomiting and vomiting due to morphine and pethidine.</p>
<p>The drug stimulates prolactin secretion.
Adverse reactions: It is a relatively safe drug. It can cause drowsiness, dystonic or extrapyramidal reactions and diarrhoea. The others include, lassitude, skin rash, hyperprolactenemia, gynecomastia and galactorrhoea. It may aggravate sodium retention and hypokalemia in patients with edema. EP reactions and malignant neuroleptic syndrome following metoclopramide are dose related; and the daily intake of this drug should not exceed <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.5 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>.</p>
<p>Preparations and dosage: It is available as 10 mg tablets, as syrup and as an injection. Dose 5-10 mg tid orally; 10-20 mg IM or IV.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>
<p>As an antiemetic, especially in postoperative vomiting, in low doses ( 10 mg IM or IV three times a day).</p>
</li>
<li>
<p>Before and during cancer chemotherapy to prevent nausea and vomiting, in high doses <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>0.5</mn><mo>−</mo><mn>3</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">(0.5-3 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> IV over 15 minutes).</p>
</li>
<li>
<p>To accelerate gastric emptying (prokinetic) before induction of general anaesthesia for emergency surgery; prior administration of atropine can, however, block this effect of metoclopramide.</p>
</li>
<li>
<p>To assist the passage of tubes (including an endoscope) into the duodenum; and</p>
</li>
<li>
<p>To treat gastroparesis and GERD with retention from a variety of causes e.g. vagotomy, diabetes, gastritis and gastric ulcers.
DOMPERIDONE: This agent acts as a selective <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">D</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{D}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonist. It does not have ACh like effect. Its antiemetic effect is due to its action on CTZ, which is functionally outside BBB. As it does not cross the BBB easily, unlike metoclopramide, it causes fewer EP reactions and rarely, hyperprolactinemia and galactorrhoea. The drug is effective orally as well as parenterally. The oral dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mn>3</mn><mo>−</mo><mn>4</mn></mrow><annotation encoding="application/x-tex">10-20 \mathrm{mg} 3-4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4</span></span></span></span></span> times a day.</p>
</li>
</ul>
<p>CISAPRIDE: This prokinetic drug stimulates GI motility by acting as a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor agonist. It modulates the activity of the primary motor neurons in the myenteric plexus. It also has an action on the colon. It has no direct antiemetic action.</p>
<p>Adverse reactions include increased urinary frequency, abdominal cramps and diarrhoea. It prolongs the QT interval and can enhance the toxicity of other drugs, which also prolong QT interval. Drugs which inhibit hepatic microsomal enzymes increase its plasma levels. Serious cardiac arrhythmias and sudden death have been reported. The drug has been withdrawn from the market in some countries including India.</p>
<p>Mosapride is another selective <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">5 \mathrm{HT}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord">5</span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonist claimed to have fewer side effects. Itopride has actions similar to those of metoclopramide.</p>
<p>Erythromycin: This macrolide antibiotic causes diarrhoea as a major side effect. This has been shown to be due to activation of motilin receptors. Motilin is a peptide hormone, found in the GI tract; it increases the smooth muscle contractibility. Erythromycin has been used as a prokinetic drug in patients with diabetic gastroparesis.</p>
<p>NABILONE: This synthetic cannabinoid is used to treat nausea and vomiting caused by cancer chemotherapy, unresponsive to conventional antiemetics. The adverse reactions are mainly neurological and comprise drowsiness, vertigo, visual disturbances, headache, dysphoria, confusion, hallucinations and psychosis. Hypotension, tachycardia and abdominal pain may occur. Its use is contraindicated in severe hepatic impairment, pregnancy and breast-feeding. The adult dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1-2 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> tid (Chapter 14).</p>
<p>DRONABINOL: This D-9 tetrahydrocannobinol (D-9 THC), a natural ingredient of cannabis, is prepared synthetically. It acts on <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">B</mi><mi mathvariant="normal">j</mi></mrow><mi mathvariant="normal">j</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{CBj}_{\mathrm{j}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0636em; vertical-align: -0.3802em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CBj</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.2234em;"><span style="top: -2.4559em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">j</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.3802em;"><span></span></span></span></span></span></span></span></span></span></span> receptors and is used orally to prevent and treat cancer-chemotherapy-induced nausea and vomiting. It acts synergistically with phenothiazine antiemetics. The ADR are wider than those of nabilone and include drug abuse.</p>
<p>Selective 5-HT <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mn mathvariant="bold">3</mn><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{3}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7944em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">3</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> antagonists e.g. ondansetron are used to prevent and treat chemotherapy induced vomiting, post-operative and postradiation vomiting (see Chapter 24).</p>
<p>Therapy of vomiting during pregnancy: The etiology of vomiting of early pregnancy is not established. It is usually mild and self-limiting.</p>
<p>The patient is advised to take frequent small meals and more fluids. Psychotherapy including reassurance and placebo therapy are often helpful. It reaches peak by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>10</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">10^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord">1</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> week and usually resolves by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>14</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">14^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord">1</span><span class="mord"><span class="mord">4</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> week. Though it is ideal to avoid drugs in the first trimester, some women are severely nauseated and need drug therapy.</p>
<p>Drugs employed are vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>6</mn></msub></mrow><annotation encoding="application/x-tex">B_{6}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">6</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (pyridoxine), antiemetic antihistaminics (dimenhydrinate, doxylamine, cyclizine, meclizine) and metoclopramide. Promethazine may be used except near delivery time and during labour, as it may cause ADR in the</p>
<p>newborn. Usually, doxylamine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">40 \mathrm{mg}+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">+</span></span></span></span></span> pyridoxine 40 mg combination bid is considered safe and effective. Dimenhydrinate ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50-100 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> ) is safe and rapid in onset, and can be used as a suppository. Prochlorperazine, a phenothiazine, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5-10 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> is reported to be safe and can be given IV in severe cases. Ginger along with sugar, is safe and effective home remedy in mild cases. Its active components are <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> antagonists. Finally, vomiting due to an unrelated but associated condition such as peptic ulcer, hepatitis, drug reaction or gall bladder disease should be ruled out.</p>
<p>Therapy of motion sickness: Motion sickness is a syndrome characterised by vertigo and nausea resulting from body motion. The word 'nausea' is derived from Greek word 'nautical' as it usually occurs at sea.</p>
<p>The receptors for motion sickness are located in the vestibular apparatus. Other stimuli such as visual, proprioceptive and emotional, may facilitate or enhance motion sickness. Children are more susceptible to motion sickness and the vulnerability diminishes with advancing age. Deaf persons with disease of the inner ear and infants, however, do not get motion sickness.</p>
<p>The susceptibility to motion sickness is determined by the balance of activation between the ACh and NA sensitive neurons in the reticular activating system adjacent to the vestibular nuclei. Drugs that block ACh in the CNS e.g. scopolamine, and those which activate the central sympathetic areas e.g. d-amphetamine are highly effective in its treatment. It is easier to prevent motion sickness than to treat it.</p>
<p>SCOPOLAMINE: The belladonna alkaloid, scopolamine is among the first drugs to be used in the treatment of motion sickness. A central muscarinic antagonism of ACh may be the basis of its therapeutic efficacy. Scopolamine is more effective when used prophylactically than during an attack. A single oral dose of 0.3 to 0.6 mg in an adult, 15 minutes before food and 30 minutes before a journey, gives satisfactory protection. The onset of the effect usually coincides with the development of dryness of mouth. The drug action persists for 2 to 3 hours and in the event of a prolonged journey, an additional dose of 0.1 to 0.2 mg is given after 2 hours. The drug may cause drowsiness, dizziness, blurring of vision, dry mouth and urinary retention.</p>
<p>Scopolamine is also available in transdermal delivery system, as an adhesive unit, for placement behind the ear (Scopoderm). The drug is released at a uniform rate for 72 hours. - Antihistaminics: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists used include the phenothiazine antihistaminics, promethazine and its chlorotheophyllinate, dimenhydrinate, and the piperazine anti-histaminics cyclizine, buclizine, meclizine and cinnarizine (Chapter 23). Some of these have antimuscarinic action.
The number of individuals protected by these agents varies from 60 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span>. They are administered orally, 30 minutes before the journey. The piperazine antihistaminics have a prolonged action, a single dose providing relief for 6-12 hours. The action of meclizine is claimed to persist for 24 hours.</p>
<p>Table 41.3 lists the applications of antiemetics in vomiting from different causes. For anti-5- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{HT}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> antiemetics see Chapter 24.</p>
<p>Table 41.3
Antiemetics in various types of vomiting
Phenothiazine and Butyrophenone Anti-psychotics; Metoclopramide;
Ondansetron; Nabilone; Dexamethasone (as adjunctive drugs during cancer chemotherapy).
Gastroperesis: Prokinetic drugs.
Postoperative: Prokinetic drugs, Antihistaminics.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><mo>−</mo><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">--&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span><span class="mord">−</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&gt;</span></span></span></span></span></p>
<table><thead><tr><th style="text-align: left;">Gl irritation: Anticholinergics; in severe cases, a Phenothiazine.</th></tr></thead><tbody><tr><td style="text-align: left;">Motion sickness: Scopolamine; Dimenhydrinate; Cyclizine, Meclizine.</td></tr><tr><td style="text-align: left;">Pregnancy: Doxylamine, Pyridoxine, Dimenhydrinate.</td></tr><tr><td style="text-align: left;">Uremia, cancer, radiation sickness, anticancer chemotherapy:</td></tr><tr><td style="text-align: left;">Phenothiazine and Butyrophenone Anti-psychotics; Metoclopramide;</td></tr><tr><td style="text-align: left;">Ondansetron; Nabilone; Dexamethasone (as adjunctive drugs during cancer chemotherapy).</td></tr><tr><td style="text-align: left;">Gastroperesis: Prokinetic drugs.</td></tr><tr><td style="text-align: left;">Postoperative: Prokinetic drugs, Antihistaminics.</td></tr></tbody></table>
<p>Antiemetics should not generally be used, especially in children, without establishing the cause of vomiting, as they may mask the underlying disease and delay the diagnosis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapy-of-vertigo-and-dizziness">Therapy of Vertigo and Dizziness<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapy-of-vertigo-and-dizziness" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Vertigo is a hallucination of movement, generally spinning, caused by a disturbance of the orientation-detecting system of a person.</p>
<p>It can be precipitated when there is a intersensory mismatch among the stabilizing systems. It can occur in normal subjects following a spin or even unfamiliar head movement. Commonly it is due to disturbances of vestibular, visual or somatosensory systems. It can also occur in the brain stem or cerebellar lesions and with migraine. Finally, phobic postural vertigo is observed in patients with panic attacks. In all cases of vertigo, complete neurological examination is a must. If a cause for vertigo can be established, it may be amenable to specific treatment.</p>
<p>Orientation in space is achieved by integrating information mainly from:</p>
<ul>
<li>Vestibular system.</li>
<li>Vision; and</li>
<li>The proprioceptors in the muscles and joints. (Somatosensory)</li>
</ul>
<p>The collected information is processed in the sensory integrating areas of the reticular formation. Such processing occurs at the subconscious level in normal persons. When the information contains a new or an unusual element, vertigo can occur. Dizziness is less specific than vertigo and comprises all symptoms of disequilibration including lightheadedness, giddiness, swimminess, floating etc; its pathogenesis is similar to that of vertigo. Individual patients may not be able to differentiate between vertigo and dizziness. Both are caused by different pathological processes in CNS, CVS and metabolic disease.</p>
<p>Cawthorne-Cooksey exercises help to induce a compensation mainly in vertigo due to peripheral vestibular disorders. The principle is to retrain the eye, neck and body musculature to generate visual and proprioceptive input to compensate for the lost vestibular information. The movements that cause vertigo must be especially practised, since the more often vertigo is induced, the more quickly compensation occurs. They should be started as soon as possible after an acute attack due to a peripheral vestibular disorder.</p>
<p>Table 41.4 lists the drugs used in the, symptomatic treatment of vertigo.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-41-4">Table 41.4<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-41-4" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="drugs-used-in-vertigo">Drugs used in vertigo<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-used-in-vertigo" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><sup><a href="#user-content-fn-0" id="user-content-fnref-0-9" data-footnote-ref="true" aria-describedby="footnote-label">1</a></sup>Antihistaminics suppress the vestibular end organ receptors and thus inhibit the activation of the central muscarinic receptors. Of the antihistaminics, cinnarizine 15 mg three times a day is highly effective antivertigo agent. The other antihistaminics used include cyclizine, meclizine, dimenhydrinate and promethazine (Chapter 23).</p>
<p>Phenothiazines (prochlorperazine) and central anticholinergics (scopolamine) suppress the central vestibular nuclei and pathways. All centrally acting sedative drugs interfere with the integration of vestibular with other sensory information; they might delay the</p>
<p>compensatory mechanisms which alleviates vertigo induced by peripheral vestibular disease. Chronic use of central sedatives (and even their withdrawal after prolonged use) can be associated with dizziness. However, benzodiazepines are likely to be helpful when anxiety is a feature in the response to vertigo. When depression is a major response, amitryptiline may be useful (Chapter 14).</p>
<p>Betahistine, a vasodilator, is useful in some cases of Meniere's disease (Chapter 23). Meniere's disease is initially treated with low salt diet ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">m</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">1 \mathrm{gm} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm">gm</span></span><span class="mord">/</span></span></span></span></span> day) and a thiazide diuretic. If this is not effective, an antihistaminic or betahistine should be used. Glucocorticoids (methylprednisolone <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>80</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">40-80 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">80</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>5</mn></mrow><annotation encoding="application/x-tex">4-5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">5</span></span></span></span></span> days, followed by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">20 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day for 4 days) have been used to suppress intralabyrinthine edema due to virus infection.
(a) An acute attack of vertigo is best treated with bed rest; parenteral prochlorperazine, an oral antihistaminic, (1-2 days) should be started when the acute symptoms have subsided. (b) Chronic persistent vertigo due to central or peripheral cause may be helped symptomatically by small doses of an antihistaminic.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-diarrhoea">Drug Therapy of Diarrhoea<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-diarrhoea" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Diarrhoea is a common problem in the tropical and subtropical countries and like vomiting, it can be caused by a variety of conditions varying from infections and allergy to emotional disturbances. It is defined as the frequent passage of liquid or unformed stools with or without blood or mucus; in the case of former it is usually due to a known cause such as amoebic or bacillary dysentery.</p>
<p>Table 41.5 outlines the pathophysiology of diarrhoea.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-41-5">Table 41.5<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-41-5" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pathophysiology-of-diarrhoea">Pathophysiology of diarrhoea<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pathophysiology-of-diarrhoea" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Osmotic diarrhoea due to poorly absorbable, osmotically active substances as after ingestion of osmotic laxatives, in lactase deficiency and in malabsorption syndromes. Secretory diarrhoea due to active ion secretion by the small intestinal epithelium as in cholera, enterotoxigenic E.coli diarrhoea and carcinoid syndrome.
Deranged intestinal motility as in irritable bowel syndrome, thyrotoxicosis and diabetic neuropathy.
Altered mucosal morphology as in viral gastroenteritis, bacterial infection with tissue invasion and radiation enteritis.
Allergic diarrhoea as in food allergy.
Drug induced diarrhoea (see later).
Miscellaneous such as in neurological and endocrine disease.</p>
<p>In nearly all forms of acute infectious diarrhoeas, the abnormally formed stools reflect small bowel hypersecretion of fluid and electrolytes and not increased intestinal motility. Most water absorption occurs in the jejunum by passive transport in response to the osmotic pressure generated by the absorption of soluble products of digestion. An excess of unabsorbed material in the gut may also cause osmotic diarrhoea. In coeliac disease, the mucosal permeability to water and small solute is decreased. Some invading infections can damage intestinal villi to cause marked reduction in absorption of fluids. Finally, PGs, 5-HT and bacterial toxins can cause hypersecretion and diarrhoea.</p>
<p>Not all diarrhoeas need drug treatment. For example, irritant diarrhoea can be selflimited.</p>
<p>Treatment of diarrhoea consists of:
I Specific treatment.
II Treatment of dehydration; and
III Symptomatic and supportive treatment.
I Specific Treatment: This depends upon the cause. The common pathogens responsible for acute diarrhoea are listed in Table 41.6. A number of drugs are available to treat bacterial and protozoal infections but no antiviral agents are available for viral diarrhoea.</p>
<p>Table 41.6
Clinical features and drugs recommended in acute infective diarrhoeas</p>
<table><thead><tr><th style="text-align: center;">Organism</th><th style="text-align: center;"></th><th style="text-align: center;">Blood</th><th style="text-align: center;">Polymorphs in stool</th><th style="text-align: center;">Vomiting in stool</th><th style="text-align: center;">Drugs recommended</th></tr></thead><tbody><tr><td style="text-align: center;">I Bacteria:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">Shigella</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">Ciprofloxacin; Norfloxacin; Cotrimoxazole; Nitazoxanide</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">Salmonella (non-typhi species)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">Cotrimoxazole; Fluoroquinolone or Ceftriaxone in severe cases</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">E. coli</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">Fluoroquinolone; &lt;br&gt; Cotrimoxazole</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">E. coli (Shiga toxin producing)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">Avoid antimotility drugs</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">Vibrio</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span></td><td style="text-align: center;">Doxycycline; Fluoroquinolone</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">Campylobacter</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">Azithromycin</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">Cl. difficile</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">-</td><td style="text-align: center;">Metronidazole</td></tr><tr><td style="text-align: center;">II Protozoal:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">E.histolytica</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span></td><td style="text-align: center;">Metronidazole</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">Giardia</td><td style="text-align: center;">-</td><td style="text-align: center;">-</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span></td><td style="text-align: center;">Metronidazole</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">Cryptosporidium</td><td style="text-align: center;">-</td><td style="text-align: center;">-</td><td style="text-align: center;">-</td><td style="text-align: center;">Azithromycin; Nitazoxanide</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">Cyclospora</td><td style="text-align: center;">-</td><td style="text-align: center;">-</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">Cotrimoxazole</td></tr><tr><td style="text-align: center;">III</td><td style="text-align: center;">Viral:</td><td style="text-align: center;">-</td><td style="text-align: center;">-</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">No antimicrobial</td></tr></tbody></table>
<p>The initial clinical evaluation of the patient with acute diarrhoea should include assessment of its severity, the need for rehydration and the likely cause, based on history, clinical findings and stool examination. Specific therapy of diarrhoea would be easy if the responsible pathogen could be identified quickly.</p>
<p>Many patients suffer from simple diarrhoea manifested by watery stools, low grade fever, malaise, nausea and sometimes vomiting. In developed countries, it is usually of viral origin and could be treated without using antibacterials. On the other hand, in developing countries, this syndrome is more often due to a bacterial pathogen. The pathogen commonly involved is enterotoxigenic E. coli, which is a major cause of infant diarrhoea. The other pathogens involved are: the enteropathogenic E. coli; enteroinvasive E. coli; shiga-toxin producing E. coli; shigella; salmonella; campylobacter; Entamoeba histolytica; cyclosporidium and others. Such patients tend to have more severe diarrhoea, fever and blood in stools (dysentery). Cyclosporidiasis causes marked fatigue in most patients. Although classical cases of amoebic or bacillary dysentery can be diagnosed relatively easily by microscopy of stool, it is difficult in the vast majority of cases. Such diarrhoea with "negative stool" could be due to the presence of E. coli endotoxin, staphylococcal endotoxin, Campylobacter jejuni, yersinia or viruses such as rotavirus or atypical adenovirus. Travellers' diarrhoea can be either simple diarrhoea or dysentery.</p>
<p>Regardless of the causative agent (documented or putative), the initial therapy should always include rehydration and nutritional support (soft rice, ripe bananas and cooked apple). Milk and milk products should be avoided since transient lactase deficiency may occur. Continued feeding improves the outcome in children. Antimotility drugs may be used in simple diarrhoea but should be avoided in infective diarrhoea and in children.</p>
<p>Antimicrobials are ineffective in viral diarrhoea. Some antibiotics (e.g. neomycin, polymyxin B, furazolidine and some cephalosporins) have potent antimicrobial activity in vitro but show no efficacy in vivo. Hence, their reckless use is not only wasteful but may be harmful.</p>
<p>Antibiotics are of value in the infective diarrhoeas. Co-trimoxaozole is effective against all the strains of E. coli mentioned above. It is also effective in shigellosis with diarrhoea; such patients may also respond to tetracycline, either 500 mg qid for 5 days or 2.5 gm as a single dose; ampicillin and amoxicillin are equally effective. Because of bacterial resistance to co-trimoxazole, ampicillin and nalidixic acid, a fluoroquinolone is now considered the drug of choice in patients with bacterial dysentery; they are now considered safe in children. Most patients show a rapid response but those infected with Campylobacter jejuni may not respond; such patients are best treated with azithromycin, 1 gm as a single dose or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>500</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">500 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">500</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day for 3 days. Travellers' diarrhoea has been treated with rifaximin, a new nonabsorbable rifampin derivative, as an alternative to quinolones, in the dose of 200 mg tid for 3 days; it is well tolerated but is ineffective in patients with fever or blood in stool and in those infected by Campylobacter jejuni. It should be avoided in pregnancy.</p>
<p>Patients with cholera or cholera-like gastroenteritis should be treated with doxycycline in a single dose of 300 mg . It is effective in reducing stool volume and eradicating Vibrio cholerae within 48 hours.</p>
<p>If diarrhoea persists for more than 5-7 days despite treatment, the causative organism is likely to be a protozoon. Lack of evidence of a pathogen should arouse the suspicion of IgA deficiency or irritable bowel syndrome. Table 41.6 summarises the salient features and choice of the antimicrobial drug in acute diarrhoea.
II Correction of dehydration and electrolyte disturbances is the most important aspect of treatment of diarrhoea and in many cases, it may be the only treatment needed.</p>
<p>Massive diarrhoea with watery stools causes marked depletion of sodium, potassium and bicarbonate and metabolic acidosis resulting in high mortality. Hence, immediate replacement of the fluid and electrolyte losses forms the most important therapeutic aspect of dehydration. It is ideal to tailor-make the fluid and electrolyte therapy in a seriously ill patient by monitoring the blood chemistry. This, however, may not always be possible.</p>
<p>The extent of dehydration in severe diarrhoea can be estimated by noting the quality of pulse, BP, condition of the neck veins and skin turgor. The plasma protein concentration and plasma specific gravity can be reliable guides, in judging the degree of dehydration. Normal plasma specific gravity is 1.025 . It has been estimated that for each 0.001 increase in the plasma specific gravity, an adult patient requires about 4 ml of fluid per kg body weight.</p>
<p>In an emergency, isotonic saline along with isotonic sodium bicarbonate, should be used in the proportion of 2:1. This would correct sodium loss and acidosis. If IV sodium bicarbonate is not available, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> solution of sodium bicarbonate may be given orally ad lib. Potassium should be given, preferably orally (see Table 37.5). About 15 mMoles of potassium is needed to correct the potassium loss in a litre of stools. The quantity of stools passed should, therefore, be noted. Potassium can be conveniently administered as 200 ml of tender coconut water for each litre of stools passed. Alternatively, potassium salts such as potassium chloride may be given orally or by IV infusion.</p>
<p>Coma and convulsions during diarrhoea often indicate hypoglycemia and need for IV glucose.
In a collapsed patient the IV fluids are given rapidly initially, at the rate of at least 100 ml per minute, to correct hypovolemia and to avoid irreversible shock. Later on, the infusion may be adjusted according to the loss of fluids in stools and sweat. In practice, IV therapy is monitored by noting the state of the neck veins and the urine output. Usually IV fluid therapy is continued until the shock state is corrected and the patient is strong enough to drink the oral glucose-electrolyte solution.</p>
<ul>
<li>Oral rehydration therapy (ORT): The sodium and water absorption by the small bowel is very much enhanced by the addition of glucose to the oral fluid. However, dehydration can be successfully treated with oral fluids containing glucose, once the initial hypovolemia is corrected by 2-4 litres of IV fluid replacement. Mild to moderate dehydration and acidosis due to diarrhoea can be corrected in 3-6 hours by oral therapy alone. In many cases it is a lifesaving measure. The treatment should continue even when diarrhoea is not controlled. The ORT has many advantages:
(1) It is far less expensive than IV fluids.
(2) No expertise is needed to administer the fluid.</li>
</ul>
<p>(3) The solution need not be sterile and can be prepared on spot with components purchased from the local bazaar, and plain water available at home.
(4) It can be given by family members and non-professionals as well as by health workers.
Patients strong enough to drink, generally take the solution avidly. They may continue to vomit and in some cases the stool volume may increase. Inspite of this, there is a net absorption of water and electrolytes. Moreover, vomiting which is probably caused by acidosis and volume depletion, is likely to be corrected by the oral therapy itself. One teaspoonful given to a child every minute can provide 200-300 ml per hour. 'A conscientious mother can work wonders'. Adults can take 750-1000 ml per hour for several hours until signs of dehydration disappear and abundant pale urine is produced. If the patient needs rest, the same fluid may be given by a nasogastric tube.</p>
<p>The composition of WHO-recommended, modified ORS is shown in Table 41.7. Earlier ORS recommended by WHO, when used in acute diarrhoea and dehydration, occasionally caused hypernatremia in some children. The newly recommended ORS has lower osmolarity. This ORS has also been found effective and safe in adults with cholera, though a few patients might develop hyponatremia. As some commercially available ORS contain less sodium and glucose than the WHO recommended ORS, their use should be avoided. ORS can be prepared at home (Table 41.7).</p>
<p>Table 41.7
Composition of ORS</p>
<table><thead><tr><th style="text-align: left;"></th><th style="text-align: center;">WHO</th><th style="text-align: center;"></th><th style="text-align: center;">Homemade</th></tr></thead><tbody><tr><td style="text-align: left;">Substance</td><td style="text-align: center;">Weight (g)</td><td style="text-align: center;">Components (mMol/L)</td><td style="text-align: center;">Home measure</td></tr><tr><td style="text-align: left;">Sodium chloride</td><td style="text-align: center;">2.6</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mn>75</mn></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+} 75</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mord">75</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mi mathvariant="normal">/</mi><mn>4</mn></mrow><annotation encoding="application/x-tex">3 / 4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3/4</span></span></span></span></span> teaspoon (Table salt)</td></tr><tr><td style="text-align: left;">Potassium chloride</td><td style="text-align: center;">1.5</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">K</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mn>20</mn></mrow><annotation encoding="application/x-tex">\mathrm{~K}^{+} 20</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">K</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mord">20</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">1 / 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/2</span></span></span></span></span> teaspoon</td></tr><tr><td style="text-align: left;">Trisodium dihydrate citrate</td><td style="text-align: center;">2.9</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub><msup><mrow></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{HCO}_{3}{ }^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9213em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span>equivalent 10</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mi mathvariant="normal">/</mi><mn>4</mn></mrow><annotation encoding="application/x-tex">3 / 4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3/4</span></span></span></span></span> teaspoon</td></tr><tr><td style="text-align: left;">Glucose <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span>(Anhydrous)</td><td style="text-align: center;">13.5</td><td style="text-align: center;">Glucose75</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>11</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">11 / 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">11/2</span></span></span></span></span> tbsp</td></tr><tr><td style="text-align: left;">Water</td><td style="text-align: center;">1000</td><td style="text-align: center;">Total osmolarity 245</td><td style="text-align: center;">1 litre</td></tr></tbody></table>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>*</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {*}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">*</span></span></span></span></span></span></span></span></span></span></span></span></span></span> Citrate in ORS diminishes stool output in high output diarrhoeas.
"Glucose 20 g can be replaced by 40 g of sucrose. Alternatively, it can be replaced by 50 g of cooked rice powder. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Cl}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8557em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span>content is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>65</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">65 \mathrm{mMol} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">65</span><span class="mord"><span class="mord mathrm">mMol</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span>
Immediate institution of ORT would avoid shock from continuing dehydration. Children under five years should be given plain water in addition to above solution in quantities approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">1 / 3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0991em; vertical-align: -0.25em;"></span><span class="mord">1/</span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> of the total volume administered.</p>
<ul>
<li>Cereal-based oral rehydration solution (CORS): The correct concentration of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>and glucose in the ORS is critical for optimal effect and safety. The ORS administered cannot greatly exceed plasma in osmolality without the risk of increased diarrhoea and hypernatremia. Fortunately, nature has provided foods containing starches such as cereals and roots which have low osmolality in solution. Studies have indicated that ORS in which rice and other food sources of starch are substituted for glucose effectively replace lost fluids, decrease vomiting, and reduce the severity of diarrhoea. Glucose based ORS does not decrease and may slightly increase the stool volume. The cereal (rice) based solutions, on the other hand, are equally effective in reducing volume losses, and may also shorten the duration of illness. Rice contains a low molecular weight fraction which has a direct effect on the chloride channel. It inhibits the response of the crypt cell chloride channel to cAMP. This suggests a cellular basis for the well documented beneficial effect of rice based ORS in cholera, since it is this ion channel that is the target of such toxigenic secretory states. Addition of sodium bicarbonate and potassium chloride is not critical to the success of cereal based ORS. Interestingly, the use of rice conjee in diarrhoea is traditional in India for ages.!
Physiologically, cereal-based ORS are identical to their glucose based counterparts. The dominant component in the cereals is starch from rice, corn, wheat, potato, sorghum,</li>
</ul>
<p>millet or even plantain. Starch is a large polymer of glucose that, on exposure to amylase in the intestine, is digested into smaller polymers that are then split by maltase into glucose at the intestinal brush border. This digestive process supplies a larger number of glucose molecules for transfer of sodium ions from lumen into the blood, while generating less luminal osmotic "back drag" than would the direct ingestion of an equivalent amount of glucose. The cereal proteins also provide small peptides and amino acids which also facilitate the absorption of additional sodium ions. Of course, the presence of sufficient digestive enzyme is essential for the success of such solutions. In the vast majority, this is not the problem, except perhaps in infants under 4 months in whom intestinal glucoamylase is not fully developed.</p>
<ul>
<li>Zinc supplemented ORS: Zinc supplementation is also considered as an adjunct therapy in diarrhea because zinc maintains the GI mucosal integrity. It is also imparts local immunity. Deficiency of zinc has been shown to worsen diarrhea. Moreover diarrhea itself leads to zinc deficiency. Hence, UNICEF-WHO have proposed zinc supplemented ORS. This ORS also has shown to reduce duration of diarrhea and the stool frequency. In children less than 6 month, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">10 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day of zinc and for the older children <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">20 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day of zinc is advocated.
III Symptomatic and supportive treatment: Symptomatic treatment includes (a) GI protectives, and (b) drugs acting on GI motility. Agents useful in symptomatic treatment of diarrhoea may act:</li>
<li>Locally, as protectives by coating the gut.</li>
<li>By decreasing the propulsion of the intestinal contents, e.g., morphine like compounds.</li>
<li>Directly on mucosal transport processes, reducing fluid accumulation in the intestinal lumen (anti-secretory action).</li>
<li>On intestinal microcirculation; some drugs may lower the hydrostatic pressure thus favouring water absorption.
Temporary reduction in the intake of foods rich in fibre (unrefined cereals, fruits and vegetables) is desirable in acute diarrhoea.
(a) GI protectives and adsorbents: These agents may be useful predominantly because of their ability to adsorb noxious substances such as gases, bacteria and bacterial toxins. In addition, some of these possess an astringent action, while others protect the GI mucous membrane from the irritants by coating it physically. They are cheap, and devoid of adverse effects but their usefulness is limited to the treatment of mild diarrhoea. However, they may adsorb simultaneously administered anti-infective agents and anticholinergics. The drugs employed are:</li>
</ul>
<p>BISMUTH SALTS: The commonly employed bismuth salts are bismuth subcarbonate and bismuth subsalicylate. They have an astringent, adsorbent and antimicrobial actions. They are devoid of serious toxicity. They also act against Helicobater pylori (Chapter 43).</p>
<p>Bismuth subsalicylate binds toxins produced by V. cholerae and E. coli. In case of subsalicylate salt, it is possible that the liberated salicylic acid may inhibit the PG synthesis responsible for intestinal inflammation and hypermotility. Salicylate may also exert an antisecretory action.</p>
<p>Bismuth subcarbonate is insoluble in water and administered as a binding mixture; the dose of subcarbonate being 0.6 to 2 g . Other bismuth salts used are bismuth subgallate and bismuth subnitrate.</p>
<p>PECTIN: It is a purified carbohydrate obtained from the extract of the inner portion of citrus fruits or from apple pomace. It consists chiefly of partially methoxylated polygalacturonic acids. Its mechanism of action is not clear. When ingested, it passes into the intestinal tract where it probably acts by physical coating. It helps to produce formed stools. It is decomposed in the colon by bacterial action.</p>
<p>It forms a viscous, colloidal solution with 20 parts of water. The solution is tasteless; it is administered either as a colloidal suspension alone or with kaolin. Pectin can also be given in the form of cooked apple or overripe banana.</p>
<p>ACTIVATED WOOD CHARCOAL: This preparation is the residue from the destructive distillation of vegetable matter such as saw dust, cellulose residue and coconut shells, treated with zinc chloride to increase its adsorptive power. It is employed in the treatment of flatulence, nonulcer dyspepsia and various types of diarrhoeas. As a suspension in water, it is used for gastric lavage and for the emergency treatment of poisoning with alkaloids like morphine, strychnine and atropine. (See Chapter 2).</p>
<p>Other preparations employed are prepared chalk, a native form of calcium carbonate (often used as an antacid); and light kaolin, which is hydrated aluminium silicate. Both these agents are insoluble in water and form a protective coating on the intestinal mucosa. They may also have some adsorbent properties. They are administered as suspension, and form an important constituent of 'over-the counter' (OTC) antidiarrhoeal remedies. There is no rigorous demonstration that these GI protectives and adsorbents help in diarrhoea, although their administration may result in more formed stools.
(b) Drugs affecting GI motility and secretion:</p>
<ul>
<li>Opioids: Morphine-like compounds act by inhibiting the first phase of the peristaltic reflex, the acetylcholine dependent contraction of the longitudinal muscle, followed by a depression of rapid PG sensitive phase. In addition, they also produce anti-secretory effect by acting on intestinal opiate receptors. Thus they provide symptomatic relief. Although these drugs have been used to treat diarrhoeas, their routine use is not advocated. In the presence of acute inflammatory bowel disease, they can precipitate paralytic ileus in children and in the elderly. Opioids, diphenoxylate and loperamide are not recommended for use in children under 2 years as they can cause respiratory depression. They should be avoided in infective diarrhoeas at all ages.
The preparations used are:
(i) Codeine phosphate, 15 to 60 mg at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>8</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">8-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span> hourly.
(ii) Tincture of opium ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mo>=</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1 \mathrm{ml}=10 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> of morphine) in the single adult dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.6</mn><mo>−</mo><mn>1.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">0.6-1.5 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">1.5</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>. (iii) Diphenoxylate, a pethidine substitute in the dose of 5 mg along with 0.025 mg of atropine 3 to 4 times a day. Atropine in such a low dose induces only dryness of mouth without exerting any antidiarrhoeal effect. The purpose is to discourage excessive intake of the formulation and thus prevent addiction.</li>
</ul>
<p>LOPERAMIDE: It has a structural resemblance to pethidine. It acts directly on intestinal opioid ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>μ</mi></mrow><annotation encoding="application/x-tex">\mu</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.625em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">μ</span></span></span></span></span> ) receptors. The action is prompt and prolonged. It has a characteristic tissue distribution; almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>85</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">85 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">85%</span></span></span></span></span> of the drug is recovered from the gut. It does not easily cross the BBB, has high antidiarrhoeal specificity as compared to morphine and is devoid of CNS toxicity. It is not used in children <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>2</mn></mrow><annotation encoding="application/x-tex">&lt;2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span></span></span></span></span> years.</p>
<p>RACECADOTREIL: Given orally, this antisecretory prodrug is hydrolysed to the active compound thiorphan. In the peripheral tissues, including the intestines, membrane-bound</p>
<p>encephalinase enzymes degrade endogenous opioids/encephalins. Thiorphan inhibits encephalinase, thus increasing the availability of local encephalins which acts on the opioid delta receptors in the GI tract. Its efficacy is claimed to be as much as that of loperamide. It may be used to treat acute diarrhoea in children below the age of 2 years, in whom loperamide is contraindicated.</p>
<ul>
<li>Atropine and its substitutes such as hyoscine butylbromide ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10-20 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> ) or propantheline, are useful to relieve colic associated with diarrhoea. They are particularly useful in controlling "intestinal hurry" following gastrectomy. Their use in chronic diarrhoeas, however, may precipitate paralytic ileus in patients with regional enteritis and fulminating ulcerative colitis (Chapter 20).</li>
<li>PG Inhibitors: Prostaglandins are known to stimulate intestinal fluid secretion and intestinal motility, thus causing diarrhoea. It is possible that <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">F</mi></mrow><mrow><mn>2</mn><mi>α</mi></mrow></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGF}_{2 \alpha}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGF</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mathnormal mtight" style="margin-right: 0.0037em;">α</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> release is involved in the genesis of certain diarrhoeas. PG inhibitors such as aspirin and indomethacin have been shown to be effective in diarrhoeas induced by bacterial toxins in animals, and in certain diarrhoeas in humans. In contrast to opiates, aspirin like drugs produce reduction in diarrhoea by acting on PG sensitive phase, without much decrease in total water excretion (Chapter 11).</li>
<li>Chloride channel Inhibitor: Crofelemer, a natural product derived from the red sap of the South American plant Croton lechleri inhibits the secretion of chloride ions into the intestinal lumen by inhibiting both cystic fibrosis transmembrane conductance regulator and calcium activated chloride channels. It is administered as 125 mg delayed release tablet orally twice daily. It is indicated for symptomatic relief of non-infectious diarrhea in patients with HIV on antiretrioviral drug therapy. The common adverse effects include URTI, bronchitis, cough, flatulence and increased bilirubin.
Nutmeg, in combination with ginger, jaggery and ghee, is an age-old Indian household remedy for diarrhoea. PG inhibition is believed to be the mechanism of its antidiarrhoeal effect. Nutmeg often works where other drugs have failed.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="miscellaneous-agents">Miscellaneous agents:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#miscellaneous-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Probiotics: These are live, nonpathogenic bacteria or yeasts which have been used for centuries in the form of cheap and easily available home-made curd (yogurt), whey and buttermilk for health benefits. Probiotics contain variable lactobacillus species and Saccharomyces boulardi, an yeast. Acetic, lactic and propionic acids produced by these bacilli lower the intestinal pH and inhibit the growth of certain pathogenic intestinal bacteria. e.g. E. coli and clostridium spp. Probiotics may also act physically to prevent adhesion and colonisation by pathogenic organisms and may also enhance immune responses. Clinically, they may be beneficial in infectious (rota-virus induced) or antibiotic associated diarrhoea, IBS and inflammatory bowel diseases. Considering this, Indian dietary habits of having curd or buttermilk with meal are commendable!</p>
<p>Probiotics are pleasant to take but may occasionally produce mild and transient flatulence. They may cause serious infections in highly immunosuppressed patients. Antibiotics may inactivate bacteria derived probiotics. Commercially, they are available as powders, liquids and capsules.</p>
<p>Energy and nutrient intake is impaired during acute diarrhoea and in the catabolic state that may persist afterwards. It is recommended that adults and children be discouraged from fasting and that they resume their usual diet (non-irritant, non-oily) with frequent</p>
<p>small snacks. Drinks and foods containing caffeine and lactose should be avoided as they may prolong diarrhoea. Fluid-electrolyte balance is maintained by drinking boiled water, fruit juice and buttermilk and by eating salted biscuits. Intake of starchy foods (rice conjee) reduces diarrhoeal fluid output and is cost-effective (See earlier).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chronic-diarrhoea">Chronic Diarrhoea<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chronic-diarrhoea" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Chronic diarrhoea, lasting for more than 3-4 weeks, is due to various causes and needs detailed evaluation. The drug therapy would depend on its cause. In many cases, it is noninfectious e.g. irritable bowel syndrome, osmotic diarrhoea, steatorrhoea (gluten sensitivity), inflammatory bowel disease such as ulcerative colitis, and drug- induced diarrhoea (Table 41.8).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-41-8">Table 41.8<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-41-8" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Drugs causing diarrhoea</p>
<ul>
<li>Magnesiumantacids</li>
<li>Antibiotics: Erythromycin, Ampicillin, Tetracyclines</li>
<li>Gl prokinetic drugs e.g., Cisapride</li>
<li>Quinidine</li>
<li>Prostaglandin analogues</li>
<li>Anticholinesterases</li>
<li>Colchicine</li>
<li>Ecretine</li>
<li>Cytotoxic drugs</li>
<li>Lithium</li>
</ul>
<p>Drugs used in the treatment of chronic diarrhoea include the 5-HT antagonist cyproheptadine employed in dumping syndrome; sulfasalazine used in the treatment of ulcerative colitis; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor blocking agents used in Zollinger-Ellison syndrome; and folic acid in the treatment of tropical sprue.</p>
<p>Irritable bowel syndrome (IBS): As per Western criteria, IBS is diagnosed when the subject complains of recurrent abdominal pain or discomfort (bloating) at least three days a month in the past three months, associated with the following: (a) relief after defecation; and (b) onset associated with change in frequency of stools or with change in the form of the stools. The disorder can be subdivided into:
(1) IBS with constipation;
(2) IBS with diarrhoea; and
(3) The mixed type with both hard and soft stools.</p>
<p>The symptoms are worse after meals, and one-third of the patients also have functional dyspepsia/gaseous abdominal distension. Some patients may also complain of non-GI somatic symptoms such as lethargy, backache and bodyache. There is no definite pathology.</p>
<p>In India, IBS is more common in middle aged men. Majority of patients ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> ) have combination of upper abdominal discomfort and lower abdominal fullness, relieved by defecation. Nearly <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> have feeling of inadequate evacuation. Diarrhoea or constipation diagnosed as per Western criteria is uncommon and stool frequency is usually within normal limits (1-2 per day) for most of the patients.</p>
<p>IBS is often associated with emotional stress, anxiety or depression. General examination is usually normal. The treatment is symptomatic. Education of the patient about the benign nature of the ailment is essential. Avoidance of fried spicy and pungent food is likely to be helpful; so is avoidance of stress. Patients with predominant diarrhoea should be tested for gluten (wheat) sensitivity and milk intolerance.</p>
<p>Treatment: Pain in these patients is considered to be due to visceral hypersensitivity to</p>
<p>physiological and noxious stimuli. Serotonin appears to be involved in this syndrome of visceral hyperalgesia. The patients in whom constipation is predominant benefit from bulk forming agents such as isapgol; while those in whom 'gas' is the major symptom are likely to benefit from a reduction in consumption of unrefined fibre products such as bran.</p>
<p>Smooth-muscle relaxants provide moderate degree of symptomatic relief to patients with IBS who complain of postprandial abdominal pain, distension and disturbed defecation. These include
(a) Antimuscarinics like dicyclomine, propantheline, isopropamide and cimetropium,
(b) Direct smooth muscle relaxants like mebeverine, alverine and doloverine. This group is devoid of anticholinergic side effects and is particularly useful when colonic hypermotility is suspected; and
(c) Misceellaneous: These are, for example, trimebutine, which exerts antimuscarinic and weak mu opioid agonistic effects, pinaverium, a GI L-type CCB and Otilonium bromide, a weak antimuscarinic and a CCB. The latter blocks <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">K</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{NK}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">NK</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors and claimed to decrease intestinal nocciceptive responses. They are more expensive.</p>
<p>Alosetron is a potent and selective <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonist. Given in the dose of 1 mg bid, it decreases intestinal motility, secretion and pain significantly. Thus, it relieves abdominal pain and discomfort and may control diarrhoea. Commonly, it causes constipation; rarely it can cause dangerous ischemia of the bowel. It is recommended only in women with IBS not responding to other therapy.</p>
<p>Tricyclic antidepressants such as amitryptiline ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10-20 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> at bed time) have also been reported to be useful in some patients with diarrhoea. Relaxation and cognitive behavioural therapy may be helpful.</p>
<p>Inflammatory bowel disease (IBD): See Chapter 45.
Intestinal malabsorption: Some of the diarrhoeas associated with fat malabsorption improve with substitution of medium chain triglycerides in place of long chain fatty acids. Bile salt binding resin like cholestyramine, colestipol or colesevelam are also used 1-3 times daily before meals. Osmotic diarrhoea due to intestinal lactase deficiency (seen in infants) improves on reducing consumption of milk and dairy products which contains lactose. Diarrhoea due to carcinoid syndrome responds to 5-HT antagonists or octreotide (Chapter 63) while that due to blind loop syndrome responds to antibacterial therapy.</p>
<p>Drugs induced diarrhoea: Many self administered OTC remedies promoted for a variety of ailments, including hyperacidity, flatulence and alleged constipation, may contain laxatives e.g. magnesium salts and herbal products. This awareness will help to reduce the need for extensive and expensive evaluation of patients with chronic diarrhoea, whose initial evaluation is unrevealing.</p>
<p>42</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacotherapy-of-constipation">Pharmacotherapy of Constipation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacotherapy-of-constipation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>People have been very particular about the 'regular bowel habit' from the earliest times and purgation, believed to be the panacea for many diseases, formed an important part of medieval therapeutics. At one time it was almost fashionable to take a regular purge or an enema to keep the bowels clean. "Fashionable seventeenth century France was a trendsetter. Louis XIII had 212 enemas, 215 purgations and 47 bleedings in one year. With Louis XIV, the enema came into its own. It became a household ritual and most uppercrust people had one every day. A celebrated legal case concerned payment for the administration of 2,190 enemas, all within two years to a Canon of Troyes." The fashion also spread to England and America and in the Victorian era constipation was treated with every conceivable concoction. Even today, many people have wrong notions about the quantity, consistency and frequency of stools in health and 'ritual purgation of children and the obsessional catharsis of adults' is still not uncommon. Purgatives are widely advertised for the treatment of constipation and are extensively used by lay people as they are easily available over-the-counter without a prescription. Almost half of the patients suffering from digestive tract disorders complain of 'constipation' and often drugs are selfprescribed.</p>
<p>Drugs which are used to promote defaecation are called laxatives.
The effect of drugs on the motility of the GI tract can be studied in a variety of in vitro preparations like isolated guinea pig ileum, rat fundal strip, rat colon and rabbit duodenum. The human methods include radiological examination after administration of barium meal, use of food markers like charcoal, colouring agents, beads and radioactive isotopes, and radiotelemetry.</p>
<p>Regulation of GI motility: Orderly movement of ingested material through the gut is essential for adequate absorption of fluids, electrolytes and nutrients. The CNS (via the sympathetic and the parasympathetic nerves), local neuronal reflexes and the circulating, enteric peptide hormones play an important role in regulating the neurohumoral control of the GI smooth muscles. The enteric neurons contain both excitatory and inhibitory neuro-transmitters (Table 42.1). The complex interactions among them coordinate the intestinal movement. The enteric nervous system (ENS) integrates information from the periphery and the CNS, and modulates the effector function.</p>
<p>Table 42.1
Some enteric neurotransmitters and peptide hormones which control GI motility</p>
<table><thead><tr><th style="text-align: left;">Excitatory</th><th style="text-align: left;">Inhibitory</th></tr></thead><tbody><tr><td style="text-align: left;">Acetylcholine</td><td style="text-align: left;">Vasoactive inhibitory polypeptide (VIP)</td></tr><tr><td style="text-align: left;">Gastrin</td><td style="text-align: left;">Noradrenaline</td></tr><tr><td style="text-align: left;">Neurokinins</td><td style="text-align: left;">Nitric oxide</td></tr><tr><td style="text-align: left;">Cholecystokinin</td><td style="text-align: left;">ATP</td></tr><tr><td style="text-align: left;">5-Hydroxytryptamine</td><td style="text-align: left;">Somatostatin (in large doses)</td></tr><tr><td style="text-align: left;">Somatostatin (in small doses)</td><td style="text-align: left;">Peptide YY</td></tr><tr><td style="text-align: left;">Motilin</td><td style="text-align: left;">Enteroglucagon</td></tr><tr><td style="text-align: left;">Enkephalin</td><td style="text-align: left;"></td></tr></tbody></table>
<p>After eating, various enteric peptides are released from the gut mucosa into the blood. These peptides act as hormones and affect gastric, small intestinal and colonic smooth muscle contractions. They are either stimulatory or inhibitory (Table 42.1). Unlike the enteric neurotransmitters which affect the function immediately, the peptide hormones may mediate a delayed GI response to eating. Since the CNS plays an important role in controlling the activity of the GI smooth muscle, psychological disturbances also cause GI motility disorders.</p>
<p>Physiology of defaecation: Intestinal movements are mainly of three types:</p>
<ul>
<li>Pendular, due to annular contraction of longitudinal muscles.</li>
<li>Segmental, due to contraction of circular muscles; and</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="peristaltic">- Peristaltic<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#peristaltic" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The first two are responsible for mixing of the food while peristalsis helps in propulsion. Normally, food leaves the stomach in about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">1 / 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/2</span></span></span></span></span> to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>21</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">21 / 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">21/2</span></span></span></span></span> hours and its residue reaches the caecum by about 5 to 6 hours. It takes approximately 18 to 24 hours before the process of evacuation starts and the total time necessary for complete clearance of the ingested material is approximately 5 to 6 days. After ingestion of barium sulfate, the barium shadow can be first seen in the caecum at about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mfrac><mn>1</mn><mn>2</mn></mfrac></mrow><annotation encoding="application/x-tex">4 \frac{1}{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.1901em; vertical-align: -0.345em;"></span><span class="mord">4</span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.8451em;"><span style="top: -2.655em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.394em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.345em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span> hours, in the descending colon at about 11 hours and in the pelvic colon at about 18 hours. The global transit time (the time after ingestion to complete clearance from the GI tract) of a radio-opaque marker, such as barium sulfate, is about 5 days. If it is normal, the patient is probably not constipated. Usually, the peristaltic waves occur frequently upto ileum while they are very irregular in case of transverse, descending and pelvic colon, except during the gastrocolic reflex.</p>
<p>The Asians have relatively shorter colonic transit time (CTT) of 15-24 hours than the mean CTT of 30.7 hours in the Americans. The normal frequency of stools (1-2/day) among Indians is higher than that ( 3 or more times a week) in the western populations. These differences could be due to differences in the diet, especially its fibre content.</p>
<p>Normally, most of the ingested water and fluids secreted by various gastrointestinal glands are reabsorbed and only 100-200 ml of fluid is excreted with the faecal matter. Most of the absorption takes place in the small intestine and caecum. Hence, a laxative which acts mainly in the small intestine is likely to produce considerable loss of fluids, electrolytes and nutrients from the gut. Furthermore, the absorption of food is also interfered with. On the other hand, laxatives which act only on the colon produce relatively less fluid loss and do not interfere with the absorption of food. Absorption of water continues even in the colon and contents which are normally fluid upto ascending colon</p>
<p>become semisolid during their passage through transverse and descending colon and are then stored as faecal matter in pelvic colon. The act of defaecation is initiated by distension of the rectum. If this sensation is ignored habitually, it may lead to the development of constipation.</p>
<p>The rate of intestinal passage of food depends on the nature of the diet and its fluidity. The greater the indigestible residue and water content, the more rapidly it reaches the rectum and produces its distension. Diminished intake of both water and indigestible residue can lead to constipation. Further, constipation, though commonly due to a lax, atonic colon, may also be associated with a hypersegmenting, high pressure bowel. Although emotional stress and physical exercise can modulate the GI transit, they are not its primary regulators.</p>
<p>Most diarrhoeal diseases act through multiple mechanisms and affect many types of cells in the intestinal tract, including neurons, endocrine cells, inflammatory cells and epithelial cells. The mechanisms include:</p>
<ul>
<li>Increasing the adenylate cyclase and cAMP content of the intestinal epithelial cells, resulting in a decrease in sodium absorption and stimulation of chloride secretion.</li>
<li>Stimulation of enteric nerves and 5-HT-containing neuroendocrine cells; and</li>
<li>Initiation of intestinal metabolism of arachidonic acid by the cyclo-oxygenase pathway with the formation of PGs.
Laxatives act through multiple mechanisms affecting the epithelial transfer, directly or indirectly, leading to decreased sodium absorption and increase in chloride secretion by intestinal epithelial cells. Similarly, increase in fecal concentration of PGs has been observed following some laxatives.</li>
</ul>
<p>Table 42.2 lists the effects of other drugs on GI contractility.</p>
<p>Table 42.2
Drugs and GI motility</p>
<table><thead><tr><th style="text-align: left;">Drugs</th><th style="text-align: center;">Stomach Small intestine Colon</th><th style="text-align: center;"></th><th style="text-align: center;"></th></tr></thead><tbody><tr><td style="text-align: left;">Cholinergics: Carbachol, Neostigmine</td><td style="text-align: center;">E</td><td style="text-align: center;">E</td><td style="text-align: center;">E</td></tr><tr><td style="text-align: left;">Dopamine antagonists: Metoclopramide, Domperidone</td><td style="text-align: center;">E</td><td style="text-align: center;">E</td><td style="text-align: center;">-</td></tr><tr><td style="text-align: left;">5-HT, agonist: Cisapride</td><td style="text-align: center;">E</td><td style="text-align: center;">E</td><td style="text-align: center;">E</td></tr><tr><td style="text-align: left;">Antimuscarinic: Atropine</td><td style="text-align: center;">I</td><td style="text-align: center;">I</td><td style="text-align: center;">I</td></tr><tr><td style="text-align: left;">CCB: Verapamil, Nifedipine</td><td style="text-align: center;">I</td><td style="text-align: center;">I</td><td style="text-align: center;">I</td></tr><tr><td style="text-align: left;">Macrolide antibiotic: Erythromycin</td><td style="text-align: center;">E</td><td style="text-align: center;">E</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">?</mo></mrow><annotation encoding="application/x-tex">?</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mclose">?</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Opioids</td><td style="text-align: center;">I</td><td style="text-align: center;">I</td><td style="text-align: center;">I</td></tr><tr><td style="text-align: left;">Nitrates</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">?</mo></mrow><annotation encoding="application/x-tex">?</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mclose">?</span></span></span></span></span></td><td style="text-align: center;">I</td><td style="text-align: center;">I</td></tr><tr><td style="text-align: left;">Peppermint oil</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">?</mo></mrow><annotation encoding="application/x-tex">?</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mclose">?</span></span></span></span></span></td><td style="text-align: center;">I</td><td style="text-align: center;">I</td></tr></tbody></table>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>E</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">E=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">E</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> excitatory;
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>I</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">I=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07847em;">I</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> inhibitory;
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">?</mo><mo>=</mo></mrow><annotation encoding="application/x-tex">?=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mclose">?</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Not clear
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span></span></span></span></span> probably act on the motilin receptors
Classification of laxatives: These drugs are classified according to the intensity of action as mild, moderate or drastic. Laxation suggests the elimination of soft, formed stool without</p>
<p>griping and without much loss of water. In large doses, many laxatives promote catharsis which means purgation, the passage of fluid stools and griping. Laxatives can also be classified according to their mechanism of action as follows:
I Stimulant or irritant laxatives:</p>
<ul>
<li>Anthraquinone group e.g. Cascara sagrada and Senna.</li>
<li>Irritant oils, e.g., Castor oil.</li>
<li>Miscellaneous, e.g., Phenolphthalein, Bisacodyl, Sodium picosulfate.</li>
</ul>
<p>II Osmotic laxatives e.g. Magnesium sulfate, Milk of magnesia, Magnesium citrate, Potassium sodium tartrate, Lactulose and Polyethylene glycol (PEG).
III Bulk laxatives, e.g. Methyl cellulose, Agar agar, Plantago seeds and Bran.
IV Emollient laxatives (faecal emollient), e.g. Liquid paraffin and Dioctyl sodium sulfosuccinate.
V Chloride channel activator, e.g. Lubiprostone, Linaclotide.
VI Prokinetic agents, such as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor agonist e.g. Tegaserod.
They may also be classified clinically according to the onset of laxative effect following the therapeutic doses into those with:</p>
<ul>
<li>Slow onset which soften the stool after 1 to 3 days of daily use: Bulk laxatives, Mineral oil, Dioctyl sodium sulfosuccinate, Lactulose.</li>
<li>Intermediate onset which cause soft or semifluid stool in 6-12 hrs of a single dose: Saline laxatives (low dose), Bisacodyl (oral), Anthraquinone group;</li>
<li>Rapid onset which produce watery evacuation in 2-6 hrs of a single dose: Saline laxatives (high dose), Castor oil, Bisacodyl and glycerin suppository (rectal).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anthraquinone-group">Anthraquinone Group<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anthraquinone-group" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The two most commonly used agents are Cascara sagrada and Senna. The active constituent anthraquinone is present as an inactive precursor glycoside in the leaves, pods and roots of these plants. Anthraquinone is also present in a variety of other plants. On oral administration of plant extracts, the active anthraquinone derivatives, mainly oxymethyl anthraquinones, are liberated in the small intestine, where they are partly absorbed. These agents do not act on the small intestine, probably because the release of the active principle is too slow. However, sufficient quantity reaches the large intestine, via the blood as well as by intestinal propulsion of the unabsorbed portion.</p>
<p>Anthraquinone acts by stimulation of the large bowel, and also probably by inhibiting NaCl and water absorption in the colon.</p>
<p>Pharmacological actions: As these drugs act mainly on the large bowel, evacuation occurs 6-8 hours after their ingestion. Stools are usually semisolid and the incidence of griping is low. There are no other important actions of the absorbed anthraquinone derivatives. However, they are excreted in milk and may cause diarrhoea in breast-fed infants. Some of the constituents are excreted in urine and colour the acid urine yellowish brown and alkaline urine reddish violet. The patient should be informed about this.</p>
<p>Cascara is more bitter in taste while senna produces more griping.
Adverse reactions: They are relatively safe and the only important toxicity is excessive purgation and griping. Chronic use may lead to benign melanotic pigmentation of the colonic mucosa.</p>
<p>Preparations and dosage: Cascara sagrada is obtained from the bark of a tree Rhamnus purshiana. The available preparations are:
(i) Cascara sagrada liquid extract. Dose: 2-5 ml.
(ii) Cascara sagrada extract in powdered preparation. Dose: 300 mg .
(iii) Cascara sagrada tablets: one to two tablets at bed time.</p>
<p>The dried senna fruits (Senna pods) and leaves, obtained from the plants Cassia acutifolia and Cassia angustifolia respectively, are employed as cold water decoction as home remedies in India for their laxative effect. The dose in each case is 0.6 to 2 g at bedtime. Other unofficial preparations are senna fluid extract, dose 2 ml and senna syrup, dose 8 ml . Laxative preparations containing standardised, purified concentrates and those containing purified senna glycosides are also available.</p>
<p>Aloe and rhubarb, used as vegetable foodstuffs, also have a mild laxative effect.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="irritant-oils">Irritant Oils<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#irritant-oils" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>CASTOR OIL: It is a fixed oil obtained from the seeds of Ricinus communis Linn. Chemically, it is a triglyceride of ricinoleic acid, an unsaturated hydroxy fatty acid. Castor oil itself is non-irritant and is used as hair oil or applied to skin as emollient. When ingested, it is hydrolysed in the intestine by pancreatic lipase to glycerol and ricinoleic acid. Ricinoleic acid acts as an intestinal irritant and produces purgation.</p>
<p>Pharmacological actions: As ricinoleic acid acts on the small intestine, it produces copious, liquid stools, with associated fluid loss. Colonic emptying may be so complete that the patient may not pass a stool for next few days. The action is evident within 2-3 hours. It causes griping. Ricinoleic acid that is absorbed is metabolised like any other fatty acid. The drug interferes with the absorption of various nutrients.</p>
<p>Castor oil is a pale yellowish or almost colourless oil with peculiar odour and an initially bland but a nauseating after-taste.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="miscellaneous-stimulant-laxatives">Miscellaneous Stimulant Laxatives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#miscellaneous-stimulant-laxatives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>PHENOLPHTHALEIN: The discovery of phenolphthalein as a laxative was purely accidental. In order to identify cheap wines, the Hungarian government ordered addition of this compound to such wines, since on the addition of alkali it turns brilliant red. The procedure was considered to be harmless. Those who took such sparkling drinks freely, obviously could not enjoy them as they suffered from diarrhoea.</p>
<p>Pharmacological actions: The drug acts as a stimulant mainly on the large bowel after 68 hours, and produces soft, semi-liquid stools, with mild griping. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">15 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">15%</span></span></span></span></span> of the dose is absorbed, some of which is re-excreted in the bile. This enterohepatic circulation of the drug causes prolongation of its effect. A part of the absorbed portion is excreted by the kidney, mainly in the conjugated form. The alkaline urine and faeces may get a reddish colour.</p>
<p>Adverse reactions: Phenolphthalein can cause excessive purgation. Allergic skin rash with colourful lesions may persist for long time.</p>
<p>Phenolphthalein is no more recommended because of its potential carcinogenicity.
BISACODYL: This drug, structurally related to phenolphthalein, is used orally and as rectal suppository. It is rapidly converted by intestinal enzymes and bacteria to its active desacetyl metabolite which directly stimulates the large bowel. It is not absorbed from the gut and is less toxic. It is supplied as 5 mg enteric coated tablets for oral use and as 10 mg rectal suppositories. Prolonged use (more than 10 days) may cause local irritation.</p>
<p>SODIUM PICOSULFATE: Like bisacodyl, this drug is hydrolysed by colonic bacteria, acts on the large bowel and results in a soft, formed stool in 10-14 hours. The oral, adult dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5-15 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> as a single bedtime dose.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="osmotic-laxatives">Osmotic Laxatives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#osmotic-laxatives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Certain salts, non-absorbable disaccharides and higher alcohols, given orally, are not much absorbed and are retained in the GI tract. Such preparations exert an osmotic effect and hold considerable amounts of water, thus increasing the intestinal bulk. This acts as a mechanical stimulus causing an increase in the intestinal motor activity and evacuation. Release of cholecystokinin-pancreozymin with consequent stimulation of intestinal secretory and motor activity has been proposed as an additional mechanism of action of the magnesium salts.</p>
<p>The commonly employed saline laxatives are magnesium, sodium and potassium salts.
Pharmacological actions: These compounds act in the small as well as the large intestines and, therefore, produce a watery evacuation within 3 to 6 hours. They have a quick onset of action, and hence are given early in the morning before breakfast. They do not cause irritation and there is very little griping. Patients should be instructed to take plenty of water along with these drugs since administration of a hypertonic solution may produce dehydration.</p>
<p>Small amounts of these drugs may get absorbed into the circulation and may cause occasional toxicity, in the presence of kidney damage. Thus, the absorption of magnesium may cause CNS depression while that of sodium may worsen the existing CHF. This is most unlikely in normal subjects, as the small amount absorbed is rapidly excreted by the kidneys.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="preparations-and-dosage">Preparations and Dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Magnesium sulfate, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">M</mi><mi mathvariant="normal">g</mi><mi mathvariant="normal">S</mi><mi mathvariant="normal">O</mi></mrow><mn>4</mn></msub><mo>⋅</mo><mn>7</mn><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub><mi mathvariant="normal">O</mi></mrow><annotation encoding="application/x-tex">\mathrm{MgSO}_{4} \cdot 7 \mathrm{H}_{2} \mathrm{O}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9275em; vertical-align: -0.2441em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">MgSO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.207em;"><span style="top: -2.4559em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.2441em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">⋅</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord">7</span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord mathrm">O</span></span></span></span></span> (Epsom salt) - bitter salt, soluble in water. Dose 5-10 g. Hypertonic solution is sometimes used rectally to reduce increased intracranial tension.
(ii) Dried magnesium sulfate, Dose: 2 to 12 g .
(iii) Milk of Magnesia is a 7.0 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>8.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">8.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">8.5%</span></span></span></span></span> aqueous suspension of magnesium hydroxide. Dose: 20 ml .
(iv) Magnesium carbonate, heavy or light. Dose: 2 to 4 g .
(v) Magnesium citrate is pleasant to take but expensive.
(vi) Magnesium oxide. Dose: 2 to 4 g .
(vii) Sodium potassium tartrate (Rochelle salt) is administered in the dose of 8 to 16 g . Tartrate ion, not being absorbed from the GI tract, does not produce systemic toxicity. (viii) Seidlitz powder is a mixture, in which 2.5 g of sodium bicarbonate and 7.5 g of Rochelle salt are dispensed together in a blue paper while 2.5 g of tartaric acid is dispensed in a white paper. The user dissolves the contents of two papers separately in 30 ml of water and drinks the mixture after the effervescence begins to subside. The powders must not be taken separately. Carbon dioxide evolved acts as a carminative and masks the unpleasant saline taste.</p>
<p>LACTULOSE: This is a synthetic non-absorbable disaccharide which acts by its osmotic effect. It is converted to lactic acid which can bind ammonia. Because of this property as well as its laxative effect, lactulose is used in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">30-50 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> of the solution ( 3.5 g of lactulose per 5 ml ) with plenty of water, three times a day in the treatment of hepatic coma; the dose is adjusted to produce 2-3 soft stools per day. The primary osmotic effect may be aided by lactate and other organic acids to which it is metabolised by bacterial action in the distal ileum and colon.</p>
<p>Lactitol: This synthetic disaccharide is more palatable than lactulose.
GLYCERIN: Glycerin is used in the form of rectal suppositories ( 3 g for adults and 1 to 1.5 g for children). It acts by its osmotic effect to soften and lubricate the dried up feces. It may also stimulate rectal contractions. Glycerin is also used as a glycerin-edible oil (30-50 ml of each) enema, introduced into the rectum with a syringe. Other uses of glycerin are:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="oral-glycerin">Oral glycerin:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#oral-glycerin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Treatment of acute congestive glaucoma (Chapter 72) and cerebral edema (Chapter 39).</li>
<li>As a sweetening/flavouring agent.</li>
</ul>
<p>Topical glycerin:</p>
<ul>
<li>As a hygroscopic agent along with magnesium sulfate as dressing for wounds, ulcers and abscesses (Chapter 71).</li>
<li>As an emollient.</li>
</ul>
<p>In vitro uses:</p>
<ul>
<li>As a vehicle for drugs.</li>
</ul>
<p>Polyethylene glycol (PEG)-electrolytes: is supplied as a powder or as a ready-to-use electrolyte solution. It is administered orally in the dose of 4 litres, 250 ml every 15-20 minutes, over a period of 4 hours. It can also be given by nasogastric tube at the rate of 25 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">\mathrm{ml} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span></span></span></span></span> minute. Since the solution is isotonic, dehydration does not occur. It can be used for bowel cleansing before bowel surgery, colonoscopy, radiological examination, and to treat acute poisoning. The dose to treat constipation is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>250</mn><mo>−</mo><mn>500</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">250-500 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">250</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">500</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> orally once a day. After reconstitution, the solution should be stored in a fridge, and used within 24 hours. It is not recommended in patients weighing less than 20 kg .</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="bulk-laxatives">Bulk Laxatives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bulk-laxatives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These are natural or semisynthetic polysaccharides and cellulose derivatives, which are not absorbed and increase the indigestible residue. They absorb water and swell up, thus providing the stimulus of mechanical distension for evacuation. Generous amounts of water are prescribed with all bulk laxatives.</p>
<p>Pharmacological actions: These agents act because of their physical property. Their action is mild and is usually seen 12-36 hours after ingestion. They produce evacuation of solid or semisolid stools without irritation or griping. Some of these agents also have lubricating properties. Usually, these drugs are administered at bed time, with plenty of water.</p>
<p>These drugs are not absorbed and do not have any systemic toxicity. Intestinal obstruction has been reported but very rarely.</p>
<p>Because these agents help to produce formed stools, they are also recommended in the treatment of diarrhoea. As many of these agents, when administered in a palatable form, can increase the bulk of indigestible material in the diet, they have also been used in the treatment of obesity for satisfying appetite.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="preparations-and-dosage">Preparations and Dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>AGAR: It is a mucilagenous substance extracted from marine algae. It contains indigestible hemicellulose. With water, it forms a gel which has emollient or lubricating properties. The dose is 4 g .; occasionally, however, a large dose 40 g . may be required.</p>
<p>ISAPGOL: consists of dried seeds of Plantago ovata Forsk. The seeds, which are hard and pinkish-grey to brown in colour, contain a large amount of natural mucilage. Many OTC preparations contain Psyllium husk derived from plantago seeds. Dose: 5 to 15 g .</p>
<p>SABZA: This consists of the dried seeds of Ocimum basilicum Linn, a plant belonging to the tulasi family. The seeds are rich in mucilage and can be used as a substitute for isapgol.</p>
<p>HALIV: Seeds of Lepidium sativum (Garden cress) are used traditionally for relieving constipation. They have shown to possess prokinetic and laxative activities. The seeds also have rich amount of proteins ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> ), fats ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>16</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">16 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">16%</span></span></span></span></span> ), calcium, iron, folic acid and vitamin A and C. The dietary fibre content of its bran is high. Used along with milk, ghee, sugar/jaggery, they have therapeutic and nutritional value. Haliv is a tastier laxative than others. However, it should be avoided in pregnancy due to its teratogenic effects.</p>
<p>BRAN: It is the byproduct of the milling of wheat and contains almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> of fibre. Processed bran is palatable as such and it may be mixed with flour for preparing chapatis/bread. Dose : 12-24 g daily, in divided doses.</p>
<p>METHYL CELLULOSE, AND SODIUM CARBOXYMETHYL CELLULOSE are hydrophilic, semisynthetic derivatives of cellulose. The latter is insoluble in hydrochloric acid. Methylcellulose is administered in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mo separator="true">,</mo><mn>1</mn></mrow><annotation encoding="application/x-tex">1 \mathrm{~g}, 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">1</span></span></span></span></span> to 4 times daily, while sodium carboxymethyl cellulose is administered in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mo separator="true">,</mo><mn>1</mn></mrow><annotation encoding="application/x-tex">1.5 \mathrm{~g}, 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1.5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">1</span></span></span></span></span> to 4 times a day. The preparations should be taken with 30 to 40 ml of water to minimise the risk of oesophageal obstruction.</p>
<p>Bulk forming laxatives are especially useful in patients with:</p>
<ul>
<li>Irritable bowel syndrome.</li>
<li>Hemorrhoids and anal fissures.</li>
<li>Chronic diarrhoea associated with diverticular disease and ulcerative colitis; and</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="colostomy-or-ileostomy">- Colostomy or ileostomy.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#colostomy-or-ileostomy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Dietary fibre and bowel disorders: Unrefined plant products (fruits, vegetables, pulses, nuts and especially wholegrain products such as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">100 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">100%</span></span></span></span></span> whole-wheat flour and unpolished rice) are rich in indigestible cell wall materials. This material, known in the past as 'roughage' or 'residue' is now called 'fibre'. Chemically, this consists mainly of cellulose, hemicelluloses, pectins and lignin. Following ingestion, they hold water, form gels, exchange cations and bind bile acids. In the colon, they are mainly broken down to shortchain fatty acids, which may influence the colonic function favourably. Thus, the stool becomes bulkier and softer so that the need for straining is decreased. Occasionally, frequency of defaecation is increased. Increased intake of such fibre has been found useful not only in simple constipation but also in spastic colon, irritable bowel syndrome, colonic diverticular disease, and in anal fissures and piles. Higher consumption of fibre rich food (vegetables and fruits) may decrease the duration of contact of locally (in the colon) formed carcinogens with the colonic wall and may be helpful in preventing colonic cancer.</p>
<p>The best way of increasing the fibre-intake is to include fibre-rich foods in the diet. In persons who cannot or will not consume sufficient fibre-rich food, wheat bran may be added to food or taken with water. Eating of raw fruits and certain raw vegetables may however, often cause abdominal discomfort, bloating, griping and diarrhoea and should be avoided. A daily intake of 20-60 g of dietary fibre would appear to be sufficient for easy bowel movements. Bran and other similar substances such as gum have been claimed to be useful in reducing hyperglycemia in diabetics, as well as plasma cholesterol.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="emollient-laxatives">Emollient Laxatives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#emollient-laxatives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>LIQUID PARAFFIN: This mineral oil is the most widely used emollient laxative. It consists of a mixture of hydrocarbons obtained from petroleum. It is not significantly absorbed on oral administration and exerts a softening and lubricating effect on faeces.</p>
<p>Pharmacological actions: It is a mild lubricant and by itself does not initiate peristalsis. Because of its lubricant action, the straining during defaecation can be avoided. It is usually given at bed time, but can be taken at any time of the day.</p>
<p>It is almost non-toxic but used repeatedly, it may interfere with the absorption of essential fat soluble substances and may cause a deficiency of vitamins A, D and K. The small amount which is absorbed from the intestinal tract may get deposited in the intestinal mucosa, liver and spleen. Its chronic use can cause granulomatous fibrosis in the intestinal wall and more diffusely in the reticuloendothelial system. Rarely, it can cause lipoid pneumonitis, if it gets into the lungs during its administration in bedridden patient and in old people. It should not be used in children under three years of age.</p>
<p>Preparation and dosage: Liquid paraffin is a colourless, oily liquid. Dose: 10 to 30 ml . It is also available in emulsified form.</p>
<p>Edible oils like coconut oil, groundnut oil, cotton seed oil and corn oil are employed as lubricant laxatives. However, they are digested and hence, fairly large doses are needed for lubricant effect. The usual dose is 30 ml .</p>
<p>DIOCTYL SODIUM SULFOSUCCINATE: This drug, which is used in pharmaceutical industry as a dispersing agent, acts by its physical property of lowering surface tension.</p>
<p>It does not stimulate peristalsis but promotes softening of faeces. It is slow acting and takes 1-2 days to act.</p>
<p>Dose: 100-200 mg three times a day. It should not be combined with liquid paraffin as it may enhance the absorption of the latter.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="8ec38992"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> Receptor Agonists<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#8ec38992" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Tegaserod: This prokinetic drug acts as a 5-HT4 agonist in the entire GI tract and was used in patients with IBS with predominant constipation. It has been withdrawn from the market for reasons of safety.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chloride-channel-activators">Chloride Channel Activators<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chloride-channel-activators" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Lubiprostone: This drug acts locally in the GI tract by opening chloride channels, resulting in secretion of chloride-rich intestinal fluid. This accelerates small intestinal and colonic transit. It also delays gastric emptying. The adverse effects are nausea ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>31</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">31 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">31%</span></span></span></span></span> ), headache, diarrhoea and occasionally dyspnoea. It is contraindicated during pregnancy and should be avoided during child bearing age. High dose ( 24 mcg bid) is used in opioid induced constipation chronic idiopathic constipation, whereas low dose ( 8 mcg bid) is used for women with IBS having predominant constipation. It is of limited value and is expensive.</p>
<p>Linaclotide, a 14 -amino acid synthetic peptide, given orally activates guanylate cyclase-C receptors on the luminal surface of the intestinal epithelium increasing cGMP within the intestinal epithelial cells. This results in activation of the chloride channel. It common adverse effects are diarrhea, abdominal pain, flatulence, and abdominal distension. Linaclotide has been used to treat chronic idiopathic constipation or IBS with constipation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses-of-laxatives">Therapeutic uses of laxatives:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses-of-laxatives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>In food or drug poisoning to flush the intestinal tract. Saline laxatives are generally preferred.</li>
<li>To provide a fresh stool sample for parasitic examination.</li>
<li>Following anthelmintic therapy, to eliminate the parasites; saline laxatives are preferred.</li>
<li>Preoperatively in abdominal surgery or prior to radiological examination of the abdomen (bowel cleansing action).</li>
<li>In drug induced constipation such as that during the use of opioids or drugs with antimuscarinic property.</li>
<li>In constipation due to diminished intestinal tone as in old age and pregnancy.</li>
<li>In patients with painful anal conditions (fissure, thrombosed piles), and in cardiac disease (acute myocardial infarction), in order to spare the patient straining during defecation. In these conditions, a lubricating laxative such as liquid paraffin is preferred.</li>
<li>In patients with severe neuromuscular disease who have poor muscle strength.</li>
<li>In patients with hepatic encephalopathy, to reduce the colonic absorption of ammonia and other unknown toxins; and</li>
<li>In children with encopresis (passage of normal stools in socially unacceptable places; it is normal in the first 3 years of life) and in congenital/acquired megacolon.
It must be pointed out that laxatives are more often misused than used properly. Such misuse can cause serious harm.</li>
</ul>
<p>Irritant laxatives should be avoided during pregnancy as these may cause pelvic congestion, although abortion following therapeutic doses of laxatives is most unlikely. Similarly, these drugs should also be avoided in case of typhoid fever and in very ill cardiac patients; in such patients, if satisfactory evacuation fails to occur following lubricant laxatives, simple enema or a suppository may be employed.</p>
<p>Laxatives are absolutely contraindicated in patients with undiagnosed acute abdomen and in cases with intestinal obstruction and inflammatory bowel disease as violent contractions may lead to intestinal perforation and peritonitis.</p>
<p>ENEMAS: See Chapter 1 for general information on enemas. Their use for bowel evacuation is discussed here; the use of retention enemas for other purposes is discussed in appropriate chapters.</p>
<p>Evacuant enemas cause fragmentation, liquefaction or lubrication of the feces. Fluid distention of the bowel wall causes reflex evacuation. They act locally and may be preferred to laxatives in some situations. As an enema, one may introduce into the rectum plain tap water (this should be used only in adults but not in infants or children); soapsuds (only neutral and not alkaline); isotonic sodium chloride (one level-teaspoon common salt per half litre of water); mineral or vegetable oil; glycerine; a surfactant (docusate sodium); or a stimulant laxative (bisacodyl).</p>
<p>The enema should be administered very gently to prevent local injury to the bowel. Tap water enema may cause water intoxication, especially in infants and children. Irritant substances such as hot water, household detergents and strongly hypertonic salt solutions should not be used.</p>
<p>The indications for evacuant enema are:</p>
<ul>
<li>Fecal impaction. This may have to be treated initially by introducing a mineral or vegetable oil, followed by enema and digital evacuation, if required.</li>
<li>To empty the colon and the rectum before radiologic or endoscopic examination.</li>
<li>To cleanse the large bowel prior to surgery or childbirth.</li>
<li>In patients with incontinence or colostomies; and</li>
<li>As substitutes for glycerin suppositories and oral laxatives to re-establish the rectal reflex in constipated patients.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="constipation-and-laxatives">Constipation and Laxatives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#constipation-and-laxatives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Constipation may be defined as "functional impairment in the inherent capacity of the colon to produce normally formed stools at regular intervals." Individuals are known to differ widely in the 'normal' habits concerning the frequency, quantity and consistency of stools, and missing a bowel movement does not necessarily affect the health adversely. Failure to realise this may lead to self medication and to laxative habit. In most cases, 'chronic constipation' is functional and can be corrected by simple measures such as increasing the roughage and water intake, exercise and by treatment of emotional factors, if any. The proper 'habit time' (conditioned effect) should be developed and the natural reflex, when it occurs, should not be ignored habitually. Presence of any local organic cause such as painful fissure should be ruled out.</p>
<p>The bulk residue can be increased and stools can be softened by simple measures such as increasing bran or leafy vegetables in the diet or by using bulk laxatives like isapgol, methyl cellulose or agar agar. Food fibre is more effective as a laxative than synthetic fibre. Cereal fibre (bran) is more effective in this respect than fruits and vegetables. Such measures are particularly useful in patients with irritable bowel syndrome, who may complain of constant or intermittent symptoms with the passage of small, round 'rabbit' or 'sheep' stools and abdominal pain aggravated by fatigue, smoking and mental tension. The pain could be related to the ingestion of certain foods such as coffee, spices, fried foods, certain vegetables and fruits and even milk. Only in a few cases of chronic constipation, mild stimulant laxatives from the vegetable group may be necessary in initial stages.</p>
<p>In old or obese individuals and in convalescing patients who find it difficult to strain, lubricant drugs or suppositories are useful, while in those in whom spastic colon is suspected, use of antimuscarinic preparations may be beneficial. Constipation associated with diseases like vitamin B deficiency or hypothyroidism will be corrected following vitamin B or thyroxine therapy. For the elderly, drinking of plenty of water and abdominal muscle exercises are recommended. Re-training of bowel habits is important. Regular use of excessive laxatives should be avoided. Use of senna lubricands along with a bulk laxative is safer, effective and economical in such patients.</p>
<p>Constipation in infants and children sometimes poses a problem. In many cases, however, it is exaggerated by the anxious parents who believe that a daily good evacuation is necessary for good health. It is essential, therefore, that parents, particularly mothers, should know that the dire consequences of constipation are mostly imaginary. It is known that breast fed babies may have infrequent stools, sometimes once every four days, without any abnormal symptoms. This obviously needs no treatment. In artificially fed babies, hard stools are often produced because of under-feeding or deficient intake of water and sugar in the feeds; the water requirement in warm countries like India is usually more than that in the temperate zones. In such cases, increasing the water intake and adding sugar to feeds corrects the constipation. Daily consumption of a few black raisins or a fig is known to help children with constipation. Occasionally, however, one has to prescribe a laxative particularly in those children in whom passing of hard stools is associated with considerable discomfort. The drug usually advocated is magnesium hydroxide mixture (Milk of magnesia). Suppositories containing glycerine may be prescribed when other methods are not helpful. It acts by its hygroscopic action within 10-</p>
<p>20 minutes. It is reliable, safe and cheap. In some cases with really formidable constipation, enemas are necessary to clear the bowel.</p>
<p>Laxatives used occasionally are not harmful but their repeated administration may produce:</p>
<ul>
<li>GI disturbances like dyspepsia, anorexia, nausea and spastic colitis.</li>
<li>Nutritional deficiency of calories, vitamins, and minerals due to interference with their absorption.</li>
<li>Loss of fluid and electrolytes, particularly potassium and calcium, giving rise to hypokalemia and osteomalacia.</li>
<li>Dependence on drugs and later even resistance to all the mild laxatives, due to the development of spastic colon.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-toxicity">- Drug toxicity<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-toxicity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>After a thorough evacuation following a laxative, it may take some days to normalise the bowel movement and individuals should be told about this. Otherwise, they may feel that the constipation is continuing and continue to take the purgative.</p>
<p>It is important that family physicians should counter the false notions created in the minds of lay people, many times by commercial advertisements, and must emphasise the limitations of laxatives rather than prescribe them readily, whenever the patient complains of 'constipation'.</p>
<p>In the clinical management of persistent constipation, it is very essential to carry out an abdominal and rectal examination to exclude any local rectal or anal lesion to exclude possible local organic disease. In patients with primary intestinal pathology and secondary constipation, attention to primary disease is of utmost importance, e.g. colonic cancer.</p>
<p>Table 42.3 gives the commonly used drugs which may cause constipation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-42-3">Table 42.3<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-42-3" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="drugs-causing-constipation">Drugs causing constipation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-causing-constipation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><sup><a href="#user-content-fn-0" id="user-content-fnref-0-10" data-footnote-ref="true" aria-describedby="footnote-label">1</a></sup></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="treatment-of-hemorrhoids-and-anal-fissure">Treatment of Hemorrhoids and Anal Fissure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment-of-hemorrhoids-and-anal-fissure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Perianal pruritus, soreness and excoriations are common symptoms in addition to bleeding in hemorrhoids; and acute anal pain due to spasm of the anal sphincter occurs in anal fissure. Avoidance of hard stools by the use of bulk laxatives and/or liquid paraffin and a high fibre diet are helpful in these conditions. Local application of a bland, zinc salt containing ointment relieves these local symptoms. Application of an ointment containing a local anaesthetic such as lignocaine before passing a stool helps to relieve the local pain and ease the sphincter spasm. There is evidence that relaxation of the anal sphincter is mediated by nitric oxide NO (Chapter 29). Nitroglycerine ointment ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.2%</span></span></span></span></span> ) or isosorbide dinitrate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> ointment is used for local application in cases of anal fissure, with relief of spasm and pain, and healing of the fissure. While prescribing the preparations, the patient should be warned that headache might follow their application. Local injection of botulinum toxin (Chapter 22) into the anal sphincter has been used in resistant cases. It acts by preventing the release of acetylcholine locally.</p>
<p>Preparations for local application containing antibiotics and corticosteroids have little rationale and may even be harmful. For sclerosant therapy of bleeding hemorrhoids see Chapter 33.</p>
<p>43</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacotherapy-of-peptic-ulcer-disease">Pharmacotherapy of Peptic Ulcer Disease<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacotherapy-of-peptic-ulcer-disease" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Peptic ulcer disease is one of the common GI disorders in clinical practice. The common forms of peptic ulcer are:</p>
<ul>
<li>Duodenal ulcer (DU)</li>
<li>Gastric ulcer (GU)</li>
<li>Stress ulcer(s); and NSAID induced ulcer</li>
</ul>
<p>Of these, the DU is largely a disease of adult males. Gastric ulcer (GU) occurs most frequently in the older age group and in the lower socio-economic class of individuals. DU, on the other hand, occurs commonly in younger individuals and is evenly distributed among various socio-economic groups.</p>
<p>Peptic ulceration occurs mostly in areas which are bathed by the acid juice. Although the exact etiology of ulceration is not known, a high association between H. pylori infection of the stomach and duodenum and peptic ulcer disease has now been established. It was Dr. Warron, a pathologist who, by chance, first noticed "numerous curved bacilli lying below the stomach's protective mucus in a gastric biopsy sample" (1979). Later work by Warron and Marshall conclusively showed the association of these bacilli, now known as Helicobacter pylori, with chronic gastritis and ulceration. They were awarded the Nobel Prize in 2005.
H. pylori is a Gram negative bacillus that colonises the stomach and the duodenum. The infection is acquired by fecal-oral route in early childhood and is mainly transmitted within families. The organism does not invade the mucosa but attaches itself to the epithelial cells. It secretes (a) a urease which hydrolyses urea into carbon dioxide and ammonia; the latter permits the bacilli to survive in the acid environment of the stomach; and (b) an exotoxin which directly damages the epithelial cells. Although H. pylori is present in the G I tract of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of the adult population, only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10-20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> of the latter develop DU. Therefore, there must be a host factor in the pathogenesis of peptic ulcer disease.
H. pylori causes chronic gastritis in majority of the persons whose GI tract it colonises. Nearly all patients with DU and almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> of patients with GU show colonisation of the stomach by H. pylori. They are also strongly implicated in the pathogenesis of gastric carcinoma and gastric lymphoma. Those with infection of the gastric antrum have hyperacidity and develop DU; those with infection of the body of the stomach develop low acidity and GU.</p>
<p>Factors modifying gastric acid secretion: The gastric juice is a mixture containing hydrochloric acid, pepsin, rennin (in children), neutral chlorides, mucus, intrinsic factor and traces of potassium, ammonium and calcium.</p>
<p>The gastric acid and pepsin are secreted by the main gastric glands, containing highly specialised cells, present all over the body and fundus of the stomach. The rate and the composition of the secretion of main gastric glands vary considerably, depending upon the number of acid-secreting cells (the parietal cell mass), emotional factors, digestive state, hormonal status and the presence of extrinsic chemical stimuli such as caffeine and histamine.</p>
<p>The parietal (oxyntic) cells are located in the walls of the midsection of the oxyntic glands, the secretory unit of the gastric mucosa. The parietal cell has prominent</p>
<p>cytoplasmic tubulo-vesicles. In addition, oxyntic glands contain chief, mucous, enterochromafin like (ECL) cells and somatostatin cells.</p>
<p>Gastric acid secretion is regulated by intricate central and peripheral mechanisms. The central mechanism acts through the vagus nerve. In addition, ACh liberated from the postganglionic nerve fibres directly stimulates the parietal cells.</p>
<p>Three distinct but interdependent pathways deliver chemical messengers that stimulate acid secretion by parietal cells (Fig. 43.1):
<img src="assets/images/image-20251214-e090c6f6.jpeg" alt="img-51.jpeg"></p>
<p>FIG. 43.1 Mechanisms involved in regulation of gastric acid secretion by the parietal cells. R = Receptors; ECL = Enterochromaffin like (cells). Gastrin acts mostly indirectly by releasing histamine. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">E</mi><mi mathvariant="normal">P</mi></mrow><mo>−</mo><mi mathvariant="normal">R</mi><mo>=</mo><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{EP}-\mathrm{R}=\mathrm{PG}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord mathrm">EP</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm">R</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord mathrm">PG</span></span></span></span></span></span> receptor for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub><mo separator="true">;</mo><msub><mi mathvariant="normal">M</mi><mn>1</mn></msub><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2} ; \mathrm{M}_{1}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">;</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord mathrm">M</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Muscarinic; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Histaminic</p>
<ul>
<li>The neurocrine pathway, that acts through the vagal efferent transmitter acetylcholine.</li>
<li>The endocrine pathway which delivers hormone gastrin from antral G cells; and</li>
<li>The paracrine pathway which delivers tissue factors, such as histamine from ECL cells.</li>
</ul>
<p>The tubulovesicular and canalicular structures of the parietal cells possess a specific hydrogen-potassium-ATPase enzyme (Proton pump). The proton pump is activated by protein kinases, histamine, acetylcholine and gastrin, and serves as a common final pathway for gastric acid secretion. When stimulated, it causes the transport of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{H}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ions across the parietal cells in exchange of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ions. Hydrogen ions combine with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Cl}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8557em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span>ions to form HCl (Fig. 43.1).</p>
<p>The fundic mucosa also contain several paracrine cells, secreting somatostatin, histamine, and 5-HT. They possess receptors that may regulate acid secretion by modulating the release of the paracrine transmitters. Thus, ACh may enhance the secretion of acid not only by stimulating the parietal cell directly, but also by reducing the</p>
<p>level of somatostatin, a potent inhibitor of acid secretion.
Prostaglandin E (PGE) is produced by cells throughout the GI tract. PGE, inhibits the secretion of gastric acid in humans, particularly food and NSAID stimulated acid secretion.</p>
<p>The pyloric glands, present in pyloric antrum, secrete:</p>
<ul>
<li>Gastrin, directly into the blood; and</li>
<li>An alkaline, viscid, mucus-rich juice, into the stomach.</li>
</ul>
<p>Gastrin stimulates acid secretion mainly by causing the release of histamine from the ECL cells which are the sole source of gastric histamine involved in acid secretion (Fig. 43.1). The chief cells of the gastric glands secrete pepsinogen, which is activated at acidic pH below 5 to the enzyme pepsin. Optimal activation occurs at pH 2 .</p>
<p>Normal gastric acid secretion acts as a chemical barrier to bacterial invasion and is important for the maintenance of optimum pH at 1.5 to 4 , necessary for the activity of pepsin, which is markedly reduced at pH above 4 and almost ceases at pH 5 . However, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi></mrow><annotation encoding="application/x-tex">H</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span></span></span></span></span>. pylori survive and multiply in acidic environment.</p>
<p>Phases of gastric secretion: Gastric acid secretion is generally divided into four phases:</p>
<ul>
<li>Basal or interdigestive</li>
<li>Cephalic</li>
<li>Gastric; and</li>
<li>Intestinal</li>
</ul>
<p>During the first three phases, acid output is stimulated when food is first encountered and it continues as nutrients traverse the small intestine. During the fourth phase, acid is secreted in the absence of an external stimulus.</p>
<ul>
<li>Basal secretion: This follows a circadian rhythm, reaching its peak around midnight and its nadir at approximately 7 a.m. measured as nocturnal acid secretion, it is high in some patients with DU but may be normal or low in patients with GU.
Secretion in response to food: Gastric secretion in response to food may be divided into two phases, neurogenic and hormonal.</li>
<li>In neurogenic or cephalic phase, the secretion occurs as a result of sight, smell, taste or even simple thought of food. The juice secreted is highly acidic and rich in pepsin. It is mediated by the vagus and is abolished by vagotomy and antimuscarinic drugs. The gastric secretion induced by emotions are also mediated centrally. In man, depression and fear result in a suppression of gastric secretion, whereas anger and resentment result in increased production. Violent emotions cause gastric congestion and hyperemia rendering it more susceptible to traumatic ulceration.</li>
<li>In hormonal phase (gastric and intestinal phases), the gastric secretion is increased due to stimulation of the parietal cells by gastrin. Gastrin-containing cells are stimulated by food in the stomach and by neuronal input to release gastrin. Gastrin is carried to the ECL (enterochromaffin like) cells where it stimulates the release of histamine, which then activates the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-receptors in the parietal cells (Fig. 43.1). In addition, acid secretion is stimulated chemically, specifically by an increase in intraluminal pH and by certain substances in the food, principally proteins and individual amino acids. A cocktail or a protein broth soup before a meal stimulates acid secretion and prepares the stomach for the main dish! Digested protein in the duodenum enhances the output of acid. After a meal, the secretion of acid is modulated by a negative-feedback mechanism in</li>
</ul>
<p>which antral acidification inhibits the further release of gastrin. As the luminal pH approaches 3.5 to 3.0, inhibition of gastrin becomes apparent and is almost complete at pH 1.5. Somatostatin and its analogue octreotide inhibit the antral release of gastrin and also decrease acid secretion directly. In addition, like gastric motility, gastric secretion is inhibited by reflexes initiated in the duodenum by distension, hypertonic contents, fatty acids, amino acids and acid in the duodenum. Thus, a highly fatty meal delays gastric emptying to 4-6 hours, whereas a meal rich in carbohydrate and proteins leaves the stomach in 2-3 hours. Fat in the duodenum stimulates the release of gut hormone cholecystokinin (CCK) whereas acid in the duodenal chyme is an effective chemical stimulus for the release of another gut hormone secretin. Both secretin and CCK act via circulation to inhibit the stomach motility and glandular secretion. The hormonal phase is inhibited only partially by antimuscarinic drugs but substantially by H2-receptor antagonists.</p>
<p>Natural gastrin is a polypeptide containing 17 aminoacids. A synthetic pentapeptide, Pentagastrin, containing five amino acids (alanine, tryptophan, methionine, phenylalanine and aspartic acid) produces secretory and other biological effects similar to those of the gastrin.</p>
<p>Histamine-stimulated gastric secretion is highly acidic but poor in pepsin content. This is similar to gastrin-induced secretion since gastrin acts through the local liberation of histamine. Histamine directly stimulates the parietal cell <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-receptors that are linked to adenylyl cyclase. Acetylcholine and gastrin may also stimulate the parietal cells directly through different receptors. Thus, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists inhibit not only gastric secretion elicited by injected histamine but also that elicited by various physiological stimuli, mediated by the vagus or by gastrin.</p>
<p>Factors which are postulated to protect the gastric and duodenal mucosa against the effects of the 'aggressive factors' are summarised in Table 43.1.</p>
<p>Table 43.1
Factors protecting the gastric and duodenal mucosa</p>
<ul>
<li>Mucus produced by the cells of the gastric mucous glands.</li>
<li>Bicarbonate secreted by the surface epithelial cells.</li>
<li>Rich mucosal blood flow which removes the acid that might diffuse through the mucosa.</li>
<li>ProstaglandinsE which enhance all the normal gastroduodenal protective mechanisms.</li>
<li>Various growth factors such as epidermal growth factor, and transforming growth factor;</li>
<li>A competent pyloric sphincter which prevents the regurgitation of the aggressive factors (bile acids and pancreatic enzymes) into the stomach.</li>
</ul>
<p>No abnormalities have been consistently demonstrated in all patients with either DU or GU, although various abnormalities have been demonstrated, each in some peptic ulcer patients. These are:</p>
<ul>
<li>Acid hypersecretion found in 30-40% of patients with DU.</li>
<li>Hereditary factors such as rapid gastric emptying and a larger than normal parietal cell mass found in peptic ulcer patients with rare genetic syndromes.</li>
<li>Diminished gastric mucosal blood flow believed to be responsible for the acute gastric erosion occurring during serious medical or surgical illnesses (stress ulcers).</li>
<li>An incompetent pyloric sphincter found in some patients with peptic ulcer; and</li>
<li>High gastric acid output in stressful situations (such as an interview or an examination)</li>
</ul>
<p>and during certain emotions such as hostility, resentment, guilt or frustration.
Principles of peptic ulcer therapy: These are:</p>
<ul>
<li>Controlling gastric acidity, hypermotility and promoting ulcer healing (Table 43.2).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-43-2">Table 43.2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-43-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Measures to control gastric acidity</p>
<ul>
<li>Neutralising gastric acid using antacids.</li>
<li>Inhibiting the gastric acid secretion and protecting the gastric mucosa:
(a) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists
(b) Proton pump inhibitors; and
(c) Mucosal protectives</li>
<li>Cessation of smoking</li>
<li>Withdrawal of gastric acid secretion stimulants such as alcohol, caffeine and soft cola drinks.</li>
<li>Avoiding acid-inducing drugs.</li>
<li>Treatment of H. pylori infection; and</li>
<li>Prevention of complications and recurrence.</li>
</ul>
<p>Exogenous factors such as smoking, NSAID, glucocorticoids and alcohol have been strongly associated with ulcerogenesis, and non-healing of peptic ulcers.</p>
<p>Classification of drugs for peptic ulcer:
I Acid neutralising agents: Systemic and Non-systemic antacids.
II Anti-secretory agents:
(a) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor blockers,
(b) Proton pump inhibitors (PPI),
(c) Antimuscarinics.</p>
<p>III Mucosal protective agents: Bismuth salts, PGE analogues, Sucralfate.
IV Anti-Helicobacter antimicrobials given in combination
(a) Amoxicillin, Clarithromycin, Tetracycline, Metronidazole.
(b) Bismuth subsalicylate</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="gastric-antacids">Gastric Antacids<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#gastric-antacids" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Gastric antacids are substances which, on ingestion, react chemically with gastric acid and lower the acidity of gastric contents. They produce symptomatic relief of pain, mainly by reducing the acidity and partly by the consequent relief of muscle spasm. Reduction in acidity inhibits the action of pepsin. It also increases the tone of the esophagogastric sphincter and reduces the reflux of the acid, gastric contents into the esophagus.</p>
<p>If adequate relief of symptoms in DU is to be brought about without seriously interfering with peptic digestion of food, the gastric pH must be raised from the usual level of 1-2 to between 3.5 and 4.5. Although this is possible with antacids, it is difficult to maintain it continuously. Hence, to achieve even a reasonable control of gastric acidity regular and frequent administration of an antacid round the clock would be necessary, which is its main disadvantage.</p>
<p>In spite of their limitations, antacids are valuable as they produce considerable, immediate, symptomatic relief in patients with DU, gastritis and reflux esophagitis. As OTC drugs, they are often used for the symptomatic treatment of dyspepsia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="antacids-classification">Antacids - Classification:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antacids-classification" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>I Non-systemic antacids: Such as aluminium hydroxide gel, magnesium trisilicate, magnesium hydroxide, calcium carbonate.
II Systemic antacids: Sodium bicarbonate is absorbed and may cause alkalosis; hence, it is called 'systemic antacid'.</p>
<p>Mechanism of action: These drugs acting as weak bases neutralise the gastric HCl . They raise the gastric pH to above 4 . Antacids like sodium bicarbonate can theoretically raise the gastric pH above 7 . Because of the varying rates of acid neutralisation by various antacids, comparison of the amount of acid neutralised per gm of the antacid does not give valid information about its relative clinical efficacy. The figures of mEq of acid neutralised per gm or per ml of the antacid' represent the number of mEq of 1 N HCl that can be brought to pH 3.5 in 15 minutes (Acid Neutralising Capacity, ANC).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="non-systemic-antacids">Non-Systemic Antacids<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#non-systemic-antacids" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These are water insoluble and largely unabsorbable basic agents. The base may be hydroxide or carbonate or trisilicate, combined with cation such as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">M</mi><mi mathvariant="normal">g</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup><mo separator="true">,</mo><msup><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">l</mi></mrow><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Mg}^{++}, \mathrm{Al}^{+++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0501em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Mg</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Al</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+++</span></span></span></span></span></span></span></span></span></span></span></span></span>or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>. In the stomach, during neutralisation of the acid, the cation e.g. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">M</mi><mi mathvariant="normal">g</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Mg}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.039em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Mg</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>forms a chloride. In the alkaline pH of the small intestine, the chloride salt reacts with the bicarbonate from the intestinal juices to regenerate the original salt (hydroxide or carbonate). There is, thus, no net gain or loss of H or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{HCO}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ions to the body. Hence, systemic alkalosis is avoided.</p>
<p>Non-systemic antacids are insoluble till they come into contact with the gastric acid. The antacid which escapes this reaction remains in the stomach and reacts with the acid subsequently secreted. Hence, their duration of action is, longer than that of soluble antacids.</p>
<p>ALUMINIUM HYDROXIDE GEL: This is available either as a white, colloidal, viscous suspension or as dried gel in the form of powder or tablets. It reacts with gastric acid to form aluminium chloride.</p>
<p>Each ml of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">4 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">4%</span></span></span></span></span> gel suspension neutralises 1.2 to 2.5 mEq of acid. The neutralising action is slow. The gastric pH is raised to 4 . The acid neutralising capacity differs according to the process of manufacture and age of the product and to vary from batch to batch. Pepsin activity is not significantly inhibited. It has, however, astringent and demulcent properties by which it forms a protective coating over the ulcer crater. It may also adsorb toxins, gases and bacteria.</p>
<p>In the intestines, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">l</mi></mrow><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">H</mi></mrow><msub><mo stretchy="false">)</mo><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{Al}(\mathrm{OH})_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">Al</span></span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">OH</span></span><span class="mclose"><span class="mclose">)</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, is regenerated from <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">l</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AlCl}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8444em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AlCl</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and chloride liberated is reabsorbed.</p>
<p>Adverse reactions: Constipation is the common adverse effect. This can be countered by combining it with magnesium trisilicate. Aluminium hydroxide may prevent the absorption of phosphate from the intestines. This may rarely cause osteomalacia. In patients with chronic renal failure, high plasma aluminium may rarely cause encephalopathy and deposition of aluminium in the bone with resultant osteodystrophy.</p>
<p>Preparations and dosage: (i) Aluminium hydroxide gel 4-8 ml every 2-4 hours. (ii) Aluminium hydroxide 0.5 g tablets; 1-2 tablets to be chewed qid.</p>
<p>ALUMINIUM PHOSPHATE GEL: It is sometimes preferred to aluminium hydroxide gel, as it does not interfere with phosphate absorption.</p>
<p>MAGNESIUM TRISILICATE: It is a fine, white, tasteless powder, insoluble in water. In the stomach, it reacts with acid to form hydrated silicon dioxide. As it becomes gelatinous in consistency, it provides a protective coating to the ulcer crater.</p>
<p>The neutralising action of magnesium trisilicate is slow in onset but prolonged. In the intestines, magnesium chloride reacts with the bicarbonate to form magnesium carbonate, which is excreted in feces; about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">7 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">7%</span></span></span></span></span> is absorbed and excreted in the urine.</p>
<p>Hydrated silica gel has adsorbent properties similar to those of aluminium hydroxide gel.</p>
<p>One gm of magnesium trisilicate neutralises about 9-11 mEq of gastric acid.
Adverse reactions: It may cause mild diarrhoea which can be countered by combining it with aluminium hydroxide. A small amount of magnesium absorbed may produce CNS depression in the presence of impaired renal function.</p>
<p>Dose: 2-4 g every 1-4 hours. The tablet should be chewed before it is swallowed. The</p>
<p>drug can also be used in powder form.
MAGNESIUM OXIDE AND HYDROXIDE: Magnesium oxide, on contact with water, is converted to magnesium hydroxide which combines with gastric acid. It is a quick acting antacid with prolonged action. In small intestine, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">M</mi><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">H</mi></mrow><msub><mo stretchy="false">)</mo><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{Mg}(\mathrm{OH})_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Mg</span></span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">OH</span></span><span class="mclose"><span class="mclose">)</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is regenerated and excreted in feces. One gm of magnesium oxide neutralises 50 mEq of the acid. The dose is rather bulky.</p>
<p>Magnesium hydroxide is available as 'Milk of magnesia' containing 7 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>8.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">8.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">8.5%</span></span></span></span></span> of magnesium hydroxide. It is more palatable than other formulations of magnesium salts. One ml of milk of magnesia neutralises 2.7 mEq of acid.</p>
<p>Adverse reactions: These are similar to those of other magnesium salts.
Dose: Milk of magnesia as an antacid 4 ml ; as a laxative 15 ml .
MAGNESIUM CARBONATE: This antacid has properties similar to those of magnesium hydroxide except that carbon dioxide is liberated during neutralisation of the acid. One gm neutralizes 20 mEq of acid.</p>
<p>CALCIUM CARBONATE: It occurs as a white, powder with a chalky taste. In the stomach, it reacts with gastric acid to form calcium chloride. In the intestine, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CaCl}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8444em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CaCl</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> reacts with bicarbonate to regenerate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CaCO}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CaCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> which is excreted in feces. Calcium carbonate acts quickly and has a high neutralising capacity. One gm neutralises 21 mEq of the acid. Its action is prolonged and it is inexpensive.</p>
<p>Magnesium salt can counteract its constipating effect. Calcium carbonate increases serum gastrin level and gastric acid secretion above the basal level. Prolonged therapy may cause hypercalcemia, hyperphosphatemia and renal calcinosis.</p>
<p>Dose: Powdered precipitated chalk or tablet containing 1 g of calcium carbonate. Dose: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>4</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2-4 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">4</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span>.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="systemic-antacids">Systemic Antacids<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#systemic-antacids" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>SODIUM BICARBONATE: Sodium bicarbonate is a white, water soluble and completely absorbable antacid. It reacts with the gastric acid to form sodium chloride, water and carbon dioxide. One gram of the drug neutralises 12 mEq of acid. In the intestine, sodium chloride remains unchanged.</p>
<p>Excess of bicarbonate of the intestinal contents is absorbed, and may cause systemic alkalosis. It is an effective and rapidly acting antacid. Its duration of action, however, is short. Eructation of the carbon dioxide liberated during the process of acid neutralisation often gives the patient a sense of relief from abdominal discomfort. This is the basis of its reputed carminative action. During its repeated administration in sufficient quantities, the output of the gastric juice and acid far exceeds the basal secretion. This is probably because the continuous maintenance of raised pH in pyloric antrum stimulates gastrin liberation.</p>
<p>Adverse reactions: The release of carbon dioxide with resultant belching, flatulence, feeling of fullness, nausea and exacerbation of esophageal reflux are the common sideeffects. Systemic alkalosis and edema due to sodium retention are rarely encountered.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>As an antacid: Dose 1-5 g in water, repeated as required.</li>
<li>Metabolic acidosis (see Chapter 37).</li>
<li>Alkalinisation of urine: To render urine alkaline in the treatment of certain urinary tract infections and to prevent precipitation of substances such as sulfonamide and uric acid.</li>
<li>Topical use: Sodium bicarbonate solution is used as an antipruritic lotion, as an eye wash, mouth wash, douche and to loosen ear wax.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antacid-therapy">Antacid Therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antacid-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Being advertised to the laity and sold OTC, antacids are among the most abused drugs. Their indiscriminate use without an attempt to establish the cause of 'dyspepsia' can sometimes lead to masking of the warning symptoms of a serious condition like cancer of the stomach. However, when used properly and in adequate doses, they promptly relieve the pain of gastritis and duodenal ulcer and promote healing. They are relatively cheap.</p>
<p>While using antacids, it is necessary to remember that:</p>
<ul>
<li>They should be prescribed in optimal dose at 1 and 3 hours after each meal, at bed time and as needed for pain. In the fasting state antacids have only a transient intragastric buffering effect, about 15-30 minutes. When ingested 1 hour after meal, however, they have a much longer effect, about 3-4 hours.</li>
<li>The in vitro buffering effect of an antacid may not necessarily correlate with its in vivo effect.</li>
<li>The quantity of an antacid required to produce optimal buffering varies from one patient to another. The hypersecretors, such as DU patients, need larger quantities.</li>
<li>Antacid tablets, though more convenient than liquids, are less effective buffers, unless they are chewed; hence, liquid formulations are to be preferred.</li>
<li>Antacids may interfere with absorption of other drugs. (Table 43.3).</li>
</ul>
<p>Table 43.3
Drug interactions of antacids</p>
<table><thead><tr><th style="text-align: left;">Antacids</th><th style="text-align: left;">Decrease in bioavailability of</th></tr></thead><tbody><tr><td style="text-align: left;">Aluminium &lt;br&gt; compounds</td><td style="text-align: left;">Phosphate, iron salts, tetracyclines, antimuscarinic drugs, phenothiazines, digoxin, indomethacin (but not aspirin), prednisolone, ranitidine, &lt;br&gt; sulfadiazine and fat soluble vitamins.</td></tr><tr><td style="text-align: left;">Calcium carbonate</td><td style="text-align: left;">Antimuscarinic agents, iron, phenothiazines, quinidine and tetracyclines.</td></tr><tr><td style="text-align: left;">Magnesium salts</td><td style="text-align: left;">Digoxin and tetracyclines.</td></tr></tbody></table>
<p>While the clinical significance of the above drug interactions is uncertain, it is prudent to avoid simultaneous administration of antacids and drugs intended for systemic absorption.</p>
<ul>
<li>Persistent reduction in gastric acidity by antacids may rarely increase susceptibility to intestinal pathogens.
Choice of the antacid: Adequate dosage and frequency of administration are more important than the actual antacid chosen. Cost is also a major consideration. In general, systemic antacids should be avoided. Magnesium trisilicate, is more effective than aluminium hydroxide. It can be prescribed as a non-proprietary, powder form which is costeffective and acceptable to many patients. Antacid combinations do not necessarily produce better results than individual antacids, but may counter the mutual adverse reactions. The commercially available, liquid preparations of antacids may vary by as much as 7 fold in their acid neutralising capacity, a fact not indicated on the product label.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antisecretory-agents">Antisecretory Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antisecretory-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These drugs reduce the gastric acidity by acting as (Fig. 43.1):
I Proton-pump inhibitors (PPI);
II Histamine ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ) receptor antagonists. or
III Antimuscarinics.
I Proton pump inhibitors (PPI): These drugs irreversibly inhibit the gastric <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{H}^{+}-\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8547em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>-ATPase proton pump which is the final common pathway for acid secretion in response to all stimuli (Fig. 43.1). All PPIs are prodrugs and require activation at an acid pH .</p>
<p>Mechanism of action: After absorption from the intestine, PPI diffuse from the blood into the parietal cells, are secreted into and get ionised at the acid pH and inactivate the enzyme <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{H}^{+}-\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8547em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>-ATPase irreversibly. This causes marked inhibition of gastric acid secretion. They have negligible effect on pepsin content. The effect lasts till the enzyme is regenerated following stoppage of the drug. There is less rebound increase in acidity following the drug withdrawal.</p>
<p>All of them have short plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mo separator="true">,</mo><mn>0.5</mn><mo>−</mo><mn>2</mn></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}, 0.5-2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0824em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span></span></span></span></span> hours but the action lasts much longer. All PPIs are acid labile and the tablet should be swallowed unbroken/uncrushed; or the drug should be given as enteric coated granules.</p>
<p>OMEPRAZOLE: This is a substituted benzimidazole (Fig 43.2) with potent and prolonged action. As the concentration of the proton pump molecules in the parietal cells is highest after a prolonged fast at night, the PPIs act best when taken about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">1 / 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/2</span></span></span></span></span> hour before the breakfast. A second dose may be administered V hour before the dinner. As only a fraction of the PP molecules are activated at a given time, a single daily dose takes 4-5 days to achieve the maximum reduction of acid secretion ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>65</mn><mo>−</mo><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">65-90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">65</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> ). It also selectively inhibits gastric mucosal carbonic anhydrase. It has negligible effect on pepsin content.
<img src="assets/images/image-20251214-f4b12065.jpeg" alt="img-52.jpeg"></p>
<p>With once a day (20-40 mg) regimen, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> DU heal in 2 weeks and almost all heal in 4 weeks. Gastric ulcers require larger doses for 8 weeks. It is highly effective in ZollingerEllison syndrome with severe gastric acid hypersecretion and DUs resistant to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor blockers, and in reflux esophagitis. For patients with bleeding ulcers, high dose IV PPI may reduce need for endoscopic hemostasis. They also reduce chances of rebleeding. Oral doses ( 40 mg twelve hourly) of omeprazole is another alternative.</p>
<p>Adverse reactions: The drug is generally well tolerated. GI disturbances, dizziness and drowsiness may occur. The main concern about this drug is that it causes marked hypergastrinaemia due to prolonged achlorhydria. Carcinoid-like lesions in the stomach have been observed in rats, but not in humans. Theoretically, marked acid inhibition should increase susceptibility for GI infections. However clinically there is no evidence of GI infection. Use of PPI for more than 5 years may be associated with increased incidence of osteoporotic fractures.</p>
<p>It inhibits the hepatic microsomal enzymes and prolongs the half life of drugs such as diazepam, disulfiram, phenytoin, carbamazepine and warfarin.</p>
<p>Experimental studies have shown that omeprazole and other PPI cause alteration in gut microflora (dysbiosis).</p>
<p>Lansoprazole, pantoprazole, esomeprazole and rabeprazole are the other analogues of omeprazole. Pantoprazole and rabeprazole are available for IV use (Table 43.4).</p>
<p>Table 43.4
Proton pump inhibitors</p>
<table><thead><tr><th style="text-align: left;">Drug</th><th style="text-align: center;">Bioavailability <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">%</span></span></span></span></span></th><th style="text-align: center;">Dose <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mo lspace="0em" rspace="0em">∘</mo></msup><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">^{\circ} \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day</th></tr></thead><tbody><tr><td style="text-align: left;">Omeprazole</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>65</mn></mrow><annotation encoding="application/x-tex">40-65</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">65</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>40</mn></mrow><annotation encoding="application/x-tex">20-40</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">40</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Pantoprazole</td><td style="text-align: center;">77</td><td style="text-align: center;">40</td></tr><tr><td style="text-align: left;">Lansoprazole</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mo>−</mo><mn>90</mn></mrow><annotation encoding="application/x-tex">80-90</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">80</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">90</span></span></span></span></span></td><td style="text-align: center;">30</td></tr><tr><td style="text-align: left;">Rabeprazole</td><td style="text-align: center;">52</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>40</mn></mrow><annotation encoding="application/x-tex">20-40</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">40</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Esomeprazole</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>89</mn></mrow><annotation encoding="application/x-tex">50-89</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">89</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>40</mn></mrow><annotation encoding="application/x-tex">20-40</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">40</span></span></span></span></span></td></tr></tbody></table>
<p>In single or two-divided doses.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mo lspace="0em" rspace="0em">∘</mo></msup></mrow><annotation encoding="application/x-tex">{ }^{\circ}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6741em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span></span></span></span></span> For peptic ulcer and GERD.
II <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-receptor antagonists: Because of their structural similarity to histamine (Fig. 43.3), these drugs act selectively by competitive blockade of parietal cell <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors. They are highly effective. However, they can cause tolerance probably due to down regulation of receptors. A rebound increase in acid secretion may occur after their withdrawal.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="histamine">Histamine<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#histamine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><img src="assets/images/image-20251214-f4ae8887.jpeg" alt="img-53.jpeg"></p>
<p>Cimetidine
<img src="assets/images/image-20251214-6d2bbd2e.jpeg" alt="img-54.jpeg"></p>
<p>Rantidine
<img src="assets/images/image-20251214-00d88fcb.jpeg" alt="img-55.jpeg"></p>
<p>FIG. 43.3 Histamine and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists</p>
<p>CIMETIDINE: Cimetidine inhibits markedly (80-90%) histamine, pentagastrin, caffeine and vagus (ACh) stimulated gastric acid secretion. It also inhibits the basal and meal-stimulated gastric secretion. Given orally, it reduces the acid secretion to about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> within an hour. The effect is on both volume and acid content of the gastric juice; the pepsin secretion is less affected. Food does not interfere with its action. It has no significant action on gastric emptying.</p>
<p>Absorption, fate and excretion: It is well absorbed ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60-80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> ) orally but its bioavailability is reduced to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><msup><mn>2</mn><mi mathvariant="normal">d</mi></msup></mrow><annotation encoding="application/x-tex">1 / 2^{\mathrm{d}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0991em; vertical-align: -0.25em;"></span><span class="mord">1/</span><span class="mord"><span class="mord">2</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">d</span></span></span></span></span></span></span></span></span></span></span></span></span> when it is given with sucralfate or large doses of antacids; these should not be given within 2 hours of cimetidine and other <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists. Therapeutic effect of a single dose lasts for 5-8 hours. It is largely excreted unchanged in the urine within 24 hours. It can cross the placenta and is secreted in milk.</p>
<p>Adverse reactions: The drug is generally well tolerated. The adverse effects include rashes, diarrhoea, muscle pain, fatigue and bradycardia. It must be noted that histamine and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-receptors are widely distributed in various areas such as brain, heart, blood vessels and bone marrow (Chapter 23). Blockade of cerebral <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-receptors can cause drowsiness, mental confusion, delirium and hallucinations in the elderly and in those with hepatic or renal failure. It is a weak antiandrogen and may cause gynecomastia, hyperprolactinemia and sexual dysfunction. On long term use, hepatotoxicity, and blood dyscrasias have rarely been reported.</p>
<p>It is a CYP3A4 and CYPIA2 inhibitor and reduces the clearance of drugs which are metabolised by oxidation e.g. phenobarbitone, phenytoin, propranolol, warfarin, theophylline and diazepam; the hepatotoxicity of INH and paracetamol is enhanced.</p>
<p>Preparations and dosage: The drug is available as 200 mg tablet and as injection <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">100 \mathrm{mg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> for IM or slow IV use. In cases with DU, it is usually given in the dose of 400 mg twice or thrice daily after meals, or 800 mg at bed-time. A single night-time dose is more effective than the split dose regimen, as suppression of the day-time acidity contributes to ulcer healing less than that of nocturnal acid secretion. With this treatment, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mo>−</mo><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70-80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">70</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> of the DUs heal in 6-10 weeks. Dosage should be reduced in patients with impaired renal function.</p>
<p>RANITIDINE: This nitroethane derivative of furan is 5-10 times more potent than cimetidine and has several advantages. It is adequately absorbed and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> gets metabolised in the liver. Its plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.6</mn><mo>−</mo><mn>2.4</mn></mrow><annotation encoding="application/x-tex">1.6-2.4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1.6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2.4</span></span></span></span></span> hours. Its action is more selective and longer lasting than that of cimetidine. A single oral dose of 150 mg controls gastric acid secretion for upto 8-12 hours. An IV preparation is also available.</p>
<p>Adverse reactions: It may cause skin rash, constipation and fecal concretions. However, it:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="does-not-inhibit-hepatic-drug-metabolism">- Does not inhibit hepatic drug metabolism.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#does-not-inhibit-hepatic-drug-metabolism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="has-less-antiandrogenic-effects-and">- Has less antiandrogenic effects; and<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#has-less-antiandrogenic-effects-and" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Causes little, if any, central effects.</li>
</ul>
<p>The dose is 150 mg 12 hourly or 300 mg once daily preferably at bed time.
FAMOTIDINE: Unlike cimetidine and ranitidine it has a thiazole ring. On weight basis, famotidine is 30 times more potent than cimetidine and 7.5 times more potent than</p>
<p>ranitidine. It has properties similar to ranitidine but is long acting. Only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> is metabolised in the liver. Its plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is 3-4 hours, and therapeutic effect lasts for 24 hours. A single oral dose of 40 mg at night for 8 weeks, produces healing of DU in most cases, while a dose of 20 mg reduces the relapse considerably. IM or IV preparations are also available. It is well tolerated but may cause headache, dizziness and GI symptoms. It does not interfere with drug metabolising enzymes in the liver. It is most cost effective and is to be preferred. Generic preparations of famotidine are the cheapest drug for peptic ulcer.</p>
<p>Nizatidine and roxatidine are other drugs with similar properties, and have no significant advantages over ranitidine and famotidine.</p>
<p>Therapeutic uses of PPI and H2 blockers:</p>
<ul>
<li>Duodenal and gastric ulcers: They are used in the treatment of DU. They appear to be less effective in promoting the healing of GU (see later)..</li>
<li>Zollinger-Ellison Syndrome: They have also been used to treat multiple peptic ulcers due to gastric hypersecretion from excessive circulating gastrin. PPI are more effective than H2 blockers</li>
<li>Gastroesophageal reflux disease
(GERD): <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blockers are effective but less so than PPI (see later).</li>
<li>Prevention of acute erosive gastritis in acutely stressed patients: In this condition, prophylaxis with intensive antacid regimens and/or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">P</mi><mi mathvariant="normal">I</mi></mrow><mi mathvariant="normal">/</mi><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PPI} / \mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">PPI</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blockers is recommended during the period of risk.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="nsaid-induced-ulcers">- NSAID induced ulcers<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nsaid-induced-ulcers" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>III Antimuscarinic drugs: Experimentally, antimuscarinic drugs like atropine and its derivatives inhibit the basal and maximum gastric acid secretion by up to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span>. Clinical evidence indicates that tension type of ulcer pain which is relatively uncommon may be relieved but the commoner pain related to the food ingestion is little affected. Further, these drugs cause various anticholinergic side effects (Chapter 20).</p>
<p>Antimuscarinic drugs prolong the gastric emptying time, which increases the stay of an antacid in the stomach and increases its effectiveness. However, in the absence of antacids, they would prolong the contact of the acid secretion with the ulcer; this may aggravate the symptoms. In the presence of pyloric stenosis, these drugs may cause gastric retention. They are no more recommended in DU.</p>
<p>Pirenzepine: This drug has selective antimuscarinic action on <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">M</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{M}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">M</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> muscarinic receptors in the stomach and has been shown to reduce gastric acidity.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mucosal-protective-drugs">Mucosal Protective Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mucosal-protective-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>BISMUTH SALTS: The preparations commonly used are: colloidal bismuth subcitrate and bismuth subsalicylate. They are not absorbed and the white precipitate (Bismuth chelate) formed in the gastric acid <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">p</mi><mi mathvariant="normal">H</mi></mrow><mo>&lt;</mo><mn>3.5</mn><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(\mathrm{pH}&lt;3.5)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">pH</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3.5</span><span class="mclose">)</span></span></span></span></span> coats the ulcer crater with bismuth-glycoprotein complex; the latter is relatively impermeable to the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{H}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ion and acts as a diffusion barrier to gastric acid. It is also toxic to Helicobacter pylori. They are used as tablets before each of the three main meals and at bed time. The drugs may commonly cause constipation, black stools and rarely neurotoxicity (see later).</p>
<p>SUCRALFATE: This drug is a complex of sulfated sucrose and aluminium hydroxide. In the acid environment of the stomach, it forms a gel which coats the ulcer crater for more than 6 hours, thus forming a physicochemical barrier which may act as a mucosal defence. The coating is not disturbed by food and is relatively impermeable to the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{H}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ions. It also binds pepsin and bile acids. It is well tolerated. It is given as 1 g tablets, taken 1 hour before a meal and at bed time (four times daily) for 4-8 weeks. An antacid should not be taken for A hour before or after sucralfate. By 4 weeks <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mo>−</mo><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70-80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">70</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> ulcers heal. The drug may cause constipation, dryness of mouth and abdominal discomfort. Rarely, it may cause aluminium toxicity and hypophosphatemia. It interferes with the absorption of ciprofloxacin, phenytoin, digoxin and aminophylline.</p>
<p>It is of no value in the treatment of reflux esophagitis.
PROSTAGLANDIN E: Both the gastric and intestinal mucosa synthesise prostaglandins (PG). PGE and PGI reduce the secretion of gastric acid and at lower concentrations may promote cytoprotection by acting on EP3 receptors. Analogues of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (Misoprostol, 15deoxy - 16-hydroxy - 16 methyl <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ) and of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (Enprostil, Arbaprostil, Rioprostil), given orally, produce similar effects. The protective effect lasts for hours. These drugs may cause dose related diarrhoea and oxytocic effects. They are inferior to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists in the treatment of DU. Their main clinical value is due to their ability to prevent ulceration and bleeding from the gastric mucosa in patients who take large doses of aspirin or NSAID. Misoprostol is administered in the dose of 200 mcg qid. They should not be used in pregnant women and those contemplating pregnancy. It is very expensive.</p>
<p>Rebapimide, a quinolone derivative, is claimed to act as a gastric mucosal cytoprotectant. It probably acts by stimulation of gastric PG generation. It has been used to treat gastric ulcers and acute gastritis. It needs further evaluation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="management-of-peptic-ulcer">Management of Peptic Ulcer<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#management-of-peptic-ulcer" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The management of peptic ulcer is essentially medical. It has undergone a major change with the discovery of the association of DU with H.pylori infection. H.pylori infection can be confirmed by:
(a) Detection of IgG antibody against H. pylori in the serum and antigen in the stool.
(b) Carbon labelled urea breath test; and
(c) Rapid urease breath test and histopathological examination of the biopsy of gastric antral mucosa at endoscopy.</p>
<p>The principles of medical treatment of peptic ulcer are outlined in Table 43.5.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-43-5">Table 43.5<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-43-5" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="principles-of-medical-treatment-of-du-and-gu">Principles of medical treatment of DU and GU<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#principles-of-medical-treatment-of-du-and-gu" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Rest and sedatives in acute stage.</li>
<li>Withdrawal of offending agents such as NSAID, smoking, alcohol and caffeine.</li>
<li>Dietary modification.</li>
<li>Antisecretory drugs.</li>
<li>Treatment of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi></mrow><annotation encoding="application/x-tex">H</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span></span></span></span></span>. pylori infection; and</li>
<li>Antacids.</li>
<li>Rest: Clinical studies have clearly shown that bed rest promotes ulcer healing. An initial period of bed rest, therefore, may be useful in patients with severe symptoms. However, with the availability of anti-secretory drugs, rest is no longer important in peptic ulcer.</li>
<li>Withdrawal of the offending agents: Cessation of smoking, avoidance of NSAID, alcohol and caffeine containing beverages are definitely helpful in promoting ulcer healing.</li>
<li>Diet: Contrary to common belief, there is no special merit in frequent, small meals nor in the additional night feeds. In fact, peptic ulcer disease can be effectively treated with the usual 3-4 meals a day. Night feeds only stimulate further gastric acid secretion at a time when a patient is asleep; hence they should be avoided. However, irritants such as chilly, other spices and fried food should be avoided. Edible vegetable oils, ghee and butter taken as such may be helpful, as these have an inhibitory effect on gastric acid secretion.</li>
<li>Antisecretory drugs and antacids: The mean diurnal gastric pH is about 1.4-2.0; low pH is mainly found at night. For the treatment of DU, the pH has to be elevated to a level higher than 3.0 for about 16-18 hours a day. For the treatment of reflux esophagitis, it must be raised to at least 4.0 for 16-18 hours per day. This can be achieved by 8-12 weeks' course of therapy with an <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-receptor blocker or a PPI. PPIs are the most potent antisecretory drugs available; all of them are equally effective. They may be prescribed twice daily for 3-5 days; after that a single prebreakfast dose may be prescribed for 8-12 weeks. If the ulcer recurs, another course of full therapy is indicated.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">H_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0813em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists, as a class, are remarkably free from adverse reactions. The total daily dose of these drugs is usually given after the evening meal. Cimetidine 800 mg is equivalent to 300 mg of ranitidine, 40 mg of famotidine and 300 mg of nizatidine. Therapeutically, there is little to choose from among the various drugs of this class. The difference is mainly in the potency as on mg basis and the cost; famotidine is perhaps the most cost-effective. However, it takes almost double time for ulcer healing as compared to PPI. Antacids can be used as adjuncts for quick pain relief. Patients with</li>
</ul>
<p>Zollinger-Ellison syndrome who are resistant to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor blockers should be treated with PPI. Although antisecretory drugs alone can cause ulcer healing, they do not cure the disease and recurrence can occur after stoppage of therapy.</p>
<ul>
<li>Treatment of H. pylori infection: Eradication of documented H. pylori infection is now considered the mainstay of treatment of documented DU and GU. For that purpose, antibiotics are used in combination regimens using tripple or quadruple therapy. Although no perfect regimen exists, currently recommended regimens are shown in Table 43.6. Any combination of above-mentioned two antimicrobials plus PPI or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blocker with or without bismuth compound is equally effective. The concurrent administration of a PPI or an <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonist enhances the eradication of H. pylori. PPIs are superior in this respect. The organism may develop resistance to metronidazole in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20-30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> of cases.</li>
</ul>
<p>Table 43.6
Suggested antimicrobial regimens for H.pylori infection</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>1 Clarithromycin 500 mg bid + amoxicillin 1 g bid + PPIbid.
</span>2 Tetracycline 500 mg qid + Metronidazole 200 mg qid + Bismuth subsalicylate 2 tablets qid + Omeprazole 20 mg bid OR ranitidine 150 mg bid.
3 Clarithromycin 500 mg bid + Metronidazole 400 mg bid + Omeprazole 20 mg bid.</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="1 Clarithromycin 500 mg bid + amoxicillin 1 g bid + PPIbid.
2 Tetracycline 500 mg qid + Metronidazole 200 mg qid + Bismuth subsalicylate 2 tablets qid + Omeprazole 20 mg bid OR ranitidine 150 mg bid.
3 Clarithromycin 500 mg bid + Metronidazole 400 mg bid + Omeprazole 20 mg bid." style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>Tetracycline can be substituted for metronidazole or amoxycillin.
Other PPI or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blocker can be used instead of omeprazole.
Duration: 10-14 days.
The drug regimens mentioned in the table are effective in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mo>−</mo><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">75-90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">75</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> of patients. Some side effects occur in 20-30% of patients. For ulcer healing and cure, antisecretory and antimicrobial therapy is usually given together for the first 10-14 days, followed by antisecretory therapy (PPI or an <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blocker) alone for 6-8 weeks to ensure complete cure.
Efficacy of the antimicrobial therapy is assessed by a negative urea breath test. Once <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi></mrow><annotation encoding="application/x-tex">H</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span></span></span></span></span>. pylori infection is eradicated, long term maintenance anti-secretory therapy is not needed. Less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> of the ulcers may recur after cure following eradication of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi></mrow><annotation encoding="application/x-tex">H</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span></span></span></span></span>. pylori infection. Recurrence may be precipitated by NSAID or some other ulcerogenic factor.
Some workers feel that a course of antimicrobial therapy is justified in all patients with documented DU even without demonstrating <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi></mrow><annotation encoding="application/x-tex">H</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span></span></span></span></span>. pylori infection. It is not indicated in reflux esophagitis and non-ulcer dyspepsia. However, patients with GU must have malignancy ruled out before such treatment.
Table 43.7 summarises the current guidelines for treatment of H. pylori infection.</p>
<p>Table 43.7
Current guidelines for treatment of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi></mrow><annotation encoding="application/x-tex">H</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span></span></span></span></span>. pylori infection</p>
<ul>
<li>Duodenal and gastric ulcer (whether active or not, including complicated peptic ulcer disease)</li>
<li>Gastric lymphoma.</li>
<li>Atrophic gastritis; and</li>
<li>Recent resection for gastric cancer.
(2) May be useful in:</li>
<li>Functional dyspepsia.</li>
<li>First degree relatives of patients with gastric cancer (prophylaxis)
(1) Strongly recommended in:</li>
<li>Duodenal and gastric ulcer (whether active or not, including complicated peptic ulcer disease)</li>
<li>Gastric lymphoma.</li>
<li>Atrophic gastritis; and</li>
<li>Recent resection for gastric cancer.
(2) May be useful in:</li>
<li>Functional dyspepsia.</li>
<li>First degree relatives of patients with gastric cancer (prophylaxis)</li>
<li>Adjuvant therapy: A sympathetic discussion of the patient's problems may be useful in relieving the anxiety and tension. A tranquilliser or an antidepressant may be needed in some cases. Tricyclic antidepressants also possess antimuscarinic action (Chapter 14). Formal psychotherapy, however, has not been shown to produce any substantial effects. With adequate drug therapy, relief of symptoms occurs within 7-10 days. This does not, however, necessarily mean that ulcer has healed, and treatment has to be continued for 6-8 weeks as described earlier. Even antacids alone given daily for long period ( 3 mths) can promote healing but recurrence is common.</li>
<li>Prevention of recurrence: In the absence of documented H. pylori infection (which is curable), no treatment available at present, however meticulously carried out, can permanently guarantee against a recurrence of the peptic ulcer. However, cimetidine ( 400 mg daily) and ranitidine ( 150 mg daily), used prophylactically reduce ulcer recurrence and prevent complications in resistant cases. Patients should be advised moderation in living and in eating, and to avoid smoking, alcohol and certain drugs (Table 43.8). Up to four-fifths of gastric ulcers have been attributed to smoking and use of NSAID. Many elderly persons with osteoarthritis often receive potent antiinflammatory drugs (NSAIDS) in high doses, whereas all that they require is an analgesic such as paracetamol or low dose ibuprofen ( 200 mg ).</li>
</ul>
<p>Table 43.8
Drugs to be avoided in peptic ulcer disease</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>• Salicylates and other NSAID
</span>    • Clopidogrel
    • Caffeine, theophylline
    • Glucocorticoid in pharmacological (but not in replacement) doses
    • Some iron salts
    • Bisphosphonates
    • Mycophenolate mofetil; and
    • Potassium chloride</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="• Salicylates and other NSAID
    • Clopidogrel
    • Caffeine, theophylline
    • Glucocorticoid in pharmacological (but not in replacement) doses
    • Some iron salts
    • Bisphosphonates
    • Mycophenolate mofetil; and
    • Potassium chloride" style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>Failure to respond to medical treatment indicates chronicity or the presence of some complication. A gastric ulcer may undergo malignant change.
Surgery is indicated when:</p>
<ul>
<li>Malignancy is suspected in a GU.</li>
<li>A DU becomes chronic and refractory to adequate medical management.</li>
<li>A complication such as organic obstruction or perforation is present; and</li>
<li>The patient suffers from repeated attacks of GI bleeding.</li>
</ul>
<p>Acute erosive gastritis (Table 43.9) with bleeding occurs as a complication of a serious medical or surgical illnesses and is common in intensive care units. Compromise in the gastric mucosal blood supply appears to be an important aetiological factor. As such bleeding doubles or even triples the mortality, patients at risk must be given prophylactic treatment; and any patient who has begun to bleed deserves aggressive management. Efforts to improve volume status, cardiac output and respiratory function are critical to both prevention and treatment. The incidence of bleeding is reduced if the gastric pH is maintained above 5.0 .</p>
<p>Table 43.9
Prevention and treatment of acute erosive gastritis</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>- Prevention of hypovolemia, systemic acidosis, sepsis and hypoalbuminemia.
</span>- Maintenance of intragastric pH above 5.0 with the use of antacids, an H, receptor blocking agent or PPI; the latter is more convenient.
- Ranitidine:50 mg IM or IV every 6-8 hours; or 6.25 mg/hour by IV infusion. Famotidine: 20 mg every 6-12 hours IM or IV. Pantoprazole repeated as bolus or by continuous infusion over 24 hours.
- Antacid in liquid form 15-30 ml/hourby a nasogastric drip.</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="- Prevention of hypovolemia, systemic acidosis, sepsis and hypoalbuminemia.
- Maintenance of intragastric pH above 5.0 with the use of antacids, an H, receptor blocking agent or PPI; the latter is more convenient.
- Ranitidine:50 mg IM or IV every 6-8 hours; or 6.25 mg/hour by IV infusion. Famotidine: 20 mg every 6-12 hours IM or IV. Pantoprazole repeated as bolus or by continuous infusion over 24 hours.
- Antacid in liquid form 15-30 ml/hourby a nasogastric drip." style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>Gastroesophageal reflux disease (GERD): This is a chronic, unremitting, essentially incurable disease that quickly relapses on cessation of drug therapy. It is characterized by "the reflux of gastric acid contents into the esophagus, leading to esophagitis and reflux symptoms sufficient to impair the quality of life." It is subdivided into non-erosive GERD and erosive GERD. The commonest symptom is heartburn followed by cough; about half the patients have erosive esophagitis. Incompetence of the lower esophageal sphincter (LES), its transient, repeated relaxation not associated with swallowing, and delayed gastric emptying seem to be the important factors in its pathogenesis.</p>
<p>The current guidelines for the treatment of GERD are outlined in Table 43.10. Acid suppression is the key measure in both acute and long term therapy of GERD. It is advisable to start the therapy with PPI given bid (30-60 min before breakfast and dinner) and once the symptoms are relieved, substitute it with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor blockers/antacids in non-erosive but not in erosive GERD.</p>
<p>Table 43.10
Current guidelines for treatment of GERD</p>
<ul>
<li>Non-pharmacological measures: Reassurance and advice about lifestyle; elevation of the head of the bed by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>20</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">15-20 \mathrm{~cm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">20</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">cm</span></span></span></span></span></span>; weight reduction in obese patients; avoidance of tight garments, large meals, and lying down for 3 hours after a meal; cessation of smoking; avoidance of reflux-inducing foods (such as spicy or fatty foods, citrus fruits, chocolates and coffee), carbonated drinks, alcohol, NSAID, CCBs, theophylline and antimuscarinics.</li>
<li>PPI (high dose) are the most effective drugs for promotion of healing of the erosive esophageal lesions. Maintenance therapy upto 1 year may be needed.</li>
<li>H, receptor antagonists are less effective than PPIs in erosive e eophagitis but may be cost-effective in long term maintenance therapy. In non-erosive GERD, they are almost as effective as PPIs and much less expensive.</li>
<li>Antacids help to relieve mild reflux symptoms promptly.</li>
<li>Prokinetic drugs are not recommended for routine use. However, they may be used as add-on drugs in refractory cases.</li>
<li>On demand therapy is a cost-effective alternative to continuous maintenance therapy in case of mild, non-erosive GERD.</li>
<li>When symptomeluse resolved, an attempt should be made to stop therapy. However, some times indefinite treatment is needed in a few cases.</li>
<li>Routine anti-H, pylori therapy is not indicated in GERD.</li>
</ul>
<p>Patients with infrequent heart-burn and dyspepsia (less than 3-4 times a week) can be managed with an <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> antagonist alone such as famotidine 20 mg bid or OD as needed.</p>
<p>NSAID-induced ulcers: Aspirin and other NSAID are known to cause dyspepsia and symptomatic gastric ulcers, particularly when given in large doses and for long periods as in RA. (Chapter 11). Among the various drugs used for prophylaxis, misoprostol, a PG analogue, given concurrently ( 400 mcg bid) with NSAID, daily, appears to reduce such complication by about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span>. The drug, however, causes diarrhoea and is expensive. PPI are equally effective and less expensive. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists such as famotidine may also offer protection against NSAID-induced dyspepsia.</p>
<p>PPI are being marketed in combination with non-selective NSAID, with the hope of preventing the ulcerogenic action of NSAID. There is no convincing evidence that such a combination prevents the GI complication in the long term. Such combinations are not recommended while prescribing the conventional low doses of NSAID for short term therapy (Chapter 11).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="section-xi-br-oxytocics-and-uterine-relaxants">SECTION XI &lt;br&gt; Oxytocics and Uterine Relaxants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#section-xi-br-oxytocics-and-uterine-relaxants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="outline">OUTLINE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#outline" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Chapter 44: Pharmacology of Ergot Alkaloids, Oxytocin, other Oxytocics and Uterine Relaxants</p>
<p>44</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacology-of-ergot-alkaloids-oxytocin-other-oxytocics-and-uterine-relaxants">Pharmacology of Ergot Alkaloids, Oxytocin, other Oxytocics and Uterine Relaxants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacology-of-ergot-alkaloids-oxytocin-other-oxytocics-and-uterine-relaxants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Oxytocics are the drugs which stimulate uterine contractions (ergot alkaloids, oxytocin and prostaglandins), and are used to:</p>
<ul>
<li>Minimise the placental blood loss</li>
<li>Induce or augment labour; and</li>
<li>Induce abortion</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ergot-alkaloids">Ergot Alkaloids<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ergot-alkaloids" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Ergot is obtained from a fungus Claviceps purpurea which grows mainly on rye and occasionally on other grains. Ergot spores, carried by insects or wind, are deposited on the ovaries of young rye where they germinate. Their hyphal filaments penetrate deep into the rye, and destroy the entire grain substance with formation of a hardened, black purple body termed the sclerotium, which serves as the commercial source of ergot. Consumption of ergot-infested rye was the cause of the disease termed St. Anthony's fire, observed in the middle ages and characterised by dry gangrene of extremities and a high incidence of abortions and stillbirths; a visit to St. Anthony's shrine was thought to be curative and hence the name.</p>
<p>Chemistry of ergot: Ergot has been termed a treasure house of pharmacological constituents. The most important of these are the alkaloids. In addition, active components like histamine, tyramine and acetylcholine are also present. Other constituents include steroids, acids, quaternary ammonium bases and inorganic compounds. Only the levorotatory forms of the alkaloids are active. They can be divided into:
I Amino acid alkaloids: Ergotamine, Ergosine and Ergotoxin. Ergotoxin is a mixture of three alkaloids, ergocornine, ergocristine and ergokryptine.
II Amine alkaloid: Ergometrine (ergonovine).
III Semisynthetic dihydrogenated amino acid alkaloids: Dihydroergotamine (DHE) and Hydergine - a mixture of dihydroergocornine, dihydroergocristine and dihydroergocryptine.</p>
<p>Pharmacological actions (Table 44.1):</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-44-1">Table 44.1<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-44-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacological-actions-of-ergot-preparations">Pharmacological actions of ergot preparations<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-actions-of-ergot-preparations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<table><thead><tr><th style="text-align: left;">Preparation</th><th style="text-align: center;">Uterus (contraction)</th><th style="text-align: center;">Alpha adrenergic blocking action</th><th style="text-align: center;">Vasoconstriction 5-HT <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mo lspace="0em" rspace="0em">∘</mo></msup></mrow><annotation encoding="application/x-tex">{ }^{\circ}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6741em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span></span></span></span></span> antagonism</th><th style="text-align: center;"></th></tr></thead><tbody><tr><td style="text-align: left;">Ergotamine</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↔</mo></mrow><annotation encoding="application/x-tex">\leftrightarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">↔</span></span></span></span></span> (delayed)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↔</mo></mrow><annotation encoding="application/x-tex">\leftrightarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">↔</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↔</mo><mo>↔</mo></mrow><annotation encoding="application/x-tex">\leftrightarrow \leftrightarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">↔↔</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↔</mo></mrow><annotation encoding="application/x-tex">\leftrightarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">↔</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Ergometrine</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↔</mo><mo>↔</mo></mrow><annotation encoding="application/x-tex">\leftrightarrow \leftrightarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">↔↔</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>÷</mo></mrow><annotation encoding="application/x-tex">\div</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">÷</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↔</mo><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\leftrightarrow \checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">↔</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span></td></tr><tr><td style="text-align: left;">D H E</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↔</mo></mrow><annotation encoding="application/x-tex">\leftrightarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">↔</span></span></span></span></span> (on pregnant uterus)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↔</mo><mo>↔</mo></mrow><annotation encoding="application/x-tex">\leftrightarrow \leftrightarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">↔↔</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↔</mo></mrow><annotation encoding="application/x-tex">\leftrightarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">↔</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span></td></tr></tbody></table>
<p>'All are also partial 5-HT agonists</p>
<ul>
<li>Uterus: All the natural ergot alkaloids cause contraction of the uterine smooth muscle (oxytocic action). The magnitude of response depends upon the alkaloid employed, the dose used, the degree of uterine maturity and stage of gestation. Thus, the amino acid alkaloids elicit a delayed but powerful response; their dihydrogenated derivatives, however, are active only on pregnant uterus at term. Ergometrine an amine alkaloid, and methylergometrine elicit an immediate and powerful response. Small doses produce an increase in the force of contraction, with normal relaxation in between consecutive contractions. With larger doses, the contractions become more powerful, tetanic, and frequent and the resting muscle tone increases markedly.</li>
</ul>
<p>This precludes the use of ergot preparations for induction of labour. Still higher doses cause a sustained contracture. Both amino acid and the amine alkaloids are capable of stimulating the uterus during any phase of estrous cycle or gestation; and even an immature uterus is stimulated. In general the uterus at full term and immediately after delivery</p>
<p>is highly sensitive.
As oxytocic, the amine alkaloid ergometrine has several advantages over the amino acid alkaloids such as ergotamine, viz.:
(a) It is effective orally and elicits a prompt and marked contractile response, even in small doses.
(b) It is devoid of significant adrenergic blocking, vasoconstrictor and emetic activity; and hence,
(c) It is less toxic.</p>
<p>Compared to oxytocin, ergot alkaloids increase the tone of the cervix. Oxytocin decreases it. Further, the frequency of contractions is increased more with ergot alkaloids than with oxytocin.</p>
<ul>
<li>Vascular actions: The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>-adrenergic blocking action of the amino acid alkaloids has been discussed in Chapter 18. In addition, they possess direct vasoconstrictor effect.
Peripheral vasoconstriction is accompanied by damage to the capillary endothelium, particularly with large doses. Ergotamine is the most potent vasoconstrictor while the dihydrogenated amino acid alkaloids are powerful alpha adrenergic blocking agents with minimal direct vasoconstrictor effect. DHE, on the otherhand, despite alpha adrenergic blockade, produces significant vasoconstriction. In contrast to the amino acid alkaloids, the amine alkaloid ergometrine has no adrenergic blocking activity and causes minimal vasoconstriction (Table 44.1)</li>
<li>Gastrointestinal tract: Ergotamine increases peristaltic activity and can potentiate the action of neostigmine on the gut.</li>
<li>Miscellaneous: The amino acid as well as the amine ergot alkaloids are partial 5-HT agonists on certain blood vessels and selective antagonists on various smooth muscles. Methysergide, a clinically used 5-HT antagonist, is a derivative of ergometrine. They all can cause nausea and vomiting due to a direct action on emetic centre.
Absorption, fate and excretion: Ergotamine and the dihydrogenated derivatives are erratically absorbed from the gut, and have poor bioavailability. Ergometrine and methylergometrine, on the other hand, are rapidly and completely absorbed; their oxytocic effect is seen within 10 to 15 minutes of oral, 3 to 5 minutes of SC and 1 to 2 minutes of IV administration. They are metabolised in the liver and the degradation products eliminated in urine. Liver damage enhances the toxicity.</li>
</ul>
<p>Adverse reactions: Toxicity of amino acid alkaloids and their dihydrogenated derivatives is mainly due to direct vascular actions leading to thrombosis and gangrene (Chapter 18). Ergotamine and erogotoxin are more toxic than the dihydro derivatives. Treatment consists of: (1) immediate withdrawal of the drug; (2) use of antiemetics; (3) administration of heparin; and (4) vasodilators like tolazoline and sodium nitroprusside, for the treatment of peripheral vascular insufficiency. Good nursing care is imperative if gangrene of an extremity develops.</p>
<p>Ergometrine and methylergometrine may produce nausea and vomiting but serious toxic effects are rare. Their use during the I and II stage of labour may, however, result in death of foetus in utero or rupture of the uterus.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Preparations of ergotamine and dihydroergotamine (Chapter 18).
(ii) Ergometrine tablet. Dose: 0.5 to 1 mg .
(iii) Ergometrine maleate injection contains 0.5 mg of the drug per ml. Dose: 0.2 to 1 mg</p>
<p>intramuscularly and 0.1 to 0.5 mg intravenously.
(iv) Ergotamine tartrate 0.25 mg with ergometrine maleate 1.25 mg injection. Dose: 1 ml IM.
(v) Methylergometrine maleate tablet 0.125 mg Dose: 0.125 mg tid.
(vi) Methylergometrine injection <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">0.2 \mathrm{mg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>; Dose: 0.2 mg SC, IM or IV.
(vii) Dihydroergotamine mesylate (DHE) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">1 \mathrm{mg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> for injection.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Postpartum hemorrhage (PPH): Ergometrine and methylergometrine are extremely useful in both prophylaxis and treatment of PPH. For prophylaxis, they are administered after the expulsion of the placenta, in the IM dose of 0.2 to 0.3 mg . If immediate action is desired, an IV dose of 0.2 mg is given. However, IV administration may result in dangerous hypertension. In abortion, where the loss of foetus is inevitable, ergometrine may be employed to control bleeding.</li>
<li>Migraine: Ergotamine is used to treat acute attacks of migraine (Chapter 24).</li>
<li>Uterine involution: Ergometrine, 0.2 mg orally tid, is employed for 7 days after child birth to hasten the uterine involution, although its beneficial effect on the normal process of involution is not established. It is, however, useful in the same dose in cases of delayed involution where it hastens involution, prevents bleeding and checks the spread of infection.
BROMOERGOCRIPTINE: This synthetic ergot derivative is discussed in Chapter 68.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="oxytocin">Oxytocin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#oxytocin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The posterior pituitary extract has two distinct pharmacologically active principles:</p>
<ul>
<li>Vasopressin which acts on the kidney and the blood vessels (Chapter 39); and</li>
<li>Oxytocin, which has a dominant action on the uterus and the myoepithelium of the mammary gland.
Oxytocin and vasopressin are synthesised in hypothalamic nuclei. They travel along the hypothalamo-hypophyseal tract to the posterior lobe of the pituitary where they are stored and released under a variety of stimuli, such as dehydration, hemorrhage, dilatation of the cervix and uterus and emotional stimuli. As both oxytocin and vasopressin are bound to a common protein, such stimuli cause simultaneous release of both the hormones.</li>
</ul>
<p>OXYTOCIN: This is an nonapeptide usually represented in the following simplified form (Fig. 44.1):
<img src="assets/images/image-20251214-3b16f8af.jpeg" alt="img-56.jpeg"></p>
<p>The polypeptide is freely water soluble and acid stable. A synthetic preparation with identical structure is also available.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacological-actions">Pharmacological actions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-actions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Uterus: The oxytocic activity of oxytocin varies according to the dose, the species, the stage of estrous cycle, and in a pregnant animal, according to the stage of gestation. These effects are highly dependent on the presence of estrogen. In the early period of pregnancy in humans only very high doses are effective. However, as the pregnancy advances, from 5th to 6th month onwards, the sensitivity of pregnant uterus to oxytocin increases rapidly.
Oxytocin, given in small doses by IV infusion, exerts a physiological action on the pregnant uterus. The upper uterine segment, consisting of the fundus and body, is contracted while the lower uterine segment, consisting of the cervical portion, is dilated. This results in an expulsion of the fetus from the uterine cavity. The contractions also squeeze the maternal blood out of the placenta into the maternal inferior vena cava. The periods of relaxation which intervene between the two successive contractions allow refilling of the placental blood vessels by the maternal arterial blood and thus prevent asphyxial injury to the foetus. Oxytocin, therefore, can be used by slow IV infusion for inducing labour at term in contrast to ergot preparations which are contraindicated prepartum.
With high doses of oxytocin, the uterine tone increases, the contractions become more powerful and frequent, and asphyxial injury to the fetus may develop due to direct compression and ischemia caused by inadequate filling of the placental blood vessels.</li>
<li>Mammary gland: The myoepithelium, a modified smooth muscle, which surrounds the alveolar ramifications of the mammary gland is stimulated by oxytocin, resulting in expulsion of milk from the alveolar lumen and ducts into large cisterns and sinuses. This is termed milk ejection or milk 'letdown'. The milk ejection reflex is initiated by the</li>
</ul>
<p>stimulus of suckling, which results in the release of oxytocin.</p>
<ul>
<li>Cardiovascular system: In small doses, it produces a vasodilator effect by direct relaxation of the vascular smooth muscle. Transient hypotension and flushing accompanied by tachycardia are usually observed. The usual infusion rates employed in obstetrics do not modify the BP. The vasodilator effect of oxytocin can be readily blocked by small amounts of vasopressin. The hypotensive phase is followed by a rise in BP, probably due to an increase in the cardiac output.</li>
<li>Kidney: Synthetic oxytocin possesses antidiuretic activity in man and a dose of 100 milliunits causes a definite antidiuresis in postpartum women; this is associated with a diminution in the renal plasma flow and the GFR. The renal effects of oxytocin may be due to constriction of renal cortical vessels.</li>
<li>Miscellaneous: Oxytocin is a bonding hormone; this effect is observed during love making and on the battlefield.
Absorption, fate and excretion: Given orally, it is inactivated by trypsin. The aqueous solution, on IM administration, is absorbed rapidly. The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> in non-pregnant women is about 10 to 15 minutes. The removal from the circulation is mainly by kidneys and the liver. Plasma from men and nonpregnant women does not inactivate oxytocin but the plasma, the uterine tissue and the placenta in pregnant women contain an enzyme termed 'oxytocinase' which inactivates oxytocin. Thus <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of oxytocin in pregnant women at term is approximately 3 minutes.</li>
</ul>
<p>Oxytocin is also absorbed from the nasal and buccal mucous membranes. Absorption from these routes, however, is erratic.</p>
<p>Adverse reactions: Oxytocin given by IV infusion may occasionally cause water retention leading to water intoxication. It is characterised by nausea, vomiting, anorexia, weight gain and lethargy. Injudicious use of oxytocin during labour may result in premature birth, foetal death, too rapid a delivery or uterine rupture.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Oxytocin injection contains 10 units of synthetic oxytocin per ml.
(ii) Oxytocin nasal spray, 40 units per ml. It facilitates breast feeding and is used 2-5 minutes before a breast feed.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Induction and augmentation of term labour: For the induction of labour, oxytocin is administered by IV infusion, 5 units in 500 ml of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> dextrose solution. Initially <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mo>−</mo><mn>0.2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">0.1-0.2 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">0.2</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> of the solution, (1-2 milliunits) should be given per minute; the rate is then gradually increased to a maximum of 2 ml ( 20 milliunits) per minute. During the whole procedure, the uterine response must be closely monitored and the dose be regulated by monitoring of foetal heart rate.
Before using oxytocin, cephalopelvic disproportion must be ruled out. Multiparous patients (para 4 and over), those with malpresentation or complete placenta previa and those with uterine scars should not receive oxytocin for induction for fear of uterine rupture.</li>
<li>Hypotonic uterine dysfunction (Uterine inertia): Oxytocin is occasionally employed to initiate uterine contractions in cases of prolonged, stubborn and hypotonic uterine inertia.</li>
<li>Postpartum hemorrhage (PPH): PPH is a major cause of morbidity and mortality particularly in developing countries. Oxytocin can be routinely administered 5-10 units</li>
</ul>
<p>IV after the delivery of placenta to produce a firm contraction of the uterus and thus prevent PPH. The drug may also be administered in the same dose after delivery of the anterior shoulder of the foetus to produce a prompt expulsion of the placenta and to prevent PPH. The same dose may also be injected directly into the uterus, after delivering the foetus by caesarean section. For treatment of PPH, a dose of 20-40 units in one litre of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> dextrose is preferred. Alternatively, it can be given IM.</p>
<ul>
<li>Miscellaneous: Oxytocin may be given intranasally in the dose of 40 units 2-5 minutes before breast feeding to promote milk ejection when this component of lactation appears to be deficient in nursing mothers.
It is often used in veterinary practice to increase the milk yield.
Oxytocin is no more employed to induce therapeutic abortion.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="other-oxytocics">Other Oxytocics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#other-oxytocics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>PROSTAGLANDINS (PG, Prostin): Prostaglandins are C20 fatty acids containing a cyclopentane ring, and are described in Chapter 25; only the actions on uterus are discussed below.</p>
<p>Apart from human seminal fluid, PGs are found in the ovary, myometrium and menstrual fluid. Their physiological significance, however, is not well understood. Majority of PGs in varying doses inhibit the spontaneous activity of isolated non-pregnant human myometrium. However, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">F</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGF}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGF</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and PGE in low doses stimulate both the tone and amplitude of the uterine contractions. Four PGs have been isolated from human amniotic fluid, obtained during normal labour and during spontaneous abortion. Experimentally, they are shown to sensitise the uterus to oxytocin as well as causing oxytocin release. Furthermore, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">F</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGF}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGF</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> was also found in samples of blood obtained during normal spontaneous labour but not during other stages of gestation. Since <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">F</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGF}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGF</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> has smooth muscle stimulating action it is possible that it participates in the process of labour.</p>
<p>During pregnancy PGs act in at least three different ways:</p>
<ul>
<li>As uterine smooth muscle stimulants, causing uterus to contract;</li>
<li>As cervical primers, thus hastening the process of softening and dilation of the cervix, sometimes referred to as 'cervical ripening'. Unlike oxytocin, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">F</mi></mrow><mrow><mn>2</mn><mi>α</mi></mrow></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGF}_{2 \alpha}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGF</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mathnormal mtight" style="margin-right: 0.0037em;">α</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> actually decrease cervical stiffness and PGs are used for cervical priming at the time of delivery and before inducing abortion; and</li>
<li>As luteolytic agents, inhibiting the secretion of progesterone by corpus luteum. This effect has not been observed in humans.
PGs are most effective in the second trimester (13th-20th weeks). Doses required to produce abortion in the first trimester may result in serious systemic effects whereas in the third trimester PGs are less effective than oxytocin. Prior administration of mifepristone (Chapter 68), a progestin antagonist sensitises the uterus to the action of PGs.</li>
</ul>
<p>Adverse reactions: These are not troublesome with smaller doses but could be severe with larger doses. They include nausea, vomiting, abdominal cramps, diarrhoea, headache, fever and vasodilatation. PGs should be used cautiously in the presence of raised intraocular pressure, hypertension, diabetes, angina or epilepsy. They are contraindicated in the presence of cardiac, renal, pulmonary or hepatic disease. Smoking and alcohol should be avoided during their use and for 48 hours afterwards.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Dinoprost (Prostin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">F</mi><mrow><mn>2</mn><mi>α</mi></mrow></msub></mrow><annotation encoding="application/x-tex">\mathrm{F}_{2 \alpha}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">F</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mathnormal mtight" style="margin-right: 0.0037em;">α</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ) 5 mg per ml for intraamniotic use to induce abortion.
(ii) Dinoprostone (Prostin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">E</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{E}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">E</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ) 500 mcg tab for oral or intravaginal use for induction of labour.
(iii) Carboprost (Prostin/15 m) is 15-15 dimethyl <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">F</mi></mrow><mrow><mn>2</mn><mi>α</mi></mrow></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGF}_{2 \alpha}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGF</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mathnormal mtight" style="margin-right: 0.0037em;">α</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> analogue with a longer duration of action. Dose <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>250</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">250 \mathrm{mcg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">250</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> deep IM.
(iv) Dinoprostone 0.5 mg per syringe for endocervical injection for cervical ripening. It also has a diuretic action.
(v) Misoprostol, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (Chapter 68) has been used orally/intravaginally to bring about medical abortion. The intravaginal administration is also used to cause cervical dilatation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Therapeutic abortion: PGs are not so useful for terminating early, first trimester pregnancies because of the high incidence of incomplete abortions and consequent need for surgical procedures. Further, the procedure takes a relatively long time, and the dose needed usually causes pain and adverse GI reactions. Many clinicians, therefore, prefer suction evacuation to PGs (Chapter 68).
PGs are now widely used to terminate the pregnancy in the second trimester. Gemeprost, administered vaginally as pessaries, is the preferred PG for this purpose. Alternatively, oral or intravaginal misoprostol may be used. They are combined with mifeprostone (Chapter 68).
The analogue <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">F</mi></mrow><mrow><mn>2</mn><mi>a</mi></mrow></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGF}_{2 a}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGF</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mathnormal mtight">a</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (Carboprost) is probably more effective and safer. It can also be given IM or as suppositories and is useful over a wide range of gestational ages. All methods of abortion using PGs alone cause a high incidence of adverse effects and there is a possibility of delivering a live fetus. Some of them may also cause bronchospasm.</li>
<li>Cervical priming: Dinoprostone has been used extra-amniotically for cervical priming. Endocervical gels, suppositories and oral tablets containing PGs may also be useful.</li>
<li>Post-partum hemorrhage: The PG analogue, carboprost, given IM, is effective in managing PPH due to uterine atony. The drug, however, loses its potency unless stored at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><msup><mn>4</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">2-4^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord">4</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span>. This is a disadvantage. Further, evidence indicates that PGs are no better, only more expensive, than ergometrine. However, misoprostol 400-600 mcg given sublingually may be an alternative when IV oxytocin is not available.</li>
<li>Induction and augmentation of term labour: Dinoprostone may be preferred to oxytocin for this purpose in the presence of chronic renal failure or pre-eclampsia because of its diuretic action. Apart from this, it offers no significant advantage, it is more expensive. Dinoprostone is given orally as 0.5 mg tablets at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>60</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">30-60 \mathrm{~min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6679em;"></span><span class="mord">60</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span></span></span>. intervals upto a maximum of four tablets. It can also be administered vaginally. The PGs can cause hyperstimulation of the uterus which compromises uteroplacental blood flow, and they have a longer duration of action than oxytocin. Signs of uterine hypertonus and foetal distress should therefore be watched for.
As the obstetric regimens of PGs are complicated, the manufacturer's literature should be consulted before using these drugs.
Medical termination of pregnancy: This is discussed in Chapter 68. There is really no absolutely safe method of terminating pregnancy in the second trimester. Introduction of various irritants into the uterine cavity for this purpose, as done by quacks, is usually associated with serious complications and even death.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="uterine-relaxants-tocolytics">Uterine Relaxants (Tocolytics)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#uterine-relaxants-tocolytics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Tocolytics are the drugs which inhibit myometrial contractions. Although they are uterine relaxants, not all uterine relaxants are effective tocolytics e.g. ephedrine and atropine. Tocolytics are used to prevent spontaneous preterm births.</p>
<p>The spontaneous preterm birth (before the conclusion of 37 weeks of gestation), may involve several contributing factors. Important among these are: myometrial and fetal membrane overdistension, decidual hemorrhage, precocious fetal endocrine activation, and intrauterine inflammation and infection. The major goal in preventing preterm birth is to eliminate the risk of neonatal complications and death. Since the contracting uterus is the most commonly recognised mechanism, stopping the contractions by using the tocolytics constitutes the major therapeutic approach.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="tocolytics-classification">Tocolytics - classification:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#tocolytics-classification" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>I Calcium channel blockers e.g. Nifedipine.
II COX (cycloxygenase) inhibitors e.g. Indomethacin.
III Beta-2 adrenergic agonists e.g. Ritodrine and Salbutamol.
IV Oxytocin receptors antagonist e.g. Atosiban.
V Magnesium sulfate; and
VI Nitric oxide (NO) donors e.g. Nitroglycerine.
Before starting tocolytic therapy, accurate estimation of gestational age, and clinical plus laboratory evaluation for the possible cause of preterm labour should be done.</p>
<p>Calcium channel blockers: Nifedipine (Chapter 29) may be administered sublingually/orally in the loading dose of 10 mg , and the dose repeated every 20 minutes for 3 doses. Maintenance dose of 10 mg may be given orally every 4-6 hours. It is effective in reducing neonatal complications and is relatively safe. It can be used at any gestational age.</p>
<p>COX inhibitors: Human decidua, myometrium and fetal membranes express COX-1 enzyme. During labour, there is a dramatic increase in COX-2 in the decidua and the myometrium. Indomethacin (Chapter 11), given early, inhibits COX non-selectivily and hence PG synthesis, and thus acts as a tocolytic. It is avoided in gestation more than 32 weeks to prevent in utero closure/narrowing of the ductus arteriorus.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-adrenergic receptor agonists: These drugs can be used as alternatives to nifedipine and indomethacin. Although they delay preterm delivery for 24-72 hours and reduce the immediate risk, a significant reduction in perinatal morbidity and mortality has not been convincingly demonstrated. Further, their adverse effect profile is less favourable than that of CCB. Salbutamol, terbutaline and ritodrine (selective beta-2 agonists, Chapters 18, 27) have been used to delay preterm delivery in uncomplicated labour. They are contraindicated in pre-eclampsia.</p>
<p>Salbutamol is used by IV infusion in the dose of 10 mcg per minute, gradually increased to 45 mcg per minute until contractions cease; then, the dose is reduced gradually. It can also be given by IM injection in the dose of 100-250 mcg, repeated as necessary. The adverse reactions include nausea, vomiting, tremor, tachycardia; hypokalemia, pulmonary edema; increased tendency to uterine bleeding; and hyperglycemia.</p>
<p>Ritodrine is used by IV infusion in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">50 \mathrm{mcg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span></span></span></span></span> minute, increased by the same amount once every 20 minutes, until the uterine contractions are controlled and then</p>
<p>maintained for an hour thereafter. Then, the lowest dose that maintains uterine quiescence is continued for about 12 hours.</p>
<p>Nitric oxide donor: Nitroglycerine IV (Chapter 29) can delay preterm labour for 48 hours. Transdermal NTG can prolong gestation to 37 weeks.</p>
<p>Oxytocin receptor antagonist: Atosiban acts as a competitive antagonist of oxytocin. However, it was associated with excess fetal and infant mortality when used before 28 weeks of gestation. Hence, it is no more used.</p>
<p>Magnesium sulfate: Although experimentally, magnesium sulfate inhibits the contraction of myometrial strips obtained from pregnant women, clinically it showed no benefit as tocolytic over placebo.</p>
<p>Tocolytics may not always prevent preterm birth. Thus, there is no first line ideal tocolytic. However, these drugs offer certain benefits. A delay of 24-48 hours in labour can be utilised (a) for administering a glucocorticoid (betamethasone, dexa-methasone) to bring about maturation of the fetal lungs and thus decrease the occurrence of neonatal respiratory distress syndrome (Chapter 66); and (b) to transfer the patient to a centre where neonatal ICU is available. Ideally, tocolytics should not be given for more than 48 hours, and the treatment should be individualised.</p>
<p>In a pregnant woman with a history of preterm delivery, the treatment of asymptomatic bacteriuria during early pregnancy may reduce the occurrence of preterm birth and low birth weight. However, routine use of broad spectrum antibiotics for eradication of asymptomatic colonization of the vagina has not conclusively shown to be useful. Similarly, the usefulness of 17 -alpha hydroxyprogesterone caproate prophylaxis for prevention of preterm delivery is controversial.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="section-xii-chemotherapy">SECTION XII Chemotherapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#section-xii-chemotherapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="outline">OUTLINE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#outline" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Chapter 45: Sulfonamides, Trimethoprim, Cotrimoxazole, Nitrofurans and Quinolones
Chapter 46: Penicillins and Other Antibiotics Effective Mainly Against Gram Positive Organisms
Chapter 47: Aminoglycosides and Other Antibiotics Effective Mainly Against Gram Negative Organisms
Chapter 48: Antibiotics Effective Against Both Gram Positive and Gram Negative Organisms
Chapter 49: Tetracyclines and Chloramphenicol
Chapter 50: Antifungal Agents
Chapter 51: General Principles of Chemotherapy of Infections
Chapter 52: Chemotherapy of Urinary Tract Infections
Chapter 53: Chemotherapy of Sexually Transmitted Diseases
Chapter 54: Chemotherapy of Tuberculosis
Chapter 55: Chemotherapy of Leprosy
Chapter 56: Chemotherapy of Malaria
Chapter 57: Chemotherapy of Amoebiasis
Chapter 58: Chemotherapy of Other Protozoal Infections
Chapter 59: Chemotherapy of Viral Infections
Chapter 60: Chemotherapy of Helminthiases
Chapter 61: Chemotherapy of Malignancy
Chapter 62: Antiseptics, Disinfectants and Insecticides</p>
<p>45</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="sulfonamides-trimethoprim-cotrimoxazole-nitrofurans-and-quinolones">Sulfonamides, Trimethoprim, Cotrimoxazole, Nitrofurans and Quinolones<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sulfonamides-trimethoprim-cotrimoxazole-nitrofurans-and-quinolones" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The word Chemotherapy can be defined as the use of chemical compounds in the treatment of infectious diseases, so as to destroy offending organisms and parasites without damaging the host tissues. The evolution of chemotherapy can be traced through three distinct periods:</p>
<ul>
<li>A pre-Ehrlich era before 1891</li>
<li>The period of Paul Ehrlich; and</li>
<li>The period after 1935, highlighted by the discovery of sulfonamides and antibiotics.</li>
</ul>
<p>In the long pre-Ehrlich era, many compounds were employed in therapeutics empirically, occasionally with beneficial and often with disastrous consequences. Thus, the usefulness of Cinchona bark in the treatment of malaria and of mercury in syphilis was known for many years. With the advances in chemistry and microbiology, a variety of infective organisms were identified and isolated.</p>
<p>Paul Ehrlich (1854-1915), an organic chemist, was struck by the fact that certain vital dyes like methylene blue specifically killed and stained certain bacterial cells and he reasoned that chemical substances might be produced that could unite with and destroy the parasitic agents of disease without in any way injuring the host cells. He aptly called them "magic bullets". In 1891, he demonstrated the efficacy of methylene blue in the treatment of human malaria. He also synthesised a series of arsenical compounds effective against spirochaetal infections. To express the therapeutic utility of these compo-unds he introduced the term chemotherapeutic index, a ratio of the maximum tolerated dose of a drug to its minimum curative dose. This index is now replaced by the therapeutic index.</p>
<p>Ehrlich postulated that the cell membrane contained specific chemical groups or 'receptors' which combined with essential materials like oxygen and caused their uptake by cells. He visualised a drug as containing a chemical grouping or 'heptaphore' that enabled the drug to get attached to the cell receptor and another grouping termed 'toxophore' which enabled the drug to produce its specific pharmacological effect. A drug could exert either a curative or a toxic effect depending upon its affinity for the parasite or the host. Thus, a compound with a high affinity for the host tissue, an organotropic compound, could be toxic while one with high affinity for parasites, a parasitotropic compound, might be curative. Based on this hypothesis, Ehrlich introduced arsephenamine, the first really effective chemotherapeutic agent in man, in the treatment of syphilis.</p>
<p>The pioneering work of Ehrlich established the importance of cellular chemistry in drug action and inspired many workers to synthesise newer antibacterial substances. Ehrlich is aptly called 'the Father of Modern Chemotherapy'. He was awarded the Nobel Prize in 1908.</p>
<p>The next major contribution to chemotherapy came from Domagk, Mietsch and their colleagues (1935), who, while working on azo dyes, demonstrated the efficacy of 'Prontosil', a dye with a sulfonamide side chain, in inhibiting the growth of Streptococci in vivo. Later Nitti, Bovet and Fuller proved that prontosil owed its therapeutic efficacy to its</p>
<p>conversion into sulfanilamide in the body. Since then, a variety of sulfonamides were synthesised. It is interesting to note that sulfanilamide was prepared by Gelmo as early as 1908 but 30 years elapsed before its therapeutic value was discovered! Domagk, a German scientist, was awarded a Nobel Prize in 1939.</p>
<p>The idea of using one micro-organism to cure the infection caused by another was repeatedly suggested during the last century. Thus, Pasteur and Joubart in 1877 demonstrated that 'common bacteria' prevented the growth of anthrax bacilli in urine, and Babes in 1885, using solid culture media, established that one bacterium could elaborate a substance that would stop the growth of another. Emmerich and Low in 1899, while working on the organism Pseudomonas aeruginosa, discovered that extracts of this organism in high dilutions could destroy a variety of pathogenic cocci, as well as diphtheria, cholera, typhoid and plague organisms.</p>
<p>In 1928, Sir Alexander Fleming, while studying staphylococcal variants, found one of his culture plates contaminated by a fungus (eventually identified as Penicillium notatum) which prevented the growth of surrounding bacterial colonies. He cultivated the fungus in a broth and showed that the filtrate, which he named penicillin, inhibited the growth of a number of Gram positive organisms. This compound was not toxic to animals. This revolutionary discovery of penicillin, however, remained for a long time more or less a scientific curiosity. The work of Chain, Abraham and Florey in 1941 during the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>2</mn><mtext>nd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">2^{\text {nd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">2</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">nd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> World War established penicillin as the first most potent anti-infective agent. In 1945, Fleming, Chain and Florey were awarded the Nobel Prize for the revolutionary contribution.</p>
<p>The isolation of 6-aminopenicillanic acid nucleus of penicillin led to the development of a variety of semisynthetic penicillins.</p>
<p>In 1944, after more than ten thousand microorganisms had been screened, Schatz, Bugie and Waksman reported the isolation of streptomycin from Streptomyces griseus. Waksman also defined an antibiotic as "a chemical substance produced by micro-organisms having the property of inhibiting the growth of or destroying other micro-organisms in high dilution". This was a major advance, as streptomycin, unlike penicillin, was found to be effective against Gram negative organisms, and also against Mycobacterium tuberculosis. The above definition has now been widened to include the synthetic antibacterial chemotherapeutic agents such as sulfonamides and quinolones.</p>
<p>Majority of antibiotics are obtained from fungi but some like bacitracin, colistin, polymyxin B and tyrothricin are obtained from bacteria. Some are now synthesised by chemical methods, e.g., chloramphenicol, imipenem. The important factors in determining the efficacy of chemotherapeutic agents are outlined in Table 45.1. Of these, the host defense plays an important part in the curative action of most of the specific remedies.</p>
<p>Table 45.1
Factors determining the efficacy of chemotherapeutic agents</p>
<p><sup><a href="#user-content-fn-0" id="user-content-fnref-0-11" data-footnote-ref="true" aria-describedby="footnote-label">1</a></sup>Mechanism of action: An antimicrobial agent may act by destroying the organism</p>
<p>(bactericidal) or by inhibiting its growth (bacteriostatic). Bactericidal drugs, in general are most effective against rapidly multiplying bacteria. Often, a bacteriostatic drug in higher concentration may act as bactericidal.</p>
<p>The selective toxic action on the infecting organism is the key to beneficial actions of antibiotics. These drugs can hit multiple targets in bacterial cell (Fig. 45.1):
<img src="assets/images/image-20251214-ce7cc68f.jpeg" alt="img-57.jpeg"></p>
<ul>
<li>The cell wall.</li>
<li>The cytoplasmic membrane.</li>
<li>The ribosomes</li>
<li>The RNA molecules involved in transcription of genetic information.</li>
<li>Enzymes required for DNA synthesis/replication; and</li>
<li>Metabolic pathways.</li>
</ul>
<p>The cell wall of bacteria is a thick rigid envelope, mainly composed of sugar and peptides called mucopeptide or murein. The mucopeptide is much thicker in Grampositive cells than in Gram-negative cells. Underneath the rigid cell wall is a cytoplasmic membrane which encloses the cytoplasm. This membrane has lipoprotein structural elements, which account for selective permeability to water, ions and nutrients. Antimicrobials attacking this membrane may alter the permeability of the cell or may disorganise the lipoproteins leading to cell death.</p>
<p>Inside the cytoplasm are ribosomes, spherical particles, which are concerned with protein synthesis. Ribosomes act as an assembly line where aminoacids are joined together into peptide chains and proteins. The process is directed by messenger RNA (mRNA), which carries the code for such synthesis from the nuclear DNA. Messenger RNA becomes attached to ribosomes where the transcribed code is translated into appropriate protein synthesis. Antimicrobials can bind to ribosomes and may interfere with nucleic acid metabolism deranging peptide chain formation in bacteria or the transcription</p>
<p>mechanisms.
Mechanisms of action of various antimicrobials are summarised in Table 45.2.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-45-2">Table 45.2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-45-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanism-of-action-of-antimicrobial-drugs">Mechanism of action of antimicrobial drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action-of-antimicrobial-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><sup><a href="#user-content-fn-0" id="user-content-fnref-0-12" data-footnote-ref="true" aria-describedby="footnote-label">1</a></sup>The therapeutic efficacy of an antimicrobial agent depends not only on the sensitivity of the organism, but also on its concentration and duration at the site of infection. Thus, the antimicrobial effect could be 'concentration dependent' or 'time dependent'. In case of former, the therapeutic efficacy of the drug depends mainly upon the peak concentration achieved at the site of infection in relation to its minimum inhibitory concentration (MIC). With drugs like aminoglycosides or fluoroquinolones, the inhibitory effect of a single dose is prolonged and the post-antibiotic effect (PAE) persists till next dose is administered. On the other hand, with beta lactam and macrolide antibiotics, whose actions are time dependent, the PAE is modest and hence for optimising its activity, it is necessary to maintain the drug concentration above MIC for a period between two doses.</p>
<p>Classification of antimicrobial agents: The organisms susceptible to the inhibitory or lethal effect of an antimicrobial agent constitute its 'spectrum'. Clinically, antimicrobials can be classified according to their spectra:
I Antimicrobials mainly effective against Gram-Positive bacteria:</p>
<ul>
<li>For systemic infections, e.g., Penicillins, Macrolides (Erythromycin), Lincomycin, Vancomycin, Novobiocin and Fucidin.</li>
<li>For topical use, e.g. Bacitracin.</li>
</ul>
<p>II Antimicrobials mainly effective against Gram-negative bacteria:</p>
<ul>
<li>For systemic infections, e.g. Streptomycin, and other aminoglycosides.</li>
<li>For local use in the intestines, e.g. Neomycin.</li>
</ul>
<p>III Antimicrobials effective against both, Gram-positive and Gram-negative bacteria:</p>
<ul>
<li>For systemic infections, e.g. Ampicillin, Amoxicillin, Carbencillin, Cephalosporins, Rifamycins, Imipenem.</li>
<li>For topical use, e.g. Neomycin, Tyrothricin and Framycetin.</li>
</ul>
<p>IV Antimicrobials effective against both Gram-positive and Gram-negative bacteria, rickettsiae and chlamydia (Broad spectrum): e.g. Tetracyclines and Chloramphenicol. V Antimicrobials effective against acid fast bacilli (M. tuberculosis): e.g. Aminoglycosides (Streptomycin), Rifampicin, INH and Fluoroquinolones.
VI Antimicrobials effective against fungi: e.g. Nystatin, Amphotericin B, Griseofulvin. VII Antimicrobials effective against protozoa: e.g. Metronidazole, Paromomycin, Tetracyclines.
VIII Antimicrobials effective against viruses: e.g. Acyclovir, Ribavarin, Zidovudine. IX Antimalignancy antibiotics: e.g. Actinomycin D, Mitomycin and Azaserine (Chapter</p>
<p>61). They can also be classified according to their mechanism of action (Table 45.2).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="sulfonamides">Sulfonamides<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sulfonamides" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>SULFONAMIDES are the antimicrobial compounds containing a sulfonamido <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">S</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub><msub><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">H</mi></mrow><mn>2</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{SO}_{2} \mathrm{NH}_{2}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">SO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord"><span class="mord mathrm">NH</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> group (Fig. 45.2). This group is also present in other non-antibacterial compounds like the antidiabetic sulfnonylureas, diuretics like thiazides and their congeners, furosemide and acetazolamide, and the anticonvulsant sulthiame.
<img src="assets/images/image-20251214-0053600d.jpeg" alt="img-58.jpeg"></p>
<p>FIG. 45.2 Basic structure of a sulfonamide.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">N</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{N}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">N</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-Nitrogen of the sulfonamido group; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">N</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{N}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">N</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-Nitrogen of the para-amino group.
The sulfonamides form water soluble salts with bases. The pH of the sodium salts, with some exception, (e.g., sodium sulfacetamide) is very high; given IM, their marked alkalinity causes damage to the tissues.</p>
<p>Classification: Clinically, the sulfonamides can be classified as:
I Those employed for the treatment of systemic infections. They are subdivided into:</p>
<ul>
<li>Short acting: Sulfadiazine, Sulfadimidine (sulfamethazine), Sulfacetamide, Sulfafurazone (sulfisoxazole), and Sulfamethizole.</li>
<li>Intermediate acting: Sulfamethoxazole.</li>
<li>Long acting: Sulfadoxine, Sulfa-methoxy pyridazine, Sulfadimethoxine, Sulformethoxine.</li>
</ul>
<p>Their use as single agents in therapy is discouraged because of their association with severe allergic reactions and development of bacterial resistance. However, they are used in combination with other drugs such as trimethoprim (see later).
II Those employed orally for the treatment of ulcerative colitis: Sulfasalazine.
III Those used topically: Mafenide; Silver sulfadiazine; Sulfacetamide.
Mechanism of action: The compound sulfanilamide exhibits a structural similarity to para-aminobenzoic acid (PABA) (Fig. 45.3). Sulfonamides, because of their structural similarity to PABA, compete with and substitute for it in the bacterial metabolism (WoodsFields theory).
<img src="assets/images/image-20251214-d00c17be.jpeg" alt="img-59.jpeg"></p>
<p>Folic acid derived from PABA is important in bacterial metabolism. Sulfonamides compete with PABA for the enzyme folic acid synthase which is involved in the conversion of PABA to folic acid. (Fig. 45.4). Inhibition of folic acid synthase by sulfonamides causes folic acid deficiency resulting in injury to the bacterial cell that can be easily phagocytosed.</p>
<p><img src="assets/images/image-20251214-dc4a6052.jpeg" alt="img-60.jpeg"></p>
<p>FIG. 45.4 Mode of action of sulfonamides - trimethoprim combination
Sulfonamides are ineffective in the presence of pus and tissue breakdown products which contain large amounts of PABA. Their bacteriostatic action can be countered by PABA; sulfonamide resistant microorganisms often show enhanced PABA synthesis.</p>
<p>Sulfonamide resistance: A variety of microorganisms, such as Staphylococci, Streptococci, Pneumococci, Meningococci, Gonococci and E. coli can acquire resistance to sulfonamides. Resistance in all enterobacteria is now common, and in Shigella sonnei it is almost invariable. Resistance can be chromosomally mediated or transferred by ' <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>R</mi></mrow><annotation encoding="application/x-tex">R</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.00773em;">R</span></span></span></span></span> ' factors (Chapter 51). Some of the resistant strains synthesise a folic acid synthase with a lowered affinity for sulfonamides while some others overproduce PABA. Widespread bacterial resistance to sulfonamides limits their clinical usefulness.</p>
<p>Pharmacological actions: They are effective against a variety of Gram positive and Gram negative organisms and certain chlamydia; these are:
(a) Streptococci, Staphylococci (some strains), Gonococci, Pneumococci and Meningococci. Streptococcus fecalis is resistant.
(b) Clostridia, Bacillus anthracis.
(c) Haemophilus influenzae, H. ducreyi, Vibrio cholerae, E. coli, Pastuerella pestis, Shigella, Donovania granulomatosis.
(d) Nocardia and Actinomyces.
(e) Chlamydia organisms causing lymphogranuloma venereum, psittacosis and trachoma.
(f) In combination with drugs that inhibit folic acid synthesis, sulfonamides are effective against protozoal infections e.g. malaria and in toxoplasmosis.</p>
<p>They are mainly bacteriostatic, but occasionally, in very high concentrations, particularly in the urinary tract, they may be bactericidal. Their clinical efficacy and potency are much less than those of other antibiotics. Thus, the minimum inhibitory concentration of sulfonamides for a highly susceptible bacterial strain is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>:</mo><mn>10</mn><mo separator="true">,</mo><mn>000</mn></mrow><annotation encoding="application/x-tex">1: 10,000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000</span></span></span></span></span> to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>:</mo><mn>20</mn><mo separator="true">,</mo><mn>000</mn></mrow><annotation encoding="application/x-tex">1: 20,000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">20</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000</span></span></span></span></span>, in comparison to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>:</mo><mn>50</mn></mrow><annotation encoding="application/x-tex">1: 50</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">50</span></span></span></span></span> million observed with penicillin.</p>
<p>Absorption, fate and excretion: Sulfonamides intended for systemic use are rapidly absorbed from the GI tract, mainly from the small intestine, and 70 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> of the dose reaches the blood stream. The absorption from the abraded skin, respiratory tract and vagina is variable, but sufficient amount is absorbed to produce sensitisation and even</p>
<p>toxicity.
In the blood, these drugs are bound to plasma proteins, particularly albumin. The degree of binding differs among the various compounds. In general, at least <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of the compound is bound to plasma proteins.</p>
<p>Protein binding of sulfonamides is important for several reasons:</p>
<ul>
<li>The bound sulfonamide has much less of bacteriostatic activity and cannot normally pass into tissue fluids or cross the blood brain barrier.</li>
<li>Since the bound form is not available for renal excretion, protein binding helps to prolong their action. The long acting sulfonamides are long acting because they are extensively bound to plasma proteins and are excreted slowly.</li>
<li>The highly protein-bound sulfonamides are not so effective in the treatment of acute infections because of low plasma levels of free sulfonamide.
The free form of sulfonamides is uniformly distributed throughout all the tissue fluids although the concentration in the tissue fluids is usually lower than in the plasma. Sulfadiazine, with lower degree of binding with plasma proteins, achieves a CSF concentration 50 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> that of the plasma levels and, therefore, is used in the treatment of meningococcal meningitis. These drugs readily cross the placental barrier and are also secreted in milk.</li>
</ul>
<p>Sulfacetamide and sulfadiazine readily penetrate into the aqueous humour.
After a single oral dose of a short acting sulfonamide, the peak plasma concentration is usually reached within 2 to 4 hours. The effective blood levels vary between 6 and 12 mg per 100 ml . As they are concentrated by the kidney, lower plasma levels of sulfonamides are adequate to produce therapeutic benefits in urinary tract infections.</p>
<p>They are metabolised in the liver by acetylation. Sulfadiazine is much less acetylated than sulfadimidine, while sulfamethoxy-pyridazine is acetylated to the extent of 10 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">15 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">15%</span></span></span></span></span>. Individuals can be differentiated into two distinct groups:</p>
<ul>
<li>Rapid acetylaters acetylate 62-90% of sulfadimidine while</li>
<li>Slow acetylaters acetylate only 40-53% of it.</li>
</ul>
<p>The acetylated form:
(a) Is devoid of antibacterial activity.
(b) Possesses the toxic potentialities of the parent drug.
(c) In addition, certain acetylated products are poorly soluble in acidic urine and may cause crystalluria and renal complications.</p>
<p>The urinary solubility of acetylated derivatives of sulfadiazine is increased in alkaline urine; the acetylated as well as the free forms of sulfafurazole, and sulfamethizole are, however, soluble even in acid urine. The free and the acetylated sulfonamides are mainly eliminated in urine, mostly by glomerular filtration. The urinary concentration of sulfonamides is higher than their plasma levels. The excretion of the intermediate and the long acting sulfonamides is slow.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>I Short acting (5-6 hours): Sulfisoxazole (Sulfafurazole): Highly soluble; urinary concentration greatly exceeds the plasma concentration and may be bactericidal. Dose: Initial 1-2 g, then <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mn>12</mn></mrow><annotation encoding="application/x-tex">0.5-1 \mathrm{~g} 12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">12</span></span></span></span></span> hourly.
II Intermediate acting (10-12 hours):
(i) Sulfadiazine: Good penetration into CSF. Can cause crystalluria. Tab 500 mg . Dose:</p>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>150</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mn>24</mn></mrow><annotation encoding="application/x-tex">150 \mathrm{mg} / \mathrm{kg} / 24</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">150</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/24</span></span></span></span></span> hrs in 4-6 divided doses. Injection <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>250</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">250 \mathrm{mg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">250</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> in 10 ml ampoules. Dose (in adults) by slow, IV injection, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">100 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> body weight, 2 gm initially, then 30-50 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mn>6</mn><mo>−</mo><mn>8</mn></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{kg} 6-8</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">8</span></span></span></span></span> hourly. The solution is strongly alkaline.
(ii) Sulfadimidine: Acetyl derivative relatively more soluble in urine. Dose: similar to that of oral sulfadiazine.
(iii) Sulfamethoxazole: Used only as a component of cotrimoxozole.</p>
<p>III Long acting (7-9 days): Sulfadoxine and Sulformethoxine: Plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mn>112</mn></msup><mn>150</mn></mrow><annotation encoding="application/x-tex">\mathrm{t}^{112} 150</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">112</span></span></span></span></span></span></span></span></span><span class="mord">150</span></span></span></span></span>-200 hrs. Used in combination to treat malaria.
IV Used in inflammatory bowel disease: Sulfasalazine (Salazopyrine): See text. V Used topically:
(i) Mafenide propionate: Prevents colonisation of burns by Gram positive and Gram negative bacteria. It is also available as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> mafenide acetate cream.
(ii) Silver sulfadiazine ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> cream): Silver is released slowly and has wide antibacterial spectrum.
(iii) Sulfacetamide : Sodium salt has almost neutral pH and better tissue penetration. Used as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">6 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">6%</span></span></span></span></span> eye ointment and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> eye drops.
Adverse reactions: Unfortunately, there is a tendency to exaggerate the ill effects of sulfonamides which were used extensively in the past and are still valuable. However, the toxic potential of these drugs should be remembered and their indiscriminate use avoided.</p>
<ul>
<li>
<p>Allergy: This can occur at any time during therapy. The commonest allergic symptoms are drug fever, skin rash and eosinophilia. Rarely, severe exfoliative dermatitis may develop. Serum sickness, characterised by fever, joint pains, urticaria, bronchospasm and leucopenia sometimes develops within the first two weeks of therapy.
The uncommon allergic manifestations include cutaneous photosensitisation, a fatal necrotising arteritis resembling polyarteritis nodosa, acute toxic hepatitis and rarely fatal hepatic necrosis, toxic nephrosis, and acute haemolytic anemia.
A severe exudative type of erythema multiforme, associated with widespread lesions of the skin and mucous membranes, termed Stevens Johnson syndrome, has been reported with long acting sulfonamides. The syndrome, which is fortunately rare, is usually self-limiting but can occasionally be fatal.
Cross sensitivity among various sulfonamides and between sulfonamides and other drugs containing the sulfonamido <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">S</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub><msub><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">H</mi></mrow><mn>2</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{SO}_{2} \mathrm{NH}_{2}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">SO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord"><span class="mord mathrm">NH</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> group is known. Local application of sulfonamides to skin can sensitize the patient.</p>
</li>
<li>
<p>GI symptoms: They commonly produce nausea and vomiting, but these are rarely troublesome. Unlike the broad spectrum antibiotics, sulfonamides do not usually produce troublesome disturbances in the gut flora.</p>
</li>
<li>
<p>Renal toxicity: In the presence of acid urine, the acetylated form of the drug may be precipitated, mainly in the collecting tubules and the calyces. This may cause urinary obstruction and may precipitate renal colic. Crystalluria, albuminuria and haematuria can occur. These can be minimised by:
(a) Adequate fluid intake to maintain urine output of 1200 ml per day.
(b) Making the urine alkaline to increase the solubility of the conjugation products.
(c) Use of sulfonamides with acetylated metabolites soluble in acid urine e.g. sulfisoxazole.
Renal damage with tubular necrosis and vasculitis can also occur as an allergic reaction.</p>
</li>
<li>
<p>Haemopoietic toxicity: This includes thrombocytopenia, granulocytopenia and rarely aplastic anemia. Sulfonamides tend to oxidise hemoglobin to methemoglobin. In patients with G6PD deficiency, they may cause hemolysis.</p>
</li>
<li>
<p>Bilirubin metabolism: Sulfonamides compete with serum bilirubin for albumin binding sites. Administered during late pregnancy, they may displace bilirubin from albumin binding sites in the foetus. The free bilirubin, by crossing the BBB, which is permeable to bilirubin only in foetuses and infants, causes kernicterus. They should not be given to neonates, and to pregnant women.</p>
</li>
<li>
<p>Nervous system toxicity: These include CNS disturbances like confusion, depression, ataxia, tinnitus, fatigue and acute psychotic episodes. Rarely, peripheral neuritis may occur.</p>
</li>
<li>
<p>Miscellaneous: Rarely they can cause goitre and hypothyroidism.</p>
</li>
</ul>
<p>Drug interactions: See Table 45.3.</p>
<p>Table 45.3
Interactions of sulfonamides</p>
<table><thead><tr><th style="text-align: left;">Interfering drug</th><th style="text-align: left;">Result</th></tr></thead><tbody><tr><td style="text-align: left;">Sulfonylureas</td><td style="text-align: left;">ID displaced from plasma protein binding, with possible bypoglycemia</td></tr><tr><td style="text-align: left;">Coumarin anicoagulants, Methotrexate, Phenytoin, Thiopenta</td><td style="text-align: left;">ID activity enhance</td></tr><tr><td style="text-align: left;">Phenylbutazone, salicylate, probenecid</td><td style="text-align: left;">S displaced from plasma binding, with enhancement of S activity</td></tr><tr><td style="text-align: left;">Methenemine</td><td style="text-align: left;">Certain S are precipitated in urine</td></tr><tr><td style="text-align: left;">PABA-containing local anaesthetics e.g. procaine</td><td style="text-align: left;">Direct inhibition of S activity</td></tr></tbody></table>
<p>ID = Interfering drug;
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>S</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">S=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">S</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Sulfonamide
Therapeutic uses: Sulfonamides are relatively cheap, broad spectrum chemotherapeutic agents. However, their importance in therapeutics has diminished because of the development of resistance by a variety of organisms. Hence, they are now used in combination with trimethoprim.</p>
<p>For routine systemic use, short acting sulfadimidine or sulfadiazine are preferred. As these drugs are bacteriostatic, effective blood levels must be maintained by a multi-dose regimen. The uses are:</p>
<ul>
<li>Urinary tract infections: See Chapter 52.</li>
<li>Inflammatory bowel disease (IBD): See later.</li>
<li>Toxoplasmosis and Malaria: Sulfonamides in combination with pyrimethamine are used in the treatment of resistant malaria and toxoplasmosis (Chapters 56, 58).</li>
<li>Acute bacillary dysentery: Used as co-trimoxazole. See Chapter 49.</li>
<li>Chancroid: See Chapter 53.</li>
<li>Trachoma and inclusion conjunctivitis: Though effective, it is no more the drug of choice. See Chapter 72.</li>
<li>Miscellaneous: Sulfadiazine, in the dose of 4 to 6 g daily, in combination with an antibiotic, for several months, is of some value in nocardiosis. Sulfasalazine therapy has been found useful in rheumatoid arthritis (Chapter 75).
Use for prophylaxis: Sulfadimidine 1 g twice daily has been used to prevent attacks of streptococcal tonsillitis in patients who have recovered from rheumatic fever, but are allergic to penicillin. Sulfonamides should not be used to treat established streptococcal pharyngitis because they fail to eradicate the bacteria, and late sequelae may develop.</li>
</ul>
<p>Although sulfonamides are mainly bacteriostatic, they do not antagonise the bactericidal effects of penicillin and can be combined with it for treating susceptible infections with beneficial effects.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="inflammatory-bowel-disease-drug-therapy">Inflammatory Bowel Disease-Drug Therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#inflammatory-bowel-disease-drug-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Both ulcerative colitis (UC) and Crohn's disease are IBD; their exact cause of inflammation is not known. UC seems to result from a breakdown of the homeostatic balance between the hostís mucosal immunity and the enteric microflora, which results in an aberrant immune response against nonpathogenic gut commensals. IL-13 and natural killer (NK) T cells appear to have a key role in the pathogenesis of UC. TNF- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> is elevated in the blood, stool samples and intestinal mucosa of patients with UC. The main abnormality driving inflammation in UC involves an exaggerated T cell response, which causes mucosal hyperresponsiveness to commensals in genetically predisposed host.</p>
<p>Ulcerative colitis affects mainly the rectum and the colon causing proctitis, left sided colitis and pan-colitis. Clinically, it causes diarrhoea with blood in the stools, urgency, tenesmus, weight loss and may cause systemic symptoms. Generally, it is mild but sometimes it can develop into toxic colitis with severely ulcerated mucosa. In contrast, Crohn's disease affects the small intestine and the colon. The lesions in ulcerative colitis are superficial whereas those in Crohn's disease are transmural.</p>
<p>In both the conditions, proper nutrition and electrolyte balance must be maintained. Antidiarrhoeal drugs are not recommended in severe colitis as they can precipitate toxic dilatation of the colon and perforation.</p>
<p>The mainstay of drug therapy for UC is sulfasalazine or mesalazine (5-aminosalicylates) and glucocorticoids (Table 45.4). They can induce and maintain a remission in UC but their beneficial effect in Crohn's disease is less predictable. Mesalazine and glucocorticoids can be used during pregnancy and are generally safe.</p>
<p>Table 45.4
Drugs used in ulcerative colitis</p>
<table><thead><tr><th style="text-align: center;">Drugs</th><th style="text-align: center;">Doses/day (in divided doses)</th></tr></thead><tbody><tr><td style="text-align: center;">Antiinflammatory</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Oral*</td><td style="text-align: center;">6</td></tr><tr><td style="text-align: center;">Sulfasalazine</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>4</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2-4 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">4</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Olsalazine</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1-2 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">2</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Mesalazine</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.5</mn><mo>−</mo><mn>4.8</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1.5-4.8 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">4.8</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Prednisolone</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>60</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">40-60 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">60</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Methylprednisolone</td><td style="text-align: center;">60 mg</td></tr><tr><td style="text-align: center;">Topical</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Mesalazine enema</td><td style="text-align: center;">1 g</td></tr><tr><td style="text-align: center;">Hydrocortisone enema</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">100-200 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">200</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Beclomethasone enema</td><td style="text-align: center;">3 mg</td></tr><tr><td style="text-align: center;">Parenteral</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Hydrocortisone</td><td style="text-align: center;">300 mg</td></tr><tr><td style="text-align: center;">Antimicrobials**</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Metronidazole; Ciprofloxacin; Rifasimin; Cotrimoxazole; Clarithromycin: In severe cases;</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Immunosuppressants</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Azathioprine</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>150</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50-150 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">150</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Methotrexate***</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">15-25 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Cyclosporine</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2-4 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Anti-TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> antibody</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Infliximab (Chapter 74)</td><td style="text-align: center;"></td></tr></tbody></table>
<p>*Used for maintenance.
**More useful in Crohn's disease.
**Parenterally once a week
SULFASALAZINE is sulfapyridine linked to 5-aminosalicylic acid mesalazine by an azo bond. Given orally, it reaches the colon unaltered; and is split by the colonic bacteria into its constituents. Sulfapyridine is absorbed, is acetylated in the liver and excreted in the urine. It has no therapeutic action in UC. Mesalazine which is poorly absorbed induces remission in UC as well as Crohn's disease.</p>
<p>Mechanism of action: This is not known. However, its anti-inflammatory (not mediated through COX) and free radical scavenging properties are believed to be responsible for its beneficial effects. It has variable effects on prostaglandin production. It modulates inflammatory mediators derived from both the COX and lipoxygenase pathways and interferes with the production of inflammatory cytokines. 5-Aminosalicylic acid inhibits the activity of nuclear factor- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> (NF- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> ), an important transcription factor for proinflammatory cytokines. Mucosal secretion is reduced. It also inhibits cellular functions of natural killer cells, mucosal lymphocytes, and macrophages including migration of inflammatory cells.</p>
<p>Adverse Reactions to sulfasalazine include nausea, malena, headache, myalgias and sulfa-induced allergic reactions. Folate deficiency can occur, and folic acid 1mg/day orally is recommended during long term treatment. The drug may reduce sperm motility and</p>
<p>cause reversible oligospermia.
Sulfasalazine is also used in the treatment of rheumatoid arthritis (Chapter 75).
MESALAZINE is rapidly absorbed from the jejunum, and hence is marketed as delayed release forms (Table 45.5). The drug may cause nausea, abdominal pain, diarrhoea, and rarely interstitial nephritis, pancreatitis, hepatotoxicity, pericarditis, and SLE like syndrome can occur.</p>
<p>Table 45.5
Mesalazine (MS) preparations</p>
<table><thead><tr><th style="text-align: left;">Preparation</th><th style="text-align: left;">Chemical/pharmaceutical form</th><th style="text-align: left;">Delivery of MS</th><th style="text-align: left;">Distribution of MS</th><th style="text-align: left;">Dose</th></tr></thead><tbody><tr><td style="text-align: left;">Sulfasalazine</td><td style="text-align: left;">MS linked to sulfapyridine</td><td style="text-align: left;">Bacterial cleavage</td><td style="text-align: left;">Colon doses</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>6</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">2-6 \mathrm{~g} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">6</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span></span></span></span></span> day in divided</td></tr><tr><td style="text-align: left;">Balsalazine</td><td style="text-align: left;">MS linked to an inert molecule</td><td style="text-align: left;">Bacterial cleavage</td><td style="text-align: left;">Colon</td><td style="text-align: left;">2.25 g (three 750 mg capsules) tid</td></tr><tr><td style="text-align: left;">Olsalazine</td><td style="text-align: left;">MS linked to MS</td><td style="text-align: left;">Bacterial cleavage</td><td style="text-align: left;">Colon</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.5</mn><mo>−</mo><mn>3.</mn><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">1.5-3 . \mathrm{g} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3.</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span><span class="mord">/</span></span></span></span></span> day in divided doses</td></tr><tr><td style="text-align: left;">MS</td><td style="text-align: left;">Time release preparation</td><td style="text-align: left;">Time release pH independent</td><td style="text-align: left;">Ileum and colon</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>4</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">3-4 \mathrm{~g} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span></span></span></span></span> day in divided doses</td></tr><tr><td style="text-align: left;">MS</td><td style="text-align: left;">pH-sensitive coated MS</td><td style="text-align: left;">Release at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">p</mi><mi mathvariant="normal">H</mi></mrow><mo>&gt;</mo><mn>7</mn></mrow><annotation encoding="application/x-tex">\mathrm{pH}&gt;7</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">pH</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">7</span></span></span></span></span></td><td style="text-align: left;">Ileum and colon</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.4</mn><mo>−</mo><mn>4.8</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">2.4-4.8 \mathrm{~g} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4.8</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span></span></span></span></span> day in divided doses</td></tr><tr><td style="text-align: left;">MS suppository</td><td style="text-align: left;">MS</td><td style="text-align: left;">Direct</td><td style="text-align: left;">Rectum</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.5-1 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> OD/bid</td></tr><tr><td style="text-align: left;">MS enema</td><td style="text-align: left;">MS</td><td style="text-align: left;">Direct</td><td style="text-align: left;">Left colon</td><td style="text-align: left;">4 g in 60 ml</td></tr></tbody></table>
<p>Preparation without a sulfonamide are better tolerated than sulfasalazine and therefore are preferred.
*Should not be co-administered with antacids, PPI and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blockers.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="glucocorticoids-see-chapter-66">GLUCOCORTICOIDS: See Chapter 66.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#glucocorticoids-see-chapter-66" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Patients suffering from mild to moderate UC, especially proctatitis and left sided colitis, respond to mesalazine suppositories ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">1 \mathrm{~g} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span></span></span></span></span> day) or enemas ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>4</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">2-4 \mathrm{~g} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span></span></span></span></span> day). The response is seen within 2 weeks. If this fails, additional mesalazine oral therapy can be instituted.
Glucocorticoid enemas (hydrocortisone <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">d</mi></mrow><annotation encoding="application/x-tex">100 \mathrm{mg} / \mathrm{d}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord mathrm">d</span></span></span></span></span> ) are also used. Patients not responding to rectal glucocorticoids are given oral glucocorticoids e.g. prednisolone. Topical enema is less likely to be effective in Crohn's disease, because of patchy distribution of lesions.</p>
<p>Patients not responding or having moderate and severe acute exacerbations of UC or Crohn's disease respond to additional oral or IV glucocorticoid therapy (prednisolone 60 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">d</mi></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{d}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord mathrm">d</span></span></span></span></span> ). Beclomethasone or controlled release formulation of budesonide can also be used. The latter is preferred for Crohn's ileitis.</p>
<p>All severe cases should receive IV glucocorticoid for 5-7 days. The patients with IBD may be classified as: glucocorticoid responsive ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> ), glucocorticoid dependent and glucocorticoid unresponsive ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> ). The therapeutic response is generally observed in 1-2 weeks. The unresponsive patients do not improve even with prolonged, high dose therapy.</p>
<p>Glucocorticoid therapy may sometimes lead to intercurrent, opportunistic infections, sepsis and osteoporosis. Reactivation of pulmonary tuberculosis is another dreaded complication.</p>
<p>Antimicrobials: These (Table 45.4) are used (a) as adjuncts to the above drugs in active IBD; (b) as treatment for a specific complication of Crohn's disease such as an intraabdominal or perianal abscess.; and (c) for prophylaxis of postoperative recurrence in Crohn's disease. Many patients with Crohn's disease benefit from oral metronidazole given for long term ( 3 months). It is also beneficial in maintaining remission in Crohn's disease. Its efficacy in UC is however, doubtful.</p>
<p>Immunosuppressants: Patients with glucocorticoid dependent UC and those who relapse after adequate mesalazine can be treated with azathioprine or mercaptopurine (Chaper 74). When given with mesalazine, their toxicity increases because mesalazine inhibits their metabolizing enzyme, thiopurine methyltransferase.</p>
<p>Those who do not respond (resistant cases) and all those with severe, extensive disease will need TNF- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="bold-italic">α</mi></mrow><annotation encoding="application/x-tex">\boldsymbol{\alpha}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4444em;"></span><span class="mord"><span class="mord"><span class="mord boldsymbol">α</span></span></span></span></span></span></span> antagonist, infliximab ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> on 0,2 and 6 weeks) with or without azathioprine. In patients with moderate to severe Crohn's disease, methotrexate can be used instead of azathioprine or mercaptopurine. Anti-TNF antibodies like infliximab, adalimumab, certolizumab. and anti-integrin antibodies, natalizumab and vedolizumab are reserved for resistant cases.</p>
<p>After remission, oral or rectal mesalazine is used for long term in the dose of 1.6-3 gm per day for maintenance of remission. Long term follow up of the patients is necessary due to the probability of colorectal cancer. Glucocorticoids, however, have no role in the maintenance therapy and after remission, the dose is tapered over six to eight weeks. They are avoided for long term therapy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cotrimoxazole">Cotrimoxazole<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cotrimoxazole" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>TRIMETHOPRIM/COTRIMOXAZOLE: Trimethoprim, a pyrimidine derivative, is effective against many common pathogenic bacteria. It is slightly soluble in water. Given alone, it is either bacteriostatic or bactericidal. In in vitro studies, it is
(i) Highly effective against Staph, aureus, Streptococci, C. diphtheria, E. coli, Salmonella, Shigella, H. influenzae, K. pneumoniae, Proteus and V. cholerae.
(ii) Somewhat less effective against N. gonorrhoeae, N. meningitidis, Cl. welchii and B. pertussis. (iii) Not effective against Mycobacteria and pseudomonas. Its action may be inhibited in necrotic wounds containing pus and other cellular debris, which contains thymine and thymidine.</p>
<p>Mechanism of action: Bacteria and protozoa synthesize folic acid from PABA, which is necessary for their growth (Fig. 45.4). Trimethoprim inhibits the enzyme dihydrofolate reductase, which converts DHF to THF, thus interfering with nucleic acid synthesis. The bacterial enzyme is far more susceptible to trimethopim than the enzyme in human cells. Further, since higher animals and man utilise preformed folic or folinic acid from the diet they are relatively immune to the harmful effect of trimethoprim. Any depressant effect of this drug on human folate metabolism can be countered by feeding exogenous folate.</p>
<p>Since sulfonamides act by inhibiting the incorporation of PABA into dihydrofolate by organisms, a combination of trimethoprim and sulfonamide acts sequentially in the same metabolic pathway in the synthesis of nucleotides (Fig. 45.4). Hence, trimethoprim which is 20-100 times more potent than the sulfonamide is combined with sulfamethoxazole. This combination, known as Cotrimoxazole, is synergistic and acts as bactericidal. Bacterial resistance to this combination develops less frequently than when either drug is used alone.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="absorption-fate-and-excretion">Absorption, fate and excretion:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#absorption-fate-and-excretion" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Trimethoprim is rapidly and almost completely absorbed from the intestines. The peak plasma level is achieved in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mfrac><mn>1</mn><mn>2</mn></mfrac></mrow><annotation encoding="application/x-tex">1 \frac{1}{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.1901em; vertical-align: -0.345em;"></span><span class="mord">1</span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.8451em;"><span style="top: -2.655em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.394em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.345em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span> to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mfrac><mn>1</mn><mn>2</mn></mfrac></mrow><annotation encoding="application/x-tex">1 \frac{1}{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.1901em; vertical-align: -0.345em;"></span><span class="mord">1</span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.8451em;"><span style="top: -2.655em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.394em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.345em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span> to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mfrac><mn>1</mn><mn>2</mn></mfrac></mrow><annotation encoding="application/x-tex">3 \frac{1}{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.1901em; vertical-align: -0.345em;"></span><span class="mord">3</span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.8451em;"><span style="top: -2.655em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.394em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.345em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span> hours. Sulfamethoxazole has absorption and excretion characteristics very close to those of trimethoprim.</p>
<p>Cotrimoxazole contains trimethoprim 80 mg with sulfamethoxazole 400 mg (1:5). Given orally it has been shown to give the optimum synergistic ratio in the plasma against common pathogens.</p>
<p>Trimethoprim is distributed more widely than sulfamethoxazole which essentially remains in the ECF. This explains the higher optimum (20:1) sulfonamide : trimethoprim ratio in the plasma than that (5:1) in the tablets. Because of their differences in the distributions, different ratios may be observed in different tissues. Adequate concentration is reached in CSF, bile, prostatic fluid, and vaginal secretions. The half lives of trimethoprim and sulfamethoxazole are 16 and 10 hours respectively.</p>
<p>Trimethoprim is a weak base and hence, its excretion increases markedly with acidification of urine, due to its ionisation. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> of the oral dose of trimethoprim is excreted in the urine within 24 hours; about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> of this is in an unchanged form.</p>
<p>Adverse reactions to cotrimoxazole: These are due to:
(a) Sulfonamide component (see earlier); and
(b) Trimethoprim.</p>
<p>The combination can cause nausea, vomiting, abdominal pain and diarrhoea. Allergic</p>
<p>reactions are more common with the combination than with individual agents. Glossitis and stomatitis are relatively common. Trimethoprim may precipitate megaloblastic anemia in persons with pre-existing folic acid deficiency. Serious toxicity (raised liver enzymes, hyperkalemia and hyponatremia) appears to be more common in patients with AIDS. Dosages must be reduced in presence of kidney damage.</p>
<p>Development of bacterial resistant is its major drawback. Further, its use in pregnant women should be avoided because of the teratogenicity of large doses of trimethoprim in animals.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Cotrimoxazole contains trimethoprim 80 mg + sulfamethoxazole 400 mg ; dose 2 tablets ( 3 tablets in severe infection) twice daily for 10-14 days for the management of most infections. The drug can also be used IM or IV in the dose of 960 mg (equivalent to 2 tablets) every 12 hours. Paediatric tablets contain trimethoprim <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">20 \mathrm{mg}+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">+</span></span></span></span></span> sulfamethoxazole 100 mg . Suspension of 40 mg trimethoprim +200 mg sulfamethoxazole per 5 ml is also available.
(ii) Trimethoprim 200 mg tablets; 1-1112 tablets every 12 hours.</p>
<p>Therapeutic uses of cotrimoxazole:</p>
<ul>
<li>Urinary tract infection due to E. coli and Proteus group of organisms (Chapter 52).</li>
<li>Prostatitis: It is the therapy of choice. Trimethoprim alone has also been used in treating UTI and prostatitis.</li>
<li>Respiratory tract infections such as bronchitis, sinusitis, whooping cough and otitis media.</li>
<li>GI infections such as shigellosis.</li>
<li>Typhoid fever (Chapter 49).</li>
<li>STD such as Gonorrhoea, Chancroid, Granuloma inguinale (Chapter 53).</li>
<li>Serious infections such as meningitis and osteomyelitis due to susceptible Gram negative organisms.</li>
<li>Infection by Pneumocystis jiroveci: It has been used in high doses ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">15-20 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day of trimethoprim plus <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">75-100 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">75</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day of sulfamethoxazole) to treat Pneumocystis jiroveci infection in immunocompromised patients where it is the drug of choice. Intravenous administration of cotrimoxazole plus carbenicillin has been used to treat infections in neutropenic patients. Low dose therapy ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>150</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><msup><mi mathvariant="normal">m</mi><mn>2</mn></msup><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">150 \mathrm{mg} / \mathrm{m}^{2} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0641em; vertical-align: -0.25em;"></span><span class="mord">150</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">m</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span></span></span></span></span><span class="mord">/</span></span></span></span></span> day of trimethoprim plus 750 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><msup><mi mathvariant="normal">m</mi><mn>2</mn></msup><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{m}^{2} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0641em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">m</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span></span></span></span></span><span class="mord">/</span></span></span></span></span> day of sulfamethoxazole) has been used for prophylaxis of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. jiroveci in severely neutropenic patients.</li>
<li>Miscellaneous: Plague, brucellosis and nocardiosis. (Chapter 47).</li>
</ul>
<p>Advantages of cotrimoxazole are that it is:</p>
<ul>
<li>A broad spectrum antibacterial drug</li>
<li>Relatively safe and well tolerated; and</li>
<li>Highly cost-effective in many common infections in practice.</li>
</ul>
<p>Trimethoprim: Given alone, like cotrimethoxozole, it acts as a broad spectrum agent for similar indications. Concentrations achieved in renal and prostatic tissues are higher and cause less ADR than cotrimoxazole. It is given in the dose of 100-200 mg bid.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="nitrofurans">Nitrofurans<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nitrofurans" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The antibacterial activity of the nitrofuran compounds was demonstrated by Dodd and Stillman in 1944.</p>
<p>Mechanism of action: They undergo enzymatic reduction, resulting in a highly reactive intermediate that damages the bacterial DNA. They also possess radiomimetic and mutagenic properties.</p>
<p>Pharmacological actions: Nitrofurans acts against a variety of Gram positive and Gram negative organisms including Staphylococci, Streptococci, E. Coli, Salmonella and Shigella organisms. Some of these compounds, particularly furazolidone, inhibit the growth of Trichomonas vaginalis, a protozoal organism, while nifuroxime is effective against Candida albicans and other fungi. Though usually bacteriostatic, the nitrofurans can be bactericidal in high concentrations. Bacterial resistance can develop and cross resistance among the various compounds is also known.</p>
<p>Adverse reactions: These include abdominal discomfort, nausea, vomiting and rashes of various types. Rarely, haemolytic anemia may develop in individuals with G6PD deficiency. Immunological reactions such as pulmonary infiltration and fibrosis, chronic active hepatitis, and SLE-like reaction have been rarely reported. The drug may precipitate antabuse-like reactions in alcoholics. Polyneuritis is an important adverse effect which particularly occurs in the presence of impaired renal function. These compounds are avoided during pregnancy and infancy.</p>
<p>Preparations: Nitrofurans are yellow, crystalline compounds, sparingly soluble in water. They should be protected from light.</p>
<p>NITROFURANTOIN: It is rapidly and completely absorbed from the GI tract. Food increases its bioavailability. It does not achieve a bacteriostatic concentration in the plasma but approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> of the drug is excreted unchanged by the kidney, achieving a bactericidal concentration in the urine. The drug is effective against many common urinary pathogens, including E. coli and Aerobacter, and is used exclusively as a urinary antiseptic (Chapter 52). Its activity is considerably less at pH 8 than at pH 5.5. Therefore, the urine should not be alkalinised during therapy with nitrofurantoin. The plasma half life is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.3</mn><mo>−</mo><mn>1</mn></mrow><annotation encoding="application/x-tex">0.3-1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span></span></span></span></span> hour. It is bactericidal to some anaerobic bacteria. However, the low plasma levels achieved by oral route make such treatment useless for systemic infections.</p>
<p>It is administered orally with food in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50-100 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> six hourly. The comparable dose in children is 50 mg upto 1 year, 75 to 100 mg from 1 to 5 years and 150 to 200 mg from 6 to 12 years in 3 or 4 divided doses. The drug should not be given for more than 2 weeks. The dose for long suppression of susceptible urinary tract pathogens is 100 mg once a day. It does not appear in the urine in severe renal failure and in azotemic patients, and hence should be avoided. The drug colours the urine brown.</p>
<p>FURAZOLIDONE: This compound has been employed effectively in the treatment of GI infections such as bacterial enteritis, bacillary dysentery and giardiasis. It is used locally, along with nifuroxime, in the treatment of bacterial, trichomonal and monilial vaginitis. The drug does not significantly depress the normal intestinal flora. It is bactericidal. It is administered orally; the adult dose is 100 mg qid for 5-7 days.</p>
<p>NIFUROXIME: The compound is effective against the fungus Candida albicans, a common vaginal pathogen, and is employed locally usually along with furazolidone.</p>
<p>NITROFURAZONE is available as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.2%</span></span></span></span></span> solution and ointment for topical application for the treatment of superficial wounds and skin infections. It is used systemically in trypanosomiasis (Chapter 58).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="quinolones">Quinolones<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#quinolones" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Quinolones, particularly the fluoroquinolones with their broad antimicrobial activity. (Table 45.6), are considered as a distinct therapeutic advance.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-45-6">Table 45.6<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-45-6" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="fluoroquinolone-generations-pharmacokinetic-features-doses-and-indications">Fluoroquinolone generations: Pharmacokinetic features, doses and indications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#fluoroquinolone-generations-pharmacokinetic-features-doses-and-indications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<table><thead><tr><th style="text-align: center;">Name</th><th style="text-align: center;">Oral bioavailability &lt;br&gt; %</th><th style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> &lt;br&gt; (hours)</th><th style="text-align: center;">Metabolism/Clearance</th><th style="text-align: center;">Dose</th><th style="text-align: center;">Indications</th></tr></thead><tbody><tr><td style="text-align: center;"></td><td style="text-align: center;">Second generation: Class I</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Norfloxacin</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>40</mn></mrow><annotation encoding="application/x-tex">30-40</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">40</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>4</mn></mrow><annotation encoding="application/x-tex">3-4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4</span></span></span></span></span></td><td style="text-align: center;">R/H</td><td style="text-align: center;">400 mg bid</td><td style="text-align: center;">UTI, Prostatitis</td></tr><tr><td style="text-align: center;">Lomefloxacin</td><td style="text-align: center;">About 90</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mo>−</mo><mn>8</mn></mrow><annotation encoding="application/x-tex">6-8</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">8</span></span></span></span></span></td><td style="text-align: center;">R</td><td style="text-align: center;">400 mg OD IV 400 mg</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">Second generation: Class II</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Ciprofloxacin</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>70</mn></mrow><annotation encoding="application/x-tex">60-70</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">70</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3.3</mn><mo>−</mo><mn>4.9</mn></mrow><annotation encoding="application/x-tex">3.3-4.9</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3.3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4.9</span></span></span></span></span></td><td style="text-align: center;">R/H</td><td style="text-align: center;">250 mg OD &lt;br&gt; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>250</mn><mo>−</mo><mn>750</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">250-750 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">250</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">750</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> bid &lt;br&gt; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>200</mn><mo>−</mo><mn>400</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">200-400 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">200</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">400</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> by IV infusion (over 30-60 min ) bid</td><td style="text-align: center;">UTI, Typhoid, Gonorrhoea, Gastroenteritis, Skin, soft tissue, bone and joint infections especially with Gram negative organisms</td></tr><tr><td style="text-align: center;">Ofloxacin</td><td style="text-align: center;">About 95</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>7</mn></mrow><annotation encoding="application/x-tex">5-7</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">7</span></span></span></span></span></td><td style="text-align: center;">R</td><td style="text-align: center;">200-400 mg OD</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Pefloxacin</td><td style="text-align: center;">About 90</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>8</mn><mo>−</mo><mn>13</mn></mrow><annotation encoding="application/x-tex">8-13</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">13</span></span></span></span></span></td><td style="text-align: center;">H</td><td style="text-align: center;">400 mg bid; &lt;br&gt; 400 mg by IV infusion (over 1 hour) bid</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">Third generation</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Sparfloxacin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">Δ</mi></mrow><annotation encoding="application/x-tex">\Delta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">Δ</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>90</mn></mrow><annotation encoding="application/x-tex">&gt;90</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">90</span></span></span></span></span></td><td style="text-align: center;">21</td><td style="text-align: center;">H</td><td style="text-align: center;">200-400 mg in one or two divided doses per day</td><td style="text-align: center;">Like Class II. Preferred in Community acquired pneumonia.</td></tr><tr><td style="text-align: center;">Levofloxacin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">Δ</mi></mrow><annotation encoding="application/x-tex">\Delta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">Δ</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>90</mn></mrow><annotation encoding="application/x-tex">&gt;90</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">90</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mo>−</mo><mn>8</mn></mrow><annotation encoding="application/x-tex">6-8</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">8</span></span></span></span></span></td><td style="text-align: center;">R</td><td style="text-align: center;">500 mg OD for &lt;br&gt; 7-14 days</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Moxifloxacin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">Δ</mi></mrow><annotation encoding="application/x-tex">\Delta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">Δ</span></span></span></span></span></td><td style="text-align: center;">90</td><td style="text-align: center;">12</td><td style="text-align: center;">R/H</td><td style="text-align: center;">400 mg OD</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Gemifloxacin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">Δ</mi></mrow><annotation encoding="application/x-tex">\Delta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">Δ</span></span></span></span></span></td><td style="text-align: center;">70</td><td style="text-align: center;">7</td><td style="text-align: center;">H</td><td style="text-align: center;">300 mg OD</td><td style="text-align: center;"></td></tr></tbody></table>
<p>Nalidixic acid and cinoxacin are first generation quinolones.
Also available for IV infusion. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">R</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{R}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm">R</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Renal. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">H</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{H}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm">H</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Hepatic.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi>a</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{a}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6644em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6644em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">a</span></span></span></span></span></span></span></span></span></span></span></span></span> These are termed respiratory fluoroquinolones because of their excellent antipneumococcal activity.
Mechanism of action: Quinolones inhibit:
(a) DNA gyrase (topoisomerase II) and
(b) DNA topoisomerase IV.</p>
<p>The former action is direct and leads to an arrest of DNA replication. The latter action also arrests DNA replication but by blocking the enzyme's normal function of delinking the daughter DNA molecule. The activity of quinolones against Gram negative bacteria is primarily due to their action on DNA gyrase, whereas that against Gram positive bacteria is primarily due to their action on topoisomerase IV. This may explain the differences in the antibacterial spectra of the various quinolones. Bacteria can develop resistance to quinolones by mutation.</p>
<p>NALIDIXIC ACID (Neg-Gram, Gramoneg): This 4-quinolone derivative is effective against certain Gram negative bacteria, especially E. coli, shigella and many strains of Proteus. It is relatively ineffective against Gram positive organisms. Bacteria can develop resistance fairly rapidly in vitro.</p>
<p>Nalidixic acid is readily absorbed from the GI tract. The serum levels of the drug are low, but approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> of it is eliminated in the urine within 8 hours. It is present in the urine in both active ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> ) and inactive, conjugated forms.</p>
<p>Adverse reactions include allergic reactions, nausea, vomiting and diarrhoea. Allergy is manifested by rash, urticaria, fever, and photosensitivity. The CNS manifestations include headache, malaise, drowsiness and myalgia. Convulsions may appear with overdosage, particularly in children. It may cause hemolytic anemia which has been reported in a two week old baby fed on breast milk, due to the presence of the drug in the breast milk. It may cause increase in intracranial pressure (pseudotumour cerebri) in young children. Erosion of weight bearing joints has been reported in growing animals. Because of its toxicity, limited utility and availability of fluoroquinolones, use of nalidixic acid has now diminished.</p>
<p>FLUOROQUINOLONES: These drugs are chemically related to nalidixic acid and are called fluoroquinolones because of the fluorine in their chemical structure (Fig. 45.5). Inclusion of fluorine increases their activity manifold and broadens the spectrum. They are:
<img src="assets/images/image-20251214-a078b821.jpeg" alt="img-61.jpeg"></p>
<ul>
<li>Highly effective orally.</li>
<li>Rapidly bactericidal with broad antibacterial spectrum.</li>
<li>Effective against bacteria resistant to beta-lactam and aminoglycoside antibiotics; and</li>
<li>Relatively safe.</li>
</ul>
<p>Antibacterial Activity: They are highly active against many Gram negative and some Gram positive organisms, in a concentration-dependent manner. They possess excellent activity against the Enterobacteriaceae (E.coli, Klebsiela and Proteus mirabalis) including many organisms resistant to penicillins, cephalosporins and aminoglycosides. They are highly effective against Shigella species, Salmonellae (including those resistant to chloramphenicol), H. ducrei. H. influenzae, B. catarrhalis and Neisseria species including penicillinase producing gonococci. Pseudomonas aeruginosa is inhibited in the urinary tract but not in other tissues/sites due to inadequate concentrations at the sites.</p>
<p>Most of them are much less active than penicillin against Gram positive organisms,</p>
<section data-footnotes="true" class="footnotes"><div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 class="sr-only" level="2" id="footnotes">Footnotes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#footnotes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li id="user-content-fn-0">
<ul>
<li>Preventing histamine release from storage sites e.g. cromolyn sodium, nedocromil.</li>
<li>Using adrenaline which has actions opposite to those of histamine and thus acts as a physiological antagonist.</li>
<li>Hasten ing the destruction of histamine by using histaminase, which is, however, clinically not effective; and</li>
<li>Blocking the actions of histamine on various receptors <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi></mrow><annotation encoding="application/x-tex">H</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span></span></span></span></span>, receptor antagonists and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi></mrow><annotation encoding="application/x-tex">H</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span></span></span></span></span>, receptor antagonists.</li>
</ul>
<a href="#user-content-fnref-0" data-footnote-backref="true" class="data-footnote-backref" aria-label="Back to content">↩</a>
 
<a href="#user-content-fnref-0-2" data-footnote-backref="true" class="data-footnote-backref" aria-label="Back to content">↩<sup>2</sup></a>
 
<a href="#user-content-fnref-0-3" data-footnote-backref="true" class="data-footnote-backref" aria-label="Back to content">↩<sup>3</sup></a>
 
<a href="#user-content-fnref-0-4" data-footnote-backref="true" class="data-footnote-backref" aria-label="Back to content">↩<sup>4</sup></a>
 
<a href="#user-content-fnref-0-5" data-footnote-backref="true" class="data-footnote-backref" aria-label="Back to content">↩<sup>5</sup></a>
 
<a href="#user-content-fnref-0-6" data-footnote-backref="true" class="data-footnote-backref" aria-label="Back to content">↩<sup>6</sup></a>
 
<a href="#user-content-fnref-0-7" data-footnote-backref="true" class="data-footnote-backref" aria-label="Back to content">↩<sup>7</sup></a>
 
<a href="#user-content-fnref-0-8" data-footnote-backref="true" class="data-footnote-backref" aria-label="Back to content">↩<sup>8</sup></a>
 
<a href="#user-content-fnref-0-9" data-footnote-backref="true" class="data-footnote-backref" aria-label="Back to content">↩<sup>9</sup></a>
 
<a href="#user-content-fnref-0-10" data-footnote-backref="true" class="data-footnote-backref" aria-label="Back to content">↩<sup>10</sup></a>
 
<a href="#user-content-fnref-0-11" data-footnote-backref="true" class="data-footnote-backref" aria-label="Back to content">↩<sup>11</sup></a>
 
<a href="#user-content-fnref-0-12" data-footnote-backref="true" class="data-footnote-backref" aria-label="Back to content">↩<sup>12</sup></a>
</li>
</ol>
</section></div></div></div></div></div></div></div><div data-testid="stAppIframeResizerAnchor" data-iframe-height="true" class="st-emotion-cache-1dumvfu eht7o1d9"></div></section></div></div></div><div data-testid="portal" id="portal" class="st-emotion-cache-1q6lfs0 e19n7mk11"></div></div><div class=""></div></div>
  

</body></html>